[{"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a strong point of the story, giving us both absolute and relative risk figures up front in the second paragraph:\nAmong children whose mothers took fish-oil capsules, 16.9 percent had asthma by age 3, compared with 23.7 percent whose mothers were given placebos. The difference, nearly 7 percentage points, translates to a risk reduction of about 31 percent.\nToo often, even when stories do provide absolute risk figures, they highlight relative risks high up in the story and bury the absolute risk information far down in the text where it\u2019s less likely to be read.", "answer": 1}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nAt six months of age, however, they could predict the high risk girls with about 80 percent accuracy, though they couldn't do the same for boys that young.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\nBut accuracy for girls at that age was only 60 percent, not statistically significant.\nWhen the babies were nine months old, researchers could predict who was in the high-risk autism group -- that is, they had a sibling with autism -- with nearly 80 percent accuracy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a lot of percentages but very little in terms of absolute differences or clear, hard numbers. It says that \u201cPrior research has shown that about 20 percent of siblings of children with autism will also develop autism and another 40 to 50 percent will have some characteristics of the disorder, such as repetitive behaviors or problems with social interaction, language or communication, but not the full-blown disorder.\u201d That\u2019s a great piece of context and should have guided the rest of the reporting. Instead, the story says that \u201cWhen the babies were nine months old, researchers could predict who was in the high-risk autism group \u2014 that is, they had a sibling with autism \u2014 with nearly 80 percent accuracy.\u201d It goes on to say, \u201cWhen broken out by gender, researchers found other differences. For example, at nine months they were able to predict which boys were in the high-risk group with near 100 percent accuracy. But accuracy for girls at that age was only 60 percent, not statistically significant.\u201d Are readers to take this to mean that the statistically significant predictions for boys were averaged with the statistically insignificant predictions for girls to arrive at the \u201cnearly 80 percent\u201d figure? If so, this seems problematic. Regardless, readers deserved absolute numbers.", "answer": 0}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nResearchers then analyzed health status information collected after the women turned 70.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We expect that a story will attempt to\u00a0provide us with some measure of the size of an association beyond just the relative risks, which can often give an inflated sense of the effects. That\u2019s what happens in this story when it says that women who drank lightly almost every day \u201cwere nearly 50% less likely to develop disease.\u201d Sounds like a big difference, but the figure would certainly be much smaller\u00a0if expressed in absolute terms. The story\u00a0could\u00a0have made these statistics more\u00a0meaningful with comments from an independent expert.\nSee how the \u201cBehind the Headlines\u201d project in the UK analyzed the evidence and included the absolute differences. ", "answer": 0}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nStudy results also revealed that urban academic or teaching hospitals performed laparoscopic anti-reflux surgery at a higher rate than open procedures, 54.4 percent versus 45.6 percent.\nLaparoscopic anti-reflux operations were less likely to result in postoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\nThe researchers also found that laparoscopic procedures were better for patients in terms of fewer complications.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release summarized how minimally invasive techniques reduced the length of hospital stay and complication rates for patients.\n\u201cResearchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\nThe researchers also found that laparoscopic procedures were better for patients in terms of fewer complications. Laparoscopic anti-reflux operations were less likely to result in postoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\u201d\nWe rate this satisfactory, but just barely, for citing cost differences between the two types of surgery and the average reduction in the number of days a patient must remain hospitalized.\u00a0 We do wish the release had delved more into the specifics of reduced complications. How common were the surgical complications in each surgical method?", "answer": 1}, {"article": "What happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nThis is why the telescope is implanted in only one eye.\nDespite its terrific potential, the new eye telescope isn't for everyone.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nAnd the population who might benefit from the new device is somewhat limited.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t spend a lot of time with the numbers, but it does a pretty good job capturing the potential benefits.", "answer": 1}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was clear about the benefits of this treatment (i.e. that the outcomes from use of the combination medication were no better than a statin alone).", "answer": 1}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\n\"These substances help keep the arteries healthy and are protective against cardiovascular disease,\" says preventive cardiologist Suzanne Steinbaum, MD, of Lenox Hill Hospital in New York City, in an email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall,\u00a0WebMD\u2019s characterization of chocolate as a \u201csuperfood\u201d\u00a0makes it sound like an arm of the Hershey marketing department. More specifically,\u00a0although the story provides data on some of the results, it doesn\u2019t quantify others and\u00a0doesn\u2019t point out that no\u00a0actual health outcomes were assessed.\u00a0In addition, it doesn\u2019t identify misleading comparisons that\u00a0might make chocolate look better than the other foods included in the study. Examples:", "answer": 0}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nGiven the fact that more hospitals are offering virtual colonoscopy, it\u2019s worth discussing with your doctor.\nBut Gollub notes that only about 8% of healthy adults getting regularly screened actually have tumors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefit.\u00a0 And no adequate comparison with other colon cancer screening techniques.", "answer": 0}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that the 6-month study yielded the following results:\nThe group randomized to receive the probiotic, on average, \u201cdidn\u2019t return to hospital as quickly \u2026 required less in-patient treatment time \u2026 [and the] beneficial effects were most pronounced in those patients\u00a0 who exhibited abnormally high levels of inflammation\u201d when compared to the placebo group.\nHowever no data are provided to support these outcomes.\u00a0The news release should have included information about the number of patients in the trial, the schedule of probiotic dosing given to the participants, the changes in inflammation levels, the difference in number of rehospitalizations, and other details.\nThe release also includes some other unsubstantiated claims, such as:", "answer": 0}, {"article": "Scientists have found an unexpected use for virtual reality headsets: to help pinpoint people who may later develop Alzheimer\u2019s disease.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nNot all will be destined to be affected by the disease, however.\nThe goal of the work is to help people as they develop the disease.\n\u201cBy pinpointing those who are beginning to lose their navigational skills, we hope to show that we can target people at a much earlier stage of the condition and one day become far more effective in treating them.\u201d\n\nThe discovery that loss of navigational skills was associated with Alzheimer\u2019s disease was made several years ago by Chan and colleagues based at several centres in the UK.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky. The study has not yet taken place, so there are no benefits to discuss \u2014 which makes it difficult to ding the story for failing to quantify the benefits. As such, we\u2019ll rate this as not applicable. However, our reasons for rating it N/A highlight a critical problem with the story, which we address in Quality of Evidence and Availability, below.", "answer": 2}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nTurner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has a fundamental flaw. The key finding of the study is that high doses of resveratrol can have an effect on the production of amyloid-beta40, a biomarker that declines as Alzheimer\u2019s disease advances. Specifically, the study looked at 119 patients with mild to moderate Alzheimer\u2019s disease. Patients who received the high doses of resveratrol did not see declines in the biomarker, whereas patients who received a placebo did see declines in amyloid-beta40. Couching that as \u201cnew evidence resveratrol may slow Alzheimer\u2019s,\u201d as we see in the headline, is misleading. More accurate is the line in the eighth paragraph: \u201cHow resveratrol may be affecting the Alzheimer\u2019s disease process isn\u2019t clear yet.\u201d And it\u2019s not until the last line of the story that readers find: \u201cWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d That\u2019s a qualifier that should have found placement much higher in the story.\nAnother concern is the story\u2019s reporting on brain volume decline in the resveratrol group, which it says is \u201ca positive sign, as the disease can cause inflammation and swelling that can interfere with nerve connections.\u201d Characterizing a shrinking brain as a \u201cpositive sign\u201d seems problematic at best. The study itself says that the \u201cThe\u00a0etiology and interpretation of brain volume loss\u00a0observed here and in other studies are unclear.\u201d And in the news release issued for the study, Dr. Turner acknowledges,\u00a0\u201cWe\u2019re not sure how to interpret this finding.\u201d\nAnd finally, the story also points to \u201cslight improvements\u201d among patients receiving resveratrol \u2014 but doesn\u2019t explain exactly what that means. More on this below in \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nDoctors and researchers will now explore how to best use these drugs -- give one before the other, or simultaneously.\nBut in many cases that are nine or 10 months they otherwise would not have had.\nIt doesn't target a specific part of the cell.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of the benefits reported in both studies.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story informed the reader that half of the people taking the rimonabant brought their blood sugar to the range considered to be the target for good glucose control, the story did not provide information about the starting blood-sugar levels for this cohort.\u00a0 In addition, the story mentions in passing that the improvements were linked to weight loss.\u00a0 It is not clear from the story whether weight loss alone was sufficient to elicit the benefits in blood-sugar level observed.", "answer": 0}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- People who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead says, \u201cPeople who take drugs called bisphosphonates to prevent bone loss may also reduce their risk of developing colorectal cancer by almost 60 percent compared to those not on the drugs, a new study suggests.\u201d What this story and the Reuters Health story failed to do was give the raw numbers that are provided in the study itself.\u00a0The story should have said that 138 women in the non-cancer group took biophosphonates and 97 in the cancer group took them, meaning that 41 women appear to have benefited from taking the drugs. If the study had found that 97 women had taken these drugs in both groups, the study would not have made headlines. Also, it might have been helpful to show that there were actually larger differences in some of the other factors that were studied. For example, 120 women in the group of cancer patients had a history of colorectal cancer in the family compared to 75 women in the control group.\nThis story did a better job of mentioning \u201cThe magnitude of the reduced risk is less important because this is an association study\u2026\u201d But then it goes on to say that the magnitude of the benefit is similar to cholesterol lowering medicines. The main difference is that this story, despite the caveats mentioned, is more enthusiastic about the findings than the Reuters story.\n", "answer": 0}, {"article": "she asked.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\n\"The other major limitation of this study is that the investigators did not look at whether these brain differences are specific to children with autism, or if they would also be seen, for example, in children with language delays who are not autistic,\" Adesman said.\n\"It is possible that children who have delayed language but not autism would also show the same pattern.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts off with a very vague description of the study\u2019s findings, saying, \u201cThe researchers found no differences in the activity in the hearing area of the brain between the two groups. However, in the language comprehension area, there was significantly more activity among typical children than among children with autism, Hirsch\u2019s group noted.\u201d What would be considered significant when comparing one group of 12 to another group of 15? The story does provide a bit more specific information later saying, \u201cTo further test this screening approach, another group of 27 autistic children, aged 5 to 17, underwent fMRI and the researchers were able to identify 26 of them as autistic.\u201d We felt this was inadequate and also misleading. As the story goes on to point out, the brain differences that were found may not be exclusive to autism. There\u2019s a chance, in fact, that were the study group much larger that there would have been many other subjects who had the same brain activity but were not otherwise diagnosed as autistic.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not provide any data to support its claims. Instead, sweeping phrases are used to describe the benefits of curcumin-loaded nanoparticles: \u201cThis formulation included substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells.\u201d\nMoreover, \u201cnano-therapeutic treatments showed a more pronounced effect\u201d in cell lines of a high-risk form of neuroblastoma, the news release states. No other benefit data are given.\nWe like to see news releases giving a quantitative estimate of the potential benefit using numbers, instead of using broad, ambiguous terms like \u201csubstantial,\u201d \u201cminor\u201d and \u201cmore pronounced.\u201d Therefore, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "It is known as BMS-790052.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nThe research is so early that the drug hasn't been named.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story got a little carried away here. It said participants treated with the experimental drug had a \"dramatic\" reduction in viral load. While this may be true, it would have been helpful to point out, as the HealthDay story did, that the study lasted only a few days.\u00a0We don\u2019t know whether this benefit can be maintained\u00a0over a longer period of time, especially considering that the\u00a0hepatitis C virus has proven to be quite capable of developing resistance to antivirals over time.\u00a0", "answer": 0}, {"article": "For more information, visit www.aacc.org.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\nThis enables doctors to predict the risk of an individual developing Alzheimer's disease.\nAs biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release names several benefits of the new test \u2014 accuracy, speed, affordability, ability to run multiple tests from one blood sample \u2014 but provides little quantification, and only in terms of its 100 percent accuracy in detecting a protein in the blood associated with increased AD risk.\nThe release suggests that early testing showing a person carries a genetic risk for AD is a benefit because they can consider medications or lifestyle changes as interventions to stall the disease. However, having a certain genetic profile does not mean a person will develop AD. Nor are there any current medications that effectively prevent or stall AD, or lessen its symptoms.", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nSerious side effects also became clear.\nThen after several months the tumors began to shrink.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nMalignant cells had spread throughout her body.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "good job providing absolute benefit data from the trial.", "answer": 1}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nThe numbers aren't huge.\nThe rest of the men used a placebo spray.\nIt's the No.\n1 sexual health problem in men.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The \"ejaculatory control scale\" wasn\u2019t explained very well.\u00a0 But the numbers were there.\u00a0 ", "answer": 1}, {"article": "Larsson isn't sure why.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe group eating the most chocolate got the most benefit, reducing stroke intake by 20%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that researchers observed a 20% reduction in strokes among participants eating the most chocolate relative to those eating the least \u2014 a statistic that\u00a0conveys very little useful information. Compare this with the much more informative\u00a0Reuters description that provides absolute risks\u00a0from data contained in one of the study tables:\u00a0\u201cAmong those with the highest weekly chocolate intake, more than 45 grams, there were 2.5 strokes per 1,000 women per year. That figure was 7.8 per 1,000 among women who at the least, less than 8.9 grams a week.\u201d", "answer": 0}, {"article": "We\u2019d be pushing it on everyone.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nnutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nCaffeine still has a number of effects parents might want to avoid for their children.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The range of studies cited and their conclusions is impressive, but the actual quantification of benefits is scant and sometimes misleading. Look at the quantification of benefits related to liver cancer which gives a relative risk reduction. \u201cA\u00a0meta-analysis published in 2007 found that increasing coffee consumption by two cups a day was associated with a lower relative risk of liver cancer by more than 40 percent.\u201d Really? 40% of what? My lifetime risk of liver cancer to start with, according to the American Cancer Society, is \u201c1 in 81, while an average woman\u2019s risk is about 1 in 196\u201d \u00a0(this equates to 1.23% for men and 0.51% in women). Reducing my (a man\u2019s) relative risk of liver cancer then goes from 1.2% down to 0.72%, a difference of about 0.48%. \u00a0Is that worth an extra 2 cups of coffee per day? If you don\u2019t like the stuff, again, you need to know these slight differences.", "answer": 0}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThis is one of the first trials in multiple myeloma to use minimal residual disease as primary endpoint and the very first one to modify therapy based on achievement of minimal residual disease eradication.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "By definition, the benefits of an experimental treatment are unknown. The release should not dangle the potential of unproven benefits, including eradicating multiple myeloma, without acknowledging that this experimental treatment may turn out to be no better, or even less beneficial, than standard treatments. In the interview mentioned above, the lead investigator noted, \u201cThere is no proof that a new therapy is better, otherwise would be no need for the clinical trial.\u201d The release should have included that fundamental caveat.\nWe think it\u2019s important to stress that a trial to determine the best therapy would ideally compare  National Comprehensive Cancer Network (NCCN) recommended treatments such as revlimid, dexamethasone and velcade with a proposed therapy.", "answer": 0}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\nThe odds are that the person is having cardiac arrest - the heart suddenly stops - which can occur after a heart attack or be caused by other heart problems.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nThis action should be taken only for adults who unexpectedly collapse, stop breathing and are unresponsive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment fails to report the percentage of the targeted population that survives witnessed sudden cardiac arrest with either of the methods of CPR. \nIn none of the studies, using various outcome measures, does survival exceed 20 percent. Viewers should know this. ", "answer": 0}, {"article": "CTE causes Alzheimer's-like symptoms, including memory loss, confusion, aggression, rage and, at times, suicidal behavior.\nHowever, there is a potential bias in that study, as relatives of these players may have submitted their brains for diagnosis due to clinical symptoms noticed while the players were alive.\nBut one of the biggest obstacles in understanding CTE has been the inability to diagnose it in the living.\nFurthermore, they found that the more years someone played football, the higher amount of the protein.\n\"This is something new,\" said Dr. Ann McKee , a neuropathologist and senior author of the studyMcKee has performed many of the high profile diagnoses of CTE among former pro-football players and is director of the Boston University CTE Center.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discusses benefits here:\nThe paper evaluated the brains of 23 deceased football players with CTE, and compared them to the brains of 50 deceased people diagnosed with Alzhiemer\u2019s disease and the brains of 18 deceased non-athletes. When compared to the brains without CTE, researchers found those brains with CTE had significantly higher amounts of CCL11, even when compared to those brains with Alzheimer\u2019s, another degenerative brain disease. Furthermore, they found that the more years someone played football, the higher amount of the protein.\nHow much higher was the protein, in numerical terms? And how do they know it\u2019s significant\u2013that the higher level means anything? All lab values have normal ranges\u2013how do they know if these measurements were abnormal? Instead of providing insight on this, the story explains that it\u2019s really too early to tell if any of this means anything valuable. So why report on it now?", "answer": 0}, {"article": "Further,Dr.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nEven with this trio of medicines, Mr. Brown\u2019s LDL cholesterol level hovered around 200.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This falls short in two different ways. First, the release only tells readers how much one patient\u2019s LDL cholesterol dropped (from 384 to 111). That\u2019s anecdotal data. And, because the release doesn\u2019t tell readers which drug the patient was taking, it is not even clear which drug was responsible for that single patient\u2019s lower cholesterol numbers. Second, the release doesn\u2019t tell readers what this reduction in LDL cholesterol means in terms of the patient\u2019s actual health. Does it reduce the patient\u2019s risk of a heart attack? If so, by how much \u2014 a lot? A little?", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "None provided. Just the lone doctor\u2019s claims that it \"stimulates DNA repair, heals scars and revitalizes wizened skin.\" ", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\n(For surgeons outside Chicago, visit envoymedical.com.)\nMerlo's doctor, ear surgeon Sam Marzo of Loyola University Medical Center in Maywood, has performed 40 Esteem implants since he was trained by its manufacturer, Envoy Medical Corp. in St. Paul, Minn., in 2010.\nFor patients with profound hearing loss, a cochlear implant is a better option, he said.\nHe is the only Chicago-area surgeon authorized to implant the device, said an Envoy representative.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits detailed in the story are only anecdotal \u2013 from a single patient and one implant surgeon. No quantitative data or scientific evidence are given to support the patient\u2019s claims. Is her experience typical? Out of the 40 patients who received Esteem implants in the Chicago area, did all of them have similar outcomes? And what about nationwide? How was hearing improvement for all of these patients measured?\u00a0We are not told of the clinical trial that was used to obtain FDA approval (easily available at http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/EarNoseandThroatDevicesPanel/ucm146740.htm).", "answer": 0}, {"article": "The women were followed for an average of about 3.5 years.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThis story presents a generally positive portrayal of the benefits of preventive surgery. Coupled with the absence of information about harms, the overall impression might be considered out of balance. But the story does not give the impression that surgery eliminates the risk of cancer and it includes cautionary comments, for instance referring to the \u201cvery complex set of considerations\u201d facing women who are considered to have a high cancer risk based on genetic test results. The story also includes some of the absolute percentages of women who developed cancer. In sum, then the overall balance seems reasonable.\n", "answer": 1}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\n\"If you look at leukemia, which is cancer of the blood cells, there is nowhere to shoot -- it's all through the body.\"\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\n\"I have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\" he said.\n\"I started to designing equipment (for) proton therapy of cancer -- that was a radically new idea,\" Jongen told CNN.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "These statements from an entrepreneur clearly do not constitute documentation of benefit:\n\u201cwhere patients receive a powerful dose of targeted radiation that kills only those cancerous cells\u2026.\u201d \u201ca therapy that offers precision and minimal side effects.\u201d \u201cIt does a lot less collateral damage to the patient \u2013 that\u2019s the great thing about proton therapy\u201d \u201cI have a number of letters from parents of young kids saying if it had not been for this treatment we would have lost our kid,\u201d he said. \u201cThat\u2019s something I really cherish. When I feel a bit depressed, for whatever reason, I go back to those letters and they are very exciting.\u201d", "answer": 0}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nThe research team found:\n\u2022 For patients receiving any beta-blocker, the median overall survival was 47.8 months versus 42 months for nonusers.\nAccording to Sood, the preliminary data from these feasibility trials will be used to design prospective, randomized clinical trials examining NSBBs on patient outcomes.\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release provides an understandable summary of the benefits seen in this retrospective review.\u00a0 \u201cThe release reports that EOC patients nonselective beta antagonists (NSBBs \u2014 a type of beta blocker) had a median overall survival of of 94.9 months. That\u2019s compared to 42 months for EOC patients who did not take beta blockers, and 38 months for those receiving beta-1-adrenergic receptor selective agents (SBBs \u2014 another type of beta blocker).\u201d\u00a0 But we think a few words about a couple of important provisos which we comment on under Quality of evidence should have been included.", "answer": 1}, {"article": "There\u2019s ample reason for caution.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\nOn average, within 24 weeks patients getting ancetrapib saw LDL levels drop by nearly 40 percent compared with the placebo group, while their HDL levels rose by 138 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does include several comments that further testing is needed before researchers will be able to say whether or not anacetrapib can save lives or reduce the risk of heart disease. However, it appears to ignore all the cautionary statements when talking about the \u201cbenefits\u201d shown in this specific trial. It reports the changes in cholesterol levels seen in this trial and then continues with a comment about the potential life-saving effect \u201cif the same benefit\u201d were seen in all patients at risk of heart disease.\nThe problem is that this new class of drugs alters cholesterol levels using a different biological mechanism than statins. While it is understandable to hope that the changes in cholesterol will predict changes in disease risk, the way they sometimes can for certain patients taking statins, that fundamental question has yet to be tested\u2026 and it certainly was not asked in this trial.\nAs mentioned above, despite the cautionary statements from independent experts, the thrust of this story assumes that changing cholesterol numbers means changing lives. Not only is that link yet to be proven for this class of drugs, but journalists have an obligation to remind people that the simple marketing messages used to promote cholesterol-lowering statins obscure a far more complex reality. ", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall, we would have wished for more specificity on the data that was reported.\u00a0 There were glimpses of specifity, as when the story reported:\u00a0\"The latest study does suggest that some subgroups of women might benefit from fish-oil supplements. For instance, those with a history of clinical depression\u2014and thus are at higher risk of post-partum depression\u2014who took 800 milligrams of fish oil daily lowered their risk of getting depressed after the birth by about 4% compared with those who didn\u2019t take fish oil. However, the difference wasn\u2019t statistically significant because of the small number of women in the study who had been previously depressed, said Dr. Makrides, who is also a professor of human nutrition at the University of Adelaide.\"\nBut we were disappointed that the story didn\u2019t disclose how much preterm birth risk was reduced \u2013 an issue of vital concern to many readers. A preemie and an induction (covered as a harm but also without any numbers provided) aren\u2019t necessarily equal.\u00a0\u00a0 \nOn balance, we just didn\u2019t get enough data on benefits. ", "answer": 0}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nIt is noteworthy that this randomized clinical trial was not designed to enroll a sufficient number of patients to definitively and prospectively address the subject of the analysis reported herein.\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nMeaning The results of this secondary subset analysis reveal a possible cetuximab-related benefit in laryngeal preservation.\nThese studies30,31 demonstrate the importance of reviewing options and potential adverse effects with patients before making a decision regarding the best treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release addresses three benefits, and provides numbers for all three. That\u2019s good. However, the release doesn\u2019t tell readers that these numbers, given the size and nature of the study, are not statistically significant. There appears to be no advantage in taking a drug that is both costly and can cause significant adverse side effects.", "answer": 0}, {"article": "One week after surgery I was off the crutches, walking on my own,\" Wallace said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\nHowever, subchondroplasty is only feasible in a narrow range of patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond serving as a \u201cless invasive,\u201d outpatient alternative to joint replacement surgery, there was no discussion about how to quantify these benefits.", "answer": 0}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\n\u201cTo see these kind of outcomes, where you have high response rates in the short term and then good remission rates out toward five or six months of therapy, it shows unequivocally that the drug is effective for treating Crohn\u2019s disease,\u201d said Dr. William Sandborn, the study\u2019s lead investigator, who presented the data at the Digestive Disease Week meeting in Chicago on Sunday.\nPatients in the study on average started at 320 or 325 on the CDAI scale, researchers said.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nClinical remission was defined as a CDAI score down to 150.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study presented lots of numbers and defined the scales. We appreciated the Crohn\u2019s Disease Activity Index (CDAI) thresholds for clinical response and remission, the subjects\u2019 baseline CDAI scores, and the explanation of what a 100-point drop feels like to patients. Bravo for including these points and for mentioning that the study met its \u2018primary goal.\u2019 Great facts for readers to consider that are often left out of news coverage.", "answer": 1}, {"article": "\"So I feel like that touches a nerve with them.\"\nOne limitation of this new study is that it relies on data from women who had to recall what they ate during high school.\n\"This is a really important study ... [suggesting] that the more fiber you eat during your high school years, the lower your risk is in developing breast cancer,\" says Kimberly Blackwell, a breast cancer specialist at the Duke Cancer Center.\n\"Unfortunately for teenagers, they're [into] instant gratification,\" and they're not necessarily focused on how their actions today will influence their future health, she says.\nFor the women on the high-fiber diet, the lifetime risk of developing breast cancer was also cut by 16 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We recognize that it would be challenging for any journalist covering this story to report on the absolute risks seen in the study. The study does not report absolute risks, although it\u2019s possible to calculate them based on the data provided. One could look at the\u00a0number of cases in each quintile of dietary fiber (found in Table 2) and divide that by the number of people in each quintile (which is found in Table 1). There are several steps involved, but for the example of early adulthood dietary fiber and breast cancer risk in this cohort, you could do the following calculation:\n\u2013 613 cases in quintile 1 / 18,364 women in quintile 1 = 3.3% later developed breast cancer (pre or post menopause).\n\u2013 567 cases in quintile 5/ 18,167 women in quintile 5 = 3.1% later developed breast cancer (pre or post menopause).\n\u2013 The difference is 0.2 percentage point, which is quite a small absolute risk reduction.\nWhen such results aren\u2019t reported in a study, we think journalists should press their sources to provide these numbers so that they can be disseminated to the public. The issue of absolute risk reduction is key to helping readers understand the impact of changing dietary behaviors. We think it\u2019s important enough to rate any story Not Satisfactory when these numbers aren\u2019t provided.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nThe generational loss of this good bacteria in the infant gut allows for potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\n\"The ability to quickly measure levels of Bifidobacterium in a stool sample would enable pediatricians to identify babies with low levels of these beneficial bacteria and take appropriate action.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Testing a baby\u2019s stool for Bifidobacterium is presumably beneficial, according to the release, because not having low levels may allow \u201cfor potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\u201d Likewise, the release implies taking the Evivo probiotic product can \u201creduce potentially harmful bacteria by 80 percent.\u201d\nBut these statements and figures are inadequate. There is not yet definitive, causal evidence that Bifidobacterium can prevent\u00a0\u201charmful\u201d bacteria from overtaking the gut and causing health problems. Both studies intimate as much by highlighting the findings are correlations, and that long-term longitudinal studies are required.\nIt\u2019s misleading to claim a benefit from testing when there is no causal link to harm in people.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article does an estimable job of describing the benefit of bystander CPR \u00a0on a select few very lucky survivors, it doesn\u2019t talk about the rates of success of various types of CPR or alternatives such as the solo or combined use of AEDs now available in many public spaces. The story says that survival rates \u201cmore than double\u201d with the use of bystander CPR, but there\u2019s no context provided with that statistic. What is the rate without CPR and what does it \u201cdouble\u201d to? The benefits are described primarily in emotional terms; we wanted to see that emotion supplemented with facts.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter does a diligent job of quantifying the results, using both relative risks and percentage of bad outcomes in the studied population. \nThe story usefully distinguishes among results for c-sections done at 37, 38 and 39 weeks.\n\u00a0", "answer": 1}, {"article": "For more on medical marijuana, visit the U.S. National Institute on Drug Abuse.\nAlmost half experienced a 50 percent or greater reduction in seizures, and about one of every 10 patients became seizure-free, the study found.\nThe study found that after a year, the treatment resulted in a 50 percent reduction in seizures for 10 participants -- about 40 percent of the group.\nBut experts say these positive findings may have been influenced by a \"placebo effect.\"\nOne child remained seizure-free, but 12 of the initial participants dropped out of the study because the cannabidiol didn't seem to do them any good.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is fairly specific about the fates of two groups of individuals\u2014mostly children\u2014with epileptic seizures resistant to\u00a0available medications. But since it uses only relative risk reduction figures to quantify the benefit, it doesn\u2019t go far enough to satisfy this criterion. The story says, for example, that \u201cseizure frequency declined by an average 45 percent in all participants.\u201d Did they go from two seizures to one seizure per day or from 10 to 5? Providing the absolute numbers would have clarified the size of the benefit.", "answer": 0}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\n\"We also know that in patients who receive stimulation there is an increase in glucose utilization in memory areas of the brain,\" he says, a finding that could mean there's a way to overcome some of the damage from Alzheimer's.\nIf the approach pans out, it could provide options for patients with fading cognition and retrieve vanished memories.\nIn terms of efficacy, however, after one year there were no significant differences in cognition between the groups, as measured by two scales commonly used to measure Alzheimer's disease symptoms, the ADAS-Cog and CDR-SB.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s unclear what if any benefit DBS might offer for Alzheimer\u2019s patients, a point that could have been made more explicitly. There were no quantified benefits included, instead the story states that results for the phase 2 study were \u201cmixed but encouraging.\u201d It does not explain that the trial was aimed at determining only the 90-day postoperative safety of the procedure, not its efficacy, and that it included only patients with mild Alzheimer\u2019s. It further states that after one year there \u201cwere no significant differences in cognition\u201d between the treatment groups, but differences \u201cmay take time to become noticeable\u201d because the disease progresses slowly.\nWhile some researchers hope DBS might be able to slow progress of the disease, the story suggests it might actually reverse memory loss. It likens DBS to \u201cretrieving memories by hot-wiring the brain\u201d and leads with an anecdote about a 63-year-old women with Alzheimer\u2019s who retrieved a latent childhood memory as a result of deep brain stimulation, though apparently under a \u201clofty voltage\u201d only safely achievable in a hospital. The story states that a finding of increased glucose utilization in patients who have received brain stimulation \u201ccould mean there\u2019s a way to overcome some of the damage from Alzheimer\u2019s.\u201d Given there was no clinical correlation, it doesn\u2019t seem relevant, and we\u2019re not sure why it was included as a sign of benefit.", "answer": 0}, {"article": "NeuroVision was formed in 2010 and is headquartered in Sacramento, California.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\n\"In 2010, our research group published an article providing the first evidence for the existence of Alzheimer's-specific plaques in the human retina, and we demonstrated the ability to detect individual plaques in live mouse models using a modified ophthalmic device.\"\nAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina.\nFindings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease,\" said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai, and a co-founder, inventor and scientist at NeuroVision.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In a news release of more than 1,000 words, we would expect some data to back things up. Instead, this release offers just two numbers by way of quantification, and both of them are couched in relative terms that, to any reader other than the authors of the study, may be meaningless. The release says:\n\u201cAmong key findings, the researchers report a 4.7-fold increase in retinal plaque burden in patients with Alzheimer\u2019s, compared to controls, and they provide observations regarding geometric distribution and layer location of amyloid pathology in the retina. \u2026 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer\u2019s, compared with controls.\u201d\nIn a study that compared the brains of 23 deceased people with Alzheimer\u2019s to 13 people without, what do these numbers mean?\nBecause the research is very preliminary, and given there is no treatment for Alzheimer\u2019s pathology and most people with dementia who are in their 80s have multiple cognitive issues, it\u2019s difficult to see how identifying amyloid \u2014 or even multiple types of pathology \u2014 is going to benefit patients.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Francisco Ponce, MD, Director of the Barrow Center for Neuromodulation, believes there are potential applications for Alzheimer's disease - the most common form of dementia - as well.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release summarizes a stage 2 trial looking primarily at safety following the first 90 days of the trial. It did not report on whether or not the device implantation improved cognition or slowed or halted decline. The news release says Dr. Ponce will report on potential efficacy after the last patient finishes two years of the study. The release was appropriately mum on this point and didn\u2019t make predictions/guesses based on incomplete and preliminary data.", "answer": 2}, {"article": "What to do?\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the US Preventive Services Task Force recommends the screening test for women without other risk factors beginning at age 65. And it provides some statistics to document the possible overuse of scanning in younger women and underuse in older women. That\u2019s all good reporting. But what\u2019s missing is why the reader should care about these numbers. The story does not say that drugs are available that can reduce the risk of fracture among those at high risk. It wouldn\u2019t have take much space or many words to deliver that important context.\nWe\u2019re also a little concerned about how some of the findings are framed by the story\u2013 for example, the fact that certain risk factors \u201chad only a slight effect on a woman\u2019s decision to get her bones tested.\u201d \u00a0That sounds a little bit like the women are being blamed for the inappropriate testing found in this study. While it is probably true that patient demand drives some inappropriate bone density testing in younger women, the majority of screening decisions are likely to be made by the physician, not the woman.", "answer": 0}, {"article": "It's very, very specific.\"\nIf those studies prove to be successful, human testing could be next.\n(CNN) Finding ways to fight the flu just got a tad more ribbeting -- that is, if you ask some researchers who have turned their attention to frogs.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nFerrets are next, then possibly humans\n\nA challenge to possibly using frog mucus as a flu-fighting treatment in humans is figuring out how to get the urumin peptide to attach to flu virus cells in the human body, Jacob said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call. The story reports that the peptide killed all of the H1 versions of the influenza A virus that it encountered in laboratory settings. And the text\u00a0sends up a cautionary flag early in the story that the peptide has not yet been tested in human beings. In fact, the next step appears to be testing in ferrets.\nBut, it doesn\u2019t really say\u00a0much about the mice research. How did they determine that it worked? Did it clear infections? We were somewhat unclear on that aspect of the story.\nAgain, though, because the story didn\u2019t oversell the findings, we\u2019re leaning toward Satisfactory.", "answer": 1}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nTo investigate, a tem led by Giovanni Strippoli, MD, PhD (University of Bari, in Italy and Diaverum, in Sweden), and Jaimon Kelly (Bond University, in Australia) analyzed the medical literature, finding 7 relevant studies that included a total of 15,285 participants.\n\u201cChronic kidney disease now affects about 10% to 13% of the adult population and substantially increases risks of cardiovascular complications and early death,\u201d said Prof. Strippoli.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does provide some numbers around the benefits, but they are mostly in relative terms, not allowing reporters or other readers to assess how many people really ended up benefiting from the healthy diets. It says, for example,\u00a0\u201cIn 6 studies, healthy dietary patterns were consistently associated with a 20% to 30% lower rate of mortality, with 46 fewer deaths per 1000 people over 5 years.\u201d It\u2019s hard to understand from this sentence what this means. If it is a range from 20% to 30% lower mortality rates, does this mean that \u201c46 fewer deaths per 1,000 people\u201d is the average reduction in mortality? And this is 46 fewer deaths than what? Than 100? Than 900? Precision would have helped here.", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nOne expert who's done her own research in this area applauded the study.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not addressed \u2013 and this ties in to our comments in the \u201charms\u201d criterion above.\u00a0 You don\u2019t test unless you know what good it will do.\u00a0 And the story is silent on that potential benefit. It just raises the picture of more testing without any discussion of benefit.", "answer": 0}, {"article": "McCabe, medical director for the March of Dimes.\nTaking folic acid before pregnancy, and through the first several weeks of pregnancy, may help reduce the risk of autism for those children, according to a new study published Tuesday in the Journal of the American Medical Association (JAMA).\n\"It is possible that folic acid ... might provide protection against other neurodevelopmental disorders like autism,\" said Zachary Warren, director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University, who was also not involved in the study.\nResearchers in Norway looked at data from 85,000 pregnancies, and found that women who took the supplement four weeks before pregnancy, and through the eighth week of pregnancy, were 39% less likely to have children with autism.\nThe same dose appears to provide some benefit in preventing autism, according to the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says women who took folic acid \u201cwere 39% less likely to have children with autism.\u201d This is inadequate, because it doesn\u2019t reflect just how rare a diagnosis of autism was in this study. (Only 114 children out of about 85,000 received that diagnosis.) The findings in absolute terms would have been more informative, as they show that autism was diagnosed in\u00a00.10% of children whose mothers took folic acid compared with\u00a00.21% of children whose mothers didn\u2019t.", "answer": 0}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nThis study looked at people who had never had a clinical stroke, but may have had smaller strokes that went unnoticed.\nThe people involved in the brain infarcts study are a subset of that original group.\nIt is complicated in general to compare the benefits of a particular diet with the benefits of not following a different food regimen.\nIt would be easier for people to focus on adding particular elements to their diets -- for example, by taking fish oil capsules -- rather than trying to readjust their eating habits altogether.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story specified that those following a Mediterranean diet were \u201836% less likely to have areas of brain damage\u2019. \u00a0This is an inadequate presentation of information because the reader has no sense of how common the thing prevented might be (36% of what?) and also how well this measurement of brain damage correlates with a clinical parameter of concern to real people. There can be a difference between being able to find something and whether that something has significance in people\u2019s lives. ", "answer": 0}, {"article": "Major tobacco players such as Altria Group and British American Tobacco are grappling with sales declines in the U.S. market and hoping to recoup revenue through novel tobacco and nicotine products such as e-cigarettes.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nGottlieb said the FDA was also seeking public opinion on whether a product standard should be implemented all at once or gradually.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story informed readers that the FDA\u2019s own analysis predicts \u201cwould help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers\u00a0by the year 2100.\u201d We think more could have said about the data this was based, but we address that below, in evidence quality.", "answer": 1}, {"article": "D.C.I.S.\nAnother issue is that the message from the cancer institute seemed to play down a shortcoming of raloxifene that cancer doctors consider important.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\nBased on those findings, it is easy to see why raloxifene was declared the winner.\nOn average, the participants actually had more than twice that risk, around 4 percent, meaning that 40 of 1,000 would be affected.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a very good job of quantifying the benefits of raloxifene compared to tamoxifen. Not only did the story provide absolute numbers in quantifying the benefit, but it also explained why presenting only relative risk reductions can be deceiving.", "answer": 1}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\n\"The children that received the interventions normal in their communities continued to show the reversed pattern.\"\n\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nJust the reverse happens in children with autism.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes a bold claim in the lead: \u201cEarly, intensive autism treatment improves children\u2019s brain development, a new study shows.\u201d It does not go on to quantify the benefits found in the study. How many of the kids showed brain improvement? And how was that improvement measured? The story provided only the qualitative description\u00a0\u201cThe [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\u201d Dawson says. \u201cThe children that received the interventions normal in their communities continued to show the reversed pattern.\u201d\nIn addition, we don\u2019t know the clinical significance of a change in EEG.", "answer": 0}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story uses numbers (447 cognitively healthy participants divided among three groups) to describe the participants but doesn\u2019t quantify the findings related to the Mediterranean diet with similar precision. Instead it provides this summary: \u201cThe results showed that, compared with the control group, memory function remained stronger in the Mediterranean diet plus nuts group, while frontal (attention and executive function) and global cognition benefited in the Mediterranean diet plus olive oil group.\u201d\nHow much stronger? How did the investigators reach that conclusion?\nNumbers are always welcome. And yet in this case, we\u2019re not sure how much it would\u2019ve added for readers to know the change in \u201ccognitive composite Z scores\u201d that were reported in the study. These certainly could\u2019ve been explained and quantified, but we think it was acceptable for the story to turn to a\u00a0Mayo Clinic neuropsychologist for interpretation instead. That expert tells us, \u201cThe changes observed in cognition were very small and didn\u2019t actually show that those diets improved cognition, they just showed less decline.\u201d We\u2019ll call that good enough for a Satisfactory rating.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nYet there was only a slight drop in deaths from the condition over the same period, suggesting many of the clots were too small to cause harm.\nBut with increasingly sophisticated tools, doctors may be spotting clots that would never have been fatal in the first place.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story succinctly summarized:", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nAnd according to the new study, it helps.\nDec. 14, 2011 -- It can be an all too common scenario for certain stroke survivors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that patients receiving TMS improved \u201c16.3% immediately following treatment and by 22.6% two weeks later.\u201d Fair enough. But it didn\u2019t tell us whether that type of improvement represents a meaningful change in patients\u2019 ability to function and care for themselves. Reuters, by contrast, cautioned that \u201cit\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\u201d\nWe were also confused by this story\u2019s use of the\u00a0word \u201cneglect\u201d without defining what the term means clinically. Better to leave it out entirely or give a complete explanation of the meaning, as Reuters did. ", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are quantified in relative terms only. The reader is told that raloxifene and tamoxifen both reduce the incidence of breast cancer by 50%, however there is no context provided for these numbers. Viewers would want to know 50% of what? They would want to know the absolute risk reduction. Viewers should have been told that even though the women in the study were high risk, the incidence of breast cancer over 5 years was still very low. The story also does not mention that raloxifene does not reduce the incidence of ductal carcinoma in situ (DCIS, which tamoxifen does), so it is not clear that when the story says the benefits are equivalent between the two drugs, if it will hold true if they include all breast cancer events (including DCIS, which is being found much more commonly now).The story also omits an important fact: the decrease in incidence of uterine cancer and clots associated with raloxifene was not statistically significant.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Let\u2019s look at appropriate use as the \u201cbenefit\u201d here \u2013 and, yes, the story quantified this \u2013 and the inappropriate use.", "answer": 1}, {"article": "See original publication for details.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nThe second group received RANKL blockade treatment for prevention with the result that virtually no malignant changes in breast tissue could be observed even over a longer period of observation.\nIf the uncovered mechanism indeed works in the prevention of breast cancer in high risk patients, this could possibly be used to prevent breast cancer in general.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the release states that the cell cultures receiving the RANKL blockade treatment had \u201csignificant reduction of growth and spreading of breast tissue cells\u201d and \u201cvirtually no malignant changes in breast tissue\u201d compared to those in the control group that developed multiple early breast cancer lesions. But no hard numbers or percentages are provided to quantify what a \u201csignificant reduction\u201d is or what \u201cvirtually\u201d means in this case.\nWe also want to underscore that the results were only seen in cell cultures and in mice, not in humans.", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It presents the benefits in both relative and absolute terms in the second paragraph of the story. It would be nice to have a NNT or number needed to treat in here. It also would be nice to see the range of performance after using the drug. Did some of the men on placebo have gains in ejaculation time that were unusually high? Did some on the drug have no gain or even a loss of time? It\u2019s also not clear how the researchers knew what the \"no drug\" ejaculation time was, how they were chosen for the research or whether they fell into a particular age bracket. The story did a \"satisfactory\" job quantifying the benefits, not a perfect job. And in an imperfect world of health stories, this part of the story was actually above average.", "answer": 1}, {"article": "and some .\nBut she says questions remain about how long the effects last and how often a patient should return for additional sessions.\n\u201cThe majority of studies that evaluated rTMS failed to find evidence of an enduring treatment effect after the initial response .\nThere\u2019s a huge range in my clinical experience.\u201d Carpenter, a physician, says research has not found any safety issues for patients returning for additional treatments, but cost is a factor.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The use of statistics in this piece was generally appropriate, and we were pleased to see reference to the Number Needed to Treat \u2014 an intuitive measure of a treatment\u2019s real world effectiveness. If there\u2019s one area in which we think the story could have done a better job, it\u2019s explaining that the benefits reported with rTMS, though larger than those associated with a placebo/sham treatment, are small in absolute terms. This could have been accomplished with less optimistic framing of certain study results. For example, the story notes that \u201cup to 17 percent of patients\u201d were symptom free after treatment in one study \u2014 \u201cabout twice as many as those treated with a sham rTMS machine.\u201d The story could have qualified this by adding that the vast majority of even rTMS-treated patients (83%) were not symptom-free. In another study, rTMS was \u201cfour times as likely to get patients symptom-free as was a sham procedure,\u201d according to the story. But again, the absolute number of patients who benefited was very small \u2014 \u00a0\u00a014.1% for active rTMS vs. 5.1% for the sham group. The authors of that study concluded that \u201c\u2026the overall number of remitters and responders was less than one would like with a treatment that requires daily intervention for 3 weeks or more, even with a benign adverse effect profile.\u201d\nNote: the AHRQ review referenced in the story concludes that the evidence in insufficient to determine the effects of ECT vs rTMS but the limited evidence suggest no difference.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes note of quantitative results related to tumor shrinkage, as well as remission data\u00a0six months\u00a0after treatment. It\u00a0also pointed out\u00a0that median survival in the study is not known.\nThere is one anecdotal quote by a patient who was facing potential stem cell transplant, but opted for\u00a0CAR-T therapy, and went into complete remission and saw his tumors \u201cshrink like ice cubes.\u201d", "answer": 1}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nThe theory behind trying DBS for Alzheimer's patients, Scharre said, is similar to the \"use it or lose it\" principle: If key brain areas can be stimulated to form new connections among cells, it might slow decline.\nOn a broader level, he noted, this study highlights an important point: \"Alzheimer's disease is more than just amnesia.\"\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study wasn\u2019t designed to prove a benefit, although the story could have explained that more clearly. We\u2019re rating this Not Satisfactory because it confuses readers with a headline stating the device \u201cmight help slow Alzheimer\u2019s,\u201d while the story itself focuses on the clinical outcomes of the three patients in the study, citing \u201csignals\u201d that the device slowed two patients\u2019 decline, for example. The fact that two of the three patients declined at slower rate compared to 96 patients in a database doesn\u2019t say anything about whether the device is really effective. Even so, there\u2019s no specific data on how those patients\u2019 outcomes differed and what was measured.", "answer": 0}, {"article": "Honey is also known to have antioxidant and antimicrobial properties.\nNatural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story could have provided some of the specific differences between the treatments. Our guess is that with a study on only 100 patients, the absolute differences were probably not that large. Putting some more numbers in the story would help parents see the results in better context.", "answer": 0}, {"article": "\"And in that case, I see this as just a waste of money.\"\nThese so-called \"hot spots\" are central to motor function, attention, facial recognition and social behavior -- types of behaviors that are abnormal in people with autism.\nThe authors also noted that apart from an increased brain size among children diagnosed with autism, there are no apparent structural differences between the brains of autistic patients and patients who are not autistic.\nThis tissue, the authors noted, is known to play a role in communication between various brain regions.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not quantified. The implication here is that these physical defecits are only found in patients with autism and are never found in patients with \"normal\" brains or with any other disorders. This, of course, is difficult to conclude based on a study of 80 patients.", "answer": 0}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nShe found that the group that did speed training showed 33 percent less risk of dementia relative to the control group, while the memory and the reasoning interventions offered no such benefit.\nResults of that study, published in 2014, found modest benefits in the reasoning and speed-of-processing groups, but not memory.\nPeople who completed 11 or more speed training sessions were at 48 percent less risk for developing dementia over the 10 years of the study, Edwards said.\nEdwards did a secondary analysis of the 10-year data, looking at the time it took individuals to develop dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After an initial analysis revealed lukewarm associations between brain games and various cognitive functions, a secondary analysis was undertaken whose findings are reported in this article. Study participants were divided into three groups who received training for either memory improvement, reasoning, or\u00a0speed-of-processing.\u00a0The findings of the secondary analysis reveal that\n\u201cspeed training showed 33 percent less risk of dementia relative to the control group, while the memory and the reasoning interventions offered no such benefit.\u201d\nand that\n\u201cpeople who completed 11 or more speed training sessions were at 48 percent less risk for developing dementia over the 10 years of the study\u201d\nBut these are relative risk reductions, and the readers has no way to judge the magnitude of the benefit in absolute terms. A competing STAT story, by contrast, gave us the figures we were looking for:\n14 percent of ACTIVE participants who received no training had dementia 10 years later, said psychologist Jerri Edwards of the University of South Florida, who led the study. Among those who completed up to 10 60-to-75-minute sessions of computer-based training in speed-of-processing \u2014 basically, how quickly and accurately they can pay attention to, process, and remember brief images on a computer screen \u2014 12.1 percent developed dementia. Of those who completed all 10 initial training sessions plus four booster sessions a few years later, 8.2 percent developed dementia.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addresses two major advantages to Counsyl\u2019s test \u2013 the fact that it much cheaper and much easier. On the latter point, previous genetic tests typically covered a single disease and required a blood sample. Counsyl\u2019s new method covers about 100 disorders, as mentioned above, with a saliva test. But the\u00a0focus\u00a0should have been expanded beyond mere\u00a0convenience.\u00a0Does this test\u00a0improve the quality of life for \"families at risk for conceiving children with familial diseases\"? No evidence is presented suggesting that it does. Does the test \"significantly reduce, and possibly eliminate, hereditary diseases\"? No evidence is presented suggesting that it does.", "answer": 0}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\nThe benefits of allergy shots, by contrast, have been shown to persist for 10 years or beyond, Nelson noted.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story only presents the benefits of therapy in terms of relative risk compared with placebo, rather than absolute risk.\u00a0 The reader is not given any information about what a 20% reduction in symptoms would mean for them. The benefit may be statistically significant, but is it clinically significant? The story should have also reported that the same benefit was not seen in children.\n", "answer": 0}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThe U.S. National Women's Health Information Center has more about treating menopause symptoms.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only stated that women who got acupuncture \u201chad significantly less severe hot flashes and mood swings.\u201d What does that mean?\u00a0 How was it measured?", "answer": 0}, {"article": "The American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\nIn a controlled study composed of HIV-positive adolescents, participants who received massage therapy showed enhanced immune function by the end of the 12-week study.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release cited three studies, but descriptions of the research were too vague to be helpful.\u00a0 Readers aren\u2019t given any benefit data or any quantitative estimate on how well massage therapy actually works. We don\u2019t know how many participants were in each trial and who actually benefited from massage therapy. The release alludes to the fact several times that the immune system became stronger, but how was this measured? There are also non-specific references to the benefits of massage therapy, such as increasing the activity of white blood cells and reducing anxiety levels, but again, we don\u2019t know who actually benefited and by how much.\nWhen we looked at the studies cited we were surprised to find that none of them related to massage therapy for reducing rates of the \u201ccommon cold, flu and other seasonal illnesses,\u201d as claimed in the release.\nThe first study was from 2010 and is described by its authors as \u201cpreliminary\u201d work that looks at a \u201csingle-session comparison of Swedish Massage Therapy with a light touch control condition\u201d measuring \u00a0\u201cOxytocin (OT), arginine-vasopressin (AVP), adrenal corticotropin hormone (ACTH), cortisol (CORT), circulating phenotypic lymphocytes markers, and mitogen-stimulated cytokine production.\u201d\u00a0 This study is far removed from patient-oriented, or even disease-oriented outcomes, and has nothing to do with their sweeping comments that massage may fend off flu and the common cold.\nThe second study (from 2001) involved 12 HIV patients. It\u2019s hard to see how the results from this study translate to healthy individuals seeking relief from seasonal colds and flu. The third study (from 2004) enrolled 34 women with breast cancer whose outcomes following massage were \u201creduced anxiety, depressed mood, and anger. The longer term massage effects included reduced depression and hostility and increased urinary dopamine, serotonin values, NK cell number, and lymphocytes.\u201d Again, this study does not provide evidence for the news release\u2019s claims.", "answer": 0}, {"article": "47(5) pp.\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\nSix months after the balloons were removed, 89.5 percent of the average total weight lost during the treatment period was maintained.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We will give the release a satisfactory rating because it notes that after one year patients receiving the Obalon balloon and counseling had lost about 7 percent of their total body weight (or about a quarter of their \u201cexcess\u201d weight) compared to a bit less than 4 percent total weight loss for those given a sham balloon and counseling. However, since other intragastric balloons are already on the market, most people would want to know how the Obalon device compares. The release should have noted that because the trial did not include competing devices, there is no evidence that indicates whether the new device is any better or worse than other devices.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nNot all EKG readings are abnormal during a heart attack, Chaparro explained.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nA more sensitive test could save a lot of money, she noted.\nAnother measure, specificity, rules in disease with a high degree of confidence.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Explaining sensitivity, specificity and negative predictive value is admittedly a task in and of itself.\u00a0 But the difficulty in explaining the concepts and applying them to the results of a study does not exempt a story from trying.\u00a0 The story only referred to the new test being \u201cmore predictive than other biomarkers\u201d or \u201cmore sensitive than the existing one.\u201d But even those relative references weren\u2019t quantified.\u00a0 No sense of the scale of improvement of was provided. That\u2019s not helpful.", "answer": 0}, {"article": ".\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nIn the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nLOS ANGELES, Jan. 25, 2018 -- Clot removal may be beneficial up to 24 hours following stroke in carefully selected patients, but every hour delayed after symptoms begin may be associated with more disability, according to preliminary research presented at the American Stroke Association's International Stroke Conference 2018, a world premier meeting dedicated to the science and treatment of cerebrovascular disease for researchers and clinicians.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release describes benefits in terms of relative risk, not absolute risk numbers. Each one-hour delay of treatment, they wrote, reduces the chance of recovery with minimal damage by 11%. Furthermore, patients who had their clots removed were 35.5% more likely to have minimal disability in the future. This was helpful, but it would be more informative to tell us how many patients had clots removed and what their outcomes were.\nIt also should have been emphasized that not all stroke patients are eligible for the procedure after 6 hours; according to the updated recommendations from the American Heart Association (AHA) and the American Stroke Association (ASA), only patients with a blood clot in a specific area of the brain, who have clinical symptoms that are disproportionate to the size of the stroke, are eligible for treatment after 6 hours.", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was careful to explicitly describe the modest advantage of Botox over placebo injections\u2014in terms of the absolute number of headache days associated with each intervention.", "answer": 1}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nThere are varying amounts of proof supporting the effectiveness of each, and each method has its advantages and limitations, the panelists said.\n\"There are multiple screening options for colorectal cancer that reduce the risk of dying from the disease.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nWEDNESDAY, June 15, 2016 (HealthDay News) -- Reiterating a recommendation last made in 2008, an influential U.S. panel of health experts is advocating that regular colon cancer screening begin at age 50 and continue until at least age 75.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the different colon cancer screening methods. While we\u2019re sympathetic to the challenges of doing so on deadline\u2013especially when the task force went out of its way to not cover this ground\u2013this nonetheless should have been included.\u00a0The effectiveness of different screening tests differ, as well as the quality of that evidence, and readers would welcome knowing these differences in quantified terms.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The JAMA study is silent on whether BMP \"works\"\u2013which is to say, whether BMP improves outcomes, quality of life, morbidity or mortality.\u00a0\nNo harm in that: This piece of research is designed to look only at prevalence, complications and costs.\nBut the news story\u2019s shorthand conclusions\u2013that the surgery is common, costly and linked to certain complications\u2013begs the question of whether better outcomes outweigh those negatives. It\u2019s hard to imagine what kind of reader would not want to know the answer.\u00a0 \nCertainly at least some comparative outcome data exists. [Or if not, then that is worth mentioning.] The reporter didn\u2019t even mention the issue.\u00a0 \u00a0 ", "answer": 0}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nA 75-year-old Connecticut man said he had the test because he was healthy and wanted to stay that way.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\nAnd doctors, he added, have many inducements to screen.\nScreening, he added, \u201cis promoted by hospitals and industry.\u201d And, he added, \u201cmany patients demand it.\u201d\n\nDr. Brooks of the cancer society says he travels the country and talks to primary care doctors about screening, and has learned that many have misconceptions about the test\u2019s benefits.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention a \u201cNational Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years\u201d", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nAnd they are already moving forward with new clinical studies using 10-1074 together with 3BNC117, with the hope that combining two antibodies targeting different parts of HIV will be more effective than either antibody on its own.\nThe majority of the people in the trial were enrolled at The Rockefeller University Hospital, while some of the HIV-1 infected participants received the antibody at the University of Cologne, in Germany.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release could do a better job of explaining that this is a very limited study looking primarily at safety. There are no meaningful clinical outcomes reported.\nWhen the release states \u201camong 13 HIV-infected people who received the highest dose of 10-1074, 11 showed a rapid decline in the amount of virus\u201d \u2014 we need to know what that means. What is rapidity and how is it important? Is it relevant to patients that the trial drug was \u201csensitive to other broadly neutralizing antibodies, including 3BNC117?\u201d What does this mean?", "answer": 0}, {"article": "The men were assigned to receive either placebo treatments or daily 0.5-milligram doses of Avodart for four years.\n\"We now have two studies showing that two different drugs in this category can reduce the overall risk of prostate cancer,\" American Cancer Society Director of Prostate and Colorectal Cancers Durado Brooks, MD, tells WebMD.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\nIn a trial involving more than 8,000 men from 42 countries, those who took the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer over four years of treatment, compared to men who did not take the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the potential benefits of Avodart in both relative and absolute terms. (However, we wish the absolute data had been described more clearly and with more emphasis.)\u00a0 First, the story describes the benefits in relative terms by stating that Avodart reduced the chance of developing prostate cancer by 23% in men with an elevated PSA but no prostate cancer on biopsy. Then it provides the same information in absolute terms by describing the incidence of cancer as 20% in the Avodart group and 25% in the placebo group. These two sets of numbers provide different perspective on the potential benefits of the drug.", "answer": 1}, {"article": "Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nThe findings suggest that for most people with prediabetes, a diet rich with vegetables fruits and wholegrains should be recommended for weight loss and could potentially improve diabetes markers.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe study, \"Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials,\" found that fasting blood sugar and/or fasting insulin can be used to select the optimal diet and to predict weight loss, particularly for people with prediabetes or diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the main claim being made is the value of using biomarkers to personalize a weight loss plan the release should have included some basic facts about how much weight study volunteers lost by following a personalized eating plan. How did their weight loss compare to others not on the personalized plan?\nThe release included some specifics about the meal plans studied. \u201cThe findings suggest that for most people with prediabetes, a diet rich with vegetables fruits and whole grains should be recommended for weight loss and could potentially improve diabetes markers. For people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss. These diets could also be effective independent of caloric restriction.\u201d \u00a0We\u2019d like to see some numbers attached to these claims.", "answer": 0}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately reported on the level of benefit observed in the study it reported on. \u00a0However, the story should have mentioned that the timeframe of the study reported on was 90 days. \u00a0This is of concern to readers who might be evaluating the benefits to be obtained through adherence to the diet.", "answer": 1}, {"article": "This is really a game changer.\"\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nAn earlier PrEP trial, the iPrEx study, looked at treatment in men who have sex with men.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers should have been given a bit more information on actual number of infections seen in the study groups. The story states that infection risk for drug-treated individuals was 63% to 73% lower relative to individuals who received the placebo. However, the story never provides the absolute risk data that are essential to determining the true magnitude of the benefit. Elsewhere, the story states that infection rates were decreased by 78% in those \u201cwho actually got the drugs.\u201d This is a confusing statement. The story should have explained that this was an analysis of outcomes based on participants\u2019\u00a0adherence to the medication regimen; those who\u00a0took the drug more\u00a0regularly were more likely to see a benefit.", "answer": 0}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The closing paragraph of the release claims that the supplement \u201chad slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\u201d\u00a0 However, the opening paragraph of the release goes quite a bit further, stating that \u201cthe supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease\u201d \u2014 a far more definitive claim than the release\u2019s information can substantiate. There\u2019s nothing in this release to suggest that the supplement affects any outcome that matters to patients such as actual heart attacks and strokes.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article opens with a claim that studies show over 75 percent of\u00a0diabetics who get bariatric surgery\u00a0\"see their disease disappear.\" While this sounds like an exaggerated claim,\u00a0it is backed up by two specific citations of remission data from credible journals later in the story.\u00a0 ", "answer": 1}, {"article": "\"I think people should be able to do this as part of their personal hygiene - just like brushing your teeth and taking a shower.\"\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nEarlier research by UT Southwestern cardiologists showed that left ventricular stiffening often shows up in middle age in people who don't exercise and aren't fit, leaving them with small, stiff chambers that can't pump blood as well.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline of the news release claims \u2018Proper exercise can reverse damage from heart aging,\u2019 but the study documents two outcomes: an \u201818% improvement\u2019 in maximal oxygen uptake, and a \u201825% improvement\u2019 in the elasticity of the left ventricle (the chamber primarily responsible for pumping oxygenated blood throughout the body).\n\u201cReversal\u201d implies a return to a previous state of function, but this study merely documents improvement in two cardiovascular outcomes that are commonly seen with regular aerobic exercise. It\u2019s not clear if this change does in fact represent a \u201creversal.\u201d\nIn addition, \u201cdamage from heart aging\u201d is a confusing phrase. Poor oxygen uptake and a loss of heart elasticity are as much a consequence of sedentary lifestyle as they are a result of an aging heart. This is why a headline implying that exercise actually reverses aging in the heart is misleading.\nFinally, the first paragraph of the release claims that exercise can help prevent the risk of future heart failure, even though the study itself makes it clear this outcome is speculative. At the very least, the release should have cautioned that a much larger and longer study would be needed to document any impact on heart failure outcomes.", "answer": 0}, {"article": "Medical providers use BMI, the ratio of a person's weight to height, to estimate body fat.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nJust 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states: \u201cBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors. Just 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later. In fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries. The proportion of participants with two or three risk factors also dropped substantially.\u201d\nThis is a useful start,\u00a0but the story needed to remind readers: Changes in risk factors predicated on lab values are surrogate markers, so they may not actually lead to improved \u201cheart health\u201d as the story states.", "answer": 0}, {"article": "In practice, Performance with Purpose means providing a wide range of foods and beverages, from treats to healthy eats; finding innovative ways to minimize our impact on the environment and reduce our operating costs; providing a safe and inclusive workplace for our employees globally; and respecting, supporting and investing in the local communities where we operate.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\nGrams of carbohydrate and total weight of the foods were not significantly different.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release talks about two types of benefits. \u201cSatiety,\u201d meaning how full people felt after eating oatmeal, and how much they actually ate after eating oatmeal. It says, \u201cThe satiety benefits of instant oatmeal alone were important findings,\u201d And it says that \u201cTotal calorie intake was significantly lower following consumption of instant oatmeal compared to the cold cereal.\u201d Neither of these benefits are quantified.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We would have liked to have seen some hard numbers attached to the benefits of these therapies. One of the studies for the foam therapy approach, led by Suman Rathbun, who was quoted in the story, covered 166 patients over a three year period. The results are clearly enumerated in that study and could have been cited here.", "answer": 0}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nDr. Bert Vogelstein, a cancer geneticist at Johns Hopkins University in Baltimore, said Pathway\u2019s figure represents the test\u2019s technical ability to detect DNA in the blood.\nPathway says its test is more than 99 percent accurate in detecting mutations in blood samples that contain at least nine copies of a tested mutation.\nDoctors, however, need an indication of how many patients will get a false positive result, something that can only be determined in a very large clinical trial, said Vogelstein.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a company figure stating that the test \u201cis more than 99 percent accurate in detecting mutations in blood samples that contain at least nine copies of a tested mutation.\u201d\nIt then knocks down that figure with a quote from a researcher who says the statistic represents the test\u2019s \u201ctechnical ability to detect DNA in the blood.\u201d It goes on to state that a large clinical trial would be needed to determine the test\u2019s true accuracy, including false positive and false negative results. But such a study hasn\u2019t yet been done.", "answer": 1}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline calls this drug \u201caggressive.\u201d But the story doesn\u2019t report data on the drug\u2019s response rate, which is the percentage of patients whose tumors shrunk after treatment. Response rate was the basis of the FDA\u2019s approval.\nAccording to FDA, there was a 75% overall response rate across different types of solid tumors, with 73% of responses lasting at least six months and 39% lasting a year or more.\nReaders are not told that there is no evidence to show patients who get this drug actually live longer or have a better quality of life than those who don\u2019t get it. (More on this under the quality of evidence rating, below.)", "answer": 0}, {"article": "I had some minor side-effects for a few weeks after the operation, but I'm back to normal now.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThis means we could accurately identify men who would benefit from VTP and deliver treatment more precisely to the tumour.\n\"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up.\n\"We can now pinpoint prostate cancers using MRI scans and targeted biopsies, allowing a much more targeted approach to diagnosis and treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the study found that 49% of patients treated with VTP went into \u201ccomplete remission\u201d compared with 13.5% in the control group. It further states:\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\nWhile it\u2019s good to see some numbers, we have concerns about the \u201cradical therapy\u201d statistic and what it means, which we\u2019ll address below in the \u201cEvidence Quality\u201d criterion.\nWe also call foul on a patient quoted in the release who says. \u201cI\u2019m now cancer-free with no side-effects and don\u2019t have to worry about needing surgery in future.\u201d Unless he has a crystal ball, there\u2019s no way to know with certainty whether he\u2019ll need surgery or not in the future.\nPerhaps the biggest issue, however, is that the outcomes reported in the news release\u2013and the study\u2013are only surrogate markers. They are proxies for the things we care about like length of life and quality of life. The key question\u2013which would take at least a decade to answer\u2013is whether men undergoing initial VTP are less likely to die from prostate cancer than those opting for active surveillance. And the release doesn\u2019t make this clear.\nWe\u2019re also uncomfortable with the release\u2019s description of patients achieving \u201ccomplete remission,\u201d \u00a0a phrase that we\u2019ve never seen used to describe prostate cancer treatments. \u00a0All we know is that these men had no evidence of prostate cancer on repeat biopsy. \u00a0However, biopsies sample only a small portion of the prostate and often miss areas of cancer. Using the phrase \u201ccomplete remission\u201d is likely to give readers a false sense of how beneficial this treatment really is.", "answer": 0}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nOf all patients referred, four-fifths (79%) went on to have dental treatment without the need for sedation and 6% had their dental treatment under sedation.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nThree-quarters of those assessed scored 19 or higher on the Modified Dental Anxiety Scale (MDAS), indicating dental phobia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here is the ability of a patient to receive dental care without sedation \u2014 which carries its own costs and health risks. The release states that 79% of patients who participated in the study \u201cwent on to have dental treatment without the need for sedation.\u201d Only 6% of patients had treatment under sedation. The remaining 15% either dropped out of CBT or were removed from the study because they were identified as having other psychological problems that required treatment. Of the patients who completed the CBT (i.e., didn\u2019t drop out and weren\u2019t removed from the study), 93% went on to have dental treatment without sedation.", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\nUsing his wife's pie pans and what he knew best - radios - Kanzius, a former radio executive, built a machine in his garage that he hoped would zap cancer cells without the horrible side effects you get with chemotherapy and radiation.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nWhen 60 Minutes correspondent Lesley Stahl first met Kanzius, he told us he didn't have a background in science or medicine; he didn't even have a college degree.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nDespite a litany of caveats near the end of the story, the overall portrayal of the Kanzius device as offering potentially revolutionary advantages over conventional treatments is without basis. It is appalling to see Stahl tease the audience by suggesting that John Kanzius\u2019s temporarily improved health might be a result of his self-treatment with radio waves, rather than the expected outcome of conventional chemotherapy. Stahl marveled at the fact that Kanzius\u2019s blood cell counts improved at one point; but since he had been through several rounds of treatment with conventional chemotherapy agents, the improvement should not have been any surprise.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that either dosage of Stelara \u201cshowed clinical remission in significantly more patients, compared with those on placebo, after eight weeks.\u201d But what does that mean? One percent more of patients? Ninety-nine percent more of patients? The story notes that the patients in this study had not responded to available treatment options, and also states that \u201cMore than half of UC patients have not experienced remission with currently available treatment options.\u201d But the story fails to say what percentage of patients who received Stelara experienced remission. (According to a news release, the answer was 15.5 or 15.6 percent, depending on which dosage they received.)", "answer": 0}, {"article": "The I.V.\nSchwartz, though, said the supplements are completely safe.\nA longitudinal study would be needed to back those claims with evidence, she added.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\nAnd despite a lack of sound evidence, experts expect consumers to keep coming back for infusions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story hinges on the lack of benefits, and we think it chose credible sources for questions about that. Besides quoting nutrition researchers Goodstein and Miller, we liked how the story explained the history behind the \u201cMyers\u201d cocktail and links to a review published in an alternative medicine journal. Readers are given their own way to check the credibility of claims of \u201cevidence.\u201d", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits in terms of kilograms lost at six months and twelve months after the FIT/MI intervention. Benefits are also described in terms of centimeters lost from their waist circumference. This information would have been more meaningful if it had provided information about the starting weight and waist circumference for the groups, since that would have shed light on whether one group would find it more difficult to shed kilograms or centimeters.", "answer": 1}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nAverage vaccine coverage among children in the nasal spray group was 76.9 per cent versus 72.3 per cent in the flu shot group.\nThe researchers randomly assigned 1,186 children in 52 Hutterite colonies in Alberta and Saskatchewan, Canada to receive either the nasal spray vaccine or the flu shot and also followed 3,425 community members who did not receive a flu vaccine.\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports similar rates of vaccine uptake for intranasal vaccine and standard flu shots.\u00a0 But it does not quantify benefits for the main outcome of the study, that is, rates of influenza in communities vaccinated with nasal vs injected vaccine over the course of the study.\u00a0 These rates were statistically no different: 5.2% for the standard vs 5.3% for the nasal vaccine.", "answer": 0}, {"article": "All rights reserved.\nNearly 15,000 male doctors who were 50 or older and free of cancer when the study started were given monthly packets of Centrum Silver or fake multivitamins without knowing which type they received.\nFor every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills.\nAfter about 11 years, there were 2,669 new cancers, and some people had cancer more than once.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was very cautious in its framing of the results, quoting a researcher who called the effect \u201cvery mild\u201d and who said he wasn\u2019t sure it\u2019s\u00a0significant enough to recommend to anyone. The story also took the time to explain exactly what the benefit looked like in absolute terms: \u201cAfter about 11 years, there were 2,669 new cancers, and some people had cancer more than once. For every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills. That worked out to an 8% lower risk of developing cancer in the vitamin group.\u201d The competing Reuters coverage didn\u2019t provide these details.", "answer": 1}, {"article": "\u201cThe noise is fairly pleasant; it kind of resembles a rush of water,\u201d says Zee.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\nZee says that the effectiveness of pink noise is all in the timing.\nOn the nights without the noise, memory recall did not improve as much.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us slow wave oscillations increase, but not by how much, or whether the increase is significant. The article is lacking important details around the intervention such as what an increase of slow wave oscillations might mean, say to a sleep wave expert or to an individual with sleep problems.\u00a0Readers also learn that in a memory test taken in the morning, participants did three times better. But there are no details on what the memory test is or even what the \u201cthree times better\u201d is compared to. (To the memory test the evening before? Or to the morning memory test after the no pink noise night?)\nThe absolute number (exact number of patients seeing a measured benefit) would be preferable to the relative number (\u201cperformed three times better\u201d), particularly in a small study like this one, with only 13 participants.\nIn addition, there\u2019s no discussion of how a memory test after sleeping can relate to long-term term memory effects. Improving memory for one day is not likely to be meaningful clinically.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nAs noted in the comments on the quality of the evidence, this story left out essential information about the key published trial data of bronchial thermoplasty. While the story includes several patients telling how much better they feel after treatment, it fails to tell readers that most of the patients in the control group also reported feeling much better after undergoing sham treatment. As the editorial accompanying the journal article on the trial noted, it is crucial to include a comparison with a control group when assessing the overall benefit of this sort of intervention. The story fails to give readers that important context.\nThe story reports that the treated patients were less likely than control group participants to have an asthma attack, go to an ER, or lose work or school days. But not only does the story leave out the absolute improvements, it fails to inform readers that when adverse events related to the treatment itself are included, there was no net benefit seen over the first year. \nOddly, the story leaves out any mention of the primary outcome measure of the key trial: what the patients reported on a standard questionnaire about their asthma-related quality of life. The story should have pointed out that while about four out of five people treated with bronchial thermoplasty reported clinically significant improvement, almost two out of three people given the sham treatment reported similar improvement. Based on the results reported by researchers, about seven asthma patients would have to be treated in order to get one additional person who says he or she has a significantly better quality of life. The story includes only glowing reports from treated patients and thus gives readers a flawed view of the potential benefits.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\n\u201cIf by imaging we could predict the tumor grade,\u201d added Robert Reiter, MD, professor of urology at UCLA, \u201cwe may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d\n\nCo-authors include senior author Anders M. Dale, Hyung W. Choi, Joshua M. Kuperman, Natalie M. Schenker-Ahmed, Hauke Bartsch, Robert F. Mattrey and William G. Bradley, Department of Radiology, UCSD; J. Kellogg Parsons and Michael A. Liss, Department of Urology, UCSD; Ahmed Shabaik, Department of Pathology, UCSD; Jiaoti Huang, Department of Pathology, UCLA; Daniel J. Margolis and Steven S. Raman, Department of Radiology, UCLA; Leonard S. Marks, Department of Urology, UCLA.\nIn a related paper to be published in the journal Frontiers in Oncology, the same team of researchers reported that RSI-MRI appears to predict tumor grade.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release provides no data to justify repeated claims that this technique performs better than existing technology. And we think the release misstates the findings of the study that forms the basis for these claims. For example, the releases talks about the new technology\u2019s ability to find small, localized tumors to guide biopsy. However, the actual study addresses only the ability of the new technology to detect cancers that have extended beyond the prostate. In addition, we found the closing quote from professor Robert Reiter, MD, about the value of the new technology, to be misleading. He says, \u201cIf by imaging we could predict the tumor grade, we may be able to spare some patients from prostate resection and monitor their cancer with imaging.\u201d \u00a0But some patients currently already enjoy the option of watchful waiting. If the biopsy grade, clinical exam, and PSA all indicate a low-risk tumor, then the patient can be offered active surveillance and avoid the need for resection.", "answer": 0}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nThis press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates.\nExtrapolating these data to a conservative estimate of 311,879 patients per year undergoing biopsy resulted in 14,035 life years in full health gained with an annual cost saving of more than $500 million for each cohort.\n\"We believe that this strategy improves the value of conventional risk assessment strategies through improvements in both quality and cost, the numerator and denominator of the health care value equation.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job of explaining the benefits of the SelectMDx test at both individual and societal levels.\u00a0 Those benefits are pretty modest for a patient: a gain of 16 days of health at a cost savings of nearly $1700, on average.\u00a0 But they are impressive when one ramps up to a societal level, given that more than 300,000 patients a year consider undergoing biopsies.\nBut it needs to be recognize that benefits and cost savings are estimated. The authors acknowledged that literature estimates for clinical benefits may not be applicable for the general population and the actual cost savings are uncertain because commercial payment rates are unknown.\n\u00a0", "answer": 1}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\n\"This study addresses the problem of resistance to the mitogen-activated protein kinase [MAPK] pathway.\n\"We found that adding the MEK inhibitor trametinib to BRAF inhibitor dabrafenib clearly delays the emergence of resistance.\nThe study was scheduled for presentation Saturday at the European Society for Medical Oncology meeting in Vienna and simultaneous publication in the New England Journal of Medicine.\nSATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not overhype the findings and uses statistics appropriately, reporting that after one year,\u00a0\u201c41 percent of patients receiving the full-dose combination treatment had no progression of their melanoma, compared with 9 percent of those receiving dabrafenib alone.\u201d\nOf course, this does not tell us whether the drug combination actually prolonged life, and the story does not\u00a0explore or\u00a0explain this important\u00a0nuance.\u00a0This is something we\u2019ll address under the\u00a0Quality of Evidence criterion below.", "answer": 1}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nDr. Richard Page, president of the Heart Rhythm Society, said doctors wonder if they can be held liable if they do not look at all the data.\nPatients whose doctors looked at the data survived 5 to 15 percent longer than patients in earlier clinical trials of the devices, Dr. Saxon reported.\nAnd, in a paper under review, the group reports that their three-year survival was significantly greater than that of patients in the study whose doctors did not see the data.\nDr. Stevenson likened such information to the game of \u201cJeopardy!\u201d \u2014 doctors are given answers in search of a question.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0Information about the potential to increase longevity was presented from a study that has not yet been published. \u00a0The information was presented as a relative increase rather than an absolute increase. \u00a0The story didn\u2019t contain sufficient information to quantify the benefit to any specific group of patients.", "answer": 0}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story repeats the relative risk reduction of major cardiovascular events of 25% that the company provided. But it doesn\u2019t grapple with the vital question: 25% of what? The true size of the benefit depends on the baseline risk of these participants, which is unknown and probably won\u2019t be known until the results are presented at a conference in November. (Read our primer on absolute risk for more information on why this is important.)\nThe story does note that the company is withholding details about the study results for now, but readers should have been clearly alerted to the fact that without knowing how many events occurred or what they were, it is impossible to judge the importance of the results. The study outcome was a combination of cardiovascular disease death, heart attack, stroke, coronary revascularization procedures and hospitalization for unstable angina. The story would have been better if it had alerted readers that based on the sketchy information released by the company, it is impossible to say whether there was an important reduction in deaths, heart attacks or strokes. It could be that much or even all of the reduction was in the number of times patients were hospitalized for chest pain. (Read our primer\u00a0Why you should be careful with composite outcomes in clinical trials\u00a0for more information on why this is important.)", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nThere was photon therapy available in San Francisco, but, in my research, I found out the photon beams don't stop at the tumor and have a greater possibility of affecting surrounding organs, too.\n\"I then determined, definitive radiation therapy was the way to go, but I had to decide which type and where.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not only does the release neglect to offer quantified benefits for context on the effectiveness of proton therapy in treating sacral chordoma in general, it doesn\u2019t even articulate how effective the treatment was in treating the sole patient discussed throughout the release.\u00a0Nor are we told how the patient\u2019s response to the treatment was measured.", "answer": 0}, {"article": "\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\nFluid can back up into the lungs, leaving people short of breath.\nThe findings were presented here at the European Society of Cardiology Congress 2011.\nSpecially developed software divides patients into groups depending on the pattern of molecules detected.\n5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "This aspect needs to be thoroughly explored,\" says Ulrik Dalgas.\nPrior to and following the six-month period, the test subjects had their brains MR-scanned, and the researchers could see that there was a tendency for the brain to shrink less in those patients who undertook resistance training.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nIn the study, the researchers followed 35 people with multiple sclerosis for six months.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No numbers putting the benefits in context are given. Instead, the release uses broad, sweeping language to describe the benefits of resistance training. \u201cThe study shows that resistance training has a number of positive effects on the brain,\u201d it states. Resistance training also \u201cminimizes brain shrinkage in patients already receiving medication,\u201d while some patients saw their brains \u201cgrow in response to training.\u201d\nIn the original journal article, researchers state that 19 out of 74 cortical areas showed absolute increases in thickness, with a mean thickness being 0.03 mm, when comparing absolute values before and after resistance training of all participants. Researchers then compared these cortical areas to changes in muscle strength and motor function by looking at various physical and psychological parameters. Patients in the intervention group had increased knee muscle strength and performed better on a couple of motor tests (9-hole peg test and the timed 25-foot walk test) compared to those in the control group.\nWe wish the news release would have explained how these numbers might differ from what researchers would expect to see.\nIt is unclear from the journal article whether all patients displayed thicker brain cortexes after resistance training. We feel the news release could have included this information by following up with researchers. Therefore, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\nThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels in the control group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides a good narrative of the potential benefits of the breath test (lower cost, reduces exposure to repeat CT scans) but does not provide any quantification. The release notes that \u201cThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels of the control group.\u201d\u00a0 We aren\u2019t told what a \u201csignificant decrease\u201d means or what a \u201cnormalized\u201d level would be. The release would have been more complete if it had given us some idea of the test\u2019s ability to accurately detect or rule out lung cancer recurrence. ", "answer": 0}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nGiven those findings, along with the results from this trial, a rapid change in clinical practice is expected, noted Dr. Jotte.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release and accompanying research abstract include specific results, the release spins them by proclaiming benefits in the headline and lead paragraph, while burying the caveats that there\u2019s no evidence patients lived any longer and that those who received immunotherapy suffered more severe or life-threatening side effects. The release highlighted a higher rate of progression-free survival, but that term can be confusing, because it doesn\u2019t necessarily mean patients lived any longer, just that more time passed (in this case a median of about three weeks) before their cancers showed signs of progression. Neither the release nor the abstract discussed the quality of life of the patients in the study groups.", "answer": 0}, {"article": "Cytology-based screening, known as the Pap test or Pap smear, is used to detect abnormal cells.\nHPV-negative/ Pap test-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%); these cancers were more likely to be regional or distant stage than other cases.\nTwo-thirds (67.9%) of women found to have cancer up to 10 years of follow-up at Kaiser Permanente were detected by the first cotest performed.\nThe analysis found that HPV testing identified more women subsequently diagnosed with cancer and precancer than the Pap test.\nHPV testing was statistically significantly more likely to be positive for cancer at any time point, except within 12 months.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is comparing two different screening methods, which both have benefits, to using either one of them alone.\nWe were especially pleased that the release included a clear description of the benefit using absolute, rather than just a relative, risk number.\n\u201cGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67%) of women found to have cancer up to 10 years of follow-up at Kaiser Permanente were detected by the first cotest performed.\u201d\nBesides this number, the release included specific numbers for benefits of each test.\n\u201cHPV-negative/Pap test-positive results preceded only small fractions of cases of precancer (3.6%) and cancer (5.9%); these cancers were more likely to be regional or distant stage than other cases.\u201d", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nThe study, funded by the National Institutes of Health, was designed to see if changing the type of diet people consumed helped with weight maintenance because dieters often regain lost weight.\nSo scientists had 21 obese participants, ages 18 to 40, lose 10% to 15% of their initial body weight (about 30 pounds).\nThe research finds that dieters who were trying to maintain their weight loss burned significantly more calories eating a low-carb diet than they did eating a low-fat diet.\n\"Participants burned 150 calories more on the low-glycemic index diet than the low-fat diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The opening sentence of this story as originally published is incorrect. It states that dieters \u201cwere more successful maintaining weight on a low-carb diet than they were on a low-fat diet.\u201d According to the study, there was no statistically significant difference in participant weights during the 3 diet phases. The main finding was that participants resting energy expenditure was increased during low-carb and low glycemic-index phases than during the low-fat phase, which might theoretically improve weight loss maintenance. The story did do a good job of characterizing the difference in energy expenditure between the 3 diets and what it would take to burn the same amount of energy via physical activity.\n[Note: the incorrect opening line appears to have been pulled from an updated version of the story.]", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story mentions two different studies as part of a broader evaluation of the new technology. In both cases, it shows that the new technology is a minor improvement. This point could have been made more forcefully by providing some absolute numbers. It says \"A 2,430-patient study by researchers at the Mayo Clinic in Jacksonville, published earlier this year in Clinical Gastroenterology and Hepatology, found adenomas in 28.8% of patients examined with high-definition colonoscopy, compared with 24.3% in those examined with standard colonoscopy. Polyps were found in 42.2% versus 37.8%. The scope tested, from Olympus, had both high-definition and a wide-angle view.\" Assuming that the groups were split exactly in half, this means that adenomas were found in about 350 patients versus about 300 with the standard method. ", "answer": 1}, {"article": "\"We didn't miss any of those high-grade cases by conducting home self-collection.\"\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\n\"This is a demonstration that mailing self-collection kits and returning them to test for high-risk HPV infection has big potential to increase screening access among under-screened women, and to do that successfully,\" said UNC Lineberger's Jennifer S. Smith, the study's senior author, and a professor in the UNC Gillings School of Global Public Health.\n\"There are a lot of different barriers that cause women to be underscreened,\" said the study's first author Andrea Des Marais, MPH, project manager with the UNC Gillings School of Global Public Health.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky question, as it is not clear how one should define the relevant benefit. The paper itself defines the goal of the study as evaluating the \u201cvalidity and acceptability\u201d of at-home self-collection of samples for HPV screening. If part of assessing \u201cacceptability\u201d was determining whether mailing self-collection kits improved screening rates, should the benefit be defined as successfully submitting a sample for screening? If so, the release failed, since it doesn\u2019t even tell readers how many women received screening tests through the mail (284 women, according to the related paper). However, validity is easier to address. How well did the at-home, self-collected samples compare to other screening tests? The release does address this head on. It states that the at-home, self-collected test indicated 12.4% of women had high-risk HPV infections. In-clinic, self-collected tests indicated 15.5% had high-risk HPV infections. And clinician-collected tests indicated 11.4% of women had high-risk HPV infections. Those are hard numbers, and we\u2019ll give the release the benefit of the doubt on this one. However, those three different numbers raise some questions, which the release doesn\u2019t do a good job of addressing. More on that below.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This entire story is essentially about comparing the benefits and risks of bisphosphonate use for treating osteoporosis. The story states early on that \u201cAn analysis in the New England Journal of Medicine last month estimated that for every 1,000 women with osteoporosis treated up to five years, bisphosphonates prevented 100 fractures and caused at most 1.\u201d But the story also notes that \u201cSome critics say the new analysis overestimates the benefits and underestimate the number of sudden thigh-bone fractures.\u201d There are some issues with the story handles benefits, but we\u2019ll address that under \u201cQuality of Evidence.\u201d \u00a0We\u2019d add that as much as we would like there to be simple and incontrovertible answers to questions surrounding benefits and risks, these numbers simply do not exist.", "answer": 1}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\n\u201cThis study suggests that these alternatives really are viable options for people who are looking for recovery support and don\u2019t like AA for whatever reason,\u201d Sarah Zemore, lead author of the study, told me.\nThe study, in short, looked at how people\u2019s self-reported outcomes with AA and 12-step programs compare with the three biggest alternative mutual help groups \u2014 Women for Sobriety, SMART Recovery, and LifeRing.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nOne tricky thing with this line of research is you can\u2019t really force people to participate in certain groups \u2014 so studies that randomly assign participants to AA, SMART, LifeRing, or Women for Sobriety may not be easy to do.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the researchers\u2019 conclusion that\u00a0\u201c[Women for Sobriety], LifeRing, and SMART are as effective as 12-step groups for those with AUDs.\u201d\nThe story also quantifies that level of effectiveness when it says that studies broadly find that \u201cabout a third of people maintain recovery from alcohol addiction due to 12-step treatment, another third get something out of the treatment but not enough for full recovery, and another third get nothing at all.\u201d\nThe story acknowledges that there were some differences in the data \u2014 for example that those who reported SMART as their primary group \u201cseemed to have worse substance use outcomes,\u201d and that \u201cthere were lower odds of total abstinence among LifeRing members.\u201d It explains that those differences might be explained by the differing goals of the programs, as LifeRing doesn\u2019t emphasize complete abstinence as intensely as the 12-step programs. While it would be interesting to know just how much worse the outcomes were with these alternate groups, we don\u2019t think the omission is enough to merit a not satisfactory grade.", "answer": 1}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nMore research is needed to determine whether neck scans should become a part of routine testing for dementia.\nThose two conditions make up the vast majority of cases of dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s what the story says: \u201cPeople with the most intense pulses, which pointed to a greater and more irregular blood flow, were up to 50% more likely to suffer reduced cognitive functions.\u201d\nFirst, we need to point out that it wasn\u2019t a pulse researchers were measuring, but something known as forward compression waves (FCW) in the neck arteries.\nThe story doesn\u2019t include vital data-driven information for readers, such as:\nAlso the story never makes it clear that, based on these observational study results, we don\u2019t really know if doctors can \u201cspot dementia 10 years earlier\u201d just because of FCW. Nor that we have no know way of knowing to what extent identifying this risk allows patients to take action to improve their FCW score and therefore improve cognitive outcomes.\nSome useful reading:\nObservational studies: Does the language fit the evidence? Association vs. causation\nAbsolute vs relative risk", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\nThus, hormones that interfere with testosterone could be deadly.\nExperts said the findings could make doctors think twice before prescribing the standard hormone treatment to men with prostate cancer, particularly if they are at risk of heart disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nOther than one general quote at the very end of the story, there is no explanation of why some men with prostate cancer are given hormonal therapies or how the expected benefits of the therapies compared with potential side effects.", "answer": 0}, {"article": "For more information visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nHowever, those who saw the most significant decline in markers of inflammation were those who took vitamin D and lost 5 to 10 percent of their baseline weight.\nThe researchers found similar results among women in the vitamin D group who lost more than 10 percent of their starting weight.\nTo explore this question, Duggan and colleagues recruited 218 healthy, overweight older women who had lower-than-recommended levels of vitamin D (less than 32 ng/mL).\nThese study participants had a 37 percent reduction in a pro-inflammatory cytokine called interleukin-6, or IL-6, as compared to those in the placebo group, who saw a 17.2 percent reduction in IL-6.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job of comparing data and providing explanations for the measurements used. We\u2019ll award a Satisfactory for that precision, but as noted below under \u201cEvidence,\u201d there was no explicit caution regarding the fact that measurements of interleukin-6 (IL-6) are only surrogates for the effects of weight loss and vitamin D on clinical outcomes related to inflammation (e.g. cancer diagnoses). IL-6 levels dropped in both the placebo and vitamin D arms, and it\u2019s not clear whether the statistically significant additional decline in IL-6 observed in the vitamin D group is clinically important.", "answer": 1}, {"article": "\"It's premature to make any conclusions,\" he said.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says, \u201cmany who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\u201d It adds some quantification with this quote from a researcher: \u201cIn greater than 60 percent of those taking it, vitamin D actually made the cancer better.\u201d But this is not enough information for a satisfactory rating here. How much \u201cbetter\u201d were the cancers in the vitamin D group? How was this measured? Would the size of the difference be considered meaningful for the patient, or is it merely a \u201cstatistically significant\u201d difference? Since findings like this are likely to generate significant interest, the story had an obligation to explore these questions more thoroughly.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that women who used an IUD were 30% less likely to develop cervical cancer but did not provide any quantification of that number. Readers need to know: 30% less than what? The incidence of the disease would have improved the story and placed the 30% reduction into perspective. There are approximately 400-500,000 case of cervical cancer diagnosed annually with a 50% death rate overall worldwide. \u00a0The incidence of the disease varies widely with an incidence of approximately 16/100,000 in developing countries compared to approximately 10/100,000 in the developed world.", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s focus is on harms of treatment, but readers are left wondering about its purported benefits. (e.g. cutting less tissue and muscle, shorter scar, quicker recovery, less postoperative pain). The story provides no quantitative estimate of these (or other) potential benefits, though several studies have looked at them. This is a major limitation of the news story. By focusing on personal stories about complications, the story doesn\u2019t give readers the hard data about benefits they need to make a well-informed medical decision. (See evidence above.)", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits is provided.", "answer": 0}, {"article": "Once-daily Victoza is typically prescribed as a third or fourth option after patients have first tried various oral medicines.\nNovo, the world\u2019s biggest diabetes company, had said in March that Victoza cut heart risks \u201csignificantly\u201d in the study but the scale of the benefit was only disclosed on Monday.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\n(Reuters) - Novo Nordisk\u2019s (NOVOb.CO) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.\nThe stock fell around 5 percent in Copenhagen on Tuesday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s\u00a0key\u00a0figure, which features in the headline, is a 13% reduction in the risk of heart attack, stroke and cardiovascular death. Unfortunately this figure\u00a0only measures the relative risk reduction; i.e. the change\u00a0in\u00a0risk for patients\u00a0who got Victoza as a percentage of the actual\u00a0risk of heart attacks, strokes or cardiovascular death for patients who didn\u2019t get Victoza.\nHowever, the story does also give actual risk figures\u00a0for\u00a0the treatment and placebo\u00a0group (13.0% vs. 14.9%). This allows a keen eyed reader to calculate the absolute risk reduction: a less impressive sounding\u00a01.9%. Because of this, the story rates Satisfactory on this criterion. It\u2019s worth nothing the news release didn\u2019t include the placebo group reductions.", "answer": 1}, {"article": "NEW YORK (Reuters Life!)\nThe study, led by Hung Fu Tseng, a research scientist at Kaiser Permanente in Southern California, compared about 75,000 vaccinated members of the Kaiser Permanente Health plan with about 225,000 similarly aged members who weren\u2019t vaccinated.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n- The herpes zoster vaccine could prevent tens of thousands of cases of shingles each year if it was offered to everyone who is eligible, with vaccinated adults half as likely to develop shingles, a study said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story reports the apparent reduction in shingles risk among vaccinated participants in three ways:\n\u00a0\n\nAlthough the half-as-likely description got top billing, readers are given the results in complementary ways that help them understand just how common shingles is among the people studied and how much difference vaccination may make. The study authors highlighted these different ways of looking at the results, thus helping journalists provide a more complete picture to the public.\nThis story is the only one of the three we reviewed that clearly noted that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.", "answer": 1}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nThe new study is notable because of the decade-long follow-up, said Maciejewski, who is also a research career scientist at Durham Veterans Affairs Medical Center.\nMaciejewski acknowledged that the study has limitations.\nMost were white.\nOnly 19 of them had regained so much weight that they were nearly back to their starting weight; the rest kept off the weight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job of making the weight loss comparisons\u2014both over time for gastric bypass surgery and across surgical options\u2014clear.", "answer": 1}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nNow Dr. Berry, the M. D. Anderson statistician, and a group of leading cancer researchers have found that the chemotherapy benefits in those clinical trials were concentrated almost exclusively in women whose cancers were impervious to estrogen.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nBut most of those studies were done at a time when doctors did not distinguish between the 70 percent of women with breast cancers fueled by estrogen and the 30 percent whose cancers were not.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, Dr. Berry\u2019s subgroup analysis of several large chemotherapy trials, published in The Journal of the American Medical Association, was mentioned but the story didn\u2019t give quantified details. The combined absolute benefit of chemotherapy for disease free survival at 5 years was 22.8% for estrogen-receptor-(ER) negative women compared with 7.0 % for estrogen receptor positive women treated with tamoxifen. The 5-year absolute survival benefit of chemotherapy for women with ER-negative tumors was 16.7 % vs. 4.0% for ER-positive women treated with tamoxifen. Nonetheless, the overall quality of the discussion warrants a satisfactory score. ", "answer": 1}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\n\"Our results were absolutely dramatic.\nMoreover, the signal does not call down the deadly all-out immune attack -- the feared \"cytokine storm\" -- that can do more harm than good.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\n\"These genetically engineered cells did what everyone in the field has tried to do for 20 years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described very well the specific experiences of the patients who were involved in the study. It showed how two were in full remission and one was in partial remission.\nBut someone at WebMD has to take responsibility for that headline and the repeated reference to \u201ccure\u201d\u00a0 that is bothersome.\u00a0 Even when the story finally comes around to asking \u201cIs he cured?\u201d it still fails to directly address the unknowns and uncertainties. \u201cCure\u201d is such a loaded term \u2013 it is almost unhelpful in discussing such research.\nEven if investigators choose to use that term, journalists have an obligation to tackle the age-old baggage and consumer confusion that comes with it.\u00a0 This story started to try to do this, but fell short in our eyes.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reports that the drug showed a 94 percent success rate in the current trial, but does not provide any more detail.\u00a0 ", "answer": 0}, {"article": "\"The faster a cancer grows and the better it is in seeding metastases, the better will it be picked up early by MRI,\" Dr. Kuhl said.\nOf the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAdditional cancers detected by MRI screening in the study had a skewed distribution towards a higher-than-normal prevalence or incidence of rapidly growing (grade 3) cancers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0supplemental cancer detection rate seems to be the main metric of success for the MRI screening. The news release does a good job presenting absolute benefits, not just relative benefits:\n\u201cBreast MRI detected 60 additional breast cancers, including 40 invasive cancers, for an overall supplemental cancer detection rate of 15.5 per 1,000 women. Of the 60 cancers detected in the study group over the observation period (7,007 screening rounds), 59 were found only using MRI, one was found also by mammography, and none by mammography or ultrasound alone.\u201d\nBut the news release only reports sensitivity and begs the question on the matter of specificity. Sensitivity and specificity are two sides of the same coin when it comes to assessing any screening method. A bit of digging on our own reveals that the MRI screening had a low false-positive rate of 2.9%.", "answer": 1}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the strengths of the competing WebMD story was its use of quotes and stats from the accompanying editorial.\u00a0 This story didn\u2019t even acknowledge that there was an editorial.\u00a0 We don\u2019t understand how that could be overlooked. ", "answer": 0}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nSo who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There was no quantification of benefit \u2013 so we can\u2019t give a satisfactory score.\u00a0 But we also don\u2019t feel an unsatisfactory score is warranted since the story made clear that \u201cregulators weren\u2019t buying the evidence put forward by the company to prove the medicine\u2019s benefits in treating travelers\u2019 \u201cexcessive sleepiness\u201d outweighed its risks.\u201d", "answer": 2}, {"article": "The weakness \u201cis significant,\u201d Dr. Tripathi said.\nWhen all seizures were taken into account, children who did not have surgery were four times more likely to have a seizure during that year than youngsters in the surgery group, the researchers calculated.\nIt\u2019s documentation that these techniques really work.\u201d\n\nAlthough 77 percent were judged by the Tripathi team to be seizure-free at the end of the study, some of those children actually had seizures immediately after surgery.\n\u201cThe study in kids shows if you reduce the time from the onset of seizures from the 15 to 20 years you see in adults down to four to five years, the outcome is much better.\nIn contrast, 16.5 percent of the children waiting for surgery had a serious injury as a result of their continuing seizures.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there is some quantification of benefits, the article doesn\u2019t specify the actual number of children who had the primary outcome \u2014 a year without seizures.\u00a0 And thus the statement in the lead that brain surgery in the study group can produce a 10-fold increase in the odds of being seizure free after one year will be difficult for readers to put into perspective. And as noted above, the article does not specify how many operations or what types of surgery were performed on what ages of children.\nEditor\u2019s note: While the story doesn\u2019t state the absolute amount of children who experienced improvement after surgery compared to the control group, the story does give readers enough information to understand the measured benefits. For this reason, we changed our initial rating from Not Satisfactory to Satisfactory.\nSeventy-seven percent of the children were free of seizures at one year after the surgery, compared with seven percent in a control group of youngsters who received medical therapy alone while waiting for surgery.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article presented no data whatsoever.\u00a0 In terms of descriptive information about benefits, it had, on the one hand, \u00a0the expert, Irwin Rosenberg indicating that if individuals are not vitamin B12 deficient, then there is no evidence that \u00a0B12 supplements are of benefit. \u00a0 On the other, you had an individual (Jane Riester, 27) indicating that although her B12 level was in the normal range (i.e. 200 pg/ml), she personally experienced benefit from supplementation.\nBy juxtaposing anecdote and evidence, it confuses the value of evidence.", "answer": 0}, {"article": "(\u201cEnjoyed\u201d?\nA team led by Robert A. Waterland, an assistant professor of pediatrics, nutrition and molecular and human genetics, selected female mice that enjoyed running, according to a press release.\nThe Baylor scientists were able to correct for those variables.\nThe offspring of those mothers turned out to be about 50 percent more physically active than those born to mothers that hadn\u2019t had the exercise wheel option.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that levels of physical activity in mouse kids of active mouse moms were 50% greater than were activity levels of kids of mouse moms who were prevented from using a wheel.\u00a0Normally, we\u2019d expect to see these numbers quantified in absolute terms, but since we\u2019re talking about mice, we don\u2019t think it\u2019s essential to get too precise, as that might feed the perception that the results are applicable to humans.", "answer": 1}, {"article": "Nucleix Ltd. develops, manufactures and markets innovative, non-invasive, molecular cancer diagnostic tests.\nTherefore, a screening test aimed at the entire risk group to assist in the early detection of the disease is highly needed and can dramatically increase lung cancer survival.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nAt the moment, low-dose computerized tomography (LDCT) screening which has been shown to reduce mortality from lung cancer in the very large NLST study is only reimbursed in the US for high-risk individuals.\n\"Lung cancer is the leading cause of death from cancer worldwide due to the high incidence of the disease, and the low rate of diagnosis at early and more curable stages,\" stated Prof. Mina Gaga, the President of the European Respiratory Society (ERS) and a lead investigator in the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release touts this as a new screening tool to detect lung cancer, and the release provides numbers on both the specificity and sensitivity of the test, indicators of how good the test is at detecting disease and at ignoring disease-free individuals.\nWhile that\u2019s a good start, there are also big problems here. The\u00a0release claims that the test will assist with the early detection of lung cancer in people who are seemingly healthy. And yet the data referenced in the release came from patients already known\u00a0to have lung cancer and either current or former smokers who didn\u2019t have lung cancer \u2014 not a general population of at-risk people whose lung cancer status is unknown. This is a crucial distinction. Testing in\u00a0a much broader group is needed to determine how effective the test would actually be when used to screen healthy people in practice.", "answer": 0}, {"article": "\"The robot is the way to go,\" Jackson said.\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nThe robotic tools are inserted through small openings made in the patient's body, minimizing trauma and significantly reducing recovery time.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nRecent concerns raised over the safety of medicated stents used in coronary angioplasty procedures have caused more patients and physicians to consider bypass surgery as a better therapy for blocked coronary arteries, said Chris Rabbitt, cardiac marketing director for the company.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not cite specific figures of benefits. It uses several anecdotes that suggest the surgery is safe, effective and likely to speed recovery time. ", "answer": 0}, {"article": "The bone cells don't have the ability to lay down new bone.\"\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nAfter six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits described in the clinical trial were not quantified or described in sufficient detail. It simply states that \u201cgreater healing\u201d was noted in patients receiving Forteo. The exact meaning of the phrase is unclear and could leave readers with an overly optimistic impression of the value of Forteo in this group of patients.\n The story provides an adequate amount of detail concerning the case report, noting the patient was pain-free after treatment. It should have noted however how long the patient was followed.", "answer": 0}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nPatients using this therapeutic are asked to identify an emotion displayed in a series of faces, and for each face, they are asked to identify the number of faces earlier in the series in which they encountered the same emotion.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nIn the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides only percentages, with no actual numbers for the patients who did and did not receive the therapy. We don\u2019t know if it was 10 patients or 10,000 patients. We also don\u2019t know how the symptoms were measured, nor how severe the depression was in the two groups at baseline and afterward. (We looked up a presentation of the study: It had just 26 people.)\nExcerpt: \u201cIn the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.\u201d\nAlso: If the groups received therapy for six weeks, how often did they receive it each week? What was the control group receiving? Was it once for 45 minutes or twice a week for 30 minutes? All these details would help us understand this.", "answer": 0}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nWhile the connection between heart disease and cancer may not seem obvious, Ridker says that many people who have had heart problems, like those in the study, are former or current smokers, since smoking is a risk factor for heart attacks.\nThe cancer data is still preliminary, and needs to be confirmed with additional studies, but it\u2019s encouraging, says Dr. Otis Bradley, chief medical officer for the American Cancer Society, who was not involved in the study.\nIn the study, 10,000 people who have already had a heart attack were randomly assigned to get injected with a placebo or different doses of a drug called canakinumab.\nAfter four years, the people who received the drug had a 15% lower chance of having a heart attack or stroke compared to people who didn\u2019t get the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\n\u201cAfter four years, the people who received the drug had a 15% lower chance of having a heart attack or stroke compared to people who didn\u2019t get the drug.\u201d\nThis is an error. The benefit only applied to second heart attacks, not strokes.\nAlso, what does 15% translate to in absolute numbers? This wasn\u2019t explained, so we\u2019ll elaborate here:\u00a0The way researchers measured results was in \u201cevents per 100 person-years\u201d, and the \u201cevents\u201d were non-fatal heart attack, non-fatal stroke, or death from a cardiovascular-related cause. In the placebo group, there were 4.50 cardiac events per 100 person-years. In the group receiving 150 mg doses of\u00a0canakinumab, there were 3.86 events per 100 person years. Of the various doses given (50, 150 and 300 milligrams), the 150 mg dose was the only statistically significant result, and it was only because of non-fatal heart attacks.\nAs noted in an editorial that accompanied the study, this was translated as a \u201cmodest\u201d benefit. The story fails readers by not including that detail. For a comparison on how to write about the study results more responsibly, see the Reuters story.", "answer": 0}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nThat's why some patients, doctors, and researchers are excited about an experimental drug based on an herb known by the Latin name Syzigium claviflorum that had been used in Taiwan to treat diarrhea and stop bleeding.\nIf all goes well, the trial could enroll up to 144 patients.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If the story is even going to report on a drug that is three or more years away from FDA approval and still undergoing initial safety testing in humans, it should at least temper enthusiasm. The story did point out that the drug is at least three years away from being on the market and still being tested. And the story did end with a \u201cproof of the pudding\u201d comment from NIH\u2019s Dr. Fauci. However what is missing is a comment that we do not know how much impact the drug would have on survival or quality of life, for example. And the story is laden with comments such as \u201cgenerating excitement\u2026researchers are excited\u2026the therapy is exciting\u2026so far it looks potent and it has a great safety profile\u201d \u2014 all without any hard data provided. ", "answer": 0}, {"article": "The CHEO Research Institute makes discoveries today for healthier kids tomorrow.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nThe overall incidence of adverse events in the study population was 11.7%.\n\"While all sedation medications and combination of medications are effective and safe in the hands of experienced providers, ketamine-alone is associated with the fewest serious adverse events and significant interventions, making it a logical choice for providing procedural sedation for children in emergency departments.\"\nAccording to the authors, this study represents the largest and most robust prospective emergency department procedural sedation cohort to date.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not give absolute numbers for the benefits, just percentages. The main benefit statement is in the excerpt below. We wish the release had told us the number of patients in the groups with the highest and lowest risk for side effects.\n\u201cThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events. The incidence of serious adverse events was lowest among patients sedated with ketamine-alone and highest among patients sedated with combination drugs ketamine plus propofol or fentanyl.\u201d", "answer": 0}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the study as \"unusually large,\" invovling 18,600 patients with acute coronary syndromes. It describes the trial as a head-to-head comparison between Brilinta and Plavix and specifies the clinical end points used in the research.\u00a0 \nThe story cites the company\u2019s description of the results as \"statistically significant\" in a way that favors Brilinta over Plavix.\nGiven the fact that little additonal data has been released [see the company\u2019s press release on the early Brilinta results], the story earns a \"Satisfactory\" rating under this criterion. ", "answer": 1}, {"article": "To alleviate symptoms, steam inhalation and nasal irrigation are widely suggested as an alternative to common treatment with antibiotics, which are often not effective and contribute to antibiotic resistance.\n\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits information was pretty spare. We would have liked some numbers \u2014 rather than simply this sentence:\n\u201cPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index. Steam inhalation did not appear to alleviate symptoms of sinusitis.\u201d\nHow much improvement? Is there a percentage or absolute number that could have been included?\nAccording to the published study, \u201cBy 6 months, significantly more patients maintained a 10-point clinically important improvement in the RSDI score with nasal irrigation (44.1% v. 36.6%); fewer used over-the-counter medications (59.4% v. 68.0%) or intended to consult a doctor in future episodes.\u201d", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that patients who received whole-brain radiation \u201cperformed significantly worse\u201d three months after treatment on memory and verbal communication tests, as well as scoring lower on a quality of life questionnaire. However, the story doesn\u2019t tell us what \u201csignificantly worse\u201d means, nor does it say how much lower the quality of life scores were. The story also doesn\u2019t tell us if all of the relevant patients scored lower, or if there was a significant amount of variation in terms of patient response. Because the relevant study is not available for review (it was presented at a conference), and the story doesn\u2019t link to the relevant study abstract, it\u2019s difficult or impossible for readers to look up these details.", "answer": 0}, {"article": "Researchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Tumors form in the pleura, a thin membrane of cells that line the lungs and chest wall.\nThe study evaluated 25 patients with pleural mesothelioma, all of whom were over the age of 18 and had either already been treated with chemotherapy or were unable to receive it.\nFourteen patients passed away during the study, while four were still undergoing treatment as of the study's writing.\nPHILADELPHIA - Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.\nPatients who had already received another checkpoint inhibitor were not included in the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits aren\u2019t put into clear context. It is only partially useful to know that 14 of 25 patients had \u201creduced tumor size\u201d with pembrolizumab every two weeks. How much reduction was there?\nWithout a control group we have no idea how long patients would survive in the absence of the therapy, even if we are told in the release that \u201cMost patients survive less than a year\u201d with chemotherapy as the first-line treatment. We\u2019re told that patients given pembrolizumab \u201cwent about six months without their disease progressing\u201d and that 14 patients passed away during the study, and that four were still undergoing therapy.\nHow significant is it that 14 patients died during the study?\nThe study states the median survival from pembrolizumab treatment to be 5.7 to 10.7 months, very similar to the 6-7 months of standard second-line therapy noted in the news release.\nMoreover, the goal of the study is to show safety, so claiming it\u2019s \u201ceffective\u201d is premature.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A new study bolsters the case that daily aspirin may help protect against cancer, although the effect seems weaker than previously thought.\nPeople who said they took daily aspirin - whether \u2018baby\u2019 or adult strength - had a 16-percent lower risk of dying from cancer than non-users overall, Thun and his colleagues found.\nStill, Thun said the results would favor broadening the aspirin guidelines to include cancer prevention based on an individual risk-benefit assessment.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\n\u201cNews about the cancer potential of aspirin use has been really encouraging lately,\u201d said Dr. Michael Thun of the American Cancer Society, who worked on the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Much better than the competing WebMD story, this story appropriately stated:\n\u201cPeople who said they took daily aspirin \u2013 whether \u2018baby\u2019 or adult strength \u2013 had a 16-percent lower risk of dying from cancer than non-users overall, Thun and his colleagues found.\nFor men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\u201d", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nOne year after surgery, more people had died from other causes than died from lung cancer.\nOnly about 2 percent of lung cancer patients are under 45 and the average age at diagnosis is about 70.\nThe study looked at more than 2,000 patients with Stage 1 non-small cell lung cancer who had surgery to remove their tumor.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is\u00a0only one short paragraph dedicated to quantifying the benefits of surgery, and it\u2019s inaccurate:\n\u201cOne year after surgery, more people had died from other causes than died from lung cancer. And, after five years, almost 9 out of 10 patients were alive and cancer free.\u201d\n\u201c9 out of 10\u201d would mean 90% survived and 10% died within the five years. But as the study revealed, 19.9% of all patients had died within five years:\n\u201cThe 30-day, 90-day, 1-year, and 5-year mortality rates were 0.7%(n=15), 1.2%(n=27), 4.1%(n=90), and 19.9%(n= 436).\u201d\nThis means nearly twice as many people died than what the NPR study suggests.", "answer": 0}, {"article": "The babies are usually born prematurely and suffer complications all their lives.\nWriting in the journal Hypertension, the researchers said they did a simple study, testing the blood of 60 women who developed pre-eclampsia later in pregnancy and 60 women who did not.\nIt detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\nThey found a series of 45 different compounds linked with metabolism that were different in the women destined to develop the condition, and said that could form the basis of a test.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the study\u00a0\"identified 40 organic molecules to be significantly elevated and 5 that were reduced in plasma at 14 to 16 weeks\u2019 gestation,\" quoting the study. It would have been nice to have some context for those numbers. Is elevation bad? Is reduction good? The numbers just float and don\u2019t add to our understanding. The story goes on to say, \"From this series of compounds they narrowed down a list of 14 sugars, fats and amino acids that were different in the women who developed the condition. It detected around 90 percent of the cases, with a false positive rate of about 24 percent, meaning 24 percent of the women flagged in the test as having a risk of pre-eclampsia would never actually develop it.\" Given that the sample size is so small, the story should have provided the numbers both in percentages and in absolute terms. That 90 percent figure sounds huge, but we are still only talking about 71 women. And, of those, 17 were false positives. Those numbers would have been good context for helping readers understand the findings. The study itself is actually fairly easy to understand.", "answer": 0}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThis randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\nBased on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren's disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren's nodule tissue.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the release, a single injection of Humira \u201cresults in the reduction of the cell characteristics responsible for progression of Depuytren\u2019s disease.\u201d\nThis is vague, misleading, and inaccurate because what causes progression in this disabling hand disease is unknown, and most certainly can not be definitively attributed to \u201ccell characteristics.\u201d\nThe study was designed to better understand the impact of adalimumab on local level of several disease markers namely myofibroblast phenotype and collagen production in excised nodule samples and not necessarily on disease progression. \u00a0The results were far from as conclusive as the report would suggest with only one marker demonstrating a difference over placebo at the highest dose level.", "answer": 0}, {"article": "\"That will be the subject of a larger study.\"\n\"Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising,\" said Weintraub, who added that results should be available relatively soon from other trials exploring the issue.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story emphasizes the safety questions that were at the heart of this trial. It also tells readers plainly that it is unknown whether the changes in cholesterol levels seen in this trial have beneficial health effects. It does an impressive job in describing the uncertainties associated with drug manipulation of HDL blood levels. After reporting that the HDL cholesterol numbers rose from 41 mg/dl to 101 mg/dl, the story quotes an independent source saying, \u201cCurrently, we\u2019re not convinced that manipulation of HDL matters, though certainly it\u2019s promising.\u201d Unlike some other stories about these trial results, this report repeatedly tells readers that any discussion of real health benefits will have to wait at least until after a trial designed specifically to measure such outcome is conducted.", "answer": 1}, {"article": "\"To make any form of health care work and to truly power economic mobility, we have to get healthy,\" says Levin.\nThe study authors also note hyperlipidemia, or elevated cholesterol and triglycerides, is often underdiagnosed and undertreated.\n\u2022 In observational studies, a plant-based vegetarian diet is associated with a 22.9 mg/dL reduction in LDL cholesterol and a 3.6 mg/dL reduction in HDL cholesterol, compared to control groups following an omnivorous diet.\n\u2022 In clinical trials, a plant-based vegetarian diet lowers LDL cholesterol by 12.2 mg/dL and reduces HDL cholesterol by 3.4 mg/dL, compared to control groups following an omnivorous, low-fat, calorie-restricted, or a conventional diabetes diet.\nThey find:\n\nA plant-based vegetarian diet is associated with total cholesterol that's 29.2 mg/dL lower in observational studies.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release clearly states the benefits of a plant-based vegetarian diet for cholesterol. In clinical trials, a plant-based diet was reported to lower total, high-density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol levels by 12.5 mg/dL, 3.4 mg/dL, and 12.2 mg/dL respectively. In observational studies, a plant-based diet was associated with reductions in total, HDL, and LDL cholesterol levels of 29.2 mg/dL, 3.6 mg/dL, and 22.9 mg/dL respectively. The release also included information on the lack of association between dietary patterns and blood triglyceride (a type of fat) levels \u2014 an important mention of results that were not statistically significant.\nHowever, the case description based on the physician\u2019s subjective personal experience was over the top and detracted from the more balanced aspects of the release.", "answer": 1}, {"article": "May 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe new study was presented at the annual meeting of the American Pain Society.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "When a person has diabetes, their body either doesn't produce enough insulin or doesn't process blood sugar properly.\nWhile there has been a lot of research on similar compounds over the past decade, no one has been able to pinpoint which ones are the most beneficial or how exactly they bring about any benefit -- until now.\nAt the root of that is the failure of beta cells, whose job it is to produce insulin.\nThe BYU team, comprised of graduate and undergraduate students in Tessem's lab and the labs of Ben Bikman and Jason Hansen (BYU professors of physiology and developmental biology), then dove in and dissected what was happening on the cellular level -- specifically, the beta cell level.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release would have been fine if it had stuck to the statement in the last paragraph that the research points the way toward refining specific compounds and then testing them as potential treatments. But that measured summary is negated by the absurd suggestion near the top of the release that people might get some benefit by eating a lot of cocoa (even though the release then questions its own suggestion). It\u2019s strange that one of the researchers gave a quote about eating chocolate when their journal article clearly states that the key insulin-secreting beta cells \u201cwon\u2019t be exposed to sufficient concentrations under physiologic conditions.\u201d\nNeither the release or the study provide any hard numbers for context, only a description of the results and\u00a0the drawings, which make the differences seem much less than \u201cdramatic.\u201d ", "answer": 0}, {"article": "By 2030, pancreatic cancer is expected to be the second deadliest type of cancer in the world.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nFrom those hundreds of markers, 29 markers were selected to detect pancreatic cancer with 96% accuracy at stage I and II.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "From the lead author:\n\u201cOur test can detect pancreatic cancer with 96% accuracy at stage I and II while there is still the possibility of successful surgical intervention\u201d\nUsing \u201caccuracy\u201d without context is misleading for two reasons. First, it\u2019s not until the end of the news release that we learn that these impressive results are in people with already documented pancreatic cancer. Second, the 96% is somehow\u00a0correlated with specificity (number of true cancers picked up by the test) and sensitivity (number of true cancers missed). That means 4% of those with cancer will be missed by the test (but the paper reports 6% false-positives; again, confusing).", "answer": 0}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\n\u201cAn option that can prevent migraine and that is well tolerated is therefore sorely needed, and we hope that this marks the start of real change in how this condition is treated and perceived.\u201d \n\n\n\n\u201cBroadly speaking I think this is a very interesting study and I think it is a good step forward for the field and I think it is a good day for migraine sufferers,\u201d said professor Zameel Cader, Director of the Oxford Headache Centre who was not involved in the research, pointing out that the results were on a par with currently available therapies for migraine.\nThe trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a decent job summing up the study design and presenting key results from the study, down to the differences between dosage and even placebo groups.\nWhile we give the story a satisfactory score on this criterion, we also suggest that the numbers could have been explained far more clearly. Our heads are still spinning a bit from this paragraph in the story:\nThe research revealed that by months four to six, at least a 50% reduction in mean migraine days per month was achieved for just over 43% of patients injected under the skin with 70-mg of erenumab each month, while half of patients injected with the higher dose of 140-mg had such results. However, those given a placebo also saw benefits, with 26.6% of participants in this group experiencing such a reduction.\nA sidebar infographic would have helped, breaking down precisely how many days, how many people, and on what dose. Yes, the results were quantified, but in a less than optimal way.", "answer": 1}, {"article": "Kale and oranges are high in vitamin C, another antioxidant.\nWhile challenging, changing diet can be a relatively easy way to alter a woman\u2019s breast cancer risk equation, beginning even at a young age.\nBut the majority of those studies have focused on adults, and it\u2019s becoming clear that many of cancer\u2019s drivers start early in life, with genes and even with childhood exposures to potential carcinogens.\n\u201cWe recommend whole fruit and not fruit juice,\u201d says Farvid, \u201cbecause maybe one of the most important ways that fruit decreases risk of breast cancer is through fiber, and even natural fruit juice often has no fiber in it.\u201d\n\nIn another study also published in the , a separate group of researchers found that among 22,000 Danish women, those who added two alcoholic drinks a day on average increased their risk of developing breast cancer by 30% over five years.\nMORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers that women \u201cwho reported eating nearly three servings of fruit a day on average [during adolescence] had a 25% lower risk of developing breast cancer than those who ate half a serving of fruit.\u201d However, it\u2019s not clear where that number comes from. And what does that mean in terms of absolute risk? I.e., how likely is someone who ate only half a serving of fruit as a teen to get cancer? The story doesn\u2019t tell us \u2014 and that is key. If a story tells readers that eating \u201cnearly three servings of fruit\u201d as a teen means a \u201c25% lower\u201d risk, it needs to say 25% lower than what.", "answer": 0}, {"article": "\"\nIn the new study, women with early tumors who took tamoxifen for 10 years cut their risk of dying from breast cancer by another 29%, compared to women who stopped after five years.\nThat's significant, given that tamoxifen is used by hundreds of thousands of women worldwide, says Gray, whose study was presented Wednesday at the annual San Antonio Breast Cancer Symposium.\nHowever, because this cancer is very treatable, death rates were low: 0.4% of those on tamoxifen for 10 years died of endometrial cancer, compared to 0.2% of those taking it for five years.\nYounger women with more aggressive tumors may want to extend their tamoxifen use, says Jennifer Litton, an assistant professor at M.D.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story was reviewed by two breast cancer survivors, both trained in how to evaluate evidence by the National Breast Cancer Coalition\u2019s Project LEAD training.\u00a0 In addition, one earned her PhD in epidemiology. Here\u2019s how they reacted:\nBenefits were confused from the beginning of the article. \u00a0Assuming all breast cancer patients have the same profile and benefit is misinformation. For example, the Young Survival Coalition sent out a statement to members that pointed out:\nOverall, the patient population in this study tended to have low nodal involvement and most participants were over the age of 45 at time of initial diagnosis.\u00a0 53% of the 10-year group were node negative and 54% of the five-year group were node negative.\u00a0 Only 16% of both groups had four or more nodes involved.\u00a0 Also, only 19% of the 10-year group and 18% of the five-year group were under age 45 at time of diagnosis.\u00a0 In both the five and 10-year group, 89% of study participants were postmenopausal at time of their entry into the ATLAS trial.\u00a0 In the five-year and 10-year groups , 47% and 48% of patients respectively had tumor sizes ranging from 1 to 20 mm (equivalent to 2 cm or under), while 39% and 38% respectively had tumor sizes between 21-50 mm (2 to 5 cm).\nWomen with breast cancer look for this kind of detail in order to make the findings meaningful in their lives.\u00a0 There are ways to summarize this data in a way even in a daily news story.\nAllowing the study author to use the word \u201ccure\u201d in an unchallenged manner is troublesome.\nA major omission from this story was survival benefits were not seen until years AFTER tamoxifen treatment had ended (rather than\u00a0during treatment).", "answer": 0}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nFive years after their diagnosis, 95 percent of people whose cancers were found through a CT scan were still alive, compared to 73 percent diagnosed with an X-ray and 40 percent of patients who had not been screened and whose symptoms led to discovery their disease.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nEverybody agrees that CT \u201cdoes find the early stage lung cancer,\u201d said Dr. Heidi Roberts, a lung cancer researcher from Women\u2019s College Hospital, Toronto who wasn\u2019t involved in the new study.\nMoreover, they warn that while regular screening might help doctors catch cancer earlier, it also comes with a high price tag and added risks to patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained:\u00a0\u201cFive years after their diagnosis, 95 percent of people whose cancers were found through a CT scan were still alive, compared to 73 percent diagnosed with an X-ray and 40 percent of patients who had not been screened and whose symptoms led to discovery their disease.\u201d", "answer": 1}, {"article": "Neuronix is also running a trial in Israel for pre-Alzheimer\u2019s patients.\nPascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The way benefits were framed in this story is almost a carbon copy of how company-controlled release of data is communicated to the public.\nThe story quoted the company CEO (!) saying \u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again. If out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\nHow many see improvement lasting 9-12 months?\u00a0 All of them? (Later in the story, an investigator said only 6 patients received the real treatment (!) and all showed cognitive improvement.)\nHow is \u201cimprovement\u201d defined and measured?\nYou also have to read the piece carefully.\u00a0 The \u201ctreatment\u201d does not include just sitting in a chair.\u00a0 It also includes unspecified cognitive training.\u00a0 Since the study design is not noted we don\u2019t know if there was a control group or a group who simply received cognitive training without the use of transcranial stimulation.\n\u00a0", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does report on the results of a major trial from 20 years ago that concluded patients who were randomized to surgery had about a 5 percent risk of stroke or death within three years, \u201cless than half that of people treated only with drugs.\u201d But this statistic is overwhelmed by the headline (The Scan that Saved My Life) and the punchline, \u201cmostly I feel lucky to have gotten a test that may have saved my life.\u201d\nA more recent review of the evidence by the international Cochrane Collaboration concludes that the \u201cnumber needed to treat\u2018 (for the type of blockage and symptoms the reporter had) would be six patients. Meaning, six people have to be treated to prevent one stroke or death over a five-year period. In other words, the surgery likely does not alter the outcomes of five out of six patients. Either they wouldn\u2019t have had a stroke or died even without treatment or they did have a stroke or died despite undergoing surgery.", "answer": 0}, {"article": ".\nIn a second, simultaneous trial, termed METREO, the team assessed the effect of a higher dose of mepolizumab in 675 patients with elevated eosinophil levels.\nThis finding indicates that patients with higher initial eosinophil counts benefited more from mepolizumab than those with lower eosinophil counts, Sciurba said.\nThe patients with high eosinophil counts who received mepolizumab had a statistically significant 18 percent lower rate of moderate/severe exacerbations (1.4 per year compared to 1.7 per year) than those in the placebo group.\nAn analysis of data from both trials found that as baseline blood eosinophil counts increased, so did mepolizumab's reduction in the annual exacerbation rate.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary endpoint of the studies was to reduce the number of flare-ups that sent COPD patients either to the hospital or to the emergency room.\nThe release reports on the findings of two studies looking at the\u00a0usefulness of the drug in a subset of COPD patients. For the METREX trial, which enrolled 837 volunteers for one year, it says, \u201cThe patients with high eosinophil counts who received mepolizumab had a statistically significant 18 percent lower rate of moderate/severe exacerbations (1.4 per year compared to 1.7 per year) than those in the placebo group.\u201d\nIt\u2019s not clear what a difference in exacerbation rate of 0.3\u00a0per year really means. Does this mean that each person will get one less exacerbation about every 3 years? That doesn\u2019t\u00a0sound like much of a difference.\nFor the METREO trial, the release said, \u201cthe exacerbation rate was reduced by 20 percent in the high eosinophil group after 100 milligrams of mepolizumab. The METREO results narrowly missed statistical significance.\u201d", "answer": 1}, {"article": "The Walter and Eliza Hall Institute is the research powerhouse of the Victorian Comprehensive Cancer Centre, an alliance of leading Victorian hospitals and research centres committed to controlling cancer.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\nThe research team showed that RANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.\n\"We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified at all. Clinical trials have not yet been conducted, so it\u2019s impossible to determine how the drug may perform at preventing breast cancer in patients with the BRCA1 mutation. However, the release says that \u201cRANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.\u201d (RANK proteins were found by the researchers to be markers associated with pre-cancerous cells.) However, the release doesn\u2019t tell us about the amount of denosumab needed to inhibit these RANK proteins. Nor does the release offer any numbers related to these preliminary tests in laboratory models. For example, what does \u201ccurtailed breast cancer development in laboratory models\u201d mean? Did it stop the development of cancerous growth completely? Slow it down a little? A lot? Details matter.\nThis study was performed in laboratory animals and that must be considered when attributing benefits. As we\u2019ve found with other cancer treatments, switching off a protein or blocking a pathway may be effective in killing cancer cells in laboratory or animal models, but does not always translate to clinical benefit when used in patients. The laboratory studies are an extremely important first step, but it is a huge leap to translate this to clinical benefit.", "answer": 0}, {"article": "A moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\nYet the closeness it sparks might not be result in deep and lasting connections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What does it mean to suggest that the drug \u201csignificantly increase feelings of loving, friendliness and playfulness\u201d?\nHow was this measured?\nDid it occur in everyone?", "answer": 0}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nIn terms of safety, researchers found that tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome.", "answer": 1}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\nIn addition, Penn says, the mother's hands were not strapped down and the intravenous line was put in her nondominant hand so she could hold the baby.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The family-centered or gentle cesarean is put forth as a good alternative to traditional C-sections, since mothers play more of more of an active role during and after the birth of their children. The piece talked about how the family-centered cesarean allows mothers to see their babies being born, with newborns being placed immediately on the mother\u2019s chest after birth. The skin-to-skin contact helps to stimulate bonding and breast feeding, the report said.\nWhile the benefits are addressed in broad strokes, we can\u2019t rate the story satisfactory because there are no numbers to back them up. (There are studies that could\u2019ve been used to quantify benefits.) We\u2019d also caution that while the notion of\u00a0a more active role for the mother seems intuitively desirable, there is no balance in this story from the perspective of a woman\u00a0who might not be so gung-ho about the idea of watching a baby being extracted from her pelvis. We do know that not all patients like to watch procedures they are undergoing.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The AP story accurately reports the proportion of children who benefited from either the inhaled vaccine or shots, i.e. the \u201cabsolute efficacy\u201d of the two vaccinations. Although the inactivated vaccine appeared to be more effective, the difference was not significant. The story states in closing that the two methods were similarly effective in preventing type A flu, the historically more common strain. But the headline is confusing and misleading. \u00a0 ", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nPeople who continued on the drug for two years were able to maintain their weight loss better than those switched to placebo after one year, researcher Steven R. Smith, MD, of the Florida Hospital and the Sanford-Burnham Institute tells WebMD.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "See comments above about evaluating the evidence. We\u2019ll rule this satisfactory because the story did a decent job of quantifying the likely magnitude of weight loss, both in terms of expected pounds lost, % who drop out, and % losing 5% or 10% body weight.", "answer": 1}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nAnd when treated with the compound myo-inositol, the gene pathway activity declined along with improvement in the troublesome lesions, the researcher noted.\nOnly 15 percent of patients are still alive at five years, said Nana-Sinkam.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Didn\u2019t give any numbers on how well the test performed.\u00a0 And didn\u2019t explain that inositol was tested in just a few people.\u00a0 Very weak in this area. ", "answer": 0}, {"article": "\"We were actually anticipating that we would see it,\" Sandrock says.\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nResults like those could also lead to the first approved drug to treat the underlying cause of Alzheimer's rather than just the symptoms.\nThe results are encouraging for pharmaceutical companies that have spent billions of dollars on efforts to come up with the first drug to treat the underlying cause of Alzheimer's.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that treatment with\u00a0aducanumab results in \u201cstriking,\u201d \u201cdramatic\u201d and \u201cremarkable\u201d reductions in amyloid plaques in the brain. But it doesn\u2019t quantify what that means. How many patients saw their plaque levels go down? By how much? Is the reduction bigger than what has been seen with other experimental Alzheimer\u2019s drugs? These details would\u2019ve been helpful.", "answer": 0}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nAnd no one knows yet whether HPV testing actually catches cervical cancer at an earlier stage, or reduces deaths from the disease, compared with Pap tests.\nExactly what impact the new research review will have on the USPSTF recommendations is anyone's guess.\nAt that time, the task force recommended that sexually active women get regular Pap tests to screen for cervical cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains the potential benefit, if more-sensitive testing for the virus turns out to prove itself effective in reducing deaths from cervical cancer.", "answer": 1}, {"article": "The rate was 26 percent lower in counties with screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe researchers compared breast cancer deaths in women who had a breast cancer diagnosis in counties that had screening with deaths in counties that did not.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story highlights the 26 percent difference in breast cancer death rates, but fails to include any information about the overall risk. The researchers reported that based on their results you would have to screen 1252 women for a decade in order to prevent one breast cancer death. In other words, for the remaining 1251 women, a decade of mammograms did not alter their breast cancer mortality.", "answer": 0}, {"article": "I saw him this morning.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\nStudy researcher John H. Loughran, MD, of the University of Louisville, Ky., could barely contain his excitement in an interview with WebMD.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\n\nThe story could have benefited from an info-graphic to break down all the numbers of patients used at various times in the story: 20 enrolled, \u201cresults are in for only the first 16,\u201d 14 patients analyzed so far, 8 seen for one year.\u00a0 Wouldn\u2019t that have been much more clear than scattering all of these numbers throughout the story? That makes it difficult to understand the scope of the benefits.\u00a0 The story spends a lot of time talking about just one patient and, in an unusual move for a study like this, the story names the patient:\u00a0 Michael Jones. \n\n\n\nThis anecdote may not reflect the results seen to date in all the subjects treated.\u00a0 Preliminary results can be statistically important but may not be clinically important in the long run. The researchers saw an improvement in the ejection fraction in subjects treated (on average going from 30.3% to 38.5%)\u00a0 It should be noted that to be enrolled, all patients needed to have an ejection fraction of less than 40%. So, in spite of the improvement, the subjects on average still had severe heart failure at the end of this phase of the study. \n", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\nAt the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\nAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement.\nThe results for the HRT group were similar, and both the HRT DHEA groups showed a higher level of sexual intercourse in comparison to the control group, the researchers said.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job specifically explaining the benefits or lack thereof. It says, \u201cAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement. At the start of the trial, all groups had similar sexual activity, but after the year, those taking calcium and vitamin D scored an average of 34.9 on the questionnaire scale, while those taking DHEA had a score of 48.6, showing that those on DHEA had more sexual interest and activity.\u201d By presenting the actual scores, readers are able to see how close the scores were and decide for themselves whether the increased benefit was worth the risk of possible side effects.\n\u00a0", "answer": 1}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\nAnother big question, he added, is whether breath analysis could pinpoint people with colon polyps.\nIt's still unclear which breath chemicals should be measured, or what statistical method is best for weeding out cases of colon cancer.\nAnd when researchers analyzed the study participants' breath samples, they correctly identified the colon cancer patients 76 percent of the time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both this story and the competing WebMD piece repeated the accuracy statistic provided by the study (76%), but neither story provides much detail\u00a0as to what this figure means. Good diagnostic tests not only have to be able to identify people with diseases correctly, but they also have to be able to rule out people who don\u2019t have the disease correctly. Ideally the story should report true positive rate (sensitivity) and the false positive rate (1- the specificity), though it\u2019s not clear that the percentages listed represent those rates. We would have preferred to see the absolute numbers of people in each group (the cancer patients and controls) who were accurately diagnosed, and a comparison of how that stacks up against currently available tests.\nThis story did note that the primary benefit of a breath test would be increased convenience and less of an \u201cick\u201d factor compared with existing tests. In addition, it pointed out that\u00a0a 75% accuracy rate is a failure for\u00a025% of patients \u2014 a nuance missing from WebMD\u2019s coverage. In\u00a0also explained\u00a0that\u00a0we don\u2019t whether this kind of\u00a0test can detect precancerous polyps, which\u00a0should ideally be identified and removed before they have a chance to develop into cancer.\nA mixed bag, but overall,\u00a0it meets our standard for a satisfactory.", "answer": 1}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article does a very good job of documenting the absolute and relative benefits of each of the three diets. Also see Evidence comments.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\n\u201cIt is exciting to see this work be transformed from an idea to experimental research, and now to directly impacting patients.\u201d\n\n\u201cEven with the shortage of donor organs, we have to decline some of our donor organs because of the damage they sustain in the retrieval process,\u201d says Dr. David Grant, Surgical Director of the Multi-Organ Transplant Program, UHN.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release compares the health of a kidney preserved via ex vivo organ perfusion favorably to the health of a kidney preserved using cold storage preservation, going so far as to say that a kidney preserved using the new technology is \u201cimproved.\u201d But the release offers no numbers to support such a claim,\u00a0and then gives anecdotal comments from the single study participant to have undergone the new procedure\u2013\u201cI feel great\u201d\u2013and from the surgeon: \u201cIt\u2019s a champion!\u201d One of the goals of the ongoing study is the outcome of the transplant at just 90 days.", "answer": 0}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nWell, the study's lead author tells Shots that it might be enough to \"tip the balance a little bit, but not overwhelmingly so.\"\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nPut another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\nSo the new data may be the best that doctors and patients in this situation can expect for the foreseeable future.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits two different ways. It says, \u201cFour years after the procedure, patients over 65 who had coronary artery bypass surgeries (called CABG or \u201ccabbages\u201d) were almost 20 percent less likely to die.\u00a0Put another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\u201d\nThis would have been a good time to use the Number Needed to Treat statistic.\u00a0 Overall, the story made a good effort to give readers numbers in a way they could easily understand.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a good job of summarizing the benefits that accrued in the course of several studies.", "answer": 1}, {"article": "Some patients describe the syndrome as feeling like an \"unrelenting, unremitting flu.\"\nWhen patients adopt a more positive attitude, Barsky points out, it often translates into greater confidence and more energy.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nA study published this year in the Lancet found that a form of talk therapy, as well as exercise, offered relief for some patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the potential benefits. Instead it says that the therapy \u201coffered relief for some patients,\u201d and it later says that those who received therapy and exercise, \u201cimproved the most, reporting less fatigue, insomnia and anxiety.\u201d Everyone knows that exercise can make a person feel healthier and more alert, but this study was looking at a more difficult question than that. Hard numbers quantifying the actual benefits of this approach would have helped readers understand the value to place on this research.", "answer": 0}, {"article": "High cholesterol levels can increase the risk of heart attack.\nThey also noted that the results can't necessarily be applied to Americans, because of differences in the food supply and diets of each country.\nNoting that blood selenium levels were relatively low across the board at the study's launch, the authors found that selenium levels did rise as a result of supplementation, while those taking selenium also experienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels.\nMONDAY, May 16, 2011 (HealthDay News) -- A daily dose of the antioxidant selenium doesn't appear to elevate \"bad\" cholesterol levels, and may in fact prompt a very modest boost in \"good\" cholesterol, a new British study reveals.\n\"The issue is that there have been an awful lot of studies, about eight, that have looked at blood cholesterol, both good and bad, and have found an association with high blood selenium,\" said study author Margaret P. Rayman, a professor of nutritional medicine at the University of Surrey in Guildford, England.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story\u00a0correctly explains that selenium supplements are not\u00a0an effective means to reduce cholesterol levels, the\u00a0coverage\u00a0is too\u00a0vague when\u00a0it says that individuals\u00a0taking selenium \u201cexperienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels\u201d and that \u201cGood cholesterol (HDL) levels rose a bit solely among those assigned to the highest selenium dosage.\u201d Instead of relying on imprecise descriptions such as \u201cslight\u201d and \u201ca bit,\u201d the story\u00a0should have provided the actual numbers, as the competing Reuters story did. The Reuters story also described\u00a0the ranges for normal and elevated\u00a0cholesterol levels, which helps puts the changes observed into context.", "answer": 0}, {"article": "\"Why does it work for some people and not others?\"\nThe investigators used a hot flash score to see how much frequency and severity changed from when the study started to what the women reported at 8, 12 and 24 weeks.\nAt 24 weeks, 16 weeks after treatments ended, acupuncture was still associated with the greatest reduction in hot flashes.\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\nOne big distinction between the two populations, though, is that breast cancer survivors do not have the option of hormone replacement therapy open to them because those hormones are linked to breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of the treatments were measured at 8, 12 and 24 weeks after receiving the treatment yet the magnitude of those effects are not quantified\u00a0nor explained in any detail. Measurements looked at\u00a0frequency and severity of hot flashes but we don\u2019t have any idea what the baseline was, or how that may have changed due to the different modalities. We\u2019re told that acupuncture had the greatest effect, but not how big that effect was or how meaningful it was for patients.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nWhy get a wire-free pacemaker?\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nIt's only been implanted in a few dozen people who were studied for a matter of months, limiting information about its long-term use and safety.\nIf the old device is left in place, it is not known what the long-term effects of this will be.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only mention of benefits was this:\u00a0 \u201cThe researchers reported positive results at up to three months.\u201d\nWhat does that mean?", "answer": 0}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\n\"It is larger than any other clinical intervention we've ever had in cystic fibrosis.\"\nThe improvement at six months was still present almost a year after the study's start.\nThe effectiveness of VX-770 looks \"best case,\" he wrote.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good enough.\u00a0 We appreciate at least the attempt to explain that the 10 percentage points improvement in lung function \u201cis a big deal for CF patients.\u201d", "answer": 1}, {"article": "Cocoa contains flavanols, plant-based compounds that also are credited with giving red wine its heart-healthy benefits.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\nStudy participants were otherwise healthy and mostly normal-weight German adults with mild high blood pressure or pre-hypertension, which includes readings between 120 over 80 and 139 over 89.\nPeople who ate that amount ended up with lower blood pressure readings than those who ate white chocolate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit reported was a \"slightly lower blood pressure in people with hypertension.\" But it didn\u2019t say how much.\u00a0 \nThe study was conducted in a group of individuals who were prehypertensive or had stage-1 hypertension; there was no benefit in terms of blood pressure reduction at 6 weeks, however after 12 weeks of dark chocolate consumption, there was a statistically significant nearly 2.5 mmHg reduction in systolic pressure and by 18 weeks, it was nearly 3.0 mmHg lower. Why not tell viewers just how much BP dropped? ", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the one hand the article is appropriately cautious in stating:\nBut while genetic testing offers tools to better guide patients\u2019 treatment, it cannot tell doctors which medicines will work \u2014 or necessarily provide the key to enduring remission from depression.\nOn the other hand, the results of Myriad\u2019s recently published \u201clarge-scale test\u201d on outcomes are given as \u201cpatients were 30 percent more likely to respond to treatment\u201d when guided by their GeneSight test.\nBut, as\u00a0we wrote back in May in a review of a Wall Street Journal article on the test, there\u2019s problems with that percentage:\n\u201cNo absolute numbers are given \u2026 just a relative improvement in \u2018response\u2019 to medication (ie. 30% greater response to the medicine when the test was applied).\u201d\nThe Philadelphia Inquirer story quotes an independent source saying he\u2019s impressed by the response rate (50%) and remission rate (40%) at six months, but again, these are relative numbers. Myriad did not provide the absolute numbers at 6 months \u2026 only at 8 weeks \u2026. at which time the absolute difference in achieving remission between those who did and did not receive genetic testing was only 5%.", "answer": 0}, {"article": "She was not involved in the study.\nInterns who got the sessions were 40 percent less likely to have suicidal thoughts during that first year compared to those who received four weekly emails with information about depressions and where to seek help.\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nSuicidal thoughts were much less common in new doctors who had four half-hour online sessions before starting their first year of training, compared with those who got no therapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has some useful information on the benefits of the online therapy. We are told that, \u201cOverall, 12 percent of interns who got online therapy said they had thought about suicide during the year, versus 21 percent of the interns who received four weekly emails with information on depression and where to seek help\u201d and \u201cthat interns who got the sessions were 60 percent less likely to have those thoughts than the other group.\u201d \u00a0However there is no mention of timeframe or the durability of the benefit over time. \u00a0The suicidal ideation actually increased in both groups from baseline. (Figure 3 in the manuscript highlights the data collection) The figures provided reflect the numbers of interns who had suicidal ideation at least once during the one year data collection. It is also important to point out that 48% of the medical interns participating had a baseline history of depression. And while suicidal thoughts might have been prevented, we don\u2019t know if the intervention would have any effect on actual suicide attempts or success rates.", "answer": 1}, {"article": "Kisco, N.Y.\nMONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\nIn Campos' study, roughly equal numbers of patients in each group experienced complications after one year (12 percent in the gastric bypass group compared to 15 percent in the lap-banding group); these included infection, internal bleeding and blood clots, but no deaths.\nThe study led by Campos compared weight loss and diabetes outcomes in 100 patients who underwent gastric bypass surgery with 100 patients who underwent lap-banding.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A little bit better job with the numbers than the LA Times. The same weight loss data are provided in absolute terms, but this story also attaches a figure to the number of patients whose diabetes resolved after bypass compared with the band procedure. The LA Times called the results here \u201cfar better\u201d for gastric bypass, but HealthDay notes that improvement or resolutions was seen in three-fourths of bypass patients and half of band patients \u2014 a more precise characterization.", "answer": 1}, {"article": "Just one, though.\nBut the MIND diet also differs from those plans in a few significant ways and proved more effective than either of them at reducing the risk of Alzheimer's.\nThe Mediterranean and DASH diets do not specifically recommend these types of vegetables, but the MIND diet study found that including greens in addition to other veggies made a difference in reducing the risk of Alzheimer's.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nWine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The evidence for the efficacy of the MIND diet over the DASH diet and Mediterranean diet exists in the paper, but is not fully conveyed in the story.\u00a0\u00a0It was challenging for the story to quantify benefits from the study because\u00a0the paper itself did not publish any absolute numbers or percentages in the key tables or in the text of the article, making it impossible to calculate absolute risk reductions without pressing the study authors for more information. We are holding the bar high here, but unapologetically so, because we believe that provision of only relative risks gives a misleading and inflated estimate of benefit. The story says that the MIND diet can provide a 53 percent reduction in the risk of Alzheimer\u2019s Disease. While this may be technically accurate, the true size of the benefit is impossible to gauge without knowing the overall rate at which participants developed Alzheimer\u2019s disease in the study. In addition, the story could have noted that the Mediterranean diet was reported at 54 percent reduction when closely followed, too. One of the most important findings was for those who don\u2019t follow diets perfectly, but perhaps moderately. The story makes a reference to this, but it does not include how well the other diets performed when only moderately followed.", "answer": 0}, {"article": "\u201cWe\u2019re delighted with the results,\u201d Hughes said in an interview.\nOur intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\n\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\n\u201cThe efficacy of Beloranib looks very promising,\u201d said Dr. Merlin G. Butler, director of research and genetics at the University of Kansas Medical Center in Kansas City, Kan., and a principal investigator for the clinical trial there.\nThere are currently no treatments for Prader-Willi syndrome, the most common genetic cause of life-threatening obesity.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only states that the data shows\u00a0beloranib met its two primary endpoints of\u00a0significantly reducing weight and decreasing excessive eating. No numbers are attached to these statements, however. In particular, how is excessive eating measured? Clearly this is harder to define than weight loss. Presumably, surrogate variables were introduced to quantify the degree of excessive eating. A significant decrease in these surrogate variables can be difficult to interpret in many situations.", "answer": 0}, {"article": "(One British unit of alcohol equals a small glass of wine.)\nFor example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nBut for those women who drink before finding out they\u2019re pregnant or who have an occasional glass of wine afterward, this study can provide reassurance that very low levels of alcohol consumption during pregnancy are unlikely to cause serious problems.\nThe authors had earlier published similar results looking at the data for children in the study when they were 3, finding those whose mothers who didn\u2019t drink had slightly more behavior problems and slightly poorer performance on mental tests than kids born to light drinkers; the results also showed increasingly negative effects of alcohol going from moderate to heavy drinking.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unlike the other story reviewed, this story notes that the children of mothers who drank lightly\u00a0were \"slightly less likely to have behavioral problems and performed somewhat better on cognitive tests.\" This is a startling finding, to say the least, but then the story, importantly, adds that\u00a0\"this does *not* mean that light drinking in pregnancy is good for your baby. When researchers controlled for factors like maternal education and income, which tend to be higher in light drinkers, it significantly reduced the positive effects associated with alcohol. For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\" But the story should have included the actual rates, for instance that the rates for high total difficulties was 6.6 percent for sons of light drinkers vs. 9.6 percent for sons of mothers who did not drink during pregnancy. Including those numbers would point out that the overwhelming majority of children in both groups did not have major problems.", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits by explaining that about 65 percent of patients lose 5 percent or more of their weight. That\u2019s enough to earn a satisfactory rating, though we wondered 65% of what? How many patients are we referring to? And were they all following the three main treatment options discussed in the story (exercise, diet changes and counseling)? More details here would have been helpful to put the benefits in context.", "answer": 1}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nBy using both methods to visualize the cervix, the researchers will be able to make a direct comparison.\nIn a new paper published on May 31 in the journal PLOS One, researchers from Duke believe they have found a better way.\nIf widely adopted, women might even use the device to self-screen, transforming screening and cure rates in low-income countries and regions of the United States, where cervical cancer is most prevalent.\nRamanujam and Asiedu are now working on clinical trials to see how their design stacks up against the traditional colposcopy used with a speculum.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The cost saving of this innovation is\u00a0the main benefit touted, but it\u2019s not quantified. The release does speak to the usability of the device when quoting one of the researchers who describes the experience of 15 university volunteers who tried the device. She says that \u201cmore than 80 percent of the women who tried the device were able to get a good image.\u201d But what exactly \u201ca good image\u201d means is not explained. (Is it good enough for an accurate diagnosis?) The release does state that trials are planned to compare the new device with the traditional colposcope, but it should have been clearer about the fact that the device\u2019s accuracy has not been objectively assessed.", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did include clear numbers for potentially lethal ruptures following surgery, reinterventions, later abdominal operations, and most importantly, it did provide the surgical mortality rates for both procedures. \u00a0It did not , however provide sufficient information about the risk of death from aortic aneurysms if left untreated in order for the reader to evaluate the relative benefit to be gained from the treatments discussed.\u00a0 We\u2019ll give a satisfactory score here, but address this in the \"Treatment Options\" section below. ", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky because both devices are still under pre-clinical development. The story\u00a0says that the Italian model allowed rats to detect light for up to six months. That\u2019s interesting, but hard for readers to assess. And it\u2019s irresponsible at this stage to extrapolate animal findings to people, especially with a headline like \u201cThis Tiny Device Is a \u2018Game Changer\u2019 for People Facing Blindness.\u201d That\u2019s far from certain.", "answer": 0}, {"article": "For more information on Down syndrome, visit the U.S. National Library of Medicine.\nIn each case, the test quickly pinpointed the chromosomal variation, identifying 14 Down syndrome cases and 26 normal fetuses, the study authors said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that \u201cthe test quickly pinpointed the chromosomal variation, identifying 14 Down syndrome cases and 26 normal fetuses.\u201d", "answer": 1}, {"article": "Even a baby aspirin might be enough.\nFor some of these cancers, the reduction in death was remarkable.\nAnd the researchers were able to gather more information about cancer deaths for up to 20 years after those studies ended about nearly 13,000 people.\nIt encompasses eight earlier studies that compared cancer deaths among more than 25,000 people randomly assigned to get aspirin (of different doses) or placebo.\nTwenty years after people had started taking aspirin regularly (and kept it up for at least five years), their deaths from esophageal cancer were reduced by 60 percent compared to study subjects who got a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does not put the relative differences between aspirin and placebo in these studies into the proper perspective. The story says, \u201cFor some of these cancers, the reduction in death was remarkable.\u201d What is considered remarkable? \u201cTwenty years after people had started taking aspirin regularly (and kept it up for at least five years), their deaths from esophageal cancer were reduced by 60 percent compared to study subjects who got a placebo.\u201d How many people died from esophageal cancer? We never find out. In fact, we don\u2019t know how many people died period. There is a mangled sentence in the story that indicates that the study captured \u201ccancer deaths for up to 20 years after those studies ended\u00a0[for]\u2026\u00a0nearly 13,000 people.\u201d Esophageal cancer is rare compared to other cancers studied, and its low numbers may account for the high relative difference in preventative benefits of aspirin. To make that determination, though, readers would need the absolute differences. The story should have at least mentioned the number of cancer deaths. Telling readers that 674 participants died of cancer out of more than 25,000 included in the original studies would help them understand the actual size of any reduction in risk. The same is true for the claims about risk reduction over a 20 year period, where there were a total of 1634 cancer deaths among 12,659 participants. When readers are told of a \u201c20 percent reduction\u201d they should be told it was 20 percent of the number of actual cancer deaths, not 20 percent of the much, much larger total number of participants.", "answer": 0}, {"article": "\u201cBecause these are very tiny wounds, they heal and close up with minimal scarring,\u201d he said.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no clear quantification of benefits. The story says, \u201cAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said. \u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d What does successfully mean? How does one judge happiness in a case like this? What is the long-term potential for this hair to stay in and to continue to grow normally? Will, as is often the case with hair transplants, the transplanted hair stay in one spot while the hair the men were born with continue to thin?\n\u00a0", "answer": 0}, {"article": "In general, \"mindfulness\" practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nThe caveat, according to Spira, is that this study tested that specific program.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In broad strokes, the benefits are satisfactorily described. But a look under the hood reveals a missing explanation of what the \u201cthe sleep-problem scale\u201d is and what its point values mean. The story\u00a0says, \u201cBy the end of the study, the mindfulness group was showing a significant improvement \u2014 shaving about three points, on average, from their scores on the sleep-problem scale.\u201d By comparison the \u201cgroup that received standard education lowered their scores by an average of 1 point.\u201d How many points were on the scale? If the people meditating were three points lower on a 50-point scale, that\u2019s not quite as good as three points lower on a 10-point scale. The story does provide an additional point of reference by comparing the benefits to\u00a0sleep medications and \u2018talk therapy.\u2019", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\n\"With today's state-of-the-art treatment options and less extensive surgery, patients are experiencing better outcomes.\"\nIn some cases, women never develop any of these symptoms, Evers noted.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nThere are three tests often used to look for breast cancer, Evers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond vague generalizations of benefits, this article is essentially data free. Based on research, to what degree do these various screening methods save lives? The story doesn\u2019t say.", "answer": 0}, {"article": "Anthocyanins are a type of flavonoid plentiful in such berries as strawberries and blueberries.\nWhen researchers compared those who ate the most flavonoids with those who ate the least, they found that only men saw a statistically significant benefit, lowering their risk of Parkinson's by 40 percent.\nThe study findings should be interpreted cautiously because the participants were mostly white professionals, and the results might not apply to other ethnic groups.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\nFor women, however, a reduction in risk was only seen when they ate at least several servings of berries a week, according to the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It should be possible to calculate absolute risks from the data in this cohort study. However, this story reported only relative risks, which likely overstate the magnitude of the potential benefit.The absolute risk reduction for dietary changes and Parkinson\u2019s risk is likely to be very small.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the second paragraph the story explains that, according to the current study, 58 percent of patients receiving the Heartmate II survived for two years. The story does an excellent job comparing this outcome to that for heart transplant [70 percent alive after 10 years] and to an earlier version of the device [24 percent after two years]. ", "answer": 1}, {"article": "Merck suffered a setback last year when its attempts to win marketing approval to sell Erbitux in lung cancer were rebuffed by regulators.\n\u201cThis study clearly opens the field ...\nSales last year were $1.7 billion.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The LEAP study spurred the reversal in advice for exposing infants to peanuts, a decision that then led to the formulation and release of Hello, Peanut! as well as the qualified health claim it now carries.\nThe NYT story details the fact that LEAP study results indicated that by the time infants turned 5, only 1.9% of the 530 allergy-prone children who had been fed peanuts regularly since infancy had developed an allergy, compared with 13.7% of the children who had not consumed peanuts.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relates the benefits of immunotherapy reported in a published, New England Journal of Medicine study in simple, absolute terms\u2014complete remission from a late-stage cancer that \u201chas stayed away for more than two years.\u201d It also uses a loaded term\u2013\"cured\"\u2014to describe this remission. However, it is not yet known if this man is \"cured.\" And if the man has been lost to follow-up, as another news report suggests, we may never know. The story\u2019s reporting of unpublished data by Dr. Rosenberg is also incomplete, stating only that \"52 of 93 patients experienced a positive result.\" What does \"positive result\" mean? ", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story misleads the reader by citing 19,000 patients in the IDEA study. However the results described actually refer to 3,979 patients from whom data were analyzed. (The story does mention that these are preliminary results, but we think it could have been much clearer on this point.)\nThe endpoint in the study was whether patients treatment plans changed after their PET scans were analyzed by doctors. The story says roughly two-thirds of patients \u201csaw their medication regimens changed or were counseled differently by their doctors about what to expect.\u201d We\u2019d like to see the breakdown \u2014 how many changed medications? how many changed prognosis? Also, a change in prognosis might go in either direction \u2014 better or worse \u2014 and might be subtle or profound.\nThe story does include a patient whose faced a worse prognosis after his PET scan, but it\u2019s not clear whether he\u2019s representative. It\u2019s a compelling patient narrative, but was it a common result?", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nWhile some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\nFor now, here\u2019s what consumers should know:\n\nPhysical therapists say it is not, \u201cthough superficially, it may look the same,\u201d says Justin Elliott, vice president of government affairs for the American Physical Therapy Association.\nTo look for that possibility, the Ohio State study will compare patients who get the real needle treatment to those poked with sham needles that don\u2019t pierce the skin.\nIn a 2011 review, the physical therapy association rated the evidence for dry needling a 3 out of 5, based on the best studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call, since the story includes a general discussion of the benefits. But what it doesn\u2019t do is report on any quantified benefits, such as\u00a0how much pain relief people report in the studies, or for how long. It does tell us that the evidence shows the technique \u201cmay be useful\u201d and points out other findings, such as the evidence overall shows \u201cmixed results.\u201d", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\nResults showed a decrease fasting glucose levels, a loss of visceral fat, improve insulin resistance, and a significant (-0.43%) improvement in glycated hemoglobin (HbA1c) values.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\nAbout half of all subjects (52.5%) achieved less than 7.0% HbA1c, which is a treatment goal for diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides quantification of the benefits of the device but would have been a lot stronger with a better description of what some of the numbers mean. It states:\n\u201cThe reduction in the visceral fat area was 5.37 sq. cm in the 2 treatment per week group, 14.24 sq. cm in the 4 per week group and 16.45 sq. cm in the 7 per week group. Declines in HbA1c were 0.10%, 0.36%, and 0.65% in the 2, 4, and 7 treatment-per-week groups respectively.\u201d\nIt also stated, \u201cAbout half of all subjects (52.5%) achieved less than 7.0% HbA1c, which is a treatment goal for diabetes\u201d in reference to the first study. (HbA1c refers to glycated haemoglobin (A1c), which identifies average plasma glucose concentration.) But the release doesn\u2019t explain the relationship between lowering of HbA1c and improvements in heat shock protein, an important underpinning of the research. The information detailed in the graphic, while related to the basic research, is confusing since it relates to the animal and not the human research described in the release.\nA statement from the lead investigator appears premature. Dr. Kondo commented: \u201cEven in patients who have difficulty exercising, such as those who are overweight, elderly, or have some form of disability, this device can be expected to provide acceptable treatment in addition to conventional diabetic medical care.\u201d", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nAt a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, researchers presented results of the largest study to date of the PCA3 test.\n\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention that biopsies for prostate cancer can result in infection and that the test might have utility in that it might reduce the number of biopsies done.\nIn general, the story focused on\u00a0enhanced ability to diagnosis prostate cancer. But the story failed to question the value of the test in providing any long term benefit to the men involved. \u00a0Did it result in fewer prostate cancer deaths? \u00a0Did it result in fewer cases of metastatic disease? The story did not examine these important features for determining value and benefit. ", "answer": 0}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nEach case is different, and using a patient's own cells to destroy tumors won't work in every patient or in every type of cancer.\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\nA clinical trial to study the drug \u2014 now called ipilimumab, or Ippy for short \u2014 was set up at Memorial Sloan Kettering Cancer Center in New York City.\nIn those days, most firms were focused on drugs that would target tumors directly, and Allison was asking them to try something very different.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified. The story relates the experiences of one patient who went into full remission, and notes that \u201cEach case is different, and using a patient\u2019s own cells to destroy tumors won\u2019t work in every patient or in every type of cancer.\u201d\nBut it offers no information on how often ipilimumab results in complete remission, how often it causes tumors to shrink, how long it prolongs survival in patients, or how often it fails to work at all. For one patient, at least, it worked amazingly well \u2014 which is great. Without offering broader information about how well it works in larger populations, this could easily mislead readers into thinking it works for almost everybody. Yet, it doesn\u2019t work for everybody \u2014 and even for patients that see benefits, it doesn\u2019t always mean long-term remission (as the FDA noted in a news release about ipilimumab last year).", "answer": 0}, {"article": "\u201cFar too many cancers are picked up too late, when it is no longer possible to operate and the chances of survival are slim,\u201d he said.\nFor example, although the test detected ovarian cancer with 90% accuracy, only 10 ovarian cancers in total were detected.\n\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\n\u201cThis is potentially the holy grail of cancer research, to find cancers that are currently hard to cure at an earlier stage when they are easier to cure,\u201d said Dr Eric Klein, lead author of the research from Cleveland Clinic\u2019s Taussig Cancer Institute.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story errs on the side of promoting potential benefits without providing critical context.\nIt includes two reckless quotes (one by a lead author, another by an independent source) which suggest that the liquid biopsy:\nThis study did not address cure, survival, or productivity.\nFurthermore, the story lists the accuracy of \u201cdiagnosing\u201d 10 different types of cancer (with an \u2018accuracy\u2019 of 56% \u2013 90% depending on the cancer) without making it clear these are the percentage of people already known to have cancer who had a positive test confirm its presence.\nWe did appreciate this inclusion:\nThe number of patients in who cancers were detected was small. For example, although the test detected ovarian cancer with 90% accuracy, only 10 ovarian cancers in total were detected.\nTo be useful to readers, the story should have included the rate of false-positives and false-negative results. Or, what\u2019s known as test sensitivity \u2014 how often the test is correct when the disease is present; and specificity \u2013 how often the disease tests negative when the disease is not present. The percentages reported likely represent the sensitivity. So the article did provide some numbers, but it was limited and not explained in a way that would allow the reader to appreciate how good (or not good) the test really was.", "answer": 0}, {"article": "Miner continued.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nThe results of this study showed that two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma, an exciting sign of progress in the cancer detection field.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states it\u2019s \u201can exciting sign of progress in the cancer detection field\u201d because researchers detected \u201ctwo mesothelioma-specific ENOX2 protein transcript variants\u201d in the blood serum of individuals exposed to asbestos \u201can average of 6.2 years\u201d before they were clinically diagnosed.\nUnfortunately, that\u2019s the only attempt at quantification found in the release. There\u2019s no mention of accuracy or sensitivity of the test, how many people were tested, or how long the study lasted.\nIt\u2019s not enough to claim that the test is useful. The sponsors should provide some data on how it improves patient outcomes, not just sound an alarm in order to get individuals to take a test. The unfortunate reality is that patients diagnosed with stage 1 disease have a median survival of 21 months and those diagnosed at stage 4 have a median survival of 12 months. It remains to be seen if early detection provides any advantage and a large clinical trial will be needed to see if this is true.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did a good job describing the current evidence for deep brain stimulation on insulin sensitivity, which is still in the earliest of stages. A single patient receiving DBS for obsessive-compulsive disorder reduced his need for insulin dose by 80%. Description of more fundamental experiments were not quantitatively detailed, which seems acceptable for the health focus here.", "answer": 1}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the study is designed to prove safety, there are no credible benefits data to report. \nThe report does allow sources to make general claims of benefit based on that preliminary data, but the reporter shows restraint by not plucking benefits data points from the study.\u00a0\nOn a close call, the story earns a satisfactory rating. ", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to describe the improvement in blood flow in absolute terms, instead noting only relative or percent improvement (e.g. 37% compared to baseline for consumption of artificially sweetened cocoa). The reported 37% improvement is much greater than that reported in a press release from the American College of Cardiology (2.4% over baseline); the reason for the discrepancy is unclear.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As mentioned above, one of the most significant benefits of the bilateral surgery is cost. However, there are others \u2014 such as the fact that a patient only has to be anesthetized once, and will likely spend less time (overall) in the hospital. The story says that the 2013 study where it got its cost numbers \u201cconcluded that bilateral surgery is more cost-effective with better outcomes for the average patient than staged procedures for two knees.\u201d We italicized the \u201cwith better outcomes\u201d part, because that\u2019s the sticking point. What does it mean? In order for readers to make sense of a term like \u201cbetter outcomes\u201d it needs to be both clearly defined and quantified. On a side note, it would be great if the story linked to the relevant 2013 study.", "answer": 0}, {"article": ".\nAfter looking at multiple trials of tamoxifen and raloxifene, the task force noted that these drugs reduced new cases of breast cancer significantly: from 23 cases per 1,000 women in the control groups to 16 cases per 1,000 women in the treatment groups.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\nKala Visvanathan, the lead author of the ASCO recommendations and a faculty member at the Johns Hopkins School of Medicine, said the cutoffs provide only a rough estimate of risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s initial discussion of benefits focuses mainly on very attractive relative risk figures. It notes that in one study, women who took tamoxifen \u201cwere half as likely to develop breast cancer as similar women who did not take the drug.\u201d And an expert says that high-risk women \u201ccould reduce their risks for invasive cancer by approximately 30 to 50 percent.\u201d\u00a0\u00a0It\u2019s not until further down in the study that the much less glamorous absolute risk estimate is provided. The story notes that \u201cafter looking at multiple trials of tamoxifen and raloxifene, the [U.S. Preventives Services Task Force]\u00a0noted\u00a0that these drugs reduced new cases of breast cancer significantly: from 23 cases per 1,000 women in the control groups to 16 cases per 1,000 women in the treatment groups.\u201d\nWhile the story\u2019s framing is problematic, we give the story credit for eventually getting to the key statistics that consumers need. We also applaud the inclusion of nuance from an independent expert. The story quotes Kenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines. He notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d He explains that the drugs may be effective at preventing nonlethal cancers rather than the more serious ones.", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nHe figured that a person who is dependent on drugs would find a replacement if heroin no longer caused a high.\nThe absence of a high could help recovering heroin users resist the temptation to relapse, the researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits were not put in quantified terms. Instead, qualitative terms are used.\u00a0Phrasing like, \u201celicited a successful immune response that neutralized heroin\u2026\u201d and, \u201c\u2026hinting that their immune systems were already primed\u2026\u201d provide insight to medical professionals, but are perhaps confusing to lay readers. With research this preliminary, far more caveats were needed to pass this criterion.", "answer": 0}, {"article": "Of these, 85 percent were mild or moderate.\nThe studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nThe Alzheimer's Association has more on this condition.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story merely mentions that this drug had \u2018shown promise\u2019 and that the studies reported are \u2018encouraging\u2019 because they indicate that people can tolerate the drug for 2- 4 years without safety concerns.\nPromise of what? \u00a0What does the drug do? \u00a0Although the story mentions amyloid accumulation, it failed to explain that though amyloid accumulation is seen in Alzheimer\u2019s disease, it isn\u2019t clear whether it causes symptoms or is secondary to the disease process.\nThe story would have added valuable context by at least mentioning the results of the placebo-controlled study from which the patients in this extension study were drawn.  http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1166655 That study found that the drug had no effect on symptoms in the study group overall, although specific subgroups seemed to benefit in an after-the-fact analysis that was not part of the original study design.", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data were given about potential benefits.\u00a0 ", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although it\u2019s too early to quantify the technique\u2019s benefits, this story does that. We\u2019re told that the study of 66 patients found that those with the most severe brain injury had 16 times the level of UCH-L1 as those without brain injury. What is the true clinical significance of that result?\nThe benefits of using biomarkers wouldn\u2019t be just they can detect brain injury but they can do so better and more usefully than the methods we have now. Otherwise, how does it benefit us? What\u2019s the clinical meaning of the 16x difference for this one biomarker? What about the other biomarkers in the panel alluded? Could the researchers use this result to distinguish mild from severe, or mild from normal, or cases that are hard-to-catch vs those that are obvious? (Dr. Hall suggests there are questions about mild cases.)\nWe\u2019re given the analogy to troponin tests for heart attacks, which is \"more precise than having a patient describe symptoms.\" The implication, thus, is that this 16x difference is a hugely superior signal to the standard cues we use to diagnose severe brain injury. But the researchers didn\u2019t compare this new technique to current diagnostic ones.\u00a0In short, the story does a poor job of describing how such a test will lead to improved care. The analogy to troponin is a good point, because early identification of a heart attack leads to treatments that have been shown to be lifesaving. A similar evidence base would be needed for biomarker identification of brain injuries.\nThat\u2019s a big problem with reporting on laboratory research like it\u2019s clinical research: we don\u2019t have hard outcomes to look at, only surrogate ones. The true benefits would be the test\u2019s specificity, sensitivity, and speed, and its effects on actual people\u2019s lives\u00a0comparative\u00a0to the standard approach. ", "answer": 0}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nAfter three weeks, 14 percent of patients in the real TMS group had recovered from their depression, compared to 5 percent of the sham TMS group; people who had the real treatment were four times as likely to get better as those who got the fake treatment.\nSomething similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\nWhile there\u2019s evidence that this technique, known as transcranial magnetic stimulation (TMS), helps depressed people get better-and the US Food and Drug Administration has approved TMS for this purpose-many skeptics have questioned whether it really works, notes Dr. Mark S. George of the Medical University of South Carolina in Charleston, the lead author of the new study.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article describes the percentage of patients who benefited from TMS in absolute terms and tells us that\u00a012 patients would need to be treated with TMS to achieve 1 treatment success. These descriptions give readers a realistic\u00a0idea of how likely a patient will be\u00a0to benefit from TMS.\u00a0\u00a0\nAn even clearer approach would have been to\u00a0say that\u00a013 of 92 (14%) benefited from\u00a0TMS and that 5 of 98 (5%) benefited from\u00a0sham treatment.\u00a0The other critical missed opportunity is to remind readers that these are remission rates in those who failed at least 1 prior treatment.\u00a0For\u00a0patients who have never been treated for depression, remission rates are much higher with any first-line treatment.", "answer": 1}, {"article": "Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.)\nFolsom, Calif., (Nov. 19, 2015) - A new study published in the American Journal of Clinical Nutrition found that consuming tree nuts, such as walnuts, may lower the risk of cardiovascular disease.1 After conducting a systematic review and meta-analysis of 61 controlled trials, one of the authors, Michael Falk, PhD, Life Sciences Research Organization, found that consuming tree nuts lowers total cholesterol, triglycerides, LDL cholesterol, and ApoB, the primary protein found in LDL cholesterol.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\nTrials directly provided nuts to the intervention group rather than relying solely on dietary advice to consume nuts.\nDietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While in most cases the release carefully states that the study analysis included \u201ctree nuts, such as walnuts\u201d without claiming the focus of the research was walnuts alone, in one paragraph the release says that decades of research have shown that walnuts can help reduce cardiovascular disease risk by decreasing LDL (bad) cholesterol by 9 to 16% and diastolic blood pressure by 2 to 3 mmHg.\nBut according to the study:\n\u201cConclusions: Tree nut intake lowers total cholesterol, LDL cholesterol, ApoB, and triglycerides. The major determinant of cholesterol lowering appears to be nut dose rather than nut type. Our findings also highlight the need for investigation of possible stronger effects at high nut doses and among diabetic populations.\u201d\nThe release could have done a better job giving and explaining absolute risk reduction for the cholesterol findings. From the study: Of 2,582 volunteers involved in one of 61 studies, lowered total cholesterol was \u22124.7 mg/dL; 95% CI: \u22125.3, \u22124.0 mg/dL.", "answer": 1}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nIn the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.\nThese findings in animal studies have spurred people to take commercially available NR supplements designed to boost NAD+.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nIn addition to showing that NR boosts NAD+ in humans without adverse effects, the trial confirmed that NAAD is a highly sensitive biomarker of NR supplementation in people.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since there are no proven benefits to humans for NR, there are no benefits to quantify, but that didn\u2019t stop the release from strongly suggesting benefits.\nA reader could assume from reading the release that claims of efficacy in humans were being made. For example:\n\u201cVitamin safely boosts levels of important cell metabolite linked to multiple health benefits\u201d\n\u201cBecause the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely.\u201d\nThis was a short-term Phase 1 safety trial, which is meant to determine whether a drug is safe by testing it on a small number of people. Phase 2 and 3 trials test a drug\u2019s efficacy as a treatment among larger groups of people.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Includes the caveat that \u201cSolid evidence of the lasers\u2019 effectiveness, is scant. In clinical practice, results have varied, according to doctors who have used the laser.\u201d\nIt was quite specific about a small, short-term study and how often it s howed \u201cnew growth without fungus\u201d or \u201cat least three millimeters of clear new nail.\u201d\nAll very helpful details to guide readers\u2019 decisions about whether this is worth it.", "answer": 1}, {"article": ".\nAuthors found a statistically significant risk reduction in repeat UTIs overall, but not significant for any particular subgroup.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\na total of 28 studies showing results from nearly 5,000 patients were considered.\nAccording to the authors, scientists and practitioners continue to explore the use of alternative therapies in the prevention of common infections as part of the global movement to reduce antibiotic use and resistance.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. According to the release, \u201cAuthors found a statistically significant risk reduction in repeat UTIs overall, but not significant for any particular subgroup.\u201d But what does \u201cstatistically significant risk reduction\u201d mean? Were patients 10 percent less likely to get a UTI? 0.1 percent? Those are both\u00a0statistically significant, but there\u2019s a world of difference. In fact, the published study reported that the risk of recurrent infection was reduced by approximately 33 percent. Including this quantitative information would greatly strengthen the release.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because the story deals with one patient who is participating in an early stage clinical trial, there is little concrete benefit information to report. The story says that the doctor conducting the clinical trial found, a month after the first treatment, that this first patient\u2019s tumor \u201chad begun to atrophy,\u201d but it notes that data from animal trials of the drug suggest that it would take \u201cthree or four months to gauge the response.\u201d The bottom line here is that because the story focuses on the first human patient in the earliest of three levels of clinical trials required for FDA approval, no one really knows how much benefit this drug will produce. The story should have noted that\u2013strongly.", "answer": 0}, {"article": "Dressed in street clothes, Tara Cassidy Driscoll lies face-down on an examining table at the Massachusetts General Hospital.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nStudies have given conflicting results, partly because there's no standardized way of doing shock-wave therapy.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\n[Other centers use lower-energy shock waves over several treatments.]\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even when it\u2019s quoting a doctor who is clearly a proponent of shockwave therapy (as discussed above in the Evidence Quality criterion),\u00a0the story\u00a0treats benefits with appropriate caution and doesn\u2019t succumb to hype. This story also seems to have avoided the compulsory anecdote about the patient who is feeling dramatically better after a new high-tech treatment. In\u00a0fact,\u00a0the story\u00a0seems to go out of its way to provide the perspective of someone got better with low-tech\u00a0standbys\u00a0such as stretching, taping, and ice \u2014 valuable \u00a0context that is\u00a0often lacking in coverage of medical treatments.\nOn the downside, the story focuses exclusively on pain and doesn\u2019t tell us whether patients who receive shockwave treatment had improved functioning\u00a0or could participate in more activities\u00a0afterward. These are\u00a0important\u00a0measures of a treatment\u2019s overall effect on patients.\u00a0", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantified the benefits seen in the study that led to FDA approval. ", "answer": 1}, {"article": "It describes circulating tumor cells as cancer cells that have detached from a tumor and are found at very low levels in the bloodstream.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\nToner says the test is like a liquid biopsy and targets almost all solid cancers -- cancers found in \"solid\" organs like the breast or prostate.\nToner said you are likely to find just one circulating tumor cell in 5 to 10 billion blood cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As mentioned above, the story regurgitates unsupported promises that early detection of cancer is inherently beneficial. But it gives no data on how the test has fared in studies to date. ", "answer": 0}, {"article": "Harvard T.H.\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\nAmong all the women, there was a strong inverse association between fiber intake and breast cancer incidence.\nIn 1991, the women--ages 27-44 at the time--filled out questionnaires about their food intake, and did so every four years after that.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We recognize that it would be challenging for anyone writing a news release about this study to report on the absolute risks seen in the study. The study does not report absolute risks, although it is possible to calculate them based on the data provided in the tables. One could look at the number of cases in each quintile of dietary fiber (found in Table 2) and divide that by the number of people in each quintile (which is found in Table 1). There are several steps involved, but for the example of early adulthood dietary fiber and breast cancer risk in this cohort, you could do the following calculation:\n\u2013 613 cases in quintile 1 / 18,364 women in quintile 1 = 3.3% later developed breast cancer (pre or post menopause)\n.\u2013 567 cases in quintile 5/ 18,167 women in quintile 5 = 3.1% later developed breast cancer (pre or post menopause).\n\u2013 The difference is 0.2 percentage point, which is quite a small absolute risk reduction.\nWhen absolute risk numbers aren\u2019t reported in a study, we think press officers should ask the researchers to provide these numbers so that they can be disseminated to the public. The issue of absolute risk reduction is key to helping readers understand the impact of changing dietary behaviors. We think it\u2019s important enough to rate any news release Not Satisfactory when these numbers aren\u2019t provided.", "answer": 0}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nNow, researchers believe a a new type of experimental drug may help change that.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story implies that the risk of heart attacks to patients is reduced by half with the new drugs. However, that\u2019s a relative risk reduction that likely overstates the size of the benefit \u2014 we think absolute risk is more helpful to readers. The key point is that this short-term benefit of a 50% risk reduction is impressive in the studied populations, but the absolute risks were very small. The absolute rates of heart attack in PCSK9 groups were 0.58% compared with 1% for placebo, a difference of less than half a percentage point. Presumably longer studies or studies in higher risk populations may show more impressive absolute reductions. It would also be relevant to compare the results of this new class to statins, the current standard. Generally statins demonstrate ~30% risk reduction. So this may be a more potent class of drugs, but the improvement (if confirmed in additional studies) will be incremental.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits from supplementation with additional vitamin D were not quantified. \u00a0In fact, as the older offspring of the author were not reported to be suffering from rickets, one might question whether increased vitamin D intake has merit.", "answer": 0}, {"article": "\u201cI don\u2019t want this strategy to be used widely in any person, clearly,\u201d Molina said.\nA commentary published with the study argued that reducing infection rates in men who have sex with men and who are highly sexually active might lower STI infection rates more generally in a community.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\n\u201cBut if you can select a group with a high incidence rate of syphilis or chlamydia, and you want to try to reduce the rate of syphilis quite quickly in this group of people, you may think that this strategy could be used for a couple of months.\u201d\n\nRates of syphilis in particular have risen steadily in recent years; the rate in 2015-2016 \u2014 8.7 cases per 100,000 people \u2014 was the highest since 1993, the Centers for Disease Control and Prevention reported.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives some relative reductions, but doesn\u2019t provide enough comparative data to give readers the scope of the benefits. For example, overall, without the antibiotic, the rate of new infection, given that condoms were not used, was 42% (45 men), and with the antibiotic, 22% (28 men).\nAlso, the story implies that there might be a benefit for anyone who is sexually active. Although it notes that the study participants were \u201cmen who had frequent unprotected sex with a number of male sex partners,\u201d the story does not make clear just how unusual the men in the study were. For example, while the story reports that syphilis rates for the general US population have risen to almost 9 per 100,000 during a year, the syphilis infection rate in the control group was 11 percent (that is, 11 per 100, not 100,000) over 9 months; a rate that is more than 1,000 times the rate in the general population. The story should have made the point that the men in the study do not resemble the general population.", "answer": 0}, {"article": "\"That makes for a powerful marketing advantage,\" Sullivan said.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nAt seven days, the percentage of subjects exhibiting reduced severity was six times greater for those using HSRx 2121, compared to those using the competing product.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that \u201cAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\u201d Various other relative comparisons are provided that are all about as clear as mud since they don\u2019t contain any absolute numbers. Example: \u201cthe percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much\u2026\u201d Three times as much as what?", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No estimate for the percentage of patients who \ndid not respond to standard treatment and who would be expected to die within the time frame of the study. (However \u2013 and \nthis is no excuse for the journalist \u2013 this information was not in the original research reported on either.)", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that these drugs in combined form would \u201cbattle heart disease, diabetes and other illnesses all at the same time,\u201d but there is no quantification of how much they would help a healthy older adult.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For a short article, the Wall St. Journal story framed and quantified the benefits adequately.\n\n\n\n ", "answer": 1}, {"article": "For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When quantifying benefits, the story allows hype to take the place of hard data. The second quote in the story, from the lead researcher, who has just been paid by the drug company to conduct this study, says, \u201cWith the new antibiotic treatment, Pimentel tells WebMD, many participants \u201dsay they are 80% improved, 90% improved, that kind of results.\u201d\u201d Note that phrase: \u201cmany participants.\u201d Just how many? And what does 80% or 90% improved mean?\u00a0 What objective measure of this was made?\nThe story also glosses over the significant placebo response in comparison with the drug group response, reporting:\n\u201cJust 31.7%\u201d ??? This is biased framing.", "answer": 0}, {"article": "\u201cMy skin has cleared up.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\nSo far, while Diamond has noted an immune response in patients given the combination treatment in clinical trials, he has not seen a clinical benefit.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\nHowever, patients whose T cells had pre-existing high levels of a protein named PD1 \u2014 a molecule that instructs immune cells to shut down \u2014 responded poorly to the anti-p53 vaccine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s irresponsible to suggest a sample of one patient represents a miracle cure as this release does, particularly without providing any hard data to back up the claims.\u00a0The release noted that the patient\u2019s skin lesions had diminished and that biopsies showed no cancer, but we do not know beyond this patient what sort of benefit the drug treatment combination should yield. The release noted that in previous trials on different types of cancer, patients had an immune response but provided no details.\nThe release also noted that the patient had not yet undergone bone and CT scans to assess whether other sites of tumor have regressed and it states the\u00a0patient was still undergoing treatment. Therefore, benefits are ambiguous at best \u2014 and should have been treated as such throughout the release.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In some cases, we might give a passing grade to a story that tells readers that one trial \u201cfound that in 17 of 30 advanced cancer patients, pembrolizumab stopped or reversed the progression of cancer, and 24 patients were still alive a year after starting the drug,\u201d but this story should have alerted readers to the fundamental difference between these sorts of trial results and what people really care about: \u201cDoes the drug extend or improve the lives of patients?\u201d\nThis point is particularly important because of mounting evidence that the slowing of cancer progression and other surrogate endpoints may not really answer the important questions about survival and quality of life. For example, one review\u00a0of the 36 cancer drugs approved by the FDA from 2008 through 2012 based on surrogate endpoints revealed that only five later showed real survival benefits. A follow-up review looked at 55 cancer drugs approved based on surrogate endpoints. Reviewers found evidence of trials eventually showing improved survival for only 10 of the 55 drugs.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nIn the new Neurology article, the researchers report associations between seafood consumption and two of the areas of cognitive ability that they tested.\nPeople who ate more seafood had reduced rates of decline in the semantic memory, which is memory of verbal information.\nThe study did not find a significant difference in the rate of decline in episodic memory (recollection of personal experiences), working memory (short-term memory used in mental function in the immediate present) and visuospatial ability (comprehension of relationships between objects).\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are discussed using only vague language. For example: \u201cage-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\u201d How much more rapidly? Or: \u201cPeople who ate more seafood had reduced rates of decline in the semantic memory, which is memory of verbal information. They also had slower rates of decline in a test of perceptual speed, or the ability to quickly compare letters, objects and patterns.\u201d But how much less decline was there of semantic memory? And how much slower was the decline in regard to perceptual speed? The release doesn\u2019t tell us.\nIt would have been helpful for the news release to present the raw numbers relating to cognitive decline in each group and to provide some context to help readers understand their significance (such as \u201cperformance on the semantic memory test dropped by X amount in this group and Y in the other group,\u201d for example).", "answer": 0}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not give the reader a sense of how significant the pain relief or avoidance was.\u00a0There was a significant improvement in rate of freedom from pain at two hours for the first treated episode (39% in the treatment arm versus 22% in the sham treatment arm), but about half the subjects in both arms thought their pain relief was fair to poor.\u00a0\u00a0 ", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\nThe findings were published in The American Journal of Sports Medicine.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are essentially quantified, but we thought the story could have gone further in helping readers understand what the numbers mean.", "answer": 1}, {"article": "Newswise \u2014 Bethesda, Md.\nBut in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nStatin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Multiple benefits are mentioned, as well as what may take place biologically in the body when taking stains, but there are no numbers illustrating an advantage for such treatment. A measurement of the benefit would only come from high quality randomized trials. What may take place biologically in the body when taking statins is not an adequate substitute for trials that show an actual cause and effect.\nIf statins can reduce inflammation in chronic liver disease one has to ask: \u00a0Do the statin patients live any longer? If there is no observable benefit on quality or quantity of life, does statin therapy make any sense? ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does not quantify benefits. It reports puported benefits (less blood loss, avoid damaging nerves during surgery) but there isn\u2019t much evidence to support these claims. ", "answer": 0}, {"article": "In Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\nSuzanne Haber, a neuroscientist at the University of Rochester Medical Center in New York who was not involved in the study, said she was \u201cvery excited about the finding,\u201d but she cautioned that the treatment is very invasive, very expensive and unproven in Alzheimer\u2019s patients.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nThey also saw signs the treatment might have an effect on memory.\nFried said the study might have implications for treatments for patients with early Alzheimer\u2019s disease, but he cautioned that the results are very preliminary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear that this test was just a preliminary experiment to see if brain stimulation can have any memory effects in people. It notes that while researchers say it is worth exploring as a potential treatment for Alzheimer\u2019s disease, there is no evidence yet that it provides such benefits.", "answer": 1}, {"article": "These include medications to lower blood pressure and diuretics to help remove excess fluid that builds up as a result of the heart's labored pumping ability.\nA phase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness.\nCimaglermin, however, may be such a drug, she said.\nDespite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.\n\"Right now we have many therapies that we use for heart failure, and these patients [in the study] were on all of those therapies and still had significant heart dysfunction,\" said lead researcher Dr. Daniel Lenihan.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While this story discusses that the drug seemed to benefit patients and was effective, it doesn\u2019t say how that was measured, and by how much the measurement improved due to the drug.\n(By digging into the research paper, via figure 3, we found that the benefits were measured by tracking absolute increases in\u00a0ejection fraction, which is the amount of blood pumped out the ventricles. It increased 8% in the group receiving a medium or high dose of the medicine.)\nOne issue that might be confusing for readers: The story notes that a \u201cphase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness.\u201d If that\u2019s the case, then why is the framing of the story about how effective it was?", "answer": 0}, {"article": "That wouldn\u2019t be surprising.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\nTaken together, those findings suggest healthy adults face no increased heart risks from calcium, in food or supplements, in amounts of up to 2,000-2,500 mg a day, researchers reported in the Annals of Internal Medicine.\nThe larger review did not include all potentially relevant studies, says Erin Michos, an associate professor of medicine and epidemiology who led the Johns Hopkins study.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does several things well here, but it does not give us any sense of the measured benefits of taking calcium supplements\u2013a systematic review\u00a0determined the evidence was \u201cweak and inconsistent.\u201d That lack of quantification is why this earns a \u201cnot satisfactory\u201d rating.\nThat said, let\u2019s look at the things the story does well. First, the story makes clear that many people do not need calcium supplements, discussing what constitutes the recommended level of calcium intake per day, and that fact that many people meet that mark through their daily diet. Second, the story also makes clear that some people can benefit from calcium supplements, pointing specifically to older adults who have been diagnosed with osteoporosis and teen girls, whose diets may not include the recommended 1,300 milligrams of calcium per day.", "answer": 0}, {"article": "Using electromagnetic radiation, infrared lamps warm your body directly.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nBeever makes it clear all of these reports were based on small groups and require further study.\n\u201cSauna bathing leads to a significant increase in heart rate and reduction in total vascular resistance, thereby decreasing blood pressure,\u201d says Dr. Ernst van der Wall, chief of cardiology at the Netherlands Leiden University Medical Centre.\nBeever says infrared heat may damage sperm as do other forms of heat, but at this point there\u2019s no data on those risks.)\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The discussion of benefits when quantified, relied on relative and vague numbers, such as \u201cpeople who spent 15 minutes a day for two weeks in an infrared sauna enjoyed a significant drop in blood pressure compared to a control group.\u201d We\u2019re not told by how many points their pressure dropped, nor if the change was clinically meaningful.\u00a0Also, the unhelpful fact that a study in Finnish men \u201cenjoyed\u00a0a 23% drop in their risk for a fatal heart disease or episode\u201d doesn\u2019t really give us a sense of the overall magnitude of the effect. (As a side note, the verb \u201cenjoy\u201d was used three times to explain findings\u00a0in clinical studies\u2013which isn\u2019t the most accurate way to explain to readers what was measured.)", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately reports\u00a0the study\u2019s implications in the middle of the piece when it says: \u201cThe results support current guidelines that say non-BRCA mutation carriers in families affected by the BRCA genes don\u2019t need special screening beyond mammography as recommended for the general population\u2026\u201d And the study does\u00a0go into detail and quantify how the test helps refine estimates of breast and ovarian cancer risk.\nHowever, the headline and opening sentence bothered our reviewers. The story suggests that women who are relatives of BRCA carriers, but who tested negative for the mutation themselves, no longer need to consider preventive mastectomies\u00a0to reduce their risk of developing breast cancer. In fact, preventive mastectomy would be considered an extreme intervention in women who test negative for the BRCA mutation,\u00a0so these findings may have little bearing on\u00a0such decisions. The findings also have no bearing on\u00a0the decision\u00a0of women who are\u00a0BRCA-positive to\u00a0undergo preventive mastectomy.\u00a0Accordingly, the results\u00a0are neither \u201creassuring\u201d\u00a0nor \u201cweaken the case\u201d for preventive mastectomy in women\u00a0who might be considering this intervention.", "answer": 1}, {"article": "HPV is the leading cause of cervical cancer in women, but also has been linked to penile cancer and other malignancies in men.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Neither this nor the WebMD story gets high marks on describing the potential benefits seen in the study. Although a total of seven endpoints were described in the study results, the writer chose to use the most optimistic of the lot. The 90% efficacy quoted is a far cry from the actual 60% efficacy based on an intention to treat analysis. The study results are complicated and simply picking one number of the many does not provide the reader with the correct information. THe vaccine was not shown to be 90% effective overall.", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nOn average, the change in seizure frequency amounted to a 39% decrease for the cannabidiol group patients, compared with a roughly 13% decrease among the placebo group.\nStill, Hall said the research, which carefully measured safety and efficacy for a \"substantial\" number of children, showed \"clear evidence of benefits in reducing seizure frequency and severity over the duration of the trial.\"\nNine out of 61 cannabidiol group patients dropped out of the study, eight of them because of side effects, compared with just three of the 59 placebo group patients.\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says in the first paragraph: \u201cAmong children taking cannabidiol, the decrease in the frequency of\u00a0convulsive seizures\u00a0\u2014 which involve a loss of consciousness, stiffened muscles and jerking movements \u2014 was 23 percentage points greater than the decrease in seizures among children taking a placebo.\u201d\nWhat exactly does this mean? That, for example, the children taking a placebo experienced seizures on 73 out of every 100 days during the trial and that those taking the drug experienced seizures on 50 out of every 100 days? We would need to know the actual number of children who did and did not experience seizures and then know more about the frequency of those seizures to understand this reduction.\nLater in the story, there is a better explanation of the comparison of frequency of seizures, and the story does something that most stories don\u2019t ever do. It explains the range of experiences during the trial, not just the average. It says, \u201cWithin the study, individual participants experienced convulsive seizures at a rate ranging from four per month, on average, to 1,717 per month. During the 14-week study, frequency of convulsive seizures decreased from an average of 12.4 to 5.9 per month in the cannabidiol group, compared with 14.9 to 14.1 in the placebo group. On average, the change in seizure frequency amounted to a 39% decrease for the cannabidiol group patients, compared with a roughly 13% decrease among the placebo group.\u201d\nThat\u2019s quite a range, and it would have been good for the story to include a sentence explaining that the sheer variety in the patient population would make it difficult to adequately assess the efficacy of the drug in a trial this small in size. We\u2019re unclear on the math here, though. It looks to us that there was a 26 percentage point difference between the reduction in the drug group and the placebo group.\nStill, this is a lot of data-driven detail we don\u2019t normally see in news stories, so we appreciated this.\n\u00a0", "answer": 1}, {"article": "\"Ebola left a devastating legacy in our country.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\n[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nAmong the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination [3].\nThe study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release explains that, among participants vaccinated immediately, no Ebola cases were identified 10 days or more after vaccination, compared to 23 cases among individuals assigned to the delayed vaccination group. The data also suggested that the vaccine reduced Ebola risks for unvaccinated individuals within the contact rings of those who were vaccinated, but the news release notes that the study was not designed to test this so-called \u201cherd immunity\u201d effect, so it will require further research to confirm that vaccinating some individuals reduces the likelihood of their contacts developing Ebola.\nThe release could have explained more clearly that the virus has a 10 day incubation period during\u00a0which the virus can develop in the\u00a0patient and not be affected by the vaccine as the body won\u2019t have time to develop immunity. But the fact that the two groups (vaccinated and delayed vaccination) had equal numbers during the 0 to 10 day period helps to confirm that the two groups were equal in their exposure to the virus and risk of developing Ebola.", "answer": 1}, {"article": ".\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nNew Rochelle, NY, September 25, 2017--A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As far as benefits of this new\u00a0drug go, the release only states that it \u201cled to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\u201d\u00a0 It adds that, \u201cchildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening.\u201d\u00a0 There is no explanation of the degree of improvement among children taking the drug compared to those on a placebo, and therefore, readers are at a loss to gauge the real value of the new formulation.\nMoreover, the new formulation is compared to placebo, but it is already known that stimulants are superior to placebo for most ADHD-related outcomes. If the novel element of this new (and presumably more expensive) formulation is that it improves morning symptoms compared to standard early AM dosing, then a more appropriate control group (or perhaps a 3rd volunteer group) would have been morning dosing of standard formulation methylphenidate.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\n\"I basically ... just wanted to close my eyes and not wake up again,\" remembers Annette Coker, who was paralyzed in a car accident.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits. By focusing on one patient\u2019s positive experience, the story implies that the treatment works perfectly for all people. In reality, the basic question \u201chow well does this treatment work?\u201d is not answered.", "answer": 0}, {"article": "\"The cells also need to have a propensity to grow elsewhere,\" she said.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\nAccording to Bernik, though, \"it makes sense that women who have circulating tumor cells would potentially be at higher risk of distant disease at some later date.\"\nAccording to Lucci, circulating tumor cells are also showing promise in predicting melanoma prognosis, so the method may be \"effective in several different tumor systems.\"\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The writer makes it clear that while\u00a0lymph node status\u00a0\u201cis currently the best way to predict survival in women with breast cancer\u201d some women\u00a0with no cancer in their lymph nodes will eventually\u00a0experience a relapse of their cancer.\nBut then the story never discussed comparing this approach with current approaches to predict risk (including Oncotype, Adjuvant online, lymph node status etc).\nSo what is the comparative benefit?", "answer": 0}, {"article": "It is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"They still drank, but they drank less.\"\nHe studied the extract puerarin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Nice job here. Instead of just telling us that the participants \u201cdrank less\u201d while taking the supplement, they quantified the reduction: about one beer less, on average, during the experimental drinking sessions (2.4 vs. 3.5 beers), and about half a beer less per day during the week they were taking the supplement compared with placebo (3 vs. 3.4 beers).", "answer": 1}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a reasonable job in describing the benefits and placing them in context with comments about potential harms", "answer": 1}, {"article": ".\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\nIn the study, pregnant women hospitalized with severe flu illness were half as likely to have been vaccinated as women hospitalized with milder illness (14 percent vs. 26 percent).\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\n\u2022 Among pregnant women hospitalized with severe flu who were treated early with an antiviral medication, the median length of their hospital stay was about five days shorter compared to similar patients treated later.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is a mixed bag here. The release adequately describes some aspects of the benefits. For example, pregnant women hospitalized with severe flu that were given oseltamivir within two days of exhibiting flu symptoms spent a median of 2.2 days in the hospital; as compared to 7.8 days for pregnant women hospitalized with severe flu that were given oseltamivir more than two days after exhibiting flu symptoms. In addition, the release addresses the benefit of vaccination by saying: \u201cpregnant women hospitalized with severe flu illness were half as likely to have been vaccinated as women hospitalized with milder illness (14 percent vs. 26 percent).\u201d But the release would have been stronger if it had done a couple additional things.\nFirst, the release notes that \u201cPregnant women hospitalized with less severe illness who were treated early also had a shorter hospital stay than those treated later, but the difference was not as great.\u201d If you\u2019re going to mention this benefit at all, even using modest language, it would be better to put a number to it. (Was it a difference of a day? 0.2 days?) Also, the release specifically mentions \u201cserious illness and complications, including death\u201d in its opening paragraph \u2014 but never tells readers whether the study found any potential connection between early antiviral treatment and reduced risk of complications for mother or child. Even if the study didn\u2019t find any such relationship, the release could have said that.", "answer": 1}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nYin Cao, an instructor in the Medicine, Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and Harvard Medical School, presented the information Monday at the American Association for Cancer Research meeting in Washington.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states the percentages of reduction of cancer among aspirin users as opposed to those who do not take aspirin and divides the results by men and women. This is a good start, but readers deserve to see the actual numbers\u2013known as the absolute risk reduction\u2013along with the relative percentages.", "answer": 0}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\n\u201cOver all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,\u201d Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.\n\u201cThey don\u2019t feel well on them, but it\u2019s their safety net,\u201d said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug.\nMr. Peto said he thought the results of the Atlas study would \u201capply to endocrine therapy in general,\u201d meaning that 10 years of an aromatase inhibitor would be better than five years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Description of benefits was adequate.\u00a0 Absolute differences between the treatment groups was provided \u2013 although AP\u2019s story broke it down a little bit farther and better for lay readers with this line:\u00a0 \u201cIn absolute terms, continuing on tamoxifen kept three additional women out of every 100 from dying of brest cancer within five to 14 years from when their disease was diagnosed.\u201d", "answer": 1}, {"article": "Ketamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nWhile controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\n\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nPatients in the study completed the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Claimed benefits are not quantified in the release. The only number we are provided comes from this statement: \u201cPatients in the study complete the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\u201d\nHow many patients? The study says 100, but the news release says nothing. How long did the \u201cpersistent\u201d response last? We never find out. The news release does say that the study included more than \u201cthree years of clinical experience,\u201d but does not say how long the improvements were seen.\nThe release relies almost exclusively on the professional experience of the study author to make its case. Referring to Henderson, \u201chis clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\u201d\nThe most intriguing possibility suggested is this: \u201cAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\u201d Alas, that statement, too, is not followed by supporting data, nor are they apparent in the study itself.\nWe aren\u2019t even told how depression is diagnosed. Without a randomized trial (and this study is a retrospective look at past studies, not a randomized controlled trial) no definitive conclusions can be drawn.", "answer": 0}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nIn their study published in Computers in Biology and Medicine, researchers detected breast cancer with more than 95 percent average accuracy using an inexpensive commercial electronic nose (e-nose) that identifies unique breath patterns in women with breast cancer.\nIn addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nIn fact, typical mammography sensitivity, which is 75 to 85 percent accurate, decreases to 30 to 50 percent in dense tissue.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefits statement is that \u201cresearchers detected breast cancer with more than 95 percent average accuracy using an inexpensive commercial electronic nose (e-nose) that identifies unique breath patterns in women with breast cancer. In addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\u201d\nReaders need the total number of patients screened and other details on how results of the study were measured.\nIt\u2019s important to keep in mind that the study was about developing a better algorithm to funnel out the noise from these tests and focus on the signal that would indicate whether someone did or did not have cancer. Any benefit described should be related to the development of a better algorithm, versus developing a better physical test.", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cAt the end of two years, patients treated with Rez\u016bm showed a 51% reduction in urinary symptoms (as measured by a seven-question survey), compared with the beginning of the study.\u201d\nHowever, without knowing what a sample baseline was, it\u2019s hard to say if this is a big improvement. (51% of what?)\nWe also wanted to know more about the patients:\u00a0Average\u00a0age, average prostate size, whether subjects had tried medications, whether investigators assessed improvement in not just self-reported\u00a0symptoms but also urinary stream.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even with a Q&A format, articles about allergies can be more useful by making sure to include relative and absolute rates of benefit from various treatments. This article leaves the readers with the idea that all or most people get relief from one or more of the triad of treatment approaches: avoidance of allergy triggers, OTC or prescription drugs like antihistamines and nasal steroids, and immunotherapies like allergy shots. But drawbacks\u00a0and side effects should be made clear, so that the true benefit is more accurate.\nFor example, while the article does note that successful immunotherapy often takes years, it doesn\u2019t report:", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news article does not quantify the potential benefits of treatment with these two Parkinson\u2019s drugs, instead describing them only in general terms. A little more information \u2013 a risk/benefit tally \u2013 might help readers weigh their advantages and disadvantages. ", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says Lynparza \u201cmodestly delayed the time until cancer worsened \u2014 7 months versus 4 months for women given one of three commonly used chemotherapies. About half the study participants responded to Lynparza compared with about a quarter of those only treated with chemotherapy. It\u2019s unknown whether treatment increases survival.\u201d\nThe story could have emphasized that last point more strongly. The outcome that was studied, known as progression-free survival, is a surrogate marker. In fact, the drug claims no benefit in terms of the most vital outcome: extending survival.", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nBoth drugs increase the risk of dangerous bleeding.\nAnd in the new study, patients had less bleeding after stent installation.\nBrilinta reduced overall death rates by 1.1% .\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story highlighted the potential benefits of this drug over the current medication as reducing overall death rates by 1.1%\u00a0\n\n", "answer": 1}, {"article": "UTMB is a part of the University of Texas System and a member of the Texas Medical Center.\n\"We found that testosterone users had a greater decrease in respiratory hospitalizations compared with non-users.\nSpecifically, middle-aged testosterone replacement therapy users had a 4.2 percent greater decrease in respiratory hospitalizations compared with non-users and older testosterone replacement therapy users had a 9.1 percent greater decrease in respiratory hospitalizations compared with non-users,\" said Baillargeon.\n\"Previous studies have suggested that testosterone replacement therapy may have a positive effect on lung function in men with COPD,\" said Jacques Baillargeon, UTMB professor in preventive medicine and community health.\nThey also used the national Medicare database to study data from 253 men with COPD aged 66 and older who initiated testosterone replacement therapy between 2008 and 2013.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were reported in quantitative terms:\u00a0 \u201cmiddle-aged testosterone replacement therapy users had a 4.2 percent greater decrease in respiratory hospitalizations compared with non-users and older testosterone replacement therapy users had a 9.1 percent greater decrease in respiratory hospitalizations compared with non-users.\u201d\u00a0 Even though this suggests that testosterone replacement therapy may slow the progression of disease in men with COPD, one is still left wondering how often that occurs. We aren\u2019t given any baseline numbers so the 4.2% and the 9.1% relative risk numbers lack context.", "answer": 0}, {"article": "\u201cBut how does the public deal with this information?\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nWilliam B. Isaacs, a professor of urology and oncology at Johns Hopkins University and an author of the new report, said that if research validates what has been found, men may want to get the new genetic test when they are young, 35, say.\nIt was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n\nResearchers long knew that the disease often runs in families.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did provide some discussion on the\u00a0conundrum\u00a0presented by prostate cancer detection \u2013 namely that it is really an incomplete piece of information. The real goal is to develop a means of distinguishing between indolent and deadly prostate cancer. \u00a0The risk of the former would not warrant treatment likely to render the individual impotent and/or incontinent. \u00a0The risk of the latter might be worth the risk, or at least participation in active surveillance to allow for detection of a cancer while it is still localized. \u00a0The story did mention this conundrum though it might have spent more time on it.\nThe benefit of this treatment is an early warning of a pathology that might develop; it is less clear what a man in his 30s would do with this information.\u00a0", "answer": 1}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nTo Arciero\u2019s surprise, after women ate pancakes containing resistant starch plus protein, they experienced an increase in fat burning, compared to all of the other kinds of pancakes.\nArciero and his team monitored the women after each meal for three hours and used a device to see how many calories they burned, and what type.\n\u201cThe ensuing structure of those bonds during the cooling process is what makes them resistant to then being digested in the small intestine,\u201d Arciero says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not use quantified benefits. One opportunity where that could have been added is in this section:\n\u201cArciero and his team monitored the women after each meal for three hours and used a device to see how many calories they burned, and what type. To Arciero\u2019s surprise, after women ate pancakes containing resistant starch plus protein, they experienced an increase in fat burning, compared to all of the other kinds of pancakes.\u201d\nAdding numbers for the calories burned or the \u201cincrease\u201d in fat burning would be beneficial. Minus these numbers, we can\u2019t assess\u00a0the credibility of the conclusions.", "answer": 0}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t give a clear picture of how many were enrolled in the study and what happened to them.\nReuters did a better job, reporting:\nRelkin presented three-year data on 16 patients in Baxter\u2019s Phase 2 study of Gammagard, which originally enrolled 24 participants.\nOverall, all 11 study participants who got Gammagard for the full three years showed improvements in thinking abilities, behavior and daily functioning.\nOf these, the four patients who received the most effective dose (0.4g/kg) for the full 36 months fared the best, showing no decline on several standard measures of cognition, memory, daily functioning and mood.\nBut Reuters also didn\u2019t explain what happened to the other 8 participants originally enrolled.", "answer": 0}, {"article": ".\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the blood test \u201cwas able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\u201d According to the published study, researchers used a statistic called Area Under Curve (AUC), a predictive model, that reflects both the sensitivity and specificity of the test. A value of\u00a00.5 implies that the test has the diagnostic accuracy of a coin flip, whereas a value of 1.0 indicates perfect discrimination between diseased and non-diseased patients. Sensitivity and specificity are important characteristics of any screening or diagnostic test and we encourage health care journalists to incorporate these concepts into their reporting. The 97 percent accuracy figure used in the story appears to refer to the state of metabolic blood levels at 36 to 60 hours after injury. It appears that the initial determination over whether the patient had mild traumatic brain injury was highly accurate.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nAnd they consider themselves lucky.\nNo?\nGot milk?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned a number of health claims so-called \u2018fans\u2019 of raw milk postulate can be derived through the use of raw milk. \u00a0(The story also included comments from the FDA in which these claims were refuted.) \u00a0It should have included some critical examination of the health claims made.", "answer": 0}, {"article": "\u201cThis is the first on walnuts and diabetes.\nBut researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated:\n\u201ccompared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\u201d\n24% of what?\u00a0 Why not provide the absolute numbers of what was observed?", "answer": 0}, {"article": "Researchers found that people with the highest blood levels of these essential fatty acidsfound in fish such as salmon and tunawere more likely to perform well on tests of mental functioning and to experience less age-related brain shrinkage.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nBut questions remain over whether fatty-acid levels really influence changes in brain size, Scarmeas added.\nThis might include reducing blood pressure and inflammation, he added.\nWhether the association would apply to other ethnic and racial groups needs to be explored, the authors said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although we think readers will come away with the correct bottom line message on this study, we\u2019re going to rate this criterion unsatisfactory, for two reasons:", "answer": 0}, {"article": "He was not involved in the study.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n\u201cThere have been some other trials that have tested combinations, often at high doses, of certain vitamins and minerals,\u201d said Dr. Howard Sesso, one of the study\u2019s authors and an associate epidemiologist at Brigham and Women\u2019s Hospital in Boston.\nThe U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits\u00a0were reasonably framed using words like \u201cmodest\u201d and \u201csmall.\u201d But the only hard numbers\u00a0provided pertain to the relative risk of cancer in the multivitamin group compared with placebo. And\u00a0it can be difficult to judge exactly what\u00a0this 8% reduction in cancer cases\u00a0looks like\u00a0without more detail.\u00a0As the competing AP coverage explains, the benefit worked out to about one fewer cancer per thousand men each year. In the AP\u2019s words: \u201cFor every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills.\u201d That\u2019s a much more informative way to describe things\u00a0than simply calling it an\u00a08% reduction, as Reuters did. The absolute risk reduction was clearly stated in the abstract and did not even require digging into the tables of the published manuscript.\n\u00a0", "answer": 0}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nSo the hypothesis is that intestinal worms could possibly reverse these problems, by damping down the immune system.\n\"The controlled trials, thus far, in a variety of different diseases including childhood allergies and asthma have not been positive.\"\nIt could be that the whipworm larvae weren't prepared correctly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There don\u2019t appear to be quantifiable benefits associated with this treatment because it hasn\u2019t been well studied in humans, and\u00a0we are told this much: \u201cThe controlled trials, thus far, in a variety of different diseases including childhood allergies and asthma have not been positive.\u201d Also, the patient interviewed experienced a negative result. With no proof of benefit and plenty of risks to ingesting parasitic\u00a0worms, we\u2019re left to wonder\u00a0why this story emerged and was run on NPR with a headline that hinted there was potential for this treatment.", "answer": 1}, {"article": "\"It affects your whole life.\"\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nScar tissue from previous surgeries and arthritis were removed before she was fitted with the prostheses which will act as her new knee.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\nO'Brien first hurt her knee when she was in her 20s and for the next 30 years her many activities only made it worse.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The patient in this story was presented as being pain free nearly immediately after surgery, without mention of any analgesic medication she may have been taking. This patient was also shown driving a golf ball 2 weeks after surgery, though again, it is not known whether this is a realistic expectation for a few, some, or most patients after this type of knee replacement.", "answer": 0}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nTHURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The claims of \"100% accuracy\" and that \"The investigators found that after just one laser treatment, misfiring ceased in 84 percent of the treated veins, and 90 percent remained inactive three months after treatment\" aren\u2019t put into any meaningful context about what difference this made in patient outcomes.\u00a0 Of course, what can you possibly say about outcomes after just three months?\u00a0 Which is exactly the point of raising this issue at all.\u00a0", "answer": 0}, {"article": "City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases.\nThis study differed from other studies that have looked at aspirin and cancer risk because it focused on the dose levels of the aspirin women had taken and tracked the frequency of the use of low-dose aspirin as opposed to regular aspirin.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nThis study -- which is the first to suggest that the reduction in risk occurs for low-dose aspirin -- was proposed by City of Hope's Leslie Bernstein, Ph.D., professor and director of the Division of Biomarkers of Early Detection and Prevention, and published online in the journal, Breast Cancer Research.\nBernstein added, \"Aspirin also reduces inflammation, which may be another mechanism by which aspirin taken regularly can lower risk of breast cancer developing or recurring.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release shares relative risk reduction numbers only, not the actual numbers of people who reduced their risk of breast cancer by taking aspirin.\nThe release notes that the research team \u201csaw an overall 16 percent lower risk of breast cancer in women who reported using low-dose aspirin at least three times per week. Such regular use of low-dose aspirin reduced the risk by 20 percent of estrogen or progesterone receptor positive, HER2 negative breast cancer, which is the most common breast cancer subtype.\u201d That\u2019s fine. The problem is that, as noted above, this was an observational study, not a clinical study designed to determine whether a specific intervention (i.e., aspirin use) was responsible for reducing cancer risk.", "answer": 0}, {"article": ".\nImprovements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were disappointed to read only very vague terms such as \u201csignificant statistical difference\u201d and \u201cimproved menopause symptoms\u201d used to describe improvements in hot flashes, sleeplessness, vaginal dryness, and anxiety.\nThe release could have done better on this score had it told us something about the scales used to measure improvement (What was the minimum and maximum score for hot flashes? The improvement in sleeplessness went from what to what?) and the absolute difference from the beginning of the trial to completion of the trial.", "answer": 0}, {"article": "Then they took tests involving memorizing words.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nMembers of a second group kept their calories the same but were instructed to increase the unsaturated fat (healthy fat) they ate by 20 percent.\nThe study was small, involving 50 men and women ages 50 to 72 who ranged from normal weight to overweight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the caloric restriction group saw a 20 percent average improvement in memory performance. The report also describes the size of the group tested and the duration of the study.\u00a0\nIt would have been useful to know how memory was tested in order to appreciate what a 20 percent improvement means in practical terms. 20% of what?\u00a0 20% that makes what kind of difference in daily functioning? Maddeningly, the story does not report how many calories the restriction group ate on a given day. \u00a0 \n\u00a0", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nIn mid-stage clinical trials, each of the four treatments has eased symptoms for about half of study participants, cutting the number of days they\u2019re afflicted by migraines roughly in half.\n(Merck\u2019s failed pill, by contrast, was meant as an on-the-spot treatment after the pain started.)\nTo date, none of the companies has reported serious side effects in clinical trials, but they\u2019ve only reported data from 12-week studies on about 1,500 total patients.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is an attempt to quantify the benefits, but it wasn\u2019t sufficient to earn a Satisfactory rating:\n\u201cIn mid-stage clinical trials, each of the four treatments has eased symptoms for about half of study participants, cutting the number of days they\u2019re afflicted by migraines roughly in half.\u201d\nThe story\u00a0needs to report enough data so we know the number of subjects in the trial(s), the number of migraine-days they had (in this case) at baseline, and the number of migraine days they had on treatment. The question is: \u201cHalf of what?\u201d", "answer": 0}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nAt the three-year mark, patients on the gemcitabine regimen achieved an average survival rate of 23.6 months.\nOne- and two-year survival rates were 80 and 49 percent, respectively, the investigators found.\nAt the one- and two-year markers, survival rates for that group was approximately 78.5 and 48 percent, respectively.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Average survival times and survival rates at\u00a0one and\u00a0two years of follow-up were provided for both treatment groups.", "answer": 1}, {"article": "It occurs when the small central portion of the retina, known as the macula, deteriorates.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Now that we\u2019ve established that the work was done in lab rats, did the news release quantify how successful the experimental approach was? \u00a0Did it give numbers about how many animals were \u201ctreated\u201d and how many benefited?\nNo.\nThe release only stated: \u201cThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\u201d \u00a0But that doesn\u2019t give any idea of the rate of effectiveness \u2013 even in rats. \u00a0And equating this \u2013 at this early stage \u2013 to what could happen in humans is, well, imaginative.", "answer": 0}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\nResearchers examined data on patients treated with both tissue plasminogen activator (tPA), the standard in stroke treatment, and stent retrievers and found that restoration of blood flow within 2.5 hours of stroke onset was associated with minimal or no disability in 91 percent of patients.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nWhen it comes to a stroke, time is of the essence and according to the National Stroke Association using the FAST approach can help one determine the warning signs.\nCurrently, stent retriever therapy is offered in just a few hundred hospitals across the country, including more than 100 Comprehensive Stroke Centers accredited by the American Heart Association and The Joint Commission.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mainly discusses the benefits as they pertain to one patient.\u00a0We had to read the story multiple times\u00a0to realize that the study in question went beyond this one patient.\nA review of the study itself shows that 196 patients were part of the study, and less than half \u2014 96 \u2014 underwent the treatment described in the story. The study says that, \u201cIn the stent retriever arm of the study, symptom onset to reperfusion time of 150 minutes led to 91% estimated probability of functional independence, which decreased by 10% over the next hour and by 20% with every subsequent hour of delay.\u201d\u00a0The story accurately reports this finding, saying, \u201crestoration of blood flow within 2.5 hours of stroke onset was associated with minimal or no disability in 91 percent of patients.\u201d\nDespite this attempt at quantification, we think the story relies excessively on an individual patient\u2019s story that is likely not representative of the broader experience. Since the optimal time window to perform this procedure is so small,\u00a0many stroke patients may not be eligible for the therapy. \u00a0In addition, the story does not explain that the study was done in 39 centers and only managed to randomize 196 patients over a 2-year period. This comes out to 5 patients per center or an average of one patient every 4 months, hardly a large\u00a0number (or even percentage) of stroke patients who would benefit from (or be eligible for) this technology.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes it clear that benefits of the lice control products have not been established.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate intake of vitamin D is necessary for prevention of rickets, a bone-deforming disease.\u00a0 The other benefits postulated in the story included prevention of a wide range of diseases for which there is not conclusive data.\u00a0 The story, however, made it seem like these were a slam dunk.\u00a0 \nIt would have been interesting to quantify \u2013 in absolute terms \u2013 the benefit of vitamin D on at least one specific disease before and after national supplementation of the milk supply (e.g. the incidence of rickets) and contrast it with the claims being made for vitamin D that aren't well supported by strong data.", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nGood Results with DTI Breast Reconstruction in Women over 65\n\nDirect-to-implant breast reconstruction has emerged as a single-stage approach to immediate breast reconstruction after mastectomy.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Multiple follow-up benefits (measured at 30 days and 1 year) are cited, with the DTI group having fewer readmissions, fewer days with a drain in place (13 vs 23), fewer days in hospital after the procedure, and fewer follow-up office visits (6.5 office visits vs 12 visits for the non-DTI group.)\nThe news release highlights the following benefit: \u201cavoiding some of the inconvenience and risks of staged approaches to breast construction.\u201d So,\u00a0It would have been helpful to clarify for readers what the staged approach with tissue expanders involves; mainly inserting an inflatable expander in the space left by the removed breast, gradually filling the expander with saline over weeks or months, and eventually placing an implant once the area can safely and comfortably accommodate it.", "answer": 1}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nDr. Heng reports her experience using curcumin gel on such injuries using three examples of patients treated after burns and scalds, and provides a detailed explanation why topical curcumin may work on such injuries.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\n\"When taken by mouth, curcumin is very poorly absorbed into the body, and may not work as well,\" notes Dr. Heng.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t give any numbers to support the author\u2019s statements about benefits. There is only one paragraph devoted to benefits in the news release, which states the \u201cuse of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\u201d Without any numbers, we don\u2019t know the extent of the reduction from this vague, comparative wording. And how were these parameters measured?\nThe original journal article also doesn\u2019t provide any benefits data. Instead, it shows before and after pictures of three patients and then describes their recovery ranging from one day to six months after treatment.\nWe still expect the news release to provide the quantitative scope of the potential benefits by asking the researcher to supply these numbers. Since no data are given, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \"The cream succeeded in 9 out of 10 cases with the rats.\"\u00a0 How is the \"success\" of an anti-impotence cream measured in rats?\u00a0 Inquiring minds want to know.\u00a0\nAgain, at least a line is warranted about the leap from animal research to human application. \u00a0", "answer": 0}, {"article": "Other patients were treated continuously.\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nTwenty men with metastatic prostate cancer, five with extra-pelvic lymph nodal disease and 15 with bone with or without nodal disease, were treated with androgen deprivation therapy (ADT), radical surgery that included a retroperitoneal lymph node dissection as needed, and radiation therapy to visible metastatic lesions in bone.\nOf the five patients with extra-pelvic lymph node involvement, four achieved an undetectable PSA after ADT and surgery, while the fifth needed radiation to reach this milestone.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here was the elimination of detectable prostate cancer within 20 months of beginning drug treatment. The release makes clear that four of the 20 patients in the study reached this endpoint. But there are some problems. For one thing, the release notes that, of the four patients who reached the relevant endpoint, the cancer \u201cremained undetectable in two patients for 27 and 46 months, respectively.\u201d What happened after 27 and 46 months? Was the cancer detected again? Or was that simply when researchers submitted the paper? And what happened to the other two patients? According to the journal manuscript, the cancer remained undetectable for the other two patients for five and six months, respectively. But, again, it\u2019s not clear if the cancer then came back or if that was simply when the study ended. Given that the entire release hangs on whether people still have prostate cancer, this should be crystal clear to readers \u2014 and it\u2019s not. In addition, it would have been very easy to include the numbers for all four patients who reached the endpoint, so this looks like cherry-picking. Lastly, it\u2019s worth noting that the benefit was not clearly defined until the sixth paragraph. Since this was the defined endpoint for the study, the release would have been stronger if it had noted this earlier.\nIn addition, the 20 month time period strikes us as arbitrary for a study endpoint. Typically, when oncologists speak of cure it implies that there is no evidence of disease five years after treatment. An undetectable PSA is a surrogate measure and we do not know whether the multiple treatment approach can \u201ccure\u201d cancer or even extend survival. The longer-term follow-up data (which was variable in length\u00a0because patients were not enrolled at the same time),\u00a0indicated\u00a0that two of the four patients did have not have recurrence of the cancer (at least based on detectable PSA). \u00a0However, this seems to imply that two of the patients could have had recurrence after 20 months.  ", "answer": 0}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nNeurologists say that only about one-third of those who could benefit by migraine-preventing medication actually use it.\n\u201cPeople need to keep in mind that all drugs, includingover-the-counter drugsand complementary treatments, can have side effects or interact with other medications, which should be monitored,\u201d Silberstein said in a statement.\nThe guidelines will be published in Tuesday\u2019s edition of the journal Neurology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s what the story states: \u201cNeurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs.\u201d\nThanks to the competing USA Today coverage, we know that this is an overly optimistic assessment, since in that story it was noted that patients may need to try 3 or 4 different drugs, alternative therapies, and lifestyle changes to achieve a 50% reduction in headaches.\n\u00a0", "answer": 0}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\nThey were told to lie still with their eyes closed as they wore headphones and listened to soothing music.\nFederal law prohibits the use of the magic mushroom compound for any purpose.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nThis exhibit in greater details demonstrates the treatment algorithm, patient cases, and the success with use of the standardized stepwise risk assessment and treatment algorithm to address dislocation risk in patients with spinal deformity.\nThe researchers reported only one dislocation in this high-risk group (or 0.5 percent of high-risk patients), compared with 3.1 percent in the previous group not assessed with the risk assessment and treatment algorithm.\nThese findings represent a six-fold decrease in the rate of dislocation in the high-risk group.\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study was done in two parts.\nPart one: a retrospective review of 1,082 conventional (not dual cup) total hip replacements (THRs), over 2 years, in which the dislocation rate was 1.8% (19 patients). We\u2019re told about a third of the total cohort (320 of the 1,082) had \u201cspinal disease and deformity\u201d on imaging scans. In this group of 320, 10 patients (3.1%) had subsequent dislocations.\nPart two: Beginning in 2016 researchers began employing their risk assessment tool \u2014 pre-operative sitting/standing scans of the hip, and factoring in other risk factors like previous spinal fusion \u2014 and identified 192 of 1,009 patients (19%) as \u2018high risk\u2019 for dislocation. About three-fourths of these patients received dual cup transplants with only 1 having a subsequent dislocation (0.5%).\nThe news release gives us the absolute rate of dislocations in both high-risk groups (3.1% vs. 0.5%), which is vital information to understand the scope of the potential benefit. And on that basis we\u2019ll award a satisfactory grade here. However, we note limitations under the Evidence criterion below that have a bearing on these statistics.", "answer": 1}, {"article": "Amgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nThe 12-week trial, presented this week at the annual meeting of the American Academy of Neurology, involved 246 patients suffering four to 14 migraine headaches a month who had tried two to four preventive treatments that either did not work for them or had intolerable side effects.\nAmgen said Aimovig trial patients also had statistically and clinically meaningful improvements in secondary trial goals including fewer monthly migraine days and better physical function.\nLOS ANGELES (Reuters) - A late-stage trial of Amgen Inc\u2019s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the drug \u201creduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal.\u201d\nAlthough this is a faithful account of what the study authors reported in the abstract, this somewhat tortured description is not helpful for readers, since it doesn\u2019t convey just how few people benefited from the drug. Nor does it explain what a reduction of \u201cat least half\u201d means. The story should have stated how many migraines participants experienced before treatment and how many afterward.\nBottom line: If 30% of participants had a 50% reduction in migraine days, this means that 70% of participants didn\u2019t achieve such benefits. The story should\u2019ve spelled this out more clearly.", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nThe research, which included 37 high-functioning autistic adults, mainly diagnosed with Asperger\u2019s syndrome, followed participants for 12 weeks.\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\nResponding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After explaining that the story was quite small and covered only a few months time, the story provides a quick summation of the benefits found in the study saying, \u201chalf of the participants taking Prozac had significant reductions in obsessive-compulsive symptoms, compared with 8% taking placebo.\u201d\u00a0 But given the very small sample size, natural frequencies would have been more informative and less likely to be misinterpreted. Also, a bit more detail on what a \u201csignificant reduction\u201d means in an autistic disorder would have been welcome.\n\u00a0", "answer": 1}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites two experiments, in which the chip\u2019s lung channel behaved like human lungs. In both cases the story says the results were \u201cexactly\u201d what would happen in human lungs under the same circumstances.\nIt\u2019s probably difficult or impossible to provide any quantitative benefit regarding this technology at the current time. Nevertheless, we think the language of the story is not measured enough. Human organs work with millions of other cells and are influenced by countless other genetic and environmental factors that cannot be duplicated in these early experiments. Human systems are variable and dynamic, and doctors often don\u2019t know ahead of time how patients would respond to a disease or treatment. So to suggest that the organs-on-a-chip behave exactly like human organs is not really supported at present.\nAnother example of the story\u2019s enthusiasm: \u201cThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\u201d \u00a0While these initial studies are encouraging, these chips haven\u2019t yet been compared to existing tools used in drug development. Until this is done, a more cautious tone regarding benefits \u2014 \u201cmay,\u201d \u201cmight,\u201d and \u201ccould\u201d rather than \u201cwill\u201d \u2014 is warranted.", "answer": 0}, {"article": "After a two-week gap, the groups were switched.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nSo to assess whether people who ate egg breakfasts were better off than their counterparts who ate cereal, they took blood samples and measured the concentration of two key hunger hormones: acylated ghrelin (which stimulates hunger) and PYY3-36 (which is how the intestines let the brain know that you\u2019re full).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify the findings. It doesn\u2019t say how much less hungry the participants felt during the egg vs. the cereal phase of the study or how much less they ate. It doesn\u2019t tell us if the differences in hormone levels reported would be considered clinically meaningful.\u00a0 Was it a difference of 50 fewer calories at lunch?\u00a0 250? How big a deal was this?", "answer": 0}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nDr. Jerome Goldstein, director of the San Francisco Alzheimer's and Dementia Clinic, said there are very few objective tests to diagnose Alzheimer's disease, and most of them are complex and expensive.\nMucke acknowledged that there are very few medical treatments for patients once they are diagnosed with Alzheimer's.\nWhile much of the scientific work, including that at Stanford, is promising, Goldstein said all the technologies are a long way from being available in clinics.\nScientists have been working for years without success to develop a simple way to diagnose Alzheimer's disease, a degenerative brain disease that saps memory, sows confusion and will eventually kill patients who may have lost the ability to speak, walk or swallow.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was really not clear about the benefits to be gained by early identification of pending Alzheimer\u2019s disease.\u00a0 Although one expert was quoted as saying that he was a \"proponent of knowing what is ahead\" and the value in doing so while people can still \"speak for themselves\", it is not clear from this story what one would do with advance knowledge that one was going to develop Alzheimer\u2019s disease.Not everyone is a proponent of knowing what is ahead, especially given uncertainty about effective treatment.\u00a0 ", "answer": 0}, {"article": "Bochner and his colleagues Drs.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\nThe findings were published in the Journal of Allergy and Clinical Immunology in May.\nBochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nIn this recent study, Bochner and his team performed traditional allergy skin tests and the basophil activation test, a related allergy test using blood cells, on cancer patients before they had taken ibrutinib and again after one week and after one to two months of taking it.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides only relative reductions in skin reactivity tests. It reports neither absolute numbers nor a description of the clinical relevance; that is, whether the patients felt their allergies symptoms had improved. The release does not tell readers that one of the patients continued to take anti-allergy medication or that the other patient was not taking any anti-allergy medication; these points in the research report raise questions about whether the patients felt any improvement in their allergy symptoms.\nThere is also no mention that the researchers wrote in their journal letter that they have yet to show that the drug has benefits for people with more than one allergy. The release touts speculation about the drug\u2019s potential to prevent or treat food allergies, even though such trials are just getting started. The senior author of the letter to the editor noted, however: \u201cI don\u2019t know if this or similar drugs will ever make it possible for a peanut-allergic person to eat peanut butter and jelly sandwiches, but we\u2019re excited to use this approach to teach us how to lessen the risks of food allergy reactions.\u201d", "answer": 0}, {"article": "The American Heart Association reports that more than 80 percent of smokers say they want to quit.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nAfter seeing the initial research, she\u2019s hopeful, but cautious, about low-level laser therapy as a way to help people do that.\nBut the government organization had only dealt with drugs - not new technology - for smoking cessation, which has slowed down the process, Camera said.\nThat\u2019s what Innovative Laser Therapy, a New Haven, Connecticut-based company, advertises on its website.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The alleged benefits are quantified, and, from there, the story takes pains to explain how much evidence supports these claims.", "answer": 1}, {"article": "But it was a small study, and \"it will take another year or two to get enough cases to nail down the predictive index,\" Veltri said.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\nAnother report at the same meeting described use of a microchip to detect tumor cells in the blood of people with prostate cancer.\nCombined with annual biopsies, or tissue samples, it was about 70 percent accurate in singling out the aggressive tumors in a small study, John Hopkins University researchers were to report Sunday at the American Association for Cancer Research annual meeting, in Washington, D.C.\n\n\"What we have shown is that using the Prostate Health Index and tissue DNA measurement is informative in separating out patients whose cancers are likely to progress vs. those that are not likely to progress,\" said study leader Robert W. Veltri, an associate professor of urology and oncology at Hopkins.\nMONDAY, April 19, 2010 (HealthDay News) -- An updated version of the standard prostate cancer test can help improve predictions about which men might not require immediate treatment, researchers report.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide quantitative data on potential benefit. The story indicated the test might help identify men who could delay or defer treatment of their prostate cancer, but it did not provide any estimate of the proportion of men that might be expected to reap this benefit. \u00a0\u00a0\nThe story also mentioned in passing an additional benefit \u00a0which was that the test might reduce the frequency of prostate biopsies from every year to every other year. \u00a0However it should be noted that current guidelines for the frequency of follow-up biopsies are variable and some recommend intervals of up to at least 18 to 24 months \u2013 which would mean this test would result in no change.\n", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Without research studies to quantify the benefits of ayahuasca, the story relies on anecdotes. \u201cProponents say that it can provide users with spiritual and personal guidance. Others report that it has allowed them to overcome traumas that conventional therapy and antidepressants haven\u2019t cured,\u201d the story says.\nThe story mentions more several\u00a0patients who\u2019ve tried it successfully, including a Chicago man who said ayahuasca \u201ceased his depression,\u201d a Texas woman who said it \u201chelped to cure her debilitating migraines, which she thinks were tied to childhood abuse,\u201d and an Oklahoma woman who said the substance help her \u201covercome the trauma\u201d of her first husband\u2019s death. There\u2019s no indication that the reporter attempted to contact clinical professionals who could comment on these claims.", "answer": 0}, {"article": "Wolters Kluwer is a global leader in professional information services.\nAbout 70 percent of ears with constricted malformations were graded as having no deformity after treatment.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nResults were judged good to excellent in 97 percent of ears with one simple deformity and 88 percent with more complex \"mixed\" deformities.\nClick here to read \"Classification of Newborn Ear Malformations and their Treatment with the EarWell Infant Ear Correction System.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is not satisfactory for several reasons. First, as noted above, the release does not tell readers that there is a difference between an ear deformity and malformation of the ear. As a result, it would be very easy for readers to assume that the benefits for patients with ear deformities would apply to patients with ear malformation. There are some other problems as well. Here\u2019s some of the language from the release: \u201cResults were judged good to excellent in 97 percent of ears with one simple deformity and 88 percent with more complex \u2018mixed\u2019 deformities. About 70 percent of ears with constricted malformations were graded as having no deformity after treatment.\u201d Here are the problems: What does it mean that results were \u201cgood to excellent\u201d? What is the difference between \u201csimple\u201d and \u201cmixed\u201d deformities? How are those different from \u201cconstricted malformations\u201d? And how many patients were in each group? Percentages can be misleading if any of the listed subgroups were particularly large or small. Benefits should be clearly explained and quantified, and that wasn\u2019t the case here.\nWe aren\u2019t told what proportion of the less severe deformations would have spontaneously improved. The study and news release claim a high rate of success but it\u2019s not clear what this should be compared to. It\u2019s possible that some reasonable proportion of such ears do OK without intervention.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites data from a recent review article in a medical journal that outlines the effectiveness (or lack thereof) of the medicinal treatments. \u201cThe medications have been found to be from 68% to 87% effective after one or two applications. Most don\u2019t require combing,\u201d the story says. We do wish they story explained what \u201c67% effective\u201d means\u00a0for a typical person, however.\nThe careful reader will note that the evidence for the effectiveness of the featured combing salons is mostly anecdotal, and it would have greatly strengthened the article to have been more explicit about this, as well as including more solid proof that standard lice medications are not as effective as they used to be.", "answer": 1}, {"article": ".\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit as described in the release is stopping dabigatran\u2019s blood-thinning effects, and the release states that: \u201cIn patients who received two 2.5-gram of idarucizumab infusions in a 15-minute period, blood tests revealed that dabigatran\u2019s blood-thinning effect was 100 percent reversed in all 18 patients with brain bleed.\u201d Because the findings were presented at a conference, there is no paper for us to read (and we looked for \u2014 but could not find \u2014 the study abstract), so it\u2019s impossible for us to compare the language in the release to any material written by the researchers conducting the study.\nWe do have some concerns about the presentation of the benefits. How the reversal of dabigatron anticoagulant effect was measured is not described. The patients included in the study had all previously suffered an intracranial bleed. Their long term outcomes are unknown and we do not know if those treated with\u00a0idarucizumab have better outcomes. We discuss some of these problems in more detail below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nThe patients were followed for two months to see if they needed a repeat surgery.\nBut the MarginProbe is another tool that might help reduce the odds of needing a subsequent surgery, she said.\nThis is much less than the cost of re-operation, he noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece notes that patients were followed for two months after their lumpectomy.\u00a0 And the story did an adequate job in describing benefits, clearly presenting the proportion of patients in each group who required a second surgery.", "answer": 1}, {"article": "That could have affected survival, of course.\nTUESDAY, Dec. 6 (HealthDay News)-- Women who get routine mammograms can lower their risk of dying from breast cancer by nearly half, a new Dutch study suggests.\nIt's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment.\nAmong the women with breast cancer, nearly 30 percent of tumors were found at screening and about 34 percent between screens.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While making an attempt to quantify benefits, the author frames the information in confusing language that appears to indicate cause and effect: \u00a0\u201cwomen who underwent screening reduced the risk of dying from breast cancer by 49 percent.\u201d\u00a0\u00a0Mammography is screening, not treatment, and does not prevent or cure breast cancer. Citing the conflicting evidence about the benefits of breast cancer screening would improve the quality of the article. \u00a0For instance, in two large, randomized\u00a0clinical trials that looked at the benefits of screening mammography for survival,\u00a0the Malmo and Canadian trials, the women who chose mammography screening had the same breast cancer mortality or death rate as the women who did not.\n\u00a0", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nIn the current study, they wanted to see if GHRH could help restore some function in people who were showing signs of a condition known as mild cognitive impairment.\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\nBaker said the researchers also saw a mild improvement in verbal memory in those treated with GHRH, but the results weren't as strong as for the executive function tasks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were puzzled by the lack of clarity of the benefits.\u00a0 While benefits were not quantified, the impact of GHRH on IGF-1 was.\u00a0 We think that the statement in the Reuters story: \u201cIt\u2019s unclear how the test differences will translate into real life,\u201d provided a clear statement on benefit", "answer": 0}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nTreating more Americans with statins is worth the small risk of side-effects and would be cost-effective, a new report finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did quantify benefits using absolute numbers when describing the potential impact on heart attacks from wider statin use.\u00a0The story said that\u00a0\u201cif even more people were given statins \u2014 if they were given to people with a 3 percent risk of developing heart disease over 10 years \u2014 another 160,000 heart attacks and strokes would be prevented, they estimated.\u201d We thought the Times, though, did a better job overall providing context for those numbers.", "answer": 1}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide information about the magnitude of benefit, either in terms of the drug\u2019s ability to improve glucose load or about longer term benefits such as its impact on the predicted chance of heart attack. \u00a0", "answer": 0}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\n(CNN) A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.\nHowever, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that 27 of 29 phase 3 clinical trial patients experienced \u201ca\u00a0gain in functional vision as assessed by a mobility test performed in a maze.\u201d That\u2019s not enough to give readers a sense of scope of the benefits. How did that compare to the control group? And what was everyone\u2019s vision like before? Given the extreme cost of the therapy, it would be useful to provide plenty of details to explain if the cost is worth the results.\nFor example, it would have been helpful to point out that the way the researchers measured success\u2013completing a maze\u2013is not the gold standard for measuring vision improvement. Instead, measuring visual acuity, such as the ability to read different-sized letters, is more common. Why was it different for this study?", "answer": 0}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nThe team plans to analyze the impact of other treatment options and carry out a cost-based analysis to establish the best treatment options for TN.\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers to back up the claims in the release. The release does not share information about the actual scores from patients in this study. In addition to providing data on the EuroQOL 5-Dimension questionairre scores before and after treatment, the release should have also provided information about what constitutes a meaningful change in the EQ-5D score.", "answer": 0}, {"article": "Who is IVM helpful for?\nPlus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nA study in the journal Facts, Views and Vision found that IVM achieved up to a 35 percent clinical pregnancy rate in young women, which is comparable to IVF.\nAlthough there are different protocols for IVF, and there aren\u2019t any randomized controlled trials that have compared IVF and IVM side by side, studies that look at standard IVF cycles show a significantly higher pregnancy rate than IVM, Shastri said.\nAlthough IVF is still considered the gold standard, there\u2019s an infertility treatment available that is offering hope \u2014 in vitro maturation (IVM).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We award a Satisfactory rating here because the story does quote a range of claimed \u201cimplantation\u201d success rates for IVM and IVF given by the American Society of Reproductive Medicine, noting that IVM appears to have much lower success rates. The article would be much stronger if it had also cited data for live births from IVF and IVM, along with the rate of adverse outcomes.\u00a0Overall, 47% of assisted reproductive technology embryo transfers result in pregnancy; 38% result in live births.", "answer": 1}, {"article": "\u201cWe can offer people hope from the start.\u201d\nNearly half of people in the study who were given a six-month diet plan and lost an average of 30 pounds went into remission and no longer had diabetes.\nIn the study, Dr. Roy Taylor, professor of medicine and metabolism at Newcastle University, and his colleagues randomly assigned nearly 300 people to either a weight management program or their usual treatments, including diabetes medications.\nAfter a year, most of the people in the diet group lost about 22 pounds, compared to two pounds in the control group.\nStudies suggest that people living with diabetes for more than 10 years, for example, may not be able to rely on weight loss alone to push them into remission.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies how much weight people lost and how many people went into remission, both in the group on the liquid diet and the control group (in which subject received the usual care for diabetes). That\u2019s good, and worthy of a satisfactory.\nHowever, the story does not explain what remission is or how it was measured. The study used hemoglobin A1c levels, which indicate blood sugar levels over the previous three months, and is often used to diagnose type 2 diabetes. Remission was defined as having a hemoglobin A1c level below the threshold for diagnosis without taking any diabetes medications. (This good outcome might still be characterized as pre-diabetes.)\nIn addition, readers aren\u2019t told how high blood sugars readings were before the diet, so it\u2019s impossible to tell how big the change was with weight loss.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nBut the picture isn't so clear for women in their 40s.\n\"The issue is, how many women are going to have to be called back because of abnormal mammogram findings?\"\nThese women will suffer the harms of early screening.\n\"If all those women were screened in their 40s, only 8,500 would die.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Surprisingly, the story didn\u2019t include a single statistic from the study it was reporting on.", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The column presents a small amount of data on the relative effectiveness of the methods discussed (\u201cIn India, the first men to test it have had it for 20 years, with no pregnancies\u2026;\u201d \u201c\u2026ineffective in about 10% of men;\u201d) for RISUG and hormone treatment. The story also points out that Vitamin A derivatives have not been tested in humans.", "answer": 1}, {"article": "A group of 1,537 women were randomly assigned to a daily diet that included five vegetable servings, three fruit servings, 16 ounces of vegetable juice and 30 grams of fiber.\n\"It sends us back to the drawing board,\" said Susan Gapstur of Northwestern University's Feinberg School of Medicine, who co-wrote an accompanying editorial.\nThe average age was 53 when the study began.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nAll the women had been successfully treated for early-stage breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided information that the two groups did not differ in terms of rates for breast cancer recurrence, the main outcome of the study. \n\u00a0", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\nNow, Brenner and his colleagues have show that UVC light can effectively kill airborne influenza.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told: \u201c\u2026 aerosolized particles of the H1N1 seasonal flu virus were released into a test chamber and exposed to very low doses of far-UVC light. The light inactivated the viruses with about the same efficiency as conventional germicidal UV light, while a control group of bacteria, not exposed to light, remained active.\u201d\nWe\u2019re also told previous studies by the same authors have shown that far-UVC light \u201ccan kill MRSA bacteria, a common cause of infections after surgery.\u201d\nHowever, it would be helpful to have data to support these claims, but that\u2019s not provided.", "answer": 0}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts by making two claims. It says that the new technique \u201cwas shown in a new study to accurately detect larger precancerous polyps\u201d and it also says that the procedure \u201cwas a better experience for patients.\u00a0It backs the first claim up by saying that \u201cThe laxative-free scan accurately identified 91% of patients with polyps of 10 mm or larger \u2014 those at highest risk of becoming cancerous,\u201d but it didn\u2019t make clear \u2013 as MedPage Today did in its story \u2013 that \u201cwasn\u2019t significantly different than the rate of 95% with standard optical colonoscopy.\u201d\nThere were no data presented to back up the second claim about patient experience. This may be a quibble given that avoiding the discomfort that comes with a colonscopy has to be a better experience, but we would have liked to have seen some attempt to quantify patient satisfaction. The promoters of virtual colonscopy make the claim, after all, that the main barrier to people being screened is a fear of discomfort.\nWith any claim about any new test, we expect to see both sensitivity and specificity details.\u00a0 MedPage Today reported: \u201cFor a diagnostic threshold of 8 or 6 mm, sensitivity was clinically significantly lower and specificity statistically significantly lower than with the conventional colon screen.\u201d\u00a0 And they gave specific numbers.\u00a0 This story didn\u2019t.", "answer": 0}, {"article": "Their conclusion?\nJogging even 5 to 10 minutes per day can reduce the risk of death from all causes I also learned about some of the incredible health benefits of going fast: Even five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nI wanted to see what the highest-quality evidence \u2014 trials and reviews are the gold standard \u2014 said about the relative risks and benefits of these two forms of exercise.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nAll the exercise researchers seemed to agree on one thing: that the best exercise routine is the one you'll actually do.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call\u2013the story\u00a0does an impressive job of discussing various\u00a0benefits of both walking and running and of comparing the health benefits of the two types of exercise. Yet, they were very general takeaways, and we wanted to know more specifics. For example:\nEven five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nWe wondered by how much does it reduce the risk of death from heart disease?", "answer": 0}, {"article": "\u201cWe call this disease a \u2018thief of vision\u2019 because most people with it have no idea that they have lost sight until it is too late to bring it back,\u201d Iwach says.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\nThe study appears in the latest issue of the journal Ophthalmology.\nNone of the participants had glaucoma when they entered the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A clear example of how incomplete relative risk reduction/benefit figures can be.\u00a0 The story only says that \u201cThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\u201d\nBut it does not explain:", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here the story excels at providing important context. Benefits, in the case of barrier condoms, are measured in \u201cfailure rates.\u201d These rates depend on behavior. The story makes this clear.\nSome of what the story gave us in benefits:\n\u201cBefore we get into the numbers, it\u2019s helpful to understand that birth control effectiveness is measured in terms of failure rates, or the percentage of people who get pregnant within the first year of using this method.\nFemale condoms have a 5% failure rate with perfect use (using it consistently and correctly every single time), making them 95% effective. In contrast, male condoms have a perfect use failure rate of 2%, making them 98% effective.\nThe failure rate for both male and female condoms goes up when you also include people who used the method inconsistently or incorrectly (referred to as \u201ctypical use\u201d). Female condoms have a typical use failure rate of 21%, while male condoms have a typical use failure rate of 18%.\nThe effectiveness of FC2 is actually taken from research on the effectiveness of its predecessor, FC1 (the original female condom approved in 1993). Since the FC2 is an improved version of FC1 (made of nitrile instead of polyurethane), no further FDA studies were required, said Fisch.\u201d\nIt also discussed two possible, but not proven, benefits that the condom may decrease the spread of sexually transmitted diseases and improve sensation. We wish the story had hedged a little more on these\u2013even a minimal degree of skin-to-skin contact can transmit some infections, such as herpes or human papilloma virus.", "answer": 1}, {"article": "But the F.D.A.\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nBut what is not known because no one could follow the development of plaque before a person died, was whether people with plaque and normal memories were developing Alzheimer\u2019s.\nThe questions though, are who should be getting the drugs and who really has Alzheimer\u2019s or is developing it?\nBut every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is ALL\u00a0about the potential benefits. It says, \"Brain scans that showed plaque could help with some fundamental questions \u2014 who has or is getting Alzheimer\u2019s, whether the disease ever stops or slows down on its own and even whether plaque is the main culprit causing brain cell death.\" But it makes no attempt to quantify.", "answer": 0}, {"article": "According to the American Cancer Society, over 160,600 new cases of prostate cancer are diagnosed each year, and around 29,400 people die of the disease.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nBut as these antigens can be present in men without the cancer, it carries a risk of returning a false positive that can kick-start unnecessary, life-changing treatment.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story says the test could \u201cpinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease.\u201d\nBut it didn\u2019t clarify two things that are essential to interpreting this result:", "answer": 0}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nAn editorial published with the studies said they \"represent a major breakthrough.\"\nRowe agreed there are still important questions about the triple-drug regimens.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said the patients\u2019 performance on a pulmonary function test called FEV1 rose by \u201cas much as 13 percentage points, on average.\u201d That\u2019s not enough information. What was the average starting number? And how did the control groups do in comparison? We\u2019re not told.\nAlso, FEV1 is a surrogate marker and we don\u2019t know how it translates into real-world benefits on infection rates, hospitalizations, quality of life and lifespan. That should have been pointed out.", "answer": 0}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nExperts commenting on the work agreed it was promising, but said its findings would need to be confirmed in larger trials.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the potential benefits of the AMH test.", "answer": 0}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nHowever, the present results provide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\"\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says of 941 respondents, 66 percent reported an improvement in respiratory symptoms, 29 percent reported no change and 5 percent reported worsening. However, respondents were not required to quantify the extent of changes in their symptoms, so it\u2019s hard to tell how significant these reported improvements are.\nWe disagree with a researcher\u2019s conclusion that the survey results \u201cprovide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\u201d That\u2019s something that requires a controlled trial.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job of sketching the benefits shown in this research. Focusing on the clinical endpoint of relapse, and using percentages of relapse with the drug and the placebo, makes it easy for readers to understand.", "answer": 1}, {"article": "NSAIDs - which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately explained: \u201c..more than 40 percent of people who were cancer-free said they\u2019d been taking NSAIDs at least once per week for more than 5 years, versus only 28 percent of those who developed melanoma.\u201d\nMore importantly, it quoted one expert, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the benefit of folate fortification of the food supply as cutting the 3,000 cases of spina bifida in half (i.e. eliminating 1500 cases of spina bifida per year).", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\n\"[2]\n\nWriting in a linked Comment, Louise Cullen and William Parsonage from the Royal Brisbane and Women's Hospital, Queensland, Australia, and Martin Than from Christchurch Hospital, New Zealand, say, \"The ultimate validation for the safety and efficacy of discharging patients with cardiac troponin concentrations less than 5 ng/L will be the report of clinical outcomes after this threshold is implemented in routine clinical practice...Finally, what further assessment, if any, is needed for those patients identified as low risk and suitable for early discharge?\nUntil now, whether new high-sensitivity cardiac troponin tests could identify very low-risk patients who may be suitable for immediate and safe discharge from the emergency department was unknown.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a mixed bag. On the one hand, the news release refers to the high negative predictive value of the test (99.6%), which suggests that the test is very good at finding those who aren\u2019t at risk of a heart attack or death over the next 30 days. But it also relies on relative risk comparisons, and does not offer data in absolute terms about risks of heart attack or cardiac death in those with various ranges of troponin levels. It refers to patients \u201cat very low risk\u201d of a heart attack in the next 30 days, but never tells readers what that means (1%? 5%? 15% chance of a heart attack?). \u00a0Despite these shortcomings, we think the reader will come away with a decent understanding of the potential benefits of the more sensitive test, and so we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated:\nGuyuron conducted a clinical trial, the most rigorous design, in which 75 patients were randomly assigned to migraine surgery or a sham procedure.\nOf those who underwent the real thing, 57 percent said their migraines were eliminated, compared with 4 percent in the control group. Headache pain, frequency, and duration were reduced by at least half in 84 percent of surgery patients compared with 58 percent of controls \u2013 a difference too big to occur by chance. The most common complication was slight hollowing of the temple.", "answer": 1}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nThe new analysis of three separate studies included more than 4,500 people.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story included quantitive information about weight loss over time. It did not quantify the impact on blood pressure.", "answer": 1}, {"article": "Being around for my daughter, my son, my wife.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "After featuring a patient who is\u00a0\u201cis alive today because of an experimental form of immunotherapy called CAR-T,\u201d the story reports that \u201cabout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\u201d\nWhile the results look remarkably better than expected for patients whose cancer has returned after several rounds of standard treatments, there has not been a head-to-head comparison (a point the story does not make clear), so claims about the benefit of this treatment compared to alternatives must be made cautiously. Notably, the story never mentions how many of the patients in this trial died despite receiving the new treatment. About 20% were not alive at the six-month mark.", "answer": 0}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nIf a specific change did not occur, that treatment could be abandoned and another tried instead.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The potential benefit wasn\u2019t quantified \u2013 not even for the mice in question.\nAs with any test, questions about sensitivity and specificity should have been addressed.", "answer": 0}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nAnd, he adds, the study did not look for a decline in death rates, and it is unlikely that any study ever will \u2014 it would take too long and be too expensive.\nThe study researchers, though, wondered if that conclusion was correct.\nWhile it might seem convoluted to offer a drug to prevent the consequences of overtreatment, that is the situation in the country today, others say.\nThe amount of benefit he\u2019ll get is not much, but his risk reduction still is 25 or 30 percent.\u201d\n\nDr. Thompson knows what he will do about finasteride.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed grade on this criterion.\u00a0 The story provided both relative and absolute risk reduction figures \u2013 although it gave more space and prime real estate (the beginning and end of the story) to the more impressive-sounding relative risk figures. But, with some hesitation, we\u2019ll give the story the benefit of the doubt. ", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nOne possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\nThose who received the higher dose walked an average of 21 meters farther after 48 weeks of treatment than at the beginning of the trial, a gain of about 5 percent.\nIf eteplirsen gets to market, it would come nearly three decades after the 1986 discovery of the gene responsible for Duchenne.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided just enough caveats to the positive aspect of the study results.\u00a0 \u201cThe study measured how far the boys could walk in six minutes. Those who received the higher dose walked an average of 21 meters farther after 48 weeks of treatment than at the beginning of the trial, a gain of about 5 percent. The boys in the placebo group walked 68 fewer meters at the end than at the beginning, a decline of about 17 percent.\u00a0 One possible reason for skepticism is that two of the boys on a lower dose of the drug rapidly lost the ability to walk, even though the level of dystrophin in their muscles increased substantially.\u201d\nThe story added a key piece of information at the end, \u201cEteplirsen actually turns off just one part of the dystrophin gene, known as exon 51, which contains a mutation that in some patients stops production of dystrophin. By skipping over this exon, muscle cells can produce an imperfect form of dystrophin that nonetheless is at least partly functional.", "answer": 1}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\n[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0dedicates two paragraphs to describing the\u00a0results, including comparing them to standard tests made by two different companies. We were particularly pleased to see reporting on the sensitivity and specificity of the test, as well as descriptions of what those numbers mean. We think those figures are important to include in any discussion of screening or diagnostic testing, but they\u2019re often not provided or reported incompletely.", "answer": 1}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\nThis second study just published in the AJCN looked to address this question.\nNote to Editors: This research trial was carried out with a special cocoa flavanol test product, designed to deliver a standardized amount of flavanols within a nutritionally suitable drink.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not include a single number related to the benefits, and notes merely that there was \u201csignficant\u201d improvement with some dosages of flavanols. The release is structured in such a convincing way, as is the\u00a0accompanying video, that it almost makes you believe that you should go out and try to make one of these drinks for yourself. Where are the numbers to back these assertions up?", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nDr. Daniel F. Hayes, a breast cancer specialist at the University of Michigan who helped develop guidelines for Her2 testing, said it would be unwise to start giving Herceptin to Her2-negative women because the drug was expensive and raised the risk of heart failure.\nOn the other hand, he said, many women who are Her2-positive do not benefit from Herceptin.\nYet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions that Herceptin could reduce the risk of recurrence by half. The story does not mention the benefit of re-testing women previously thought to be Her2/neu negative. And if these women are now considered positive, how will they receive Herceptin if they have already had chemotherapy? The story lists some of the problems of inconsistent cutoff values for testing, but only provides limited quantitative evidence. ", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests benefits throughout:\nBut the study it reported only pointed to surrogate markers \u2013 hormone levels \u2013 not to any outcomes that are immediately meaningful in women\u2019s lives.\u00a0 The limitations of this finding simply weren\u2019t discussed.\nReaders would be well advised to read last Friday\u2019s blog post about The Ten Commandments of the New Therapeutics.\u00a0 Two of them came into play in this story:", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned a 47% increase in cancer detection, but 47% of what? \u00a0Also, the story mentioned the recall rate for women needing a follow up mammogram was reduced with the new device from 11% to 6.6%, but recall rate is not the true gold standard of how the device could be beneficial to women.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article notes the percentage of women who took the new pill and stopped having periods\u2013but it does not note how often this happens in women who take currently available pills. It\u2019s also not clear how long the pill was taken by women who resumed menstruating after they stopped taking it\u2013and how it compares with the experience of women who take traditional pills. ", "answer": 0}, {"article": "http://www.\n\"There is no one metabolite that we can put a finger on but when we looked at all of them, those profiles are different enough that we could easily distinguish concussed patients from non-concussed.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn the relatively inexpensive test, blood is drawn from an individual that may have suffered a concussion as the result of a sudden blow to the head (or from transmitted forces from a sudden blow to the body) within 72 hours of the incident.\n\"This relatively quick and inexpensive blood test for concussion is by far the most accurate reported with tremendous potential for clinical management and commercialization,\" says Kirk Brown, Manager of Business Development for Lawson.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even though we are told that \u201cwith fine tuning we can now look at sets of as few as 20-40 specific metabolites and maintain the diagnostic accuracy level of the test over 90 per cent,\u201d we\u2019re not sure what this means. It appears that the reference to more than 90 percent comes from the study abstract. While this provides some quantitative data on the overall effect, it does not provide the sensitivity (how many with a concussion had a positive test results) or specificity (how many without a concussion didn\u2019t have a positive test result).\nA key question is diagnosing a concussion at the time of the potential injury is to determine whether a player can return to the game. It appears this test is not designed for that. The question then is how could this test be used. It isn\u2019t clear.", "answer": 0}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nBut even a little can help, and according to Bernstein it doesn't have to be jogging for miles and miles.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\nBut what has changed is supply and demand.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When you first read the headline of this story \u2014 \u201cFor Headaches, A Lifestyle Change May Be Better Than A Doctor Visit\u201d \u2014 you assume that it will show you evidence of lifestyle changes improving a significant number of people\u2019s lives where medicine has failed. The story does not do that. It provides no quantification of the benefits of lifestyle changes and, in fact, does not even mention them until the final two paragraphs of the story.", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\nYou can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\n\u201cYou really hold the reins to guiding this community [of bacteria] through the choices you make,\u201d says Justin L. Sonnenburg, PhD, associate professor in the department of microbiology and immunology at Stanford University School of Medicine and author of .\nThe authors of the new study wanted to look at what changes in diet do to one particular gut microbe species: a strain that\u2019s been associated with leanness and better glucose tolerance in mice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that: \u201cPeople who started out with lower stores of Akkermansia had more after they followed the fiber-rich calorie-restricted diet. You can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\u201d We applaud the cautious language used here (i.e., employing the phrase \u201cresearch suggests\u201d). However, that language only presents half of the research findings. As the BMJ paper itself reports, study participants who began the study with higher levels of A. muciniphila actually saw their abundance of the bacteria decline after following the six-week, high-fiber, calorie-restricted dietary intervention in the study. And that decrease in A. muciniphila abundance continued even after the participants returned to a more \u201cnormal\u201d diet for an additional six weeks. While it\u2019s not clear if that decrease in A. muciniphila has any affect on reducing health risks, it\u2019s worth mentioning. In addition, the story would have been more useful for readers if it had offered even general information on what constitutes a \u201chealthy\u201d amount of fiber. For example, Harvard\u2019s School of Public Health reports that adults and children should get \u201cat least 20 to 30 grams of fiber per day.\u201d", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no\u00a0data provided for the potential benefit of \u201cincreased strength\u201d that the article says is possible if surgery is chosen \u201cearlier\u201d in the progress of the damage to the rotator cuff. The story does not give attribution for this claim: \u201cone\u2019s strength tends not to improve without surgery.\u201d While the entire story makes a case for the benefits of the newest surgical techniques, no data is provided comparing new to old or new to non-surgical alternatives directly.", "answer": 0}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nPeople treated with the balloons lost an average of 7 percent of their weight, compared to less than 4 percent for those who received the sham device, the researchers found.\nAn advantage of the balloons is that patients have no downtime and can go back to work the same day, the researchers said.\nFRIDAY, Nov. 4, 2016 (HealthDay News) -- Obese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\nWhether the weight loss will last over the long term isn't known, said lead researcher Dr. Aurora Pryor, director of the Bariatric and Metabolic Weight Loss Center at Stony Brook University in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified benefits by stating:\nObese patients who swallowed balloon capsules that helped them eat less lost an average of 15 pounds, roughly two times more weight than patients who just dieted and exercised, researchers report.\nand:\nPeople treated with the balloons lost an average of 7 percent of their weight, compared to less than 4 percent for those who received the sham device, the researchers found. Six months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nIn addition to reporting the weight loss results announced by researchers and that, unlike other balloons, this device doesn\u2019t require patients to be sedated during placement, the story adds important context by including comments from independent sources who are skeptical that many patients will maintain their lower weight long after the device is removed.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nOf the 10,253 women in the study, 16 percent were classified as low risk, 67 percent as intermediate and 17 percent as high risk for recurrence by the test.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nMany women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease \u2014 good news from a major study that shows the value of a gene-activity test to gauge each patient\u2019s risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the low risk population, women who had foregone chemotherapy had less than a 1 percent chance of cancer occurrence at another faraway spot, the story says. It also mentions that 16 percent of the 10,253 study participants were classified as low risk.\nLater down in the article, it lists more study findings: \u201cAfter five years, about 99 percent had not relapsed, and 98 percent were alive. About 94 percent were free of any invasive cancer, including new cancers at other sites or in the opposite breast.\u201d\nThe only feedback we have is that the story could have been a bit clearer in pointing out that all of these figures pertained to the low-risk group.\nBut the quantifying of benefits was good enough to merit a Satisfactory rating here.", "answer": 1}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nThe study is in the May 1 issue of Cell Metabolism.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If an entire consumer-targeted story is going to be based on research into mitochondrial function in mice, it could at least discuss how much such function improved. A little?\u00a0 A lot?\u00a0 In a few mice?\u00a0 All mice?\u00a0 How many mice?\u00a0 This story whiffed on giving any sense of the scope of the finding.", "answer": 0}, {"article": "Read more at The Wall Street Journal.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\nExisting drugs, including Tamiflu, work to block these viral copies from escaping the cell, the Journal reported.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says a \u201csingle dose\u201d of the \u201cnew drug\u201d was tested in a clinical trial and eliminated the virus in 24 hours. But we learn nothing about how many and people of what ages of people were involved in the clinical trial, how viral load was measured, whether elimination of the virus was complete or partial, or whether there were drug failures.\nWe also don\u2019t learn exactly when the drug was given \u2014 i.e. at what stage or stages of flu infection or who the control group were (Tamiflu patients, or those without Tamiflu treatment- i.e. already out of the effective treatment window). We\u2019re told that the drug worked \u201cthree times faster\u201d than Tamiflu, but not how fast Tamiflu works. In short, readers learn nothing that supports the drugmaker\u2019s claim.", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nBut when all 96 original participants were included in the analysis, the researchers found no significant difference in weight loss between the two treatment groups.\nAmong people who stuck with the trial, those on the fiber supplement lost 15 pounds, on average, compared to 11 pounds in the placebo group.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the weight loss, with caveats about \u201cno significant difference between the two treatment groups when all 96 original participants were included in the analysis.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story earns points for noting the absolute reduction in blood pressure in each group. We wish, though, that it had provided the weight loss in similar terms of actual\u00a0pounds or kilograms lost instead of as a percentage of bodyweight.", "answer": 1}, {"article": "\u201cHe and some of the other guys on the Nike team, it\u2019s well known they take advantage of the anti-gravity treadmill and the aqua track,\u201d Coates said.\nWalking on the underwater treadmill produced better measures when it came to maximal oxygen consumption (VO2max), a reflection of heart and lung function during exercise, and metabolic equivalents, a measure of energy use.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\nResearchers asked 21 patients who\u2019d had a stroke within the past two months to undergo two treadmill exercise tests \u2013 one submerged in water and one on a regular treadmill.\nIt\u2019s also an easy-on-the joints form of exercise for seniors and others who suffer from arthritis, and a recent study shows it can speed recovery from stroke faster than using a traditional treadmill.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on multiple benefits, none of which are quantified. For example, the story discusses the ways in which being underwater can reduce joint pain during exercise. How much does it reduce pain? What are the benefits in terms of health outcomes? Unclear. There also was no attempt to quantify speed of recovery and final recovery state compared to other treatments such as standard physical therapy.\nIt also cites a study showing cardiovascular benefits for stroke patients, but it doesn\u2019t even appear that this study directly compared outcomes of water-based PT vs. standard PT in patients following a stroke. Rather, it sounds like the study compared physiologic measures in stroke patients comparing two forms of exercise testing, which isn\u2019t proof that one method resulted in better recovery outcomes for patients.", "answer": 0}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story outlines the potential benefits of such a test in general terms, it does not quantify the results of the study or tell readers how accurate the test was found to be. We think any story about diagnostic testing or screening should discuss the sensitivity and specificity of the test \u2014 numbers which tell us about how well the test finds people who actually have the disease and rules out people who don\u2019t have it.", "answer": 0}, {"article": "Those on beta blockers had a substantial reduction in the formation of distant cancers, or metastases, and of local recurrence.\nTo learn more about inflammation and cancer, visit the U.S. National Cancer Institute.\nFRIDAY, March 26, 2010 (HealthDay News) -- Treatment with blood pressure-lowering drugs known as beta blockers appears to help reduce the spread of breast cancer in women, a team of British and German researchers report.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that those taking beta blockers reduced their risk of dying by 71% compared to those not taking beta blockers. The story also suggests that beta blockers reduce the risk of recurrence by 57%; however, it is not apparent how this percentage was calculated, as it does not appear in the abstract.\u00a0 The results are only provided in terms of relative risk, but absolute risk would give\u00a0the reader\u00a0a better sense of the magnitude of the benefit. See our primer on this topic. ", "answer": 0}, {"article": "They are used to prevent dehydration, maintain blood pressure, or give patients medicines or nutrients if they can\u2019t eat.\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nKellum had no role in the two studies, which were discussed Tuesday at a critical care conference in San Antonio and published by the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states:\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nAnd not much else is said. Unfortunately, this is an oversimplification, combining the findings of two studies (one on critically ill patients, one on non-critically ill patients) into one result. CNN\u2019s reporting was much more detailed:\nAlso, regarding this statement in the AP story: \u201cThe difference could mean 50,000 to 70,000 fewer deaths and 100,000 fewer cases of kidney failure each year in the U.S.\u201d\nThis should be edited to include the statement, \u201cif the study is replicated across the country.\u201d", "answer": 0}, {"article": "Have a question?\n\"We always thought [acetaminophen] was safe, but there are increasing signals of accidental overdose in people who are regularly using it for chronic pain, and some liver toxicity,\" explained Conaghan, who has studied adverse events data related to this popular drug.\nA limitation of the study is that the evidence on acetaminophen was mainly for acute low back pain, but as the University of Leeds's Philip Conaghan explained, \"There is very little long-term data [on chronic back pain], and if a drug doesn't work in the acute problem, it seems unlikely to work in the chronic phase \u2014 though back pain may be even more complex than osteoarthritis pain.\"\n\"[Tylenol] is an old drug, obsolete, and should be avoided altogether\"\n\nKay Brune, a professor of pharmacology and toxicology at Germany's Friedrich-Alexander University who has also studied the toxicity of painkillers, was even more direct in his thoughts on acetaminophen: \"It's an old drug, obsolete, and should be avoided altogether.\"\nAs the researchers wrote, \"We found that [acetaminophen] is ineffective on both pain and disability outcomes for low back pain in the immediate and short term and is not clinically superior to placebo on both pain and disability outcomes for osteoarthritis.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article takes a close look at the drawbacks and benefits of each drug. For example, while the experts said acetaminophen is less effective than ibuprofen in treating pain (and carries more risks than the others), it is beneficial in\u00a0treating fever, especially in children age three and up. Ibuprofen is deemed less toxic for pain relief but it carries the risk of\u00a0bleeding in the gastrointestinal tract and kidney damage. There\u2019s also a reasonable amount of quantification provided by an expert source, Dr. Andrew Moore, who says:\u00a0\u201cIf you\u2019re talking about aspirin in doses of 500 to 1,000 mg or two tablets, 30 percent of people get relief from acute pain. For acetaminophen at doses of 500 to 1,000 mg, about 40 percent have a success. For ibuprofen, in its normal formulation at something around 400 mg or two tablets, about 50 percent have success.\u201d The story would have been even stronger had it provided links or additional details regarding where this expert obtained his estimates.", "answer": 1}, {"article": "I think it's important to understand that more is not necessarily better.\"\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n\"Clinical enthusiasm for supplemental vitamin D has outpaced available evidence on its effectiveness,\" JoAnn E. Manson and Shari S. Bassuk of the Division of Preventive Medicine at Brigham and Women's Hospital in Boston wrote last week in the journal's online version.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about vitamin D-rich foods and supplements (including high-dose supplements). Are there benefits? Yes, and the story addresses (some of) them. The story makes clear that vitamin D is an essential nutrient for bone health, and that if you cannot get enough vitamin D from your diet (or from exposure to sunlight), then supplements can help you reach your target vitamin D consumption goal \u2014 which is 600 international units (IUs) per day for men and women between the ages of 1 and 70. The story could also have mentioned that vitamin D is involved in a variety of other health functions, including \u201cmodulation of cell growth, neuromuscular and immune function, and reduction of inflammation,\u201d according to the CDC.\nAnother strong point of the story is explaining that many of the purported health benefits of high-dose vitamin D supplementation \u2014 for example, prevention of cardiovascular disease, diabetes, and cancer \u2014 have not been based on strong scientific evidence.", "answer": 1}, {"article": "\"You're killing the bad cells and regenerating with cells that are more functional.\"\nThe food items used, however, were specific to the trial and if translated to the public would involve designing meals made up of the right combination of nutrients.\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\n(CNN) How much -- or how little -- you eat could influence how long you live.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is painfully lacking in quantified benefits. How many people were in the study? And what kind of people were they? (Overweight or healthy weight? Male or female?) Were they compared against a control group?\u00a0How much actual weight did participants lose? What specific aging\u00a0risk factors were researchers measuring and how much did those improve? Similar information is missing for the mice portion of the study.\nWe were also dismayed at the extent of medical jargon included in the piece, since uselessly granular details about cellular pathways, cell regeneration and \u201chormone-like growth factors\u201d don\u2019t provide important details about if this research is actually meaningful and worth reading about. What it does instead is fluff up the piece by making it sound smarter than it actually us.", "answer": 0}, {"article": "\u201cBut it does give us hope.\u201d\n\u201cAnd, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable.\nOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here is what the story offered for the benefits:\n\u201cOn average, the score on a scale for ranking gastrointestinal symptoms dropped 82 percent from the beginning to the end of treatment, while average developmental age increased by 1.4 years, according to the release. Researchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\u201d\nThis is not enough information to assess the scope of the potential benefits. For example, related to the 82% drop, what was the average number on the scale before\u00a0the study and after? If it wasn\u2019t that high to begin with, then an 82% drop isn\u2019t very notable.", "answer": 0}, {"article": "To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nAnother expert described the problem this way.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides active and placebo group response rates for patients in the Zecuity studies, which we\u2019ll call good enough for a satisfactory. However, the story doesn\u2019t compare these results with injection and nasal spray treatments \u2014 the other options that are available for patients with severe nausea who can\u2019t tolerate pills. That information would have been helpful.", "answer": 1}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nJust replacing a third of a serving of white rice with brown each day could reduce one\u2019s risk of Type 2 diabetes by 16 percent, a statistical analysis showed.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story presented the potential benefit only as relative not absolute risk of developing type II diabetes, which we find troubling.\u00a0 What does it mean when you say \"reduce their risk of developing Type 2 diabetes by about 10 percent\" or \"almost 20 percent more likely to develop Type 2 diabetes\"?\u00a0 10 percent of what?\u00a0 20 percent of what?\u00a0 What were the absolute numbers in this huge observational study? \nThe statement \"Just replacing a third of a serving of white rice with brown rice each day could reduce one\u2019s risk of type II diabetes by 16%\" is just not helpful for consumer comprehension. \u00a0 ", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\nThis story fails this criterion because it reports that the trial showed benefits of exercising to piano music, when in fact the trial was not capable of showing that music or any other specific feature of the classes could claim credit for the lower rate of falls and improved walking technique that was observed.\n\u00a0\nThe story does include some of the specific information expected to meet this criterion, including the number of falls in each group of participants, although it gives readers only vague descriptions of \u201csignificant improvements in balance and overall function\u201d and \u201cincreased their usual walking speed and stride length and improved their overall manner of walking\u201d without providing any specific numbers.", "answer": 0}, {"article": "Or eat turkey or bananas, both of which contain tryptophan, which is believed to trigger sleepiness.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nInstead, choose whole-wheat crackers, which can control insulin.\n\"It's such an intriguing idea.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, there are no interventional trials discussed, only biological studies of hormones, so benefits shouldn\u2019t be relevant. But by passing along Aziz and Vorona\u2019s recommendations, the author claims that these interventions have weight loss benefits. Those benefits are not quantified. \nOne could say that the benefits can\u2019t be quantified because there are no studies. And that\u2019s the point.", "answer": 0}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\nFORT LAUDERDALE, Fla., July 26, 2016 /PRNewswire/ -- New research published in Lancet Neurology and reported by CNN has found using a green tea extract (decaffeinated) in combination with cognitive training improves some measures of cognition and behavior in subjects with Down syndrome.\nIt is very encouraging that this catechin, EGCG, from green tea extract, has the potential to benefit people with Down syndrome.\"\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any context for understanding the clinical importance of the observed changes in memory, control, and adaptive behavior. Vague language (\u201csome measures of cognition and behavior\u201d) is used to describe the benefits experienced by subjects in the study. We are told that participants taking the supplement showed improvements in neuronal connectivity and had \u201cscored significantly better on assessments of visual recognition memory, inhibitory control and adaptive behavior,\u201d compared to those who took the rice flour pills.\nBut we aren\u2019t told the extent of the benefit, how long the benefits lasted and how many people even took the supplements out of the original 87 volunteers. And the use of the word \u201csignificantly\u201d here could be confusing for readers, since it\u2019s meant as \u201cstatistically significant\u201d instead of the colloquial use of the term, which could mean \u201cimpressively\u201d or \u201clargely.\u201d\nWe are told that participants underwent a series of \u201cassessments\u201d for cognition and behavior, but we don\u2019t know how these evaluations were conducted and what exactly these neuropsychological measures were.\nWe think quantification of potential benefits and a description of the measurement tools used are necessary in a news release, which is why we are giving it an Unsatisfactory rating here.", "answer": 0}, {"article": "The active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\nAnd, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story alludes to the benefits but never attempts to back them up with data. \u201cThe patches also deliver their medicine directly to the site of a person\u2019s pain. This may eliminate some of the side effects that come with taking pills. For instance, some analgesics are likely to cause an upset stomach unless they\u2019re taken with food. \u2026 And, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\u201d Note that in the previous sentences, there are no declarative statements about benefits. \u201cThis may eliminate,\u201d the story says. \u201cPeople also should get more,\u201d it says. Is the story hedging because of a lack of evidence or because the evidence was never reviewed?", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\nAn editorial accompanying the study, by the University of California, San Francisco's Patricia Katz and the University of South Carolina's Russell Pate, also noted that people who engage in physical activity have a lower risk for heart disease, diabetes, certain cancers, depression, cognitive impairment and functional decline.\nPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While quantification was minimal in this story, we\u2019ll rate it barely satisfactory since it states those participating in the physical activity part of the study \u201ccut the amount of time that people spent with a \u201cmajor mobility disability\u201d \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\u201d \u00a0But 25% of what?\nIt also stated that, \u201cPrevious findings from the same study showed that the exercise program lowered the risk of becoming disabled in the first place; this one showed that it sped recovery from an episode of disability and lowered the risk of subsequent episodes.\u201d\u00a0 However, it failed to explain how much that risk was lowered, or whether it was an absolute risk or a relative risk.\u00a0 Statements offered by others in the story said that \u201cpeople who engage in physical activity have a lower risk for heart disease, diabetes, certain cancers, depression, cognitive impairment and functional decline,\u201d but gave no measures of how much those risks were lowered.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We note a couple of flaws:\u00a0", "answer": 0}, {"article": "Coffee or tea?\nWe've heard a lot about the health benefits of tea, especially green tea.\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of drinking 5 or more cups of green tea a day was presented as a decreased chance of dying in the 11 year period of the study. However, there was no information about the amount that risk decreased. Although increased green tea consumption was seen to be associated with decreased risk of death from heart disease, the percentage of individuals dying of heart disease was less than half the number in Americans of comparable age. It is difficult to know the meaning of this difference.\nThere is no evidence presented about the how the type of green tea may influence the outcome of cardiovascular mortality, only that the larger amount of green tea consumed was associated with decreased cardiovascular mortality.", "answer": 0}, {"article": "SOURCE: bit.ly/2rcPLh0 Annals of the Rheumatic Diseases, online May 22, 2017.\nA daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn\u2019t have dangerous side effects, researchers say.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\nDr. Rachel Wolfe of Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, agreed that chondroitin is \u201creasonable to try\u201d for some people, especially those with contraindications to NSAIDs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn the qualitative benefits\u2013better than placebo and on par with the analgesic drug Celebrex\u2013but no quantitative data is cited.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the main outcome measure \u2014 how long subjects could exercise on a treadmill before experiencing pain \u2014 and the change in exercise duration \u2014 a 28 second improvement after stent insertion versus 12 second improvement after sham surgery. Readers are told that no statistical difference exists between those averages.", "answer": 1}, {"article": "Unlike CT scans or MRIs, PET scans can show a tumor's internal activity, not just its size.\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nOne report that impressed him involved 28 patients in Korea who were treated for advanced lung cancer \u2013 just like Stevens, who had to wait six weeks to learn whether it was working.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nGraham figures there's a good chance FLT PET scans will become routine for assessing therapy in the next 10 years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes brief references to two studies, one involving 28 people in Korea, the other 7 patients in the U.S. \nThe reporter cites positive results of the studies, implying efficacy. But no caveats other than small study size are offered to provide a more balanced view. ", "answer": 0}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nBut after another 18 months, there was no such difference.\n\u201cOverdiagnosis is threatening to become an increasingly important public health problem because of the enthusiasm for and proliferation of unproven screening tests,\u201d Lauer writes.\n\u201cWith these new imaging techniques, we are left with the dilemma of what to do with the results,\u201d he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Much more clearly than the competing WSJ story, Reuters reported:\u00a0\u201c\u201dTesting might lead to more harm than good.\u201d", "answer": 1}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\n\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes benefits in relative terms vs. absolute rates (which is the gold standard). It also does not tell readers that the most benefit was seen in older men. ", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nBut, Prystowsky continued, \"this analysis does show two impressive things: one, that patients who are not super-selected for a trial do well with these devices from a mortality standpoint; and two, that patients who had home-monitoring had better outcomes.\"\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give the story a barely passing grade here for at least providing readers with some numbers, although we feel that ultimately the numbers provide very little clarity. What was needed were some absolute numbers to show how many patients were in each group, how many died, how many lived and how many suffered side effects, etc. Instead, we are given sentences like this, \u201cAmong those outfitted with CRT devices alone, one-year survival was pegged at 82 percent, while five-year survival came in at 48 percent, the investigators found.\u201d\nIn addition, the study was observational and as such, the benefits of remote monitoring seen may not be applicable to all patients. For example a selection bias (motivated patients and physicians signed on to the manufacturers registry) could explain a good deal of the results. The cautionary comments of Dr. Prystowsky provided sufficient balance to the comments of the investigator.\n", "answer": 1}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nAccording to Breteler\u2019s team, studies should continue to look at the relationship between antioxidant intake and dementia \u2014 including whether antioxidant consumption at different points in life might have different effects on dementia risk.\nNor is it clear why vitamin E, but not vitamin C or beta-carotene, was linked to a lower dementia risk.\nFor the new study, researchers led by Dr. Monique Breteler, of Erasmus Medical Center in Rotterdam, used data from 5,395 adults age 55 and older who were dementia-free at the start of the study.\nResearchers found that among 5,400 Dutch adults age 55 and older, the one-third who reported the highest vitamin E intake from food were 25 percent less likely to develop dementia, including Alzheimer\u2019s disease, over the next decade than the third with the lowest intakes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story comes a whisker away from earning a satisfactory on this one.\u00a0It leads by noting that participants with the highest vitamin E intakes had a 25% lower risk of dementia compared with those who had the lowest intakes, It more precisely quantifies this benefit later in the story, where it\u00a0explains\u00a0that\u00a0120 people developed dementia in the group with the highest vitamin E intake compared with 164\u00a0people in the low- intake\u00a0group.\u00a0What would have been most informative, however,\u00a0is if the story\u00a0had provided some\u00a0denominators for this comparison \u2014 that is,\u00a0120 out of how many people developed dementia in the first group compared with 164 out of how many people in the second?\u00a0This would given readers a better sense of the\u00a0absolute risk reduction associated with higher vitamin E intake. We know this sets the bar high, but for good reason, we think. ", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nThis study included 9,153 patients (average age, 60 years) from a Veterans Affairs medical center who presented for major, elective, noncardiac surgery.\nThe researchers found that overall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a very strong point for the release. It states clearly that absolute reductions were seen before and after the intervention: \u00a0i.e.: \u00a0\u201coverall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation. Improvement was greatest among frail patients (12.2 percent to 3.8 percent), although mortality rates also decreased among the robust patients (1.2 percent to 0.3 percent).\u201d", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nThe scientists were then able to identify that WAY-316606, a compound used to treat osteoporosis, has a similar effect on how SFRP1 is expressed.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\nThe compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since WAY-316606 hasn\u2019t apparently been tested on actual human heads, there are no benefits to quantify, but that didn\u2019t stop the story from suggesting benefits, stating the drug \u201ccould hold the key to the cure for baldness.\u201d\nThe story stated that CsA \u201cchanged how the follicles expressed a protein called SFRP1, which stunts the development and growth of hair follicles and other tissue in the body,\u201d and that WAY-316606 \u201chas a similar effect\u201d and \u201ccould therefore be used to treat baldness.\u201d\nThe story had no data on the size of the effect this drug had on hair follicles in the lab.", "answer": 0}, {"article": "The United Kingdom\u2019s National Health Service offers free HIV testing.\nWhen asked if any test similar to BioSure\u2019s new take-home test was in development, Tara Goodin, a press officer for the Food and Drug Administration, said: \u201cThe FDA cannot confirm the existence of or comment on any current/pending product applications.\u201d\n\nThe FDA has approved two take-home HIV tests, but neither has all the strengths of the BioSure test.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\nBioSure\u2019s test goes beyond any of the at-home tests available on the U.S. market, which are either not as fast or not as accurate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides concrete percentages\u00a0for false negative rates and does a good job explaining the different methods for calculating undiagnosed cases. But it doesn\u2019t substantiate or quantify the main benefits that home testing should presumably deliver \u2014 earlier treatment and fewer infections. In fact, the benefits of testing that are mentioned in the story are based on studies of testing that is coupled with counseling, not self-testing. The story does not include any evidence that self-testing, unconnected with counseling, leads to either earlier treatment or safer sex behavior.", "answer": 0}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\nNewswise \u2014 A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women, report University of California, San Diego School of Medicine researchers in the journal Cancer Epidemiology, Biomarkers & Prevention.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release discusses how increasing nighttime fasting is associated with a lower postprandial glucose level, but there is no discussion about\u00a0how this is associated with a reduced breast cancer risk. This is a significant gap that needed to be addressed.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nCAVEATS Most participants were white.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us individuals with lower omega-3 levels \u201cscored lower on cognitive tests measuring such things as memory, problem solving, abstract thinking and multi-tasking.\u201d But how much lower were the scores and did they indicate a meaningful difference in how these people functioned? The story doesn\u2019t say.", "answer": 0}, {"article": "\"I see this as an alternative because it doesn't cause those side effects.\"\nAnd DeGiorgio says he's found an interesting benefit to trigeminal nerve stimulation.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\nAbout 3 million Americans have epilepsy, and for about one-third of them, drugs alone do not control their seizures.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is one attempt to quantify the benefits in the story. It says, \u201cA study of 50 people with drug-resistant epilepsy found that the trigeminal nerve stimulator was able to greatly reduce seizures for about 40 percent of them.\u201d This does not give people enough information to make an informed choice about their treatment options. For example, what does \u201cgreatly reduce\u201d mean? Did people go from 10 seizures a week to one seizure? Did people stop taking their medications and only use the device or just reduce the amount of medicaiton, as the woman in the story did? To back up the headline that says \u201cNew Device Reduces Seizures, No Surgery Required,\u201d we expect the story to quantify the scope of benefits better than it did.", "answer": 0}, {"article": "\"We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.\"\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\n\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions only potential benefits for human beings. There\u2019s no data on how much of these substances might need to be consumed over what period of time and in what quantity to offer cancer protection or tumor shrinkage. A researcher\u2019s comment that \u201cwe were able to inhibit tumor growth in mice without toxicity\u201d sheds no meaningful light on these questions.\nAlso, the news release seems to contradict itself by suggesting that eating a diet containing cancer-fighting substances could offer a benefit, but later quoting a researcher saying, \u201cWe only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.\u201d This comment seems to suggest people would have to take a supplement in order to get a benefit.", "answer": 0}, {"article": "But, it definitely needs more research,\" said Leath.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\nThe Italian researchers wanted to compare the electronic nose to the other commonly used tests -- spirometry and FENO -- to see which test was best at confirming a diagnosis of asthma.\nWEDNESDAY, April 7, 2010 (HealthDay News) -- Using an artificial breath-sensor system dubbed the \"electronic nose,\" Italian researchers were able to spot more cases of asthma than with traditional diagnostic tools.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us the percentage of asthma patients who were correctly diagnosed by the electronic nose, fractional exhaled nitric oxide, and spirometry. It provided this data in absolute terms and didn\u2019t muddy the waters with relative comparisons of the three techniques. Although the study data by itself might suggest that the new device is superior to the other methods, the comments from the expert sources put the results in the appropriate context. They make it clear that we\u00a0can\u2019t tell yet whether this\u00a0technology represents\u00a0a better option than existing techniques.", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nBut it takes no position on MRI imaging for women who have had breast cancer, saying there is not enough evidence to recommend one way or the other.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAs noted above, the story reports that this study indicates women who have had breast cancer could benefit from annual MRI scanning. But since the women in the study had just one scan, not a series of scans over time, it does not appear to be able to evaluate the potential benefits of annual scans.", "answer": 0}, {"article": "\"... obesity, smoking, certain types of genetic predisposition,\" Devi said.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nHigh cholesterol is one risk factor for dementia - but experts stress focusing on all risk factors.\nResearch has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The correspondent reports that study subjects taking statins \"were about half as likely\" to develop dementia or early warning signs. On-screen, a graphic shows this number more precisely, 52 percent.\u00a0 But that\u2019s a relative risk number, which can be less helpful to understanding.\u00a0 \nThe report should have stated what the absolute risk of dementia was in the statin group and the non-statin group. According to the study abstract, the risks of developing dementia or early signs within five years appeared to be about 8 percent for the non-statin group and about 3.5 percent for the statin group.", "answer": 0}, {"article": "After doing it for so long, it's not hard to do.\"\nFirst published on October 29, 2009 at 12:00 am\n\nCorrection/Clarification: (Published Oct. 30, 2009) The educational position of Elizabeth M. Venditti was reported incorrectly in this story as originally published Oct. 29, 2009, \"Pitt program to prevent diabetes shows promise.\"\nThe prevalence of diagnosed diabetes has more than doubled in three decades due in large part to an upsurge in obesity, the study states.\nBut those who did undergo lifestyle changes showed such notable results that Pitt offered to enroll all 159 participants, including Mr. Held, in a lifestyle modification program.\nFor 10 years, researchers tracked 2,766 people nationwide with pre-diabetes -- a metabolic condition featuring slightly elevated blood-glucose levels that often serves as a precursor to type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter\u00a0 quantifies the benefits of the lifestyle or drug intervention, but never does so in absolute risk reduction terms.\u00a0 So when the story states risk reductions of 34% or 18%, we want to know \"34% or 18% of what?\"\u00a0 \n\u00a0", "answer": 0}, {"article": "The answer?\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\n\"But the individual differences were really easy to pick up, even in a population that is really very similar.\n\"Before we can develop diagnostic tests based on fcMRI, we need to know what it is actually measuring.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some numbers would have been helpful here to put the findings in context. Consistency of the brain scans for the various mental tasks is not quantified in the news release. Furthermore, contrary to the implications of the headline, this study didn\u2019t actually develop any diagnostic tools for depression, migraines, or other brain ailments.\u00a0It simply laid the groundwork for research about these issues by testing whether functional networks in individuals\u2019 brains are relatively stable over time. That\u2019s a preliminary step that is needed, but it\u2019s still preliminary.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nTUESDAY, April 12, 2011 (HealthDay News) -- Eating apples every day may be good for your cardiovascular health, new research suggests.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\n\"Another good thing in apples is pectin.\n\"A large reason apples are so good is the fiber.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the supposed benefits were only stated in terms of test scores \u2013 and then only in relative risk reduction terms, not absolute.\u00a0 Read our primer on this topic. ", "answer": 0}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nThe article also noted that there was a shift during the three-year course of the study toward increasing use of hypo-fractionated radiation methods.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there were numerous potentially useful benefits stated, there was no attempt in the news release to quantify them. Rather, the claims made were quite general: \u201cless radiation,\u201d \u201cbetter overall cosmetic outcome,\u201d \u201cmarker allowed physicians to be more confident in their targeting.\u201d The release would have benefited from quantified measures of at least some of the benefits listed.", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAblation was successful in 74 percent of patients, Arbelo said.\nIt causes 20 to 30 percent of all strokes and can decrease quality of life due to palpitations, shortness of breath, tiredness, weakness and psychological distress, the study authors explained.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does provide a numerical picture of the data analysis. It states: \u201cAblation was successful in 74 percent of patients, Arbelo said. These patients had no atrial arrhythmias\u2013irregular heart beats\u2013for three to 12 months after the procedure.\u201d This means that nearly three out of four patients benefited in some way\u00a0by having the surgery, although it was not a permanent solution.\nHowever, the story didn\u2019t mention that the success rate fell to 66% when you considered the entire 12 month period, including the first 3 months.", "answer": 1}, {"article": "Currently, food-allergic people have only two options: to avoid the substance that causes their reaction or to try to stop a reaction with an injection of epinephrine.\nA mere sip would leave her vomiting and gasping for breath.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nBut even that can be helpful.\n\"I think it's an important advance in the field,\" said the NIH's Plaut.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story included absolute risk reduction data from the milk and peanut studies. \u00a0\n\u00a0", "answer": 1}, {"article": "\u201cI had no idea how hard this would be,\u201d Dr. Warren said.\n\u201cThis may be the key to solving the mystery of autism and other developmental disorders.\u201d\n\nGeraldine Dawson, chief science officer at Autism Speaks, the world\u2019s largest autism advocacy organization, said that a growing body of research suggests that the many genetic causes of autism all seem to affect synapses, suggesting that a treatment for one form of the disease might help others.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nThe predictions were premature because, like most of genetic research, discovering how the flawed gene caused disease was far harder than anticipated and required multiple leaps in neurology and biology.\n\u201cWe have been promising for a long time that unlocking the molecular basis for hereditary diseases would lead to dramatic therapeutic advances, and that promise is finally coming true,\u201d said Dr. Francis S. Collins, director of the National Institutes of Health, in discussing the science leading up to the trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the story falls down here when it passes along\u00a0a Novartis researcher\u2019s vague account of what happened in the study instead of providing us with actual statistics. \u00a0The researcher says there was \"clear improvement\" in the treated patients, but the\u00a0story should have pressed for a more\u00a0detailed account of how many patients benefited,\u00a0by how much, and according to what outcome.\u00a0Also unsatisfactory\u00a0was the rampant speculation about who else might benefit from the drug beyond\u00a0patients with fragile X syndrome.\u00a0According to\u00a0the Novartis account of the\u00a0research, only a\u00a0subgroup of patients with\u00a0an \"undisclosed biological trait\" benefited from therapy with the experimental drug. And this was in a study that was already\u00a0extremely small (\"a few dozen patients\") to begin with.\u00a0But\u00a0The Times\u00a0quotes\u00a0three different sources\u00a0who suggest, based on no evaluation of the data,\u00a0that the drug might be\u00a0useful for\u00a0a broader spectrum of autism disorders. And the quotes include some over-the-top language about the drug perhaps being \"the key to solving the mystery of autism and other developmental disorders.\" \nBy relentlessly playing up the positives and failing to rein in these more exuberant proponents, we think the story\u00a0gives an unbalanced view\u00a0of progress in the development of this drug and what it will likely be capable of. The fact is\u00a0that very few drugs in this stage of development\u00a0will be\u00a0approved by the\u00a0FDA and become available to patients. \u00a0\u00a0", "answer": 0}, {"article": "Complete tables of content and a sample issue may be viewed on the JACM website.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\n\"While a small study, the tolerance and adherence with acupressure this pilot are both hopeful signs for families of those in their care with autism spectrum disorder,\" states JACM Editor-in-Chief John Weeks, johnweeks-integrator.com, Seattle, WA.\nNew Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the news release, the researchers \u201cidentified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\u201d While it is good to know that the patients were able to complete the study, most readers probably wanted to know if the patients benefited from the treatment in any way. The release notes that \u201cresearchers measured the effects of the intervention on factors such as the children\u2019s behavior, ability to pay attention, sleep, and aspects of parenting stress\u201d \u2014 but doesn\u2019t tell readers whether any of those things changed as a result of treatment.\nThe closest the release comes to quantifying a benefit is when it states that \u201cmost parents reported that the intervention had a positive impact on their relationship with their child.\u201d It\u2019s not clear what they mean by \u201cmost parents,\u201d how much their relationship improved, how it improved, or why it may have improved. In fairness, the release states that the goal of the study was \u201cto determine if young children with autism spectrum disorder and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention.\u201d However, the release also says \u201cWhile a small study, the tolerance and adherence with acupressure this pilot [sic] are both hopeful signs for families of those in their care with autism spectrum disorder.\u201d Why should families be hopeful? Who knows? Given that there had been more than a dozen clinical trials involving acupuncture and children with ASD as of 2012, it\u2019s not clear what questions this new study has answered.", "answer": 0}, {"article": "\u201cI\u2019d be very rich.\u201d\nSome people treated with Xiaflex in clinical trials for the Dupuytren\u2019s hand condition said it had made a big difference in their lives, and had allowed them to avoid painful surgery.\nIn a midstage trial, injections of Xiaflex into the collagen plaque in the penis reduced the curvature.\nBut the drug did not reduce pain or discomfort during intercourse by a statistically significant amount.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The sidebar describes the\u00a0outcomes\u00a0of the main clinical trial of Xiaflex in absolute terms. It reports that 64% of treated joints straightened out, compared with 7% of control group joints. The story relied a bit heavily on a positive patient anecdote in the sidebar lead-in, but it also managed to find a second patient who offered\u00a0a unique perspective on the treatment.\u00a0This second patient\u00a0had successful Xiaflex injections on three fingers and open surgery on a fourth finger which didn\u2019t respond to the\u00a0drug.\u00a0In this patient\u2019s view, the drug was\u00a0preferable to surgery.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is still a very new procedure and there is not much long-term data on outcomes from humans with reconstructed bladders. There is no quantitative data from the results of this study. This study also is very small (9 recruited, 7 had the transplant), and so results would not be generalizable to a larger population. The story discusses this limitation", "answer": 1}, {"article": "\"I think this is going to shake things up pretty significantly.\"\nAfter about five years, the number of patients who experienced a heart attack, were hospitalized or died because of their heart problems was virtually identical in the two groups, the researchers found.\nAlthough study patients receiving angioplasty were somewhat more likely to be free of chest pain, known as angina, even that benefit was marginal, Boden said.\nSome cardiologists who specialize in the procedures, however, argued that the study did not focus on the sickest patients who are most likely to benefit, and that the main purpose of angioplasty in many is to alleviate chest pain, not to prevent heart attacks.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide actual rates of events (the primary outcome) between the two groups, although it does state that the numbers were not statistically significant.\u00a0 The story does provide absolute rates for angina, a secondary outcome which was significantly different between groups.\u00a0 Yet, it would have been best to report absolute rates, even if they are non-significant, for the primary outcome. There was no discussion about what \"statistically non-significant\" might mean.\u00a0 ", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\nAt William\u2019s worst point, a night in July 2010, he had a seizure every time he fell asleep, suffering 23 grand mals between midnight and 6 a.m.\n\nDr. Devinsky had prescribed weekly doses of prednisone, a steroid, and in desperation Ms. Moller decided to administer a mega dose.\nReplacing anticonvulsants is not merely an end in itself.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Everyone loves emotional anecdotes, and what could be more compelling than the story of a young boy who collapses and hits his head every time he suffers an epileptic seizure? Now that same boy, William Moller, is on a restrictive diet and is taking high doses of steroids regularly because his mother and his doctor believe that the steroids will control the inflammation that is leading to his seizures. In this 1,100-word story, 30% of the text is devoted to Moller, and the fact that his seizures have been under control for one year is used as the framing for a story claiming that \u201cinflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\u201d What would have been much more useful to readers is more proof, both to back up the claim that Moller has had a \u201cmiracle intervention,\u201d as the story says, and to back up the claims in the story that, anti-inflammatory therapies \u201ccould at least supplement, and perhaps replace, anticonvulsants,\u201d the drugs of choice currently for epilepsy. Yet the actual benefits from all the studies mentioned in this story are never quantified.", "answer": 0}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story is simply wrong to state that the \u201cstudy shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease.\u201d As noted above, this story does mention that \u00a0after similar studies pointing to health benefits of certain fruits and vegetables, follow-up studies have not shown that beta-carotene supplements reduce risks of dying from heart disease or cancer; nevertheless, the overall thrust of the story is that the study provides evidence of benefits\u2026 when the researchers actually limit themselves to saying the results are consistent with potential benefits and that they encourage further studies.\nThe story reports only the relative differences in death rates associated with one-time measurements of alpha-carotene blood levels, which is what the researchers and the news release highlighted. The actual numbers of deaths were in the article in the Archives of Internal Medicine, but they are hard to interpret, since they are not adjusted for age or other factors that were included in the analysis.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not adequately explain the intended appropriate use for this new stent. \u00a0The story indicated that the new stent decreased the need for repeat treatment in the target vessel and that the new stent decreased the occurrence rate for heart attacks. \u00a0There was no comparison of this stent with no stent at all. \u00a0In addition \u2013 as the information provided either came from the oral presentation at a conference or from the company news release \u2013 and has not been peer reviewed \u2013 the story should have been explicit about the source of the limited information it did present.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many different claims were made in the story from several different studies over time.\u00a0 But only vague descriptions of benefit were provided \u2013 no quantification.\nThe claim that the women \u201cwho got the real stuff\u201d had significantly less inflammation, as measured by C-reactive protein (CRP), as compared to those who drank a placebo, is not accurate.\u00a0 The researchers only saw the decrease in CRP in a subset of 12 of the women who had active inflammation and thus elevated CRP.\nWhat\u2019s not mentioned in the story is that in the study on women with OA, only 1 of the 4 serum biomarkers of inflammation (TNF-a) showed a statistically significant decrease.\nThis is another example of a news story reporting on a surrogate marker (read our primer on this topic), but not on an outcome such as \u201cWhat difference did that make in their everyday lives?\u201d\n\u00a0", "answer": 0}, {"article": "\u201cIdeally, we would all get sufficient sleep on a nightly basis.\u201d\nBut when researchers checked again after two nights of extended rest, the men\u2019s insulin sensitivity, and the amount of insulin their bodies produced, had returned to normal, mirroring what was seen during the portion of the experiment when the volunteers consistently got a good nights\u2019 rest.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\nAfter the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin.\nChronically sleep-deprived people are more likely to develop other health problems, though, ranging from obesity to high blood pressure to cognitive deficits, the study authors point out.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified in a meaningful way. The story says, \u201cinsulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin. But when researchers checked again after two nights of extended rest, the men\u2019s insulin sensitivity, and the amount of insulin their bodies produced, had returned to normal.\u201d \u00a0A 23% drop sounds substantial, but was it clinically important? What were the absolute numbers? We think the story could have done more here to help readers understand what was observed and what it means.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\n\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\n\"It reduced the odds of suicidal behavior by half,\" says Barbara Stanley, a psychologist at Columbia University and the lead author of the study.\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\nThat's because, as his own work has shown, almost 83 percent of people who die by suicide make a health care visit in the year before their death.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that people who received the Safety Planning Intervention cut their odds of repeated suicidal behavior in the next six months by nearly half. But that what\u2019s known as the relative risk reduction, and it\u2019s not the full picture.\nMore precisely, 3.03% of the patients who received the SPI intervention engaged in suicidal behavior compared to 5.29% of those receiving usual care. This is a key example of why news stories should report the absolute risk reduction.", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nThat's why he said it was important for MUSC to be involved in the study, which was funded by a grant from the commercial weight loss program, Weight Watchers.\nThe other half went to Weight Watchers meetings, had access to Weight Watchers' online materials and had two phone consultations and follow-up email contact with certified diabetes educators who told them how to modify the Weight Watchers plan to help with their diabetes.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides minimal quantification of the weight loss results in the two groups of participants:\n\u201cAfter a year, people in the Weight Watchers group had an average weight loss of about 4 percent of their starting weight, compared to 2 percent for the standard care group.\u201d\nBut we wanted it to go further, especially with respect to outcomes most specific to type 2 diabetes which is the focus of the headline.\u00a0The release states, \u201cThe Weight Watchers group also had a bigger improvement in a measure of long-term control of their blood sugar, which can reduce the risk for serious problems related to Type 2 diabetes.\u201d It would have been helpful had the release told us what measure they are talking about, how much it changed, and provided readers with a target or range of preferred blood sugar levels. We would also liked to have seen weight loss described in actual pounds lost, since that is how most people track their own weight.\nIn general, the release got the headline right, but overall took far too long to make clear exactly what the end points of the study were (weight loss primarily) and how small \u2014 albeit statistically significant \u2014 they were.", "answer": 0}, {"article": "Cancer is the No.\nThat's important, said Dr. Wyndham Wilson of the National Cancer Institute, because there is no point detecting cancer in people if the cancer is not going to actually cause trouble.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\nThere were no false positives in 44 people who did not have cancer, they said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says, \u201cThey identified 62 percent of the patients with stage I cancer \u2013 four out of eight colon cancer patients, and 90 percent of colon cancer patients with stage II, III or IV disease. They got a positive in 45 percent of the lung cancer patients with stage I disease, 67 percent of ovarian cancer patients with stage I disease and 67 percent of breast cancer patients with stage I disease.\u201d\nThis is a good start and we\u2019ll rate it Satisfactory, but one very important thing to make clear with this type of research: It used samples where cancer was already confirmed to exist\u2013which is different from testing only on samples where it\u2019s not known if there is any cancer present. That could affect the accuracy.", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is filled with general statements about the\u00a0benefits of Modafinil in reducing impulse eating but provides no numerical data to back up the claims. It uses\u00a0statements such as \u201cWe found Modafinil . . . did reduce people\u2019s impulsive behavior,\u201d and \u201cModafinil was found to have an effect on impulsivity in healthy individuals.\u201d\nThe study was based on just a single dose given to healthy volunteers who were followed up with psychological testing. The release does not provide any explanation of what the test measured or revealed, only that Modafinal \u201csignificantly reduced level of impulsiveness.\u201d", "answer": 0}, {"article": "These are moments that caregivers can cherish.\u201d\nPrevious research on communication in couples affected by Alzheimer\u2019s has tended to focus on deficits, said study author Christine Williams, professor and director of the PhD in Nursing program at Florida Atlantic University\u2019s Christine E. Lynn College of Nursing.\nA new study identifies patterns of communication that can help couples affected by Alzheimer\u2019s maintain a sense of connection, which could improve quality of life for both partners.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\nYet Williams hopes that the more supportive and positive communication patterns that many of the caregivers showed will help nurses coach spouses and family members affected by Alzheimer\u2019s.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline of this story reads, \u201cBetter communication can help couples affected by Alzheimer\u2019s,\u201d and the lead sentence says, \u201cA new study identifies patterns of communication that can help couples affected by Alzheimer\u2019s maintain a sense of connection, which could improve quality of life for both partners.\u201d But these claims don\u2019t seem to be supported in the body text of the story. There\u2019s nothing in the story that quantifies how these couples were helped, and there\u2019s no description to support the claims of increased connectedness or improved quality of life. The researchers reviewed and analyzed recorded conversations between patients and caregivers and then derived what seemed to be the most successful approaches in fostering communications. How those successful approaches were identified by the researchers, or what effects they had on the couples, are described only in the most general of terms. The story does suggest a \u201clist\u201d of actions caregivers can take in these conversations, which is helpful.", "answer": 0}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\nHowever, CURATE.AI has shown that patients can still respond to the therapies that have seemingly stopped working by continuously identifying the patient's optimal dosing parameters.\"\n\"Using CURATE.AI to dynamically modify drug doses and successfully treat a metastatic cancer patient represents a landmark breakthrough for the use of AI to truly personalise patient care.\nThis calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not attempt to quantify benefits. In fact, it would be impossible for the release to address this issue in any meaningful way, given that the relevant study was of one patient. The release says that the patient was \u201csuccessfully treated\u201d \u2014 but what does that mean? Lower down in the release, readers are told that \u201cdisease progression was halted,\u201d meaning that the cancer was not getting worse. Further, no information is given about the tumor\u2019s biology nor can any conclusions be drawn in the absence of a comparator such as\u00a0enzalutamide alone vs the combination.\nReaders are told that \u201cpatient care guided by CURATE.AI is currently ongoing.\u201d In other words, by the time anyone is reading the release, the patient could be in remission. Or the cancer may have spread. Or the patient\u2019s condition may not have changed at all. We just don\u2019t know.", "answer": 0}, {"article": ".\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both the lacto-ovo vegetarian diet (Vd) and the Mediterranean diet (Md) were effective in reducing body weight, body fat, and body mass index with no significant differences between them. The release presents these benefits in absolute numbers. However, the Md led to greater reductions in triglyceride levels, while the Vd led to greater reductions in low-density lipoproteins (so called \u201cbad\u201d cholesterol). These were well covered in the news release.\nBut the latter benefits are changes in surrogate markers measured over just 3 months in people at a low risk for cardiovascular disease. Whether these results translate into meaningful, sustained, and clinically relevant outcomes that actually affect people\u2019s risk for developing heart or vascular disease can not be answered by this small randomized, controlled study.", "answer": 1}, {"article": "Want to embed a link to this report in your story?\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\nBottom Line: Obese patients who underwent weight-loss surgery had a lower rate of death from any cause compared with obese adults who received nonsurgical care to manage their obesity.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\u201d\nThe release further notes that \u201cThe association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\u201d\nBut the results state only that the rates of death were \u201clower\u201d over the 4.5 year follow up period.\u00a0 There is no attempt to put the size of the difference in context.", "answer": 0}, {"article": "\u201cRemember this day.\nAnd when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\nRival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarizes findings\u00a0of clinical study results, all of them positive. But what is a reader to make of relative risk claims such as the treatment \u201chalved the risk of disease progression and cut overall deaths by 40%\u201d compared to standard chemotherapy treatment? What does this mean in actual terms?\nOne story disseminated by Targeted Oncology\u00a0and\u00a0also apparently stemming from the Copenhagen\u00a0oncology\u00a0conference where these results were reported, noted that the \u201cestimated 6-month overall survival (OS) rate was 80.2% with pembrolizumab (Keytruda) versus 72.4% with chemotherapy.\u201d And when it came to risk of disease progression, the\u00a0median \u201clength of progression-free survival was 10.3 months with pembrolizumab versus 6.0 months with chemotherapy.\u201d", "answer": 0}, {"article": "While Drs.\nPublished today in the New England Journal of Medicine and simultaneously presented at EuroPCR 2018 in Paris, France, the five-year analysis of the FAME 2 trial shows that initial PCI along with medication was associated with a significant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment.\nJ\u00fcni and De Bruyne agree there is more research to be done using modern PCI technology, this five-year follow-up offers evidence that PCI has the potential to provide long-term benefits to patients with stable coronary artery disease.\nThe present analysis was not supported by industry funding.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that PCI resulted in a \u201csignificant reduction in urgent hospital admissions and revascularizations to restore blood flow in the blood vessels of the heart and a likely reduction in heart attacks as compared to medication as the only treatment.\u201d However, it does not give any numbers that would help readers understand the size of the benefit we\u2019re talking about.", "answer": 0}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\nAdditionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release highlights the fact that information from the test changed physician recommendations for treatment. Some physicians changed to recommending whole breast irradiation while others recommended against. A company official says the study is evidence that the test \u201ccan play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\u201d\nBut while changing practice recommendations may be an indication that the information provided by the test could\u00a0be useful and beneficial, it\u2019s not evidence that the test actually improves results for patients. Without clinical outcomes, it\u2019s difficult to know the true extent of benefits \u2014 if any. The release should have qualified the findings with some mention of the fact that the study was not designed to\u00a0assess outcomes that are meaningful to patients. Without such a warning it\u2019s too easy for readers/patients to be misled about the real impact of the test. Any statement along those lines would have earned the release a Satisfactory rating here.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We would have liked some more information here. Although the news release says: \u201cMore than 66 percent of patients treated with the DigniCap reported losing less than half their hair,\u201d we don\u2019t have a comparison to the control group. Without treatment, how much hair do patients actually lose?\nThere are other unanswered questions: How many times throughout the month did patients have to wear the caps to prevent hair loss? How long will patients have to undergo this therapy? And how long will the benefits last? How did the rate of hair loss compare with women who didn\u2019t use the cap?\nIn addition, the patients themselves assessed how much hair they actually lost based on photographs and questionnaires, making this step prone to recall bias. Since this also was not a double-blind trial, this could have also introduced other biases into the data.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "An important benefit for people to know who may be thinking about this would be their chance of kidney survival with a live-organ donation. Those numbers are provided (84% at 5 years for live-donor kidneys). Another benefit of interest would be how many more people might be able to receive a transplant through organ swapping. Those estimates are provided, although they are based on theoretical modeling. Interestingly, large numbers of people are required to increase the number of matches made, and even then, the increases are quite small. ", "answer": 1}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nA few years later, she felt chest pains, and doctors thought she was having a heart attack.\nBlackwell says the FDA risks setting the bar too high.\nBut chemotherapy took a toll.\nShe roamed from Chinatown to the Upper East Side, went sightseeing in Central Park and painted the town with her husband of 33 years, their two 20-something children and assorted friends.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "For more information, visit www.chronothera.com.\nCHICAGO, March 4, 2016 /PRNewswire/ -- Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\nThe Chrono Solution is designed to deliver the first dose of nicotine replacement therapy (NRT) shortly before a smoker wakes up and then creates a pattern of \"peaks and troughs\" of nicotine delivery throughout the rest of the day to assure the smoker has more nicotine support when cravings are predicted to be strongest.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that \u00a0\u201ctest subjects had a statistically significant and clinically meaningful reduction in cravings for all assessment methods (p=0.035; p=0.034 and p=0.016, respectively).\u201d Although we appreciate the mention of the p-values, it would have been more helpful to understand what a reduction in nicotine cravings meant in real terms, and if it could be sustained since the trial was only over 30 hours. In addition, it should be made clear that craving reduction is not synonymous with smoking cessation. The news release also uses a quote from a member of Chrono\u2019s Board of Directors who\u00a0says that this product has \u201cthe potential to solve such a serious problem.\u201d There doesn\u2019t seem to be enough evidence to say that this device would \u201csolve\u201d smoking in the United States.", "answer": 0}, {"article": "AMHERST, Mass.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\nThey observed that women consuming approximately 6.5 percent of their daily calories as vegetable protein had a significant 16 percent lower risk of early menopause compared to women whose intake was approximately 4 percent of calories.\nFew studies have evaluated how protein intake is associated with menopause timing, they add, and to their knowledge this is the first to look specifically at early menopause.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does the minimum in conveying the size of the link between diet and early menopause risk, saying women who consumed about 6.5 percent of their daily calories as vegetable protein had a 16 percent lower risk compared with women whose vegetable protein intake was approximately 4 percent of calories.\nIt further states: \u201cFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\u201d\nThe release could have provided better perspective by giving some absolute numbers. With a 10 percent overall risk, a 16 percent reduction would amount to one or two women in every hundred.\nIt also could have helped readers interpret this quote from researchers: \u201cThough relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\u201d compared to those eating less than 4 percent.\nIn more understandable terms, women consuming 9 percent or more of the calories from vegetable protein developed early menopause at slightly less than half the rate of those getting less than 4 percent of their calories from vegetable protein.", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe findings show women who took the drug had more sex, wanted more sex and experienced less distress related to lack of desire.\nWomen who took the medicine, known as flibanserin, reported 22 percent more \"satisfying sexual events\" than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nRaymond Rosen, the former chief psychologist and associate dean at Robert Wood Johnson Medical School and now chief scientist at the New England Research Institutes, said that like the introduction of Viagra, a treatment for women\u2019s dysfunction will provide an opportunity for women to discuss the problem with their doctors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Most of the benefits reported in the story were described in general, lay terms:\u00a0having more sex, wanting more sex and experiencing less distress related to lack of desire.\u00a0 The only detailed\u00a0benefit reported in the story was\u00a0the result of 2 clinical trials in 1,378 women that reported a 22% increase in \"satisfying sexual experiences\" compared to women taking a placebo.\u00a0 \"Satisfying sexual events\" was not defined and the 22% is not accurate based upon the data presented in the research abstracts.\u00a0The story should have placed\u00a0any benefits in context and\u00a0noted that while results were\u00a0statistically significant the medical or individual significance appears to be quite small.\u00a0 For example, the story should have noted that\u00a0women taking flibanserin had an average increase of 1.7 \"sexually satisfying events\" over the course of 6 months compared to an average increase of 1 event in women taking placebo.\u00a0", "answer": 0}, {"article": "\u201cNo,\u201d Dr.\nBut it also sends a signal to the brain that says \u2018you\u2019ve eaten.\u2019 Fructose doesn\u2019t stimulate insulin secretion, and if there\u2019s no insulin, you don\u2019t get the information that you\u2019re full.\u201d\n\nDoes this mean that it is a good idea to avoid fruit, because it contains fructose?\nThe study, published in the journal PNAS, found that compared with glucose, consuming fructose produced greater responses to food cues in the orbital frontal cortex of the brain, a region that plays an important role in reward processing.\nThe type of sugar you eat may affect your cravings for high-calorie foods, researchers report.\nWhen choosing between tasty high-calorie food or a delayed monetary reward, fructose drinkers were more likely than glucose drinkers to choose the food.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that avoiding fructose may curtail cravings for high-calorie foods. But it never quantifies this finding. For example, the story says, \u201cWhen choosing between tasty high-calorie food or a delayed monetary reward, fructose drinkers were more likely than glucose drinkers to choose the food.\u201d What amount of money are we talking about? How much more likely? How was this measured? We thought the story needed some numbers to earn a Satisfactory rating on quantification.", "answer": 0}, {"article": "This is a better story.\"\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nRight now the American Cancer society recommends an MRI in addition to a mammogram for women who are at high risk for breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify some of the benefits of treatment, namely, 49% of cancers were detected by mammogram alone, and 78% of cancers were detected by mammography plus ultrasound. The broadcast does not list important absolute data included in the study, namely, that the addition of ultrasound found about 4 additional cancers per 1000 women (7.6 per 1000 with mammography v. 11.8 per 1000 with ultrasound and mammography). We believe that absolute benefit data are far more helpful for viewers and should have been included. \u00a0 \n ", "answer": 0}, {"article": "Nearly 47 million people have Alzheimer's or a related dementia for which there is currently no cure.\nExtensive preclinical investigation, which took place as part the LipiDiDiet project, indicated that the nutrient combination in Fortasyn Connect has effects on multiple biological pathways that contribute to an overall neuroprotective effect.\nPredefined analyses showed significant differences between active and control study groups for hippocampal and whole-brain atrophy, and favourable effects for CDR Sum of Boxes and episodic memory (both were most pronounced in patients with high baseline cognition with regular intake).\n[2]\n\nThe trial was the first to investigate the impact of Fortasyn Connect on patients with very early AD (pre-dementia) who were randomised to receive either Fortasyn Connect or an iso-caloric control drink once daily.\nThe study did not find a significant benefit in broad cognitive function (the study primary endpoint).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We had to read the release three times to make sure, but, rest assured, there are no useful numbers about the benefits found in this study. Let\u2019s be clear, the study did not meet its expected primary outcome related to cognitive function and only three of the host of secondary outcomes. \u00a0So, from the purely scientific approach, Fortasyn Connect did not demonstrate a predefined clinical effect. The Australian not-for-profit, NPS Medicine Wise group concluded in a 2014 report that Fortasyn failed to demonstrate a significant effect in cognitive decline based on three previously published studies.", "answer": 0}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nThe group that used honey also reported more favorable results than those who used cough syrup, but since the study group was small, those differences weren't statistically significant.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\nPaul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nUnlike older children, infants can't fight the bacteria.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of honey. By how much did the children cough less and sleep better? Did this result in a shorter duration of symptoms?", "answer": 0}, {"article": "The single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\nThe report describes the use of the test to analyze samples from six patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were expecting a thorough explanation and some numbers that illustrate how this test could more regularly track the growth and spread of cancer cells. But there was no quantification in the release.", "answer": 0}, {"article": "I couldn't get anything done,\" Ham said.\nBut there's a problem: There is very little research showing marijuana works as a treatment for such addictions.\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\nGetting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are many mentions of research studies and evidence but very little detail in terms of quantified benefits. Even the mention of the\u00a02014 JAMA study showing that \u201cstates with medical marijuana laws had nearly 25 percent fewer opioid-related overdose deaths than those without,\u201d would have been more complete if we\u2019d known what that amounted to in absolute terms. The implications are that a 25% drop in opioid overdoses would be huge, but we\u2019re not really sure.", "answer": 0}, {"article": "WhoCosette Wheeler, PhD is a UNM Regents Professor in the Departments of Pathology and Obstetrics and Gynecology at the University of New Mexico Health Sciences Center.\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nThe study showed that women in this age group were still protected from HPV infections.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\nThis study focused on the benefit of vaccinating women 26 years and older.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of HPV vaccination for women 26 years and older are qualitatively described in the news release in statements such as:\n\u201cThe study showed that women in this age group were still protected from HPV infections\u201d and \u201cThe scientists followed each woman for four to seven years. They found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\u201d\nBoth statements lack quantification. In the first statement, the reader is left wondering exactly how many women were still protected. The second statement seems to suggest that the vaccination protects against any types of HPV infections while a close reading of the study suggests that only certain strains of HPV were considered, and for those strains only persistent infections were counted.\nIn general, statements such as the ones above\u00a0should be tempered with further details on the study design. In this case, there is a lack of crucial information such as how\u00a0many women were enrolled in the study and what proportion already had a history of HPV. Finally, what was the measured outcome? What does it mean exactly to be \u201cstill protected from HPV infections?\u201d Did none of the women enrolled in the study have HPV going into the study? The release isn\u2019t clear.", "answer": 0}, {"article": "\"To create the jet, you have to instantaneously create 100 times more pressure than you've got in the tire of a car,\" he says.\nA number of the people in the flu patch study applied it to themselves.\nPeople who received the flu patch had comparable immune responses to people who had gotten the flu shot.\nNow, the syringe is changed for each patient and the injections are gentler.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification of benefits in this article is a mixed bag. The description of the Georgia Institute of Technology flu patch study does provide some information about benefits of this vaccine delivery methods, but there is no\u00a0description of the measured benefits of the jet injectors.\u00a0The most complete comparative data on the benefits of the vaccine delivery method are in the briefer discussion of nasal spray. There we learn that the CDC reported the effectiveness of the spray was only 3 percent, so low that \u201cno protective benefit could be measured\u201d for children ages 2 to 17.\u00a0The effectiveness of the flu shot was about 63% for the same age group. We would have liked to have seen this kind of discussion for all three alternatives in the story.", "answer": 0}, {"article": "The Foundation was established in 2007 with the support of the Queensland Government.\n\"Of more than 400 patients in the trial, we found those who received Tamsulosin passed their large kidney stones more often than the placebo group.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the release, the clinical trial leader describes the benefits as:\n\u201cOf more than 400 patients in the trial, we found those who received tamsulosin passed their large kidney stones more often than the placebo group.\n\u201cThis means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs. We\u2019re very excited because Tamsulosin treatment may also allow patients to be treated closer to home rather than needing referral to a major centre.\u201d\nThe release would have been much better had it stated what \u201cmore often\u201d actually meant. How many more patients on tamsulosin passed their stones compared to those on placebo?\nIn addition, the release could have more carefully differentiated which patient group might benefit from the drug intervention. According to the study abstract:\n\u201cWe found no benefit overall of 0.4 mg of tamsulosin daily for patients with distal ureteric calculi less than or equal to 10 mm in terms of spontaneous passage, time to stone passage, pain, or analgesia requirements. In the subgroup with large stones (5 to 10 mm), tamsulosin did increase passage and should be considered.\u201d\nThe published study reported that of the 36 patients on the drug with large kidney stones \u2014 those between 5 and 10 mm \u2014 30 (83.3%) passed their stones compared with 25 of the 41 (61%) volunteers with large stones who were given placebo. Those would have been good numerical reference points to include in the release.", "answer": 0}, {"article": "Drs.\nAsher and Burri emphasize that the real importance of this study is its potential to make us think differently about what really matters in cancer therapy.\nIn this study, although whole brain radiation decreased the number of new brain tumors over time, its addition to focused radiation interestingly did not result in a survival benefit over focused radiation alone.\n\"Whole brain radiation patients also reported worse quality of life compared with patients who only received the focused radiation,\" adds Dr. Burri.\nThe trial authors concluded that the benefit of adding whole brain radiation was outweighed by its risks in patients with one to three newly diagnosed brain metastases.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is far more emphatic than the study. The release says focused radiation treatment alone proved to be \u201csubstantially less toxic\u201d than a combination of focused and whole brain radiation treatment for these brain tumor patients. By contrast, the study referred to \u201cless cognitive deterioration\u201d and lower rates of decline in the quality of life. However, the lack of detail about benefits in the release is largely due to the lack of detail in the study itself, which reported only on a combined measure of cognitive function and did not spell out specific benefits. The same can be said of the discussion of survival rates, because the study itself said only that there was no significant difference between the treatment groups. The release should have included a vital point: that few patients in either group lived more than a few months. Indeed, 20 percent had died before the first evaluation just three months after treatment.\nOn the other hand, the release does a great service by highlighting the finding that although patients who received whole brain radiation in addition to focused radiation had better brain scan results, they did not live any longer than those whole were given only focused radiation treatment. The finding is yet another example of the danger of putting too much stock in measures of disease progression or other tests that logically seem to be related to important health outcomes, but often fall short.", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story mentions that \u201cbad memories had been erased\u201d in the mice, it does not provide any data or any indication\u00a0of how fear manifests\u00a0in a mouse. Furthermore, the story should have made it clear that is it not known if this same effect would be seen in humans. ", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nAll were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.\nThey had an average of 10 chest pain episodes a week \u2014 moderately severe.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nHalf of the participants also were assigned to get angioplasty.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of treatment, reduction in chest pain, rates of heart attack and death, were presented.", "answer": 1}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not include specific numbers on specificity and sensitivity (see harms, below), only stating that the Facebook model was \u201cmoderately accurate.\u201d\nAlso, we think it would have been helpful to point out that the U.S. Preventive Services Task Force recommends depression screening, giving the evidence a B rating, meaning that there is moderate certainty that screening will be beneficial.", "answer": 0}, {"article": "\u201cIt wasn\u2019t effective.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\nWhile Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nRather, he says it\u2019s because facial expressions are part of the circuit of the brain related to mood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article gives next to no\u00a0information about the size of the benefit. A single statement by Eric Finzi, a cosmetic dermatologist, explains that 50 to 60 percent of patients may benefit from botox as treatment for depression. (CBS reported those estimates came from past studies, but provided no details about nor links to those studies.)\u00a0How big are those benefits?\u00a0Are they sufficient to make a notable difference in daily life? Are they a slight improvement that is useful only when combined with other treatments? The article doesn\u2019t address those questions.", "answer": 0}, {"article": "Currently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nThe effect of the drug was substantially better than seen with other antidepressants, the researchers found.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\nThe GLYX-13 study is a phase 2 trial, which evaluates a drug's effectiveness while continuing to assess its safety.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about how antidepressant effects of the drug were seen within 24 hours, but it fails to quantify\u00a0how many patients out of the 120 saw such effects. And how were the effects measured in these patients? The article also notes, \u201cThe effect of the drug was substantially better than seen with other antidepressants,\u201d but what exactly was better? How much were depressive symptoms reduced?\u00a0 What proportion of study participants benefited?", "answer": 0}, {"article": "\u201cIn the next pregnancy, if you don\u2019t get it off, you may go from obese to very obese,\u201d Thornburg said.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nWomen who took part in diet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight while pregnant, the researchers report.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that women who took part in \u201cdiet, exercise or combination programs were about 20 percent less likely than women in standard-care groups to gain too much weight.\u201d And the story does a nice job of articulating that there is significant variation in how much weight is \u201ctoo much,\u201d depending on the mother\u2019s weight prior to pregnancy. However, the absolute reduction in risk was also reported in the study tables, and so we would\u2019ve expected the story to cite that information. The study reported that excessive weight gain would be expected in 452 of 1000 women in the standard care groups compared with 362 per 1000 in the diet and exercise groups \u2014 that\u2019s the 20% reduction mentioned in the story.\nThe story also wasn\u2019t quite as clear as it could have been when discussing other potential benefits of diet and exercise. For example, the story says \u201cThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\u201d That statement is a little confusing. To clarify,\u00a0the article could have said something like: Women who participated in combined diet and exercise programs were 13% less likely to have a C-section compared to women who did not, though this difference was not quite statistically significant \u2014 in other words, it may have arisen by chance.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nThe beta cells performed \u201cevery bit as good as the body\u2019s own cells,\u201d said Melton, a co-author on the Nature Medicine paper.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\nJust because the system produced strong results in mice does not mean people will respond the same way.\nThe researchers behind two studies published Monday demonstrated they had made progress on both fronts, encapsulating the cells in a protective bubble to shield them from the body\u2019s immune response, and creating beta cells from stem cells, which are potentially limitless.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not break down the actual number of positive findings in either study, and we wish it had. It may be that the way in which the benefits were measured was hard to explain. But we still think the story should try to give readers some specifics. We\u00a0want to know more than just that the beta cells performed \u201cevery bit as good as the body\u2019s own cells.\u201d", "answer": 0}, {"article": "For more details and to read the full study, please visit the For The Media website.\nA limitation of the study was its small sample size and short follow-up period.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release briefly summarizes the results. It states, \u201cA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\u201d\nIt also notes that both the small sample size and short follow-up period were limitations of the study. ", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release discusses benefits in only the broadest of terms, citing \u201cpositive preliminary results,\u201d and fails to quantify those results.", "answer": 0}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\n\"Also, many women in our study may have been continuing to lose weight when they became pregnant.\nBut Johannson said those outcomes might be due to reduced nutrient absorption resulting from the surgery, with a fetus not receiving sufficient nutrition.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article generally does a good job of describing the benefits. In one instance, it mentions the absolute difference in outcomes between the intervention and control group for gestational diabetes. (\u201cOnly 2 percent of women who had weight-loss surgery developed gestational diabetes, compared to 7 percent of the other group, the researchers said.\u201d). That\u2019s very useful. But we\u2019re concerned that the story never explains why readers should be worried about a \u201clarger than normal\u201d baby. It sounds, at most, mildly worrisome, and some readers might even hope for a baby that\u2019s \u201clarger than normal.\u201d But a baby that\u2019s significantly larger than normal can increase risks for a variety of delivery complications such as difficult labor and need for cesarean delivery, vaginal tearing, and bleeding after delivery. Although we wish the story had explained this, we think its overall treatment of benefits merits a satisfactory rating.", "answer": 1}, {"article": "CHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\nThey said ensuring that pregnant women get this basic prenatal care could have a big effect on the educational futures of children who live in poor communities where iron deficiency is common.\n\u201cThese results speak to a large swath of people residing in that part of the world.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not quantified, which is a shame. If there were tangible differences between the groups of kids, they should be spelled out. Literally billions of dollars in global health funding could be at stake for programs like this. Policymakers need strong guidance not optimistic quotes. We need to understand the absolute benefits of this program and others like it.", "answer": 0}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is fairly vague on the benefits conferred on prediabetic patients using CPAP devices. For example, the release notes that \u201cblood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\u201d But this improvement is not quanitified. In addition,\u00a0the study was not designed to show how likely it is that this improvement measured during\u00a0a 2 week test period has a lasting impact on developing frank diabetes or, if so, how big that impact might be.\nAnd although the original study paper was clear to state the limits of the findings, the first author exaggerates them in the news release. Consider the following comparison:\nPaper: \u00a0\u201cIn this proof of concept study, the CPAP treatment was limited to 2-weeks, and thus the study does not provide information on the potential effects of CPAP on glucose metabolism over a longer period of time. Importantly, in our study, CPAP was applied in the laboratory under continuous supervision, but 8-hour nightly CPAP use may be difficult to achieve in real-life conditions. Thus, our findings should be interpreted with caution, particularly in regards to CPAP recommendations to patients in clinical settings.\u201d\nAuthor in release: \u201cOur study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for 8 hours, a full night\u2019s sleep.\u201d\nBenefits are further exaggerated (by implying that a population beyond that studied [everyone with sleep apnea, not just prediabetics with OSA] could benefit)\u00a0in the following statement from the author in the release: \u201cOur results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction.\u201d", "answer": 0}, {"article": "The skin synthesizes vitamin D when exposed to sunlight, making supplementation all the more important where long winters reduce the opportunity for this to happen.\nWhile there were no significant differences in body composition across the different dosage groups, the researchers found children who had vitamin D stores above the threshold recommended by the Canadian Paediatric Society (CPS) averaged around 450 grams less body fat at 3 years of age.\n\"Vitamin D supplementation trial in infancy: body composition effects at 3years of age in a prospective follow-up study from Montr\u00e9al\", by T. J. Hazell, S. Gallo, C. A. Vanstone, S. Agellon, C. Rodd, and H. A. Weiler, Pediatric Obesity doi:10.1111/ijpo.12105\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\n\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a borderline Satisfactory rating because the release provides a number associated with vitamin D supplements \u2014\u00a0 450 grams less body fat. However, the release presents some of the findings in a confusing way that could be misleading to readers. It confuses blood levels of vitamin D with doses of vitamin D supplements and it reports that children with higher blood levels of vitamin D averaged around 450 grams (1 pound) less body fat, but the headline says supplements reduce body fat. The researchers clearly stated, \u201cThis long-term follow-up of a vitamin D supplementation study in children demonstrates no difference in body composition across any dosage groups (400, 800, 1200 and 1600\u2009IU).\u201d The release notes that \u201cthere were no significant differences in body composition across the different dosage groups\u201d, which makes the headline claiming that vitamin D supplements reduced body fat incompatible with what the researchers actually reported.\nThe release does report that physical activity also made a difference, but did not offer any comparison to the claimed effects of vitamin D levels.", "answer": 1}, {"article": "Have a question?\nSo, as this Cochrane review notes, it's impossible to draw firm conclusions on the effectiveness of the flu vaccine for those over 65 because the data is so biased and poor.\nIt's true that flu vaccines don't work spectacularly well, at least according to the best evidence we have (and most of the evidence on flu vaccines is of poor methodological quality).\nBut the downsides to getting a vaccine are extremely minimal, and flu shots may still be helpful in reducing some illness and saving lives, which is why public health experts say you should get vaccinated anyway.\nFor one, in those years when the WHO guesses correctly which strains will circulate, the shot tends to be a lot more helpful than some of these averages suggest.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of explaining what the actual benefits of the influenza vaccine really are.\u00a0 Just as a recent HealthNewsReview.org\u00a0blog post did, the story goes way beyond the typical media version touting claims of X-percent effectiveness and explains what that means in terms of individual people escaping flu symptoms.\u00a0 This accuracy of interpretation does carry with it, however, one risk:\u00a0 For a public so used to hearing that vaccines are, say, 60 percent effective, actually finding out that they\u2019d only prevent one person from getting symptoms for every 33 people vaccinated may\u00a0not sound good enough for the\u00a0lay person.", "answer": 1}, {"article": "The F.D.A.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article mentions several studies and case reports of the benefits of this procedure, but does not share details necessary to evaluate it. The article says \u201cFor those who could not have surgery, a\u00a0valve replacement\u00a0with TAVR reduced the death rate by 20 percent in the first year.\u201d \u2013 20% from what? Compared to what?\nThe article also says: \u201cMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years. And new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\u201d\nWe would hope to see absolute numbers here, not just percentages. How many fewer deaths compared to surgery? In what way did patients at intermediate risk do better?", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\n\u201cI know we can do more.\u201d\n\nAlthough there\u2019s no direct evidence that heart patients who are screened fare better, depression can result in poorer outcomes and a poorer quality of life, the panel said.\n\u201cA lot of patients with depression don\u2019t follow up on it,\u201d said Dr. Mary Whooley, a professor of medicine at the University of California, San Francisco, who was not on the panel.\nOne doctor said screening isn\u2019t enough; patients need close monitoring to make sure they get help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of depression screening.", "answer": 0}, {"article": "Treatment usually involves replacing one of the steroids they are unable to produce - called cortisol - with a medication.\nThey found the effects were reduced because fat cells have a pump that removes corticosterone - but not cortisol - from the fat cells.\nThe team found that corticosterone was as effective as cortisol, but had reduced effects on fat cells compared with cortisol.\nIn a mouse study, the team showed that the effects of corticosterone on fat cells were reduced compared with cortisol.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a brief but nice job of explaining the effects of corticosterone on fat cells. We would have liked to have seen a bit of quantification of the differences between cortisol and corticosterone. The study demonstrated statistically significant differences on fat cells but the duration of the study in a small number of patients with Addison\u2019s disease was 330 minutes.", "answer": 0}, {"article": "Founder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nAfter 20 minutes, 88.5% reported their ear pain dramatically reduced or vanished.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\nThe earache episode was totally resolved for 80%.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0does not adequately quantify the benefits of the lollipops. It says:\n\u201cChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices. After 20 minutes, 88.5% reported their ear pain dramatically reduced or vanished.\u00a0The earache episode was totally resolved for 80%.\u201d\nIt does not explain how many children were studied. Is it 88.5% of 100 kids? Is it 88.5% of 50 kids? As it turns out, the number is 88.5% of 25 kids, meaning 22 kids. The release should say, \u201cOut of the 25 children studied, 22 reported their ear pain reduced by X on a scale of Y.\u201d\nUsing\u00a088.5% is also misleading (on the part of the study report and the press release) because it doesn\u2019t include in the denominator the number of subjects who stopped the treatment.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains why a portable, inexpensive device that could determine if a lump\u00a0is probably\u00a0benign or malignant would be a useful tool for patients in rural areas and in developing countries.\nReaders should be told before the 5th paragraph that a pilot\u00a0test on the featured device included only 7 patients.\nAt this stage of development, any presumed benefits should by couched very carefully.\u00a0 Although the story does provide several provisos, we think that readers should have been told bluntly that because the device is only in very early testing its sensitivity and specificity in detecting breast cancer is purely speculative.", "answer": 0}, {"article": "They should try medical therapy, and if medical therapy fails and the surgeon feels that part of the problem is anatomic, then surgery would be a good tool for them to use,\" Josephson said.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\nNone of which is to say that patients shouldn't try medical therapies first, he added.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nMONDAY, Nov. 14, 2011 (HealthDay News) -- Preliminary research suggests that a single injection of a man-made protein might lower levels of \"bad\" cholesterol.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\n\"Cardiovascular disease is the number one cause of death in the U.S., and while statins are very effective, a good proportion of people are not meeting their goals, and in this setting the shot could be a valuable addition,\" he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0says that AMG 145 decreased LDL cholesterol by up to 64%. Although this description isn\u2019t quite as useful as simply telling us what the cholesterol numbers were before and after treatment, the number does convey the point that this was an impressive amount of cholesterol lowering \u2014\u00a0which is accurate. The story also explains other features\u00a0of the drug that might be attractive \u2014\u00a0e.g.\u00a0the potential for less\u00a0frequent dosing and fewer muscle-related adverse effects compared with statins. As already noted, the potential limitation of impacting a surrogate marker was worth mentioning. There\u00a0was room for improvement here, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nOne theory, backed by the new British study: the results are skewed by the fact that some non-drinkers are former drinkers with health problems.\nBut those studies do not prove alcohol is the reason for the differences.\nBut that's not the only reason, says Lori Mosca, a professor of medicine at Columbia University Medical Center and a spokesperson for the American Heart Association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article stated: \u201cthe science suggesting a benefit has never been conclusive,\u201d which could explain why the story hesitated to put numbers down in this case.\nBut the story pointed out that women over the age 65 could be an exception, as this age group experienced some health benefits with moderate drinking. What were these health effects? And how much more benefit did this group see?\nAlso, with a Swedish study mentioned in the story, it\u2019s said that middle-aged people who had more than two drinks a day \u201chad a markedly increased stroke risk.\u201d What does that mean? And by how much?\nSome numbers could have clarified sweeping statements such as these.", "answer": 0}, {"article": "Old friendships fell apart.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nIt was overpowering.\u201d\n\nRobison\u2019s TMS research team was led by Harvard neurologist Dr. Alvaro Pascual-Leone, who supplies an introduction to \u201cSwitched On.\u201d In a separate interview, Pascual-Leone says Robison\u2019s book demonstrates how small changes in brain function, however temporary, can have a life-changing impact.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While Robison refers to improvements in his life, there is no discussion of how long the effects last, what changes occurred and how they actually benefited Robison. And, while personal anecdotes are powerful, they don\u2019t provide evidence that can be used to assess the likelihood of benefit or harm in general. A discussion of the research in this area should have been included.", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on what the company media briefing wanted to report:\u00a0 less pain, stiffness, disability and decreased use of pain medications in the braced group.\u00a0 But the story didn\u2019t say if there was a control group and how results compared. \u00a0\u00a0 ", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicated that 215 individuals who were screened were identified as having heart disease and received additional testing and treatment. \u00a0Nonetheless, there was no statistical benefit between the groups of healthy individuals who did and did not undergo a CCTA test.", "answer": 1}, {"article": "Treatment-related side effects included mainly low-grade fatigue, itching, elevated lipase, rash, nausea, joint pain and anemia.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nThe study found no significant difference in response rates between those with little to no PD-L1 on their tumors (26 percent) and those with greater PD-L1 expression (24 percent).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a pretty good job here, explaining that: \u201cThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease. Thirty (38 percent) patients had disease progression.\u201d Later, the release states that \u201cAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which [one doctor] noted \u2018is better than anything we\u2019ve seen in the past.'\u201d The release also places analysis of survival in context by noting that \u201cOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\u201d", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides data that there was little positive difference between radiologists' and CAD detection of cancer via mammogram images.\u00a0 However, the story does not mention results of any other evaluations of the technology (e.g. how it has been used in UK and other countries where results did show benefit in terms of increased detection of cancer). ", "answer": 1}, {"article": "Visit an urban park in China any given morning or late afternoon, and you're likely to find elderly people engaged in a slow, elegant dance, their arms and legs lifting and circling in unison.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not detailed enough. The story says that participants in the tai chi group \u201cscored significantly higher\u201d on a quality of life questionnaire\u00a0\u00a0and \u201creported an improvement in mood.\u201d\u00a0Readers\u00a0deserve to have these benefits quantified in absolute terms so they can judge for themselves how \u201csignificant\u201d the\u00a0findings are. The story also failed to mention that tai chi had no effect on participants\u2019 peak oxygen uptake or performance on a six-minute walk test, which are objective\u00a0measures\u00a0of functional capacity.\u00a0While it is useful and important to know that\u00a0heart\u00a0patients \u201cfeel\u201d better after tai chi, as the\u00a0quality of life measures suggest, it\u2019s also key to point out that\u00a0patients should not\u00a0expect to function more effectively just because they\u2019re taking a\u00a0tai chi class.", "answer": 0}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\n\"Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThis is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "If this release would have only discussed the primary outcome goal of the study \u2014 \u201cto examine the effects on inflammation in the airway by measuring the sputum eosinophil count\u201d \u2014 then we\u2019d probably give it a satisfactory rating on this category since it provided clear numerical data showing a significant reduction in percentages among patients taking the drug versus those on placebo. But the release didn\u2019t stop there. It had the principle investigator add glowingly, \u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.\u201d\nIf these additional measurements were so significant in the study, then why was that data excluded from the release?\u00a0 We need quantification of the actual results of the clinical tests to be able to judge benefits.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a borderline call that we ultimately ruled unsatisfactory. \u00a0On the positive side, certain aspects of the two studies published in the NEJM are well described: \u201c\u2026among the 35 subjects who were assigned to get both treatments, 100% of the subjects\u2019 brain tissue initially affected by blockage had blood flowing to it after 24 hours. Among the subjects who only got alteplase, also known as tPA, the median level of restored blood flow was 37%.\u201d \u201cThe studies suggest that for every 2.5 to 4\u00a0patients, on average, treated with intra-arterial therapy, one could be expected to have an outcome better than they would have had with alteplase alone.\u201d\nHowever, percentage of brain tissue affected by blockage isn\u2019t the most important outcome for readers \u2014 they\u2019re more interested in results like neurologic function and death. And on those key statistics, the story relies mainly on relative risk figures that likely inflate the benefits of the procedure. Example: \u201cCompared with stroke patients who got clot-dissolving medicine alone, those who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days, had 81% better function 90 days after their stroke, and were nearly half as likely to die.\u201d \nIn these types of situations, absolute risk is the number that really matters to patients. So we\u2019d prefer for the story to have reported 1. the percentage of\u00a0patients who got\u00a0clot-dissolving medicine alone and regained function, and 2. the percentage of those who got both treatments and regained function. That would give readers a more accurate sense of how well the treatment works.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits in relative terms only. The story should have provided context for these numbers by showing the actual rates of fracture in the treatment group compared to the placebo group. Furthermore, the story only presents one outcome, vertebral fractures. These are fractures found on x-rays that only sometimes cause symptoms. Treatment reduced the chance of vertebral fractures from 10.9% to 3.3%.\u00a0Equally important would be risk of hip fracture, which can substantially impact an individual's quality of life. In this study, the risk of hip fracture was reduced from 2.5% over 3 years\u00a0in the placebo group to 1.4% in the treatment group.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nGilbert cautioned that the study results are preliminary.\nFor one patient in the study, the Temodar-vaccine combination by itself has worked fine.\nHe noted the impressive results could be the result of cherry-picking patients, accepting only those whose tumors had been excised by surgery and radiation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The impact of the treatment on time to cancer recurrence was provided in the story. \u00a0The story included a hint that the study may also demonstrate an increase of survival time. \u00a0However since the information about survival time was not available at the time the story was published, it is not fair to make this suggestion. \u00a0Inclusion by the clinician involved in the story that\u00a0\"It appears very promising for a cancer where there\u2019s been little hope.\" may suggest more benefit than may be attained with this treatment.", "answer": 0}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\nSome experts say that estimate is overly alarming.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since the story focused on the harms of the approach, quantifying the benefits of CT scans is not imperative in this case. ", "answer": 2}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nSpecifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients' seizures stopped entirely.\nThe difference in the degree of seizure reduction between the CBD group and the placebo group was both statistically significant and clinically consistent.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nThe new study confirms results from a December 2015 open-label expanded access program led by Dr. Devinsky that reported reductions in seizure frequency.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits in clear terms, and provides numbers to add context. It states:\n\u201cSpecifically, seizure frequency dropped in the CBD-treated group by 39 percent from a median of nearly 12 convulsive seizures per month before the study to about six; three patients\u2019 seizures stopped entirely. In the placebo group, there was a 13 percent reduction in seizures from about 15 monthly seizures to fourteen.\u201d\nIt also notes that the difference in the degree of seizure reduction between the CBD group and the placebo group was \u201cboth statistically significant and clinically consistent.\u201d", "answer": 1}, {"article": "Bernard M.Y.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\nThis benefit was seen even among those whose cholesterol levels were already low, researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story failed to provide information about the absolute benefit that might be expected to be obtained with higher statin dose use. \u00a0For example, by presenting the 13% reduction in cardiovascular death or heart attack rate, a reader has no way of knowing what the actual rate was to start with.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article was about one patient\u2019s subjective account of pain relief. The only mention of evidence is by one of the doctors quoted, saying he did a literature search and found the evidence supporting this treatment to be \u201cgrim.\u201d A quantitative assessment of that evidence would have been useful to include.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides at least a ball park estimate for people about the amount of weight that might be \nanticipated to be lost with the use of this medication.", "answer": 1}, {"article": "\u201cI just need a calculator to add a few things,\u201d said Falcone, who was not involved in the study.\nTo test this idea, they looked back at 78 minor surgeries that were done on women with endometriosis - half using the assistance of a robot, half without it.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nDr. Tommaso Falcone, chair of obstetrics and gynecology at Cleveland Clinic, said this study shows that more technology is not always better.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are two possible benefits here. 1. People spend less time in surgery to achieve roughly the same outcome and potentially a better outcome, which, by all accounts, is better. 2. Hospitals and medical groups spend less money on robots and are allowed to devote those health resources elsewhere. Both are not so much quantified as addressed. In order to truly establish the second point, one would need to perform a longer term and larger study to find\u00a0out whether\u00a0humans outperform robots on a wider range of surgeries. These $1.5 million machines are not just specific to endometriosis. They are used for hundreds of procedures, and so to decide whether they are worth the money would require more research. Still, the story is measured in its claims.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nThe median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS.\nIn the intent-to-treat population, Grade 3 or higher, hematologic adverse events were similar for overall infections, febrile neutropenia, and bleeding events.\nThe percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm.\nThe percentage of patients alive 12 months after randomization was 41.5% on the VYXEOS arm compared to 27.6% on the 7+3 arm.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gave extensive data on median overall survival (9.56 months compared to 5.95 months for patients receiving 7+3, the standard treatment) and the \u201cpercentage of patients alive 24 months after randomization\u201d (31.1% in the treatment\u00a0arm compared to 12.3% on the 7+3 arm).\nIt also, helpfully, added the \u201csixty-day all-cause mortality\u201d as 13.7% versus 21.2%, in favor of patients treated with\u00a0the intervention\u00a0drug. The release notes that the treatment gives a Number Needed to Treat (NNT) of about 7, which is very good. (NNT is a measurement of the impact of a therapy by estimating the number of patients that need to be treated in order to have an impact on one person.) The median survival doesn\u2019t look as good. In about half of the patients, there is a four month or less increased survival. This implies that there is a group that has much longer survival. To see that there is a clinically important survival benefit (14% absolute increase) does make a difference.", "answer": 1}, {"article": "It's very exciting.\"\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n\"I see no moral problem in this basic technique,\" said Richard Doerflinger of the U.S. Conference of Catholic Bishops, a leading opponent of embryonic stems cell research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Framing this approach as one that could someday cure not only diabetes, but also heart disease, stroke, and \u2018many other ailments\u2019 is troubling.\u00a0 This extrapolation to diseases other than diabetes was not supported by the data presented in the study reported on.\u00a0 There is a great gulf between proof of concept in an animal model and cinical application in a single disease.\u00a0 Suggesting the same approach could be applied to other diseases is pure speculation that is not supported by the data in the Nature study. ", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some absolute data on patients' self-reported recoveries and mood. At 26 weeks follow-up, of 366 bipolar patients, 27% of patients who took a mood stabilizer and placebo experienced 8 weeks of of positively improved mood, but did not become manic; 23.%5 of patients receiving anti-depressants and a mood stabilizer achieved the same 8-week period of improved mood. ", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nMM36 was also associated with improvement in patient-reported outcomes, most notably rapid and sustained itch relief, with Visual Analog Scale scores showing improvement from moderate to mild within the first week (36.4% mean change; p=.0011).\nThe randomized, double-blind, vehicle-controlled study in 121 patients showed that MM36 demonstrates a statistically significant effect on the primary endpoints versus vehicle as measured by improvement in IGA score (Investigators Global Assessment) and percentage change in EASI score (Eczema Area and Severity Index).\nThe mean percentage improvement in baseline EASI score was notable very early at week 1 (31.4% vs. 6% for vehicle; p=.0005) and at week 2 (39.0% vs. 3% for vehicle; p=.0001).\nThese effects were sustained through week 8 of the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release does give the mean percentage improvement scores compared to baseline measures and patient-reported outcomes (39% improvement for those volunteers assigned the MM36 compound compared to 3% on the placebo at week 2 and throughout the remainder of the 8-week study), it could have been greatly improved by saying specifically how many of the 121 experienced what percentage of improvement. There also is no information on what it actually means to say a condition has improved from \u201cmoderate\u201d to \u201cmild,\u201d especially given that the treatment is being tested only for those with \u201cmoderate to mild\u201d eczema. According to the published study, the number needed to treat (NNT, or the number of patients that need to be treated for one to benefit compared with a control in a clinical trial) was about 6 for an improvement of at least 2 levels on a 0 \u2013 5 scoring system. According to that measure, the difference in improvement between the high dose cream and the placebo was about 18%.", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nFor the moment, the researchers recommend incrementally incorporating additional fish into a diet; consumption even once a week moves a family into the \"high\" fish-eating group as defined in the study.\nAnalyzing these data points, the Penn team found that children who reported eating fish weekly scored 4.8 points higher on the IQ exams than those who said they \"seldom\" or \"never\" consumed fish.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\nIn addition, increased fish consumption was associated with fewer disturbances of sleep, which the researchers say indicates better overall sleep quality.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that children who said they ate fish weekly \u201cscored 4.8 points higher on the IQ exams than those who said they \u201cseldom\u201d or \u201cnever\u201d consumed fish.\u201d\u00a0 The children who reportedly \u201csometimes\u201d ate fish consumers scored 3.3 points higher. How big is a 4-point difference on the IQ test and would it translate to better school performance or other outcomes that would be meaningful for the children? That question isn\u2019t addressed.\nThe release also claims that those who consumed fish had fewer sleep disturbances but doesn\u2019t give us any clue as to how sleep disturbances changed \u2014 from what to what?  \nIt would also be useful to know how much fish they ate and what kinds.  ", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\nDrugs now used to treat advanced prostate cancer, like Taxotere, do not have much affect on bone scans, Dr. Smith said.\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms.\nThat could give Medicare grounds for denying payment when the drug is used off-label, as cancer drugs often are.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story included the numbers of men who were seen to have improvement in their bone scans. \u00a0While reporting on the improved bone scans seen in the men treated with XL184, the story did include some balance by indicating that this scan change might not translate into a change in the cancer in the bone and that nothing was yet known about how the drug affected longer term outcomes.\nThe increase in median longevity observed with Provenge was reported from one study, without including the insight from the two other larger scale studies.\nIn a split decision, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 0}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\n\"If they had a problem with folic acid, it would be too late at that point to prevent the birth defect.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives the reader an idea of how many neural defects could be prevented by adding folic acid to corn flour. \u201cAnd studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\u201d", "answer": 0}, {"article": "\u201cShe couldn\u2019t get over the background buzzing,\u201d Dr. Kaufman said.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\nBut spinal cord stimulators offer significant relief to only about half the patients who try them.\nIn August, the medical journal Neurosurgery showed that spinal cord implants were far cheaper than additional operations to treat pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately characterizes the results of a 2007 multinational randomized trial showing that the device helped reduce pain by about half in about half of people who received the treatment, compared to only 9% of people receiving conventional medical treatments. The study is the largest of its kind and a fair representation of the literature. A 2004 review, for example, found that spinal cord stimulators provide mild to moderate pain relief in selected individuals for anywhere from 6 months to several years. (Pain 2004;108:137-47)\u00a0 Still, the story could have probed the absolute reduction in pain.\u00a0 For instance, halving moderate pain may be less beneficial than halving severe pain.\u00a0 ", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nHowever, there are also some limitations to this study, the researchers say.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\nRelated: Post-workout cold immersion likely won\u2019t help you heal\n\nThere are risks that come with a weekend warrior exercise schedule, especially for people who aren\u2019t used to being active.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story used only relative risk numbers to quantify the benefit. This is inadequate, as we explain in Reporting the findings: Absolute vs relative risk.\nAlso, the story confused association with causation, i.e.,\u00a0\u201cresearchers in the U.K. found that weekend exercise appears to be just as effective at preventing heart disease and cancer as exercise done more frequently.\u201d\nThe title of the paper suggests otherwise: \u201cAssociation of Weekend Warrior and other Leisure Time Activity Patterns with Risk of All Cause Cardiovascular Disease and Cancer Mortality.\u201d See more on the importance of not overstating observational findings.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\nThe study team also found evidence that the better outcomes likely were due to lower rates of bleeding in the brain and of a brain injury called cystic periventricular leukomalacia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release gives figures for the number of study participants and their gestational ages, it doesn\u2019t provide any quantitative data on the benefits of steroid therapy. Instead, it uses broad, vague language, such as \u201csignificant differences in rates of death.\u201d It also states, \u201cInfants in the complete treatment group fared best,\u201d and \u201cinfants in the partial treatment group fared better than untreated infants.\u201d\nAs we have pointed out in previous reviews, the word \u201csignificant\u201d is confusing and ambiguous, since it could mean \u201cstatistically significant\u201d or \u201cremarkable/substantial,\u201d the colloquial use of the term.\nWithout any numbers to put \u201cbest\u201d and \u201cbetter\u201d into perspective, readers are left wondering just how well each group fared. The original journal article gives the rates of various complications in percentages. Since the study\u2019s primary objective was to compare the rates of death or neurodevelopmental impairment in infants born between 22-27 weeks, it would have been sufficient to disclose only these figures for the three groups. Researchers wrote, \u201cDeath or neurodevelopmental impairment occurred in 68.1%, 54.4% and 48.1% of patients in the no, partial and complete ANS (antenatal steroids) groups, respectively.\u201d\nSince the news release does not quantify the benefits for its readers, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\n\"So we\u2019re cautiously optimistic.\u201d\n\nAnd if problems turn up, there are the three potential vaccine described in the new study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag. \u00a0We could have gone either way with this grade but give the story the benefit of the doubt. The story does detail the findings of one of the four vaccines being tested: That 16 monkeys appeared to become immune to Zika.\u00a0More information about the three other vaccine trials should have been given, though.", "answer": 1}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "How is a 50% reduction in pain measured?\u00a0 What are the potential flaws in such measurements or self-assessments?\u00a0 31% of how many?\u00a0 These are critical lapses. These questions were better answered in a company news release than they were in the WSJ news story. ", "answer": 0}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nAn international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead author of the study is quoted as saying:\nOur results suggest that the unique polyphenol mixture in tart cherries may help positively shape the gut microbiome, which could potentially have far-reaching health implications.\nWhat are the \u201cfar-reaching health implications\u201d? They\u2019re not specified. Nor are any specific benefits described. The release says the researchers analyzed study participants\u2019 stool samples but offers readers no glimpse into the findings or what was measured.", "answer": 0}, {"article": "\"I thought I could eat like regular people.\"\nWatson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nThe problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\nWhen Bariatric Surgery's Benefits Wane, This Procedure Can Help\n\nFor most of her life Fran Friedman struggled with compulsive eating.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story links to an abstract from a randomized trial of the procedure, the story is almost purely dependent on the experience of one person and the comments of an expert: \u00a0\u201cAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating. And\u00a0research\u00a0conducted over the past decade suggests it works.\u201d\u00a0The story does not provide any additional details. How well did TORe work in the research? \u00a0Did it work for everyone? \u00a0How long did the researchers follow the subjects?\nIt would have been especially useful, in our opinion, to point out that the weight loss was modest in the intervention group (3.5% from baseline) and that most everyone in the study (including 78% of the control group that received a sham procedure) achieved weight loss or stabilization.", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nCompared to those who received care from an OB, low-income women receiving midwifery care had a 41 per cent reduction in odds for small-for-gestational age birth, the researchers found.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study looked at three specific pregnancy outcomes:\u00a0 babies who were small for gestational age, had a low birth weight, or were delivered pre-term.The news release said low-income women who received prenatal care from a midwife had a 29% \u201clower odds\u201d of a small-for-gestational age birth compared to women who received care from a general practitioner and a 41% \u201creduction in odds\u201d compared with women who used an obstetrician.\nThis was insufficient for two reasons.\nFirst, it didn\u2019t provide absolute numbers that would give readers an idea of the size of the difference.\nAccording to the study, 7.09% of all births were small-for-gestational age births. Of those who used midwives, 4.83% had small-for-gestational age births, compared with 7.06% of women who used general practitioners and 8.59% of women who used obstetricians.\nSecond, the news release did not give any figures about the study\u2019s findings that women who used midwives were less likely to go into early labor or to have a low birth weight baby.", "answer": 0}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThey usually die within five years of diagnosis.\nOne of medicine\u2019s greatest villains: HIV.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the outcomes for all 17 patients who were enrolled in the study, 15 of whom did not have symptoms of ALD after two years.", "answer": 1}, {"article": "Researchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nThe drug is called Gammagard.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For reasons described in the Evidence criterion above, we don\u2019t think the story adequately explained what the study found. ", "answer": 0}, {"article": "Vitamin D can be obtained in the diet, particularly from fortified foods, from supplements, and from sun exposure.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\n\"In the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\" explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article.\n\"Currently, health agencies do not recommend vitamin D for the prevention of colorectal cancer,\" said Marji L. McCullough, ScD, American Cancer Society epidemiologist and co-first author of the study.\nThe few randomized clinical trials of vitamin D supplementation and colorectal cancer completed thus far have not shown an effect; but study size, supplementation duration, and compliance may have contributed to their null findings.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are only presented in relative terms \u2014 not absolute numbers.\u00a0For example: \u201cthose with deficient concentrations of vitamin D had a 31% higher risk of colorectal cancer during follow-up, which averaged 5.5 years (range: 1 \u2013 25 years). Similarly, concentrations above bone health sufficiency were associated with a 22% lower risk.\u201d\nWhile that\u2019s not good enough for a satisfactory rating, we acknowledge that it would probably be quite difficult to provide absolute risk reduction figures based on these data. And the release does provide the lifetime absolute risk of colon cancer in men (4.5%) and women (4.2%) \u2014 which helps contextualize the 22% relative reduction associated with higher vitamin D levels.\nTo meet our standard, however, the release should have attempted to provide some clarity on what that 22% reduction might indicate in terms that are actually meaningful for readers. In other words, if my lifetime risk of colorectal cancer is 1 out of 22 (the rate given for men in the news release), how might a 22% reduction change that risk?", "answer": 0}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\n\"When we talk about reducing fear memory, we are not talking about deleting the memory of what actually happened,\" explains lead author Professor Dominik Bach (UCL Wellcome Centre for Neuroimaging, Max Planck UCL Centre for Computational Psychiatry and Ageing Research and University of Zurich Division of Clinical Psychiatry Research).\n*\n\nThe fear response was 60% lower in participants who had doxycycline in the first session compared to those who had the placebo, suggesting that the fear memory was significantly suppressed by the drug.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release how statistically strong the results are. The release notes that volunteers taking the antibiotic had a 60% lower fear response in the first session compared to those who took the placebo, \u201csuggesting that the fear memory was significantly suppressed by the drug.\u201d But that number is an average response rate in the treated group and we\u2019d like to see some actual numbers \u2014 the number of responses and the range of responses \u2014 to assess how many people were helped and to what degree.\nThe article published in Molecular Psychiatry also reports only the approximate percentage of study volunteers who experienced a reduced reaction to the fear marker, so there are no absolute numbers that could be taken from the study and used in the news release. However, communications staff and journalists are the eyes and ears for readers and it behooves them to seek clarity from the authors of research.", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nDespite hundreds of studies, there's still surprisingly little research on whether tonsillectomy really helps reduce the risk of sore throats.\nThe premise of tonsillectomies, back in their heyday, was that tonsils get infected themselves and no longer help fend off germs.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nBut it wasn't until clinical trials were completed in the early 1980s that there was proof that tonsillectomy really only helped children with severe, recurrent throat infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are never quantified, which is a big problem in this case because so much time is spent on the anecdotal family in the lead. We can\u2019t understand why a headline this bold was put on a story that actually takes pains to point out the lack of evidence supporting tonsil surgeries.", "answer": 0}, {"article": "\"We're kind of on the edge of this becoming more accepted.\"\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nPeople with the largest amounts of calcium in their arteries carry an early death risk that's six times greater than those with no calcium deposits, researchers found in a 15-year study of nearly 10,000 patients.\nResearchers then tracked the participants for roughly 15 years, taking special note of the 936 patients who died.\nPatients with small levels of arterial calcium had a 68 percent increased overall risk of death, compared to those with no calcium deposits at all.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that CAC testing can provide health benefits, but that\u2019s not what the study looked at.\nThe story includes a claim by an expert that this study confirms the usefulness of CAC testing for determining the best treatment of people who do not have symptoms of heart disease, but do have high cholesterol or a family history of heart problems. However, the research article cautions that, \u201cDespite evidence of increased risk, current effectiveness evidence does not support targeted treatment of patients with high-risk CAC scores to improve outcomes.\u201d In other words, even if people in this study who had higher scores were more likely to die, this study does not provide any evidence that more or different treatment would extend their lives.\nThe story also quotes a researcher saying that telling someone they have a high CAC score \u201ccan be a very potent motivator\u201d for changing lifestyle or sticking with treatment. However, once again, the actual text of the research article undercuts this claim, noting that any effect of CAC test results on patient behaviors \u201ccannot be quantified\u201d. What\u2019s more, health behavior literature generally indicates that test results by themselves tend to have little effect on people\u2019s behavior, unless ongoing support is provided.\nLastly, the story describes a 68% increase in risk of death for those with small amounts of CAC and a risk that was \u201c6 times greater\u201d for those with another group. But these are relative comparisons that are difficult to interpret. It would have been easier and more informative to simply give the absolute rate of death in each group as the study did \u2014 these rates were 3% in the zero CAC group, 6% for those with small amounts of CAC, and 28% for those with large amounts of CAC.", "answer": 0}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nDo melatonin supplements really help people sleep?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of treatment, an extra half-hour of sleep compared with control subjects in a trial, was presented. Kudos for clearly laying out that the gain in sleep time was not helpful for all insomnia \u2013 only that from change in time zone or shift work.", "answer": 1}, {"article": "; Brian Silver, M.D.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\nDALLAS, Aug. 22, 2018 -- Breastfeeding is not only good for babies, there is growing evidence it may also reduce the risk for stroke in post-menopausal women who reported breastfeeding at least one child, according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one to call. The release clearly lays out the research findings that breastfeeding is associated with reductions in stroke risk, even breaking it down by subgroups. That\u2019s good. However, the release only tells readers about relative reductions in risk, as opposed to absolute reductions in risk. What does that mean? Well, let\u2019s say that the women in a study have a 0.25% risk of getting Disease X. If the study reports that a specific behavior doubles the risk of Disease X, that sounds like a big deal \u2014 a 100% increase in risk! But that\u2019s a 100%\u00a0\u00a0relative increase in risk. The absolute risk would go from 0.25% to 0.5%. The difference between relative and absolute risk is something HealthNewsReview.org has written about, and it is a key distinction that we feel is important. So, when the release tells us that breastfeeding was associated with a 23% decrease in stroke risk, readers still don\u2019t know what that means in terms of absolute risk. And because the baseline absolute risk numbers aren\u2019t mentioned, savvy readers can\u2019t even do the calculation for themselves.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\n\u201cNo one medication works for all patients suffering from chronic gastrointestinal disorders,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nParticipants were randomly assigned to receive a placebo or Trulance, once daily.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As noted in the summary above, the release did not provide readers with a realistic picture of the actual rate of improvement over placebo in the two clinical trials cited by the FDA in its approval process.", "answer": 0}, {"article": "Newswise \u2014 Columbus, OH.\nEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\n\u201cThe prototype dressing mimics this physiological process, and while it has proven to create an optimal environment where chronic wounds can heal, we are always looking for new ways to keep pathogens under better control.\u201d\n\nRoy notes that chronic wounds are particularly susceptible to infection because bacteria, which at times are free floating within a wound \u2013 can sometimes mobilize, creating colonies covered by a thick sticky coating called a biofilm.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits is provided. A scientist is quoted as saying the research takes the technology \u201cto the next level\u201d and that they have \u201coptimized the bandage\u2019s design and the amount of electrical current delivered\u201d allowing \u201celectric fields and currents to penetrate more deeply into wounds, and really get to where these biofilms may be hiding,\u201d but offers no data to support the claims.\nIn comparing the technology to traditional dressings, the release states that \u201cinfected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\u201d\u00a0 We aren\u2019t given any data on what \u201chealed better\u201d\u00a0 and \u201cmore quickly\u201d actually means.", "answer": 0}, {"article": "Both VEGF Trap-Eye and Lucentis block a protein called vascular endothelial growth factor that causes blood vessels to grow and leak into the eye.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nBut the drug works best when given every four weeks, which can be inconvenient for patients and doctors.\nThe hope is that the implanted cells will replace those injured by the disease.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A pretty good job here. The story notes that the major benefit of the new drug over existing treatments would be the potential for less frequent dosing and follow-up visits. It also quantifies the benefit in terms of the numbers of letters and lines that were legible on any eye chart \u2014 a metric that should have \u201creal-world\u201d significance for most readers.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece states that statins reduced the rate of deaths by half compared to those not taking statins; however, it would have been more useful to the reader had the results been presented in terms of absolute risk reduction. (See our primer on absolute vs. relative risks.)\u00a0 ", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\nJolly said there are mechanical methods of removing clots, which were not tested in this study.\nJolly said the lesson from his team's trial is that clot removal should be used only as a rescue treatment when an angioplasty fails to clear an artery.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the absolute difference in the primary composite outcome in the two groups in this study (in fact there was no difference between those groups, indicating no added benefit for clot removal), which earns the story a satisfactory rating here.\nWith that being said, the general benefits of angioplasty are not really discussed in the story. The assumption made is that after a heart attack, where clogged arteries occur, angioplasty is an accepted and effective treatment.\u00a0 A bit of background on angioplasty as a treatment and stent placement might have filled out this story and made it clearer why these two approaches were being evaluated in the first place.", "answer": 1}, {"article": "Olive oil is a key ingredient in the so-called Mediterranean diet.\nBut he also stressed that the study does not prove that olive oil, per se, helps prevent strokes.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nWhen the researchers factored in other diet habits, exercise levels and major risk factors for stroke \u2014 like high blood pressure and diabetes \u2014 heavy olive oil use was tied to 41 percent reduction in the odds of stroke.\nPeople who said they used olive oil for both cooking and as a dressing were considered \u201cintensive users.\u201d\n\nOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did the best job of the three stories we reviewed in quantifying the potential benefits observed in the study.\n\u201cOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year. That compared with just over 0.5 percent among non-users, and 0.4 percent among moderate users.\nWhen the researchers factored in other diet habits, exercise levels and major risk factors for stroke \u2014 like high blood pressure and diabetes \u2014 heavy olive oil use was tied to 41 percent reduction in the odds of stroke.\u201d\nThere are better ways to try to communicate numbers of less than one percent.\u00a0 But we applaud the detail provided.", "answer": 1}, {"article": "Shingles is a viral infection, caused by the herpes zoster virus--the same virus that causes chickenpox.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\nThe vaccine also contains an adjuvant--a substance that helps your body fight off the virus.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nThe full paper is published online by the Journal of Infectious Diseases as Editor's choice: https:/\n\nThe Shingrix vaccine is developed by GlaxoSmithKline.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit being reported here is that \u201c90% of recipients had an increased immune response sustained across the 3-year duration of the study.\u201d\u00a0 It would have been more helpful if the release had noted the actual incidence of shingles in those vaccinated with the new vaccine versus the old (or no vaccine).\nThe news release says the study \u201cshows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells. This is 12 times higher than other less effective shingles vaccines.\u201d T cells are white blood cells that kill infected cells.\nWe did have some concerns with a statement in the release projecting how long the vaccine protects against shingles. The release quotes a researcher saying, \u201cWe anticipate that this protection will actually last much, much longer. We are now measuring the efficacy of the vaccine over the next 10 years and are very optimistic about the results.\u201d However, it doesn\u2019t say when and if that will translate into a benefit for patients.", "answer": 1}, {"article": "The study appears online in the Journal of Clinical Investigation.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that certain heart hormones, if they behave the same way in humans as they do in mice, may hold \u201cthe key to an effective weight loss treatment.\u201d We think this is a premature and misleading statement. Even if these hormones do activate brown fat in humans (something yet to be determined), there\u2019s no guarantee this will translate into weight loss or that the weight loss that is produced will be safe or beneficial (see more under the \u201charms\u201d criterion).", "answer": 0}, {"article": "Follow her on Twitter @drfernstrom.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\n\u201cWhat's important here is for us to understand what we know and what we don't know, and the conventional wisdom, the evidence that saturated fat and cholesterol in the diet are the main drivers of heart disease is not supported by the study,\u201d says cardiologist Dr. Steve Nissen, chair of cardiovascular medicine at the Cleveland Clinic.\nThe new report, which analyzed 40-year-old data from the Minnesota Coronary Experiment, found no association between lower cholesterol levels and longer life, suggesting that reducing the amount of saturated fat in the diet isn\u2019t enough to reduce risk of death from heart disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify. We are told the 45-year-old data showed a \u201clowering\u201d of cholesterol for study participants who swapped animal fats for vegetable fats. But we aren\u2019t given any numbers for by how much or even by what percentage.\nIn a similar shortcoming, one of the most counter-intuitive findings was dismissed.\n\u201cIn fact, the study found that the lower the cholesterol, the greater the risk of death. But that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\u201d\nThe story should have given us some numbers for that \u201cgreater risk.\u201d Even if it is misleading, we are entitled to know the size of the risk found in the study.", "answer": 0}, {"article": "We suspect this strategy could benefit other cancer patient populations.\"\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the flu infection rate fell to 6% in the patients who received a booster vaccine 30 days after the first shot, compared to the \u201cexpected\u201d rate of 20% infection. We\u2019d much rather see actual numbers here than percentages. How many people were vaccinated with the follow-up booster shot? Was there a comparison group that received only one high-dose shot during the same flu season?\nThe release also claims that the booster strategy protected against all flu strains in 66% of patients.\u00a0 Again, 66% of how many?\nThe study was small with just 51 patients. To say the vaccine lowered the infection rate to 6% is misleading because there was no comparison group. It would have been helpful to point out that a 6% infection rate is lower than historical controls, but that the effectiveness needs to be studied in a controlled clinical trial to really see the benefit.", "answer": 0}, {"article": "\"That could save their life.\"\nFor example, the test was successful only about 40 percent of the time in the patients the researchers studied with the earliest stage 1 cancers.\nThey also looked at 812 people without cancer diagnoses and found just seven of them \u2014 less than 1 percent \u2014 apparently had a false reading that found cancer.\nBut Schiffman points out that there are many issues to work out \u2013 even assuming the test proves reliable among people who have not been previously diagnosed with cancer.\nTheir experience will help answer the next big question, which is whether CancerSEEK will pick up cancer in people who don't have symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes the two key results of the test quite clear. First, that the 1,005 people tested already had been diagnosed with one of eight common cancers, and the blood test was able to detect cancer in about 70 percent of them. Second, the test was also given to 812 people without cancer and only a false reading for cancer less than 1 percent of the time.\nIncluding the additional finding that the test was only able to detect cancer in about 40 percent of the patients with early cancer (ie. stage I) was a thoughtful way of introducing the relevant issue of falsely negative tests.", "answer": 1}, {"article": "None had been diagnosed with breast cancer.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nHowever, she noted the ASBS added a few extra conditions:\n\u2022 Women should start mammograms earlier than 45 if they have a calculated lifetime risk greater than 15 percent.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nThe researchers also found that 32 percent of the women met the groups' eligibility standards for regular screening MRIs, and 25 percent would be eligible for genetic testing, Plichta said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is the claim of benefit made in the story: \u201cMany women could benefit from earlier mammograms, analysis finds.\u201d But this claim is left unsupported, only describing the number of women at higher risk identified by the study. Of the women identified, what number would actually go on to experience some meaningful beneficial outcome like detection of an invasive cancer, or more importantly, a longer life? Even if the study didn\u2019t dig into those numbers, it\u2019s crucial to explicitly state in the story that the numbers reported don\u2019t reflect the actual number of women who might experience a meaningful benefit\u2013only the number who would be screened.", "answer": 0}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that in one study, \u201c32% of subjects on Deplin had responded, compared with 15% on the placebo.\u201d Although\u00a0 this is better than saying simply that twice as many patients responded to Deplin as to placebo\u00a0(which is how some stories would no doubt have communicated this statistic), the story never says\u00a0how the researchers defined \u201cresponse\u201d to the medication, which is an important omission. Typically, a \u201cresponse\u201d\u00a0means that patients had a >50% reduction on a depression symptom scale, but readers of this story can\u2019t be expected to know this.\nIn addition, there are other trials with different formulations of folate (some that can be purchased over the counter for pennies per pill) that are relevant to the evidence.\u00a0 Collectively, these trials raise the possibility that the forumulation (L-methylfolate, folinic acid, or folic acid) may be important.", "answer": 0}, {"article": "Oral medicines can be used to systemically limit sweating.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nIn the second trial, a significant improvement was seen in 66.1 percent of the drug-treated patients, compared with 26.9 percent in the control group.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not enough detail is contained in the description of the drug\u2019s benefits: \u201ca significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company. (and\u00a066.1 percent versus\u00a026.9 percent in the control group in the second trial).\nHow are we to know what this means\u00a0when we don\u2019t know how \u201cimprovement\u201d or \u201cseverity\u201d is measured?", "answer": 0}, {"article": ".\nAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for endoscopic sleeve gastroplasty patients and 14.46 percent for laparoscopic banding patients.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a direct comparison between the three procedures: \u201cAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for [ESG] patients and 14.46 percent for laparoscopic banding patients.\u201d That earns it a satisfactory rating. However, based on an abstract of the conference presentation, the researchers also collected data on weight loss 18 months after the procedure. This raises the question: why didn\u2019t they include the 18-month follow-up numbers here? In addition, the release would have been stronger if it had told readers whether there was any significant variation between the patients who had the various procedures. For example, were the patients who had the gastrectomy procedure more obese to start with? Or were there differences in age across groups?\nIn addition, following surgery the patient volunteers all went to a weight-loss \u201ccenter of excellence\u201d for a full year. \u00a0The release doesn\u2019t mention whether that made a difference in the results within each group or among the entire group. In any case, \u00a0this year-long stay at a weight loss center after a procedure is not likely to be replicated in other studies and in the real word.", "answer": 1}, {"article": "It matters.\nIt's not known at this time if the drug can improve overall survival, and a sizable proportion of participants developed resistance to the drug, the researchers say.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThe drug, PLX4032, just completed a phase 1 clinical trial in which 81 percent of participants with a particular gene mutation had a partial response, meaning at least some shrinkage of the tumor.\nTen of 16 patients who had the BRAF gene mutation had a partial response to the drug, meaning the tumor shrank by at least 30 percent, while one had a complete response, with the tumor disappearing altogether.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0story does a good job of\u00a0quantifying the benefits. It explained that 81% of patients had a partial response, meaning some shrinkage\u00a0of the tumor,\u00a0and gives the absolute number of people this represents. It also explains that the drug is effective in only the 50% of advanced melanoma\u00a0patients with a\u00a0specific\u00a0genetic mutation.\u00a0Although\u00a0it cautions that a \"sizable proportion\" of patients developed\u00a0resistance to the drug,\u00a0we wish it had been a bit\u00a0more precise in\u00a0its\u00a0characterization of this problem.\u00a0\u00a0\u00a0", "answer": 1}, {"article": "The U.S. National Heart, Lung, and Blood Institute has more about heart failure.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided absolute numbers for two categories of patients who had had heart attacks and did not have angioplasty. \u00a0In the first group, the chance of survival for those with heart failure at 18 months appeared to be higher for those that took Plavix than those who did not. \u00a0In the second group, at two years, there did not appear to be a difference in survival between those without heart failure whether they took the drug or not.\u00a0\nWhile presenting the reader with the quantitative results, the story neglected to indicate if the differences observed were statistically significant.\nIt would also have been helpful to note the number needed to treat:\u00a0 37 heart failure patients would need to be treated for a year in order for one life to be saved.\u00a0 For non-heart-failure patients, 667 patients would need to take the drug for a year in order for one life to be saved. ", "answer": 1}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe findings are at odds with clinical trials, Connolly says.\nIt gives a more ''real world'' picture, he tells WebMD.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story, like the others, provides no hard numbers for quantifying the benefits, but we thought it did an adequate job explaining what the study found. Unlike the NY Times and LA Times stories, this one provided accurate information about the number of subjects who started and completed the study.\nAll three of the stories have the same problem of not explaining whether ultimately two-thirds of the study participants relapsed or the same one-third relapsed at two different intervals.\nNonetheless, we\u2019ll give the story the benefit of the doubt with a satisfactory score on this.", "answer": 1}, {"article": "Osteoporosis is a global health problem that will affect one out of three women and one of out five men worldwide, with a multi-billion-dollar pharmaceutical industry dedicated to finding treatments to stop its progression.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nThe researchers tested a compound derived from red sage in human and mouse bone cells and a mouse model.\n\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the red sage compound was tested \u201cin human and mouse bone cells and a mouse model. They found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\u201d\nThe release should have mentioned that benefits shown in mice don\u2019t necessarily translate to humans. The release doesn\u2019t provide any results relating to the chemical compound\u2019s effect on the cells that were tested.\nFurther, bone mineral density doesn\u2019t precisely measure fracture risk, which is what matters to patients. None of these important caveats are mentioned.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a thorough job of describing the findings by specifying the percentage of patients who had minor and more serious complications. It also compares days spent in the hospital.\u00a0 \nHowever, the article reports a 27 percent reduction in risk of short-term complications and a 40 percent greater risk of scarring without indicating the underlying risks for either of these outcomes.\u00a0 See our primer on absolute versus relative risk statements. ", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that \u201cThey found that during the study, patients who received candesartan were 66 percent less likely to develop true hypertension than those who received the placebo.\u201d That\u2019s a relative risk reduction (or benefit, depending on how you view it); but readers would be better guided by the absolute risk reduction figures. ", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nIn this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma.\nFor the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A report on a diagnostic procedure should at the very least tell readers the proportion of patients with disease who tested positive (sensitivity) and the proportion of patients without disease who tested negative (specificity). Neither the news release nor the study on which it\u2019s based offer these numbers.\nIn fact, there are no figures in the news release summarizing the accuracy of IMS in diagnosing the 102 ambiguous tumors included in the study, or comparing it with the accuracy of using a microscope. In each case, the initial diagnosis with a microscope was compared to a diagnosis of the same tumor with IMS and the patient\u2019s clinical outcomes. According to our review of the study data, IMS correctly identified as benign 38 tumors that had been classified as ASM, or indeterminate, when previously examined under a microscope.\nThe news release offers this quote from a researcher: \u201cInstead of pathologists being dependent solely upon the physical appearance of the cells, they now have the additional advantage of molecular information regarding the protein makeup (of cells) provided by mass spec imaging. \u2026 This test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\nIf it\u2019s useful and meaningful, there should be data showing how. In addition, even some reporters without a strong grasp of statistics may have difficulty gleaning the numbers from the published manuscript. That makes it even more important to include reliable data in a news release.", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of benefits in this story, period. \u00a0It states that both groups in the trial \u201creported a significant decrease in their symptoms,\u201d but offered no numbers to back that up. Nor do we know exactly what \u201csymptoms\u201d they are referring to that supposedly decreased. Where these the itchy, watery eyes and sneezing or where they more subtle symptoms? The only other \u201cresults\u201d are basically a testimonial from one participant, which has little or no value to readers.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\nThis disrupts the normal function of MLL by creating a new \u201cfusion protein\u201d that behaves wrongly, switching on genes that drive the development of leukemia.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\n\u201cThis ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLL-leukaemias,\u201d said Tony Kouzarides of the Wellcome Trust/CRUK Gurdon Institute at Cambridge University, who co-led the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Inadequate explanation.\u00a0 See \u201cevidence\u201d criterion above. While the story does provide several qualifications, it fails to place this very early research into perspective. Given the tortuous road to a drug\u2019s demonstration of effectiveness and eventual approval any suggestion of patient benefit (such as \u201cearly potential\u2026could treat\u2026could halt the disease\u201d) is excessive.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\nThey estimated in their Archives of Internal Medicine report that about 50 percent of patients had their symptoms cut in half with acupuncture, compared to almost 43 percent of those treated with sham acupuncture and 30 percent with no acupuncture-like therapy.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story puts the benefits in terms readers can understand and that accurately reflects the magnitude of the benefit: \u201c\u2026about 50 percent of patients had their symptoms cut in half with acupuncture, compared to almost 43 percent of those treated with sham acupuncture and 30 percent with no acupuncture-like therapy.\u201d", "answer": 1}, {"article": "Blueberries are rich in flavonoids, which possess antioxidant and anti-inflammatory properties.\nCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release gives us the broadest brush about benefits, but does not provide numbers or quantify how much improvement occurred.\nIt states that \u201cbrain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults\u201d\u00a0 and\u00a0 \u201cCompared to the placebo group, those who took the blueberry supplement showed significant increases in brain activity in brain areas related to the tests.\u201d\nHow much improvement was there? How did brain activity change before and after taking the supplement?\nBut even with those numbers, brain activity is not a clinically meaningful measure. It\u2019s a surrogate end point, not a measurable clinical benefit. ", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\n\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d\n\nThe Valiant Navion\u2122 thoracic stent graft system is delivered from a groin blood vessel into the aorta, is positioned above the affected aneurysm, and is deployed under x-ray guidance.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\nNewswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No benefits were mentioned other than this treatment might be better than open surgery. The surgeon points out that:\u00a0\u201cNow, patients can undergo a minimally invasive procedure to fix complex problems of the aorta without having open surgery.\u201d \u00a0We have consistently advised readers to be wary of claims about \u201cminimally invasive procedures.\u201d", "answer": 0}, {"article": ".\nTo address this issue, the SPRINT study tapped more than 2,600 volunteers aged 75 and older, assigning half to a target blood pressure of less than 140 mm Hg and half to target of less than 120 mm Hg.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release points out that those study participants whose blood pressure goal was 120 mm of mercury had 33 percent fewer cardiovascular events, such as heart attacks or heart failure, and had a 32 percent reduction in the risk of death, compared to those participants with a higher goal.\u00a0 Based on this, it recommends that people 75 and older benefit from a lower systolic blood pressure.\nBut these numbers don\u2019t tell the whole story. It should be noted that these relative reductions correspond with absolute risk reductions of only about 0.8 to 1.3 percentage points \u2014 reflecting a number needed to treat (NNT) of roughly\u00a0100. In other words, approximately 100 people need to be treated to this target in order for 1 person to experience an improved outcome. The other 99 don\u2019t benefit but have the potential to experience adverse effects.", "answer": 0}, {"article": "What's next?\nSo far, with a full year, it doesn\u2019t look like that is happening.\u201d\n\nLindsey George, the lead investigator and a hematologist at Children's Hospital of Philadelphia, said that nine of the 10 men in the trial didn't experience any bleeding episodes after the gene therapy treatment.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nThe one patient who needed clotting factor because of bleeding used 91 percent less than before, she said.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarizes the outcome of the small, 10-person trial that dominates this narrative:\nLindsey George, the lead investigator and a hematologist at Children\u2019s Hospital of Philadelphia, said that nine of the 10 men in the trial didn\u2019t experience any bleeding episodes after the gene therapy treatment. The one patient who needed clotting factor because of bleeding used 91 percent less than before, she said.", "answer": 1}, {"article": "\u201cIf screening is going to work, you\u2019ve got to keep at it.\u201d\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\nOverall, research is suggesting that CT scans of people at risk of lung cancer might make a dent in cancer mortality, and it\u2019s possible that more frequent screening might make an even bigger dent, Hanley noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story generally meets the specific requirements of this criterion, but the overall tone and structure of the report lead readers toward an exaggerated sense of the benefits reported in this study. \nPutting aside fundamental questions about study design addressed earlier, there should have been more attention to the absolute differences in the actual versus expected outcomes for the smokers included in this study. The story highlights mortality reductions of 36 to 64 percent. While it does report deep into the story that 64 smokers died of lung cancer out of almost 8,000 in the main study group, readers would have to pull out their calculators to learn that based on these numbers\u2026 a 36 percent relative reduction in lung cancer mortality translates into an absolute reduction of less than half a percent. Specifically, 0.8 percent (64 out of 7995) of the smokers screened with CT died of lung cancer, while based on one comparison the researchers say the expected lung cancer death rate would be 1.2 percent (99.8 out of 7995). That is a difference of 0.4 percent. The story should have noted that based on these statistics, more than 200 smokers would have to be screened in order to make a difference for one of them.\nThe story also errs by highlighting that another report (based on an actual comparison of screening to not-screening) reported a 20 percent reduction in lung cancer deaths, without also noting that those researchers reported about 300 smokers would have to be screened in order to stave off one lung cancer death.\nThe story should have also clearly told readers that even if screening reduced lung cancer deaths by 20 percent in the most rigorous trial to date, that does not mean that screening would prevent 30,000 lung cancer deaths a year (20 percent of the 157,000 lung cancer deaths per year reported in the story).", "answer": 0}, {"article": "\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nIt will also cost money to change the composition of food.\u201d\nBut that study, others say, will never happen.\nDr. Frank Sacks of the Harvard School of Public Health agreed and also said the study was flawed.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The combination of the two drugs also led to far higher levels of side effects, such as colitis and inflammation of lung tissue, at 54 percent versus 24 percent for Yervoy alone.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\n\u201cLonger follow-up will be helpful to see the durability of these responses and what happens to patients who had complete responses,\u201d said Hodi, who presented data from the Checkpoint-069 study at the American Association for Cancer Research meeting in Philadelphia.\n(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Admittedly, the published study in NEJM provides a bewildering array of information about outcomes that would confuse many medical professionals. Nevertheless, simply recounting the information from a press release or from the study abstract does little to inform the average reader. The outcomes reported by the story were tumor shrinkage and disease progression. These are what are known as \u201csurrogate endpoints\u201d \u2014 i.e. proxies for more important outcomes that patients care about, such as survival. Surrogates can certainly be useful and important indicators of a treatment\u2019s effectiveness, but they may also fail to accurately reflect an outcome that\u2019s important to the patient. In our view, a story that ONLY reports surrogate endpoints MUST provide some cautionary language about the limitations of those surrogates. In this case, the study hasn\u2019t been going on long enough to determine whether the treatment confers a survival advantage, and the story appropriately called attention to that fact. Some additional caution on the limits of surrogates would also have been useful.", "answer": 0}, {"article": "Feb. 20, 2017.\nWe want to outline health-care pathways that provide the best care for patients.\u201d\n\nThe analysis demonstrated an average cost of $13,389 for the wrist approach with same-day discharge, compared with $17,076 for the groin approach with at least one night of hospitalization, resulting in a cost savings of about $3,700 for outpatients who get the wrist-access procedure.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nThe investigators estimated that if a hospital performing 1,000 of these procedures annually shifted 30 percent of these patients to the wrist-access with same-day discharge approach, the hospital would save $1 million over that period.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefit discussed here was the cost savings since that was the focus of the study. But what are the tangible benefits to patients who might be facing this procedure? The claims made are backed up by estimates of the cost savings based on the 9% of PCI patients that had the procedure using the wrist method. The first author of the study mentions reduced bleeding and fewer complications from angioplasty procedures that use the wrist artery and discharge patients on the same day, but it doesn\u2019t provide any numbers for a reference point.\nThe published report stated that bleeding at the arterial site, the most common problem examined, occurred in 1.4% of patients receiving the lower cost wrist procedure and in 3% of those receiving the traditional groin entrance procedure (use of the femoral artery and at least one overnight hospital stay). While the complication rates are pretty low in both procedures, it\u2019s something that could have been better explained in the release.", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said: \u201cAmong those who received only medical treatment, 151 were hospitalized for heart failure in the ensuing two years. Sixty-one died. In contrast, just 92 who got the device were hospitalized for heart failure during the period, and 28 died.\u201d\nWe wish the story had clarified that the figures for deaths referred only to deaths from heart failure, not deaths from any cause.\nAlso, the story could have provided percentages to help readers draw precise comparisons. Among those who received only medical treatment, 56.7% were hospitalized for heart failure and 25.9% died from heart failure. Among those with the device, 35.7% were hospitalized for heart failure and 12% died from heart failure.\nDeath from any cause: During the study period, 29.1% in the device group died, and 46.1% in the control group died.", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nDublin City University's Anne Matthews, the review's lead researcher, says it was disappointing not to find more studies that were consistent in testing the same approaches.\n\"The onus is back to researchers to carry out studies that would stand up\" to rigorous review and that would build on what's already been tested.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A mixed bag here, but ultimately unsatisfactory in our view. The story does note that there \"wasn\u2019t much hard data\" on psychological, social or economic outcomes \u2014 all of which are important to look at considering the lost work time, anxiety, and reduced quality of life that women may experience because of morning sickness.\u00a0But then the story goes on to state that there was\u00a0\"some evidence\" that ginger, vitamin B-6 and anti-vomiting drugs relieved nausea. Well, how much evidence was there and what exactly did it show? While the story states that the evidence for these treatments \"isn\u2019t strong enough to make a recommendation,\" we feel the story should\u00a0have tried to quantify this benefit\u00a0in a way that would be meaningful for readers, whether\u00a0as episodes of nausea/vomiting or some other \"real world\" outcome.\u00a0", "answer": 0}, {"article": "\u201cYou are looking at a therapy that can avert, we hope, complications and be as effective,\u201d he said.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nDr. Douglas P. Zipes, a professor at the Indiana University School of Medicine in Indianapolis, said the new device could someday displace existing models used in many patients Every month, about 10,000 patients in this country get a defibrillator, either for the first time or as replacements for devices whose batteries have worn out.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThis story outlines the problems with the electrical lead wires of existing devices that have harmed patients and required re-operations and recalls. It explains that by using wires placed under the skin, instead of through blood vessels into the heart, the new device might reduce the risks associated with implantable defibrillators for certain patients. The story cautions that only about a quarter of patients who currently are given implantable defibrillators might be candidates for the new type of device.", "answer": 1}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story had lots of interesting anecdotal discussion but few numbers.\u00a0\u201cThere is less muscle injury\u201d and a patient\u2019s early recovery is \u201cdefinitely better\u201d is one example. Those are huge claims for the story to trumpet without including any data to back them up. The story also talks about less need for pain medication but doesn\u2019t quantify the benefit. The anecdotes are very much stacked in favor of the same-day procedure.\nThe story also had a link to a head-to-head comparison study. That is great. Those readers who take the time to click on the link will find interesting stuff. But while it\u2019s a close call here, we are not persuaded that including a link is enough.", "answer": 0}, {"article": "\"Doing something is better than doing nothing.\"\nAlthough survival rates for cardiac arrest hover around 10 percent with CPR, Hazinski noted that rates have been pushed as high as 30 percent in cities, such as Seattle, that combine high bystander participation with a strong system of professional emergency medical response.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nStudies show that either mouth-to-mouth or hands-only CPR may double the survival rate from cardiac arrest, but bystanders typically step in to provide the potentially life-saving intervention in only about one-third of cases.\nThe new guidelines, published in the journal Circulation, recognize that recent research has shown no real advantage to conventional mouth-to-mouth CPR in outside-the-hospital cardiac arrest cases.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says that CPR in any form \"may double the rate of survival from cardiac rest.\" According to a spokesperson for the American Heart Association, this means that \u201cwe can save tens of thousands of lives.\u201d\u00a0 Later in the story the spokesperson is reported as saying that when more people use CPR in cities such as Seattle, survival rates have jumped to as high as 30%. An AHA scientific statement says cities such as Seattle have reported survival of \u201cmore than 15%.\u201d It adds that hands-only CPR and other changes (e.g. dispatcher-assisted \"telephone\" CPR) could save \"thousands of additional lives\" every year.\" This mix of relative and absolute estimates suggest there is surely some real benefit to increasing the use of CPR, but the precise amount of that benefit remains a bit fuzzy.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that some DXA scanners \u201cestimate how much visceral fat you have, a measure that can help predict risk for diabetes and cardiovascular disease.\u201d It also states that scans\u00a0show \u201cthe amount of fat and lean tissue in each body part, such as the right arm or left leg\u2014information that can be helpful for athletes to see if an injured limb is regaining muscle.\u201d However, these claims are not quantified. How much different might one\u2019s risk for diabetes or cardiovasular disease be on a DXA scan vs. traditional body composition measures? How much faster might one recover from an injury using DXA monitoring? To its credit, the story does note that one study found that 18.5% of women with a normal BMI had excess fat when measured using a DXA scan \u2014 \u201cmaking them \u2018skinny fat.'\u201d But readers aren\u2019t told what \u201cskinny fat\u201d means \u2014 does it have health implications? Does it increase risk and by how much? More quantification here would have helped readers judge the value of this tool.", "answer": 0}, {"article": "JACC is ranked No.\nWASHINGTON (Jan. 11, 2015) -- Symptoms of mild to minimal depression were associated with early indicators of heart disease in a research letter published today in the Journal of the American College of Cardiology, but the study found regular exercise seems to reduce the adverse cardiovascular consequences of depression.\nResearchers found arterial stiffening and inflammation--the early heart disease indicators--that accompany worsening depressive symptoms were more pronounced in people who were inactive.\nResearchers used questionnaires to evaluate patients for depression and levels of physical activity.\nThis research also demonstrates the positive effects of exercise for all patients, including those with depressive symptoms,\" said study author Arshed A. Quyyumi, M.D., co-director of the Emory Clinical Cardiovascular Research Institute in Atlanta.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release does provide some numbers on the association between cardiovascular risk and depression, it does not do enough to quantify the effect\u00a0of exercise in modulating the relationship between the two.\nStating that people who exercised regularly had less arterial stiffening and inflammation in general than those that didn\u2019t exercise isn\u2019t enough to show causation. Even if the goal was to show causation, numbers weren\u2019t provided.\nIt should also be pointed out that the patients enrolled weren\u2019t clinically depressed as the title may indicate. They had not previously been diagnosed with depression and were evaluated with a symptom scale for two weeks, with most of them coming up with minimal to mild symptoms.\nAs any person seeking treatment for depression learns there\u2019s a wide spectrum of diagnoses and treatments falling under the broad heading of depression: general anxiety disorder, dysthymia, major depressive disorder and postpartum depression to name a few. Some, but not all, can be mitigated with exercise alone.", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nCMA detected chromosomal abnormalities in slightly more than 7 percent of patients, making it the best available genetic test for autism spectrum disorders, the study authors said.\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\nResearchers offered about 933 people aged 13 months to 22 years who had been diagnosed with an autism spectrum disorder three genetic tests: G-banded karyotype testing, fragile X testing or chromosomal microarray analysis (CMA), which has been available only for the past few years.\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately presents the efficacy of three different genetic tests in identifying abnormalities that may be associated with autism\u2014karyotype: 2%; fragile X: 0.5%; CMA: 7%.\u00a0 It would have been helpful to let readers know that not all 933 people included in the study were tested with each of the three tests. According to the results, the CMA tests performed best in females with autistic disorder, but this was not reported. ", "answer": 1}, {"article": "Omega 3 fatty acids are a class of nutrients considered essential for neural and retinal development during pregnancy.\n\"The data suggested that for most of the symptoms we looked at, duration of symptoms was less when mothers received DHA.\nRamakrishnan said it's probably too soon to recommend routine use of DHA supplements for pregnant women, because the findings weren't \"dramatic.\"\nBut, she added that the supplements did appear to be safe for pregnant women to take.\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits associated with prenatal exposure to DHA supplement were reported only as relative benefits. \u00a0So while there was a 24% drop in the odds of having cold symptoms, 26% shorter cough duration, 15% less phlegm and etc., the reader really has no insight about whether these differences were meaningful or not.\u00a0 Is a 24% drop the same as only 1 less cold over the course of a year?\u00a0 The story needed to explain.\nIn addition \u2013 while these differences may have been statistically significant, would they really make a difference to the baby or its parents?\nBesides \u2013 the lead researcher on the project was quoted as indicating that the findings weren\u2019t \u2018dramatic\u2019. \u00a0Does this suggest that there are more impactful ways to infant health?", "answer": 0}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nHe said a doctor at Mercy Hospital also is using the therapy on patients.\nAGH doctors have used the procedure in cardiac arrest victims five times since November, and three of those patients survived the procedure.\nWithout the therapy, cardiac-arrest patients have a greater risk of suffering dementia, loss of memory or severe devastation of mental capacity, Dr. Tayal said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story estimates that this treatment could save \"tens of thousands\" of lives, though\u00a0this estimate is several orders of magnitude greater than the data\u00a0in the article supports.\nIt contains a quote from a physician who stated that\u00a0they\u00a0\"believe the people who do go home have fewer neurological problems,\" but no evidence is given for this.\u00a0 ", "answer": 0}, {"article": ".\nAmong 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did.\nOf the 192 low-risk participants (93 intervention, 99 control), most participants remained low risk, indicating that the assessment correctly identifies who is at risk for caries.\nWhile not as significant as the CAMBRA group in this study, the risk level of these patients dropped more dramatically over time than for those in the 2012 UCSF CAMBRA study.\nAmong the study limitations, the researchers noted a high study attrition (65 percent), which partly may have contributed to observed declines in risk level at each subsequent recall visit.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release described benefits this way:\nAmong 242 patients (137 intervention, 105 control) initially identified as high risk for caries, only a quarter of the patients remained at high risk in the CAMBRA group at 24 months, while just over half (54 percent) of the control group did. Of the 192 low-risk participants (93 intervention, 99 control), most participants remained low risk.\nAs noted under Evidence criteria below, the release listed as a limitation the fact that only about one-third of the patients who started the study completed the 24 month checkup.", "answer": 1}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nStudies suggest that a single IV dose of ketamine far smaller than used for sedation or partying can help many patients gain relief within about four hours and lasting nearly a week or so.\nExactly how ketamine works is unclear, but one idea is that by elevating glutamate levels, ketamine helps nerve cells re-establish connections that were disabled by depression, said ketamine expert Dr. Carlos Zarate, chief of experimental therapies at the National Institute of Mental Health.\nFor now, ketamine has not received approval from the U.S. Food and Drug Administration for treating depression, though doctors can use it for that purpose.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t focus on a particular study that measured a benefit. It said: \u201cStudies suggest that a single IV dose of ketamine far smaller than used for sedation or partying can help many patients gain relief within about four hours and lasting nearly a week or so.\u201d\nHowever, the story could have given readers a more detailed description of ketamine\u2019s benefits, as measured in clinical trials.\nFor example, a meta-analysis of five randomized placebo-controlled trials concluded ketamine had a \u201clarge\u201d immediate effect \u2014 measured one day after treatment \u2014 on symptoms in patients with major depressive disorder and bipolar depression. That effect fell to \u201cmedium\u201d after seven days. The studies used various standardized rating scales to track symptoms such as reduced appetite or sleep, difficulty concentrating, sadness, and suicidal thoughts.", "answer": 0}, {"article": "Click for more from The Sun.\nThe system was able to identify dementia in 40 patients an average of six years before they were formally diagnosed.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story highlights a single benefit:\n\u201cThe [artificial intelligence algorithm] was able to identify dementia in 40 patients an average of six years before they were formally diagnosed \u2026 with 100% accuracy\u201d\nBut who these patients were, and how they were chosen is not mentioned. Nor is it mentioned that the specificity was 82%. In other words, nearly 1 in 5 subjects (18%) were predicted to develop dementia who were never diagnosed with it (aka a \u201cfalse positive test\u201d).", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\n\u201cThe side effects of traditional treatment were not worth it to me, and I wasn\u2019t afraid to try the most cutting-edge technology.\nIt is the first trial of its kind in the world.\n\u201cIn fact, the first patient in the trial was actually riding a bike within a week of his treatment.\nI am excited as we continue tracking the progress of this groundbreaking improvement to prostate cancer care.\u201d\n\nDoug Flewellen, the first patient in Texas to receive the new method of care, says for him, the procedure was a no-brainer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no data to speak of in this news release so no reliable discussion of benefits either.", "answer": 0}, {"article": "\u2018\u2018Open your mouth and say I\u2019m concerned about this so you can get the assistance,\u2019\u2019 Williams said.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\nMcCans says the complimentary items like diapers and onesies are nice, but the more important objective behind the boxes is bringing down infant deaths and grounding parents on safe sleep practices: Place babies on their backs to sleep; Don\u2019t use bumpers in cribs; Keep stuffed animals and blankets out of infants\u2019 sleep spaces; Avoid sleeping in the same bed as infants.\nThe Centers for Disease Control and Prevention says the U.S. rate of sudden unexpected infant deaths has been declining since the 1990s when public health officials began recommending parents put infants to sleep on their backs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify any of the benefits. It does not tell us how much risk of sudden infant death is decreased by the child sleeping in these particular boxes. In the excerpt below, a pediatrician is quoted saying the boxes \u201cprovide a clutter-free sleep space\u201d and that has been shown to reduce accidental deaths. But just to clarify \u2013 it would seem you don\u2019t have to use one of these boxes in order to provide a \u201cclutter-free sleep space?\u201d Can\u2019t a family create a clutter free space in their own cardboard or an empty clutter-free crib?\nThe quoted pediatrician does not give us any research source for the proof of a benefit.\n\u201cThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board. The boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\u201d\nCan\u2019t parents provide a clutter-free sleep space for their infants on their own? Yes, but it doesn\u2019t mean they will. The convenience and no cost of the box to the parents might be sufficient motivation to use it and the parents don\u2019t need to do anything to make it safe \u2014 it already is. This in essence makes the right thing to do into the easy thing to do \u2014 a key tenet of patient safety. However, the concern that there simply are no numbers showing a benefit is a real one.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the story\u2019s descriptions of \u201cpromising\u201d drugs from Biogen, Merck and Lilly, there is essentially zero quantification data. There needed to be some, even in a wrap-up or trend article such as this.", "answer": 0}, {"article": ".\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nThis form of cancer strikes about 57,760 Americans every year, according to the organization.\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\nTechnically known as single-port cryosurgery, the technique is used only for cancers no bigger than an inch and a half wide that haven't spread beyond the kidney, Lee said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefit of cryosurgery, other than in reducing recovery time.", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a nice job outlining the potential benefit of the test and the number of limitations", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some trial data on benefits were cited for both Solesta and InterStim.", "answer": 1}, {"article": "\u201cHe wanted to be at home with his dog.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHe died at home in November, a year and a half after saying no to dialysis.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cited appropriate studies for a range of statistics. \u00a0We learn, for example, that \u201c58% of patients died within a year of beginning dialysis\u201d and that\u00a0about 40% of patients over 75 with end-stage renal disease die within a year. We also learn about the concerns of the patients, including the fact that 61% of patients in one study said they regretted starting dialysis. It adds that \u201cwithdrawal from treatment accounted for about a quarter of deaths of dialysis patients in 2006,\u201d though that seems a little unsatisfying in terms of what additional lifespan might be attributed to dialysis. Another fact included is that 66% of patients in one study told researchers that their doctors had not mentioned the treatment\u2019s risks or burdens, and they felt they had no choice.", "answer": 1}, {"article": "They are then injected directly into the patient\u2019s heart.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\n\u201cThe idea is to find a treatment for this group of people before they get to that stage,\u201d Henry said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article outlined the 37 percent reduction in adverse events due to the stem cell therapy, and explained that the outcome was mainly due to difference in deaths and hospitalizations between the therapy and placebo groups. And, we were very pleased to see the inclusion of absolute numbers related to this\u2013i.e., 7 deaths versus 2 deaths. The story also let us know that the study didn\u2019t show a benefit in secondary endpoints, like heart pumping efficiency and a walk test.\nHowever, we\u2019d have liked to have seen more discussion\u2013ideally from an independent medical experts\u2013on what investors already seem to know, but the reader is left to deduce: Were these results as meaningful as the lead investigator is making them out to be?", "answer": 1}, {"article": "By Amy Norton NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping.\nBut another limitation, she pointed out, is that the study looked at the effects, and side effects, of marijuana over only a few days.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\nBut it\u2019s not clear if that would have any long-term consequences, Corey-Bloom said.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many times a story stops at reporting something like \u201cbrought some relief.\u201d\nThis story explained exactly how the study was conducted, what the measurement scale for improvement was, and what was observed on that scale.\nAnd then it carefully itemized limitations of the study.", "answer": 1}, {"article": "www.petermunkcardiaccentre.ca\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nWith this device, we can see warning signs days in advance, and adjust treatment accordingly.\u201d\n\nThe most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We only know that one heart failure patient in Canada underwent the implantation procedure. \u201cThe device\u2026was successfully implanted by interventional cardiologists,\u201d the news release states.\nNo other data were given. We don\u2019t know how other patients have fared after the fact, including the one mentioned in the news release.\nAlthough this is a first for Canada, the US has been treating heart failure patients with the CardioMEMS system since 2007. The US FDA approved CardioMEMS after reviewing results from the CHAMPION clinical trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients). Clinicians followed 550 heart failure patients and looked at heart failure-related hospitalizations in the treatment group versus the control group at 6 months. At this point in time, there was a 28 percent reduction in heart failure hospitalizations, with 84 hospitalizations in the treatment group, compared to 120 in the control group. Researchers also observed a 37 percent reduction in heart failure-related hospitalizations in the treatment group during the entire follow-up period of approximately 15 months.\nSince none of this data were given, we rate this one Not Satisfactory.", "answer": 0}, {"article": "\u201cEveryone has gotten on the bandwagon.\nSuch findings are why she, Mowry and Pittas strongly advise people against taking more than the currently recommended upper daily limit of 4,000 IU, even though doses as high as 10,000 IU are available online and at many stores.\nThe report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nBefore we make a blanket recommendation for the 86 million people in the United States who are at risk for Type 2 diabetes to go out and buy vitamin D supplements, we need to know for sure if they help.\u201d\n\nA third trial, designed to test whether 5,000 IU of vitamin D per day will slow the progression of multiple sclerosis in 172 patients, is being led by Ellen Mowry, an associate professor of neurology at the Johns Hopkins University School of Medicine.\n\u201cIt\u2019s just preposterous to say it\u2019s not proven.\u201d\n\nIn January 2014, Autier published a statistical analysis of results from hundreds of studies of vitamin D. He concluded: \u201cUnfortunately, there is probably no benefit to expect from vitamin D supplementation in normally healthy people.\u201d\n\nGarland, on the other hand, is the co-author of dozens of studies showing a strong, inverse association between vitamin D levels and seemingly every disease under the sun.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story begins from a baseline context of controversy and uncertainty, rather than one of assumed benefit \u2014 an approach that frames the issue appropriately in our view. There is detailed discussion of research showing benefits, and research NOT showing benefits. In the absence of definitive large trials, the benefits accepted by the Institute of Medicine are limited to bone health.\nThe story quotes the Institute of Medicine, which concludes that vitamin D and calcium are \u201cnecessary for bone health\u201d but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was insufficient.", "answer": 1}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nYou can see this clearly in the chart below: The number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story satisfactorily reports the main results of the study and describes the benefits of mammography as seen across a large body of research. It explains that in the study, \u201cThe number of diagnosed breast cancers rose with more screening, yet the number of deaths from breast cancer 10 years later remained stubbornly stable.\u201d It doesn\u2019t quantify the increase in breast cancer detection in the text (the study reported a 16% increase in breast cancer diagnoses for every 10 percentage point increase in screening), but it does include a figure from the study which clearly demonstrates that while more cancers were found, mortality from breast cancer remained stable.\nThe story also includes a risk communication illustration, based on a systematic review of available evidence, that presents the absolute mortality benefits (as well as harms) for women over 50 who participate in screening for at least 10 years.\nThe story mentions that screening may be more effective in women with a family history of breast cancer. It does not discuss whether the study found any significant results among demographic subgroups for whom screening mammography may be more effective, but it doesn\u2019t appear that the authors were capable of making such distinctions based on the data available (see Evidence section below).", "answer": 1}, {"article": "He drank to forget.\n\u201cI was actually able to forgive myself,\u201d said Nigel McCourry, 36 a Marine veteran who was deployed in 2004 to Falluja, Iraq, whose experiences mirrored those of three other patients interviewed.\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\nResearchers say this allows patients to re-examine traumatic memories.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that after two sessions of MDMA-assisted psychotherapy \u2026\n\u2026 a majority of 26 combat veterans and first-responders with chronic PTSD (who had not been helped by traditional methods) saw dramatic decreases in symptoms. The improvements were so dramatic that 68 percent of the patients no longer met the criteria for PTSD. Patients taking the drug also experienced \u201cdrastic\u201d improvements in sleep and become more conscientious, according to the study.\nThis is enough to rate Satisfactory, but we think the story needed more details on how the study was designed to help readers understand this result (see evidence quality, below).", "answer": 1}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\nAssessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the all-Penn team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumors that while rare, often afflict younger patients.\nIn addition to inhibiting the cell cycle, palbociclib has been shown, for example to alter several recently described non-cell cycle functions of CDK4/6, a finding expected to expand its therapeutic role, O'Dwyer added.\nAlso, combining palbociclib with other anti-cancer agents is feasible, and early results in myeloma and some solid tumors have led to more definitive studies.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that the drug offers lower toxicity than other drugs, ease of use, and effectiveness as either an add-on or stand alone treatment but with very little data backing up the claims. The release summarizes the outcomes of two small trials using palbociclib in somewhat muddy terms. In one involving 17 previously treated mantel-cell lymphoma patients, the drug is attributed to one \u201ccomplete\u201d response and \u201ctwo partial responses.\u201d Another trial with 29 sarcoma patients treated with palbociclib showed \u201cprogression-free survival of 66 percent at 12 weeks.\u201d\nThe release might have added more specifics about the impact and meaning of \u201ccomplete\u201d and \u201cpartial\u201d responses as well as extended \u201cprogression-free survival\u201d with hard data that would help readers compare such survival with and without the use of the drug.", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nJay lays out the hows and whys of spinal stimulation, and she paints a vivid picture of a life in agony, a journey that has included skeptical doctors, plenty of painkillers and unanswered questions about the future.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nThat aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "To its credit, the story offered a nuanced view of the benefits as seen through the eyes of this single patient:\n\u201cEven for me, the battle is not over,\u201d Jay writes. \u201cSince this surgery I\u2019ve actually had another disc herniate, complicating everything. My spine isn\u2019t cured, and I still hurt all the time. But the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\nStill, it didn\u2019t give readers a picture of an idea of the scope of the benefits for all patients who have had this procedure. What percentage see improvements? And how much better are they? We aren\u2019t told.\nIn essence, there is no information provided to say what the chance of the next person having this procedure is of achieving pain relief. Moreover, it isn\u2019t clear how this may compare to other treatments. It is implied that this was the last step, but that is rarely the case.", "answer": 0}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\n\"This will reawaken both the users and the nonusers to say, wait a second, now we have data.\"\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nIt also has a significant presence in the Twin Cities.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data were provided \u2013 only superlatives from the local company:\nA company news release did provide more details on potential benefits.", "answer": 0}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nLondon, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe drug reduced by 87 percent the risk of disease progression or death.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presents the reader with a set of apparently contradictory information on the benefits of the drug.\nHow many patients were in the study: 108 or 31? What were the results and when were they recorded? While all of the statistics are indeed correct, they are not provided in a way that a reader can get a true picture.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies overall outcomes and benefits for the 61 patients followed for three years in absolute terms. It notes that \u201cForty percent of those who had received a gastric bypass procedure and 29% who received a gastric band were considered in remission from diabetes and no longer needed to take medication after three years. In comparison, no one in the group who received intensive lifestyle intervention resolved their diabetes.\u201d\nThe story would have benefited from more information about the participants\u2019 full spectrum of risk factors and the impact of the surgery on those markers (e.g. blood pressure). It also would have been more enlightening if it had stated clearly how many of the 61 study subjects got what kind of bariatric surgery and supplemental therapy. But the story does a good job of covering the necessities here.", "answer": 1}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\nThe study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\nThis new study included 76 adult patients, aged 18 to 70, with either episodic cluster headache (57) or chronic cluster headache (19).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlines the most basic outcomes\u2013that 78 percent of patients receiving oxygen reported relief at 15 minutes, and that pain relief was better than placebo at 30 and 60 minutes. Still, both the study and the article fail to address longer-term benefits or harms. ", "answer": 1}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency; however researchers from Houston, TX and Torrance, CA have been evaluating the long-term safety and tolerability of LPCN 1021, a novel oral testosterone undecanoate formulation for the treatment of low testosterone.\nTestosterone therapy is used to treat men with clinically diagnosed testosterone deficiency (serum T levels <300 ng/dL), also known as hypogonadism.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t quantify potential benefits of oral testosterone therapy. It barely mentions why it might surpass one currently available form, topical products, which carry FDA warnings related to inadvertent transfer to other people. \u201cMaking sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we\u2019ve found so far has shown we\u2019re on the right track,\u201d says Tobias S. K\u00f6hler, MD, an AUA spokesperson, in the release. More light is shed on the web site of the drug manufacturer. In a company-sponsored survey of 28 leading endocrinologists and urologists reported on the manufacturer\u2019s web site, 94% of responded that they believed an oral testosterone replacement therapy would improve patient compliance. The web site\u00a0 also cited problems with existing products, including skin rashes for topical products and risk of infection, scarring, injection site reactions, and lung impairment for injectables.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nBut while the research clearly shows that the interval between diagnosis and death was longer in screened patients, it does not definitively show they lived longer -- a subtle difference with significant public health consequences.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nThe new research, which appears in today's issue of the New England Journal of Medicine, seems destined to heat up that argument.\nIn the ensuing years, about 27,000 more scans were done, with some people having them annually.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the benefits of treatment. Because this study had no control group, there is no way to directly compare screening to no screening \u2013 and the story explains that. Furthermore, the story rightly points out that the study looked at survival at 10 years as the outcome (although the study only followed patients for an average of 3 years and 10-year survival was estimated), not mortality, leaving open the question about whether or not screening actually extends life or if\u00a0it only pushes forward the time of diagnosis (a\u00a0situation known as lead-time bias).", "answer": 1}, {"article": "Some studies have found a higher risk of jaundice, a buildup of bilirubin in the blood from the breakdown of red blood cells.\nBut Rabe said these infants may actually benefit most from the practice.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\nThis study is among the few looking at healthy, full-term infants in a country high in resources, as opposed to developing countries where iron deficiency may be more likely.\nThese babies often need more blood volume to help with blood pressure, breathing and circulation problems, Rabe said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough call. This story did put some context around the benefits \u2014 calling them \u201cmodestly higher scores in social skills and fine motor skills.\u201d It also pointed out that only the boys showed \u201cstatistically significant improvement.\u201d But we\u2019d like to have seen some actual numbers (for example, 3.7% of delayed cord clamping children scored 2 standard deviations below average in fine motor skills compared to 11% in the early cord clamping group). The story could\u00a0easily have massaged that technical language to make this understandable to an average reader. In addition, it might have added some nice color and helped readers to get a sense of the nature of the benefits if the article described the sorts of tasks the subjects were asked to do (e.g. threading beads).", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\nWhat often makes the difference in whether or not a diet is successful, she said, is whether or not there's a counseling and support component to the plan.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives a reasonable\u00a0overview of the effects of the two interventions on a variety of\u00a0different\u00a0markers associated with health. Although it earns points for noting the absolute reduction in blood pressures and not just providing them as a percentage, it\u00a0should have\u00a0provided the weight loss in similar terms of actual\u00a0pounds or kilograms lost instead of as a percentage of bodyweight.\u00a0\u00a0", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\nThat's because the study didn't include a comparison group that did not receive stem cells.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits, instead using general language: \u201cOver the next year, the patients generally showed small improvements in their symptoms \u2014 including the ability to walk without becoming breathless and fatigued.\u201d How was that measured? And by how much did those measurements change?\nThat said, we\u2019d really like to applaud the way that the story made clear the benefits couldn\u2019t be explicitly tied to the stem cell treatment. We\u2019ll talk about that a bit more under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "\"Obviously, these findings need to be replicated on a larger scale,\" he said.\nIn addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can't or don't do well, Ahlquist said.\nTHURSDAY, Oct. 28, 2010 (HealthDay News) -- A new noninvasive test to detect pre-cancerous polyps and colon tumors appears to be more accurate than current noninvasive tests such as the fecal occult blood test, Mayo clinic researchers say.\nThe sensitivity of the test is much better than what has been seen in other stool screening tests, the ACS' Brooks added.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the potential benefits, although the numbers are incomplete. It\u2019s not clear, for one, how this compares to other colon cancer screening tests.\nThe story didn\u2019t specify the sensitivity of the test, but stated:\u00a0\u201cThe sensitivity of the test is much better than what has been seen in other stool screening tests, the ACS\u2019 Brooks added.\nOverall, we didn\u2019t think the story gave readers a way to judge the scope of the potential benefits.", "answer": 0}, {"article": "\u201cAnd you need all hands on deck.\u201d\nIn the biggest study, sponsored by the National Institute on Drug Abuse, about 300 offenders \u2014 most of them heroin users on probation or parole \u2014 were randomly assigned to receive either Vivitrol or brief counseling and referral to a treatment program.\nThere\u2019s widespread agreement that counseling, support groups and treatment for underlying problems such as depression are crucial for Vivitrol patients, said Dr. Joseph Garbely of Pennsylvania-based Caron Treatment Centers, which supports medication-assisted treatment and prefers Vivitrol.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nWhen the injections stopped, many in the study relapsed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One randomized clinical study of Vivitrol was published recently\u00a0in The New England Journal of Medicine, and this AP story gives it ample space. We\u2019re told specifics like \u201cAfter six months, the Vivitrol group had a lower rate of relapse, 43 percent compared with 64 percent.\u201d\nThe experiment found no overdoses and fewer relapses in the Vivitrol group compared to individuals referred to a treatment program instead. However, within months of the study\u2019s end, relapses among those in the Vivitrol group rose to the same level as that of the control group; the story makes that quite clear as well.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nIn this study, however, the investigators said they found that even a short delay in giving blood thinners to patients at low risk for stroke increases the risk for dementia.\nA score of zero to one usually means blood thinners aren't needed because the risk for stroke is low.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nIn patients with atrial fibrillation, the risk of stroke is usually measured using the so-called CHADS score, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story renders benefits not in terms of reduction in risk but, rather, in terms of increased risk for signs of dementia. Specifically, it notes that delaying use of blood thinners in patients at low risk of stroke increases the risk of dementia by 30% and, in patients at high risk of stroke, by 136%. What it does not provide is any baseline numbers to permit a reader to judge \u201cpercentage of what?\u201d Without that, it is difficult to decide if these risk increases are substantial or trivial. See more on the importance of including absolute risk numbers.\u00a0", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nHere\u2019s how he got out.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Examples of benefit are presented in very general terms (walked a little faster, fewer falls) without any frame of reference for the magnitude of improvement or whether the change was statically or clinically significant.", "answer": 0}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\n[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not tell readers how important a 7 to 17 percent increase in risk for the measured outcomes really is. There are no absolute figures included, only relative risks. What\u2019s more, the release makes no mention of how this sort of risk stratification would be used. Would people identified as having a 10-20 percent higher risk of certain conditions be offered different tests or treatments than those with stronger grips? Without this sort of context, readers of this release don\u2019t have any way of knowing what the benefits of grip testing might be.\nIt is also odd that the headline and lead paragraph of the release highlighted heart attack and stroke, when the risk stratifications for those events were smaller than those for other outcomes.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some quantitative benefits of treatment provided, but it would have been better if the story provided a statement of baseline risk of transmission instead of \u201ccuts risk in half.\u201d However the point of the article is that the transmission rates with and without exposure to drug during prior pregnancy are the same (14.6 vs 17.6%). The problem here is that we don\u2019t have an explicit transmission rate for comparison. The literature says it was 25 to 40% in Africa before antiretroviral therapy. Thus rates of both 14.6% and 17.6% would represent a significant reduction in transmission.", "answer": 0}, {"article": "In the new study from Denmark, taking low-dose aspirin continuously for at least five years appeared to reduce the risk of colorectal cancer by 27%, and using nonaspirin NSAIDs for at least five years appeared to reduce it by 30%.\nAspirin and NSAIDs carry their own risks, however.\nLong-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nNow, using data on more than 113,000 individuals, researchers have been trying to sort out the relationship between aspirin and NSAIDs, duration of treatment, and colorectal cancer rates.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a 27 percent decrease among low-dose aspirin users who had taken the drug for five years or more. It also notes the incidence of the disease among different populations, and even gives readers a link to a risk calculator to determine their individual risk.\nOf course, we almost always prefer stories to use absolute risk reductions over the relative risk reduction reported here (technically an odds ratio \u2014 not a \u201crisk\u201d reduction per se). But in a case-control study such as this one, the issue can be complicated. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nYet along with the enthusiasm come pressing questions about safety, cost and the complexity of the procedure.\nIf the panel gives the nod, the agency probably will follow suit by the end of September.\nMany of them took part in the clinical trial, and all have gotten extensive training by Grupp and others.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is satisfactory, but barely. Here\u2019s how the story addresses benefits for the CAR T-cell treatment: \u201cIn the pivotal trial testing the therapy in almost a dozen countries, 83 percent of patients went into remission. A year later, two-thirds remained so.\u201d\nThat information would be much more useful if it placed those numbers in context. For example, how many patients were enrolled in the study? 83 percent could be 13 out of 16 patients, or it could be 1,328 patients out of 1,600. And how does 83 percent compare to standard treatment?\nSimilarly, is the story telling us that two-thirds of all patients were still in remission a year later? Or did it mean that two-thirds of the 83 percent were still in remission a year later? Contextual information would have provided some much-needed clarity here.", "answer": 1}, {"article": "\u201cBut it is definitely a breakthrough.\n\u201cOn average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefits of treatment in two different ways: \u201ctwo thirds of people in the study were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment,\u201d and on average, \u201cparticipants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\u201d\nThat barely passes the bar.\nUnfortunately, both those descriptions are in the form of canned quotes from the study author and neither compares the result to the control group (which had a placebo treatment).\nWe also think more detail could have been added to show the extent of benefit, and what it means for kids. For example, it would have been helpful to note that almost 20% of the treatment group withdrew from the study, which suggests many patients might quit the therapy.", "answer": 1}, {"article": "Botox injections are also used, often in cases where the medicine does not work.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\n\u201cThis gives patients the information to make an informed decision.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story briefly mentions that the two treatments \u201cvary in side effects and long-term effectiveness,\u201d but these are never quantified. Instead, the article mentions the certain side effects are \u201cmuch more common,\u201d such as dry mouth for the anticholinergic drugs, but actual figures would have helped to put expressions like \u201cmuch more\u201d into perspective.\nThe article twice uses the word \u201csignificantly.\u201d For example, the story states : \u201cScientists\u2026 found that both treatments significantly reduced incontinence episodes,\u201d and also, \u201cSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\u201d And here, actual figures are a must, since \u201csignificantly\u201d has a very different meaning to the general population than to researchers, who usually mean \u201cstatistical significance.\u201d For example, 27 percent of the botox group saw their urinary symptoms disappear, versus 13 percent of the anticholinergic group. The inclusion of these figures put the story\u2019s \u201csignificantly\u201d into perspective.\nJournalists can help readers understand the difference between statistical significance and clinical significance.", "answer": 0}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nDuring the periods when each group was taking the drug, the neural signal from the eye to the back of the brain was significantly accelerated over the baseline measurements taken before the patients began the study.\nThis \"flip-flop\" technique gave the researchers the ability to compare patients to themselves -- a form of control that increased the statistical power of the study by nearly an order of magnitude, Green said.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t cite any figures to support its benefits claims. It only states that neural signals from the eyes to the brain were \u201csignificantly accelerated over baselines measurements.\u201d\nThe study authors report that clemastine reduced the delay by 1.7 ms/eye in the treatment group compared to the placebo group.\nWe caution against using the word \u201csignificant\u201d when describing benefits data due to its ambiguity. \u201cSignificant\u201d in a scientific context usually refers to a result being \u201cstatistically significant,\u201d which means the result is probably not attributable to chance.\nIt\u2019s important to recognize the distinction between significance on a lab test (a surrogate outcome) and something patients actually care about\u2013a clinical improvement in a symptom. In this study they measured visual acuity, for example, and found no difference between the groups. Perhaps in a longer trial they would find a difference, but this should be made clear. A lot more work needs to be done to see if this drug will be truly useful.\nSince benefits data are not given quantitatively, we rate this one Not Satisfactory.", "answer": 0}, {"article": "According to a study published in the journal Birth, labor clears liquid from the infant's lungs, preparing the baby to breathe outside the womb.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nNew research into the risks associated with elective Caesareans supports their view.\nIf you have customers who sit at a table and don't order anything, you're not making any money,\" says Jennifer Block, author of \"Pushed: The Painful Truth About Childbirth and Modern Maternity Care.\"\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides information on the risks of C-section versus vaginal birth in absolute terms. [Because the story focuses on the harms of C-section, this criteria will be applied to the presentation of harms of the surgery, not the benefits.]", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nIn 2006, varenicline was approved as a safe and effective means to quit smoking and achieved permanent quit rates of approximately 25 percent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits here would presumably be the reduction in premature deaths among people who successfully quit smoking. The release provides one number, saying: \u201cThe authors speculate that if use of varenicline had not plummeted by 76 percent following the black box warning in 2009, perhaps 17,000 premature deaths from cardiovascular disease may have been avoided each year during the last few years.\u201d However, that\u2019s a somewhat vague estimate, and it\u2019s not clear exactly where this number comes from. To be clear: the number may be completely accurate, but the release needs to explain where the number comes from. And it doesn\u2019t.\nIt also states that those using Chantix have a 25 percent success rate at stopping smoking, but they don\u2019t say how this compares to overall success rates for those attempting to quit.", "answer": 0}, {"article": "Lovaza is an omega-3 drug FDA-approved for the treatment of severe high triglycerides at the dose of 4 milligrams daily.\nManni added that, with obesity-related cancers on the rise, the findings could have implications beyond breast cancer.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nSome epidemiological data supports the idea that omega-3s protect against breast cancer, but the findings have been inconsistent.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline states,\u201dOmega-3 Fatty Acids May Lower Breast Cancer Risk in Postmenopausal Obese Women,\u201d and the opening paragraph follows with basically the same statement. But nowhere in the release does it explain how much this supplement may lower a woman\u2019s risk. It says that breast cancer density is a biomarker for breast cancer risk and that obese women taking the supplement had a reduction in tissue density after two years but no details to back up the claim. In stories and releases focusing on cancer risk, the public wants, and rightly deserves, real numbers so that they can make informed decisions. This release only offers a vague prediction of risk reduction. Lastly, the release states that the omega-3s \u201cmay lower\u201d the cancer risk, but readers could just as easily conclude that it \u201cmay not\u201d without more information.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThat clinical trial was funded by the company that makes the ReShape system, according to a presentation from the Obesity Society annual meeting in Boston.\nIn the clinical trial, the 187 participants who used the device lost an average of more than 14 pounds, or about 7 percent of their total body weight.\nThe balloons take up space in the stomach, which presumably makes people feel fuller faster, the FDA said in its announcement Tuesday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u00a0states \u201cthe ReShape system helped people more than double their weight loss compared to those trying to lose weight through diet and exercise.\u201d\u00a0We also\u00a0also note that because\u00a0previous studies on weight loss suggest that the average individual is hoping for a loss of 20% or more of presenting weight, \u201cdouble\u201d as a descriptor, when discussing very small losses, may be a bit loaded.\nIn\u00a0the final paragraph, the story includes absolute values of weight loss:\n\u201cIn the clinical trial, the 187 participants who used the device lost an average of more than 14 pounds, or about 7 percent of their total body weight. Patients who did not receive the device lost about half that amount of weight \u2014 just over 3 percent of their total body weight, the FDA said.\u201d\nKudos to the writer for including the comments from the researcher who said the results may be temporary.", "answer": 1}, {"article": "\u201cCounting is expensive.\nGiven that the stem cell-treated knee was no better than the control-treated knee \u2014 both were significantly better than before the study began \u2014 the researchers say the stem cells\u2019 effectiveness remains somewhat uninterpretable.\n\u201cOur findings can be interpreted in ways that we now need to test \u2014 one of which is that bone marrow stem cell injection in one ailing knee can relieve pain in both affected knees in a systemic or whole-body fashion,\u201d says the study\u2019s lead author, Shane Shapiro, M.D., a Mayo Clinic orthopedic physician.\nEach of the 25 patients enrolled in the study had two bad knees, but did not know which knee received the stem cells.\nThey are only able to conclude the procedure is safe to undergo as an option for knee pain, but they cannot yet recommend it for routine arthritis care.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release talks about \u201cdramatic improvement\u201d in the injected knees, but gives the reader no clue about what the baseline level of pain was, or how the improvement was measured. The investigators used a standard international measure of pain relief and function to score the patients before and after treatment. The release needed to describe the results more meaningfully. For example, it could have noted the range of improvement in the 25 patient volunteers.\nIt\u2019s unclear why the release positioned this as a positive study suggesting that the treated knee got better. The problem is that the study design was testing to see if there was a difference between treatment and placebo \u2014 and there wasn\u2019t. This means that the stem cell treatment was no better than the saline placebo, or a sham treatment. In claiming that the stem cell treatment was effective, the release quotes a study investigator saying that it is possible that the injection of stem cells into one knee resulted in benefit to the other.\nNo evidence is provided to support this hypothesis.\u00a0", "answer": 0}, {"article": "I hurt so bad, everything hurt,\" Marylin adds.\nDr. Bill Gray has done several of the procedures at New York Presbyterian Hospital, and he demonstrated to LaPook how the clip works to close the valve.\nDesperate for an alternative, she surfed the Internet and found an investigational new procedure, one that uses a tiny clip to repair the valve \u2014 and most important, does not require open-heart surgery.\nLaPook notes that it will be a few more years before this procedure is widely available.\nHe says it's in the final stages of testing at about 30 hospitals around the country.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What we learn about benefits in this story are that the use of this procedure reduces time spent in the hospital, the length of the recovery period, and eliminates having the scar associated with an open heart procedure.\u00a0 \nHowever, the story included nothing about the extent to which the medical problems associated with heart valve disease are repaired with this device, how long the repair is expected to be functional, or other benefits that might come from the use of this device.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says that \u201cthe device did appear to be more cost-effective in the larger, longer-term trial,\u201d but it does not say what made it appear to be more cost-effective.\nIt then adds a quote from the lead author, Dr. James Freeman, in which he says longer-term results are needed to be certain of the device\u2019s value in clinical practice. But, since it never quantifies the length of the results that were obtained, we do not know how long the longer-term data need to be.\nPerhaps more importantly, it does not talk about the effectiveness of the product compared with the effectiveness of standard treatments.", "answer": 0}, {"article": "The risks and uncertainties include, but are not limited to, the following:\n\u2022 the proposed combination with Baxalta may not be completed due to a failure to satisfy certain closing conditions, including any shareholder or regulatory approvals or the receipt of applicable tax opinions;\n\u2022 disruption from the proposed transaction with Baxalta may make it more difficult to conduct business as usual or maintain relationships with patients, physicians, employees or suppliers;\n\u2022 the combined company may not achieve some or all of the anticipated benefits of Baxalta's spin-off from Baxter International, Inc. (\"Baxter\") and the proposed transaction may have an adverse impact on Baxalta's existing arrangements with Baxter, including those related to transition, manufacturing and supply services and tax matters;\n\u2022 the failure to achieve the strategic objectives with respect to the proposed combination with Baxalta may adversely affect the combined company's financial condition and results of operations;\n\u2022 products and product candidates may not achieve commercial success;\n\u2022 product sales from ADDERALL XR and INTUNIV are subject to generic competition;\n\u2022 the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for the combined company's products may affect future revenues, financial condition and results of operations, particularly if there is pressure on pricing of products to treat rare diseases;\n\u2022 supply chain or manufacturing disruptions may result in declines in revenue for affected products and commercial traction from competitors; regulatory actions associated with product approvals or changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;\n\u2022 the successful development of products in various stages of research and development is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;\n\u2022 the actions of certain customers could affect the combined company's ability to sell or market products profitably, and fluctuations in buying or distribution patterns by such customers can adversely affect the combined company's revenues, financial condition or results of operations;\n\u2022 investigations or enforcement action by regulatory authorities or law enforcement agencies relating to the combined company's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;\n\u2022 adverse outcomes in legal matters and other disputes, including the combined company's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect the combined company's ability to attract and/or retain the highly skilled personnel needed to meet its strategic objectives;\n\u2022 failure to achieve the strategic objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. (\"Dyax\") may adversely affect the combined company's financial condition and results of operations;\n\u2022 the combined company will be dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 the combined company may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners;\n\u2022 difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and other risks and uncertainties detailed from time to time in Shire's, Dyax's or Baxalta's filings with the Securities and Exchange Commission (\"SEC\"), including those risks outlined in \"ITEM 1A: Risk Factors\" in Shire's and Baxalta's Annual Reports on Form 10-K for the year ended .\n\"These results represent an important step toward a new treatment option for patients with ADHD.\nThe CGI-I is a standardized assessment tool that allows clinicians to rate the severity of ADHD illness, change over time and efficacy of medication.\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\n\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job of explaining the benefits of the drug to children and adolescents with ADHD in relationship to a placebo and to a standardized measurement of improvement, but does not compare this new drug with existing treatments. It\u2019s difficult to estimate how many people would want a stimulant that lasts 16 hours. Even if they do, it would be much cheaper to take a dose of an existing, shorter acting drug in the early afternoon.", "answer": 1}, {"article": "Mannitol pulls water out of the tightly packed cells lining the capillaries so that they shrink and pull away from one another, opening up gaps through which drug molecules can pass into the brain.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\n\u201cThe early data is very interesting and exciting.\u201d\n\nThe complexity of a study like this goes beyond the science.\nBut how long the effect will last remains to be seen.\nWhat\u2019s exciting about our results is that we\u2019ve proven there is a local effect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "With only a Phase I study underway, there is no data to report. The story makes this clear. ", "answer": 1}, {"article": "And nitrites help open blood vessels in the body, increasing blood flow and oxygen to places lacking in oxygen.\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\n\u201cThere are areas in the brain that become poorly perfused as you age, and that\u2019s believed to be associated with dementia and poor cognition.\u201d\n\nResearchers from the Translational Science Center looked at how dietary nitrates affected 14 adults aged 70 and older over a four-day period.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As we said in the \u201cdisease-mongering\u201d criterion above, benefits were not expressed in terms of any outcomes that people would really care about in their lives, but, rather, only in terms of improved test scores which may not correlate with improved outcomes.", "answer": 0}, {"article": "\u201cAll it does is allow us to choose the best embryos to transfer so that we can get the patients pregnant faster,\u201d he said.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nPre-implantation genetic screening doesn\u2019t necessarily get patients pregnant unless they have good embryos, Robbins noted.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits. The story tells readers 1 out of 33 births has a genetic disorder. We want to know: Does the screening identify all of them? How accurate are the tests? How much do they \u201climit the chances of an embryo carrying a chromosomal disorder from being implanted?\u201d Readers deserve to see numbers around these limits. It\u2019s also far from clear this applies only to IVF. The story makes it sound like this applies to any pregnancy.", "answer": 0}, {"article": "You're fighting depression and you're wondering, 'Is an era of your life over?'\nSeveral studies of hips and knees implanted in patients long ago have found that 85% to 90% are still functioning well after 20 years.\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\nLast year, one manufacturer, Smith & Nephew , won clearance from the Food and Drug Administration to market its latest technology as a \"30-year knee\" based on tests mimicking 30 years of wear.\n\"Metal-on-metal\" hip parts were supposed to wear better than plastic, but their use is declining due to concerns that they can release metal ions into patients' bloodstreams and cause soft-tissue damage.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not adequately quantify the benefits of knee and hip replacement in terms of pain relief, function, or quality of life.\u00a0 It would have been useful, for instance, for readers to learn that in older patients roughly 90% of primary knee and hip replacement procedures result in significant pain relief and functional improvement\u2014with low levels of complications. Younger patients might expect similar short-term outcomes but their long-term outcomes would be less predictable. (The story cited studies showing 85-90% of implants \u201cstill functioning well after 20 years\u201d but that\u2019s not a comment on pain relief and peoples\u2019 functional improvement.)\n\n \n", "answer": 0}, {"article": "\u201cNow, it\u2019s just impatience,\u201d Kefalis said.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nBut then they need a vehicle to insert the good gene into the stem cells before those are put back into the patient\u2019s body.\nHere\u2019s what\u2019s really amazing: That vehicle is the HIV virus, re-engineered so the children can\u2019t get AIDS.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not clearly state the quantified benefits seen in the experimental trial, though it does make reference to the research. All we\u2019re told is \u201cAt least 70-80% of them have an outstanding benefit coming from the treatment.\u201d But, what does \u201coutstanding\u201d mean? And how many kids are we talking about? It sounds like possibly 24, but we\u2019re not sure. And, what\u2019s happening to the other third who aren\u2019t seeing \u201coutstanding\u201d benefits?\nThe reporter\u00a0does say that \u201cit will take years to know for sure\u201d if the treatment works, but ends the story on the word \u201cmiracle\u201d and leans heavily on the anecdotal experience of a single family, which diminishes the previous cautious statements.", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nWEDNESDAY, Feb. 6, 2013 (HealthDay News) -- Enduring dietary wisdom -- that polyunsaturated vegetable fats are better for your heart than saturated animal fats -- may be turned on its head by a fresh analysis of a nearly 50-year-old study.\nSo, it's a very complex picture.\n\"Because there's very robust evidence showing the cardiovascular benefit of linoleic acid.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide statistics regarding the percentage of people who died, from what causes, in each group of this study. That information would have been easy to communicate, so we\u2019ll provide it here:", "answer": 0}, {"article": "\u201cBut it\u2019s piecemeal,\u201d she said.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nDoctors and patients \u201ctraditionally see palliative care as something extended to a hospitalized patient in the last week of life,\u201d said Dr. Jennifer S. Temel, an oncologist and author of the paper.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\nIt shows that palliative care and cancer care aren\u2019t mutually exclusive.\u201d\n\nDr. Atul Gawande, a Harvard Medical School surgeon and writer who just published a long article in The New Yorker about hospitalized patients\u2019 suffering before death, called the study \u201camazing.\u201d\n\n\u201cThe field was crying out for a randomized trial,\u201d he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like the competing coverage, this story\u00a0featured prominent discussion of\u00a0the survival benefit associated with palliative care.\u00a0We were pleased to see that it also\u00a0spent\u00a0some time on\u00a0the improvement in quality of life\u00a0and depression scores as well as the reduction in aggressive chemotherapy usage toward the end of life in the palliative care group. We wish the story had been more precise in its quantification of some the benefits \u2014 it notes that the palliative care group reported \"less depression\" and \"happier lives\" but offers no way to judge the magnitude of the benefit. However, we don\u2019t think these\u00a0shortcomings\u00a0were enough to throw the story out of balance.", "answer": 1}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\n\u201cWhen that\u2019s placed on the skin just like an elastoplast then the drug will actually diffuse across the skin into the body at the site of the pain and then relieve the pain in the same way as current gels and creams.\n\u201cOne of the interesting areas that we plan to explore in partnership with large companies is actually using our platform technology to include other drugs that previously maybe haven\u2019t been suitable for topical or transdermal delivery - or drugs which may have not got through the regulatory filings because, for instance, they might have caused stomach irritation or other side effects when taken orally,\u201d said Lee.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is full of superlatives but provides absolutely no information on how the TEPI patches were tested. \u00a0All of the information provided appears to be related to results in the lab and not on people. \u00a0We are told, \u201c\u2026capable of releasing between five and ten times the amount of drugs used in gels and patches currently on the market, for periods of six hours, 12 hours, and even 24 hours.\u201d How long do current gels and patches last? How much medication do they release? Is is important to be able to achieve the higher dosages discussed in this story? While it all sounds very impressive,\u00a0the reader isn\u2019t provided enough information to tell if any of these results are meaningful.", "answer": 0}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nOn average, the patients\u2019 tremor \u201cscores\u201d had gone from a 5 to a 3 six weeks after Botox treatment \u2014 which essentially means moving from \u201cmoderate\u201d to \u201cmild,\u201d LaRocca said.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nThe study\u2019s lead researcher agreed on the need for more work.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate.\nThe story reported:\nOn average, the patients\u2019 tremor \u201cscores\u201d had gone from a 5 to a 3 six weeks after Botox treatment \u2014 which essentially means moving from \u201cmoderate\u201d to \u201cmild,\u201d LaRocca said. Their ability to write and draw a straight line had also improved by week six, and the benefits were still there at week 12.\nIn contrast, there were no improvements after the placebo injections.\nBut the \u201con average\u201d doesn\u2019t tell much about the range of progress across the 23 people.\u00a0 That wouldn\u2019t have been difficult to explain.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\n\"These results highlight the need for addiction treatment programs to offer a multifaceted approach that doesn't only address substance use but also the other factors that might be driving substance use, including pain,\" says Mark Ilgen, Ph.D., the study's lead author and a VA and U-M psychologist specializing in addiction research.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release addresses benefits in two ways: perceived effects, and how long they last. Here\u2019s what it said about the beneficial effects: Patients \u201cfound that the intensity of their pain decreased, their ability to function increased, and their alcohol use went down, compared to [patients] who received a less-focused approach. However, the two groups had similar rates of drug use.\u201d Kudos to the release for highlighting the lack of effect on rates of drug use.\nHowever, it\u2019s important to tell readers how much the patients\u2019 pain decreased, alcohol use went down and ability to function increased. Are we talking about a statistically significant, but functionally irrelevant, margin? Or are we talking about a substantive difference? Readers want to know.\nThe release also notes that \u201cJust 10 weekly sessions of [ImPAT] had an effect that lasted up to a year in 55 [patients] who took part.\u201d That\u2019s good to know \u2014 but that\u2019s 55 patients out of how many? If you read the paper, you\u2019ll see that the finding was true for 55 out of 65 patients who participated in ImPAT. That\u2019s a strong result. But readers can\u2019t know that if the release doesn\u2019t tell them.", "answer": 0}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides early data from a trial of metastatic breast cancer patients. Cancers in these patients remained stable (i.e. it did not spread further in the body) nearly twice as long with the addition of lapatinib to chemotherapy (8.5 months vs. 4.5 months). There were fewer incidents of metastases to the brain in the women who took lapatinib and chemotherapy compared with chemotherapy alone (4 vs. 11 cases of cancer spreading to the brain). However, many drugs have been shown to effective in prolonging response in metastatic disease without impacting length of life so it would be good to get data on survival data to back up these claims or at least on quality of life to see whether it made a difference and how much.", "answer": 1}, {"article": "For babies born at full-term, \"we should trust nature more than we do now,\" she said.\nHis previous research has shown that babies whose cords were clamped a few minutes later than usual were 90% less likely than others to have iron-deficiency anemia when they were 4 months old.\nIn the new study, Andersson found that healthy, full-term newborns whose umbilical cords were left attached for three extra minutes had better fine motor control when they reached preschool than those clamped immediately.\nIron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nThere was not enough evidence before to extend that recommendation to full-term babies, but Rabe thinks this study should tip the balance in favor of delay.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story asserts that healthy, full-term newborns whose cords were left unclamped for three extra minutes at birth \u201chad better fine motor control when they reached preschool\u201d than a control group whose cords were clamped immediately. But we aren\u2019t provided adequate context or any numbers for how much better some of the children performed. Was this a large, meaningful benefit? Or something barely distinguishable from statistical noise?\nThe story also notes: \u201cHis previous research has shown that babies whose cords were clamped a few minutes later than usual were 90% less likely than others to have iron-deficiency anemia when they were 4 months old.\u201d This is an incomplete representation of the benefit, since the absolute reduction in anemia was lower than this number suggests.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addresses benefits in only general terms. For example, when summarizing the NICE guidance, the story states \u201chome births are safer than hospital births for women who are having their second or later child with a low-risk pregnancy.\u201d And when describing the findings of the U.K. study that was the basis for the guidance, the story notes that \u201camong low-risk women who chose to have a second or later child at home, there were fewer interventions and complications, such as cesarean sections, forceps delivery, infections and hemorrhage compared with hospital births, while the health of babies didn\u2019t differ.\u201d How much safer are home births under the relevant circumstances? How much lower was the risk of complications? It would be helpful to have at minimum an estimate of a summary figure, such as the frequency of complications and interventions overall for home and/or hospital births. In addition, while the story makes clear that the reduced risk is only for women with low-risk pregnancies \u2014 it doesn\u2019t tell readers what that means. Does having had a previous C-section rule out a low-risk pregnancy? Which chronic medical conditions might rule a low-risk pregnancy out? It\u2019s not clear.", "answer": 0}, {"article": "\"We want to reach as many people as we can as early as we can,\" he said.\n\"That's why the acid test for screening is not how many cancers you find or what stage the cancer is,\" Thomson said, rather what screening does to lung cancer death rates.\nAlso, like lung cancer has been coincidently found in CT scans for other reasons, physicians like Thomson and Schroeder are now incidentally finding cardiovascular disease in their lung cancer screening.\nAnd while some lung cancers are super aggressive, screening also may uncover some slow-growing versions that - like some prostate cancers - will not threaten life but need to be treated and/or closely followed once found.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells us how many cancers were found with the screening program, but it includes a misleading statement about what this might mean for survival rates. It notes that if lung cancer is identified in its early stages, the \u201coverall survival rate\u201d is 90 percent, whereas five-year survival rates for patients whose cancer is identified in the advanced stages is approximately 5 percent.\nA 90% vs. a 5% survival rate sounds impressive, but this is likely a significant overstatement of the true difference. Why? As Professor Gerd Gigerenzer of the Max Planck Institute explained in a BMJ editorial, the answer has to do with something called \u201clead time bias.\u201d He said, \u201cEarlier detection implies that the time of diagnosis is earlier; this alone leads to higher survival at five years even when patients do not live any longer.\u201d\nThis Youtube video by Dr. H Gilbert Welch discusses this issue in more detail. The bottom line is that when cancers are diagnosed at an earlier stage due to screening, patient survival time will be longer than if they were diagnosed later. This may or may not mean their survival was prolonged. They may have been destined to die at the same age regardless of when the cancer was diagnosed.", "answer": 0}, {"article": "The effect, however, typically lasts only about seven months before the cancer starts to grow again, though some patients benefit for more than two years.\nIn the latest trial, a big one was liver damage.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nChance said the drug caused such extreme pain at one point that \u201cI called in the children and said, \u2018I\u2019m done, I can\u2019t do this any more.\u2019 \u201d But she had her dose reduced and took other medications for the pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good job describing the benefits reported in the two drug studies. The two papers present a bewildering array of statistics. This story did a nice job distilling the information into a couple of very understandable sentences.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Did not present estimate of absolute risk or benefit.", "answer": 0}, {"article": "Keytruda is already approved for treating melanoma, lung cancer, head and neck cancer and Hodgkin lymphoma.\nMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy.\nThe study did not detect a difference in the length of time patients lived without their disease getting worse.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\nAfter 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits of the intervention, and it does so in absolute terms.\n\u201cMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy. The study\u2019s median follow-up was 18.5 months. After 18 months, 36 percent of Keytruda patients were alive, compared with 20.5 percent of chemotherapy patients, according to research published by ASCO. The study did not detect a difference in the length of time patients lived without their disease getting worse.\u201d\nThis is sufficient to be satisfactory, but we do think more could be said about if this minimal time difference truly make an impact on patients\u2019 lives, or not. Are the patients healthy enough to make meaningful use of the additional time they receive with treatment?", "answer": 1}, {"article": "Their median age was 63.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\nIn interviews, Schroeder and Thomas stressed that each decision about whether to have surgery is based on many factors that only a woman and her doctors can assess, in particular how far the cancer has spread and how sick she is.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The Washington Post story quantifies the potential benefits of surgery, detailing that women who underwent breast surgery had better survival rates than those that didn\u2019t (median of 28 months versus 19 months). Despite the better outcomes, the article adds the number of surgeries dropped from 67.8 percent in 1998 to 25.1 percent in 2011, which it describes as an \u201cintriguing question\u201d about that approach.\nFurthermore, the story is quick to point out early in the story that surgery may not be the right option for all women and \u201cmay be better for some women than it was in 1995.\u201d\nWe applaud the fact that the benefits are reported in absolute terms and in a more cautionary manner, which is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "\"Everyone heals differently.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nMONDAY, Jan. 2, 2012 (HealthDay News) -- Spinal manipulation and home exercise are more effective at relieving neck pain in the long term than medications, according to new research.\nHe also noted that it's important for anyone receiving spinal manipulation to know that there are rare, but serious risks that can occur with neck manipulations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes both some of the specific results reported by researchers as well as more conversational descriptions of the overall experiences of people in this trial. Readers get the message that people with neck pain tend to feel better as time passes no matter which treatment option they used and that none of the treatments is clearly superior or can deliver sure-fire pain relief.", "answer": 1}, {"article": "Women who reported using these drugs, called NSAIDs, at the beginning of the study and three years later had a roughly 30 percent lower rate of death from colorectal cancer than women who did not take the drugs, or women who took them at only one of these two points in time, according to an American Association for Cancer Research (AACR) news release.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nThe U.S. National Cancer Institute has more about colon and rectal cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit mentioned in the story was the \u201croughly 30 percent lower rate of death from colorectal cancer,\u201d as stated in the press release, but 30 percent of what?", "answer": 0}, {"article": "For more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nIt is one of the largest and longest studies to explore how planned C-sections differ from other deliveries.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn\u2019t go far enough in explaining the difference in risk between the planned and unplanned C-sections, and the vaginal deliveries.\nThe story presented only the relative increased risk of 35% (from a hazard ratio of 1.35) in type 1 diabetes, despite the fact that the absolute risk was 0.22 (less than 1/4 of 1 percent!). This is a VERY modest increase and was only statistically significant because of the huge sample size.\nReaders need this kind of context to be able to interpret the findings.", "answer": 0}, {"article": "Baltimore, Md.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\nDiagnosis and therapy with the theranostic agent PSMA-617 could offer more effective and sensitive visualization, better staging and significantly higher therapeutic potential.\n(Embargoed until 12:30 p.m., June 8, 2015) - A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that PSA\u00a0levels dropped from 38.0 to 4.6 nanograms per milliliter and that the result was verified by PET scan and computed tomography. But we have no information about the time period over which the PSA dropped, whether there were additional treatments, and whether PSA\u00a0levels remained low (and for how long) \u2014 and whether the patient is still alive. In treating metastatic cancers,\u00a0survival benefits are often quite short, e.g., the median survival benefit for sipuleucel (Provenge vaccine) was only 4 months. So we\u2019d want some evidence that patients are living longer (and more than just one of them) before talking about \u201cnew hope\u201d for this disease. We also disagree with the comment that \u201ccurrent clinical methods are not sensitive enough for detecting disease beyond the prostate.\u201d Currently used radionuclide bone scans can readily detect metastatic disease.", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nIt is by no means clear that doctors or patients will follow the new guidelines.\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nOn the other hand, Ms. Jemison said that now that she is over 21, \u201cI would still go every year\u201d for the Pap test.\nThat is curious.\u201d Mr. Specter, who was treated for Hodgkin\u2019s lymphoma in 2005 and 2008, said Congress was committed to increasing cancer screenings, not limiting them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify benefits of screening.\u00a0 ", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\n\"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy,\" said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.\nMONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nThe study was released online Sept. 27 ahead of print publication in the Oct. 5 issue of the Journal of the American College of Cardiology.\nAfter a year, Park's team tallied the number of adverse cardiac events the patients experienced, including death, heart attack and the need for a new angioplasty on the same artery in which the stent was placed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article gives the absolute rates of major adverse cardiac events for each treatment group.\u00a0\nAlso, while this is likely not a major issue for most readers and not an official strike against the article, as an FYI we point out that there are some interwoven\u00a0concepts that can be confusing. The article\u2019s headline is that SES won this contest. If you want to get technical, there are two buts.\u00a0First, while SES did have the fewest cardiac events of the 3 stents, the difference with ZES wasn\u2019t statistically significant. In other words, the apparent superiority of SES may have been do to chance. Or not. We don\u2019t know. Researchers call this\u00a0a trend but not significant evidence. \u00a0Second, this contest, the study, wasn\u2019t designed to answer whether SES was the best. The researchers concluded,\u00a0as quoted in the story,\u00a0that this study answered two main questions:\u00a0ZES and SES were similar, and ZES fared better than PES did. Notice it didn\u2019t say SES was the best.\u00a0", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story used absolute measures to report the patients\u2019 outcomes, but it focused on results that showed the greatest advantage for surgery. The researchers presented several analyses. One analysis showed a very small but significant (~8/100 points) advantage for surgery at 2 years in pain reduction, but no advantage in function or disability; these were the outcomes of the randomized patients, analyzed according to their assigned treatments (an intention-to-treat analysis), and likely underestimate the value of surgery. Another analysis looked at all patients according to the treatments they actually received, and showed a modest but significant 11- to 14-point advantage for surgery in pain relief, function and disability. The news story did not report either of these analyses. The \u201ctruth,\u201d many observers would say, likely lies somewhere between the minimal/modest benefits that the news story did not report and the larger benefits that it did.", "answer": 0}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Insufficient.\u00a0 All we\u2019re told is that \u201c29 out of 36 participants experienced a decrease in histological grade of the precancerous lesion, or a slowing in the growth of the lesion.\u201d\u00a0 We\u2019re not told what the grade was to begin with nor what it decreased to nor how many of the 29 had what degree of decrease.\u00a0 And again, there was no discussion about what\u2019s known at all about the potential benefits of treating precancerous esophageal lesions.", "answer": 0}, {"article": "\"Our body knows best.\"\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nWhen Wang and his collaborators removed the devices after 12 weeks, the study's rats resumed their normal eating patterns and weight bounced right back on.\nIn laboratory testing, the devices helped rats shed almost 40 percent of their body weight.\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release refers to \u201cseveral advantages over an existing unit that stimulates the vagus nerve for weight loss;\u201d however, since this device has yet to be tested in human subjects, it is too early to claim that it offers benefits greater than the FDA-approved device. What\u2019s more, while the release states that rats in this trial lost almost 40% of their body weight, studies of the existing weight loss device say people lost less than 10 percent of their body weight, and that was when they were in a program that included diet and exercise counseling. These important caveats should have been included.", "answer": 0}, {"article": "Some previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\nWhile the spiral CTs emit less radiation than standard CT scans used to diagnose disease, researchers also will analyze whether the radiation exposures from three scans changes a smoker's lifetime risk of other radiation-related cancers.\nNor is it clear if the study results are applicable to all smokers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story does a better job than some others in how it portrays the potential benefits of CT screening for lung cancer. The headline and lead report that deaths were reduced somewhat. The third paragraph of the story notes that among the 53,000 participants there were 20 percent fewer deaths among those offered CT scans compared to those offered chest x-rays, but that the \u201cactual number of deaths averted was fairly modest\u201d (354 in the CT group vs. 442 in the x-ray group). This way of presenting the results helps readers put the results in perspective. The story also notes that the National Cancer Institute said \u201cit\u2019s not clear that all smokers should get the scans.\u201d However, the story could have made it more clear that the reduction in lung cancer death rates was seen after five years of folllow-up, which leaves open the question about whether that difference will persist over a longer time frame.\nIt would have been helpful for this story to tell readers that 300 smokers had to be screened in this trial in order to extend the life of one of them.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nHe found an association, not cause and effect.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nHe describes that reduction as modest.\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re going to take an admittedly hard-line stance on this because we think such a story can easily do a better job.\nThe story acknowledges at one point that the study \u201cfound an association, not cause and effect.\u201d\u00a0 Yet it uses cause and effect language in various places, such as:\n\u201cBenefit\u201d and \u201crisk reduction\u201d and \u201creduced risk\u201d convey more than an association.\u00a0 Those terms convey cause and effect.\u00a0 Take aspirin, get the \u201cbenefit\u201d of \u201creduced risk.\u201d\u00a0 This study, strongly suggestive though it may be given the numbers of people involved, cannot establish cause and effect.\nSo the suggestion of benefit needs to be couched in more careful language than this story did.\nThe competing Reuters story gave absolute risk reduction and was more cautious in general in interpreting results.\n\u00a0", "answer": 0}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nAnd though statins are widely used and most often successful, an alternative to them would be welcome, Ladenson said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nThe trial was funded in part by Karo Bio, a small commercial spinoff of the institute.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A major weakness of the story:\u00a0 it did not quantify the effects seen in the study in any way. ", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified at all. The release refers only to \u201cstatistically significant improvement\u201d for IKDC and \u201call five KOOS sub-scores.\u201d The release does not tell readers what \u201cstatistically significant improvement\u201d means, nor do they explain what IKDC or KOOS stand for \u2014 much less what the various sub-scores are. We assume from the language in the release that it is intended largely for an expert audience. However, news releases are ultimately aimed at reporters \u2014 that\u2019s what makes them news releases. While some reporters may be familiar with IKDC or KOOS, many reporters (even very good ones) are not. It would be more than worthwhile to include a few additional sentences articulating what the scores are, what the relevant numerical benefits were, and why the researchers deemed the changes in these scores to be important.", "answer": 0}, {"article": "Pancreatic cancer is the fourth leading cause of cancer-related death in both men and women in the United States.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\nBut few studies have explored the direct association of magnesium with pancreatic cancer; of those that did, their findings were inconclusive, said Daniel Dibaba, a Ph.D. student at the School of Public Health-Bloomington, who led the IU study.\n\"The five-year survival rate is really low, so that makes prevention and identifying risk factors or predictors associated with pancreatic cancer very important.\"\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There\u2019s very little quantification offered in the release. The release states that the 66,000 people who missed the recommended daily intake for magnesium by 100 mg were at a 24% increased risk for developing pancreatic cancer. Then it makes a strong recommendation to increase magnesium through diet and supplements.\nThe release would have been much stronger had it included measures of absolute risk. Unfortunately, the abstract and paper both make it difficult to calculate the absolute numbers. From Table 2, we can see that 44/14395 (0.30%) people in the cohort who were in the <75% of the RDA group developed pancreatic cancer, compared with 64/35348 (0.18%)people in the >100% of RDA group. \u00a0The absolute risk difference is 0.12%. \u00a0That is extremely small. \u00a0Giving only relative reductions is very, very misleading. \u00a0And, when the appropriate exclusions are done (the people who had cancers diagnosed in the first two years of the study), the results are not statistically significant anyway.", "answer": 0}, {"article": "Johnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe volunteers got one of three doses - low, medium, or high - and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a well balanced and thoughtful presentation of the benefits seen in the trial. \u00a0It notes the study was a phase 1 trial designed to identify safety. \u00a0We liked the caveats given in the story. \u00a0\u201cIt is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\u201d \u201c\u2026the immune responses are okay, but not great\u2026\u201d \u201cHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys\u2026\u201d The reader gets a good overall impression of the study results and the need for additional information on the efficacy of the vaccine and that repeated dosing may be needed. The last sentence summarizes the study well, \u201c\u2026we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation.\u201d", "answer": 1}, {"article": "\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nTwo studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story nicely explained that while one of the new studies showed, as expected, that following the updated statin guidelines did increase the number of people who would be treated with statins, following the guidelines would apparently not have saved a significant number of people from dying or having a heart attack\u00a0or stroke. The story said, \u201cAmong the people eligible for statins under the old guidelines, 6.9 percent had a heart attack or\u00a0stroke\u00a0or died from coronary disease over the ensuing nine years. Among those eligible for statins under the new guidelines, the figure was 6.3 percent, almost as high.\u00a0That suggests that the new guidelines do not lead to treatment of many more people who do not need statins.\u201d\nAt the same time, the story noted that the new guidelines \u201cover all did a better job in discriminating between those who should and should not get statins.\u201d It said that \u201conly 1 percent of participants deemed ineligible for statins under the new guidelines had a heart attack or stroke over nine years, compared with 2.4 percent of those ineligible under the old guidelines.\u201d\nWhile an NBC story also used absolute numbers in talking about the potential benefits in terms of heart attacks, we liked the greater level of context provided in the Times piece. Nevertheless, we think it would have been useful for the Times to include the Number Needed to Treat in its discussion of benefits \u2014 \u00a0this is an easy-to-understand metric that was reported in the study. In addition, we question the Times\u2019s contention that the new criteria \u201cdo not lead to treatment of many more people who do not need statins.\u201d According to the study, approximately 94% of both guideline groups did not have a cardiovascular event, and yet the new criteria now extend the use of statins to much larger number of people. In light of such findings, it\u2019s unclear that the new criteria don\u2019t lead to unnecessary treatment for more people as the Time states. We wish the story had explored this result more thoroughly.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nResults demonstrated that 95\u201399 percent of patients who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting the patients\u2019 infections had been cured.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nThe safety and efficacy of Epclusa for 12 weeks was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis).\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes results from Phase III clinical trials in about 1,600 patients showing a benefit.\n\u201cResults demonstrated that 95\u201399 percent of patients who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting the patients\u2019 infections had been cured.\u201d\nThe release also notes that after 12 weeks, 94 percent of patients with more advanced disease who received Epclusa in combination with ribavirin showed no virus in their blood.", "answer": 1}, {"article": "Prostate cancer is the most common cancer among men.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\n\u201cFocal therapy of individual prostate-cancer lesions, regardless of whether they are multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early freedom from clinically significant prostate cancer,\u201d the authors concluded in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that \u201cOverall, about 95% of the men were cancer-free after a full year following the trial.\u201d But, again, that may have been an incomplete picture.\nThe Lancet article indicates that this includes 4 men who required retreatment.\u00a0 \u201cCancer-free\u201d is based on MRI results.\u00a0 Most men were also biopsied after 6 months to determine whether there was microscopic evidence of cancer and 9 of 39 did have evidence.", "answer": 0}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nAll told, costs can easily exceed $40,000, money Montoro doesn't have.\nBut the limit is tricky to impose.\nStill, Widra would like a larger-scale, longer-term track record.\nIt's not clear when \u2014 or if \u2014 a big-scale study might happen.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Yes. The story is generous with describing the potential benefits.", "answer": 1}, {"article": "The first CT scan was OK.\nBut the authors of the study say CT screening can be a cost-effective way of detecting lung cancer \u2014 one that could dramatically lower cancer death rates.\nSays Henschke: \"This is a way of finding it early and taking it out early, because it is a much better chance of being cured from the disease.\"\nOne problem: Chest CT scans, which usually cost about $300, typically are not covered by insurance.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of screening. Furthermore, highlighting a patient who had symptoms is inappropriate in this situation. The purpose of screening is to find people before they have symptoms, not after, when treatment is less likely to be helpful. Also, the story implies that the test can save lives, a fact that is still uNPRoven.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nTwo studies out Wednesday in the New England Journal of Medicine report on patients given monthly injections for two years.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\nAnd patients may need to continue treatment.\nPeople with macular generation have to look at the world through a magnifying glass,reports.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides estimates of benefit for the drug group only. The story should have given the estimates of benefit for both the drug group and the control group.", "answer": 0}, {"article": "Their average age was 69.\nIn this phase 3 trial funded by the drug's maker, Radius Health, fewer women on the injectable drug abaloparatide had spine fractures (0.58 percent) than women receiving a placebo (4.22 percent) and slightly fewer than those taking a similar injectable drug, teriparatide (Forteo) (0.84 percent).\nWomen taking abaloparatide also had fewer other types of fractures (2.7 percent) than those who got a placebo (4.7 percent) and slightly fewer than those on Forteo (3.3 percent), the researchers found.\nFor the study, Miller and colleagues randomly assigned nearly 2,500 postmenopausal women with osteoporosis to receive daily injections of abaloparatide, Forteo or a placebo for 18 months.\nAmong the nearly 2,000 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a\u00a0good\u00a0job discussing\u00a0the quantitative evidence from the study. (The few missteps, which are actually quite critical in their nature, were related to a not-entirely-adequate grasp of the study design. This we discuss in detail in a separate criterion, Quality of Evidence, below.)\nThe story discusses several measures by which the effectiveness of abaloparatide was compared to the placebo (and Forteo), including the number of spine fractures, the number of other types of fractures, and the number of cases of hypercalcemia. And it does so using actual numbers. For example:\n\u201cFewer women on the injectable drug abaloparatide had spine fractures (0.58 percent) than women receiving a placebo (4.22 percent)\u2026\u201d", "answer": 1}, {"article": "In 2015, he was ranked the No.\nThey looked at data from non-Hispanic, white or black women; Hispanics were not included because Hispanic white women have substantially lower mortality than non-Hispanic whites, and the number of Hispanic blacks is small.\n\u2022 10-year risks were more than three times higher among white and more than two times higher among blacks aged 69 to 84 years with no or irregular screening compared with annual screening.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the study revealed that \u201cblack and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\u201d\nThe implication is, of course, that having a mammogram during those years and receiving treatment for it (surgery, chemotherapy, radiation) lowers the risk of dying from breast cancer.\nHowever, the release doesn\u2019t tell us how many women went on to receive a cancer diagnosis, how many received any treatment and if so, what kind. The study is observational and doesn\u2019t prove that annual mammograms in elderly women extends life.", "answer": 0}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nMany of her participants said that sometimes it felt like their pets could sense when they needed help the most, and were able to provide it \u2014 just like the owners took care of them.\nHe feels this study is important because, although there's a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\nMany of the study participants are unemployed because of their illness, she notes.\nThis may be especially true for people with serious mental illness, a study finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits associated with pet ownership for patients with schizophrenia or bipolar disorder\u2013perhaps because the study being reported on doesn\u2019t quantify benefits. But, in this case, where the benefits can\u2019t be quantified, the story should tell us why that\u2019s case (i.e. the researchers didn\u2019t systematically measure the effects of pet ownership). What the story does instead is essentially present a series of anecdotes from people who are already benefiting from pet ownership, which isn\u2019t reflective of the full range of experiences.", "answer": 0}, {"article": "The Lasker Foundation, which is based in New York, praised their work in the development of artificial heart valves, saying they had \u201cprolonged and enhanced the lives of millions of people with heart disease.\u201d\n\nIn the November 2009 bulletin of the Acad\u00e9mie Nationale de M\u00e9decine, Dr. Carpentier wrote that, instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\nOthers are in development.\nGray Jr., the University of Louisville professor of surgery who implanted the first AbioCor heart in 2001, said.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data, no evidence of any kind provided. ", "answer": 0}, {"article": "He is a professor of fetal medicine at Kings College Hospital in London.\nJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nThe new study looked at an aspirin dose of 150 milligrams (mg) per day because some past studies with smaller daily doses of aspirin have produced conflicting results, according to Nicolaides.\nWomen who delivered at less than 34 weeks were 82 percent less likely to have preeclampsia if they were taking 150 mg of aspirin, Nicolaides said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offered, \u201cJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\u201d We appreciated that this was given in absolute terms, instead of just percentages, so we could get clearer sense of the impact.\nHowever, the story does not make it clear that this is referring to women who delivered at or\u00a0before 37 weeks.\nThis is important because for deliveries that occurred after 37 weeks (which is when most preeclampsia develops), there\u00a0was no statistically significant benefit to taking aspirin. In this group, preeclampsia affected 53 of the women in the aspirin group and 59 in the placebo group.", "answer": 0}, {"article": "\u201cWhat we\u2019ve been able to show in our advanced cancer studies of men with prostate cancer and women with breast cancer, is when they have tumor in their bone that Prolia is more effective than the best available therapy at delaying significant fractures or other skeletal-related events,\u201d Perlmutter said.\nAmgen shares rose to $52.92 in extended trading from their Nasdaq close at $50.76.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nInvestors greeted the good news by sending Amgen shares more than 4 percent higher in after-hours trading.\nProlia, or denosumab, was compared with Novartis\u2019 Zometa in late stage clinical trials of advanced cancer patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nThree patients described sensations of smell (including reports of onions, antiseptic, sour and fruity aromas) as a result of the stimulation.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release suggests that this is a \u201cbreakthrough for human patients.\u201d \u00a0None of the participants (incorrectly referred to as patients) in the study had lost their sense of smell, so none could have their sense of smell restored. The release notes that three of the five participants who underwent the experiment reported sensations of smell when their nerves were stimulated by electrodes. Importantly, the release neglects any qualification or description of the sensations. \u00a0The manuscript notes the smells as \u201conion like,\u201d \u201d fruity but bad,\u201d \u201cantiseptic like\u201d and \u201csour.\u201d \u00a0Yes, electrical stimulation did create smells but creating de novo smells is hardly a benefit.\u00a0 Indeed the sensation of smells where none are present is referred to as olfactory hallucination.", "answer": 0}, {"article": "The F.D.A.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\nHe cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\nThat covers fewer than 10 percent of the patients who currently undergo carotid surgery, which is routinely covered by Medicare and commercial insurance plans.\nBy far the most important such trial under way is the Carotid Revascularization Endarterectomy Versus Stenting Trial, commonly known as Crest.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mentions 10% risk of stroke or death following stenting, though data source is not mentioned. Mentions side effects without \nrates. Includes report from one patient of perceived benefit. Therefore incomplete.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that a mother getting a Tdap vaccine in her third trimester cuts the risk by 78% of a baby less than 2 months old of getting pertussis \u2014 and that even when a mother-vaccinated baby did get the disease, 90% of cases were mild.\nHowever, the story cites risk numbers calculated from odds ratios \u2014 a statistical concept that most readers are not familiar with. A clearer way to present the results would have focused on absolute numbers. For example: 7% of vaccinated mothers had babies who contracted pertussis within the first 2 months of life, and 90% of those cases were mild. A comparison of unvaccinated mothers showed the infection rate to be about 43%. That said, this was a retrospective case control study, which can have many \u201cconfounders\u201d that could have affected the results (see evidence quality, below).", "answer": 0}, {"article": "It looks for blood in the stool, which can arise from colon cancer.\nBut gastroenterologists say that, if nothing else, the study points up the paucity of evidence for the common suggestion that anyone who had a clean bill of health from a colonoscopy is almost totally protected for at least a decade.\nStill, he said, that does not mean that patients should have more frequent colonoscopies.\nCT colonoscopies, so-called virtual colonoscopies, are not a solution, some screening experts said.\nThere is no evidence, he added, that a virtual colonoscopy will help with the inspection process.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the mortality benefit from colonoscopy screening. But we wish the story had quantified the benefit in absolute rather than relative terms.", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\n\"Participants on the very-high-fat diet also had substantial improvements in several important cardiometabolic risk factors, such as ectopic fat storage, blood pressure, blood lipids (triglycerides), insulin and blood sugar.\"\n\"The very high intake of total and saturated fat did not increase the calculated risk of cardiovascular diseases,\" says professor and cardiologist Ottar Nyg\u00e5rd who contributed to the study.\nBut even with a higher fat intake in the FATFUNC study compared to most comparable studies, the authors found no significant increase in LDL cholesterol.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not use many numbers to quantify the benefits of consuming one diet over another. For example, it states:\n\u201cIn the randomized controlled trial, 38 men with abdominal obesity followed a dietary pattern high in either carbohydrates or fat, of which about half was saturated. Fat mass in the abdominal region, liver and heart was measured with accurate analyses, along with a number of key risk factors for cardiovascular disease.\n\u201cThe very high intake of total and saturated fat did not increase the calculated risk of cardiovascular diseases,\u201d says professor and cardiologist Ottar Nyg\u00e5rd who contributed to the study.\u201d\nThe italicized words reflect where some quantification would have helped the release. What does \u201chigh\u201d refer to? Which measuring tools were used to assess fat mass in the abdomen, liver and heart?", "answer": 0}, {"article": "Markar is from Imperial College London in England.\nBoth tend to be diagnosed at a late stage and the five-year survival rate for the two cancers is 15 percent, the researchers said.\nTUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\nIt was 85 percent accurate in detecting these cancers in more than 300 patients, the new study found.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were glad that the story did provide a number, which was that the test seemed to be \u201c85 percent accurate.\u201d But, that\u2019s not enough information, because this is trickier than it sounds. Health professionals need to know both a diagnostic tool\u2019s sensitivity \u2014 which is how good the test is at positively identifying people who actually have the problem \u2014 and the tool\u2019s specificity \u2013 how good the test is at ruling out people who don\u2019t have the problem. Presumably, the breath test has an 85 percent success rate in regard to its sensitivity (though that\u2019s not entirely clear). But we don\u2019t know the\u00a0tool\u2019s specificity \u2014 and it\u2019s difficult or impossible to tell how useful a diagnostic tool is without understanding both. (According to the news release, the test had a sensitivity of 80 percent and a specificity of 81 percent.) And, as well, this test was performed on people who had advanced cancer\u2013not early cancer\u2013which may not be as detectable, and the numbers may be different.\nYet, the story quotes a researcher (in a line from the news release) as saying that the breath test could mean earlier diagnosis and treatment of stomach and esophageal cancers, with a higher survival rate. This is speculation\u2013we don\u2019t know if this test picks up early forms of these cancers, nor if earlier detection means a higher rate of survival, or just getting bad news earlier. The accuracy of the test when used to detect early cancer in healthy-seeming people is also likely to be far lower, as our review of the news release points out in some detail.", "answer": 0}, {"article": "For more information go to GetAwair.com.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not only are the benefits not quantified, but the potential benefits are not clearly defined at all. Instead, the story makes statements like \u201c[Awair] can help you breathe easier by tracking air quality.\u201d But what are the benefits of knowing the air quality levels via this device compared to other monitors? Or no monitors at all?", "answer": 0}, {"article": "She had taken care of her husband for the last eight years of his life, through his blindness, through cancer and heart failure.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had terrible pangs of sadness and despondency.\n\u201cI volunteered, to get myself out and doing things, to fill the gaps,\u201d she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains how the participants in one small study were randomly assigned to different kinds of psychotherapy. The group receiving what is called \u201ccomplicated\u201d therapy showed more than 70 percent\u00a0 \u201cmuch improved\u201d or \u201cvery much improved\u201d in the severity of their symptoms and impairment, compared with 32 percent in the standard psychotherapy group. That\u2019s a useful and user-friendly way to characterize the results. Much better than saying something like, \u201cMore than twice the number of patients receiving complicated therapy saw significant improvement,\u201d which is how many stories might have put it.", "answer": 1}, {"article": "\u201cObviously it\u2019s something we need to worry about, but if you apply it to a population that\u2019s suitable for diagnosis you wouldn\u2019t run that risk,\u201d he said.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis.\nIn an editorial accompanying the study, however, experts wrote that using CT scans to gauge bone density could lead to some people being incorrectly diagnosed, particularly if people at low risk are tested.\nThe panel also suggests younger women at an increased risk for bone fractures should be screened, but there\u2019s no recommendation for men of any age.\nCT scans, however, are considered overused - with more than 80 million performed in the U.S. during 2011.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never actually described the sensitivity, specificity or positive predictive value of CT scans \u2013 something described clearly in the study on which the story is based.\u00a0 Granted, this can get to be complicated stuff, but we think the story could have tried.\nThe benefit of the strategy of using CT scans obtained for another purpose to also diagnose osteoporosis could have been discussed in more detail. The article correctly notes that CT scans are regarded as an overused test.\u00a0CT overuse carries the harms of\u00a0 radiation exposure, costs and risks associated with additional testing for incidental findings that are more often than not clinically unimportant. The notion that\u00a0these downsides of an overused technology can be mitigated by the benefit of picking up a small number of cases of osteoporosis seems like a stretch.", "answer": 0}, {"article": "With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the \"success stories\" of modern cancer treatment.\nThat could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.\nThe investigators found that patients in either arm responded very well overall to treatments, but those in the high dose group had a significantly better outcome, by 5 to 6 percent, which translated into a significantly decreased relapse rate for these patients.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThe high-dose methotrexate protocol outlined in the study - along with a parallel finding that the steroid decadron is beneficial for younger (but not older) patients - has quickly become the standard practice for the treatment of high-risk ALL patients in North America, the researchers report in the April XX issue of the Journal of Clinical Oncology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that patients receiving high doses of the drug methotrexate \u201chad a significantly better outcome, by 5 to 6 percent\u201d than did patients receiving the current standard of care, which is gradually escalating doses of the drug. The release also explains that patients nine years old or younger who were also treated with a steroid called decadron (dexamethasone) for\u00a0half as long as normal (14 versus 28 days) benefited from the treatment while patients 10 and older did not.\nWe\u2019re not sure of the meaning behind these results as portrayed in the release. Which outcome was better by 5 or 6 percent? The study has several. Does that mean the relapse rate was reduced or is it the event free survival that was better? It would be more meaningful to readers if the release had included the actual relapse and event free survival rates for each group analyzed in terms most people can understand. For example: \u201crelapse rates were 5 percent lower in Group X compared to Group Y.\u201d", "answer": 0}, {"article": "Earlier this year, dementia overtook heart disease as the leading cause of death in England and Wales.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\nDavid Reynolds, chief scientific officer at Alzheimer\u2019s Research UK, said: \u201cIt is conceivable that changing brain cell rhythms could be a future target for therapies, but researchers will need to explore how light flickering approaches could not only reduce amyloid in the visual area of the brain but in those areas more commonly affected in Alzheimer\u2019s.\u201d\n\nThe authors suggest that it may be possible to take a multi-sensory approach, using a combination of flashing lights and vibrating chairs.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research under consideration here involved mice \u2014 and genetically bred mice at that \u2014 there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to quantify the likely benefits for human.\u00a0The story does acknowledge this. But in the process, it also overstates what is known about the causes of Alzheimer\u2019s and therefore how relevant this approach is to treating it. The story states flatly that \u201ctoxic proteins\u201d are the culprit, but this is the subject of much debate within the Alzheimer\u2019s research community and increasing evidence points against it.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nBut a study led by a Loyola Medicine thoracic surgeon has found just the opposite: Patients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\nPrior to surgery, 31 percent of the patients had a performance status score of 0 (fully functional); 65 percent had a performance status score of 1 (able to do light house work or office work); and 4 percent had a performance status of 2 (ambulatory and capable of self-care, but unable to work).\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives the impression that all patients experienced improved quality of life after surgery: \u201cPatients who underwent an operation called pleurectomy and decortication (PD) generally reported their quality of life improved after surgery.\u201d It also states, \u201cImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\u201d In the abstract, however, researchers explicitly state that not all patients experienced a benefit. For example, pain, fatigue and insomnia were worse at 1 month in all groups, while overall global health worsened at the first post-operative month, according to researchers. In one subset of patients, quality of life remained unchanged, while functional domain, physical functioning, role functioning and social functioning deteriorated at 1 month. \nIn the abstract, researchers conclude that quality of life was not significantly better among patients with epithelioid (a type of immune cell) histology, pre-operative performance status of 0 and tumor volume <600 mL. But the news release didn\u2019t include these findings but instead cited only the positive cases, ignoring the fact that all patients experienced worsening symptoms at 1 month.\u201dQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 mL or a type of tumor cell called non-epithelioid,\u201d it states. \nDue to all these factors, we give it a \u201cNot Satisfactory\u201d rating here. ", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers of this story are likely to get an exaggerated sense of the benefits of this drug. As noted above, the preliminary trials completed so far did not produce evidence of improved outcomes or survival, nor did those trials include any comparison of the new treatment with existing alternatives. The story reports that \u201ctumors disappeared, shrank or stopped growing in just over half of patients for nearly two years on average.\u201d The drug label indicates that tumors \u201cdisappeared\u201d in only three patients out of 255. The story reports on two patients who gave glowing reports of their responses, but there were no quotes from more typical patients who had limited, if any, responses or who endured serious side effects. The story then includes a reference to the short survival of typical lung cancer patients, without included the necessary caveat about the unreliability of such historical comparisons.\nThe one-sided reporting provides an unbalanced view of the drug\u2019s potential benefits. The story should have been clearer that the main reason this drug received conditional approval is that there is a reasonable likelihood of benefit; and that we won\u2019t know if that benefit is real until the ongoing trials are completed.", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nWhile response rates were moderate, TMS is a welcome addition to the therapeutic repertoire especially for patients who do not respond to medication.\"\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cresearchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded.\u201d Of equal importance, the release clearly defined what \u201csignificant response\u201d meant: \u201ca more than 30% decrease in the Total Auditory Hallucinations Rating Scale score.\u201d In addition, the release quotes one study author\u2019s qualification of the finding: \u201ctreatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term.\u201d That\u2019s good context.", "answer": 1}, {"article": "Watching her patients undergo bone marrow transplant ?\nGiving these cells when disease is in remission after transplant \"might actually be helping patients who have a high risk of relapsing to not relapse down the line,\" said Dr. Aude Chapuis, cancer physician and immunotherapy researcher at Fred Hutch, one of the study's leaders.\nThe findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports that all 12 participants in the trial (those who received the T-cell therapy after a transplant) remained in remission during a median follow-up period of more than two years, while more than a quarter of transplant-only patients relapsed within 10 months. Although that seems like clear quantification of benefits, there are many examples of cancer treatments that have produced higher remission rates, but ultimately failed to help patients live longer or better. To be clear, we have no problem with the release reporting on the surrogate outcome, which may be the only measure available to estimate the treatment\u2019s effects in these patients. However, we believe that the release should have cautioned that the remission rates do not necessarily predict survival or even quality of life\u2026and that these factors, the ones that really matter to patients, will be measured only in future experiments.", "answer": 0}, {"article": "; Walter Rocca, M.D.\nIn the study, women with APOE e4 \u2014 one form of the most common gene associated with late-onset Alzheimer's disease \u2014 had lower levels of amyloid deposits.\nOf the 68 women, 21 received estrogen via a skin patch, 17 received estrogen orally and 30 received a placebo.\nThe authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.\n\n\u201cIf our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer\u2019s disease field today,\u201d Dr. Kantarci says.\nResearchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the news release summarizes the pattern of results\u2014that recently postmenopausal women who received estrogen via a skin patch were found to have \u201clower\u201d amyloid depositions in their brains relative to those who took estrogen by mouth or who were in the placebo group\u2014that pattern is not explained in any numerical or statistical way.\u00a0 Is it a strong association?\u00a0 A weak one?\u00a0 We have no idea from the release.\nAccording to the published report, the benefits were statistically significant but the sample size was too small to be meaningful. Just 21 of the enrolled women received the patch, 30 received a placebo and 17 received estrogen orally.", "answer": 0}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\nBy 1999, more than 115 gene therapy clinical trials were approved in the U.S, ranging in illnesses from cancer to blood disorders to graft-versus-host disease.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\nAAVs are not quite as efficient as adenoviruses at getting genes into human cells, but they are much safer: The human immune system barely notices the virus\u2019s outer coat or \u201cdress,\u201d as Gao calls it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports chiefly on what appear to be full recoveries in some mice engineered to have genetic deficiencies, but we\u2019re given no details on the quantified results nor any words of caution on the limitations of extrapolating these benefits to humans. For the one human research trial that\u2019s discussed (for a vision disorder unrelated to Canavan disease), we\u2019re\u00a0told 21 vision-impaired patients experienced \u201cmaximum possible benefit\u201d of vision restoration, a description that sounds like good news, but falls short of quantifying the actual benefits.", "answer": 0}, {"article": "\u201cIt\u2019s an interesting idea,\u201d he said.\nFor example, they wrote, if a scan showed advanced disk deterioration, the report should say, \u201cRoughly 40 percent of patients with this finding do not have back pain so the finding may be unrelated.\u201d\n\nIt is an idea that only would work for back pain, because that is the one area where radiologists have enough data.\nIf you are a 60-year-old guy, the chance that you have a meniscal tear is 40 percent.\u201d\n\nIt is a result that paralleled what spine researchers found over the past decade in what is perhaps the best evidence on what shows up on scans of healthy people.\nBut in many cases it is just not known whether what is seen on a scan is the cause of the pain.\nBut even the data on knees comes from just one study, and researchers say the problem is far from fixed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not say how many meniscal tears were found on MRI in the current study. The story could have also\u00a0said that there have been no randomized trials of MRIs for knee pain that quantify the benefits and harms of such a management strategy.", "answer": 0}, {"article": "Therefore investigators recommended that only patients who are younger than 76 years old, and who do not suffer from other health problems use FOLFIRINOX.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nThe study is published in this week\u2019s issue of the New England Journal of Medicine.\nThe purpose of the study was to record the overall survival rates of each group.\nThe treatments lasted for six months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story barely explained the benefits seen in the study, and failed to put them into the context of what pancreatic cancer patients face as well as the competing USA Today story did.", "answer": 0}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All the stories reported the results in absolute terms, which emphasizes for readers that the study is very small and that even though most people ultimately had better vision, we are still only talking about 10 people.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tough call. The story reported that the drugs \u201cappeared to be equally effective. About half the patients had a 50 percent or greater reduction in the number of headaches they experienced. Almost three-quarters had at least a 30 percent reduction.\u201d\nThat\u2019s not really enough information to assess the benefits (what was the frequency of headaches per month?), but the story follows that up with:\nIt also reported that chronic migraine patients \u201chad about two fewer headache days a month than those who took placebos. The placebo group had a small reduction in headaches, too. In the treatment groups, the intensity of the headaches also went down.\u201d\nWhile this is more informative, it still doesn\u2019t give readers a sense of the scope\u2013how many migraine days were people experiencing before taking the drug, and then after? What about the placebo group?\nFor example, in a trial for Emgality, patients who averaged 19.4 migraine days per month saw their migraine days reduced by 4.8 or 4.6 days per month depending on their dosage, versus a reduction of 2.7 days for those who took a placebo.\nThis gives a more specific sense of the benefits than what the story included. It\u2019s especially interesting to see how the drug compared to the placebo.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify how effective liver transplants are or how effective various treatments are at reducing non-alcoholic cirrhosis of the liver. \u00a0While the two cases reported on were said to demonstrate relief of symptoms \u2013 one child being treated with a liver transplant and the other child being treated with lifestyle change \u2013 the story did not indicate how successful either approach was in a broader population. \u00a0Although it mentioned that the boy who had the liver transplant had not been successful with his weight loss efforts to date, there was no discussion about what that might mean in terms of longer term prognosis for his new liver.", "answer": 0}, {"article": "\"Our goal is to reach 100 percent.\"\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\nCompared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often.\nAnd that early screening also means that colorectal cancer can be treated more effectively.\nIt joins six other tests, including the traditional colonoscopy and the new CT colonography, or virtual colonoscopy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article says that experts at the American Cancer Society have added the newly recommended stool DNA screen to its screening guidelines because many people are averse to the leading alternative\u2013invasive, inconvenient, and expensive colonoscopies. But when it says the screen is \u201ca huge step forward\u201d that can \u201csignificantly increase the rate of detection,\u201d the story\u2019s quantification of benefits is more hype than help. By how much will this screen reduce the likelihood that someone will die of colorectal cancer? How many people over the age of 50 will need to be screened\u2014for how long, and how often\u2014to prevent one death by colon cancer? How does that compare to other screening methods? (For example, with the traditional fecal occult blood test, about 1000 people over the age of 50 must be screened for 10 years to prevent one death from colon cancer.) Is there evidence that \"you could reach a lot of people and prevent deaths from happening every day of the year\"? Compared to other methods, is there any added benefit for people whose genetic makeup increases their likelihood of colorectal cancer?\u00a0", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nImportantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.\"\nPatients also experienced a significant improvement in quality of life.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201cdata from clinical trials showed that patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function. Patients also experienced a significant improvement in quality of life.\u201d\u00a0 All is good, but what was the magnitude of benefits and, more importantly, \u201ccompared to what\u201d?", "answer": 0}, {"article": "The Hass Avocado Board (HAB) is an agriculture promotion group established in 2002 to promote the consumption of Hass Avocados in the United States.\n(See conclusion of study)\n\n\"Interestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\" says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\nAdditionally, avocado consumption did not impact \"good\" high density lipoprotein cholesterol (HDL).\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are several benefit claims but no quantification is provided. For example:\n\u201cResearchers found avocado consumption (1 to 1.5 per day) significantly reduced total cholesterol (TC), \u201cbad\u201d low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) when they were substituted for sources of saturated fat.\u201d\nHow much is a significant reduction? From what level to what level?\n\u201cInterestingly, our results indicate that even healthy subjects with a relatively normal baseline TC (100 to 240 mg/dL), LDL-C (75 to 150 mg/dL), and TG (50 to 175 mg/dL) had significant reductions,\u201d says Sachin Shah, PharmD, corresponding author and expert in cardiovascular health.\u201d\nAgain: what were the actual reductions?\nStatistically significant findings are not the same as clinically important findings, and the public needs to know how much cholesterol reduction was found in the study. It would also be useful to point out that cholesterol changes do not necessarily equate to reduced risk of actual heart attacks and strokes.", "answer": 0}, {"article": "The patients were selected at random from a national database.\n\u201cWe found cancer was more commonly diagnosed in men with raised platelet counts than it was in women with raised platelet counts and we believe that is because there are more causes of raised platelet counts in women that are not cancer,\u201d said Bailey.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\nFor about a third of cases of lung and colorectal cancer in patients with thrombocytosis, there had been no other symptoms that raised the suggestion of cancer.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s author did a good job of describing the numbers of patients whose data were\u00a0drawn from a national database, and the percentages across ages and genders who were identified with some form of cancer within a year of a high platelet count, compared to percentages of who were not diagnosed with cancer. It also noted the rate of cancer diagnosis in the general population overall as a comparative factor. There were also data given about the types of cancer most diagnosed and the potential impact for early diagnosis. The thoughtful reader will come away with the notion that even if platelet counts are utilized widely, they are not going to serve as markers for\u00a0most cancers that arise in adults.\nOne thing the story needed on this note was\u00a0better framing on how these results differed by age. Our\u00a0concern is there may be unnecessary anxiety for some people to pressure their doctor into performing a platelet count beginning at a young age that may not be necessary.", "answer": 1}, {"article": "Others had them two to three times a week.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nFor the study, researchers recruited 338 people who had vertigo with an unknown cause.\nThe researchers followed the new vertigo patients for an average of 12 years.\nThey were compared to 35 others whose vertigo is triggered by other conditions, including the inner ear disorder Meniere's disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to provide clear information on benefits.\u00a0 It does effectively quantify the number of patients in the study thought to have this new form of vertigo \u2014 35 \u2014 and also cited how many patients with it who appeared to benefit from the unnamed medication \u2014 one-third of 20.\u00a0 It\u2019s worth noting that those suspected of having this new form of vertigo comprise only 10 percent of those recruited in the study, and only two percent of the total recruited were successfully treated by the unnamed medication.", "answer": 0}, {"article": "So our recommendation is not to consume any alcohol at all,\" Pressman tells WebMD.\nOct. 5, 2010 - Pregnant women who have up to two alcoholic drinks per week do not harm their children, a U.K. study shows.\n\"Our results suggest that children born to mothers who drank at low levels were not at any risk of social or emotional difficulties or any risk of emotional impairments compared to mothers who did not drink,\" Kelly tells WebMD.\nChildren in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\nIn the U.S., pregnant women are strongly advised not to drink at all, says Eva Pressman, MD, director of maternal/fetal medicine at the University of Rochester, N.Y.\n\nPressman points out that women who are light drinkers during pregnancy tend to be from households with relatively high incomes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide readers with specifics. It reports that the children of light drinkers did not appear to have a greater risk of behavioral problems than the children of women who reported not drinking during pregnancy. But what are the risks of problems? Readers are not told. Including a few statistics, for example that the rate of high total difficulties was about 7 percent for sons of light drinkers vs. about 10 percent for sons of non-drinkers would have revealed both the differences and provided a sense of the overall risk; that is, that in both groups the overwhelming majority of children appeared to be fine. In fairness, the main and most reliable finding of the study was failure to show an association between light drinking and adverse behavioral/cognitive effects.", "answer": 0}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides one surgeon\u2019s average fat-grafting and stem cell survival rate, about 54%.\u00a0\u00a0 The story notes current research on this new fat-grafting to determine short and long-term health and cosmetic outcomes.\u00a0 The story clearly and carefully explains the procedure and the rationale for the addition of stem cells to a transfer of a woman\u2019s fat to her breast tissue. The story notes that the makers of a machine that would mix fat and stem cells more effectively is sponsoring tests in Europe and is proposing tests in the U.S. ", "answer": 1}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\nThis one has a small number of outcomes (only 35 incident cases of breast cancer), the women were not all screened for breast cancer with mammography, they were not blinded to the type of diet they were receiving, and all were white, postmenopausal and at high risk for cardiovascular disease.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release points out that the participants following the Mediterranean Diet supplemented by EVOO experienced a 68 percent lower relative risk of breast cancer than did the control group. While that\u2019s one way to report the findings, we always ask that stories also include a measure of the absolute risk, which provides important additional information to help readers gauge the size of the benefit. These absolute risk figures were reported in the study abstract and could have easily been included in the release as well. The researchers found breast cancer rates of 1.1 per thousand people per year in the Med Diet plus EVOO group, 1.8 per thousand people per year in the Med Diet plus nuts group, and 2.9 per thousand people per year in the control group.", "answer": 0}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nA study by researchers at the Nicholas Institute of Sports Medicine and Athletic Trauma, Lenox Hill Hospital in New York demonstrated this benefit.\n(Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\nAnd the FlexBar makes it simple to do this kind of stretch.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes no attempt to quantify the benefits associated with the FlexBar, and we don\u2019t think linking to the study abstract is sufficient to satisfy this criterion (especially when the full text of the published study is also available online). The average reader can\u2019t be expected to interpret differences on a \u201cvisual analog pain scale\u201d or \u201cDASH questionnaire\u201d without some explanation of what these measures mean.", "answer": 0}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThose who took the highest doses saw their recurrence risk drop by half.\n\u201cIf this is the case, dosage shouldn\u2019t matter.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As explained above, there are many numbers given about the potential benefits, but it is hard to say what they all mean. A big missing piece is some explanation of what they did to \"control for other factors.\"", "answer": 0}, {"article": "Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nIn a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.\nThe next step is more testing for effectiveness against different strains of Chlamydia and in different formulations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0mentions the antigen being studied,\u00a0BD584, \u201cwas able to reduce chlamydial shedding \u2013 a symptom of C. trachomatis \u2013 by 95 per cent.\u201d Without any context for how many people (or mice in this case) were studied, we have no way of knowing what that means.", "answer": 0}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\nThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\n\u201cHowever, it has been shown that in the early stages of development, individuals have been aided by intense one-on-one caring to help them with language, social function with their peers and also with emotional problems,\u201d he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The second sentence of the story says, \u201cThe test, which uses conventional magnetic resonance imaging or MRI machines, detected 94 percent of individuals with a high-functioning form of autism, they reported on Thursday.\u201d The 94 percent number is completely out of context and exactly the kind of overstated statistic that gives readers false hope based on flimsy evidence. This was, after all, a study in 30 people with autism and 30 without.\u00a0 Unlike the CNN story we reviewed, this story fails in keeping inappropriate enthusiasm at bay. The potential benefits of such a scan can only be speculated at this stage, and readers should have been provided absolute numbers to make it clear how many people were correctly identified, at what ages and to what end.", "answer": 0}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nThis can reveal if there's an increased risk of certain disorders, but it's not very accurate and produces a lot of false alarms.\nShe didn't want an invasive procedure like amniocentesis or chorionic villus sampling.Those are considered the gold standard for prenatal genetic testing, but doctors must put a needle into the womb to collect cells that contain fetal DNA, which means a small risk of miscarriage.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\nUntil the new testing technology came along, the only less invasive option was for an expectant mother to get an ultrasound, plus have her blood tested for specific proteins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The accuracy level\u00a0of the new screening tests was described as better than existing screening\u00a0tests (blood tests plus ultrasound), but this benefit was not quantified (i.e., the screening tests can detect X disease Y% of the time compared with traditional tests, or false alarms occur for X% of new tests vs Y% for traditional screening tests). A linked study abstract provided this detail, but the jargon-filled text would be difficult for most readers to understand. A quick rundown of those numbers would have been easy to provide in the story itself.", "answer": 0}, {"article": "\u201cThe key question is, will the consumer view as credible that ingesting a pill will prevent (sun) damage?\u201d\n\nIn another experiment, Laboratoires Inneov scientists gave the tanning pill to 80 women and asked them to sunbathe as they normally would over the summer, applying sunscreen at their discretion.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nAccording to Bleiker, \u201cthe authors stated very clearly that there was no conflict of interest.\u201d\n\nHowever, more than half of the authors work for Laboratoires Inneov, as indicated on the cover page of the report.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear the expert opinions that \"there are no data there.\" ", "answer": 1}, {"article": "It's a substantial number of women,\" Lyman said.\nThe five-year \"disease-free\" survival rate was 83.9 percent in those who did not have the more aggressive surgery compared with 82.2 in those who did, the researchers reported.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThey found no significant difference in the patients' chances of surviving five years after their diagnosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The potential benefits were included in the article.\u00a0 The \u201cfive-year\u00a0\u2018disease free\u2019 survival rate was 83.9%\u2026\u201d for women who did not\u00a0have the more aggressive surgery \u201c\u2026compared with 82.2% in those who did\u2026\u201d \u00a0Because full axillary lymph node dissection did not decrease mortality or decrease disease free survival, this may no longer be the standard recommendation.", "answer": 1}, {"article": "Shares of BioTime Inc, a company that owns nearly 70 percent of Asterias, were little changed at $3.07.\nLichtinger said he was confident the data would be positive but was not expecting miracles.\nIts success is a key step toward proving that embryonic stem cell research could cure diseases such as cancer, Parkinson\u2019s and serious health conditions such immune deficiencies, stroke and spinal injuries.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We think this report could have done a more thorough job here, especially since its headline claims the stem cell therapy \u201cshows promise.\u201d We think that it is helpful to point out that this is a phase 1/2 trial and is the first cohort of patients to be enrolled.\u00a0 A very early stage in the arduous path to commercialization.\nThe only mention of benefits in this Reuters story is that \u201cseverity of the spinal injury was reduced in the first patient,\u201d but the story doesn\u2019t try to quantify his improvement. To what extent was the spinal injury reduced? And in what time frame? Since there is no control group in this study, it would have been helpful to know if patients normally experience improvements over time. The news release provides a bit more useful information in this regard with a quote from one of the investigators;\u00a0\u201cThis progress in the first patient is very encouraging and is observed in less than 5 percent of our AIS A patients at this stage of their recovery.\u201d\nThe story does include a restraining quote from the company CEO who says,\u00a0\u201cIt is important to know that we do not expect patients to get up and play basketball. But we do expect the patients to have significant improvements in mobility.\u201d But what does \u201csignificant improvement\u201d mean?", "answer": 0}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\nAmerican Cancer Society guidelines currently recommend a full breast MRI, not an AB-MR, in women who, based on family history of breast or ovarian cancer and/or previous treatment for Hodgkin disease, have a 20 to 25 percent or greater lifetime risk of breast cancer.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release described better cancer detection rates using the abbreviated breast MRI compared with mammography and 3D mammography. Unfortunately, the release didn\u2019t compare the cancer detection rate of the abbreviated breast MRI with whole breast screening ultrasound which is the current standard supplemental screening tool to use for women who are asymptomatic.\nIt remains unclear if the abbreviated breast MRI is better than ultrasound, the current standard of care.\nWhile calling out ultrasound screening for having a high number of false positives, the release offers no details on the number of false-positives for abbreviated MRI screening.\nFurther, the release offers no information about the stage of the cancers diagnosed with abbreviated MRI. Readers deserve to know how many cancers identified in the study were ductal carcinoma in situ (DCIS). Many healthcare professionals believe DCIS should be re-named because this condition refers to abnormal cells inside a milk duct in the breast, is not invasive, and there\u2019s a debate over whether it is breast cancer.  ", "answer": 0}, {"article": "\"Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?\"\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\nOAK BROOK, Ill. - Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.\nIn 73 of those 285 patients, or 25.6 percent, MRI identified at least one additional cancer in a different quadrant of the breast than the index cancer, or the cancer detected by mammography and/or breast palpation.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that potential benefits are uncertain and that the researchers\u2019 conclusions that additional cancers found through MRI imaging might justify altering treatment plans is based on a belief that tumors larger than 1 cm are clinically significant, not specific study evidence. But we believe that the release\u00a0should have specifically noted (as the journal article did) that other studies have not found benefits to treating tumors discovered through preoperative MRI, and then explained the different way this study looked at the issue.\u00a0We have no data to suggest that treatment of the additional cancers (which in the case of multicentric disease would require mastectomy) improves outcomes. We know that if we look harder for additional cancers, we will find them. What is unclear is which of the additional cancers need to be found.", "answer": 0}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nYet fewer than 10 percent of sexually active women currently rely on long-acting reversible contraception, and a major reason is doctors\u2019 reluctance to recommend them.\nOf course, some couples fail to use any contraception, but others rely on contraceptive methods that have significant failure rates even when properly used.\nOf the many embarrassing health statistics in this country, the huge number of unwanted pregnancies is perhaps the easiest to rectify.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives figures on the effectiveness of a variety of contraception methods.\nHere is an excerpt:\nIn a 2012 study of 7,486 women aged 14 to 45, long-acting reversible contraceptives, or LARCs, were shown to be 20 times as effective in preventing pregnancy than the pill, contraceptive patch or vaginal ring. The risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nAbsolute risks are also cited in the report on one-year pregnancy rate with real-world use, which is another strength of the story.", "answer": 1}, {"article": "\"We have many options for depression and need more for alcoholism, considering it is one of the most common diseases around the world.\"\nWhether the drug might someday be approved to help problem drinkers cut back remains to be seen, said the researchers, who acknowledged that the study's small size is a limitation.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nWEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nThe participants found the Chantix-booze combination increased the unpleasant effects of alcohol and reduced the rewarding aspects of drinking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead of the story misstates the results of the study. These researchers measured how a few participants felt after taking Chantix or a placebo and drinking alcohol or a placebo drink. They found that overall the participants did not feel as good after drinking a low dose of alcohol, if they had taken a Chantix pill earlier. However, they didn\u2019t see the same difference with higher doses of alcohol. This test did not look at whether these people voluntarily would change the amount of alcohol they drank when they took Chantix. The story headline and lead both focus on the possibility that Chantix could curb problem drinking. Although some other reports indicate people taking Chantix might drink less that is not what this test looked at.", "answer": 0}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nWhile the company has done studies of women taking the drug up to a year, some experts believe the long-term health profile of a drug needs to be evaluated up to seven years, Dr. Jacoby says.\nThere\u2019s some chance of recurrence with most of them.\nThe company hopes to have a product available by 2020.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article offers general statements about the \u201cdramatic\u201d and rapid effects of UA from Allergan researchers, but does not provide any numerical context or offer summaries of research with that information.", "answer": 0}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\nStudies of about 2,000 people showed Dupixent injections resulted in clear skin or nearly clear skin for about two-thirds of those who tried it, and it reduced itching sharply in 40 percent.\nActual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts, rebates or patient assistance programs,\u201d it said.\n\u201cOf the adults with uncontrolled moderate to severe atopic dermatitis in the United States, it is estimated that 300,000 are most in need of new treatment options,\u201d Regeneron said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that studies in about 2,000 people showed injections \u201cresulted in clear skin or nearly clear skin for about two-thirds of those who tried it, and it reduced itching sharply in 40 percent.\u201d\nThis is enough for a satisfactory rating, but the story should have mentioned that close to 10 percent of patients on a placebo saw the same improvement in their rash. It also would have been stronger if it had explained how the benefits were measured (how is a \u201csharp\u201d reduction in itching measured?), how much time it took to achieve the results, and if the results were sustained.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nIt\u2019s inflammation, also.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\nBy the time someone knows he or she has blocked arteries, it\u2019s too late to do much more than bypass surgery or putting in a stent to prop open the narrowed vessels.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide any data to give a sense of the potential benefit of the new approach. No numbers were given to explain how well it worked.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is insufficient detail about the benefits and how long they last. We learn that at least one urologist who has become a convert to the procedure is \u201cunsure how long the improvement will last.\u201d \u00a0The link to a study abstract\u00a0adds a bit more detail, but its not discussed much in the story. We learn that the manufacturer-funded trial found \u201cpeak urinary flow have lasted so far for five years,\u201d but no details on how this compares to controls. It is useful to know that \u201cone in 10 patients\u00a0ended up needing surgery anyway.\u201d", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\n\"No study has, however, specifically addressed the extent and type of sexual bother in this patient category.\"\nBut one expert cautioned that men are playing with fire if they tinker with their penis size simply for vanity's sake.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are discussed but not adequately quantified.", "answer": 0}, {"article": ".\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\nTUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\nThey found that benign lesions had high levels of elasticity, whereas cancerous lesions were much less elastic.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story repeats the quantification of benefits as they are presented in the press release but these differ slightly from what is published in the abstracts. The story mentions that elastography correctly identified 98% of cancerous lesions and 82% of benign lesions, however the abstract states that elastography identified 76% of benign lesions. It isn\u2019t clear where this discrepancy comes from and for that reason we must judge this unsatisfactory. The story states that these numbers are better than conventional utrasonography but provides no quantification for comparison. The story should have placed them both into context with other technologies including MRI, computer assisted detection and full field mammography as well as ultrasonography. ", "answer": 0}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nThe DNA stool test methods were developed at the Mayo Clinic.\nHowever, findings from both pilot studies need to be corroborated in larger studies,\" Ahlquist said.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did an adequate job of quantifying the benefits seen in two trials, but didn\u2019t comment on the small sample size in one study and didn\u2019t disclose the size of the sample studied in the other. ", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\n\u201cThis asthma data and the data we already have in atopic dermatitis really raises the possibility the scientific community has finally hit upon the key pathway across all these allergic diseases,\u201d George Yancopoulos, Regeneron\u2019s research chief, said in an interview.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts out by providing what appears to a quantification of the benefits of the drug saying that the \u201casthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent,\u201d and it goes on to quickly provide some much needed context by saying that the drug was studied in a trial involving 104 patients. It takes quite a while for the story to explain where that 87% number came from, and the explanation itself is a little unsatisfactory. It says, \u201c\u2019By end of the trial, after 12 weeks, 44 percent of those in the placebo group had exacerbations, compared with 5 percent of those on dupilumab,\u2019 Wenzel said. That represented an 87 percent reduction in exacerbations, which was highly statistically significant.\u201d We don\u2019t doubt that it was statistically significant, but we would have liked to have known how many patients really saw a benefit.\nHere\u2019s what the authors said in the paper:\n\u201cAsthma exacerbations occurred in 26 patients: 3 receiving dupilumab (6%) and 23 receiving placebo (44%) (odds ratio with dupilumab, 0.08; 95% confidence interval [CI], 0.02 to 0.28; P<0.001).\u201d", "answer": 0}, {"article": "To learn more about ASTRO, visit www.astro.org.\nAt two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\n\u201cThe low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer.\u201d\n\nFindings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015.\n\u201cWhile multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects,\u201d said Richard J. Cassidy III, MD, lead author of the study and a resident in radiation oncology at Emory University\u2019s Winship Cancer Institute in Atlanta.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides some data on benefits with this statement: \u201cAt two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\u201d\nSo the release is claiming that SBRT can add years to the lives of elderly patients. But the study was merely a review of a series of cases and did not actually compare SBRT to any other treatment, so it provides no direct evidence of a survival benefit. The same section of the release refers to other studies, but provides no numerical description of the benefits from the other studies. In fact, other studies have relied on comparisons to historical controls, not randomized trials, so even though SBRT has become standard care for this sort of lung cancer patient when surgery is not an option, there is a lack of evidence about the precise benefits.", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, \u201ccompounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\u201d\u00a0 But there is no information as to how these measurements were acquired, or to which of the \u201ccertain body muscles\u201d they were referring.\u00a0 And again, there is no mention of what these compounds actually were. Simply throwing out some percentages without providing an adequate context isn\u2019t helpful for readers.\nIf the release had transparently claimed that the benefits listed above applied to the \u201csedentary mice\u201d finally mentioned at the end of the release, we\u2019d still rate this criteria as Not Satisfactory. The mice were not noted to have cancer, COPD, heart failure, and other conditions which brought about wasting sickness. The findings, as such, are specific to non-human species without any of the conditions that are purported to be creating the setting for wasting.", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\nThe double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints.\nIn memory tests, the people taking curcumin improved by 28 percent over the 18 months.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions these benefits in the 21 subjects who took curcumin: \u201csignificant improvements in their memory and attention abilities (ie. \u2018improved 28 percent over the 18 months\u2019) \u2026 mild improvements in mood \u2026and their PET scans showed significantly less amyloid and tau signals in the amygdala and hypothalamus\u201d when compared to the 19 subjects in the placebo group.\nWe are told that standardized tests were used but not where the improvements were seen or how widespread the improvements were seen. Nor are we given context to answer \u201c28 percent of what\u201d? We\u2019re also given no context to understand what reduced amyloid and tau signals mean (nor what \u201csignificantly less\u201d means), only that \u201cthe amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\u201d", "answer": 0}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nThe gap was similarly wide when the researchers looked at the number of participants who no longer met the criteria for insomnia: 55 percent versus 13 percent.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nOn average, for every 2.4 participants treated, one responded favorably and one overcame insomnia, report the researchers in the Archives of Internal Medicine.\nTo find out, they studied 79 adults with chronic insomnia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story tells readers that 55 percent of people in the active intervention group no longer met the criteria for insomnia after four weeks. However, readers are not told how the researchers defined insomnia. Was it a complete inability to sleep? How frequently did the participants have trouble sleeping? How much more did they sleep after treatment? Without these and other details, it is difficult to get a feel for what effect the treatment had.\nWhile this story reported how many people needed to be treated in order to make a difference for at least one\u2026 a statistic we encourage journalists to use more\u2026 the story reported twice as many people benefited as the researchers actually said they saw. The researchers wrote that one person either had remission (no more insomnia) or response (significantly less insomnia) for every 2.4 people treated. But the story says that for every 2.4 participants treated one responded and one overcame insomnia.", "answer": 0}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nThe test could speed up the diagnosis process, saving thousands of lives.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nHowever, she stressed the fact this new test has not undergone clinical trials.\n\"In order for it to be valued by clinicians we would need to get to 90% accuracy in detection,\" she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides both sensitivity and specificity for the test and notes that both need to be in excess of 90% for it to be useful.\nOf course, there is an assumption that the test\u2013if proven to be validated\u2013would reduce deaths from melanoma due to early detection. That will take a lot more research to determine. \u201cEarly detection saves lives\u201d is not always true.", "answer": 1}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nThe abstract was one of thousands of studies released on Thursday ahead of presentation at the American Society of Clinical Oncology (ASCO) next month in Chicago.\nData from a second arm of the study is still being evaluated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThese trials did not compare the experimental drug ipilimumab to standard therapy. Although the story accurately transcribes what the researchers wrote about the potential use of the drug, it should have pointed out to readers that this sort of experiment is usually not designed to be able to answer questions about the relative benefits of the experimental intervention.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nNor will it work very well in someone who has severe nasal allergies and has a blocked nose at night, said one of the leaders of the Provent studies, Dr. Meir H. Kryger, a professor at Yale Medical School and founder of the National Sleep Foundation.\nTests showed that in a typical night, Mr. Bleck, 47, awoke or stopped breathing 42 times an hour.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nLast year, in a large study of 250 apnea sufferers published in the medical journal Sleep and subsidized by Ventus, researchers found that those who used Provent devices over a three-month period saw their apnea episodes fall sharply, compared with people who were given a sham, or placebo, device.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story references \u201ca large study of 250 apnea sufferers published in the medical journal Sleep and subsidized by Ventus,\u201d the maker of the Provent patch. But it fails to quantify the benefits found in this study. Instead it says \u201cthose who used Provent devices over a three-month period saw their apnea episodes fall sharply, compared with people who were given a sham, or placebo, device. A follow-up study tracked people over the course of a year and had similar results.\u201d\nLet\u2019s put this in perspective:\u00a0 One of the patients profiled in the story awakened 42 times a hour prior to using the Provent device.\u00a0 Subjects who used the Provent device in the published study reduced awakenings by about 50%.\u00a0 So someone like Mr. Bleck would be expected to reduce awakenings to ONLY 21 per hour.", "answer": 0}, {"article": "\u201cIt\u2019s like eating a whole bottle of Tums every day,\u201d Dr. Evans said.\nOne serious uncertainty is whether, in the mouse experiments, resverattrol in fact acted through the sirtuins or by some other unknown mechanism.\nThis is an ancient strategy, Dr. Guarente believes, that allows an organism to live through famines and postpone breeding until good times return.\nThough his mice did not lose weight, they lived far longer than undosed mice that were fed the same high-calorie diet.\nDr. Auwerx cites evidence that resveratrol does activate sirtuin, but Dr. Evans said the case was not yet fully convincing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The opening statement of the story, discussing 100% improvement in performance takes results observed in a single study of mice and extrapolates to humans.\u00a0 Later in the story, there is mention of a 30% increase in lifespan in mice, though these results are again\u00a0from a study of a single strain of mice. (Strains of mice are genetically identical individuals and therefore results observed in a single strain need confirmation in several strains before it can be concluded that the results are generalizable to the entire species.)\nMention of a genetic analysis of different forms (alleles) of a human gene and energy expenditure was based on a very small study and in itself should not be seen to imply that the mechanism in mice and humans was the same as stated in the story.", "answer": 0}, {"article": "New Zealand's scrubby manuka trees with their creamy blossoms used to be chopped down for farmland.\nHence the hope that a naturally occurring substance such as honey might help fill the void.\nThe most promising research, he and many other scientists say, focuses instead on bioactive honey's potency as a topical application.\n(And there's wide agreement among medical professionals that people should not test the treatment themselves by slathering their cuts and burns with honey from the pantry shelf.)\nOn average, the report said, \"research and development of anti-infective drugs takes 10 to 20 years.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story talks about \u2018success rates\u2019 for the honey compared to \u2018conventional interventions\u2019, it is not clear\u00a0how this was defined, how it was measured, etc.", "answer": 0}, {"article": "She concluded: \u201cThe question of whether multivitamins are good for you still remains!\u201d\nWhile conventional wisdom holds that taking vitamins could help prevent heart disease, the researchers add, there\u2019s actually little evidence to back up this claim.\n\u201cEven if we have controlled for many of those factors that are associated with a healthy behavior we cannot exclude the possibility that we might measure a healthy lifestyle via multivitamin use.\u201d\n\nIn industrialized countries, Rautiainen and her team note in the American Journal of Clinical Nutrition, multivitamin use is widespread.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nDuring the observed period, 932 heart attacks occurred among the women without heart disease, while 269 women with existing heart disease had heart attacks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the numbers so that readers could calculate the absolute reduction in heart attacks in the group of women taking multivitamins who did not have heart disease (with multivit = 2.6%; without multivit = 3.4%). \u00a0However, it is unfortunate that instead of choosing to report that there was \u00a0a1% reduction in heart attacks, a decision was made to report it as a 27% reduction in heart attacks. \u00a0While a 27% difference sounds pretty exciting, it is a bit misleading.", "answer": 1}, {"article": "Zinc gluconate is another salt that has been frequently used in zinc lozenges.\nIf that outlier trial was excluded, the difference between the three zinc acetate and the three zinc gluconate trials shrinked to just 2%, i.e., a 40% vs. 38% reduction in common cold duration.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nHowever, in future studies the optimal composition of zinc lozenges should be investigated.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release release gives details from the original study regarding benefits of both types of zinc lozenges, as well as dosages.\nBut the benefits are only given in relative terms, and not actual numbers. The release would have been improved if it had\u00a0included the number of days a cold lasts with or without zinc supplements. We\u2019re not sure a 30 percent shorter duration is a meaningful measure, especially without mentioning how long the average cold lasted, with ot without zinc supplementation. Another important consideration is when the zinc was taken. Does it need to be taken continuously as a preventative or does it need to be started immediately at the first sign of symptoms? If you don\u2019t start right away does that affect how well it works?", "answer": 0}, {"article": "During menopause, levels of estrogen decline in vaginal tissues, which may cause a condition known as VVA, leading to symptoms such as pain during sexual intercourse.\n\"Intrarosa provides an additional treatment option for women seeking relief of dyspareunia caused by VVA.\"\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states simply, \u201cIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\u201d No data are provided to back up this claim.\nWithout any numbers, it\u2019s impossible to evaluate how beneficial the treatment actually is. How many women from the treatment group experienced this benefit? And although it\u2019s difficult to quantitatively assess pain, it could still be addressed by scores (e.g. On a scale from one to ten, how bad was the pain before treatment and then after treatment?). Without any idea of how much pain was actually reduced, readers have no idea whether the advantages of this therapy outweighs its costs and risks.\nThis is a point that we recently addressed in one of our blog posts, since news releases put out by the FDA often miss the mark on this criterion. More details, especially in the form of quantitative data, are badly needed.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\nWhile patients who received Tecentriq experienced a tumor response across the study, the greater effect in those who were classified as \"positive\" for PD-L1 expression suggests that the level of PD-L1 expression in tumor-infiltrating immune cells may help identify patients who are more likely to respond to treatment with Tecentriq.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven\u2019t been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent.\nAs noted above, tumor shrinkage doesn\u2019t always lead to improvements in survival or quality of life. It is a surrogate endpoint \u2014 a substitute \u2014 for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the \u201cSummary,\u201d another larger study is underway to assess the drug\u2019s impact on extending life and improving quality of life.", "answer": 0}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nFasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "How many of the 10 people taking resveratrol had changes in \"pro-inflammatory markers\"?\u00a0 All of them?\u00a0 Half of them?\u00a0 How big were the changes?\u00a0 How meaningful were the changes?\u00a0 We weren\u2019t told any of this.\u00a0 ", "answer": 0}, {"article": ".\nThe authors found that the risk of new vertebral or nonvertebral fractures dropped consistently among the participants taking abaloparatide-SC, irrespective of their baseline risk factors; and they found an increase in bone mineral density by abaloparatide in each of the baseline risk subgroups.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release would have been much more helpful to the reader if it had included some absolute numbers along with the relative risk reductions. The release notes that of 2,463 osteoporosis patients, ages 49 to 86, the drug increased bone mineral density in the lumbar spine by 9.2%, in the hip 3.4% and in the femoral neck by 2.9% compared to placebo. The release also describes the reduction in vertebral fractures by 86%, and other risk reductions, also in terms of percentages. But what were the actual rates of fractures in each group? That would give readers the best sense of the size of the benefit.", "answer": 0}, {"article": "\"That's a very important message.\"\nAnd it turns out that perhaps 40 percent of people who are identified as candidates based on their risk factors such as cholesterol levels and age actually have clear heart arteries, Grundy says.\nPuhan says, based on his assessment, perhaps 15 to 20 percent of older adults should be taking statins \u2013 far less than the 30 or 40 percent suggested by current medical guidelines.\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nScott Grundy, a physician at the University of Texas Southwestern Medical Center who chaired the guidelines committee, says the new recommendations urge people in this gray area to get a special kind of CT scan that looks for calcium deposits in heart arteries, a signal for clogs that could cause trouble.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201canywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years.\u201d That\u2019s helpful information. It also notes that the observed benefit is less for older patients.\nThe story could have added that even those numbers might disputed by some experts who perceive no meaningful benefit. For example, one review found being on a statin does not help people with low risk for heart disease live longer.", "answer": 1}, {"article": "November 16, 2015.\nAnother effect was that they consumed 16.4% less energy in the 24 hour period after eating the seaweed enriched bread.\nIn many cases we also get tastier food, and it may also help reduce the risk of cardiovascular diseases\", the authors believe.\nSeaweed's content of potassium salts does not led to high blood pressure - unlike the sodium salts, typically encountered in the processed food.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no actual quantifications of benefits in this release. It says that, \u201cBy eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per. 100 g) than when they ate the control whole-meal bread. Another effect was that they consumed 16.4% less energy in the 24 hour period after eating the seaweed enriched bread.\u201d Honestly, we have no idea what this means. Is 4.5 grams more fiber meaningful? Does it have any measurable health impact? Does consuming less energy during a 24-hour period lead to positive health benefits or negative? There\u2019s no help in interpreting this information.", "answer": 0}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nIndeed, the comparison of gut bacteria in normal and AIM2-deficient mice showed a different 'microbial landscape' in the two types of mice.\nThey found that the mice showed drastically reduced AIM2 function, confirming the finding in humans with the cancer.\nThe scientists found a striking reduction in colon tumors in the AIM2-deficient mice and an increase in tumors in the normal mice.\nThey also found that mice genetically altered to have reduced AIM2 function, when treated with the chemicals, showed significantly more tumors than normal mice.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is overrun with general statements and specificity is mostly missing.The release says that AIM2 suppresses \u201cabnormal expansion of intestinal stem cell populations,\u201d but it doesn\u2019t quantify what that means. How much more proliferation of these stem cell populations was there in mice that had a \u201cmalfunction of AIM2\u201d? And how does stem cell proliferation translate to cancer growth? Similarly, the release noted that when \u201cnormal\u201d mice and AIM2-deficient mice had the opportunity to exchange gut bacteria, \u201cscientists found a striking reduction in colon tumors in the AIM2-deficient mice and an increase in tumors in the normal mice.\u201d But it doesn\u2019t give readers any numbers that tell us how different those tumor numbers were or what that meant in terms of survival rate.\nAlso, importantly, the release does not make clear how much can be inferred about the behavior of AIM2 in humans from the behavior of AIM2 in mice. What level of uncertainty is there? What are \u201cgood bacteria\u201d and how are they transferred to experimental mice?\u00a0 How would that happen in humans?\u00a0 The release speaks of AIM2 findings and suggests possible meanings but fails to provide conclusive evidence to support the researchers\u2019 conjecture.", "answer": 0}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nOne theory is that's because the operation suppresses the levels of a stomach hormone called \"grelin\" that activates the sensation of hunger.\nAsked how many people gain the weight back, Dr. Hutcher tells Stahl, \"You know I think when you're dealing with an incurable disease that kills many people, if you have an 85 to 90 percent success rate, that's pretty darn good.\"\nDr. David Cummings, an expert on appetite at the University of Washington, says as a rule these patients end up just one third lighter.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment uses figures repeatedly to back up assertions made by the sources. But with the exception of the American Cancer Society data on cancer, the information comes from sources that are either self-interested (surgeons who perform the surgery) or not specified.\u00a0 ", "answer": 0}, {"article": "Other insurance companies may have varying policies.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nTUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\nFor uninsured patients, the cost of having spine stimulation devices can range from $15,000 to $50,000 or more, according to a 2008 report funded by the Washington State Department of Labor and Industries.\n\"In certain patients who have not gotten relief from other treatments, this therapy may give sustained pain relief and may allow them to reduce opioids for at least 18 months and perhaps longer,\" said lead researcher Robert McCarthy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes this claim high up:\nThe [DRG] therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nWhile there are theoretical reasons why DRG stimulation may be better than spinal cord stimulation, only studies directly comparing these treatments can determine this, and there is no mention of such studies in this piece.\nBased on the study findings that are discussed, it may have helped some patients, but the story needed to make it clear that we can\u2019t know from this one study if it\u2019s better than alternatives. It\u2019s also unfounded to speculate that it may reduce the use of opioid drugs.", "answer": 1}, {"article": "\"This refutes that.\"\nThis may indicate that the women who underwent lumpectomy were generally healthier, Hwang said.\n\"The group that benefited the most -- who had the biggest difference in breast cancer survival -- were those women over 50 with estrogen-receptor positive disease,\" Hwang said.\nBut, Woodward added, \"I am not sure the study convinces us that lumpectomy and radiation is better for breast cancer survival, but it may be.\"\nThe findings, published online Jan. 28 in the journal Cancer, are especially strong for women over 50 with hormone-sensitive cancers, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only attempted to quantify a benefit for one subset of women, when it reported:\n\u201cThe group that benefited the most \u2014 who had the biggest difference in breast cancer survival \u2014 were those women over 50 with estrogen-receptor positive disease,\u201d Hwang said. This means their cancer depends on estrogen to grow.\nAmong those women, the lumpectomy group had a 13 percent lower risk of death from breast cancer and a 19 percent lower risk of death from any cause than those who had a mastectomy.\u201d\nBut that was only a subset of women.\u00a0 And even in that subset, what was the risk of death? Was the difference of 13% and 19% really that much of a difference?", "answer": 0}, {"article": "\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\nWhile he is not against patients going home the same day, he cautions that total joint replacement is a major procedure and doctors need to be careful to avoid sending patients home too soon.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\nDouglas E. Padgett, M.D., chief of the joint replacement service at Hospital for Special Surgery in New York, is a lot more conservative about who he believes is the optimal patient for going home the same day.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The basic premise of the story is that \u201csame-day\u201d hip replacement offers important advantages to patients, but the only benefit specifically noted in the story is that people who opt for this procedure are less likely to spend a night in the hospital. Even then, there are only vague references and quotes from the surgeon on how many patients really go home the same day. Indeed, the one patient named in the story did not go home the same day.\nThe story does note that studies following hip replacement patients for at least six months find no important differences in how they fare depending on which sort of procedure they had. Still, the overall thrust of the story is that \u201csame-day\u201d is superior, without critically evaluating the differences between going home that day or the next.", "answer": 0}, {"article": "JAMA.\nWomen with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\nImprovements in both recall rate reduction and invasive cancer detection were greatest for women with heterogeneously dense breasts, with a 50 percent increase in invasive cancer detection and a simultaneous 14 percent reduction in recall rate.\nMARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\nHigher breast density may increase a woman's chance of getting breast cancer, make detection of cancer on conventional mammography more difficult, and increase the chances that a woman will be recalled for additional imaging.1,2 Mammograms are categorized into four density groups: almost entirely fat, scattered fibroglandular densities, heterogeneously dense, and extremely dense.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions a 50% increase in invasive cancer detection which on the surface sounds impressive, but they don\u2019t provide enough detail to understand what the 50% increase really means. According to the original study, the digital mammography plus tomosynthesis increased detection of invasive cancers from 3 per 1000 screens to 4.5 per 1000 screens and this high percentage increase was seen in only one of the four groups of breast tissue density. The other two groups had lower increases. (\u201cMammograms are categorized into four density groups: almost entirely fat, scattered fibroglandular densities, heterogeneously dense, and extremely dense,\u201d according to the release.)\nThe news release failed to mention that in women with extremely dense breasts, the 3D mammography was not significantly better at detecting invasive cancer than digital mammography alone. The published study called for caution \u201cin drawing conclusions regarding the performance of tomosynthesis [3D mammography] for the small proportion of women with extremely dense breasts.\u201d\nWe also question the release\u2019s portrayal of 3D mammography providing a \u201chigh percentage increase\u201d in detection over conventional mammography. Our calculations show a 0.15% increase in detection rates (0.3% detection rate for conventional vs. 0.45% for 3D).\nFinally, we need to address outcomes. There is no evidence from the study that finding these additional cancers leads to better outcomes. Finding more cancers with a more sensitive test could be\u00a0leading to over-diagnosis. Furthermore, the value of finding these cancers earlier is of uncertain value in the absence of outcomes data\u2013which ideally should come from a randomized trial to avoid bias in lead-time.\nThe many broad claims in the release are not fully supported by the evidence.", "answer": 0}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nResearchers say that until now, the function of POPG has been unclear.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\n\"While these are still early studies, several characteristics of POPG make me believe that it has real potential as both an antiviral and anti-inflammatory treatment.\"\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \"the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\"\u00a0 What does dramatically mean?\u00a0 Totally?\u00a0 Partially?\u00a0 Was this in all mice?\u00a0 Half the mice?\u00a0 You can easily start to see how the story doesn\u2019t ask or answer tough questions about the evidence. ", "answer": 0}, {"article": "\u201cCould we do a better job collectively?\u201d he asked.\nBut skin-testing results can vary from one allergist to the next, and most allergists don\u2019t rely on a prior allergist\u2019s results when a patient switches practices.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nBut allergists contend that these generalists are not qualified to assess the laboratory results.\nThe blood test is also part of a larger debate about who should be treating allergy sufferers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the blood test compared to the skin test. It is not clear from the story if the blood test results in better outcomes for the patient other than convenience and fewer side effects. The question of whether using the blood test in combination with treatment results in better outcomes for the patient is unanswered.", "answer": 0}, {"article": "\"Everybody wants to be creative, but you have to look at the data, and they used TXA,\" Levy said.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\nMONDAY, June 14 (HealthDay News) -- A drug commonly used to prevent excess bleeding in surgeries could keep thousands of people from bleeding to death after trauma, a new study suggests.\nUsing this drug to treat trauma patients is a completely new idea, Levy said.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unlike some competing coverage, this story describes the benefits of TXA in both\u00a0relative and absolute\u00a0terms, providing readers with an accurate view of the magnitude of the\u00a0effect observed in the study. Unfortunately, the story\u00a0loses this balance when it\u00a0unquestioningly passes along the claim that TXA could save 100,000 lives in a\u00a0year if it were used around the globe. While\u00a0a back-of-the-envelope calculation may suggest that this is possible, many hurdles stand in the way of\u00a0this drug being\u00a0universally dispensed for trauma cases worldwide.\u00a0It\u2019s also far from clear that the findings of this study can be replicated under everyday conditions in emergency departments around the globe. The story should have tapped an expert to help put this\u00a0pie-in-the-sky figure in a more appropriate context for readers.\u00a0\n\u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story always qualified any potential benefit as possibility by qualifying every claim with the term \u2018may\u2019. \u00a0It would have improved this piece to include an explicit statement that there is currently no way to quantify what the benefit of early detection might be. \u00a0", "answer": 0}, {"article": "To contact editorial co-author Anne R. Cappola, M.D., Sc.M., email Abbey Anderson at Abbey.Anderson@uphs.upenn.edu.\nThe way forward for fracture prevention involves not only the development of better therapies to prevent fracture and easier delivery systems but also improved adoption of existing osteoporosis therapies for patients with prior fractures and minimization of adverse effects, particularly those associated with long-term use.\u201d\n\n: Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nEditorial: Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture\n\n\u201cUltimately, which therapy is selected for osteoporosis treatment may be less important than identifying and initiating an approved treatment,\u201d write Anne R. Cappola, M.D., Sc.M., of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and Associate Editor, JAMA, and Dolores M. Shoback, M.D., of the University of California, San Francisco, in an accompanying editorial.\nOverall, there were no differences in serious adverse events between the treatment groups.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "High in the release, the benefits of the drugs being studied and the placebo being compared are quantified clearly in both relative and absolute terms. Readers can see clearly that we are talking about quite a small group of people who saw benefits from either drug compared to the rather large group of women who were studied.\nMost of the data presented was absolute risk which was excellent. This shows the benefit as well as the fact that most patients didn\u2019t have a fracture regardless of which treatment was given.", "answer": 1}, {"article": "Lobular breast cancer forms in the milk glands.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Only relative risk reduction figures were used \u2013 \"32% reduced risk.\"\u00a0 But readers should be told \"32% of what?\"\u00a0 What were the actual absolute numbers in the group that took the supplements versus the numbers in the group that didn\u2019t take the supplements.\u00a0 Why is that so difficult to include?\u00a0 It would be far more meaningful than 32%. ", "answer": 0}, {"article": "http://jama.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\n\"The results reported by Willett et al demonstrate that most unstable ankle fractures in older patients can be treated with a cast without the need for surgery,\" writes David W. Sanders, M.D., M.Sc., F.R.C.S.C., of Western University, London, Ontario, Canada, in an accompanying editorial.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes a list of benefits of the modified casting method, with some quantification, mostly in terms of reduced complications. It says, \u201cAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery. Infection and wound breakdown were more common with surgery (10 percent vs 1 percent), as were additional operating room procedures (6 percent vs 1 percent).\u201d", "answer": 1}, {"article": "Barua is with the Kansas City (Mo.)\nThe sharpest contrast emerged between Group 1 (those who were treated and attained normal levels) and Group 3 (those whose low testosterone went untreated).\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nMore research is needed, they say, to clarify how testosterone affects the cardiovascular system.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the press release does provide likelihood estimates of illness or death as a result of testosterone treatment, indicating that individuals whose treatment returned their testosterone to normal levels were less likely to suffer a heart attack, a stroke or to die during follow up, it provides no baseline numbers that would permit us to evaluate those ratios. We learn that the differences are statistically significant, but we have no means of determining if they are important. The absolute reductions are not quantified.", "answer": 0}, {"article": "Men with prostate cancer face a confusing maze of options today, including not only surgery but hormone therapy, different kinds of radiation therapy and even simply foregoing medical treatment while monitoring the cancer closely (\"watchful waiting,\" also known as \"active surveillance\").\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\nThe benefit was primarily seen among men younger than 65 and the authors estimated that seven men under the age of 65 and 8 over the age of 65 would need to be treated to save one life.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nThe data presented in the May 5 issue of the New England Journal of Medicine is a 15-year follow-up of a study for which three-years of follow-up had previously been reported.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While describing some of the differences observed in general terms without quantification, the story provided absolute percentage of men dying from prostate cancer in the two study groups.\nThe story then went on to explain that the difference was in the men who were less 65 years of age at the time of diagnosis. \u00a0The story would have been better if it had more clearly explained this important caveat about the benefit seen.", "answer": 1}, {"article": "Eat as you dare.\nLook at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death.\nParticipants eating a Mediterranean diet showed a lower risk of heart attack and stroke, the researchers discovered; yet, eating healthy food appeared to be more important than avoiding unhealthy foods identified as typical of a so-called Western diet, such as French fries, fatty red meats, and, yes, even cake.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story helped clarify the somewhat confusing data points in the study by quantifying the benefits\u00a0this way (italics added by us):\n\u201cOver nearly four years, 1,588 (about 10 percent) of the study participants suffered either a heart attack or stroke, or died. Those who ate more foods in the Mediterranean diet category were 3.5 times less likely to experience one of these three events than people whose diets more closely resembled the Western standard.\nIn fact, every one-point increase in a participant\u2019s Mediterranean diet score was linked with a 7 percent reduction in risk of heart attack, stroke, or death. Look at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet. These findings held for every geographical region.\u201d\nWe applaud the writer for including\u00a0the 100 people example to help readers understand the risk reduction.", "answer": 1}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nReviewing 26 studies comparing spinal manipulative therapy (SMT) to other treatments such as medication, exercise or physical therapy, researchers from the Netherlands found that SMT appears to be no better or worse than other options at relieving back pain long-term.\nWEDNESDAY, July 6, 2011 (HealthDay News) -- For the millions of Americans with chronic low back pain, a silver bullet to alleviate the condition has yet to be identified, a new study suggests.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nAn unrelated study of 401 patients with low back pain, published July 5 in Annals of Internal Medicine, suggested that massage may be better than medication or exercise for short-term pain relief.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe article offered only broad characterizations about the treatment effects of spinal manipulation for chronic low back pain. It did not attempt to quantify the treatment effects in terms of pain relief or functional improvement.\nHowever, the systematic review that served as the focus of the article is complex and somewhat difficult to decipher, with outcomes including pain and function at different time points.\nAnd the story did provide the reader with a reasonable summary. Manipulation appears as good or bad as other treatment options\u2014and it may lead to more rapid pain relief.\n \n \n \n", "answer": 1}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In many ways, the story does a very nice job of explaining the benefits of SDF. It addresses cost, the ability to avoid anesthesia, and the ease with which it can be applied. It even discusses the limits of those benefits, noting that patients with mouth sores or a silver allergy can\u2019t use SDF \u2014 and that patients with \u201csevere\u201d cavities still need fillings. The story also includes links to supporting materials, which we like to see.\nHowever, this criterion is very specifically focused on whether a story quantifies benefits, and this story does not do that\u2013we\u2019re given little information on the status of the medical evidence for this procedure overall.\nA 2009 paper, linked to from this story, looked at two clinical trials of SDF and found that it \u201carrested\u201d at least 96.1 percent of cavities (i.e., prevented them from getting worse). If the story had noted that, it would have gotten an enthusiastic thumbs up here.", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided some insight into possible regain of function (i.e. eating and hair brushing).\u00a0 From this, the reader could infer that while the treatment might provide some benefit, it did not hold out promise of complete recovery.\u00a0 However \u2013 the reader is not provided with any guidance about what percentage respond to this treatment.\u00a0 It is not possible for the reader to derive a sense about the probability of success or failure.", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\n\u201cIf motor function is also more likely to improve, then treating before symptoms of depression emerge is likely to be even more beneficial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites the absolute improvements on motor skill test scores.\nBut these numbers are unanchored from context. All we know is that it was the score on a test of motor skills. We don\u2019t know the measurement, the scale, or baseline values. So the numbers have no meaning for readers. It\u2019s as if I told you \u201cmy running speed has increased by 10.\u201d The lack of a baseline score is particularly relevant in this story because, as it turns out, the group receiving fluoxetine started with slightly more severe problems than the control group. Although the difference was not reported to be statistically significant, any difference in baselines scores for the primary outcome may reflect a flaw in how the study randomized people.\nSecond, none of the \u201cpositive effects\u201d of the drug mentioned are challenged. In light of the preliminary nature of the study, these apparent benefits are not conclusions, they\u2019re open questions. That perspective is missing, misaligning the tone of the piece.\n Please see some related comments under Quality of Evidence.", "answer": 0}, {"article": "\u201cThe rate was remarkably lower,\u201d Arnett told Reuters Health.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nMore than two thirds of the patients in the study had a score of 4 or higher but the researchers caution that \u201climiting urgent assessment to patients with a score of 4 or more would miss approximately 20 percent of those with early recurrent strokes.\u201d\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story satisfactorily quantified the benefits, by including relative and absolute reductions in stroke risks when patients are treated at a TIA unit. It also makes it clear that the measured benefits seen weren\u2019t\u00a0obtained via a comparative trial, but by looking at older data on stroke risks from TIA and comparing it to this newer set of data. (See quality of evidence criteria for why these benefits are shaky, though.)", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThere is no attempt to quantify the benefit of total knee replacement, either for older patients or younger ones, except in the testimony of one knee surgeon. Although the scientific literature reports that most patients are satisfied after surgery, the results are neither as spectacular nor as risk-free as the article suggests.\n", "answer": 0}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nA meta-analysis was then used to compare the RLS device with three historic studies of the medication ropinirole and a placebo.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports summaries of two types of measures of restless leg syndrome. However, the release would have been better if, in addition to the numerical results for the two scales, it had offered some definition of what the numbers mean in more common terms, such as how many nights per week people lost a lot of sleep because of leg movements. Or, since this treatment is focused on improving sleep, one could have focused on the number of nights with uninterrupted sleep.\nAnd as noted below, the release offers a comparison only to one type of drug, without any reference to numerous alternatives.", "answer": 1}, {"article": "About 800,000 people in the United States suffer from a stroke each year.\n\u201cWhat surprised us most was the remarkable recovery some patients had,\u201d Dr. Gary Steinberg, professor and chair of neurosurgery at Stanford, told Medical Daily, \u201cWhile we had hoped for that, we didn\u2019t really expect it.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nIn addition to setting the stage for an expanded trial of the procedure, the promising results also change \u201cour notion of what happens after a stroke,\u201d Steinberg explained.\nMotor improvement was also independent of the severity of the stroke patients\u2019 conditions\u2014 an important detail considering older adults tend to respond less to treatment, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The\u00a0story\u00a0is clearly upbeat about the promise of the therapy and uses a great deal of positive\u00a0language from the news release. But the story\u00a0did not really quantify the results in a way that would give readers a sensible picture of just how many of the 18 could \u201cwalk again\u201d and what exactly the metrics used to assess results consist of.", "answer": 0}, {"article": "Nothing.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\nThere are vaccines for several Neisseria meningitidis strains, but designing a vaccine to protect against the B strain was a particularly difficult nut to crack.\nThey found people who were vaccinated were 31 percent less likely to be infected with gonorrhea than those who hadn\u2019t received the meningococcal B vaccine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just passes the bar, giving actual numbers far down in the story. It states researchers \u201cfound people who were vaccinated were 31 percent less likely to be infected with gonorrhea than those who hadn\u2019t received the meningococcal B vaccine.\u201d\nWe would have liked to see that data higher in the story. Instead, the story states in the third paragraph that the gonorrhea rate was \u201csignificantly lower\u201d among those who were vaccinated. The story doesn\u2019t give the overall risk of getting gonorrhea, so it\u2019s hard to tell whether a 31 percent drop amounts to a significant benefit for individuals.\nThe study itself states that the findings provide preliminary evidence of \u201cmoderate\u201d cross-protection, and we think that should have been given more discussion so people get a better sense of how little is known about the efficacy compared to other vaccines.", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn\u2019t report much in the way of quantitative data and results.\u00a0 The article could have included additional detail about the specific results.\u00a0 The findings that are presented are somewhat overstated and not entirely accurate.\u00a0 The article states that the \"results showed a modest improvement in vision\" when the improvement in vision was based on self-report for the three patients in the U.S. study and but was only found by objective measure in one patient in the British study.\u00a0 While the results of\u00a0both studies suggest efficacy in\u00a0improving the pupil\u2019s ability to respond to light, improved visual function\u00a0and mobility was only found for one patient in the British study.\u00a0Further, the patient in the\u00a0British study\u00a0who experienced\u00a0the best results had the least advanced retinal disease compared to the other patients.\u00a0 Other improvements including a reduction in nystagus or roaming eye movements in all patients in the U.S. study (not measured in the British study).\nNitpicking details?\u00a0 We don\u2019t think so in a story headlined \"hope for a cure.\" \u00a0", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story used absolute reduction numbers, instead of relative risk figures. The WebMD story and the press release led with how hypnosis could help cut hot flashes by as much as 74%. But the LA Times writes, \u201cThe frequency of hot flashes in the hypnotherapy group dropped by 48% at six weeks and 56% at 12 weeks, compared to drops of 7% and 13% at six and 12 weeks, respectively. among those in the trial\u2019s control condition.\u201d That does a better job putting the benefits of the therapy into perspective.\nSome aspects of the data presentation were still confusing, especially since there is no explanation at the end of the article regarding all the numbers. For example, what is the exact difference between \u201cdrop in frequency of hot flashes\u201d versus \u201cimprovement in severity and frequency of hot flashes?\u201d And how was improvement measured?\nNonetheless, because the story gave readers detailed views of what the study found, we think it earns a satisfactory grade.", "answer": 1}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\nIn all four studies, eye dryness was significantly reduced, with two of the studies showing improvements at week two.\nFocusing her research on all aspects of the eye, Nichols discussed the mechanics of the three layers of the tear film and the importance of each from the cornea outward:\n\u2022 Mucin layer: helps tears adhere to the eye\n\u2022 Aqueous layer or water layer: nourishes and protects the cornea\n\u2022 Lipid or oil layer: lubricates and prevents evaporation and provides smooth refractive surface needed for optimal vision\n\n\u201cWe are unsure which of the 200-plus different lipids and 500-plus unique proteins are most important for protecting and lubricating the eye, and the absence or insufficiency of which results in dry eye,\u201d Nichols said.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were summarized this way: \u201cIn all four studies, eye dryness was significantly reduced, with two of the studies showing improvements at week two. Results from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\u201d\nHow was eye dryness measured? How reduced was \u201csignificantly reduced?\u201d How was \u201cimprovement\u201d of abrasions measured? How improved was the improvement?\nThe news release does not say.", "answer": 0}, {"article": "For years, women took estrogen or a combination of estrogen and progestin to help alleviate hot flashes and other symptoms of menopause, and in the belief that the drugs had a host of health benefits, including protecting their hearts.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nThat\u2019s the good news.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThe women had taken estrogen for about six years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story didn\u2019t quantify the benefits.\u00a0 The competing NY\u00a0Times did a somewhat better job, although it got an unsatisfactory score as well.\n", "answer": 0}, {"article": "They work by promoting the release of dopamine, which is impaired in ADHD and other disorders characterized by executive function problems.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n\"There are approximately 90 million post-menopausal women living in the US alone, and with the average age of onset occurring at 52, the great majority of those women will live in the postmenopausal state for at least one-third of their lives.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes benefits like this: \u201cThe researchers found a 41 percent overall improvement in executive functions for women receiving LDX, compared to a 17 percent improvement when taking placebo medication.\u201d\u00a0 And it points out that in four of the five areas of cognitive loss, those taking the drug experienced \u201csignificant improvements,\u201d although it fails to provide specific details on those areas.\nWe\u2019d add that on the objective measures of cognitive function (the neuropsychological tests where performance is externally graded), only 2 of 12 tests showed a statistically significant improvement, and these would not have been significant if the study authors had made the appropriate statistical adjustments for multiple comparisons. This is perhaps more of a problem with the study itself and the journal that published it rather than the release per se, but it\u2019s a problem that deserves comment. And while the subjects\u2019 self-rated improvements in function were greater, as would be expected, than the objective measures, it\u2019s hard to know whether these statistically significant changes are clinically meaningful. In other words, are they large enough and durable enough to make a real difference in people\u2019s lives? The release doesn\u2019t say or give us any context for judging the importance of the benefit.", "answer": 0}, {"article": "In 2008, about 8,000 U.S. men were diagnosed with metastatic prostate cancer.\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nJuly 30, 2012 -- If it weren't for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits claimed in the University of Rochester study, saying, \u201cIf it weren\u2019t for routine PSA prostate cancer screening, an extra 17,000 Americans each year would learn that they had the worst form of the disease, a new study suggests.\u201d\nMore important, it made an effort to question this type of statistical modeling \u201clook-back\u201d study.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nAlthough these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\nNoctiva\u2019s efficacy was established in two 12-week, randomized, placebo-controlled trials in 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\nThe U.S. Food and Drug Administration today approved Noctiva (desmopressin acetate) nasal spray for adults who awaken at least two times per night to urinate due to a condition known as nocturnal polyuria (overproduction of urine during the night).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release is vague on benefits, stating that although trials \u201cshowed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.\u201d\nThe benefit of being able to \u201chalve the number of night-time urinations\u201d is uninterpretable.\nIn fact, data submitted to the FDA shows patients using the drug went from an average of more than three urinations per night to about two, but the placebo was almost as effective. By our calculation, those using a placebo got up an average of one extra time every three nights compared with those who took the real drug. In other words, not a huge difference. The percentage of patients who experienced one or fewer nighttime urinations was 40 to 45 percent for those using Noctiva versus 30 to 34 percent for those taking a placebo. Again, a modest benefit.", "answer": 0}, {"article": "They didn\u2019t advise against using the devices.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\nCHICAGO \u2014 Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths, a review by federal regulators finds.\nThe pumps are used for those with Type 1 diabetes, which accounts for about 5 to 10 percent of all diabetes cases and used to be called \u201cjuvenile diabetes.\u201d The more common form is Type 2, which is often linked to obesity and more often affects adults.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article fairly communicates the risks and benefits of insulin pump use among adolescents.\u00a0 It does not overstate the main benefit of allowing young people to live more normal lives by eliminating the need for multiple daily insulin injections.", "answer": 1}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nSo far, the treatment has restored immune systems in all 23 patients in the most recent clinical trials, including Evangelina.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nClinical trials for that treatment are now underway.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies heavily on one child\u2019s journey and notes that \u201d \u2026the treatment has restored immune systems in all 23 patients in the most recent clinical trials.\u201d \u00a0But we aren\u2019t told how long these children were followed after the procedure or what a \u201crestored immune system\u201d is or how it was measured. There is simply too little information provided to assess this treatment\u2019s potential.", "answer": 0}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nWhile the study was small and lacked a control group, Dr. Streeter and her colleagues are planning a randomized controlled trial to further test the intervention.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nIf you have the time to learn only one technique, this is the one to try.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story asserts that controlled breathing \u201chas been shown to reduce stress, increase alertness and boost your immune system.\u201d It also states that studies have found breathing practices \u201ccan help reduce symptoms associated with anxiety, insomnia, post-traumatic stress disorder, depression and attention deficit disorder.\u201d\nBut none of these purported benefits\u00a0are quantified in any measurable way\u2013i.e., by how much does it reduce symptoms? And for how long? \u00a0And the story\u2019s opening line that you will have \u201ccalmed your nervous system\u201d by taking just five deep breaths isn\u2019t backed up by evidence.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the harms of oophorectomy. Specifically, the story provides quantification in relative terms only by stating that \"surgical removal of the ovaries before menopause raises by half a woman\u2019s risk of neurological problems.\" What that statement does not show is how rare those neurological problems are. By stating the increased risk in purely relative terms, the story appears to inflate the actual risk. See our primer on absolute versus relative risks. ", "answer": 0}, {"article": "Other Northwestern authors are senior author Dr. Ronald Ackermann and co-authors Mercedes Carnethon and Dr. Namratha Kandula.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nBut O'Brien said it is unclear whether insurers will be required to pay for diabetes screening if patients only meet the expanded criteria.\nOnly 23 percent of patients with prediabetes or diabetes would be missed if expanded screening criteria were used to make screening decisions, the study found.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cOnly 23% of patients with prediabetes or diabetes would be missed if expanded criteria were used to make screening decisions, the study found.\u201d\nWhile the study itself dived into the sensitivity of the tests used in screening, none of that data are shared in the release.\nThe larger problem is that it\u2019s not clear whether finding more cases of prediabetes or diabetes would actually lead to improvements in outcomes people care about like fewer heart attacks and less nerve damage.\u00a0 The release should have clarified this.", "answer": 0}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of describing groups for comparison: coffee-abstainers, light drinkers (1-6 cups per week), and heavier drinkers (>2 cups per day). However death rates were presented as relative risk. How many of the 18,000-plus subject died during the average 16 years they were followed? What does \u201c18% less likely to have died\u201d look like in absolute numbers?", "answer": 0}, {"article": "Santarelli describes gantenerumab as a drug engineered to bind itself to plaques known as amyloid-betas, which accumulate as Alzheimer's progresses.\nThe study is published in the online edition of Archives of Neurology.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nOct. 10, 2011 -- A small study shows that a new drug being tested for the treatment of Alzheimer's disease reduces the buildup of plaques in the brain associated with the fatal disease.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of results observed in study participants at different dosing levels.\nMore importantly, the story simply explained: \u201cSince it\u2019s not completely clear what reductions in brain plaques mean for Alzheimer\u2019s patients, the researchers are unable to say whether treatment with gantenerumab will bring improvement to patients with Alzheimer\u2019s. They are currently involved in a new study that they hope will answer that question.\u201d", "answer": 1}, {"article": "It is for use only in those aged 12 or more, the F.D.A.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a really close one. The story does a lot of things well here. It notes that, in one trial, there was no difference in the benefits between Xofluza and existing flu treatment drug oseltamivir (better known as Tamiflu). However, it does not actually quantify the benefits associated with Xofluza. Instead, the story states that it \u201cmay alleviate some symptoms and shorten the time patients feel sick.\u201d\nWe approve of the cautious language used throughout the story, but we like to see quantified benefits in instances where the information is available. In this case, an article published in the New England Journal of Medicine in September reported that Xofluza reduced the \u201ctime to alleviation of symptoms\u201d by a mean of 25-38 hours, compared to placebo (the difference depended on the age group of the patient). Ergo, a not satisfactory rating here.", "answer": 0}, {"article": "\u201cMany babies with Down syndrome appear normal on an ultrasound,\u201d she says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\nIt can help women put some of the information from other tests into context.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the story does quantify the benefits in one way. It says, \u201cIt could help avoid up to 98% of these screening procedures, according to the study, which appears in BMJ.\u201d It also says, \u201cThe new study included 753 pregnant women who were at high risk for having a child with Down syndrome. Of these, 86 women were determined to be pregnant with a child with Down syndrome.\u201d", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the benefits are not quantified.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As explained above, the story analyzes the benefits in both relative and absolute terms.", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story tosses around the word \u201cbenefit\u201d in a way that would make most readers believe that anything that lowers LDL \u201cbad\u201d cholesterol always reduces the risk of future heart-related problems. However, tests of some unrelated drugs (e.g., clofibrate) showed that despite lowering LDL, the risk of heart problems was not reduced. It may turn out that this drug reduces future health risks for certain patients, but that is not what this trial tested. This story perpetuates common confusion between a mere lab test number and meaningful health outcomes.", "answer": 0}, {"article": "Many Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the potential benefits. For one, the story relies to heavily on the relative differences between the aspirin group and the placebo group. As the study itself notes, for some of the cancers studied, the number of deaths in both groups was quite small \u2013 16 versus 14, 10 versus 19, 15 versus 19. This story and the other stories reviewed should have made this clear. What\u2019s more while the story highlights the total number of participants included in the data analysis (25,570) it doesn\u2019t tell readers that only 674 of them died of cancer. And then for the longer-term follow-up there was a total of 1634 cancer deaths among 12,659 participants.  Overall, the study that 3 percent of the patients in the control (placebo) group died of cancer during the original trials, compared to 2.3 percent of the patients who were assigned to recieve aspirin. Yes, that is a 23 percent reduction overall, but a 0.7 percent absolute reduction. Put another way, if indeed aspirin is preventive, you would need to treat 150 people to prevent one death from cancer during that time period. The way this story is written creates an inflated impression of the potential cancer prevention benefits of aspirin seen in this study.", "answer": 0}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of presenting the harms of the failed drug in terms of natural frequencies (actual numbers) instead of relative rates.", "answer": 1}, {"article": "For example, children with Down syndrome often have flat nasal bridges \u2014 as do typically developing African or African-American children.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\n\u201cSince Face2Gene is a search and reference informational tool, the terms sensitivity and specificity are difficult to apply to our output,\u201d Gelbman cautioned.\nMeanwhile, Muenke and his colleagues at the NIH last month published an important advance: the ability to diagnose disease in a non-Caucasian face.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits for a related bit of science but not for the core product being described in the piece. For that, it says, \u201cFace2Gene declined to provide similar numbers for their technology. \u2018Since Face2Gene is a search and reference informational tool, the terms sensitivity and specificity are difficult to apply to our output,\u2019 Gelbman cautioned.\u201d\nIf we don\u2019t know anything about sensitivity and specificity, we\u2019re not sure how this can play any role in helping with diagnosis, even in narrowing the list of possible/probable disorders. The story needed to explore this problem more.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nThe findings were published online today in Pediatrics.\nColic affects up to 28% of infants and has no known cause or cure.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the number of minutes per day that children cried in the probiotic and placebo group \u2014 a\u00a0reasonable characterization of the main findings. Although we\u2019ll award a borderline satisfactory, we wish the story\u00a0had avoided some of the following\u00a0vague\u00a0language:\u00a0", "answer": 1}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nAfter six weeks on Paxil, his fear level dropped to a 4 -- an improvement that led him to continue the medication after the trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story contained an anecdote on the improvement one person observed after taking Paxil.\u00a0 However, there was no quantification of the average benefit, the range of benefit observed, or even an explanation of what benefit was observed.", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n\"This is hugely promising and very significant research,\" he tells WebMD.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Compounding the effects of the sensational headline and use of the term \"artificial pancreas\" (which, as we explain in our review of the competing New York Times piece, is an overly promotional and misleading term), this story wasn\u2019t\u00a0careful enough in its description of the benefits reported in the study. It had most of the same problems as the Reuters story (see that review for detailed analysis), including\u00a0reporting relative and not absolute benefits, and not mentioning the fact that the primary outcomes of the study were negative. \nOn the positive side, the story did mention that experimental group in this study had no instances of severe hypoglycemia compared with 9 episodes in the control group. This is a potentially important finding that was not mentioned by Reuters.", "answer": 0}, {"article": "The American Heart Association has more on heart failure.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nFor this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThis story doesn\u2019t seem to distinguish between \u201cgetting better\u201d and \u201cnot declining as fast.\u201d As one line states, \u201cAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\u201d That sentence seems to say that the patients had lower risks than before they enrolled in trial, when what researchers actually reported was that the patients given the gene therapy were only half as likely as the patients who got a placebo to have one of those bad events.\nThe story reports only relative benefits without telling readers the absolute numbers. One result reported in a company news release was particularly striking, that during the year following treatment, the average number of days spent in the hospital was 0.4 per patient for the 9 patients who got the highest dose and 4.5 days per patient for the 14 who received a placebo. The story could have at least included the actual numbers of deaths reported in each group. ", "answer": 0}, {"article": "For more information on stroke, visit the U.S. National Library of Medicine.\n\"It is also unclear how optimal medical management [lifestyle changes in addition to anti-platelet medication and statins] would affect overall stroke and cardiovascular risk, and stroke-free survival,\" he said.\nThe problem is identifying the patients at the highest risk for stroke, he said.\nThe patients who are at high risk are candidates for surgery, he said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story got the \u201cgist\u201d correct that surgery\u2019s benefit increases with increasing risk. One of the saving graces of the piece was this independent perspective:\n\u201cIt is also unclear how optimal medical management [lifestyle changes in addition to anti-platelet medication and statins] would affect overall stroke and cardiovascular risk, and stroke-free survival,\u201d he said.", "answer": 1}, {"article": "\"They are a gateway out of smoking,\" says Etter.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\n\"[They may] expand their market to other customers who didn't use cigarettes but might consider nicotine use.\"\nBauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that e-cigarettes could be a better alternative to combustible tobacco. It\u00a0walks us through many different points of view on the topic, but its quantification of potential benefits isn\u2019t satisfactory. The story notes, for example, that a third of smokers trying to quit turn to e-cigarettes, and that ENDS are \u201cabout 60% more effective than going cold turkey or buying nicotine replacement therapy over the counter.\u201d But since the success rates for the other approaches are never stated, it\u2019s impossible to tell just how big that 60% improvement is. Providing the actual success rates of those who quit with ENDS compared with other approaches would\u2019ve given readers the best perspective on the size of this potential benefit.", "answer": 0}, {"article": "Steven Storey, who was diagnosed with MS in 2013, said: \u201cI went from running marathons to needing 24-hour acute care.\n\u201cIt is important to stress, however, that this treatment is only suitable for patients with relapsing remitting multiple sclerosis disease who have had two or more significant relapses in the past 12 months, failed to respond to standard drug treatment and who have had the illness for at least 10 years.\u201d\n\nOne patient who has undergone the treatment, known as autologous haematopoietic stem cell transplant (HSCT), told the BBC\u2019s Panorama programme that he had made incredible progress.\nA treatment traditionally used on patients with certain cancers is being tried on a small number of people with multiple sclerosis with \u201cremarkable results\u201d, according to a professor involved in the research.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Quantification of benefits may not be possible at this point, as the \u201cabout 20 patients\u201d in this UK branch of an international trial are still presumably embedded in the trial protocol.\u00a0 The story, instead, relies on personal testimonials from two patients who had received the treatment, who describe major improvements in their conditions. \u00a0Note: There seems to have been at least some empirical data available. \u00a0At least one earlier study, published in January 2015 in JAMA, showed that the treatment was linked to reduction in level of disability in 64% of the 123 patients treated.\nIt isn\u2019t clear why this story is coming out now. If this is part of a larger trial, why are these results being shared? Presumably this isn\u2019t a blinded trial, but it isn\u2019t even clear if there is a control group that received standard treatment without the bone marrow transplant.", "answer": 0}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\nDuring the first six months of evaluation, 68 devices were activated for treatment, while 73 were left inactive as the control group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were glad to see absolute numbers and not just percentages used to quantify the benefits of the study.\n\u201cAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group. Only eight (11 percent) of those in the control group achieved the same reduction.\u201d\nA bit more discussion on how the device might impact future quality of life or how long the benefit might be sustained \u2014 provided the data was available \u2014 would have been useful context.", "answer": 1}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits provided in this story, only a statement that \u201call of the men who followed a physical activity program showed improvements in a variety of measures of their sperm,\u201d compared to those men who were in the non-exercise group. The story states that, \u201cthe men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups,\u201d but it doesn\u2019t characterize those improvements except in the vaguest of ways. Readers are left to wonder the degree of differences between the three exercise groups.", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\n\u201cSo why would the proposed 2015 dietary guidelines recommend that pregnant women eat more of it?\u201d\n\nBut Dr. Steve Abrams, a panel member involved in the seafood recommendations and medical director of the Neonatal Nutrition Program at Baylor College of Medicine, said that while women need to be aware of the types of fish they are eating, the evidence is strong that fish consumption by mothers is good for the brains of their babies.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\nThe point is that you should have a variety of types of seafood and not limit yourself to one type, and variety includes canned tuna.\u201d\n\nAlice Lichtenstein, senior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University said the panel hasn\u2019t suggested that pregnant women eat more tuna.\nFor people who want to safely eat more seafood, the magazine recommended shrimp, scallops, sardines, salmon, oysters, squid and tilapia as the lowest-mercury seafood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that fish are rich in nutrients that \u201care particularly important for brain development in fetuses and nursing infants,\u201d and discusses a 2005 study that found a link between fish consumption in general by pregnant women and how well their children later scored on visual recognition memory tests. While that\u2019s useful context, the story is specifically about tuna and the supposed fact that tuna is a \u201cspecial case\u201d \u2014 i.e. a high-mercury fish that doesn\u2019t require strict consumption limits.\u00a0Quoting the Dietary Guidelines Committee, the story says that \u201call evidence [for tuna] was in favor of net benefits for infant development and (cardiovascular disease) risk reduction.\u201d But what specifically were those tuna-related benefits? Why should we make an exception for tuna? The story\u00a0would have been stronger if it had quantified these tuna-specific benefits, and discussed the nutrient profile that makes tuna different from other fish.", "answer": 0}, {"article": "The World Health Organisation predicts that by 2020, depression will rival heart disease as the health disorder with the highest disease burden in the world.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No description of the size of the potential benefit \u2013 only this vague quote:\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nThe researchers measured response using 3 scales (2 interviewer-administered and 1 self-administered). \u00a0There was only a clear response on one scale (and it looks clinically significant). \u00a0One scale showed no response and one was equivocal.", "answer": 0}, {"article": "\"Every time I hear this story, I get goose bumps,\" Cowles says.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\n\"We know how to use it but we really don't know how it works,\" says cardiologist Mark Vossler.\nThe American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of this treatment was described as an improved survival rate by 14%.\u00a0 However, without the starting point, i.e. the number of individuals who have had a heart attack and are brought to an emergency treatment facility within a specified amount of time, it is not possible to understand the magnitude of the benefit that may be gained. Viewers are left wondering \"14% of what?\"", "answer": 0}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\n\"Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol.\nThe eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed.\nWhile there is no cure, a new study published in Cephalalgia in March shows single-pulse transcranial magnetic stimulation is a new way to prevent migraine attacks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that twice daily, self-administered TMS reduced the frequency of headache days by nearly three days per month. Also, just under half the patients had at least 50% or less migraine attacks per month with treatment.\nThe release reports that patients had nine migraine days per month at baseline and this was reduced by 2.75 days with TMS treatment. This earns a satisfactory for describing the benefit in numerical terms. However, quantifying the improvement at followup would have been more helpful for readers wanting to assess TMS as a treatment option.\nThe release would have been improved had it included what the baseline severity and frequency of the 95 volunteers headaches were, and that claims of benefits were self reported. Furthermore, there was incomplete information regarding the concomitant use of pain medications during the 3-month study period.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\nIn the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release does provide some numerical context, it\u2019s insufficient to give credit here. The release could have provided much more useful information about the quantitative benefits. For example, a summary of the trial upon which the approval was based stated,\n\u201cAt a median follow-up of 57 months, midostaurin reduced mortality risk by 23% compared with placebo plus chemotherapy. The median OS was 74.7 months for the group receiving midostaurin versus 26 months for the placebo group (P = .007), representing a 23% reduction in the risk for death favoring midostaurin.\u201d The release should have provided both absolute as well as relative benefits, both of which were available from the trials.\nWhat the release does say is that patients who received a combination\u00a0of standard chemotherapy and Rydapt for treating AML \u201clived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated,\u201d compared to patients receiving chemotherapy plus a placebo.\u00a0 That\u2019s pretty vague. In addition, it said that \u201cpatients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\u201d ", "answer": 0}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nThe group that started on the combined treatment scored, on average, more poorly on both measures at the beginning of the trial.\nIn the new study, doctors used the medications as part of a package of treatments and worked to keep the doses as low as possible minimizing their bad effects.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says drug doses were 20-50% lower, which is a very big deal considering the side effects of these drugs. But overall it leaves us hungry for numbers. It says patients in the therapy group, who received more one-on-one talk therapy and family counseling \u201cmade greater strides in recovery over the first two years of treatment than patients who got the usual drug-focused care.\u201d But nowhere in the story does it tell us how \u201cstrides\u201d were measured or give us a percentage by which they exceeded those for the control group.\nIt would have taken some additional legwork to find these numbers, which were not reported in plain English in the study itself. But the paper did report some numbers that were very easy to understand and were not mentioned in the story:\n\u201cOver the 2 years, 34% of the NAVIGATE group and 37% of the community care group (adjusted for length of exposure) had been hospitalized for psychiatric indications (not significant).\u201d\nWe wished the story had pressed the study authors more about this.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\nOver the course of the study, the average score on the MMSE questionnaire significantly increased (from 8.7 to 10.6, out of a maximum of 30) in the group receiving probiotics, but not in the control group (from 8.5 to 8.0).\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that over the 12-week intervention period, \u201cthe average score on the MMSE questionnaire significantly increased (from 8.7 to 10.6, out of a maximum of 30) in the group receiving probiotics, but not in the control group (from 8.5 to 8.0).\u201d\u00a0 While the exact numeric values are correct, and the release is to be applauded for attempting to quantify the results (even going so far as to include the range of the scale being used \u2014 very helpful), the word \u201csignificantly\u201d is incorrectly applied in this statement. The MMSE scores at the end of the study are being compared between groups \u2014 not within the same group. A correct comparison might read, \u201cWhen comparing the change in MMSE scores over the 12-week study, there was a statistically significant difference between the two groups- \u2013 the intervention resulted in an improvement in MMSE score in the probiotic group compared to the control group.\u201d The researchers phrased it right in the original publication, but the news release misinterpreted the finding.\nIdeally, the release (as well as the published study) would have discussed what the improvement in MMSE scores means to an individual with Alzheimer\u2019s. Authors stated that \u201call patients remained significantly cognitively impaired\u201d \u2014 so what effect would a two-point increase in MMSE have on a person\u2019s daily life? It would be beneficial for readers to understand the clinical and personal significance of these improvements.", "answer": 0}, {"article": "An ultrasound instrument with a vibrating needle is used to break up the cataracts, and a vacuum sucks them out.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nThe new studies looked at using the so-called femtosecond laser to deliver near-infrared light to fragment the cataract into tiny segments prior to removal.\nThat's important because ultrasound can cause collateral damage to the eye, he says.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We felt that the caveats presented in this article came too late, and were took weak, to provide readers with a balanced perspective on the findings. The headline and first three paragraphs include talk of the laser procedure being \u201csafer\u201d and offering a \u201cbenefit\u201d in terms of \u201cless damage to the eye.\u201d There is also the suggestion later down that the procedure might lead to \u201cfewer complications, less inflammation and swelling of the eye, and faster recovery of vision.\u201d Only far down in the piece does it begin to become clear that these studies looked only at surrogate outcomes such as the amount of ultrasound energy applied during the procedure and the number of movements the surgeon performed. As the story belatedly points out, it is uncertain if improvements in these outcomes reflect benefits that actually matter to patients.", "answer": 0}, {"article": "Xarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\nOf those patients, 136 had bleeding in the brain.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Exactly how should one interpret, \u201c\u2026mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\u201d\u00a0 Without any level of quantification, how is this information at all helpful to the reader.\u00a0 There is a suggestion that the bottom line is fewer deaths but that is merely implied.\u00a0 How much did it lower cardiovascular events, What were the bleeding events and how did the two balance out?\u00a0 Isn\u2019t that the real question that needed to be answered?", "answer": 0}, {"article": "His spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nHowever, 37 percent showed only a minimal reduction of 9.6 percent in frequency of hot flashes, while 4 percent reported a 100 percent increase in hot flashes.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a nice job here, breaking down the results in a detailed, quantified way: \u201cOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said. Forty-seven percent of the study group reported a 47 percent reduction over this same time frame. However, 37 percent showed only a minimal reduction of 9.6 percent in frequency of hot flashes, while 4 percent reported a 100 percent increase in hot flashes.\u201d\nWhat would have made the release stronger would have been to note that 79.5 percent of the control group \u2014 who received no acupuncture \u2014 saw a 10 percent decline in hot flash frequency. That casts the 37 percent of the acupuncture group who had a reduction of 9.6 percent in a different light. i.e., it indicates that any reduction they saw may not have been tied to the acupuncture at all.", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nHowever, she adds, \"I would never comment on a device that's not FDA-approved.\"\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\n\"So we do not need FDA clearance for the device because we are not using it to diagnose or manage disease.\nHe said they have received Nima prototypes and he and his girlfriend, who has celiac disease, are already trying it out.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story references a company official who says that\u00a0Nima can tell if the food sample has 20 parts per million or more of gluten. But the story never provides any data tor numbers to back this up.\u00a0The inventors claim that they are doing \u201ca huge amount of testing,\u201d to \u201cbe sure\u201d of \u201c99.9%\u201d accuracy, but there are no test data given in the story.\nOne could argue that since the company owns up to the fact that it has carefully elected not to seek FDA approval, it has no requirement to offer hard data about the product\u2019s accuracy or benefits for peer review or to the public. But we hold news stories to a higher standard. Clearly the company has done some testing \u2014 what have those tests found? The story had an obligation to push for and analyze those numbers, or make it more clear to readers that we have no idea how accurate this test might be.", "answer": 0}, {"article": "Other studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey treated the mice with metformin either orally or with an injection.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unsatisfactory because all risk reduction figures were in relative terms, not absolute.\u00a0 Read our primer on this.\u00a0 Why not tell us 40-50% fewer tumors THAN\u00a0WHAT?\u00a0 72% fewer tumors \u2013 compared TO\u00a0WHAT? ", "answer": 0}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nThe researchers are a now starting a small study in healthy human volunteers to look for effects on brain function.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story misses the mark in two main areas. No benefits are quantified, and no risks are quantified. Readers are only told \u201cmice\u2026were able to be calmed again with ebselen\u2026.In mice ebselen works like lithium.\u201d\u00a0 Even if the technical explanation for how the mice improved in the study is difficult to explain to a general audience, we think readers deserve some hard data here. All mice were calmed?\u00a0 Half the mice?\u00a0 How many mice were made manic?\u00a0 How big was the experiment?\u00a0 Over what period of time.\nAt a very high level, it is troubling to see a study in mice headlined as \u201cExperimental drug may help people.\u201d\u00a0 It may just as readily be found NOT to help people.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although lots of suggested benefits are mentioned and not quantified, we will still give this story a passing mark, because the \u201cVerdict\u201d is that there isn\u2019t enough evidence to prove red palm oil provides any specific health benefits. To put it another way, readers are given a clear message that while there are many claims and hints bouncing around, the documented health benefit of red palm oil is zero\u2026 and that is a hard number.", "answer": 1}, {"article": "\"Whether the vaccine is going to look anything like this one I don't know.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\nThe vaccine, a complicated mixture of six \"prime\" and \"booster\" shots, reduced a person's risk of becoming infected by about one-third compared with people getting placebo injections.\nHe predicted that information gained from the trial after the results are fully analyzed will have \"important implications for the design of future HIV vaccines.\"\nThe study cost $105 million, most of it provided by the National Institutes of Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It provided the outcomes in absolute terms \u2013 which we appreciate:\u00a0 \"Of 8,197 people who got vaccine, 51 became infected in the three years after their shots. Of the 8,198 who got placebo injections, 74 became infected. While that difference \u2014 23 infections out of more than 16,000 people studied \u2014 is significant, it could have occurred by chance.\"", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article explains that there is so far no independent data quantifying the benefits of the new Gender Knee implant for women. ", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the benefits of breast reduction surgery but does not use any data to quantify the frequency or magnitude of the benefit. ", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in relative terms only. The story says, \u201cResearch has shown an 86 percent to 94 percent success rate.\u201d Readers need to know: 86 to 94 percent of what? And how is \u201csuccess\u201d measured? Also, the story does not compare the effectiveness of spinal decompression with that of other alternatives.", "answer": 0}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nFading, close-up vision is one of the more vexing and ubiquitous consequences of growing older.\nFor Cheri Ekstadt of Lakeville, Minnesota, it\u2019s meant buying nine pairs of reading glasses, which she places wherever she might come across something with fine print.\nJust 15 minutes after the surgery Ekstadt can already see better and can make out a line in the eye chart that she couldn\u2019t decipher before.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story gives us an anecdote about a single patient, who is apparently the first person to have the implant outside of clinical trials.\u00a0This is not helpful for the readers who want to know the research evidence about the surgical implant(s)\u2013what were the measured benefits in clinical trials?", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately describes the main outcome, energy expenditure, and puts it into context, noting that the low-carb group burned about 300 calories more per day than those on the low-fat diet\u2014\u201dabout the same as an hour of moderate exercise\u201d \u2014 and that the low-glycemic group burned about 150 calories less than the low-fat group.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives the absolute number of participants (697) who were enrolled in the trial and then reports the percentages of participants who stopped smoking. While it reported reduced cigarette consumption in relative numbers, it did specify that participants smoked at least 15 cigarettes a day, giving somewhat more meaning to these percentages (e.g. \u201cdecrease their smoking by an average of 29%\u201d). It told us quit rates at four weeks and six months, too\u2013so we get some sense of change over time on results. It also placed these results in the greater context of what we know about quit rates among smokers.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not explain why it is that these two medications might be so commonly prescribed for the same patient. \u00a0It should have explained that Plavix, which is strongly recommended for use by patients who have had a revascularization procedure (such as coronary bypass or stent implantation), can often result in stomach upset \u00a0and bleeding. \u00a0 The use of a PPI was thought to confer benefit as a preventative by lessening this gastric distress side effect.", "answer": 0}, {"article": "U.S.\nThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nThe patient experienced very little downtime and was able to resume normal activities in less than 1 week.\nDuring the 12-month follow-up period, the patient reported a reduction in pain and an improvement in knee function.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t give any data on how large/small are the potential benefits. It only offers general statements\u00a0such as,\u00a0\u201cthe patient reported a reduction in pain and an improvement in knee function.\u201d The release notes that two images were taken, the latter which shows the absence of a tear while the former shows the tear present. The release also offers, \u201cThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities. The patient experienced very little downtime and was able to resume normal activities in less than 1 week.\u201d\u00a0 As noted above, this report is of\u00a0a single patient case \u2014 there was no clinical trial involved.", "answer": 0}, {"article": "(Health.com) -- People who consume lots of foods rich in vitamin B12 -- such as fish and fortified cereals -- may be at lower risk of developing Alzheimer's disease than people who take in less of the vitamin, a small study conducted in Finland suggests.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\nMaria Carillo, Ph.D., the senior director of medical and scientific relations at the Alzheimer's Association, a nonprofit research and advocacy group, urges caution in interpreting the new findings, especially given that so few study participants developed the disease.\nAnd he worries that the results may spur doctors to recommend B12 injections to their patients -- a preventive treatment that he says is unfounded and already overused.\n\"The role of supplementation remains unclear.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nThe researchers followed up with 75 percent of the patients after an average period of five years.\nIn the study, researchers randomly assigned 660 hernia patients to one of the two surgical procedures.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified how often the hernias recurred in each group and how many patients had chronic pain at follow-up. It noted that \u201cthe vast majority of patients do well, regardless of the approach.\u201d This is enough for a satisfactory, though the story could have provided data about how quickly patients were able to return to work with each procedure, and how satisfied they were overall with their results.", "answer": 1}, {"article": "Children slept in the MRI machine while researchers read them bedtime stories.\nBut in the autistic children, there was slightly more right hemisphere response than left hemisphere, and there was no change in activity across the age range.\n\"This is probably not going to be used for wide-scale screening but it could be used for children who we have some sense that they have autism and want to gather more information,\" said David Amaral, president of the International Society for Autism Research and research director of the University of California Davis MIND Institute.\nBut another expert pointed out that the study is still extremely preliminary.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It talks about the potential benefits, but it doesn\u2019t quantify them. There were 30 children in the study with autism and 14 without. It does not make it clear whether all 30 children showed differences in their brain activity patterns or some fraction of them. Instead of a he said/she said between experts, the research may show that all children, no matter where they are on the autism spectrum, show a clear difference in brain activity compared to chilldren without autism. This is what the story indicates, but it doesn\u2019t make it clear. It also does not even attempt to estimate how many people might benefit from this.", "answer": 0}, {"article": "Calorie levels, as well as protein, carbohydrate, and total fat, were kept the same.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not give us numerical measures of the benefits it reports from the study. Instead, the release uses the phrase \u201csignificantly improves\u201d in relation to \u201cinsulin sensitivity\u201d and further states that pecans had a \u201csignificant effect on markers of cardiometabolic disease in otherwise healthy overweight and obese adults with excess belly fat.\u201d\nNone of that helps readers gauge the impact of pecan supplementation.\nThe lead researcher is quoted saying, \u201cWhat\u2019s really interesting is that just one small change \u2014 eating a handful of pecans daily \u2014 may have a large impact on the health of these at-risk adults.\u201d But no where in the releases are readers provided any evidence of a large impact.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\n(Agatston does not make any money from the coronary calcium scan.)\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\nThere's a third test Agatston likes: a $65 blood test that looks at a patient's LDL, or bad cholesterol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only quantifiable statement about benefits included in this story is that \u201cdoctors who are practicing aggressive prevention are really seeing heart attacks and strokes disappear from their practices.\u201d A claim that any combination of tests and treatments can completely prevent heart attacks and strokes is unbelieveable. The incremental benefits that some recent studies have reported in certain patient groups are not clearly spelled out in this story. Those the kinds of numbers that readers should have been provided.", "answer": 0}, {"article": "They had been treated with an average of seven different therapies, including Herceptin, Tykerb, and Xeloda, and each had failed.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\nIn another 12%, tumors stopped growing for at least six months.\nTumors shrank in one-third of women with metastatic breast cancer given T-DM1, says Ian Krop, MD, of the Dana-Farber Cancer Institute in Boston.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the article does present numbers for the outcomes, it does not mention the number of subjects in the study, a key piece of information needed to put the outcomes in perspective. There are further concerns\u00a0about the language used to describe the results. Most importantly,\u00a0the article claims that \"Women remained cancer-free for an average of seven months.\" This sentence appears to be a significant misinterpretation of the data because the\u00a0Dana Farber press release\u00a0states that the median time to\u00a0progression\u00a0was 7.3 months. That doesn\u2019t mean the cancer vanished in these subjects for 7 months: it was there but it just didn\u2019t progress.\u00a0The study abstract from the conference does not provide the relevant data, and thus we cannot confirm the numbers and metrics presented by the author.\u00a0If, however, this was a misinterpretation, it\u2019s significant because a reduction in tumor size (only\u00a0observed in one third of women) is not the same as being cancer free.\nThere are several other points of critique regarding how potential benefits are described. The key result that \"Tumors shrank in one-third of women with metastatic breast cancer given T-DM1\" fails to mention that this population was\u00a0a minority subset of metastatic breast cancer: those with HER2-positive disease. Perhaps readers would infer this caveat from the discussion of HER2 prevalence in the article\u2019s second section, but it should have been stated much earlier, at the very least when the study population was described. Otherwise it overstates the potential applicability of the benefits.\nThe title of the article \"drug shrinks tumors\" is an exaggeration: tumors only shrunk in one third of subjects. Growth was stable in another 12% of subjects, which means that the other half of subjects progressed during the study.\nThe editorial definition of the term \"refractory\" as \"sick\" is\u00a0overly simplistic and perhaps misleading.", "answer": 0}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nThe study is published in the New England Journal of Medicine.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of the potential benefits seen in the study.", "answer": 1}, {"article": "\u201cAfter the first, I needed pain medicine when I came home from the hospital.\nHamilton says that \u201cduring this time, they\u2019re taught both approaches.\u201d But he adds that \u201csince 2009, of the 13 fellows he trained, 12 use the anterior procedure as their primary approach in their practices.\u201d\n\nHamilton says that \u201ca decade ago, very few residencies and fellowships taught the anterior approach.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\n\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the anterior approach to hip replacement, and so we give it a failing grade here. But it should be noted that the story, unlike many in this vein, actually points to the lack of evidence that the approach is superior. The story says: \u201c\u2018He says that while he\u2019s heard about the benefits of the anterior approach, he\u2019s \u2018not aware of a randomized, controlled trial comparing the posterior and anterior approach that shows a definite superiority of one over the other.\u2019 What\u2019s key is that \u2018surgeons need to do the approach they\u2019re most comfortable with to get the best outcomes.'\u201d\nThe clear implication in this story is that most doctors aren\u2019t doing this technique because of convenience around retraining. It should have been pointed out that if there were stuies showing a clear benefit, providers would be morally pushed to make the effort and appropriately pushed by well-informed patients.", "answer": 0}, {"article": "\u201cI knew starting a family was a few years off,\u201d said Gold.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\nThe test has traditionally been offered to women who are struggling to get pregnant and helps assess the possible next steps, such as getting pregnant sooner or freezing eggs.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t provide any quantified information, such as research outcomes involving this test, and instead relied heavily on patient and physician anecdotes. If research is lacking, that should be noted.\u00a0Presumably this test has been studied among women actively struggling to get pregnant, but the quantified benefits of this test for that patient group aren\u2019t\u00a0discussed, either.", "answer": 0}, {"article": "\u201cSurgery puts the diabetes into remission.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on the impact of gastric bypass surgery on diabetes in a very small group of patients (10) in which all of them experienced improvement in their diabetes. \u00a0However \u2013 there are numerous larger studies which have been conducted that have examined the impact of this surgery on diabetes. \u00a0While the impact on diabetes is good, rather than all patients demonstrating benefit, broader experience indicates that about 80% of those with type Ii diabetes will see improvement.\nThe story also implies that there could be some benefit to readers of knowing that branch chain amino acids are reduced by surgery. There is no quantifiable benefit to this piece of the puzzle.", "answer": 0}, {"article": "The associated pain can last months or even years.\n\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nJan. 11, 2011 -- The herpes zoster vaccine, better known as the shingles vaccine and recommended for adults 60 and older, cuts the risk of getting the painful disease by 55%, new research finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story leads with only the relative risk reduction of 55 percent that researchers found in this study, it quickly places that effect in context with that of other vaccines (which generally provide greater protection). The story also reports the absolute risk figures of 6.4 cases per 1,000 people per year among those vaccinated and 13 cases per 1,000 people per year among those who were not vaccinated. These numbers help readers put the effects into the overall context of the risk of shingles. We think readers would have benefitted from also being told that based on the results of this study, one case of shingles is prevented for every 71 people vaccinated. This figure makes clear that while some people who are vaccinated are spared from a shingles attack, not everyone should expect to personally benefit from vaccination.\nThe story should have pointed out  that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.", "answer": 1}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nOral doses of melatonin haven't worked much better at inducing sleep than a placebo in most studies, Scharf says, and a single, concentrated shot of the stuff doesn't exactly mimic the body's time-release system.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not report in detail on any one study,\u00a0but comments from a sleep expert\u00a0 tell readers what they need to know here. He remarks that melatonin\u00a0(a constituent of many of the drinks) doesn\u2019t seem to work much better than a placebo, and that we have\u00a0no idea how\u00a0well valerian\u00a0root\u00a0\u00a0(another supplement found in some drinks) works compared with prescription sleep medicines because they haven\u2019t been compared.", "answer": 1}, {"article": "The investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nAuthor Contact: To arrange an interview with the author please contact Susan Wyatt of the University of Tennessee Medical Center's press office, at SWyatt@mc.utmck.edu or +1 (865) 305-6845.\nOver five months, patients had 10 clinic visits with one overnight stay.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release simply states that \u201cenclomiphene citrate restored blood testosterone levels to normal after 16 weeks.\u201d\nBut in a news release for which the headline states testosterone \u201chelps safeguard a man\u2019s fertility,\u201d we look for something more. And even the limitations discussion of the journal article in question discusses what isn\u2019t revealed in the news release. \u00a0Excerpts:\n\u201cImprovement in patient-reported outcomes (PROs) was not addressed in the present study\u201d\n\u201cThe true impact of a medication on male fertility is difficult to assess without actual pregnancy or live birth data,\u201d admitting that semen analysis is \u201cfar from being a true proxy for fertility.\u201d\n\u201cFinally, the duration of the study is relatively short-term compared with the length of therapy seen in clinical practice.\u201d\nThe release doesn\u2019t tell us about the fertility rates in subjects receiving the new drug, nor to what degree the \u201cmarked reductions\u201d in\u00a0sperm counts in the testosterone group affected fertility.", "answer": 0}, {"article": "They focused on genes known to play a role in folate metabolism.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nStill, she says, the finding points to a gene-environment interaction that may possibly help explain some cases of autism.\nOverall, Hertz-Picciotto says, \"For the women who didn't take prenatal vitamins, there was about a 60% higher risk of having a child with autism.\"\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story communicates the results using relative\u00a0terms, noting that women who didn\u2019t take vitamins had \u201cabout a 60% higher risk of having a child with autism.\u201d In women with a high-risk genetic profile who didn\u2019t take vitamins, the risks were 4.5 to 7 times higher compared with women who didn\u2019t have the high risk genes and took prenatal supplements, according to the story. While\u00a0these relative numbers probably give readers an overinflated sense of the benefits of taking supplements (or the harm of not taking them),\u00a0using absolute numbers, which we normally\u00a0prefer,\u00a0would be inappropriate and probably\u00a0even more misleading in coverage of a case-control study such as this one \u2014 for the reasons discussed here. The use of relative numbers is acceptable in a case-control study\u00a0if there is some indication of the underlying population-wide risk, which this story\u00a0provides when it says that autism\u00a0affects \u201cup to one in 110 children\u201d\u00a0\u2014 or\u00a0about 1%.\u00a0\u00a0While admittedly complicated and imperfect, this mix of numbers\u00a0should help readers\u00a0draw appropriate conclusions about the significance of the findings.", "answer": 1}, {"article": ".\nWhile on the whole grain diet, participants saw a three-fold improvement in diastolic blood pressure (the lowest pressure when your heart relaxes between beats) compared to the refined grain diet.\nIn the study, a group of 33 overweight and obese adults followed a whole grain diet (intervention) or a refined grain diet (control) for two eight-week periods.\nOverall, there were substantial reductions in body weight, fat loss, systolic blood pressure, total cholesterol, and LDL cholesterol during both diet periods, but these differences were due to the people changing their normal dietary habits to carefully controlled diets.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, \u201cWhile on the whole grain diet, participants saw a three-fold improvement in diastolic blood pressure (the lowest pressure when your heart relaxes between beats) compared to the refined grain diet. This improvement equates to reducing the risk of death from heart disease by almost one-third, and the risk of death from a stroke by two-fifths.\u201d However that is a relative risk reduction, not an absolute risk reduction which would have provided readers with a better understanding of the observed change.\nThe release also said, \u201cOverall, there were substantial reductions in body weight, fat loss, systolic blood pressure, total cholesterol, and LDL cholesterol during both diet periods,\u201d but provided no numerical data explaining those reductions.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nWEDNESDAY, Sept. 22, 2010 (HealthDay News) -- Routine mammograms account for only about one-third of the decline in breast cancer death rates, according to a large new analysis of data from Norway's expansive breast cancer screening program.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\n\"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress,\" said the study's lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Right off the bat, the story says, \"Routine mammograms account for only about one-third of the decline in breast cancer death rates, according to a large new analysis of data from Norway\u2019s expansive breast cancer screening program.\" It takes too long, we think, for the story to follow this up with more data. Instead, we are given this dubious statistic from an oft-quoted member of the American College of Radiology. He says that \"since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent.\" Ask an oncologist about what has happened to cancer care since the 1990s, and you may get a different answer as to why that death rate has dropped. ", "answer": 0}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\n\u201cIt shows the relative impacts of screening versus therapy in an era in which therapy has been improving.\u201d\n\nDr. Otis Brawley of the said in a statement that the investigators used \u201ccareful methodology.\u201d The society, Dr. Brawley said, \u201cbelieves that the total body of the science supports the fact that regular mammography is an important part of a woman\u2019s .\u201d\n\nDr. Carol Lee, a radiologist at and chairwoman of the breast imaging commission of the American College of Radiology, said the new study affirmed that mammography saves lives.\nIn their study, the investigators analyzed data from all 40,075 Norwegian women who had received a diagnosis of breast cancer from 1986 to 2005, a time when treatment was changing markedly.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nThis story uses several different statistics and expert perspectives to explain what the researchers found in their examination of the effects of mammography screening. It not only include the relative risk reduction (10 percent) and an absolute risk reduction statistic (among women in their 50s, a decade of screening would boost the likelihood of avoiding a fatal breast cancer from 995.6 out of 1,000 to 996 out of 1,000), but it also offered comments from different experts about how they would personally value effects of that size. ", "answer": 1}, {"article": "That accounts for a small percentage of people.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nThese tests might help with prevention, but cannot diagnose cancer and cannot rule out your chances of getting cancer, 23andMe said.\nThose most at risk of developing such cancers are of Eastern European Jewish descent.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits in this context would, presumably, be an increased awareness of one\u2019s risk for breast cancer; information that can be used to make informed decisions about monitoring and prevention. However, the story does not use numbers in a way that would help women choose the best course of action. For example, it does not explain how accurate the test is, nor does it tell readers how much their cancer risk is increased with a positive result. It also does not explain what women might do to mitigate that increased risk, and how much their risk would decrease as a result.\nWhile it might be too much to ask the story to include all of this information, providing at least some of these numbers would be necessary to meet our expectations for this criterion.", "answer": 0}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nBut the risks of nutrient deficiencies are greater with duodenal switch, and include some not seen with gastric bypass, Livingston pointed out.\n\u201cAnd a closer follow-up after surgery is required after such procedures.\u201d\n\nBut an expert not involved in the study went further.\nBut according to Sovik, duodenal switch might be appropriate for some superobese patients.\nThere was no evidence that surgery improved longevity over the next seven years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear that the duodenal switch surgery, in comparison with the bariatric surgery, may give patients greater weight loss in pounds but the value of that reduction is not clear. The additional information from the paper published by Livingston demonstrating no advantage to surgery over medical management was very useful.", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nKite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\n\u201cIt raises the potential that a cure can be possible.\u201d Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the scope of the benefits for the patients this way:\n\u201cAn independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer. Kite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.\u201d\nWhile the story is murky on the details, this is in reference to 101 patients who received the therapy. This survival outcome was compared to historical data related to how long most people survive if they have no response to first-line treatments. This comparison is not the same as having an actual control group, and the story should have been clearer about that and what it means.", "answer": 0}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nLearn more about psoriasis treatments from the National Psoriasis Foundation.\nThe study lasted one year.\nAn ongoing three-year trial involves 248 people from the current study.\nWEDNESDAY, Oct. 26, 2011 (HealthDay News) -- An experimental psoriasis treatment performed significantly better than the commonly prescribed medication methotrexate in a new clinical trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate explanation of what the study showed for potential benefits.", "answer": 1}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nBefore the zero suicide plan went into effect, says psychiatrist Doree Ann Espiritu, acting head of the zero suicide program at Henry Ford, you might make a contract with a patient where the patient agrees not to commit suicide.\nAs Dr.Thomas Insel, longtime head of the National Institute of Mental Health, prepared to step down from his job in October, he cited the lack of progress in reducing the number of suicides as his biggest disappointment.\nThe Suicide Prevention Resource Center has run two zero suicide training academies for teams from health care systems based on the Henry Ford principles.\nSo they applied to a foundation for a grant to provide something they called \"perfect depression care\" for the 200,000 patients in the health system.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the Henry Ford Health System currently has a suicide rate of 20 per 100,000 among patients with mental health and/or substance abuse problems, which is 80 percent lower than than it had been when the \u201cperfect depression care\u201d was launched in 2001. It also notes that the overall suicide rate for system patients is five per 100,000 \u2014 which is significantly lower than the national average of 12.6 per 100,000. It would have been good if the story had simply given the starting suicide rate among patients with mental health and/or substance abuse problems in 2001 (according to Henry Ford it was apparently 89 per 100,000), rather than asking readers to do the math.", "answer": 1}, {"article": "Ceramic materials have been used since the 1960s.\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\n\u201cPublished research shows squeaking is rare compared with other total-hip-related risks like infection, dislocation and leaving patients with uneven leg length.\u201d\n\nBut plaintiffs lawyers, who have already filed scores of lawsuits on behalf of ceramic hip patients, are gearing up to argue that squeaking is not a minor problem for many who experience it.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news story notes in a sentence that hip replacement has a success rate of more than 90%, and defines \u201csuccess\u201d as \u201crelatively pain-free mobility.\u201d The article also clearly states why this new device was developed \u2014 to provide longer lifetime use prior to device failure. It quantifies this benefit vaguely, saying the device is \"much more durable\" and lasts \"much longer.\"", "answer": 1}, {"article": "That's not what this study says at all.\"\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTUESDAY, Jan. 17, 2017 (HealthDay News) -- Because of stringent tonsillectomy guidelines, some kids who could benefit from tonsil removal surgery aren't getting it, two new reviews suggest.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nGuidelines say a tonsillectomy to treat throat infections is justified if a child had seven or more sore throats during the previous year; five or more sore throats two years running, or three or more sore throats for three years in a row, according to the background notes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is little quantification of the benefits claimed in this story. It summarizes the findings: \u201cChildren experienced nearly half as many sore throats when they underwent a tonsillectomy, even if they didn\u2019t meet the guidelines.\u201d\u00a0 But half of three infections occurring during a 1 to 3 year time period is 1 infection in a year. This is hardly life-changing.\nIt does say that in terms of throat infections, that kids receiving tonsillectomies showed fewer infections in the year following the procedure than did kids not undergoing the surgery, but that advantage disappeared after the first year or so.\nThe story rightfully points out that kids experiencing obstructive sleep-disordered breathing (OSDB) appeared to benefit from the surgery compared to those in the watchful waiting group. But regardless, nowhere in the story is there any quantification to get readers a clear picture of the extent of improvement following surgery.", "answer": 0}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article refers to preclinical \u201cresults,\u201d but gives no data or explanation of what those results involve, much less any quantified benefits. From what we could find, this was based on\u00a0research using mice\u2014a level of evidence hardly worthy of the headline \u201cType 1 diabetes treatment could end need for insulin shots.\u201d", "answer": 0}, {"article": "Someone has a stroke in the United States every 40 seconds, and it has become the leading cause of serious long-term disability among Americans.\nBut for 10 years, Machado and his team have been studying the effects of DBS on rats.\n\u201cDespite advances in physical therapy and acute treatment of stroke there are still too many people who live with long term disabilities, and new technologies are needed,\u201d said Dr. Andre Machado, the chairman of the Cleveland Clinic Neurological Institute who is leading the trial and will perform the procedures.\nDBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Human trials have not yet begun. \u00a0The story discusses rat research:\n\u201cBut for 10 years, Machado and his team have been studying the effects of DBS on rats. They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\u201d\nBut no data were provided to explain what \u201cmore proteins\u201d means \u2013 how much more? In how many of the rats? \u00a0What is the significance of twice as many synapses? \u00a0So the discussion\u00a0of the animal research is almost meaningless.\nNonetheless, we\u2019ll grade this Not Applicable since it\u2019s clear there are no human data to report. However, this does raise the question of why this pre-trial announcement is newsworthy in a national news outlet.", "answer": 2}, {"article": "Feb. 4, 2016.\nThose who received the chlorhexidine-alcohol combination had a 4 percent infection rate, which is nearly half that of the patients who received the iodine-alcohol combination \u2014 7.3 percent.\nAlthough the new study was conducted at only one hospital, the researchers said the patient population was racially diverse and that more than 60 percent received public insurance.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\nThe research shows that patients in the chlorhexidine-alcohol group developed significantly fewer infections than patients in the iodine-alcohol group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits well, explaining that a randomized-controlled trial showed \u201cpatients in the chlorhexidine-alcohol group developed significantly fewer infections than patients in the iodine-alcohol group. Those who received the chlorhexidine-alcohol combination had a 4 percent infection rate, which is nearly half that of the patients who received the iodine-alcohol combination \u2014 7.3 percent.\u201d\nThe news release includes both relative and absolute numbers \u2014 a big plus. The absolute numbers included the number of women who developed infections after being treated with either chlorhexidine-alcohol (23) or iodine-alcohol (42) and the size of their co-hort (572 vs. 575).", "answer": 1}, {"article": "About half of breast cancers develop in the upper-outer quadrant of the breast, which is largely inaccessible to mammography scanners.\nShe stopped routinely teaching self-exams to patients after the large trials in China and Russia showed no benefit.\nThe preferred method, known as the vertical strip, three-pressure test, has proved the most sensitive and least likely to produce false alarms, Steiner said.\nShe said that could partly explain why the Shanghai study failed to find improved survival.\nGiven the lack of evidence, the\n\nconsiders the exams unproven.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discusses two international studies upon which the Cochrane report is based and discusses the findings that there is no demonstrated benefit from regular BSE. ", "answer": 1}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nWhen both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nHowever, they will have to keep an eye on potential side effects from Clostridium novyi-NT, Janku added.\nPatients also could be susceptible to immune response side effects, such as low blood pressure or fever, he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did provide some specific numbers on the scope of the benefit, but we found the wording confusing and unclear:\nThe bacteria germinated in the cancers of 11 out of the 24 patients, with tumor cells dying off as a result.\nTumor shrinkage of greater than 10 percent was observed in 23 percent of patients. However, Janku said this could be an underestimate since the infection causes surrounding tissue to become inflamed, making the lesion appear larger than it actually is.\nFollowing bacterial therapy, cancer stabilized in 21 patients. When both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\nDid the tumor shrinkage occur in 23% of the 24 patients in trial, or the 11 patients in which the bacteria \u201cgerminated?\u201d It appears to be the latter, meaning it\u2019s an even tinier subset of patients who had tumor shrinkage greater than 10 percent\u2013just about 3 patients. (The story also could have explained why researchers picked 10 percent as a measuring point for tumor shrinkage. It did explain that the therapy could have caused inflammation that made the tumors harder to measure.)\nBased on the next sentence\u2013that 21 out of 24 patients had unchanged cancer\u2013the story would have been more clear had it simply explained that\u00a0most tumors neither significantly grew nor significantly shrunk after the therapy. Also, it\u2019s not clear when these measurements were taken\u2013if this was after a year, it seems notable that the majority had stable tumors. But if they measured tumors after just one week, it\u2019s not very surprising.\nContext is also lacking\u2013we don\u2019t know the cancer stage, what is considered a \u201cclinically important\u201d tumor shrinkage, and how the observed shrinkage compares with current treatments. Lastly,\u00a0all of this needs to be taken into consideration with the fact that there was no control group to compare these results against.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides absolute numbers (a percentage) of people in the study who achieved a blood sugar level (A1C) less than 7%, which is the national recommendation, although this goal\u00a0is not appropriate for all.\u00a0 The story also provides the proportion of people who reached an A1C of less than 6.5%.\u00a0 However, there appears to be no comparison group or reference to compare these numbers with.\u00a0 Readers don\u2019t know how much better these results might be compared to other treatment alternatives.\u00a0 So, although it appears absolute numbers are provided, readers don\u2019t have any sense for the absolute benefit these represent.\u00a0\u00a0 ", "answer": 0}, {"article": "They take it up from the soil through their roots.\nTo put the importance of these findings in context: The authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7 percent and the risk of stroke by 10 percent.\nThis is the first study that shows evidence of dietary nitrate supplementation's long-lasting benefit in a group of patients with high blood pressure.\nDuring the 4 weeks in which they were taking the juice, patients in the active supplement group, whose beetroot juice contained inorganic nitrate, experienced a reduction in blood pressure of 8/4 millimeters of mercury (mmHg).\nThe researchers found that \"Inorganic nitrate and beetroot juice supplementation was associated with a significant reduction in systolic blood pressure.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that people in the experimental group who consumed the nitrate-containing beetroot juice showed a reduction of 8/4 mmHg in their blood pressure\u00a0after drinking the juice.\u00a0 In addition, the experimental group showed as much as a 20 percent increase in blood vessel dilation, which may be helpful in reducing the risk of heart disease.\u00a0 No such changes appeared in those people taking the placebo. Finally, the story notes how the changes in blood pressure might be expected to influence overall cardiovascular risk: \u201cThe authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7% and from\u00a0stroke\u00a0by 10%.\u201d", "answer": 1}, {"article": "- People born without the CCR5 gene are generally healthy, but will deleting it have unforeseen consequences?\n\"The cells are engrafting - they're staying in the bloodstream, they're expanding over time,\" said Lalezari, who has no personal financial ties to Sangamo, the study's sponsor.\nAs much as 6 percent of their total T-cells appear to be the new type - resistant to HIV, Lalezari said.\nThis is the first time researchers have permanently deleted a human gene and infused the altered cells back into patients.\nIt will take longer to determine safety, but several AIDS experts said they were encouraged so far.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave very specific details on what happened to trial subjects\u2019 cell counts \u2013 and over what span of time. Of course it\u2019s too soon to know if those lab results will translate into differences in the peoples\u2019 lives.\nBut a MedPage Today story carried a more significant statement from a member of the conference program committee:\u00a0 \u201cWe do not know yet from the experiments whether there is any antiviral activity.\u201d", "answer": 1}, {"article": "The women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\nBut the data are reassuring for millions of middle-aged women without a uterus who take estrogen to relieve hot flashes and other menopause symptoms.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nI hope it gets across to women, because we are not reversing ourselves.\u201d\n\nIndeed, the investigators emphasized that the results do not change recommendations concerning combination hormone therapy for the two-thirds of menopausal women who still have a uterus.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here. The story does some of this, giving readers a \u201cquantifier\u201d example about how many of 10,000 women might forgo heart attacks due to taking estrogen, based on the study\u2019s findings. But sadly, they don\u2019t give a similar quantifier for the perhaps exaggerated headline: \u201cEstrogen lowers breast cancer risk.\u201d\u00a0 The same type of absolute risk calculation shows that the margin of benefit, if it exists, would be small: 8 fewer cases per 10,000 women per year. There may be a statistically significant difference, but it is small.\u00a0 Because of this omission, we judge this one unsatisfactory.", "answer": 0}, {"article": "Since 1960, CF Canada has invested more than $244 million in leading CF research and care.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would appear to be that diagnostic testing for CF would be better able to identify infants who have CF, and possibly understand more about the expected course for individual patients \u2014 particularly patients with borderline results on the sweat chloride test currently used to diagnose CF in newborns. However, it\u2019s not clear how common these cases are. Are there a lot of patients who have borderline sweat chloride tests?\nIn addition, the release doesn\u2019t tell us how much better the new biomarkers are at diagnosing CF. It suggests that the new tests add accuracy to the diagnosis \u2014 but by how much? ", "answer": 0}, {"article": "In addition to Jaffe, co-authors include Andrew D. Dick, Antoine P. Br\u00e9zin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are well-represented in the release, and so is their context. By working adalimumab into the standard treatment, most of the key measurements of uveitis are held in check for nearly twice as long in a typical patient \u2014 24 weeks instead of 13 weeks.\nThis represents improvement \u2014 but not a cure \u2014 for a chronic disease.", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nPalliative Care Consults for Patients with Advanced Cancers Reduces Hospitalization and Improves Quality of Care\n\nIntegration of Palliative Care Improves Many Measures of Quality\n\nNewswise \u2014 (NEW YORK \u2014 March 15, 2017/Embargoed until March 17, 4:00 pm ET) Cancer patients admitted to the hospital with advanced stages of disease who were referred early to palliative care had decreased health care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPatients were eligible for this prospective cohort study if they met one or more eligibility criteria: advanced solid tumor cancer, prior hospitalization within 30 days, hospitalization for more than 7 days, or active symptoms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn from this announcement that early referral to palliative care \u201cdecreased health care utilization and increased use of support services following discharge\u201d for cancer patients at advanced stages of the disease. But how much? Did health care utilization decrease by 1%? 5%? 40%? The specific results of the study are not reported. To be able to interpret the importance of these results, readers need numbers. Without that, the assertion by one of the researchers that hospitals across the country should adopt this practice appears tenuous.\nThe study in the Journal of Oncology Practice provided both relative and absolute risk numbers for the claimed benefits of palliative care (PC) referrals. It would have made the release much stronger had the absolute numbers been included.\nAmong patients that were part of the study in either the control group or the intervention group, 30-day hospital readmission rates decreased from 35% (17 of 48) of patients in the control group compared to 18% (13 of 65) of those receiving the intervention. Referrals to hospice increased from 14% (7 out of 48 patients) among controls to 26% (17 of 65 patients) of the intervention group, and receipt of chemotherapy after discharge decreased from 44% (21 of 48) of controls to 18% (12 of 65) of those in the intervention group.", "answer": 0}, {"article": "\u201cYou have to be pretty bad to do poorly on this exam,\u201d she said.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\nDuffy said his tool holds promise as a relatively inexpensive and easy way to test people\u2019s memory and ability to think.\n\u201cWhat we are all about is making cognitive care part of primary care.\u201d\n\nMore than 5 million Americans have Alzheimer\u2019s disease, the leading cause of dementia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline suggests that the FDA approved the test for \u201cdiagnosing dementia in the doctor\u2019s office.\u201d But the actual FDA approval notice says: \u201cThe Computerized Cognitive Assessment Aid is not intended as a\u00a0stand-alone or adjunctive diagnostic device.\u201d The story\u00a0does later qualify that the device \u201cis not intended to be a stand-alone diagnostic tool,\u201d but the FDA says the device isn\u2019t a diagnostic device at all, which is a confusing disparity. We acknowledge that reporters often don\u2019t have any control over their headlines but nonetheless the issue needs to be raised. We thought this needed more explanation.\nThe story suggests that this non invasive, simple and quick (10 minutes sitting at a computer terminal) is either more accurate or just about as accurate as a commonly used test called the Mini Mental State Exam and is easier to use.\u00a0 The suggestion is supported by comments from the inventor of the test and two primary care physicians.\u00a0\u00a0We are also told that the device/test was applied in a sample of 401 older adults who were classified as cognitively normal, slightly impaired or impaired and compared to the results of another test with the acronym SLUM.\u00a0 But, we are never provided with any information about the\u00a0test characteristics that have to do with accuracy (e.g. sensitivity, specificity) or how the two tests compared in the actual study. What were the rates of false positive and false negative results seen with Cognivue as compared to SLUM?\nTo the article\u2019s credit, it does bring up an important point about how the tool can be incorporated into physician workflow in a way that may make adoption easier (patient does the test right before or after seeing the doctor, for example). That\u2019s useful context, but not enough for Satisfactory rating here.", "answer": 0}, {"article": "There is also a suggestion that statins reduce systemic inflammation and may be protective against RA and other chronic inflammatory diseases.\n\"But one important message is that people who have been prescribed them should adhere to treatment.\nIn the newly published study, Chodick and colleagues examined data on 1.8 million members of Israel's Maccabi Healthcare Services HMO.\nBut it is not driven by inflammation, so statin use is not as likely to affect its development or progression.\nBetween 1998 and 2007, 2,578 new cases of rheumatoid arthritis were identified in this group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not clearly explain what a 40 percent reduction in the risk of developing rheumatoid arthritis really means. How many fewer cases developed than were expected? The story doesn\u2019t say. It reports that the researchers reviewed medical records of almost 2 million health plan members in Israel and that about 2,500 new cases of rheumatoid arthritis were diagnosed during the study period. But readers can\u2019t tell from this information what the typical risk of rheumatoid arthritis might be, so they are left to ask: 40 percent of what?", "answer": 0}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\nAbout half them had brain-related injuries, and half had other traumas, including broken bones and chest injuries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers should be informed of how many people with a concussion were accurately identified, and how many people without concussions were accurately ruled out. The story doesn\u2019t tell us, nor any other quantified benefits.", "answer": 0}, {"article": "\"It's all about being creative and finding environments where the cold doesn't become an issue.\"\nResults were overwhelmingly clear: those who engaged in optimal levels of physical activity on a regular basis were nearly two-and-a-half times more likely to have good control of their symptoms, compared with those who did no exercise.\nCould a prescription for exercise be the result of this study Bacon is hopeful.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\nOnly 100 said they engaged in the optimal 30 minutes a day.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reported the benefits of physical activity in relative numbers, stating \u201cthose who engaged in optimal levels of physical activity on a regular basis were nearly two-and-a-half times more likely to have good control of their symptoms, compared with those who did no exercise.\u201d To which we respond:\u00a0Two-and-a-half times more than what? While the statistic is technically accurate, there is no translation of this into an absolute number that a reader could use to interpret the result \u2013 such as x% of those who exercise reported adequate control versus y% of those who did not. The news release also prefaced this statement with \u201cResults were overwhelmingly clear.\u201d But many questions were left unanswered. What does it mean to have \u201cgood control of their symptoms?\u201d And who exactly experienced these benefits? Does \u201coptimal levels of physical activity\u201d mean 30 minutes every day? More clarification would have been welcome here.", "answer": 0}, {"article": "The practice was repeated at home every day.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n\u201cOur findings are encouraging, as they represent an improvement in the core symptoms of autism previously thought very resistant to change.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify the benefits with this statement:\nAt the start of the trial, 50% of those in the control group who did not get the therapy and 55% of those who did were assessed as severely autistic. The children in the intervention group, though, got better. The proportion assessed as severe in the control group was 63% by the end of six years, compared with 46% in the intervention group.\nBut as we point out in the summary, there were some important limitations to this finding.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\nWhy, Dr. Anderson asked the company executives, couldn\u2019t there be a polymer to put on skin?\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Though we\u2019re told there\u2019s a new published paper about several pilot studies, the story does not include any hard numbers from the research on what the measured benefits were. The photos included with the story\u2013do they represent a best-case scenario? They have the potential to skew reader perception.", "answer": 0}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\n\"It's a technological approach that makes a lot of sense,\" said Dr. Jan Drutz, a general pediatrician at Texas Children's Hospital who calls needle-phobia common in both kids and adults.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is simply not accurate to state, as this story did in the first sentence, that this patch \"vaccinates against the flu\"\u00a0because it hasn\u2019t been tested in humans yet. We\u00a0also can\u2019t believe the story quoted a researcher saying the patch\u00a0\"appears to vaccinate against influenza at least as well and probably better than a traditional hypodermic needle.\" Again, these are mice, not people, we\u2019re talking about here, and so these statements\u00a0go far beyond what the evidence reasonably supports.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nWhat if we told you that a guy with no background in science or medicine - not even a college degree - has come up with what may be one of the most promising breakthroughs in cancer research in years?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only evidence of benefits given is a brief description of the effects the technique appears to have had on the cells of rat tumors. Even within the realm of animal testing, there is no quantification of benefit.\u00a0 Were all cancer cells killed in all rabbits and rats tested?\u00a0 Some in all?\u00a0 Some in some?\u00a0 None in some?\u00a0 Sweeping statements such as \"They\u2019ve already shown that the Kanzius machine can heat nanoparticles and cook cancer to death in animals\" does nothing to educate viewers. \u00a0 ", "answer": 0}, {"article": "Scientists still haven\u2019t discovered a cure for the common cold, but researchers now say zinc may be the next best thing.\nThe review found that not only did zinc reduce the duration and severity of common cold symptoms, but regular zinc use also worked to prevent colds, leading to fewer school absences and less antibiotic use in children.\nSince that study, 18 more trials of zinc for colds have been conducted: 11 of them showed it to be a useful treatment, while seven of them showed no benefit, according to the review.\nAll the studies compared zinc use with a placebo, but in several studies the zinc users complained about the taste of lozenges, suggesting that some people may have known that they were using zinc rather than a placebo.\nThe authors declined to make recommendations about the optimal dose, formulation or duration of zinc use, saying that more work was needed before they could make recommendations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that when zinc is taken within the first 24 hours of developing cold symptoms, it cuts the duration of a cold by an average of 1 day. No data from the review were provided regarding other outcomes, such as severity of symptoms, reduced absences from school, and reduced antibiotic use. Also, the story should have noted that a preventive effect was found after 5 months of zinc use and people who experienced a therapeutic benefit took zinc for at least 5 days during their cold.\u00a0", "answer": 0}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt slowed the damage and in some cases reversed it, they found.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story has just a vague reference to treating heart symptoms. It does not offer any specific data, not even about the mice in this trial. \n ", "answer": 0}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n\"What makes this paper unique is that it looked at the effects of EPA and DHA on coronary heart disease specifically, which is an important nuance considering coronary heart disease accounts for half of all cardiovascular deaths in the U.S.,\" said Dr. Dominik Alexander, lead author and Principal Epidemiologist for EpidStat.\n\"Remember that increasing omega-3 intakes is basically just improving the quality of one's diet slightly, like reducing the amount of sodium or increasing your dietary fiber.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that, among the RCTs, \u201cthere was a statistically significant reduction in [coronary heart disease] risk in higher risk populations, including\u202616 percent in those with high triglycerides and 14 percent in those with high LDL [low-density lipoprotein] cholesterol.\u201d So the release is claiming that seafood, supplements and pharmaceuticals offer a 16 percent reduction in risk of coronary heart disease for people with high triglycerides. That sounds good, right? But over what time span? A year? A lifetime? And how high does a person\u2019s trigylceride count need to be in order for that person to have \u201chigh triglycerides?\u201d The release doesn\u2019t tell us. And then things get really confusing. Consider this statement: \u201cA non-statistically significant 6 percent risk reduction among all populations in RCTs, a finding supported by a statistically significant 18 percent reduced risk of [coronary heart disease] among prospective cohort studies.\u201d Does the statistically significant finding somehow make the non-statistically significant finding more, well, significant? No. Does bundling those two things together into one sentence muddy the waters for readers? You bet. Does the release still fail to explain the time-frame it is using when discussing risk reduction? Yes.\nProviding readers with figures describing the absolute risk reduction would have been very helpful here. ", "answer": 0}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nAnd many of the studies were short in duration, comparing sleep duration in snapshots before and after a school made a switch.\nWhen it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nThe study also found some preliminary evidence that later school start times were associated with better mental health outcomes.\n\u201cThe aggregated quality of the evidence,\u201d the study reports, \u201cis only moderate.\u201d The researchers also found no effect on academic performance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is specific about the average sleep advantages of a later start time among teenage participants in the 18 studies evaluated. For this reason, it rates satisfactory.\nHowever, its discussion of other benefits\u2014including fewer accidents involving teens behind the wheels of cars, mental health indices and actual school performance\u2014is general and, with respect to school performance, more optimistic than the meta-analysis\u00a0that is the centerpiece of the story.", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nDr. Papakostas agrees the study \u201cneeds replication\u201d but said he is hopeful about the potential for future research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the proportions of the active and control groups who showed improvement and experienced complete remission. The piece could\u2019ve been more specific about what improvement meant.\n It was too vague when summarizing the 2002 AHRQ analysis that found \u201cclinically meaningful benefits\u201d and that SAMe worked \u201cas well as tricyclic antidepressants.\u201d (See our comments on Novelty.)", "answer": 1}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nThe average weight loss was below what experts consider good results.\nNearly half of the 82 patients followed for 12 years or longer required removal of the bands and about 40% had major complications, the researchers found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit reported on in this story was the average loss of excess weight experienced by those who had had the procedure and in those who still had their Lap-Bands at the end of the study period.", "answer": 1}, {"article": ".\n\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\nThe rate of fractures in the treated women who had osteoporosis declined by 50 percent during the 10-year-long study.\nA decade after the study began, the women who received the larger growth hormone dose still had higher bone mineral density levels than the participants who received the lower dose or the placebo.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes that the rate of bone fractures among study participants declined by 50 percent over the 10-year course of the study and provides an absolute measure of that benefit: 56 percent of participants had experienced a bone fracture before the study, and 28 percent had a bone fracture over the course of the study. We\u2019ll give credit for the quantification, however it must be noted that this before and after comparison is seriously limited in what it can tell us about the benefits of growth hormone treatment \u2014 something addressed below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "\"This is a very expensive drug,\" he said.\nThey looked at 83 gout patients in 27 U.S. study centers who had a history of gout flare-ups and high levels of uric acid.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\nRilonacept patients were less likely to have flare-ups, with 15 percent experiencing flare-ups three-months into the study compared with 45 percent among the non-rilonacept group, the researchers found.\n\"To reduce deposits of crystals in the joints, we advise patients to initiate treatment with medications that lower levels of uric acid in the blood,\" study author Dr. H. Ralph Schumacher, Jr., a professor of medicine at the University of Pennsylvania School of Medicine, said in a journal news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that \u201cRilonacept patients were less likely to have flare-ups, with 15 percent experiencing flare-ups three-months into the study compared with 45 percent among the non-rilonacept group.\u201d\nBut not all flare-ups are equal.\nHow was a flare-up measured?\u00a0 The story doesn\u2019t explain.\nWas it a measurement of uric acid levels?\u00a0 Or was it patient self-reporting?\nIn other words, what difference did this make in subjects\u2019 lives?\u00a0 We can\u2019t judge from the story the way it was reported.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes an astonishing mess of the key data:\nAfter more than six years of tracking, the study found that 44% of the patients had tumors that had a 12% risk of recurrence within three years, which the researchers considered low risk. An additional 26% had a three-year recurrence risk of 22%, which researchers put in the high-risk group. The rest were in the middle.\nEven a reader lucky enough to have within easy reach a calculator and a high school student taking advanced statistics is unlikely to figure out what this means in practical terms.\nBut this is what you get when you report on abstracts far in advance of any possible publication.\u00a0 ", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story starts with the premise that screening for bone density is recommended by many health care organizations and that doing so will lead to fewer bone fractures and, in the case of hip fractures, perhaps reduce deaths in men whose health declines after a fracture. The story says that the study \u201cfound women were about three times as likely as men (53% versus 18%) to be tested using a bone-density scan.\u201d But that doesn\u2019t tell us the benefits of doing the scan. The assumption is that scanning everyone who comes in with a fracture for bone density will lead to health improvement. Some proof to back that up would have been nice. The closest the story comes to this is an anecdotal reference to Kaiser Permanente in Southern California, which apparently started a screening program in 1997 and, since then, \u201cthe rate of hip fractures at Kaiser is down 40%.\u201d\nTo be clear, our understanding is that evidence supporting a fracture prevention benefit for screening in men doesn\u2019t exist, so the best the story could have done would be to extrapolate from studies involving women. The story doesn\u2019t go that far or acknowledge an evidence gap in this area. But that\u2019s an omission we\u2019ll penalize the story for below in the Evidence section, while ruling the Benefits description satisfactory.", "answer": 1}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nMore patients on the drug had the required improvement in symptom severity.\nBut Human Genome Sciences, in consultation with the Food and Drug Administration, restricted the Phase 3 trials to a subset of patients who seemed to respond better to the drug in the earlier trial.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided quantitative information about meaningful improvement of symptoms, comparing two doses of the drug with placebo. \u00a0However \u2013 the story gave no insight about what symptoms it was measuring and whether the difference between the two doses significantly differed from one another. \u00a0It should have provided more detail about the nature of the improvements observed.", "answer": 0}, {"article": "Here's why.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nThe trial that grabbed much of the spotlight Monday is a randomized effectiveness study that involved more than 600 untreated patients with advanced nonsquamous non-small cell lung cancer \u2014 a common type of the disease.\nIn a second study published Monday, researchers used two other immunotherapy medications \u2014 Opdivo and Yervoy, both made by Bristol-Myers Squibb \u2014 to treat newly diagnosed patients with advanced non-small cell lung cancer with a high number of mutations in their tumors.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When it comes to the overall survival benefit, the story reports that after a median follow-up time of 10.5 months patients who received both Keytruda and chemotherapy were 51 percent less likely to die, compared with patients who received only chemo.\nBut actual percentages aren\u2019t given. According to the study, the estimated proportion of patients who were alive at 12 months was 69% in the combination group and 49% in the chemo-only group.\nThe story also describes \u2014 but doesn\u2019t give numerical data \u2014 on a different Keytruda trial that it says \u201cshowed that the medication prolonged survival even when used alone, compared with chemo.\u201d\nThe story mentions two other immunotherapy lung cancer studies, one using two medications called Opdivo and Yervoy to treat newly diagnosed patients with advanced non-small cell lung cancer with a high number of mutations in their tumors, and another treating patients with early-stage lung cancer with Opdivo before and after surgery. Only some data were reported for those studies.", "answer": 0}, {"article": "However, oral pills cause side effects such as bleeding between periods, mood swings and nausea in women.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nOppenheimer analyst Leland Gershell said he expects Amphora, the company\u2019s lead product, to bring in sales of up to $415 million by 2032.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story briefly describes a study in 1,400 young women, from which researchers calculated that the gel had an 86% efficacy rate \u2014 a common measure of birth control efficacy. However, it could have explained that better: In the contraceptive research world, this generally means that the failure rate is 14 pregnancies per 100 women in a year. But researchers only studied the gel for seven menstrual cycles.\nThe story compares this pregnancy rate to a couple of of other forms of birth control, which is good, but it\u2019s worth pointing out that those failure rates have far more evidence behind them. The efficacy rate for this new product is based on just one industry study.\nAlso, the story makes a vague reference that the gel may kill \u201ccertain viral and bacterial pathogens that can cause sexually transmitted diseases.\u201d Only at the end of the story do we find out that researchers have no data yet for this claim.", "answer": 1}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nThe hormone therapy started two months before radiation.\nAn ongoing trial among patients with intermediate risk prostate cancer aims to answer that question, Jones said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided a clear description of the potential benefit seen in the group of men with intermediate risk prostate cancer who were treatment with male hormone therapy in addition to radiation therapy alone.", "answer": 1}, {"article": "One therapy at M.D.\nThe treatment \u2014 shots that grab the immune system and jolt it to fight against rebel tumor cells \u2014 has been a dream for more than a century.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nBecause it doesn't inflict the damage to healthy tissue caused by chemotherapy and radiation, immunotherapy's great appeal is its nontoxicity.\nOverton chose the experiment, an injection he receives every three weeks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of immunotherapy.", "answer": 0}, {"article": "At least half of all sexually active males and females have had HPV, according to the Centers for Disease Control and Prevention.\nThe phase 1 results are very early in the experimentation of this vaccine.\nThe vaccine consists of three injections in the arm over three months, Kim said.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nBut there are a lot of people out there who still have HPV, and nothing protects against all 130 strains of the virus.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the benefits of the vaccine in the first clinical trial.", "answer": 0}, {"article": "\"We've got a lot of repeat customers, unfortunately,\" Shah said.\nIn the January issue of American Heart Journal, a meta-analysis of 28 years of studies, some of them conducted in Europe and Canada, found a 73 percent reduction in bleeding and shorter hospitals stay among radial patients.\nShah and Mazhari say that their patients, many of whom have undergone both kinds of catheterizations, much prefer the wrist approach.\nA report in the August 2008 Journal of the American College of Cardiology: Cardiovascular Interventions compared outcome data for more than 593,000 procedures -- 7,800 of them radial -- performed between 2004 and 2007 at 606 hospitals.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of the treatment was presented in terms of patient comfort and time, and presented quantitative information indicating the radial approach results in a reduction in bleeding complications as compared with the femoral artery. But it did not provide any data about the outcomes of the procedure, namely, \"How did it do in opening arteries?\"\u00a0 It is interesting to note that the meta-analysis cited in the story concluded that additional studies are needed to better define the role of this approach, which was not mentioned in the story.\u00a0 ", "answer": 0}, {"article": "\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\nIt is meant for people looking for an extra jumpstart on a diet, whether the purpose is cosmetic or for health reasons.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not address benefits in any kind of meaningful way, much less offer any quantification of the benefits. Instead, the story tells readers what the \u201cobjective\u201d of Orbera is. It also offers an anecdote from one patient who used Orbera and credited it with helping her lose weight.\u00a0Is this one patient\u2019s experience normal for other users of Orbera? The story doesn\u2019t tell us. Other than this one patient\u2019s testimony, the story offers no evidence that Orbera works at all, much less how well it might work. Is the weight loss short-term or long-term? Obesity is a chronic disease, but this device is temporary. How does that impact the patient\u2019s weight in the long range?\nThe story also doesn\u2019t tell readers how weight loss might be related to an individual\u2019s actual health. Instead, it notes that Orbera should not be used by people who are \u201cmorbidly obese.\u201d The story says Orbera is for people with a body mass index of 30 to 40 and \u201cis meant for people looking for an extra jumpstart on a diet, whether the purpose is cosmetic or for health reasons.\u201d Why that BMI range? Another question the story doesn\u2019t answer.", "answer": 0}, {"article": "This test will most definitely save lives.\"\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nSome questioned its reliability, while others worried that the results could either lull women into a false sense of complacency or needlessly alarm them, prompting them to take unnecessary tests or even undergo unneeded surgery.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n\"What this does for women is allow them to assess their personal risk for the common forms of breast cancer,\" said K\u00e1ri Stef\u00e1nsson, Decode's chief executive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman\u2019s lifetime risk of developing cancer.\u00a0 There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test.\u00a0 Most experts advise against women taking this test, and the American Cancer Society does not promote the test.", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, exercise did boost bone mineral density, a proxy for bone strength, their report shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "From a purist\u2019s perspective, we wish the story had quantified the benefit seen from exercise.\u00a0 We\u2019re told that adding supplements to the exercise program didn\u2019t provide any extra benefit.\u00a0 But just what was the degree of benefit from exercise?\u00a0 We\u2019re never told.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nIdeally, the team could develop the enzyme into a food additive such as the gas remedies Beano or Gas-X and offer it without a prescription, said lead study author Justin Siegel, assistant professor of chemistry and biochemistry at the University of California, Davis.\nThe process of identifying the precise trigger for a disease or condition and engineering a drug to circumvent the disease-causing process is part of what some call the personalized medicine revolution, Siegel said.\n\"People need alternatives, and this is an example of the scientific community taking novel approaches to helping people with celiac disease,\" Murray said.\nMurray said that dismantling 95 percent of the protein component that is thought to trigger celiac disease may still not be enough to provide celiac patients protection.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is far more\u00a0generous in discussing potential benefits than these results warrant. Quoting a study author,\u00a0the story\u00a0suggests that patients with mild cases of celiac disease\u00a0could \u201cpop one [pill] before each meal and eat anything they want.\u201d\u00a0Really? Based on a single test tube experiment?\u00a0Even if the enzyme was capable of dismantling\u00a095%\u00a0of the harmful protein, as the story suggests,\u00a0we\u2019re never told how quickly\u00a0the protein\u00a0was neutralized, or how much enzyme was\u00a0needed to break down how much\u00a0gluten, or what amount of actual food the gluten in the test corresponded to.\u00a0In other words, we\u2019re given no reason to believe that these data have any real-world application to celiac patients at this time, and so such\u00a0speculation would only be acceptable if accompanied by strongly worded caveats. Unfortunately, the only caveats\u00a0come at the very end of the story, long after it has been\u00a0suggested that the pill might allow celiac patients to \u201ceat freely.\u201d", "answer": 0}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\nDerek Ochiai, a surgeon with the Nirschl Orthopaedic Center in Arlington, who began performing hip arthroscopy six years ago, estimates that he did only about a dozen of the procedures that year.\nOchiai said many patients see three or four orthopedists before getting a proper diagnosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story provides no quantification of benefit. The anecdotal evidence of long-term benefit provided by one surgeon\u2013that \u201chip arthroscopy may be a way of delaying or even possibly preventing hip arthritis\u201d\u2013is controversial, and viewed with skepticism by many experts. (Clin Orthop Rel Res 2009;467:605-7) ", "answer": 0}, {"article": "Ongoing updates are expected in journals and meetings later in 2017.\nPrevious trials concurrently targeting estrogen and HER2 have been, according to Borges, \"lackluster,\" resulting in no changes to the standard of care.\nWorking with Borges's Young Women's Breast Cancer Translational Program at CU Cancer Center, young investigator Elena Shagisultanova, MD, PhD, recently earned a $1.4m competitive ASPIRE grant from Pfizer, Inc., to conduct a clinical trial exploring the use of tucatinib against so-called \"triple positive\" breast cancer - those cancers driven by both estrogen and progesterone receptors and the HER2/neu oncogene.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nTwenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least \"stable disease\" at 24 or more weeks after the start of treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The discussion of benefits is somewhat confusing. The news release says that 27% of the women treated with tucatinib \u201csaw clinical benefit\u201d from the drug. However, the article itself states that evaluation of the drug\u2019s impact was possible for only 35 women, and of these women, 20 showed no progression of their disease, while there was a \u201cpartial response\u201d for three women, meaning that their tumors shrank by at least 50%. The most important benefit identified by the original study actually was that tucatinib caused less frequent and less severe side effects (including diarrhea and rash) than the alternatives currently used in treating these types of breast cancers. The news release barely mentioned this finding, stating simply that the drug \u201chas a very favorable side effect profile\u201d without explaining what that means.", "answer": 0}, {"article": "The disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nAs Schiff explained, people's genetic makeup has a lot to do with whether they respond to the treatment.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\nAt this point, it's not clear how much the drug might cost or how it would work with existing drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the story, patients who received BMS-790052 had lower levels of the hepatitis-C virus in their bodies for several days.\u00a0While this is an appropriately\u00a0sober description of an early phase clinical test, the discussion of the other two experimental drugs mentioned in the article was, as discussed above,\u00a0not nearly as judicious.\u00a0Saying these unapproved drugs will\u00a0\"boost\u00a0cure rates,\" without delving into any of the\u00a0evidence which supports the claim, strikes\u00a0us as hype rather than help.\u00a0\u00a0", "answer": 0}, {"article": "Rates are rising, in part because tanning became fashionable.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\n\"These are patients whose disease cannot be surgically removed, cannot be cured by surgery and usually the majority of these patients have disease that involved vital organs,\" said Dr. Stephen Hodi, a melanoma specialist at the Dana-Farber Cancer Institute who worked on the study.\n\u201cThis is huge in the melanoma community,\u201d said Tim Turnham, executive director of the Melanoma Research Foundation.\nThat means 60 percent of patients are not living that long \u2014 but it\u2019s still far more than the usual 11-month survival with advanced melanoma.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the total study population of 655 people with advanced melanoma, and how the average patient lived 2 years. The story also notes a 3-year survival of 40%, which the headline teases, and notes a 15% \u201ccomplete remission\u201d result. We\u2019re also glad the story was frank about the fact that 60% of patients didn\u2019t live three years.\nThe story does a nice job putting those numbers into perspective by quoting Tim Turnham, executive director of the Melanoma Research Foundation, who notes people with a similar diagnosis typically only live 11 months.\nAlthough no study can account for all variables, a doubling of lifespan with limited side effects is worth writing home about.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nThe test correctly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nThe group also has trained many international colleagues to use and advance the test.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the test \u201ccorrectly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\u201d The author also noted the number of people tested.", "answer": 1}, {"article": "\"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says.\nThe patients received 10 such injections during a single catheterization procedure.\nStudy participants received one of three treatments: low-dose CD34+ injections, high-dose injections, or placebo.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Again, the bulleted breakdown of impact on number of angina attacks, exercise tolerance test scores, and nitroglycerin use was appreciated.", "answer": 1}, {"article": "The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report.\n\u201cWhat\u2019s really unique here is that all the patients in the study with TP53 mutations had a response to decitabine and achieved an initial remission,\u201d said the study\u2019s senior author, Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, noting that in AML, TP53 mutations have been correlated with an extremely poor prognosis.\nAmong patients in the study with such mutations, median survival was 12.7 months \u2013 which is not significantly different from the 15.4 months\u2019 survival seen in patients without the mutations \u2013 and is longer than the typical four- to six-month survival observed in such patients treated with more aggressive therapies.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nIndeed, 66 percent of patients with an unfavorable risk achieved remission, compared with 34 percent of patients who had more favorable prognoses.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes the benefit of the preliminary trial in sufficient depth and with appropriate cautions. It relates that each of the 21 patients with TP53 mutations had a remission, compared to 46 percent of the entire trial group of 116 that achieved some remission following treatment. According to the release, standard treatment typically induces remission in about 20 to 30 percent of patients with TP53 mutations.\u00a0 While the numbers look good from this trial, the researchers note that larger studies need to be done.", "answer": 1}, {"article": "\"I could ride a bike!\nPetresky says they ask every family about the child's favorite color, superhero and interests, so the new limb can \"not just be a piece of plastic ... but be a part of them.\"\nThe organization creates and shares bionic arm designs for free download at EnablingTheFuture.org that can be assembled for as little as $20 to $50.\nHe was wrapped in the joy of leading and advising students on how to help children like himself,\" she wrote in her iReport.\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that this sort of 3D printed arm can be made to look really cool. Other than that, it doesn\u2019t say anything about how well the arm actually works. The cheery impression conveyed by the story oversells the performance of this sort of device. The website of the E-Nable group mentioned in this story cautions that their 3D printed hands \u201cshould be seen as TOOLS and not a fully functional prosthetic device.\u201d", "answer": 0}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nBut even the oldest cyclists in this study averaged barely 5 seconds for the walk, which is \u201cwell within the norm reported for healthy young adults,\u201d the study authors write.\nThe scientists then ran each volunteer through a large array of physical and cognitive tests.\nOf course, this study is based on a single snapshot of an unusual group of older adults, Dr. Harridge said.\nThey also had the volunteers complete the so-called Timed Up and Go test, during which someone stands up from a chair without using his or her arms, briskly walks about 10 feet, turns, walks back and sits down again.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made a reasonable attempt to quantify the study results in a way that would make sense to readers. It explained what the \u201cTimed Up and Go\u201d test is, and compared the results from the study participants with those of typical older adults and normal young adults.", "answer": 1}, {"article": "It is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\nRogers said up to 50 percent of men discontinue drug therapy \u2014 which includes Viagra, Levitra and Cialis \u2014 either because it did not work or because they could not tolerate side effects, including lowering of blood pressure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As stated above in the \u201cevidence\u201d criterion, the potential benefit wasn\u2019t made clear.\u00a0 There was no critical evaluation or explanation of what it means to improve by 4 points on the 30-point index of erectile dysfunction scale.\nWhat difference does such an improvement mean in men\u2019s lives?\nBasically, to interpret the results, we would also need to know baseline function and then post-procedure function. More interpretable data would be responses to specific standard questions about erectile function, e.g., whether erections were firm enough for intercourse, how often did the man have an erection when he wanted one.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide much numerical context to tell us how this test would benefit patients. It does state that the test predicted with 73% accuracy whether a blood sample came from a child with CP. This phrasing could be misleading to readers since 73% accuracy means that just over one-in-four of the samples was wrong.", "answer": 0}, {"article": "In the United States avocados are not a mainstream food yet, and they can be expensive, especially at certain times of the year.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reduction in LDL or \u201cbad\u201d cholesterol levels are clearly stated for each study group referenced in the article. However, we\u2019re never told what the participants\u2019 baseline LDL cholesterol values were, so it\u2019s difficult to know how meaningful these changes are. The competing NBC story, by comparison, told us that an LDL level below 100 is considered healthy, so the reader has some context from which to judge the 13-point drop seen in the study.\nThe story also fails to communicate any bottom line assessment of what the findings mean for outcomes that matter to readers \u2014 for example, their risk of suffering a heart attack or stroke. It doesn\u2019t explain that LDL is one of many factors that may affect the likelihood of suffering heart disease. To provide the appropriate context, the story might have communicated how the changes seen in the study would affect an individual\u2019s 10-year risk of suffering a heart attack or stroke.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The absolute difference in heart disease risk between women who took hormones and those who did not, and the differences among age groups, are not provided. ", "answer": 0}, {"article": "\"Some people are doing three on and three off.\"\nIn the study, published in current issue of JAMA, researchers looked at 716 of these fractures in more than 200,000 Ontario women who had taken bisphosphonates.\n\"So although we believe there is an increased risk of these unusual fractures, it doesn't outweigh the benefit\" of taking osteoporosis drugs.\n\"The big message really is the number of typical hip fractures is much, much larger than the number of unusual thigh fractures,\" says Dr. Gillian Hawker of St. Michael's Hospital in Ontario, an osteoporosis specialist and study author.\nBut the \"absolute risk\" of these unusual fractures is still pretty low \u2014 13 fractures per year for every 10,000 people taking bisphosphonates for five years or longer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job explaining the tradeoffs of benefits and harms and quotes a doctor who worries that fear of rare events may be preventing women from taking drugs that could save them from the typical hip fractures.\nIf only the article took the extra step by talking about treatment benefits in absolute terms, rather than relative. The competing Reuters article tries to put the absolute benefit in perspective by noting that about half of people with osteoporosis will have a fracture in their lifetime.", "answer": 1}, {"article": "Hyperbaric wound treatment, often for diabetics, is booming.\nOften, Efrati and others say, injured brain cells don't die, but may persist for years or decades, alive but hobbled.\nEfrati said the brain is no different from any other part of the body.\nOf course, such anecdotes are not the same as rigorous scientific research.\nSo, just as the brain needs extra resources, it faces an energy crisis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that for at least some of the research, no benefit was found\u2013that it didn\u2019t work. For the studies that are mentioned that did see a positive benefit to hyperbaric therapy, the results are not quantified.\nAlso, there were some details that had the potential to confuse readers about the potential benefits. First, the story uses two anecdotes of dramatic improvement with the therapy, and this runs the risk of misleading readers. It\u2019s not until the very end that we find out that \u201csuch anecdotes are not the same as rigorous scientific research.\u201d\nOne of these anecdotes involved a woman recovering from brain tumor removal. The mechanisms of injury are very different from a mild traumatic brain injury and post-concussion syndrome.\nLastly, this quote was problematic:\nEfrati said the brain is no different from any other part of the body. Pressurized oxygen has the power to repair many kinds of tissue damage. \u201cA non-healing wound in the leg and a non-healing wound in the brain,\u201d he said, \u201cthey are the same basic thing.\u201d\nThe statement that a wounded brain and a wounded leg are basically the same thing isn\u2019t quite accurate: One is typified by damage to brain cells, which are notoriously slower growing than soft tissue cells in the legs.", "answer": 0}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nStill, they cautioned that \u201cthis study does not answer whether pet dogs have direct effects on children\u2019s mental health or whether other factors associated with acquisition of a pet dog benefit their mental health.\u201d\n\nIt was a classic case of conflating correlation and causation, which Herzog says is common.\nStudies also tend to generalize across animals, she noted: If participants are measurably soothed by one golden retriever, that doesn\u2019t mean another dog \u2014 or another species \u2014 will evoke the same response.\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nOverall, Crossman wrote, animals seem to be helpful in a \u201csmall-to-medium\u201d way, but it\u2019s unclear whether the critters deserve the credit or something else is at play.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky one, given that the focus of the story is on the dearth of quantifiable benefits associated with therapy animals. So, what do we look for? Well, in this case, we looked for some meaningful, big-picture discussion of benefits. For example, the story notes that the body of evidence regarding therapy animals \u201csometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress.\u201d Is that quantifiable? No. Does it offer meaningful insight into the nature of benefits found in a wide variety of studies on the subject? Yes. Given the thrust of the story, and the in-depth discussion of benefits (or lack thereof), we think this qualifies for a Satisfactory rating.", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\nBut in the new review, researchers found that across 16 studies of more than 10,000 high-risk pregnancies, Doppler ultrasound testing was linked to a 29 percent reduction in fetal and newborn deaths.\nBut there is not yet strong evidence that these women benefit, Alfirevic said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story clearly states the reduction in fetal death rates the review authors calculated by combining the results of the studies ithey looked at. It reports the absolute risk calculation of fetal or newborn deaths (1.7 percent among women who did not receive ultrasound monitoring vs. 1.2 percent among those who did). This reporting of absolute (as opposed to relative) risk reduction is a strong point of the story since it conveys to readers that while the intervention did improve outcomes, the underlying risk is small. We only wish, however, that the story had cited the Number Needed to Test that was included in the study \u2013 203 would need to be tested in order to find one case of fetal distress that would otherwise not have been seen using other routine exams.\u00a0\u00a0", "answer": 1}, {"article": "\u201cThere is a lot more to be done to fill in the research on the biological mechanism,\u2019\u2019 Dr. Horne said.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\nBut the researchers say the findings are important because they affirm the results of an earlier, larger study, published in 2008 in The American Journal of Cardiology, that found a similar association between fasting and heart disease among 448 patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that \u201cpeople who fasted regularly had a 58 percent lower risk of coronary disease compared with those who said they didn\u2019t fast.\u201d\u00a0 But 58% of what?\u00a0 The story could have noted baseline risk in the general population or in people diagnosed with coronary heart disease.\u00a0 But even in the latter category, that\u2019s a very wide spectrum of disease.\u00a0 All of which shows how the 58% figure lacks any context for readers.", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nIn the company study submitted to the FDA, patients who got Absorb fared about as well as those receiving Abbott's older metal stent after one year.\n\"We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,\" said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A major message of this story, to its credit, is that the benefit\u00a0of these dissolving stents has not yet been established\u2013there is no data yet. This is important, because the whole point of designing a dissolvable stent is to minimize longer-ranging complications resulting from metal stents.\nThe story does briefly describe a company-conducted study. It says \u201cpatients who got Absorb fared about as well as those receiving Abbott\u2019s older metal stent after one year.\u201d However, we\u2019re not told really what that means in terms of survival and reduced cardiac events.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\nThe task force looked at the most up-to-date research on both the benefits and harms of taking aspirin for the primary prevention of both heart disease and colorectal cancer to arrive at their recommendations.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While we are told of the benefits to cardiovascular prevention, those effects are never quantified. This strikes as a missed opportunity to \u201cshow the numbers,\u201d which are easily obtainable from the USPSTF recommendations and tables that\u00a0discuss the quantified benefits.", "answer": 0}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\nIt\u2019s unclear how the test differences will translate into real life, said Baker.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\nBaker said researchers have failed so far to come up with effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We wish the story had quantified the test results a bit more explicitly.\u00a0 However, the story got the gist right \u2013 and, more importantly, added that \u201cit\u2019s unclear how the test differences will translate into real life.\u201d", "answer": 1}, {"article": "However, antibiotics do come with significant side effects including diarrhea, rashes, yeast infections and vomiting.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nDr. Jerome Klein, a pediatric infectious disease specialist from Boston University's Medical School, says in an accompanying editorial that these two studies resolve the controversy over giving antibiotics versus watchful waiting in kids with confirmed ear infections.\nThese 2 new studies were designed to provide the research to fill the gap, and clarify treatment recommendations for babies and toddlers.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although a bit more detail would have been useful on the findings from both studies, the story does provide an account of the absolute rate of symptom relief after 7 days for antibiotic (80%) and placebo-treated (74%) patients, which is the expectation for this criterion. It also provides valuable expert commentary on how parents can put these benefits into context vs. the risk of harm and the likelihood of spontaneous recovery in children who don\u2019t receive antibiotics.", "answer": 1}, {"article": "In the year after a heart attack, about 12% of people have a second heart attack or stroke.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the second sentence, the story states that \u201cThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\u201d\u00a0 But it never addressed whether that goal was addressed by the findings reported.\nWhat does it mean for cholesterol removal from the cells of health volunteers to rise 164%?\u00a0 That sounds whopping.\u00a0 But what does it mean?\nWhat does it mean for levels of ApoA-1 to double?\u00a0 Again, sounds impressive.\u00a0 But does this translate to any clinical benefit?\nCome on!\u00a0 This was a study in 57 healthy volunteers who received a single infusion of CSL 112 and were followed for a short period of time.\u00a0 Suggesting any benefit is pure speculation", "answer": 0}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nSuch a marker would allow doctors to identify infants at high risk of developing autism before symptoms are present.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nIt may be possible to predict autism in infants as young as 6 months who have older siblings with the disorder, according to a new study by a national network of researchers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits in terms of detection are described, including limitations of the current state of knowledge. The article is careful to draw parameters around the immediate significance of the findings and to express the need for further research. Numbers are even provided for how accurate researchers would like the MRI to be in predicting autism in infants before the procedure could be\u00a0recommended\u00a0for siblings of autistic children.", "answer": 1}, {"article": "Those questions are no longer hypothetical.\nAmong patients diagnosed with mild cognitive impairment, about 60% have amyloid plaques and will go on to develop dementia that is likely Alzheimer's disease, said Dr. Michael W. Weiner of the Department of Veterans Affairs' Center for Imaging of Neurodegenerative Diseases.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nThe FDA says that Amyvid \"is not a test to predict the development of AD-associated dementia\" in those who have no problematic symptoms.\nA brain biopsy now can be used to detect Alzheimer's plaques but is highly invasive and may miss parts of the brain where the plaques and tangles of Alzheimer's are densest.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is not careful enough in its description of what information the test provides and how it should be interpreted. The story states that the test \u201cis an early test for those who already have cognitive concerns and who wonder whether Alzheimer\u2019s disease may be the cause.\u201d The implication is that the test can distinguish Alzheimer\u2019s disease from other forms of dementia in people with cognitive impairment, which is not true.\nAs manufacturer Eli Lilly makes clear in its statement about the FDA approval, a negative scan indicates the absence of amyloid plaques and suggests that the cognitive impairment is probably not due to Alzheimer\u2019s. However, amyloid plaques are found in patients with many other neurologic conditions and in patients with normal cognition. Thus, a positive scan cannot tell us if the patient has Alzheimer\u2019s disease or some other cognitive problem or even if they are destined to develop dementia.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nAs this study was conducted on animals, results cannot yet be implied for humans.\n\"Our research demonstrates that a walnut diet causes significant changes in the expression profile of miRNAs in localized colorectal cancer tissue, and that a walnut diet incorporates protective fatty acids in the colonic tumor either through its direct effects or through additive or synergistic effects of multiple other compounds present in walnuts,\" said Dr. Mantzoros.\nIt is estimated that 30-50 percent of colorectal cancer in men and 20 percent in women can be prevented by diet and other lifestyle changes.2\n\nAn article detailing these findings, \"Dietary Walnut Suppression of Colorectal Cancer in mice: mediation by miRNA patterns and fatty acid incorporation\" has been published in the Journal of Nutritional Biochemistry.3\n\nThis study was supported from a grant by the American Institute for Cancer Research and the California Walnut Commission.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research on a small group of mice showed slowing of the growth of colon cancer tumors. The research proved that tumors in mice fed walnuts had \u201c10 times the amount of total omega-3 fatty acids, including plant-based alpha-linolenic acid (ALA), in the tissue compared to the mice fed the control diet.\u201d Although the quantification here is limited, we\u2019ll give the story credit for accurately reporting the outcomes in broad strokes. The detailed results of what happened in a mouse study have limited use for the average human reader anyway.\nBut while the release does not state that the mouse study could lead to prevention for humans, we\u2019re worried that a normal reader may see the suggested effects of an enhanced walnut diet \u2014 increased anti-inflammatory activity, reduced angiogenesis, increased protective lipid content \u2014 and assume that these affect actual cancer outcomes. Set aside the major caveat that it is an animal study for a moment \u2014 the release says that walnuts \u201cmay\u201d slow the growth of colon cancer.\u00a0 It also equally may not.", "answer": 1}, {"article": "\"I don't like to play my son's video games, but I keep telling myself to challenge myself,\" said Marsiske, 41.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nRather, as is the case with physical exercise, strengthening the mind appeared to slow decline.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits that a senior citizen might reasonably expect to obtain through cognitive training were not presented clearly.\u00a0\u00a0 The reader has no idea from the information presented the size of the changes observed.", "answer": 0}, {"article": "Dec. 29, 2009 -- Scientists at the Dana-Farber Cancer Institute say they have developed a compound that may be capable of halting a common type of drug-resistant lung cancer.\nTheir study is published in the Dec. 24/31 issue of the journal Nature.\nNon-small cell lung cancer constitutes about 85-90% of lung cancer cases.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are considerable benefits to be had, presumably. Because the number of patients is so huge, even a small improvement over present diagnositic techniques could have a big impact. As the study itself points out, \"Presently, the only specific, approved therapy for acute ischemic stroke is IV tissue plasminogen activator (tPA) given within 4.5 hours.\u00a0 tPA use has been limited due to the short treatment window, concerns about the limitations of CT-based diagnosis, and fear of hemorrhagic risks.\" Does the story get into this, though?\u00a0No. There is no attempt to quantify the benefits.", "answer": 0}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\nTo address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There were no absolute numbers included here, and that\u2019s a big omission. The CMAJ study notes how, per a score of 1-10 on the Modified Behavioral Pain Scale (MBPS) \u2014 with 10 being the highest level of pain \u2014 an improvement of 0.6 is generally necessary for doctors to change their practice on a procedure. Yet the study showed that the absolute effect of lidocaine cream (plus an educational video and sugar water) on vaccination pain was less, at 0.5.\nThere\u2019s also this: As\u00a0noted in the comments at a NEJM Journal Watch post,\u00a0it can take more than an hour for lidocaine creams to make pain relief effective for tissues deeper than the skin (and vaccines are often injected into muscles). For the CMAJ study\u00a0only about 20 minutes elapsed, since the cream was applied right before parents watched a 20-minute video and taken off immediately afterward.", "answer": 0}, {"article": "Editor\u2019s Note: Please see article for additional information, including other authors, author contributions and affiliations, etc.\nA separate analysis of 15 studies found that ever being breastfed compared with never being breastfed was associated with an 11 percent lower risk of childhood leukemia.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/jamapediatrics.2015.1025\n\nBreastfeeding for six months or longer was associated with a lower risk of childhood leukemia compared with children who were never breastfed or who were breastfed for a shorter time, according to an article published online by JAMA Pediatrics.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the release, this analysis of 18 studies found that \u201cbreastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\u201d A sub-analysis of 15 studies further showed that \u201cever being breastfeed\u201d for a shorter period of time was associated with an 11 percent lower risk in developing leukemia compared to those who were never breastfed.\u00a0But how big really is a \u201c19% lower risk\u201d? That depends upon whether leukemia is generally common or rare. A 19% reduction in a rare condition like childhood leukemia won\u2019t amount to a very large absolute benefit. The release could have put a number on it.", "answer": 0}, {"article": "The study found none.\nThe number of hot flashes among the women taking Lexapro, which is also known as escitalopram, dropped to about five on average after eight weeks--a 47 percent decrease or about 4.6 fewer hot flashes per day, the researchers reported.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nA study involving 205 women found those taking the antidepressant Lexapro experienced a 47 percent reduction in number of hot flashes they were experiencing and the hot flashes they did have tended to be less severe, researchers reported in the Journal of the American Medical Association.\nWhen the study started, the women were having an average of nearly 10 hot flashes each day.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in appropriate\u00a0terms using measures that are meaningful to readers. It explains that women taking Lexapro had a 47 percent decrease,\u00a0or about 4.6 fewer hot flashes per day, whereas women taking a placebo had a 33 percent decrease or 3.2 fewer hot flashes per day.\u00a0The\u00a0story could have made the effects even clearer with a statement along the lines of \u2026 \u201cOn average, women with moderate to severe menopausal hot flashes had 5.4 hot flashes daily when taking lexapro and 6.4 hot flashes daily when taking placebo, a difference of 1 fewer hot flash daily.\u201d\u00a0As usual, the emphasis on percent reduction tends to obscure the absolute benefit.\nThe story\u00a0did\u00a0attempt to put the size of this\u00a0effect into some kind of context \u2014 calling it \u201cmodest\u201d \u2014\u00a0which is something the WebMD coverage failed to do.", "answer": 1}, {"article": "It develops in four stages.\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nChanges in DNA methylation at genes like PPAR\u03b3 that controls scar formation are then used to stratify patients by fibrosis severity.\nPublishing in the academic journal GUT, the Newcastle team describe the proof of principle research in which they measure specific epigenetic markers to stratify NAFLD patients into mild or severe liver scarring, known as fibrosis.\n\"If we are able to accurately tell the extent of a person's liver damage with a blood test, and even track the scarring as it gets better or worse, it could provide reassurance for patients, save NHS resources and avoid patients having to undergo a liver biopsy.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits here are not clear, much less quantified. At one point, the release quotes a researcher as saying: \u201cWe know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it\u2019s important to be able to detect liver scarring at an early stage.\u201d But why is that important? Are there therapeutic treatments or interventions available to change the course of the disease or otherwise affect the patient\u2019s health and well-being? Lower down, a second researcher is quoted as saying \u201cIf we are able to accurately tell the extent of a person\u2019s liver damage with a blood test, and even track the scarring as it gets better or worse, it could provide reassurance for patients, save NHS [National Health Service] resources and avoid patients having to undergo a liver biopsy.\u201d So, the benefit is that patients could avoid having a biopsy? Is that the benefit?\nWithout knowing the prognostic value of the test results, it\u2019s hard to see how it could provide reassurance for patients. \u00a0As noted above, the value of knowing this diagnosis in terms of directing targeted therapy is uncertain and the authors actually note that their data do not suggest superiority to existing fibrosis biomarkers.", "answer": 0}, {"article": "Their waistlines shrank by 1 to 2 inches.\nIn effect, the diet reduced the study participants' risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\nFor example, baseline fasting glucose levels for participants with high blood sugar levels (putting them at risk for diabetes) dropped into the healthy range, below 99 mg/dl -- but these levels didn't drop among participants who already had healthy levels at the beginning of the study.\n\"This study provides evidence that people can experience significant health benefits through a periodic, fasting-mimicking diet that is designed to act on the aging process,\" said Valter Longo, director of the USC Longevity Institute and a professor of biological sciences for USC Davis and Dornsife.\nThe researchers also noted that participants considered \"at risk\" because they had risk factors such as high IGF-1, cholesterol, blood pressure or blood sugar levels, made significant progress toward better health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release reports only surrogate or intermediate endpoints of disease risk, not a change in disease risk itself. For example, changes were reported\u00a0in blood pressure, waist circumference, and body weight in participants after three fasting diet periods, which the release equates with a reduction in disease risk. However, measuring surrogate endpoints or disease biomarkers without looking at actual disease incidence is not a measure of individual health outcomes. To do this, researchers would need to measure endpoints like the number of cardiovascular events that occurred during or after the study or the number of people diagnosed with diabetes \u2014 which requires much longer than a few months of follow-up.\nSome of the claims made in the release were inappropriate. For example, \u201cIn effect, the diet reduced the study participants\u2019 risks for cancer, diabetes, heart disease and other age-related diseases, according to the findings published Feb. 15 in Science Translational Medicine.\u201d", "answer": 0}, {"article": "\u201cWe need more information on how this works precisely in people before we can advise them to take anything,\u201d he said.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\nIndeed, one scientist not involved with Elysium questions the company\u2019s marketing pitch, saying there is too little information to know what Basis can do.\nWith Basis, for example, there is no scientific evidence yet that the pill would produce the same beneficial effect in humans as in mice.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article quotes the company as saying that higher levels of the \u201cnatural compound\u201d (found already in the human body) that is targeted by active ingredients in Basis has been associated with improved health in older mice, and that the pill has not been studied in humans. However, the article doesn\u2019t tell us anything about the mouse studies directly: What sort of \u201cimproved health\u201d did researchers find in the mice? Have researchers studied the active ingredients in Basis, or just the compound that these ingredients target?\nTo be clear, the story also quotes skeptical researchers who are asking very similar questions. For example:\u00a0\u201cWhat does it mean, to improve metabolic health? And what exactly is being repaired in the body? And is the outcome the same for everyone?\u201d But did the story pose these tough questions to the company and fail to get a response? If so, a brief acknowledgment of that effort would have earned the story a satisfactory rating here.\nAnother route to a satisfactory score would have been to summarize some previous studies involving the active ingredients in Basis, such as pterostilbene.", "answer": 0}, {"article": "Current ACS prostate screening cancer guidelines recommend that men make an informed decision with their doctor about whether to be tested for prostate cancer.\nThe men in the study were all from the placebo arm, meaning they had not received the drug.\n\"The velocity didn't add anything more to detecting aggressive prostate cancers.\"\n\"PSA velocity measurement is not useful,\" Brawley said.\nThe National Cancer Institute has more on the PSA test.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the potential reduction in biopsies.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nStill another study discussed yesterday involving 1,500 college students concluded that those who experienced early puberty were more likely to engage in abnormal eating behaviors and have feelings of anxiety in early adulthood.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nAnother researcher who presented a different study at the conference also emphasized the importance of staying active and maintaining a proper diet.\nA tablet that stimulates the production of growth hormone may help older adults improve their physical functioning and lower their body fat percentage, a researcher said yesterday.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions there was an increase in physical functioning in the growth hormone group, but we are not told how much they improved in physical functioning or increased muscle mass. How big was the benefit? Was it statistically significant? And, more important, was it clinically significant for these people?", "answer": 0}, {"article": "\u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d\nThe current study, however, looked at longer-term data from the WHI study and found no increased risk of death from all causes, or from cancer or cardiovascular issues in particular, associated with hormone use.\nOne limitation of the study is that the WHI didn\u2019t look at different dosages of hormone pills, and the findings may be different for other dosages or different types of therapy such as gels or creams or skin patches.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study does not aim to quantify the benefits of treatment, rather to show whether there is any difference in risk of death associated with taking hormone therapy for 5 to 7 years.\u00a0 The original Women\u2019s Health Initiative trial was designed to examine whether there was any benefit of hormone therapy for prevention or heart disease, which had been suggested by earlier studies.", "answer": 2}, {"article": "But researchers at Johns Hopkins suggest that a common diagnostic technique doesn't help doctors much for patients whose chronic lower back pain appears to be due to arthritis of the joints in the spine.\nNeither is figuring out the cause of chronic back pain a lot of the time.\nDoctors may not change their approach anytime soon, however.\nPatients don't care much about the finer points of diagnostic accuracy.\nDoing away with a painkilling injections, or nerve blocks, as a test to determine the root cause of the back pain didn't hurt patients who went on to have their pain treated by zapping nerves with electrodes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of potential benefits.\u00a0 Only a vague, borrowed (from Reuters) reference to \"the value of the diagnostic tests\" and an anecdote from the researcher supposedly supporting the case that they can be skipped.\u00a0 ", "answer": 0}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nIt\u2019s an exciting time in early phase drug development when we are observing these results in so many different types of cancer.\nOf those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release used careful language when describing the limited benefits seen in this Phase 1, safety oriented clinical trial. We appreciate the fact that this is not a journal article, but an abstract presentation for a conference. But we think that readers deserved a bit more information\n\u201cAt the time we reported our results, six of the 22 patients remained on treatment. Of those who completed therapy, two patients had a partial response for an overall response rate of 9.1 percent, and there was a stable disease rate of 54.5 percent. The six-month overall survival rate was 100 percent and the six month progression free survival rate was 58.7 percent.\u201d\nThat being said we are not provided with any information about the expected stable disease rate or progression-free survival rate in untreated patients. While the stable disease and progression free survival rates were provided, the reader has nothing to compare them to.", "answer": 1}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nThe research found that babies, born after 2007, who received the cooling treatment, had much less epilepsy than before cooling treatment was introduced.\nThe study showed that more children had epilepsy when they reached the age of four to eight years with seven per cent on regular medication.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline claims a reduction in epilepsy but the release does not provide any numbers backing up that claim. The closest the release comes to describing a benefit is stating that the children \u201chad much less epilepsy than before cooling treatment was introduced.\u201d How much less?\nThe release would have been somewhat stronger if it had offered some firm numbers for this group of patients given the lack of a control group.", "answer": 0}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nBut drinking tequila won't help, the study authors noted.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "First, this was in mice \u2013 a fact that was minimized in the story.\u00a0 But we don\u2019t know how many mice were tested. Was it two?\u00a0 Was it 200? And we\u2019re only given a relative benefit statistic \u2013 \"50 percent increase in levels of a protein associated with the build-up of new bone tissue.\"\u00a0 50% of what?\u00a0 \nYet this mouse story allowed the researcher \u2013 based on a quote from a news release \u2013 to say:\u00a0\nShameful. ", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nThe pulses are so fast, Dr. Kessel said, that two photons hit a target molecule simultaneously, with the same effect as if UV light was used.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ve already told you what the story didn\u2019t:\u00a0 that this was an experiment on 9 human organ donor lenses.\u00a0 But the story also didn\u2019t say if the approach had the intended effect on all 9, half of them, or how many.\u00a0 The story also didn\u2019t capture what the researchers reported:\u00a0\nSo the leap to knowing how this might work in the bodies of living people is large, despite a headline that stated, \"Laser Treatment May Work For Cataracts.\" ", "answer": 0}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nThe study\u2019s lead investigator, Rebecca Kristeleit, defended the performance of rucaparib, adding that one can\u2019t compare Clovis\u2019s drug to Tesaro\u2019s: \u201cIt\u2019s a completely different population, and a different use of the drugs,\u201d she said.\n(The study did not assess whether the drug helped women live longer, just how long it stopped tumors from growing.)\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nThough its own PARP inhibitor, rucaparib, showed that it could help some women compared to chemotherapy alone, its data didn\u2019t measure up to the other two trials.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s description of benefits is uneven. The story touts one drug \u2014 niraparib \u2014 as being \u201cthe clear front-runner\u201d because among BRCA ovarian cancer patients taking it they \u201cgot an extra 15 months without their disease getting worse,\u201d compared to a control group. The story also said that Pfizer\u2019s drug \u2014 talazoparib \u2014 \u201crecently showed similarly compelling results\u201d and that \u201ctumors shrunk on average 78 percent\u201d in a pilot study of breast cancer patients. But an \u201caverage\u201d result can mask great variation in response among patients \u2014 was this representative of what most patients experienced? The third drug \u2014 Clovis Oncology\u2019s rucaparib \u2014 \u201cdidn\u2019t measure up to the other two trials,\u201d the story said, but the only data provided about it was that its stock price dropped 18 percent after data was released, but the story offered none of that data.", "answer": 0}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story appropriately characterizes this spinal fluid test as something that could help improve the confidence of Alzheimer\u2019s diagnoses. It would have been helpful to point out that the test is most likely to be used first by researchers testing potential treatments. The story points out that this sort of test could be useful for screening once effective treatments are available. However, the story should have been more clear that the test as presented in this study, if used in isolation, could lead to many people being incorrectly labeled as having Alzheimer\u2019s Disease.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nThe researchers studied 2,915 patients who were tracked by 17 Canadian hospitals in 2004-05.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nKrahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article includes the numbers of patients who had serious complications after replacement surgery, as well as how many had minor problems. Data are also included that would help readers assess how the risks of replacing a device compare with the device manufacturers\u2019 estimates of how often something could go wrong if it was left in place. ", "answer": 1}, {"article": ".\nLimitations: Patnaik explained that because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care.\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nBottom Line: The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is appropriately restrained in its description of the potential benefits of a drug just starting the long process of trials in patients. It specifically reports the number of trial participants whose tumors appeared to respond or at least not advance during the test, without making premature claims of effectiveness. However, we would like to see news releases about early trials of cancer drugs go further, to state explicitly that signs of partial responses or stable disease do not imply potential cures or even extended survival. More emphatic cautionary statements seem particularly appropriate to releases like this one that point out an experimental drug has been given \u201cbreakthrough therapy designation\u201d by the FDA, which is a technical definition that the FDA notes is frequently misinterpreted by the public and even health care professionals. Since it referenced \u201cdurable response,\u201d it would have been nice to see the release include a definition. In brief, the term refers to the length of time that a partial or complete response is observed as a result of treatment.", "answer": 1}, {"article": "High blood pressure is a major contributor to a form of heart failure that affects the way heart relaxes between contractions.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release refers to \u201cencouraging cardiac improvements\u201d and says \u201ccardiac health improved,\u201d but those benefits are not quantified. The release also tells readers that \u201cT3 treatment inhibited the major cause of stiffening of the heart in hypertension\u201d and \u201coverall improvement in\u2026heart function.\u201d But it doesn\u2019t tell readers what this means. How much improvement was there? And what, exactly, was improving?\nWe recognize that this issue would have been difficult to address, since the paper itself does not provide specifics on these benefits. But we maintain a high standard, and the researchers could have been prodded to provide answers. It would have been nice at the least to have some sense of how the changes compared with those observed other studies.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites several studies to support the story\u2019s statement that \u201ca handful of new studies have shown it helps relieve back, neck, carpal tunnel and knee pain.\u201d\u00a0 However, none of the alleged benefits are ever quantified, and that\u2019s our expectation with this criterion.\u00a0 The article uses phrases, such as \u201cmore effective on average in relieving pain\u201d and \u201csignificantly reduced chronic neck pain.\u201d But what do these mean? And how were these benefits measured? A discussion on some numbers from the trials (how many patients experienced relief, how much pain relief), as well as the research methods to measure benefits, would have been welcome.", "answer": 0}, {"article": "Einstein had a somewhat different take on the findings.\nDNA testing for HPV, though, does have drawbacks -- namely that it is less specific, meaning it is likely to pick up more false-positives, than a Pap smear.\nScreening for HPV DNA appeared more effective in older women, but the testing in younger women led to over-diagnosis of a particular type of cervical lesion, the study found.\nYounger women got a colposcopy if their Pap smear was abnormal or if HPV results were positive several times, indicating that their body had not been able to clear the infection.\nDuring the first phase of the study, women 35 to 60 who tested positive for HPV were given a cervical examination, called a colposcopy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t really quantify the benefits of HPV DNA testing in terms that are particularly useful to consumers. The story describes the \"callback rate\", or the number of women who will need additional testing after the initial screening, which makes HPV DNA testing appear as though it catches many\u00a0 more cancers than pap smears. However, according to the study, the number of cancers found in the first round of screening was similar in both groups (7 in the HPV DNA group, 9 in the pap smear group). It was in the second round of screening two years later that HPV DNA testing appeared to prevent cases of cervical cancer relative to pap smears (7 cancers in the HPV DNA group versus 18 in the pap smear group). ", "answer": 0}, {"article": "''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nJan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provides n values and quantifies the results from the first stage of the study. The potential benefits of the test have to do with its ability to rule out malignancy based on X-ray results; thus, the specificity and sensitivity data are particularly relevant.\u00a0\nWe wish the paragraph on subjects with stage I disease would have quantified the results. It provides no sensitivity or specificity rates to justify the conclusion of the technique\u2019s potential application in early stage disease.", "answer": 1}, {"article": "These latest findings do not alter that advice.\nOf the 34,433 HRT users, 193 were diagnosed with colon cancer during the study period; that compared with 151 cases among the 13,778 women who had never used hormone replacement.\nHRT \u2014 with either estrogen alone or a combination of estrogen and progestin \u2014 was linked to a lower colon cancer risk even when the researchers accounted for the women\u2019s age, weight, exercise levels and race.\nAmong these women, HRT use was linked to a 55 percent lower risk of the disease versus non-use.\nWhile women who were current HRT users at the start of the study showed a lower risk of the disease, the same was not true of those who were former users.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nOf the 34,433 HRT users, 193 were diagnosed with colon cancer during the study period; that compared with 151 cases among the 13,778 women who had never used hormone replacement.\nHRT \u2014 with either estrogen alone or a combination of estrogen and progestin \u2014 was linked to a lower colon cancer risk even when the researchers accounted for the women\u2019s age, weight, exercise levels and race.\n", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nIn the study, De Meyer and colleagues analyzed spinal fluid from 114 adults with normal brain function, 200 who had mild cognitive impairment \u2014 a precursor to dementia \u2014 and 102 who had Alzheimer\u2019s.\nThey said measuring traces of beta amyloid and tau \u2014 two proteins associated with the telltale plaques and tangles that form in the brains of patients with Alzheimer\u2019s \u2014 accurately detected Alzheimer\u2019s in 90 percent of patients with the disease.\nThey were also able to detect 100 percent of people with memory impairments who would progress to Alzheimer\u2019s disease within five years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough this story does a generally careful job of highlighting the potential use of spinal fluid testing to help diagnose Alzheimer\u2019s Disease in people who are already experiencing severe memory problems, it states that the results \u201cpredict\u201d which patients with memory problems will develop the disease. What the researchers actually reported was that all of the patients who progressed from mild cognitive impairment to Alzheimer\u2019s Disease during the study period had the disease-associated biomarker pattern. They did not state that having the \u201cdisease\u201d pattern predicted progression. Indeed, while 142 participants with impairment had the \u201cdisease\u201d pattern, only 57 (less than half) progressed from impairment to Alzheimer\u2019s during the study.", "answer": 0}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\nThe authors report having no personal financial interests related to the study.\nWhen study participants were evaluated separately by race/ethnicity, associations were significant among white breast cancer survivors; however; while a trend was seen in the benefit for Chinese women, results were not statically significant.\nIndeed, in this study, Chinese breast cancer survivors ate more than twice as much soy and cruciferous vegetables.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond vague descriptions of benefits such as \u201cfewer reports of menopausal symptoms,\u201d the news release does not offer any meaningful measure of what the patient\u2019s symptoms were at the beginning of the study and how much symptoms were reduced among those who ate \u201cmore\u201d of the soy and cruciferous vegetable diets. It also isn\u2019t clear on which menopausal symptoms were decreased.", "answer": 0}, {"article": "Irritable bowel syndrome can be highly debilitating, if not virtually paralyzing, and affect work, sleep and personal and family relationships.\nWhile the results are highly encouraging for IBS sufferers, there are a few important caveats, Eswaran says.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\n\u201cOur next step will be to more precisely determine the underlying chemistry of how and why particular foods can yield dramatically different results for different people.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports some numbers. It says more than half of the patients on the low FODMAP diet experienced \u201cmajor improvement\u201d of their abdominal pain compared with 20 percent of the control group, and 61 percent of low FODMAP patients had a \u201cmeaningful improvement\u201d in quality of life versus 27 percent for the control group. However, it should have described for readers what these improvements mean from a clinical standpoint. Is the researchers\u2019 definition of \u201cmajor improvement\u201d the same as what patients expect when they hear that term? Offering some specifics would have helped clarify.", "answer": 0}, {"article": "\"We didn't expect that at all,\" Dackis says.\nIn a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give any quantitative evidence of the benefits of this drug over placebo to reduce withdrawal symptoms and cravings for cocaine, though this evidence is provided in the journal article for the small pilot study. Abstinence from cocaine was measured as clean urine tests and of the 24 test required, 43% of the modafinil group vs. 24% of the placebo group were without evidence of recent cocaine use. Futher evidence from larger randomized trials is needed. The discussion of modafinil allowing former cocaine user to \u201cthink strategically\u201d might be an overstatement as there is no evidence in the pilot study of improved decision making with modafinil. ", "answer": 0}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nIt's a myth, he adds, that older, sedating antihistamines, such as Benadryl, are extra effective against nasal allergies.\nFor example, Walmart sells Equate loratadine tablets (the same active ingredient as Claritin) for about $7 for 60 24-hour doses\n\nAntihistamines make perfect sense for someone who suffers a few sneezy days each season and doesn't want to use a spray for weeks or months, Eghrari-Sabet says.\nBut that does not mean they work for everyone, says James Sublett, a Louisville allergist and president of the allergy group.\nWorth knowing: so far, insurers have continued to pay for similar prescription sprays, Eghrari-Sabet says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story claims steroid nasal sprays are the \u201csingle most effective drug class for treating nasal allergies\u201d \u2014 a quote that is attributed to the American College of Allergy, Asthma & Immunology\u2019s website. But this statement is not backed up with any quantitative data. How effective are these treatments? And how do they compare to other alternatives out there, like antihistamines and decongestants? How many patients put on this treatment would report experiencing a benefit? The story acknowledges that these sprays won\u2019t\u00a0work for everyone, but it wouldve been better to provide an estimate. There are several Cochrane reviews (meta-analyses based on multiple studies) on this topic, such as this one\u00a0and this one, that could\u2019ve been used to help quantify the story\u2019s claims.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\nResults from 12 months after the study show that when guidance was coupled with medication, a blood pressure measurement of less than 130/80 was achieved by 68% of men who participated in the study program, versus 11% of those who didn't.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\nAlso, pharmacists aimed to lower blood pressure in the program participants to less than 130/80, whereas the primary care providers of those in the control group probably targeted a blood pressure of less than 140/90.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states that men in the intervention group experienced a much greater reduction in their blood pressure readings as compared to the control group. It included this quantified statement, \u201cIt turned out that, when the guidance was coupled with medication, a blood pressure level of less than 130/80 was achieved among 63.6% of men who participated in the study\u2019s program, versus 11.7% of those who didn\u2019t.\u201d", "answer": 1}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nWilt noted there is no information on the effectiveness of treatments in pregnant women, young or old patients, those with milder symptoms or those with other serious medical conditions.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\nThis is just a compilation of evidence that follows guidelines that have been long established in both Europe and the United States, Niethammer said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides the absolute percentage of patients who experienced at least 50% reduction in symptoms in the treatment groups and control groups. Although it\u00a0specified that these benefits were \u201cshort-term,\u201d we wish\u00a0the story\u00a0had quantified the length of these studies more precisely.\nSee our comments above in the \u201cWhy This Matters\u201d section about the framing of the benefit. Short-term 60% vs. 40% reduction in symptoms of at least 50% with 25-50% stopping the medicine over a year. This should have been the first point. Then the results don\u2019t seem quite as remarkable.", "answer": 0}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\n\u201cSubstantial savings could be seen if open surgery is done in a laparoscopic fashion.\u201d\n\nBut he acknowledged that the study has major limitations.\n\u201cOverall, this study shows benefit from laparoscopy on every aspect, including cost,\u201d he told Reuters Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As already noted, the story did a good job comparing death rate, readmission rate and hospital stays between the two procedures.", "answer": 1}, {"article": "\"\"It's encouraging to see that eating walnuts may benefit this particular population.\"\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\n\"Given walnuts are a high-energy food, a prevailing concern has been that their long-term consumption might be associated with weight gain,\" said study author Dr. Emilio Ros, director of the Lipid Clinic, Endocrinology & Nutrition Service at the Hospital Clinic of Barcelona, in a press statement.\nAfter one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification in this story. The story says that the walnut eaters had reductions in bad cholesterol, but not how much. Is it even clinically significant? The story also says that neither group showed weight gain or changes in other cardiovascular markers, but nothing concrete is presented.\u00a0 A mention of good gut effects of walnuts is totally without any supporting information.\u00a0 About the only information actually given is that walnuts can be a fattening food and that portion control is necessary.", "answer": 0}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nThe outcome was excellent, but the recovery was long and horrible.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives no information on quantified benefits measured in PRP research, and instead focuses only on the author\u2019s experience.", "answer": 0}, {"article": "A bone marrow transplant is a last-ditch treatment for cancers such as leukemia.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\n\u201cFrom these results, it is reasonable to conclude that cure of HIV infection has been achieved in this patient,\u201d they wrote.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nSchneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re giving this one a pass here. The story makes quite clear that it is a report on the experience of only one patient and that while the researchers say there are now no signs of HIV infection in this individual, the tests don\u2019t completely rule out the possibility that the virus is lurking somewhere. In particular, the comments of Dr. Gallo to place the apparent benefit in this single patient into context.", "answer": 1}, {"article": "Dr. Michele Green is a dermatologist at Lenox Hill Hospital in New York City.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nAfter a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated with Yervoy.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly defines the benefit (survival without recurrence of the cancer) and offers clear numbers: \u201cAfter a year of treatment, 71 percent of patients in the Opdivo group were alive without any recurrence of the disease, compared with 61 percent of those treated with Yervoy. And at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\u201d\nOne detail we think would have been good to add\u2013\u201crecurrence-free survival\u201d doesn\u2019t tell you how many patients are actually living longer specifically because of the treatment. It\u2019s just telling you how much time elapses before recurrence.", "answer": 1}, {"article": "They\u2019re not producing the antimicrobials they need,\u201d he explained.\nA day later, much of the staph on the treated arms was killed \u2014 and in two cases, it was wiped out \u2014 compared to the untreated arms, Gallo said.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\nLearning what makes a healthy microbiome is a huge field of research, and already scientists are altering gut bacteria to fight diarrhea-causing infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201ccustomized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin\u201d and later, \u201cmuch of the staph on the treated arms was killed \u2013 and in two cases, it was wiped out \u2013 compared to the untreated arms,\u201d according to Gallo, the lead researcher.\nIs two out of five a proper measure of effectiveness? A bit of skeptical context would have helped explain these benefits.\nMoreover, this study, even if taken at face value, does not in any way assure that infections will be prevented, simply that the bad bacteria will be lowered. Sure, the researchers have a theoretical hypothesis that this would translate to fewer infections, but at this point, zero proof.", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nThe Italian study participants all had blood levels of vitamin D measuring in the lowest 25 percent of normal at the study's outset, although the researchers didn't report the womens' blood levels afterward.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nIn the study, 40 Italian women were split into two groups: one receiving a single oral dose of 300,000 IUs of vitamin D3 and the other getting a placebo five days before the expected start of their menstrual periods.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that pain was reduced in the experimental group by 41% (where the control group experienced no pain reductions), but 41% of what?\u00a0 And in reality, was this reduction significant enough that women were able to resume their normal level of activity?\n\u00a0", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some quantitative comparisons between folks in a treatment group relative to those in a control group: \u201cIn late-stage studies, roughly half of patients taking crisaborole had their diseases cleared or nearly cleared, a statistically significant improvement compared with 30% to 41% of patients using moisturizing placebos. The most common side effect was pain where the ointment was applied, experienced by about 4.4% of crisaborole patients and 1.2% of control-group patients.\u201d\nThis is sufficient for a Satisfactory rating. However, it doesn\u2019t say how long the follow-up period was or if the disease clearing lasted, which are very important pieces of information.", "answer": 1}, {"article": "However, common side effects included headache, dizziness and nausea.\n\"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug.\n\"What's most impressive about this two-year clinical trial is how unimpressive it is,\" said Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nThe report is published in the July 15 issue of the New England Journal of Medicine, and was sponsored by Arena Pharmaceuticals, of San Diego, Calif., which used its own doctors as part of the study group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did give weight loss amounts for people in the study.\u00a0 We wish they had calculated the number needed to treat \u2013 how many people would have to take the drug for how long in order to have one benefit.\u00a0 The one truly independent voice in this story, Dr. David L. Katz, says \"What\u2019s most impressive about this two-year clinical trial is how unimpressive it is.\"\u00a0Instead of going on to attribute all of the analysis of what that is to Katz, the story could have gone the extra step of seeing if others shared that view and really bearing down on the numbers to see how strong the results really are. By our rough count, by the second year, they were dealing with a trial consisting of fewer than 500 people.\nNonetheless, because the story met the minimum standard for this criterion, we\u2019ll judge it to be satisfactory.", "answer": 1}, {"article": "Moffitt is the No.\nThey report that 13 patients achieved a pCR and patients who had early non-invasive disease called ductal carcinoma in situ (DCIS) achieved a higher rate of pCR than patients who had early-stage invasive disease.\nIn order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.\n\"These results suggest that vaccines are more effective in DCIS, thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint,\" said Brian J. Czerniecki, MD, PhD, Chair of the Department of Breast Oncology at Moffitt Cancer Center.\nApproximately 80% of evaluable patients had a detectable immune response in their peripheral blood and/or in their sentinel lymph node wherein their cancer is most likely to spread to first.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that \u201capproximately 80% of evaluable patients had a detectable immune response in their peripheral blood and/or in their sentinel lymph node wherein their cancer is most likely to spread to first.\u201d It also states that 13 patients achieved an absence of disease after treatment, though it doesn\u2019t give a percentage, and that patients who had early non-invasive disease called ductal carcinoma in situ (DCIS) achieved a higher rate of disease absence than patients who had early-stage invasive disease.\nFurther, it says those patients who saw absence of disease had a higher immune response in their lymph nodes, which, says a researcher, \u201cmay serve as a more meaningful immunological endpoint.\u201d\nThe news release states that immune responses were similar regardless of whether the vaccine was administered into a lymph node, a breast tumor, or both, though it doesn\u2019t explain why this is an important finding.", "answer": 1}, {"article": "\u201cThey showed it was safe and tolerable treatment at least for this small number of people,\u201d Fargo said.\nThis does not mean that blood transfusions could treat Alzheimer\u2019s disease, researchers cautioned.\nSha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nThere was no measurable effect on memory or thinking, the team told the Clinical Trials on Alzheimer\u2019s Disease conference in Boston.\nStanford was doing what\u2019s called a proof of concept trial, just to check the safety of the treatment, in 18 volunteers with moderate Alzheimer\u2019s disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantifiable data reported in this story. In fact, there\u2019s little if anything that can be considered to be actual data. The \u201csuccess\u201d of this approach, the story says, is based on the reported observations of Alzheimer\u2019s patients\u2019 caregivers to the researchers.\u00a0This is all just subjective opinion, not actual fact. Moreover, it refers only to half of those in the so-called trial, and they were no longer blinded to whether they received plasma or a sham transfusion.\nAdditionally, the report states that researchers told a conference that, \u201cThere was no measurable effect on memory or thinking,\u201d which are arguably the most important effects that Alzheimer\u2019s has on its victims. Given that and the paucity of other real information in the story, its questionable why it was even written at all.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions.\nIn HALT-MS, researchers tested the safety, efficacy and durability of HDIT/HCT in 24 volunteers aged 26 to 52 years with relapsing-remitting MS who, despite taking clinically available medications, experienced active inflammation, evidenced by frequent severe relapses, and worsened neurological disability.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized.\nNotably, participants did not take any MS medications after receiving HDIT/HCT.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states:\n\u201cFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions\u2026.\nFive years after HDIT/HCT, most trial participants remained in remission, and their MS had stabilized. In addition, some participants showed improvements, such as recovery of mobility or other physical capabilities.\u201d\nIt also points out that none of the participants resumed MS drugs after their treatment.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the drug may lower blood pressure, glucose and cholesterol, as well as making dieting less painful, there was no estimates for the amount of weight a person might expect to lose or the extent to which these other parameters\u00a0 (blood pressure, glucose and cholesterol) might be improved.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThis story reports the absolute survival numbers of 15 months for advanced prostate cancer patients who received the new drug and a steroid vs. 11 months for those given a placebo and a steroid. However, it reports only the average survival figures. With many new cancer drugs, it appears that certain patients get most of the benefit, while most patients get little or no benefit, perhaps because of genetic or metabolic differences. The story should have addressed this issue.\nAlso, while the story notes that the drug has been tested only in patients with advanced disease who have run out of treatment options, it goes on to dangle the hope that the drug \u201cwill lead to much longer survival when studied in patients with early-stage disease.\u201d Will it? The statement is premature. No one knows if other types of patients will benefit from this treatment because it has not been tested in them.", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only states that, \u201cfremanezumab, an immunotherapy drug, has been found to reduce the number of days that chronic migraine sufferers experienced headaches.\u201d\u00a0 This is not enough numerical information to help readers understand the scope of the benefits. By how much did it reduce the number of days? By 1? 5? 10?", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is nothing in the news story\u00a0that quantifies the\u00a0benefits of the claim made\u2013that drinking wine or coffee is \u201cgreat for your microbiome.\u201d This is a major problem with the story, as it\u2019s making a claim not found anywhere in the findings.", "answer": 0}, {"article": "[3] Yokell et al.\n\"In Baltimore, we believe that naloxone should be a part of everyone's medicine cabinet and everyone's first aid kit.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\n\"People at an overdose scene may be very emotional, so it really helps that EVZIO has audio instructions on how to administer this potentially life-saving medication,\" said Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release asserts that Evzio is reported to be saving lives. It then offers testimonials, but no data. For example, the president and CEO of the company says that, since October 2014, \u201cwe have received reports that EVZIO Auto-injectors have helped save an average of 14 lives per week.\u201d\nThat\u2019s it. No mention of where the reports came from, how they were compiled, what happened in October 2014 to start those reports being filed. It turns out the drug/delivery combo was approved by the Food and Drug Administration in April 2014.\nThen, Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention, says this: \u201cIt has already helped save many, many lives in Georgia.\u201d How does she know? How many are \u201cmany, many?\u201d When she says \u201chelped save,\u201d does she mean that something else was needed to complete the save? If so, what was it?\nThen, we get another anecdote, this one from Dr. Michael Kilkenny of the Cabell-Huntington Health Department in West Virginia: \u201cFollowing initial deployment of EVZIO on February 3, we had a confirmed life saved on February 12th.\u201d \nWho made the confirmation? How? What happened?", "answer": 0}, {"article": "About half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that the product \u201cincreased stool frequency, but not significantly.\u201d\u00a0 Given the apparent existing controversy over the use of these products \u2013 at least as framed in the story \u2013 we think the story should have provided actual numbers.\nIt became very confusing when the story jumped", "answer": 0}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nThe compounds screened in this study were obtained from a drug library maintained by NIH\u2019s National Center for Advancing Translational Sciences (NCATS).\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nNext, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination.\nThe study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides insufficient detail regarding what occurred in this study and the outcomes that were reported. The release states that \u201cboth drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs.\u201d But how many animals were studied, and how many of them regained use of their limbs? Was there total resolution of symptoms or only partial resolution, and how was this measured? The release never quantifies these results.", "answer": 0}, {"article": "Yoga classes started with relaxation exercises, warm up, then gentle yoga poses like wall dog and chair twist.\n\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nDr. Robert Saper at Boston Medical Center is one of the authors.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify how much \u201cbetter\u201d patients felt who received yoga classes compared to patients who received only education, or who received only physical therapy.\nHere is the statement by the researcher. Italics by editor.\n\u201cYoga was as effective as physical therapy for reducing pain intensity,\u201d Saper said. \u201cPerhaps most importantly reducing pain medication use.\u201d\nThere should have been numbers for \u201cas effective as\u201d showing us the comparison of some measurement.\nWhat this news story and many others missed: The study\u2019s primary outcomes were pain and functional status. It found that neither yoga nor physical therapy were statistically better than education (the control group). And due to the lack of numbers in this story, it\u2019s not clear how effective any of them are.", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nAnd it\u2019s much cheaper: iFOBT is more expensive than the older stool tests, but it is still roughly $30.\nImmunochemical FOBT is now largely replacing the older test.\nPositive results on the screen prompt a follow-up colonoscopy to investigate the source of the blood.\nAnd they can pick from a number of tests that have all been found to cut the risk of dying from colon cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Sensitivity and specifity of the test were explained very well.", "answer": 1}, {"article": "\u201cWith further testing we may reveal specific plasma and urinary profiles \u2013 or \u2018fingerprints\u2019 \u2013 of compounds with damaging modifications.\nThey found the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called advanced glycation end-products (AGEs).\nThey said the next steps were to repeat the study with further groups of children to confirm the good diagnostic performance and to assess if the test could identify ASD at very early stages, indicate how the ASD is likely to develop further to more severe disease, and assess if treatments were working.\nThis may help us improve the diagnosis of ASD and point the way to new causes of ASD.\u201d\n\nThe research has been published in the journal Molecular Autism.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the study found \u201ca link between ASD and damage to proteins in blood plasma \u2026 the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker \u2018dityrosine\u2019 (DT) and certain sugar-modified components called \u2018advanced glycation end-products (AGEs).\u201d\nHowever, the story doesn\u2019t include actual data, so the reader has no way of knowing how reliable these tests might be.\nAccording to the study, a computer was used to analyze several combinations of various biomarkers, and the best diagnostic association was found in children with ASD who had higher levels of DT and AGEs.\nThe sensitivity of this model (ie. how many children with ASD were correctly identified) was 92 percent. The specificity of the model (ie. how many people without ASD were correctly identified) was 84 percent.\nIt means that 8 percent of the children with ASD were missed by the model, and 16 percent of the children that were diagnosed with ASD didn\u2019t actually have the condition.", "answer": 0}, {"article": "The opposite of the CT Scan, an exam that lasts a long time and cannot be done anywhere,\" he adds.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\n\"We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.\"\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the device \u201cwill not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\u201d A physician was quoted stating that the test was designed \u201cto determine whether the athlete can return to the field or if his condition requires hospitalization.\u201d\nBut it did not give sufficient data to demonstrate all of those claims.\u00a0The accuracy of the test is not described by the release nor is it clear if the test improves care in any way. Also, important long term outcomes (disability, difficulty concentrating, etc.) were not part of the study so any claims made on these outcomes would be inappropriate.\nThe news release did state that measuring the level of one protein, H-FABP, \u201cmakes it possible to confirm that there is no risk of trauma in one third of patients,\u201d based on a study of patients who had already been admitted to a hospital after undergoing a shock to the head. It stated: \u201cThe rest of the patients will have to undergo a CT scan to confirm the diagnosis.\u201d\nThe release also stated \u2014 prematurely \u2014 that the company is \u201ccurrently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home,\u201d based on the levels of two proteins.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides statistics on the percentage of people who lost weight after one year of wearing the device \u2014 \u201c38.3% of subjects who received the active Maestro device lost at least a quarter of their excess weight, and 52.5% of subjects lost at least 20% of their excess weight.\u201d \u00a0But how much \u201cexcess weight\u201d did these participants have when they started the study? Since we don\u2019t know that number, we can\u2019t calculate what \u201cat least a quarter\u201d of that weight amounts to. To make sense of this study for the average reader, the story could have said what a typical/average patient weighed at the start of the study and much weight they lost over the course of the study.", "answer": 0}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\nBut there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\nThe researchers used questionnaires and tests to gauge participants\u2019 visual ability, and then compared the Apple iPad versus two traditionally used magnification devices, to see if reading rates varied across devices.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The short release does not quantify benefits in a way that is easy for us to understand. It promises a comparison of the seniors reading \u201cquality\u201d on an iPad with the same patients reading on a different device. Here is an excerpt: \u201cThe researchers used questionnaires and tests to gauge participants\u2019 visual ability, and then compared the Apple iPad versus two traditionally used magnification devices, to see if reading rates varied across devices.\u201d But we are never given a true apples to apples number for how many of the readers showed better or equal visual ability on the iPads compared to their ability on other devices. We are told it is \u201cunsurprising\u201d that about one-quarter (25) of the 100 volunteers could read magnified text better whether using an iPad or two other magnification devices. What were the other devices? How large was the magnification?\nThe release did quantify one benefit, namely it said that study volunteers who had previous experience reading on an iPad or closed circuit television system (CCTV) device could read 30 words faster than those trying the iPad for the first time. This seems like a side observation, not entirely relevant to the central issue of comparing iPads and more expensive alternative devices.\nThe release also cited social acceptance of the iPad as a benefit. People are seen carrying their portable devices everywhere and so an older person seen using their tablet as a reading aid won\u2019t draw attention to their age-related vision impairment. It would have been nice to see some quantification of this benefit, even if it was drawn from a survey of the volunteers.", "answer": 0}, {"article": "recommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\n\u201cAccording to NOAA\u2019s own statistics, per capita consumption of seafood has risen from 14.8 pounds in 2001 to 16.6 pounds in 2004.\u201d\n\nJane Houlihan, the research director of the Environmental Working Group, another advocacy group, said, \u201cThe Harvard study reads like an advertisement for the seafood industry.\u201d\n\nBoth studies reinforce advice from the Food and Drug Administration and the Environmental Protection Agency in 2004, to eat about six ounces of fish a week, preferably high in omega-3\u2019s, with a caveat for women of childbearing age and children under 12 not to eat swordfish, shark, tile fish or king mackerel and to limit their intake of albacore (white meat) tuna to six ounces a week to avoid mercury.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\nreports to address the risks of mercury in tuna,\u201d said the consumer organization, \u201cwe are also concerned that both reports dismiss concerns about PCB\u2019s in most fish.\u201d\n\n\u201cThese reports are urging Americans to eat more seafood as if it were a crisis,\u201d Dr. Goldberg said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article expresses the most significant reported benefits of fish consumption\u2014decreases in coronary death and total mortality\u2014as reductions in relative risk. The article does not explain how this translates into reductions in absolute risk. (Read more about absolute vs. relative risk.) The story also doesn't explain what the risk of death is for those who do not consume fish\u2014but neither does the JAMA study that makes the health claim. The story does quote one source who quips, \u201c[The study] would indeed make eating fish the single most important decision you can make for your health.\u201d", "answer": 0}, {"article": "\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\nThey found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.\nThe team found that the incidence of depression symptoms in patients who took ketamine in addition to other pain therapeutics dropped by 50 percent (with an error margin less than 2 percent) compared to the patients who took any other drug or drug combination for pain.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release strongly suggests ketamine is beneficial for depression, but gives almost no evidence. It states that compared to other patients in the database, ketamine users showed a 50 percent reduction in depression, but no absolute numbers of people aided by the drug were provided. The absence of depression as a side effect is a novel but invalid way of defining effectiveness.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe researchers noted that which drug they should be prescribed is unclear.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nThe researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits were not fully described to back up the lead.\u00a0 The information on the decreased number of heart attacks and strokes with linagliptin treatment is mentioned in the Lancet abstract and could have easily been added to this article.\u00a0 Instead, all we got were vague comments of \u201cworked as well\u201d or \u201ceffectiveness of the drugs were (sic) similar. \u201c", "answer": 0}, {"article": "Loyola's department of urology is ranked 39th in the country by U.S. News and World Report.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nSixty-seven percent of robotic surgery patients experienced adverse effects such as urinary tract infections and intestinal obstructions, compared with 69 percent in the open surgery group.\nRobotic surgery patients lost less than half as much blood as open surgery patients, but spent more time in the operating room (seven hours, eight minutes compared with six hours, one minute).\nThe study is titled \"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomized, phase 3, non-inferiority trial.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does report the percentage of patients in the robot-assisted and open surgery groups that were still alive with no signs of disease progression two years after their procedures: 72.3 percent of patients in the robotic surgery group compared with 71.6 percent in the open surgery group\u2026 and it notes the difference was not statistically significant. It also reports that the robot-assisted surgery patients checked out of the hospital after six days on average, compared to 7 days for those in the open surgery group. The release reports only half as much blood loss in the robot surgery group, but does not report the amounts, which averaged 300 mL in the robot-assisted group vs. 700 mL in the open surgery group\u2026 that\u2019s a difference of less than one pint.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nThe study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said people on the diet \u201cconsumed\u00a0around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg. However, their fat mass, insulin resistance\u00a0and cholesterol levels were similar to the control group\u2019s.\u201d\nThat\u2019s a start. The story would have been more informative if it gave actual weights and blood pressure readings along with information on how big the changes need to be to lower a person\u2019s metabolic disease risk, which is the real goal.\nFor example, according to the study, evidence suggests at least 5% weight loss is required to improve cholesterol and glucose regulation.\nThe story incorrectly reported that the results \u201cmirror those\u201d of other intermittent fasting diets. In fact, the researchers said compared with other forms of intermittent fasting, time-restricted feeding \u201cappears to produce less weight loss.\u201d", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job in cautioning the reader that the study\u2019s\u00a0sample size was too small and that the study time too short to draw firm conclusions of \u201cno increase in breast cancer, stroke, heart attack or blood clots.\u201d However, the article states : \u201cWomen on both forms of estrogen reported fewer hot flashes, night sweats and mood swings, as well as an improvement in bone density,\u201d but this statement is not supported with any data in the story. Similarly, the story points out that estrogen in pill form, but not the patch, improved symptoms of depression, anxiety and tension \u2013 but again, these benefits were not quantified. In addition, how were these benefits measured by researchers?\nThe statement about the NIH-funded branch study on mood symptoms and cognition was particularly awkward. From the little we know of the published description of the KRONOS trial, it was not designed to look at effects of hormone therapy vs placebo specifically in women with mood and/or cognitive symptoms related to menopause. Showing a global benefit on such symptoms is not surprising, but we don\u2019t know enough to understand whether the methods used were appropriate to the task. This study should not be interpreted as a justification for menopausal women to run to the doctor for estrogen prescriptions if they are feeling depressed or noticing some trouble remembering names\u2013and the article doesn\u2019t make that clear.", "answer": 0}, {"article": "Epilepsy is a neurological disorder in which the brain's normal electrical activity is temporarily disrupted, leading to a seizure.\nBut experts said the results are promising, and should prompt further studies.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nBut any benefits need to be weighed against the risks.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was appropriately cautious in describing the potential benefits based on what was observed in only 15 patients.\u00a0 The limitations were clearly presented.", "answer": 1}, {"article": "\u2022 Cardiovascular disease affects one in six Australians or 4.2 million people.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nIn this UniSA study, published by the American Journal of Clinical Nutrition, researchers compared the health benefits of a MedDiet supplemented with two to three serves of dairy each day, and a generic low-fat diet.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A statistically significant reduction in blood pressure doesn\u2019t always translate to a clinically significant reduction. This release doesn\u2019t make that distinction for readers. It mentions that a dairy-supplemented Mediterranean diet significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function, but it doesn\u2019t describe how much each outcome improved.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019ll be interesting to see how this translates into making it into a pharmacy, and into the hands of patients.\u201d\n\nCorrection: A previous version of the story misstated some aspects of Aimunne\u2019s work on peanut allergies.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nTo understand how it works, you have to back up and look at why you get all itchy and wheezy when you encounter an allergen.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article finally does get to the point that biologics, immunologics, and quicker ways to achieve desensitization may not \u2014 for many patients \u2014 work better than golden oldies like antihistamines, the story could have, but didn\u2019t, make any attempt to pin down what kinds of patients and how many of them might need or want the newer drugs, which are at best mostly years from being available.", "answer": 0}, {"article": "At least 3.8 million people in the United States sustain a concussion or traumatic brain injury every year, many not for the first time.\n\"Sensitivity to light can be common and impact activities of daily life suggesting that light mitigation might improve quality of life in many of these patients.\n\"We believe that an athletic trainer, in consultation with team physicians, may find it useful to apply this photophobia assessment and recommend colored glasses to his or her athlete,\" Clark says.\n\"We found that 85 percent of patients reporting photophobia had relief of the symptoms with one or more colors-- blue, green, red and purple--with no reported adverse events,\" Clark says.\nOur goal in this study was to provide medical staff like athletic trainers with a method and means to assess and subsequently provide relief to an athlete who may be experiencing symptoms of photophobia,\" Clark adds.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study provides no actual numbers to back up the claim that 85 percent of the patients had improvements in their symptoms. The only hard number it mentions is \u201c51 patients.\u201d But the study itself says, \u201cOf the 39 patients studied who had vision symptoms, 76% complained of photophobia\u2026symptoms were relieved in 85% of patients reporting photophobia.\u201d So first that drops the number to 30 (depending on how they rounded). Then, 85 percent of that would be 26 (generously rounding up), which is a pretty small number. Not to mention that we have no idea what relief of symptoms means. And for how long did these symptoms go away?", "answer": 0}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\nSUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\nIn a series of tests, the Brigham and Women's Hospital researchers also found that the memory of T-cells -- the cells that mount an immune response against invading viruses -- may be more important than the antibodies generated by injected vaccines.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave no data on scarification vaccination effectiveness in the animals studied.\u00a0 The story described \"much greater effectiveness\" but didn\u2019t explain nor quantify.\u00a0 \nIt did say that \"scarification requires 100 times less vaccine to prompt an immune response\" but did not project whether that result in mice might translate to humans.\u00a0", "answer": 0}, {"article": "Scientists working for Google\u2019s parent company Alphabet have used artificial intelligence to determine a person\u2019s risk of having a heart attack from their retinal scan.\nFurther tests are required before this latest method can be used within a clinical setting.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only numerical data offered by this story is that they used \u201cdata from more than a quarter of a million patients.\u201d\u00a0 There is no comparison of the success rate of this new approach with other mechanisms for determining cardiovascular risk, so readers have no way of assessing its potential value.", "answer": 0}, {"article": "\"It's not.\"\nThat said, Dr. Moses Rodriguez, a professor of neurology and immunology at the Mayo Clinic in Rochester, Minn., disputed the premise that ocrelizumab is shaping up as anything new and innovative.\nThe new therapy's potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.\nAnd all this new drug is attempting to do is replicate the same that rituximab already does.\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Same criticisms as in the \u201cevidence\u201d criterion:\nWhat does an 89 percent drop in lesion count mean?\u00a0 What is the relationship between lesion count and symptoms or eventual outcome? How does a patient relate lesion count to something meaningful in his/her life?\nRelapse rates may have been a more helpful indicator, but we\u2019re only told they were \u201cmuch lower.\u201d\u00a0 How much lower?\u00a0 What does that mean to patients?\nAnd if the Mayo expert says that a competing drug has been in early trials for years \u2013 why not provide the evidence from those trials?\nThe headline says \u201cpromising\u201d but the independent expert says \u201cI see no major advantage of this drug versus that older drug. It\u2019s not better or worse. It\u2019s the same\u201d\u00a0and that it\u2019s not a breakthrough.", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, it is difficult to quantify the benefits because of the lack of evidence. Here we think the story relies a little too much on anecdotal evidence. On balance, the story presents a complete picture, though.", "answer": 1}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nNevertheless, it raises hope that a simple, noninvasive intervention might go a long way towards countering the fatigue, poorer prognosis and impaired quality of life that can result from chemo-induced muscle mass loss.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The weight loss figures for the two groups were given.\u00a0 But the muscle mass figures were given in percentages, which is clumsy.\u00a0 Rather than 70% in the fish oil group kept their pre-chemo muscle mass, why not say 11 out of 16.\u00a0 And rather than less than 30% in the standard care group, why not just say 7 of 24? (Or whatever the actual numbers were.)\nBut let\u2019s drop back to the big picture.\u00a0 Rather than merely reporting numbers, why didn\u2019t the story report on what difference these results may have had in peoples\u2019 lives, if any?\u00a0 Or is that impossible to gauge after just a 10-week study?\u00a0 If so, perhaps that, too, should have been discussed because it again reflects on the limitations of such a small, short-term study.", "answer": 0}, {"article": "For more information, visit www.joslin.org.\nBecause Lucentis is commonly injected to treat diabetic macular edema (DME)\u2014a build-up of fluid in the center of the retina\u2014the study permitted the use of Lucentis for DME in the laser group, if necessary.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\nFunded by the National Eye Institute (NEI) and conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), the trial compared Lucentis injections with a type of laser therapy called panretinal photocoagulation, which has remained the gold standard for PDR since the mid-1970s.\nAmong people without this condition at the start of the study, only 9 percent of Lucentis-treated eyes developed it, compared with 28 percent in the laser group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are, for the most part, reasonably well explained. But those explanations lack numbers to back them up and are overstated in at least one place.\n\u201cOne benefit discussed in the release is that study participants who received laser treatment were more likely to suffer peripheral vision loss than participants who were treated solely with Lucentis \u2014 although this isn\u2019t quantified. A second benefit was that participants who received laser treatment were more likely to require subsequent surgery to remove blood from the eye \u2014 and this was quantified. But the release pushes things a bit when it comes to vision, or visual acuity. The release states: \u201cAt two years, vision in the Lucentis group improved by an average of about half a line on an eye chart, compared with virtually no change in the laser group.\u201d But here\u2019s how the journal article puts it: \u201cThere was no statistically significant visual acuity difference between the ranibizumab and PRP [laser] groups at 2 years.\nThe language in the journal article itself stresses that what was being evaluated was whether Lucentis was at least as good as laser treatment \u2014 and they found that, after two years, the visual acuity of patients who took Lucentis (and had no laser treatment) was as good as patients who had the laser treatment. The release could have simply stated this and avoided confusion.\nIn short, this was a close one \u2014 but the lack of numbers on peripheral vision and the overstatement of the visual acuity results make this a \u201cNot Satisfactory.\u201d", "answer": 0}, {"article": "The General Director of the Danish section of MSF Jesper H. Brix notes:\n\n\"Acute malnutrition is still a major global health problem.\nThe study found that children who received LNS experienced greater weight gain, and the large majority of the weight gain was healthy lean tissue.\nThe main Treatfood results are presented in the paper: Effectiveness of food supplements in increasing fat-free tissue accretion in children with moderate acute malnutrition: A randomised 2 \u00d7 2 \u00d7 3 factorial trial in Burkina Faso, published in the open access medical journal PLOS Medicine.\nEarlier peer-reviewed articles from the study have appeared in the American Journal of Clinical Nutrition, BMC Nutrition, and Appetite.\nDuring the trial, 1609 small children with moderate acute malnutrition were given either LNS or corn-soy porridge for 12 weeks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary outcome in this study was weight gain that was not primarily fat; it is important to note that this study did not address survival or neurodevelopment, which are the presumed benefits of greater fat-free weight gain. The news release tells us that children who received LNS gained more weight than children on the corn-soy porridge, and that weight was primarily lean mass. It doesn\u2019t tell us how much more weight they gained, nor does it describe the difference in progression to severe acute malnutrition. Studies with large samples like this one can give results that are statistically significant even when differences are small. Specific information about the size and clinical importance of the difference should have been included.", "answer": 0}, {"article": "\"Oh, absolutely!\"\nShe says she'd like to do follow-up research to look at the bioactive compounds in avocados, which may explain the added reduction in LDL cholesterol in the study participants.\nIt's also possible that the fiber in avocados plays a role in the cholesterol-lowering effect, she says.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does compare the reduction of LDL cholesterol in study participants who ate avocado to reductions in LDL among study participants who did not. However, it is not clear if the differences are significant relative to the overall amount of LDL cholesterol found in blood \u2014 and the story never explains how LDL cholesterol is linked to human health. It would have been nice if the story had explained why people should care about their LDL cholesterol or why it is termed the \u201cbad\u201d cholesterol. Comparing the reductions seen with a common dose of Lipitor (atorvastatin), or explaining how the changes would affect one\u2019s overall cardiovascular risk, would be helpful for readers.", "answer": 0}, {"article": "\"It was surprising, and exciting,\" Dr Belmer said.\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\nAlcohol is specifically very damaging for neurons.\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\nTheir studies in adult mice show that two weeks of daily treatment with the drug tandospirone reversed the effects of 15 weeks of binge-like alcohol consumption on neurogenesis - the ability of the brain to grow and replace neurons (brain cells).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release assumes that binge-drinking in selectively-bred rodents and the brain and behavior changes they evidence have some relevance to humans. Quantification of benefits are irrelevant since rodent drinkers are not the same as human drinkers. Some evidence on human benefit is needed.\nAs to the benefits of using tandospirone in mice, the release provides the following:\u00a0 \u201c\u2026.two weeks of daily treatment with the drug tandospirone reversed the effects of 15 weeks of binge-like alcohol consumption on neurogenesis \u2013 the ability of the brain to grow and replace neurons (brain cells).\u201d Simply saying it \u201creversed the effects\u201d or \u201cthe drug was effective\u201d isn\u2019t adequate for conveying any potential benefits from the drug\u2019s use.", "answer": 0}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A study author is quoted as speculating that lactoferrin \u2026\n\u201celicits changes in the salivary protein profiles in cancer patients \u2014 changes that may be influential in helping protect taste buds and odor perception\u201d \u2014 which in turn \u2014 might \u201creduce TSA (\u201ctaste and smell abnormalities\u201d), restoring their ability to enjoy food during a time in which nutrition can play a key role in recovery.\u201d\nAlthough the logic here appears sound there is no data included to support this chain of eventualities.", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\n\"We also found the risk of MS among daughters whose mothers were in the top 20% of vitamin D intake during pregnancy was 45% lower than daughters whose mothers were in the bottom 20% for vitamin D intake during pregnancy.\"\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presented the results in terms of relative risk, rather than absolute risk (56% lower than what?).\u00a0 Additionally, the story suggests that daughters of mothers who drank 4 glasses of milk per day had a lower risk of MS compared to those whose mothers who drank 3 glasses of milk per day.\u00a0 However, we\u2019re not told whether this difference is statistically significant. ", "answer": 0}, {"article": "Antidepressant medications are one treatment option, but there are safety concerns.\n\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nFor their study, she and her colleagues randomly assigned 52 women to receive depression-specific acupuncture twice a week for four weeks, then weekly for another four weeks.\nOverall, Manber\u2019s team notes, the response to acupuncture in this study was comparable to what has been seen in studies of psychotherapy for depression during pregnancy.\nBut while the findings are promising, questions still remain \u2014 including whether acupuncture as practiced in the real world can reliably help women with depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only reported benefits in percentages in each group that \"responded to therapy,\" but later the story provided the actual numbers of women assigned to the three study groups \u2013 so it\u2019s possible for readers to do the math.\u00a0 Nonetheless, why make them do the math?\u00a0 Why not just give the absolute numbers of how many in each group responded?\n", "answer": 0}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\nBut the authors of the study, published in the American Journal of Clinical Nutrition, stopped short of recommending people take a daily magnesium supplement because their analysis focused on magnesium in food \u2014 and it may be another aspect of the food that is responsible for their finding.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\nBut Larsson told Reuters Health in an email that she could not say whether other aspects of what the people ate partially or entirely explained the finding.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the absolute number of strokes observed in the analysis, and the relative risk reduction observed. With a meta-analysis it is not statistically appropriate to pool absolute risk reductions, so the way the story treated the evidence is as good as can be done (showing the relative risk reduction and an \u201canchor\u201d in terms of absolute risk.)", "answer": 1}, {"article": "For more information, see www.scripps.edu.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\n\u201cDoctors could use this modified form of vancomycin without fear of resistance emerging,\u201d said Boger, whose team announced the finding today in the journal Proceedings of the National Academy of Sciences.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that \u201cCombined with the previous modifications, this [new] alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\u201d It\u2019s not entirely clear what this means. Does it kill relevant bacteria more quickly? More efficiently? Clinical trials in humans haven\u2019t been conducted, so it\u2019s not clear what the benefits would look like in patients \u2014 and the release doesn\u2019t tell readers that.\nAs the final sentence in the abstract of the scientific article states: \u201cSuch antibiotics are expected to display durable antimicrobial activity not prone to rapidly acquired clinical resistance.\u201d No where could we find quantifiable benefits of the drug in fighting antibiotic-resistant infection.", "answer": 0}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nPetersen and his team wanted to develop a test that any physician can administer to patients, without the need for any new technology or expensive equipment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give the story credit for pointing out that there are few if any meaningful interventions available for MCI, and the testing may be useful in the future to identify patients who might benefit. But we have some concerns.\nOur first issue with the story is the emphasis on the early diagnosis of Alzheimer\u2019s disease. \u00a0The study was actually directed at early identification of mild cognitive impairment and not Alzheimer\u2019s per se. \u00a0The distinction is important. Although many people with mild cognitive impairment go on to full blown Alzhemier\u2019s, not all do.\nOur second problem with the story is the lack of any meaningful quantification of the results. The story notes, \u201c\u2026those who scored higher on the test of risk factors had a seven-fold higher chance of developing mild cognitive impairment than those with lower scores.\u201d That doesn\u2019t really tell us anything useful about the test results. As a reader, I want to know how good is the test at predicting whether I\u2019m going to be impaired? As it turns out, the \u201c7-fold increase\u201d is not as definitive as suggested by the story. For example, a 70-year-old man with the highest score in the tests has a 1 in 4 chance of developing mild cognitive impairment in the next 5 years. \u00a0That same individual would have about the same risk of a major cardiac event based on the American Heart Association risk calculator. So individuals who score highly on the test are hardly condemned to develop Alzheimer\u2019s, or even mild cognitive impairment. The story would have done well to communicate that fact to readers.", "answer": 0}, {"article": "Anderson.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nWEDNESDAY, Sept. 29, 2010 (HealthDay News) -- Another study evaluating the value of mammograms for younger women finds that screening can lower the risk of dying from breast cancer for women in their 40s.\n\"There was a significant improvement in survival overall, including all patients with all stages of breast cancer...even those who had disseminated cancer,\" said study author Dr. Aman Buzdar, a professor of medicine and breast medical oncology at M.D.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does note the benefit of screening at age 40-44, 44-49 and for women 50 and older; however, only the relative benefit was given. The story should have reported the number of women in the cohort, who was screened, how long they were followed, and the absolute reduction in breast cancer mortality observed. That has been our standard all along on this site and this is no time to change. \n", "answer": 0}, {"article": "My brother or my sister wasn't a match.\nIn such transplants, patients have chemotherapy, radiation or both to kill the cancer cells and to suppress the immune system so that the new stem cells are not rejected.\nCord blood stem cell transplants have the same risks as adult bone marrow transplants: the new blood rejecting the host, called graft-versus-host disease.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\nTirpak and Mumford represent a growing number of patients taking advantage of stem cells from cord blood, which can be used in patients with leukemia, lymphoma and myeloma.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "See the larger discussion of the evidence evaluation.\nNone of the potential benefits were quantified \u2014 survival, quality of life, etc. Advantages over bone marrow transplant are enumerated, but the only patient outcome discussed is 100% cure for these two patients and, in a vague afterword, the potential for rejection. The lack of more detail about outcomes fans the flames of this \"medical breakthrough that\u2019s saving lives.\" The truth is that this procedure doesn\u2019t cure everyone who gets it. One 2004 study found that adults with leukemia who received cord blood transplants didn\u2019t live any longer than those who received bone marrow.\u00a0", "answer": 0}, {"article": "If all it requires is to take a closer look at the images, how can we ignore it?,\" he said.\nDigital mammography is more sensitive to the presence of calcifications and is now available in 96 percent of mammography units in the U.S.\n\nAnother intriguing point that deserves additional study, according to the researchers, is that the nature of the atherosclerosis is different in breast arterial calcification and CAC, making it unclear why one should be related to the other.\nNotably, breast arterial calcification also appeared to be as strong a predictor for cardiovascular risk as standard risk scores such as the Framingham Risk Score, which underestimates women's risk, and the 2013 Cholesterol Guidelines Pooled Cohort Equations, which tends to overestimate risk, Hecht said.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\nIt's a freebie and provides critical information that could be lifesaving for some women,\" Hecht said, adding he hopes these findings will prompt clinicians, who rarely report breast arterial calcification, to routinely report not just the presence or absence of breast arterial calcifications but also to estimate and note the amount.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does attempt to quantify the accuracy of the test when it states that 70 percent of the women that were shown to have breast arterial calcification (BAC) were also found through CT scans to have coronary artery calcification (CAC). While that may sound impressive, the release doesn\u2019t acknowledge that this equates to a 30 percent false-positive rate. So 30 percent of women may be unnecessarily worried or inconvenienced and sent for additional testing based on these results. Also, we\u2019re not told what percentage of women who tested negative for breast calcification in fact would have have had CAC according to a CT scan of their chest. That\u2019s an important piece of information that speaks to the test\u2019s usefulness. And if it wasn\u2019t addressed in the study, we think the release should have said so. We always encourage news release writers to address both the sensitivity and specificity of screening tests.\nThe release also suggests that measuring breast arterial calcification is a better, more accurate risk factor assessment tool than standard risk scores (Framingham Risk Score and the 2013 Cholesterol Guidelines Pooled Cohort Equations). But it doesn\u2019t provide us with any quantification. Instead it says calcification is a \u201cmore powerful\u201d measure for assessing risk than the standard risk assessment. What exactly does that mean?", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\n\"This is a field that has been full of skepticism and misconception, where patients have been viewed to have invented their disease.\nTwo classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\nSo why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The most relevant text here is: \u201cOut of 51 cytokines investigated via sophisticated\u00a0fluorescence-based testing, only two of the cytokines differed, in their total concentrations, between the ME/CFS and control groups. But, levels of 17 of the cytokines varied dramatically between the patients with mild versus severe ME/CFS symptoms. Of those 17 cytokines, 13 were types that promote inflammation.\u201d\nThe issue is, though, what does this actually mean in terms of diagnosing a patient as having ME-CFS and treating them with a potentially risky drug such as rituximab that is mentioned in this piece. While the story could have done a better job on that point, we think the discussion here is sufficient for a satisfactory grade. We\u2019ll address the broader implications and the story\u2019s shortcomings below under the evidence quality criterion.", "answer": 1}, {"article": "Those are considered important for the development of depression and are the targets of most antidepressant medications.\n[Why it's so hard to find a mental health professional ]\n\nLam and his colleagues followed 122 patients and evaluated whether light therapy improved their mood when it was used both with and without fluoxetine, or Prozac, a commonly prescribed antidepressant.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nLight therapy is cheap, easy to use and comes with few side effects compared to medication such as antidepressants, said lead author Raymond Lam, a professor of psychiatry at the University of British Columbia.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only attempt to describe benefits is vague.\nHere it is, with italics by editors:\n\u201cAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant. About 60 percent of those using light therapy with the antidepressant reported feeling almost back to normal, Lam said.\u201d\nQuantifying means we\u2019d like to know some metric or measure that researchers used to compare the different groups of patients. In the original journal article, the authors said they used MADRS (Montgomery-Asberg Depression Rating Scale) changes from baseline to 8 weeks into the different therapies. It would be useful to know where they started on that scale and where they ended up \u2014 and whether that difference was meaningful.", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nIf they're right, we all may soon be taking a pill that could give us an extra decade or two of healthy old age.\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a lot of speculating about the number of years of life extension possible, without any basis to back up these claims. The story also has the audacity to imply that somehow this pill will help us have a better death \u2013 that with this pill people will die \"quietly in their sleep\". As if anything could have that kind of control over how we die! ", "answer": 0}, {"article": "\u201cIt\u2019s a combination,\u201d Hagan said.\n\u201cSo in our study we wanted to expand that and look at all-cause mortality and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d\n\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\nTo measure levels of optimism, participants were asked to use a five-point scale to either agree or disagree with six statements, such as, \u201cIn uncertain times, I usually expect the best.\u201d\n\nThe results showed that the most optimistic women \u2013 those in the top 25 percent \u2013 had a nearly 30 percent lower risk of dying from any of the diseases analyzed in the study when compared to the least optimistic participants in the lowest 25 percent.\nSpecifically, the researchers found that the most optimistic women had:\n\nThe researchers controlled for a number of factors that could have had an impact on lifespan, including marital status, education level, and other socioeconomic factors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers are told that the most\u00a0optimistic\u00a0nurses (top 25%) had nearly a one-third lower chance of dying, at least compared to the the most\u00a0pessimistic\u00a0group (lowest 25% of the survey group for\u00a0optimism). We\u2019re also clued into some of the data behind the longevity numbers: the drop in risk of diseases and conditions that kill the most Americans. For example, according to the study\u2019s analysis, the most optimistic nurses had a 39% lower risk of\u00a0having\u00a0(and dying from) a stroke.\nThe problem? All these numbers are presented in relative risks, instead of absolute\u00a0risks. To know how meaningful these findings were, we need to see the absolute risk of death among the most optimistic of nurses compared to the least optimistic.", "answer": 0}, {"article": "\u201cNow I feel like we\u2019re armed with information,\u201d she said.\nPetrozza said he worries that women might wrongly interpret a long litany of genetic risks to mean that their hopes to start a family are \u201cdoomed.\u201d He also said he sees the test as \u201cvery costly for what it\u2019s trying to do \u2014 and not really giving, at least at this point, what I would consider meaningful information.\u201d\n\nThe Fertilome test was eight years in the making.\nBut others caution that Fertilome is just the latest genetic test promising more than it can deliver \u2014 and, in this case, playing to the fears of women who are anxious about becoming a mother.\nCelmatix held webinars earlier this summer for OB-GYNs, telling them that the test could help \u201coptimize management plans from the very start.\u201d\n\nDr. Aimee Eyvazzadeh, a reproductive endocrinologist in private practice in the Bay Area, is among a few doctors who\u2019ve been given vouchers by the company to offer the test for $500.\nThe Fertilome test can help you decide if it is right for you.\u201d\n\nThe company\u2019s website also features testimonials from women who say they have used Fertilome to help guide their decisions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A primary goal of the story is to drive home the point that benefits are highly uncertain. The text is clear about the intended benefit, to provide genetic information that could inform a woman\u2019s reproductive decisions.\u00a0 But it also tells the reader, in no uncertain terms, that there is as yet \u201cno evidence\u201d that the test actually accomplishes that. It even busts the company for using fictitious patient anecdotes to sell women on the benefits of the test.\nA strong point for the story is its characterization of one woman\u2019s increased risk of a condition known as primary ovarian insufficiency, which the test notes is 4-fold higher than in women without a specific genetic variant.\nThat sounds alarming, and might prompt a younger woman who\u2019s planning to delay pregnancy to freeze her eggs to be sure she has them available down the road. But the report does not explain that the condition is fairly rare \u2014\u00a0affecting just 1 in 1,000 women by age 30 and 1 in 250 women by age 35 \u2014 so the absolute risk is still very small.\nWe have a primer on the difference between relative and absolute risk that readers can turn to for more information.", "answer": 1}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\n\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\n\u201cWe had outstanding results, and our study, we think, is representative of these treatments in the and ,\u201d said Dr. Thomas G. Brott, director for research at the campus in , Fla., and lead author of the North American study, called Crest (for Carotid Revascularization Endarterectomy versus Stenting Trial).\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a satisfactory job of presenting the major findings using the appropriate statistics.\u00a0Like the LA Times,\u00a0however, this\u00a0story suggests that the disparate findings of the two studies might be explained by the better training and experience of the\u00a0American CREST surgeons compared with their European counterparts in the ICSS trial. We wish it had spent some time exploring whether the typical patient in the U.S. can expect to receive the kind of expert care offered by the top CREST surgeons.\u00a0In many cases, the\u00a0\"real-world\" outcomes\u00a0of patients will be less favorable than what the CREST team reported.\u00a0\u00a0", "answer": 1}, {"article": "\u201cThis is great science,\u201d says J. Stephen Jones, MD, chairman of the department of regional urology at the Cleveland Clinic in Ohio.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\nResearchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nThe two tests together appeared to generate both sensitive and specific results.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the benefit of using these markers to avoid unnecessary biopsies. Typically, biopsy thresholds for the markers will be set to detect a large majority of the cancers (>= 90%) which will then reduce the number of unnecessary biopsies\u2013which can be quantified.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits of these tests are touted, but not quantified. An officer of the National Ovarian Cancer Research Fund Alliance, an advocacy group, testifies that the outcomes of women who have surgery from a gynecologic oncologist\u00a0\u201care much better.\u201d But we don\u2019t know\u00a0what that means. Is it longer survival?\nLater the story explains\u00a0that combining the two blood tests with assessment by a clinician \u201cbetter determined the patients who should be referred to a [gynecological oncologist], identifying well over 90 percent of the women who actually had cancer.\u201d \u00a0(Note that this statistic reflects only referral to a gyn-onc, not patient survival.) But how does that compare to the\u00a0standard assessment tools?\nA 2016 study described\u00a0as publication \u201cof the first clinical utility data\u201d demonstrating that use of OVA1 resulted in referral of ovarian patients to gynecologic oncologists offers similar outcomes but is not mentioned in the story.", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nScientists don\u2019t know exactly how perceptual learning relieves presbyopia, but they have some clues based on how our brain processes visual information.\nThen the brain must coordinate activity across sets of neurons to assemble these features into recognizable objects like chairs, faces, letters or words.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\nOne study published in Psychological Science trained 16 college-aged adults and 16 older adults (around age 71) with Gabor patch exercises for 1.5 hours per day for seven days.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article cites a couple of studies that offer qualified support for\u00a0benefit of the vision training, but specifics were lacking. For example, it says that through use of this training, \u201cpresbyopia lessens.\u201d But how much does it lessen?\nThe piece does describe one small study as finding that older adults who used the training were able to see \u201clow-contrast images\u201d as well as college-aged participants. Does this mean they could read without glasses? And how long do these improvements last? Is continual training required?", "answer": 0}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nAnd, according to the company, a study of 30 women showed that after 10 days of using the Algenist serum, they had a 25 percent decrease in wrinkles as shown by silicone replicas of their faces.\nBut he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter apparently had access to an \u201c84-page patent application\u201d for the product being sold, but\u00a0the story\u00a0does not present\u00a0quantify any of the evidence that\u00a0may have bene found there.\u00a0Instead, it allows a company vice president to say that \u201ca study of 30 women showed that after 10 days of using the Algenist serum, they had a 25 percent decrease in wrinkles as shown by silicone replicas of their faces.\u201d", "answer": 0}, {"article": "According to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nCoffee was the main, or only source, of caffeine among people in the study.\nThere may even be a reason to start for people in their late 30s and up, he says.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\n\"There is no reason to stop if you are experiencing memory problems.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just had too many unsupported statements about the benefits of coffee to earn a satisfactory here. Examples:", "answer": 0}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\nWhen we give progesterone back to these women, the endometrium makes more nutrients and prevents their pregnancy loss.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that progesterone prevents miscarriages. How many miscarriages did it help prevent and how was this assessed? There aren\u2019t any numbers.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\n[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\nMarb\u00e1n says the amount of new heart tissue that grew was not subtle.\nNot only did this show that the procedure was safe, it also showed that the cells can help reduce scarring and even cause new heart muscle to grow.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide a lot of hard data on benefits, and we would have liked to have seen more. For example, it says that \u201cabout half of their scar tissue dissolved and the reduction in scar size appears to get bigger after the first six months.\u201d But we appreciated some of the specific details it does provide, including: \u201cMarb\u00e1n says the amount of new heart tissue that grew was not subtle. [On average] \u201c22 grams (about .78 ounces) of new heart tissue grew,\u201d which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\u201d\nHaving said that however, the story misses an important point.\u00a0 The patients treated with the stem cells did not have an improvement in their overall heart function.\u00a0 So while there appeared to be a considerable amount of regenerated heart muscle, it did not make any difference in the performance of the heart so that patients did not likely see any benefit to the procedure.", "answer": 0}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nShe still can't lift more than 11 pounds, but the pain has greatly subsided.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of benefits. The story reports ony the anecdotal experience on one patient with one surgeon.", "answer": 0}, {"article": ".\nBut self-experimenters such as Burke often don\u2019t restrict themselves to medication alone.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\nIt\u2019s a weird but handy trick for someone who swallows 25 pills a day, most of them purchases off the Internet.\n\u201cWe don\u2019t use it at all and never have.\u201d\n\nAs for newer nootropic drugs, there are unknown risks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify any known benefits of these brain enhancers, for example if memory increased by a certain percent.", "answer": 0}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits discussed in this story\u00a0were ALL anecdotal. \u00a0In addition, the story reports on a newly approved pharmaceutical intervention without citing any success rates, absolute or relative.\u00a0Not\u00a0satisfactory. \u00a0", "answer": 0}, {"article": "Research has shown that vitamin D plays a key role in maintaining muscle integrity and strength and some studies suggest vitamin D may reduce the risk of falls.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nIn addition, people in the vitamin D group reported approximately half the falls of those in the control group.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the positive side, the release notes that participants in the vitamin D group had higher blood levels of the vitamin and tells us how many achieved \u201csufficient\u201d and \u201coptimal\u201d levels. It provides the cutoffs that were used to determine those outcomes.\nHowever, with respect to the key clinical outcome \u2014 falls \u2014 the story says, \u201cpeople in the vitamin D group reported approximately half the falls of those in the control group.\u201d It\u2019s not clear from this description how many falls were actually prevented. The study itself clarifies this in absolute terms: \u201cThe mean number of reported\u00a0falls over the 5-month follow-up period was 0.5 (range 0\u2013 4) in participants randomized to vitamin D3 and 1.1\u00a0(range 0\u20138) in participants randomized to active placebo.\u201d", "answer": 0}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made clear that patients who participated in one of two online self-help interventions had a 27 percent rate of experiencing major depression disorder (MDD)\u00a0in the 12 months following the study, compared to a 41 percent rate for those who did not participate in the online interventions. That\u2019s enough to earn a satisfactory rating.\nIt would have been even better if the story had addressed whether there was any difference in performance for patients who received the \u201ccognitive behavioral therapy\u201d intervention versus the \u201cproblem-solving therapy\u201d intervention. And if the study didn\u2019t differentiate between results for the two interventions, the story could have said that. This is significant because it\u2019s not clear to readers whether one approach might have been significantly more effective at preventing the onsite of MDD, or if they had comparable results.", "answer": 1}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never\u00a0clearly explained why breath testing would be an advantage over current screening methods, and it didn\u2019t tell what stage of cancer the patients being tested had or whether the test would be useful for detecting precancerous polyps. In addition, as we noted with the competing HealthDay piece, good diagnostic tests not only have to be able to identify people who have a\u00a0disease correctly, but they also have to be able to rule out people who don\u2019t have the disease correctly. Given that context, it\u2019s unclear\u00a0what the accuracy statistic provided by the story means.\u00a0The story says that the test was\u00a0able to distinguish between the cancer and non-cancer patients 76% of the time. We would have preferred to see the absolute numbers of people in each group (the cancer patients and controls) who were accurately diagnosed, and a comparison of how this\u00a0stacks up against\u00a0existing screening methods.\n\u00a0", "answer": 0}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nThe researchers looked at 386 15-year-olds who were finishing up ninth grade.\nWhen all their grades from ten core classes were added up, there was a clear difference between teens who got the most and the least folic acid in their diets.\nDuring the study, Sweden did not fortify foods, nor did kids use a lot of supplements.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the data on the summation of grades showing the difference in folic acid levels in the children in the highest and lowest groups. \u00a0While it is nice to have absolute grade difference provided, it would have been useful to indicate whether these differences were statistically significant or whether the differences in folic acid intake were clinically significant.", "answer": 1}, {"article": "\"That's how I do pretty much everything in my daily life when I'm not hooked up to the system,\" he says.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nDr Jonas Zimmerman, a neuroscientist at Brown University in the US, who was also not involved with the study, echoed Jackson's point.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article included important caveats about the limited actions that the patient was able to perform, and made it clear that this device was highly experimental. But most of these details are mentioned only near\u00a0the end of the story. We might have given the story a Satisfactory rating if the headline and opening paragraphs had matched the tone of these later sections. However, the overly broad claims at the top of the story overwhelm the cautionary details.\nAlso, the story should\u00a0have more clearly pointed out that (as a Nature news article specifically noted) this approach may not work for people who, unlike this patient, don\u2019t still have at least some ability to move their shoulders and elbows. As a result, the story implies that this experiment is relevant to a far broader group of people than the researchers claim.", "answer": 0}, {"article": ".\nIn the eight-week randomized controlled trial led by Back and Kalivas, 35 veterans with PTSD and SUD, all of whom were receiving cognitive behavioral therapy (CBT) for their SUD, were randomized to either 2400 mg/day of NAC or placebo.\nBecause evidence suggests that SUDs and PTSD share overlapping neurobiological pathways, Sudie E. Back, Ph.D., lead author on the article, hypothesized that NAC treatment with CBT would be a novel approach to treat co-occurring PTSD and SUD.\nVeterans in the NAC-treated group showed a 46% reduction in PTSD symptoms, compared with a 25% reduction in the placebo group on the Clinical-Administered PTSD Scale (CAPS), which assesses trauma history and symptom severity.\nVeterans in the study had low rates of substance use during the trial, and the study found little effect of medication on use, perhaps due to the fact that all participants were receiving SUD treatment and exhibiting low levels of use.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The intent of the pilot study was to determine the effect of N-acetylcysteine on PTSD symptoms, cravings and substance use. All three endpoints are described in the news release albeit in relative terms.\nWe are told that the 8-week trial randomized 35 veterans with PTSD and substance use disorder. Some received N-acetylcysteine and others a placebo, but all of the participants received cognitive behavioral therapy (CBT).\nThe release reported that \u201cVeterans in the NAC-treated group showed a 46% reduction in PTSD symptoms, compared with a 25% reduction in the placebo group on the Clinical-Administered PTSD Scale (CAPS), which assesses trauma history and symptom severity. The threshold CAPS score for diagnosis of PTSD is 50.\u201d\nThe release quotes the lead author: \u201cAs a group, the NAC-treated veterans were below diagnostic level for PTSD at the end of treatment.\u201d This establishes that the benefit was clinically meaningful. But we prefer to see absolute rather than relative numbers as used here. For example, the actual before and after scores on the PTSD scale would have better illustrated how large the benefit was.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nNow, the task of estimating death or disease linked to diet is tricky.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\nHe says the bigger point is this: \"Whether poor diet is causing 1,000 cardiovascular and diabetes deaths per day, or 500, it remains among the leading causes of preventable suffering.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study includes some numbers, for instance that \u201cConsuming too much salt was associated with 9.5 percent of the deaths\u201d and that \u201cdiets low in seafood, whole grains and fruits and vegetables were found to contribute to about 6-8 percent of the deaths.\u201d \u00a0It also paints the larger picture: \u201cIn 2012, about 700,000 Americans died from these diseases. Diet was linked to nearly 319,000 of these deaths.\u201d\nThis is a satisfactory summary of the numbers as far they go, though the story could have provided more examples of how much more or less of these foods people would have to eat in order to achieve the claimed benefits. (How much salt is too much?) \u00a0The bigger issue is the claim that certain dietary factors \u201ccontributed\u201d to deaths, which overstates what the evidence can tell us. We\u2019ll address that issue below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "Take lorcaserin, for example.\nPeople need to realize that in obesity treatment, just as in hypertension therapy, one drug won\u2019t fit all, Aronne said.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\n\u201cThe challenge with lifestyle interventions is that patients tend to lose weight up front, and then the weight is regained, sometimes beyond the original weight.\n\u201cMost prior studies of weight loss only followed patients for a year, and a few out to two years,\u201d said the study\u2019s lead author, Dr. Erin Bohula, an assistant professor of medicine at Harvard Medical School and a cardiologist and investigator with the TIMI Study Group at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Th story claimed the latest generation of diet pills can help \u201cshave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol.\u201d\nSpecifically,\u00a0that the drug lorcaserin (Belviq) helped \u201cnearly\u201d 40% of patients have sustained weight loss of more than 5% of body weight, which it said \u201cis associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\nIt also said patients in a lorcaserin study \u201cdid see improvements in hypertension and blood sugar levels with weight loss.\u201d\nWhen we looked up the results in a large\u00a0study published in the New England Journal of Medicine, the numbers aren\u2019t as impressive sounding:", "answer": 0}, {"article": "So any energy-consuming process usually turns off the moment the body doesn't need it.\"\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\n\"Scientists were finding that this compound affected metabolism,\" said Wu, who also is an assistant professor of molecular and integrative physiology at the U-M Medical School.\nThis long-term storage was beneficial to our distant ancestors, who had much less access to high-fat foods and thus a much greater need to store fat.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release does not offer any numbers providing context beyond making the claim that triggering fat burning in cells could reduce obesity. There are no numbers on how much or how quickly cinnamaldehyde induces fat burning, While we recognize that the objective of the study was to determine the mechanism through which cinnamaldehyde acted and to determine its metabolic pathways, we\u2019d still like to see some description of the type of measurements used by researchers.", "answer": 0}, {"article": "Sometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\nWhen you visit the website, you\u2019ll see a pop-up window with a portal to take the quiz.\nTo raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that \u201cAllergan\u2019s prescription drug RESTASIS\u00ae, works by increasing the eyes\u2019 natural ability to produce tears,\u201d but nothing about\u00a0how it was tested or how well it actually works.", "answer": 0}, {"article": "AOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids\nAfter treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\nThe study examined 121 patients at an average of 51 months post-surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release encapsulates the differences observed: \u201cThe study examined 121 patients at an average of 51 months post-surgery,\u201d it says. \u201cOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively. After treatment with an arthroscopic bankart repair, the postoperative dislocation rate in the first-time injury group was 29%, compared to 62% in those who did not have surgery after their initial injury.\u201d\nAnd 7% of those with surgery after the initial dislocation vs 32% after a recurrent dislocation had to have another surgery, according to the release.", "answer": 1}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\n\u201cIt took people less time to lose 10 pounds\u201d on a high-fat diet-and-exercise program, about 45 days on average, than the 70 days it took for those who exercised and followed a high-carbohydrate, low-fat diet constructed using guidelines from the American Heart Association, said Kerry J. Stewart, director of clinical and research exercise physiology at Johns Hopkins University School of Medicine and lead author of the report.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\nThe other 23 volunteers were assigned to a meatier, cheesier, high-fat, low-carbohydrate spread, with about 55 percent of calories derived from fat; the diet avoided trans fats.\nIn a study overseen by Dr. Phillips and published earlier this year, sedentary people on a low-carbohydrate, high-fat diet lost pounds but few inches from around their middles.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the rate of weight loss as being faster on the low-carbohydrate diet than the low-fat diet (45 days versus 70 days) though there was no information about how the two groups compared in terms of sustaining the weight that was lost or whether weight loss continued beyond the initial 10 pounds. The story also did not mention whether the difference reported was significant or if the range of time it took the two groups was overlapping.", "answer": 0}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of eribulin over various treatments chosen by the physicians was clearly stated in the article.\u00a0 \u201cThe researchers found that among patients whose cancer had spread, those who took the drug (eribulin) lived a median of 2.5 months longer than those who received a physician-chosen treatment \u2014 13.1 months versus 10.6 months.\u201d", "answer": 1}, {"article": "Results of the regenerative medicine study published in the journal Nature Nanotechnology.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\n\"As a matter of fact, we were even surprised how it worked so well.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that \u201c..it is achievable, successfully working about 98 percent of the time,\u201d yet there\u2019s no accompanying description of what \u2018works\u2019 really means, how the technology benefit is measured, or how it would compare to a similar technology.", "answer": 0}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nFurthermore, a special study of bone quality done on 18 of the participants showed that they had \u201cbetter internal support of their bones, which is not measured by a bone density scan but is important to resisting fractures,\u201d Dr. Fishman said.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes, \u201cThe findings, as\u00a0reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\u201d\u00a0[emphasis ours] What exactly does that mean? How much did bone density improve? Did all 227 subjects see improvement or was the improvement seen in aggregate? \u00a0There is a big difference between the two and the common take away would be that all saw improvements, which is far from the reality. We also would like\u00a0to know why only 227 out of 741 original enrollees are reported on. How many of the remaining 500+ participants dropped out? Research study dropout is an important factor as it gives us some idea of the tolerability or acceptability of the \u2018treatment.\u2019", "answer": 0}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\n*The headline of this release was edited for clarity to match the content in the body of the release.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release appropriately describes the outcomes in absolute terms. For example, \u201c16 percent of the women who were enrolled in both Text4baby and Quit4baby had quit compared with just 11 percent of women getting just Text4baby.\u201d\nBut while the body of the release clarifies that this difference between groups was not statistically significant, the headline and lead sentence gloss over this fact. We\u2019ll address that issue below under the Evidence criterion.", "answer": 1}, {"article": "In some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nAmong 787 adults who had quit smoking within the previous two years, nearly a third reported having returned to using cigarettes, according to a study published online Monday by the journal Tobacco Control.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story and the New York Times story both failed to mention the actual number of people in the study who used nicotine products. Instead, it talked about the overall number of study participants and then provided percentages for the people who relapsed, perhaps leaving readers confused about whether and to what extent nicotine products made a difference in smoking cessation. It says, \u201cThe new study examined former smokers three times over a five-year period. At the midpoint of the study, 30.6% of recent quitters had gone back to smoking. By the end, 31.3% had relapsed.\u201d It isn\u2019t clear whether we are talking about the same 30% in each period or a total of roughly 60%.", "answer": 1}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\n''This is a simple test that has high accuracy and can be run from a single drop of blood,\" says Robert Nagele, PhD, a professor of medicine at the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.\nAug. 3, 2011 -- A new blood test for Alzheimer's disease is 96% accurate at identifying the disease and can perhaps detect it even before symptoms such as memory loss appear, says the test's developer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nIt would be difficult for readers to get a true sense of the value of this test from this story. Readers should have been told more clearly that in this study, the test failed to correctly identify 4 percent of the Alzheimer\u2019s patients and it mislabeled more than 7 percent of the healthy participants. Also, the phrase that \u201cknowing early has many advantages\u201d is likely to create a misperception about the potential benefits of testing \u2013 at least until some treatments are developed. The story mentioned only two potential benefits, financial planning and the ability to participate in clinical trials of experimental treatments.\n\n\n\n\n", "answer": 0}, {"article": "The U.S. National Institutes of Health has more on insomnia.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\n\"We've shown that these compounds improve sleep at doses that don't impact cognition,\" said Jason Uslaner, lead author of a study published in the April 3 issue of Science Translational Medicine.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead sentence is simply wrong. It says this type of drug \u201cappears to help people fall asleep without causing grogginess the next day.\u201d But besides the fact that this experiment didn\u2019t actually include any people (just animals), the researchers specifically pointed out that the \u201ccurrent study design is limited in that it does not address the issue of next-day \u201changover\u201d or carryover effects.\u201d In other words, grogginess the next day was not tested.\nFurther, allowing the lead author, an employee of the drug company studying the drug to say, \u201cWe\u2019ve shown that these compounds improve sleep at doses that don\u2019t impact cognition,\u201d allows the reader to assume that the benefits of DORA-22 have already been shown.", "answer": 0}, {"article": "Vaginal and vulvar cancers are usually caused by the human papillomavirus, which also causes cervical cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nAmong 18,172 women, ages 15 to 26, there were 5 cases of precancerous vaginal and vulvar lesions in the women who got the vaccine, compared with 27 in those who got a placebo, after about 18 months.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that both tamoxifen and raloxifene cut the risk of breast cancer in half, but does not indicate how many fewer cases that reduction represents. For balance, it would have been useful to have stated more explicitly how many women would have to take the drug to prevent one case of cancer, and how many women will experience a serious side effect.", "answer": 0}, {"article": "People in the early stages of dementia.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nStandardized tests given at the start and end of the study showed that working memory, sometimes thought of as short-term memory, improved for those given 40 milligrams of insulin but not for those given the smaller dose or the placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Neither this story nor a competing story by Fox News actually quantified the benefits adequately. At least the Fox News story talked about the people who took the nasal spray experiencing a \u201c25 percent\u201d improvement in mental function. In both cases, it would have been good to explain how many people in the study saw how much improvement in both groups.", "answer": 0}, {"article": "The results were striking.\nIt lasts, and the placebo effect doesn\u2019t last once you stop a treatment.\u201d\n\nBut acupuncture believers say it doesn\u2019t really matter whether Western scientific studies find that the treatment has a strong placebo effect.\nStill another study, this one financed by the National Institutes of Health and published in 2004, found that acupuncture significantly reduced pain and improved function in knee arthritis patients compared with a sham treatment or routine knee care.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "      \n\n\n \n\n \nMixed bag.\u00a0 \nOn the knee arthritis study, the story didn\u2019t explain what \"an average reduction of one point on a scale of 1 to 7\"\u00a0for pain relief really meant to people. It says \"critics contend that the study was poorly designed\" but didn\u2019t explain how it was poorly designed. That could be letting critics get away with potshots without explaining whether their criticism was well-founded. \nOn the NIH knee arthritis study, it said \"acupuncture significantly reduced pain and improved function\" but that doesn\u2019t meet our standard for quantifying the benefit. What does \"significantly\" mean in their lives? Again, in this case, the story said \"that result has been called into question\" but this time the story explained why.\u00a0 \nOn the Henry Ford Hospital study of hot flashes in breast cancer patients, the story said the results were \"striking\" but again didn\u2019t quantify what that meant. \nSo we can\u2019t give this a satisfactory score but it didn\u2019t meet the true spirit of our criterion.\n ", "answer": 0}, {"article": "\u201cThen I know exactly what they\u2019re getting, and there is no mercury,\u201d he said.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nA study published last month in The Journal of the American Board of Family Medicine found that only 17 percent of family doctors were likely to prescribe fish oil to their patients, including patients who had suffered a heart attack.\nBut the landmark Gissi-Prevenzione trial of fish oil had methodological weaknesses: the patients treated with prescription fish oil pills were compared with untreated patients, rather than with patients given a dummy pill.\nAfter three years, the study found that the number of deaths was reduced by 20 percent and that the number of sudden deaths by 40 percent, compared with a control group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The overall focus of this story is that because fish oil is more often prescribed in Europe than in the United States, that the disease is better treated there than here. The study cited to support the contention that fish oil reduces the number of deaths three years after a heart attack involved patients that consumed a Mediterranean diet which differs than typical American fare, and also did not compare the patients taking fish oil to a placebo control. The article contains more enthusiasm for the use of fish oil than examination of the data supports. The story also framed trial results only in relative terms (20% reduction in the number of deaths and 40% reduction in the number of sudden deaths), not in absolute terms. ", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report adequately describes the methodology and outcomes of the study in question. It does a good job raising the question of potential harms, while indicating that data supporting those harms aren\u2019t statistically significant.", "answer": 1}, {"article": "Mammograms are less effective in detecting growths in younger women, whose breasts may be denser.\nAlthough the task force concluded that the net benefit of mammography in the 40s is small, Hardesty said: \"If you're the one person we find your cancer, it's the world to you.\"\nInside the task force\n\nIn November 2009, the group stated that yearly mammograms should not be automatic at age 40 and that physicians should discuss their risks and benefits with their patients.\nAlthough 85% of those biopsies turned out to be noncancerous, some \"may show us the patient is at higher risk of breast cancer,\" she said.\nThat decrease, Hardesty said, \"is a statistically significant difference,\" but it also showed more doctors were discussing mammograms with patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\n\u201cThe data that we have suggests that 1 in a thousand will benefit from mammograms in the 40-49 age,\u201d (the USPSTF chair) said. \u201cThere are whole lots of assumptions that are not supported by the data they presented.\u201d", "answer": 1}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\nFor the new study, the researchers compared data on people hospitalized between 2002 and 2013 for heart attacks or strokes in counties that did or didn\u2019t restrict trans fats.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reader is offered both percentage and\u00a0absolute numbers to describe the decreases in hospitalization for heart problems. The story also makes clear what differences are or are not statistically significant. Lastly and importantly, the story makes clear that the study established an association, not a causal link.", "answer": 1}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nWhile the story is accurate in reporting that researchers saw signs of improved sleep and reduced pain in the small number of fibromyalgia patients in this trial, the relative attention given to the self-promoting claims of the drug company president as compared to the dismissive comments of the independent source leave readers with an unbalanced view. If the independent expert says he is \u201cnot impressed with the findings\u201d and that the new drug dose \u201cis not going to change things substantially,\u201d it\u2019s hard to see how a headline, sub-head, and lead paragraphs all devoted to grand claims about the benefits of the drug can give readers a fair view of the potential benefits.", "answer": 0}, {"article": "Apixaban is a so-called Xa inhibitor, a class of anticoagulants (anti-clotting drugs) that work by blocking factor X, a protein involved in blood clotting.\nIn that trial, published in July in the New England Journal of Medicine, apixaban's use was associated with raised odds for bleeding -- without providing patients with any reduction in heart attack risk.\nOver an average of 1.8 years of follow-up there were fewer strokes or clots among patients taking apixaban (1.27 percent a year), compared with patients taking warfarin (1.6 percent per year), the researchers found.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nSUNDAY, Aug. 28, 2011 (HealthDay News) -- An experimental drug, apixaban (Eliquis), appears better than the old standby warfarin in preventing strokes in people with the abnormal heart rhythm called atrial fibrillation, a new study finds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided the absolute decrease in the number of strokes or clots, major bleeding events and hemorrhagic stroke as compared to the people in the study taking warafarin.", "answer": 1}, {"article": "Airways became less likely to close off after exposure to an allergen.\nBut, this powerful cancer drug can't be recommended for them on the basis of this small study, Israel and other specialists noted.\nFurther, allergy challenge tests showed a decrease in airway reactivity among patients taking Gleevec, the researchers reported.\nPeople whose severe asthma isn't controlled despite use of high-dose steroid medications are at risk of declining lung function and poor quality of life, the researchers said in background notes.\nIt likely will be three to four years before Gleevec could be approved for asthma treatment, Israel estimated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes a researcher saying the drug \u201creduced the \u2018twitchiness\u2019 of airways\u201d by a third, which \u201cwas significant compared with the placebo group,\u201d making airways less likely to reflexively constrict when exposed to an allergen or asthma trigger.\nThat\u2019s a good start, but we wanted to know, by a third of what? Also, it\u2019s not clear if this measurement\u2013or any of the other benefits mentioned\u2013resulted in fewer symptoms for patients, or just improved their lab values.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not claim that smartphone apps are beneficial, just that the potential benefits are being studied.", "answer": 2}, {"article": ".\n(1)\n\nThis paper emphasized that overall diet quality, rather than individual foods, may have a greater impact on reducing risk of physical function impairments.\nthat other lifestyle habits which are more common in adults who eat walnuts could contribute to the study findings); and, thus, the results should be interpreted with caution.\n\"The simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\"\nThe sample only included women, so these results may not be generalizable to men.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not quantify the purported benefits of including walnuts in one\u2019s diet. It says the study \u201csuggests that consuming 1-2 servings of walnuts per week (1/4 cup per serving) was associated with reduced risk of developing impairments in physical function, which helps enable older women to maintain independence throughout the aging process.\u201d What was the reduced risk? How did women who followed a healthy diet compare in their physical function to those who did not?\nThe release later tempered the message that walnuts \u2014 specifically \u2014 reduce the risk of physical impairment. It notes that the researchers \u201cemphasized that overall diet quality, rather than individual foods, may have a greater impact on reducing risk of physical function impairments. Specifically, diet quality traits most associated with reduced rates of incident physical impairment were higher intake of fruits and vegetables; lower intake of sugar-sweetened beverages, trans fat, and sodium; and moderate alcohol intake.\u201d It adds that among specific foods studies, \u201cthe strongest relations were found for increased intakes of oranges, orange juice, apples, pears, romaine or leaf lettuce, and walnuts.\u201d\nIt also provides this insight from a researcher: \u201cThe simple message from this study is that eating an overall healthy diet, including certain foods, such as walnuts and other whole foods, may help women with the ability to do key everyday tasks as they age, like carrying groceries or dressing themselves.\u201d\nNor does it state that walnuts were the only nuts examined in the study, so we don\u2019t know if similar benefits might be found for women who consumed large quantities of almonds or pine nuts, for example.", "answer": 0}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\nBy the last ten weeks of treatment, weeks 15 to 24, the group taking the pill had significantly higher abstinence rates than the group on placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are two ways to think about benefits in a story like this one: the benefit of quitting smoking and the benefit of using the smoking cessation drug. The story thoroughly addresses both. First, the story tells readers exactly how much more likely people were to quit smoking when using the drug (compared to those using a placebo) \u2014 and that they were able to stay smoke-free for up to a year. Second, the story offers some specifics on how quitting smoking reduces health risks. For example, the story states: \u201cTen years after quitting [smoking], the risk of lung cancer drops by half, according to the CDC.\u201d\nAnother area where the story excelled is in characterizing the motivation level of the study participants. It noted that they wanted to quit and were willing to start reducing their cigarette consumption \u2014 they just couldn\u2019t \u201cgo cold turkey.\u201d The competing Times piece wasn\u2019t as clear on that point.", "answer": 1}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nThis small difference is significant, says Dr. Richard Fried, a member of the National Psoriasis Foundation medical board, since responses to drug treatments can vary dramatically from person to person.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nIn the three clinical trials considered for drug approval, more than 50% of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This also is\u00a0a barely passing satisfactory. The story states that, \u201cIn the three clinical trials considered for drug approval, more than 50 percent\u00a0of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\u201d\u00a0 It would have been more helpful to provide more data, but this statement at least gives us a sense of the scale of the benefit.", "answer": 1}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\nThe study found that weight and BMI improved significantly at all follow-up times following surgery from three months through to 45 months and, in some cases, as long as five years.\nNewswise \u2014 Lap band surgery has significant benefits for severely obese teenagers and, despite its controversial nature, should still be considered as a first option to manage obesity during adolescence, a new study has found.\n\u201cIt is also important that teenagers undergoing this surgery have access to an experienced surgeon as part of a multidisciplinary paediatric team of doctors and Health professionals to ensure there is long-term regular follow-up.\u201d\n\nPaediatric surgeon Mr Sanjeev Khurana, who did all the lap band surgeries between 2009 and 2013, says lap band surgery is a reversible surgical procedure that can be safely used in teens with severe obesity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give this a tepid \u201csatisfactory.\u201d The release specifies the range of BMI loss for individuals in the study but never gets around to explaining what BMI is or how a reader should interpret the numbers. As discussed in more detail in the Evidence section below, the release doesn\u2019t share that a third of patient volunteers had the laparoscopic bands removed due to no change in weight loss or regained weight.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported: \u201cA September 2011 Cochrane Review of 14 studies found \u201cweak\u201d evidence that probiotics could help prevent the common cold and other upper respiratory infections in infants, children and younger adults. And an April 2011 study in the European Journal of Clinical Nutrition found a Lactobacillus probiotic seemed to improve the immune system\u2019s response following a flu vaccination.\u201d\nWe would have preferred to read some of the actual data about \u201chow weak\u201d (in the Cochrane Review) and how much improvement in the other study. But we liked that the story quantified, via an independent expert, how many people might expect to avoid a cold by taking probiotics, if these \u201cweak\u201d studies are correct: \u201cperhaps as few as 1 in 30.\u201d\n\u00a0", "answer": 1}, {"article": "\"The standard treatment for localized, high-risk prostate cancer for people who are fit for radiotherapy should be a combination of hormone therapy plus radiotherapy.\"\nOf the blood thinners used in the study, aspirin was the one which seemed to account for most of the benefit, the researchers said\n\nThere has already been some evidence that cancer and the body's coagulation system might be linked in some way.\nMONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\nAspirin also comes with some risks of its own, including stomach bleeding, Choe pointed out.\nThis translates to a risk reduction of about 50 percent, the researchers calculated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nWhen reporting the results of observational studies, it is important to avoid saying the results show cause-and-effect, when such studies can only identify associations. This story flunks that test by saying the study suggested that aspirin and other anticoagulants \u201cmay cut the risk of dying.\u201d Indeed, the story quotes the researcher saying it would be premature to recommend treating prostate cancer patients. The story should have put that caveat near the top of the story, rather than burying it.\nThe story further errs by stating that those who were taking anticoagulants had lower death rates. What the researchers actually reported was only the death rates from prostate cancer, not how many of the men overall were still alive after several years.\nOn the plus side, this story tells readers how many men were included in this research analysis. It also reports the actual differences in death rates, not just the relative differences (though as noted above, the researchers actually reported differences in death rates from specifically prostate cancer only.) Still, the story emphasized relative risk reduction twice in the story \u2013 \"risk of dying from cancer was reduced by more than half\" and \"this translates to a risk reduction of about 50 percent.\"\u00a0 That seems pointless when you\u2019ve already provided the absolute numbers. ", "answer": 0}, {"article": "http://www.\nA total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\nThe clearance rate was 68% for patients treated with fluorouracil and 58% for individuals receiving PDT.\nThe three study groups had a similar distribution of baseline characteristics, with the exception of tumor size.\nHowever, between one- and three-year follow-up, more recurrences were diagnosed in the fluorouracil group compared with the imiquimod group.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives us lots of data \u2014 a total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\nAnd then it gives us the results: \u201cAround 80% of patients with superficial BCC were tumor free after imiquimod treatment after three years. The clearance rate was 68% for patients treated with fluorouracil and 58% for individuals receiving PDT.\u201d", "answer": 1}, {"article": "The study was divided into three parts.\nThey verified that detailed quantification of the tested and retested tracer in those five patients with Alzheimer's and five older controls generated good and reproducible results.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\nAccording to Wong, this body of work reveals that, as compared with the currently used Tau tracer, F-18 AV1451, the new tracer, F-18 RO948, does not bind randomly to other tissue, offering greater clarity into quantification of potential tau burden within the human brain.\nOne of the biggest challenges in studying Alzheimer's disease thus far, according to Wong, is the inability to watch these so-called neurofibrillary tangles develop in real time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would be the accurate diagnosis of tau protein tangles in patients with Alzheimer\u2019s disease. There is no quantification of findings in this regard. Instead, the release uses general language, such as the statement that one of the studies \u201cgenerated good and reproducible results.\u201d\nAlso, the news release could have been clearer that no diagnostic tool has been developed, as the few people tested with heavy tau tangle loads already were known to have Alzheimer\u2019s.", "answer": 0}, {"article": "Testing cholesterol in toddlers and babies?\n\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\nFor every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease.\nThey did a heel-stick blood test on 10,059 children ages 1 to 2 during routine immunization visits to check for high cholesterol and 48 gene mutations that can cause the disorder.\nBut many parents balk at the idea of testing children for a disorder associated with middle age, experts say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the findings this way: \u201cFor every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease. That\u2019s nearly twice as many as most studies in the past have suggested.\u201d That lets us know how many more people might get identified if screening was widened, but readers should also be informed that it isn\u2019t clear if this ultimately reduces cardiac deaths.", "answer": 1}, {"article": "The most common side effects patients undergoing viscosupplementation may endure are flare-ups - where the knee becomes hot and swollen within 24 hours after the injection - and effusions, where excessive joint fluid collects inside the knee.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\n\"This is most effective in relatively younger patients, 40 to 50 to 60 year olds, and...in people with mild to moderate forms of the disease,\" says Richmond.\nNow, a new report questions the efficacy of this treatment for osteoarthritis in the knee.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only discussed the Swiss meta-analysis conclusion of \u201cminimal benefits and potential for harm.\u201d Yet it allowed a US orthopedist to claim that \u201cThis is most effective in relatively younger patients, 40 to 50 to 60 year olds, and\u2026in people with mild to moderate forms of the disease.\u201d\u00a0 Neither statement is backed up by any numbers.", "answer": 0}, {"article": "That, in turn, may rev up inflammation in their tissues.\nAccording to the findings, among 50 patients drinking pomegranate juice for a year, about two would have to go to the hospital at least twice.\nBy comparison, that number would be nearly 11 in patients not drinking the juice.\n\u201cWe found significant reductions in hospitalization due to infections, with more than 40 percent reduction in the first hospitalization and 80 percent in the second,\u201d said Kristal.\nIn the study, funded by the Israeli Ministry of Health, 101 patients were randomly assigned to either a concoction without pomegranate juice, or the real thing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Good use of absolute risk reduction:\n\u201cAccording to the findings, among 50 patients drinking pomegranate juice for a year, about two would have to go to the hospital at least twice. By comparison, that number would be nearly 11 in patients not drinking the juice.\u201d\n\u00a0", "answer": 1}, {"article": "Find her on Twitter at @aliceparkny.\nIn the current trial, researchers looked at all cancer cases in the Danish Cancer Registry from 1991 to 2009 and compared this data against that of a prescription-drug database that recorded patients\u2019 histories of using aspirin, NSAIDs or COX-2 inhibitors, drugs that all work in similar ways to reduce inflammation and dull pain.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although absolute risks generally cannot be estimated from case-control studies such as this one, we think the story could have done a better job putting these statistics into context. For example, the story notes that researchers found a 17% lower risk of basal cell carcinomas (\u201cthe most common form of skin cancer in the U.S..\u201d) in those taking long-term, high dose NSAIDs, but doesn\u2019t mention that this cancer almost never spreads beyond the skin. Squamous cell carcinoma is also a slow-growing type of cancer that is usually treated before it can cause complications. Meanwhile, melanoma \u2014 a very dangerous type of cancer \u2014 is thankfully quite rare, and so the modest 13% relative reduction reported in this study is likely to represent a very small number of cancer cases when put in absolute terms. In the grand scheme of things, the reductions seen were small and many of the cancers possibly prevented would not be clinically important.", "answer": 0}, {"article": "Friday 5 p.m.\n\"Survival was consistently better at one year in all of the studies, indicating that this is a safe and effective option.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\nThursday, Woodcock held out the possibility that Avastin might eventually prove helpful in a targeted group of patients.\nSuch research is already underway, Arnold said, but it's too early to discuss the findings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article meets the standard here by presenting data for progression-free survival and explaining that none of the trials showed a survival benefit for Avastin compared to standard chemo. (The quantity 0 seems implied.)\u00a0While it\u2019s notoriously difficult to explain the ins and outs of cancer studies in such a short space,\u00a0we nonethless criticize the article on this criterion because, although most of the messages were generally accurate, readers could\u2019ve benefited from more clarity on one of them and a little help overall in squaring up some potentially contradictory messages. We\u2019ll explain in 3 acts.\nAct I: Story Highlights. One of these summary bullets states that \u201cSubsequent studies showed no greater survival benefit.\u201d In isolation this statement may be misleading. It seems they mean it to refer to progression-free survival. But that doesn\u2019t jibe with the practical meaning of the term \u201csurvival benefit\u201d as actually used in the body of this article: overall survival. And in fact, as we learn, all 4 studies showed\u00a0no\u00a0survival benefit compared to standard chemo.\nAct II:\u00a0Dr. Sparano\u2019s zinger. In his opposition to the FDA decision, the source notes that one-year survival for Avastin was consistently better in all studies. How is a reader to reconcile that message with the message that survival was not better for Avastin in ANY\u00a0study? What was needed was not just quantification but qualification. Perhaps it would\u2019ve been as simple as giving us the timeframe for Dr. Woodcock\u2019s conclusion that there was no survival benefit in all studies, or more context about Dr. Sparano\u2019s point. Without some explanation somewhere, we think Dr. Sparano\u2019s\u00a0line should not have been quoted, since it\u2019s essentially out of context and it somewhat throws the messages up in the air for a reader, perhaps with consequences on the balance of the story.\nAct III:\u00a0Mixed messages?\u00a0The story gives us 2 messages that, taken together, may also seem contradictory for lay readers:\n1. Later trials showed that Avastin offers a small increase in progression-free survival compared to standard chemo \u2014 but still an increase. 2. The 4 studies together shown no survival benefit.\nHow is a non-clinician to make sense of these messages? How can it slow tumor growth \u2014 and lengthen the time people lived without progression \u2014 but not lengthen the time people lived? These head-butting messages\u00a0might\u2019ve been reconciled by clarifying, as the FDA press release\u00a0starts to, how these data show that Avastin\u2019s effects on tumor growth were temporary enough that people taking Avastin didn\u2019t live any longer,\u00a0on average.", "answer": 0}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nFunding: Research reported in this publication was supported by the National Institutes of Neurological Disorders and Strokes of the National Institutes of Health under award number K23NS079477-01A1.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides readers with a numerical comparison of the study\u2019s results, in this case, the prevention of subsequent strokes or death among these patients.\u00a0 According to the release, in those receiving the EDAS procedure, after one year, 9.6% of patients had a later stroke or died, compared to more than twice that number (21.2%) from a matched control group who didn\u2019t receive this surgery.\n(We discuss the limitations of these results under the Evidence criteria, below.)", "answer": 1}, {"article": "Vitamin C is an important building block for the growth and repair of tissues throughout your body, including skin, tendons, ligaments and blood vessels.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\nBut, she emphasized, this doesn't mean vitamin C is useless, not by a long shot.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The physician-journalist accurately describes the findings in a way people can easily understand on television\u2013essentially that there is no benefit of taking C in preventing colds, with\u00a0the exception\u00a0of one key subgoup of little relevance to most Americans.\u00a0Given the nature of the findings, more precise quantification is not needed. ", "answer": 1}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nThe main side effect from the device is that people can wake up with a sore tongue.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn that a \u201cclinical trial of Inspire therapy found a 78 percent reduction in the number of sleep apnea events per hour for patients.\u201d \u00a078% reduction\u2013compared to what? And how does that compare to the CPAP machine?\nThe story also creates a false sense of equivalence between the large body of evidence behind CPAP machines and the small uncontrolled pilot studies on the new device.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nBut for people who do have that mutation, the drug works remarkably well.\nThey have to have a particular mutation in the CF gene, or the drug is of little use.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We kept reading this piece and listening to the audio for any sort of data to back up some of the claims made. We understand that numbers don\u2019t always translate well on the radio, but even a supplementary graphic illustrating how effective this drug is would have provided some much needed context. The story does say, \u201cIt only works on a small subset of people with CF. They have to have a particular mutation in the CF gene, or the drug is of little use.\u201d Then it says, though, \u201cBut for people who do have that mutation, the drug works remarkably well.\u201d How small is that subset? And how well does it work?", "answer": 0}, {"article": "Traditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\nHowever, the findings do not apply to every stroke victim.\nMany more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article describes the impact of blood clot removal on \u201cfunctional independence\u201d and death rates for stroke patients. Readers learn that 45 percent of patients who had blood clots removed became functionally independent compared to 17 percent who did not have their blood clots removed. Additionally, the death rate was 12 percentage points lower in the group who had their blood clots removed compared to patients who didn\u2019t have them removed.\nHowever, since the story\u2019s headline says that extending the time window for blood clot surgery will \u201csave lives,\u201d it would have been more informative if the article reported on the additional lives saved by expanding the treatment window to 16 hours, by including the sizes of the treatment and control group. All we know is that there were 182 patients involved in the study.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We understand that the focus of this story was the FDA approval.\u00a0 Nonetheless, we wish that even a brief description of the data that led to approval had been provided.\n\u00a0\n\u00a0\n\u00a0", "answer": 0}, {"article": "The lower the amount of free PSA, the more likely cancer is the cause and the more likely the disease is aggressive, requiring treatment, according to Dr. Patrick C. Walsh, a Johns Hopkins urologist and the author of \u201cDr.\nThe revised guidelines are expected to reduce the cost of screening, the cost per life saved and overall deaths from prostate cancer.\nThe guidelines also suggest limiting screening to men with more than a 10-year life expectancy.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nThey will also suggest that testing start at 40 to obtain a baseline measurement, with the test repeated at 45 and 50, after which it should be given annually until 70.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article doesn't provide any evidence of the potential benefits of PSA screening.\u00a0 ", "answer": 0}, {"article": "Through a blood vessel in the groin, doctors snake a tube to a blocked heart artery.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nAbout 40 percent of patients in the study had a prior heart attack more than three months previously.\nTo the surprise of the researchers, both groups fared about the same: approximately 19 percent had a heart attack or died within seven years, adds LaPook.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does give the rate of heart attack or death as 19% within 7 years for both the stent and the medication group.", "answer": 1}, {"article": "\"Not screening patients annually could save millions in health care costs and spare patients the radiation exposure and the downstream effects of false positive screenings.\"\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A thorough discussion of the absolute numbers affected gives a good sense of the magnitude of the benefits. The release noted, \u201cIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.9 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\u201d\nAnother benefit described is the potential to dramatically reduce the number of false positive tests. According to the release, almost 40 percent of the entire group of patient volunteers (26,231 people) in the 7-year National Lung Screening Trial were given a false positive study result.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe prostate study sought a better way to use PSA tests, which are troublesome because PSA can be high for many reasons besides cancer, and doctors don't know which cancers need treatment or whether screening saves lives.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nTwo big studies suggest possible new ways to screen healthy people for cervical or prostate cancers, but a third disappointed those hoping for a way to detect early signs of deadly ovarian tumors.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits, or lack of benefits, in terms that everyone can understand. For example, it says, \u201cOnly about three out of 100,000 women each year developed cervical cancer after negative HPV and Pap tests. HPV tests were twice as good as Paps for predicting risk. Adding a Pap after a negative HPV test did little to improve risk prediction.\u201d", "answer": 1}, {"article": "To learn more, visit njhealth.org.\nIt may seem strange to fight bacteria with more bacteria, but it could lead to a long-term solution for eczema patients\n\nEczema is the most common skin disease worldwide.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nPowerful antibiotics are commonly prescribed for eczema, but they kill good bacteria on patients' skin along with the bad.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the lotion contains \u201cbeneficial bacteria to fight harmful bacteria,\u201d and the lead investigator is quoted as saying that this will \u201chelp the skin gain back it\u2019s natural balance and create that barrier needed to keep it healthy.\u201d\nBut we\u2019re given no data from the trials to support this. We\u2019re also not given any context regarding what good bacteria, natural balance, or \u201cthat barrier\u201d are.\nThe only example of a \u201cbad\u201d bacteria mentioned is Staphylococcus aureus. The news release informs us that Staph. aureus makes eczema worse. Previous studies have shown that high levels of Staph. aureus do correlate with increasing severity of eczema.\nThe lead investigator suggests that applying the lotion twice a day will \u201celiminate all staph aureus.\u201d But there\u2019s no evidence included to show that this lotion actually improves the eczema.\nIt should have been acknowledged that staph aureas colonization might be associated with eczema severity and not a cause of it. For example, if people with more severe eczema scratch more, they are more likely to colonize themselves with bacteria they pick up in the environment around them.\u00a0 This does not indicate that reducing the staph will result in improvement of the underlying disorder.", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nMost of the women in the study had never been smokers, and there\u2019s a lot of evidence to suggest that lung cancer is a different disease in smokers versus non-smokers.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nOf the 444 patients with lung cancer, 318 died during the three years of follow-up, the researchers wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is careful to describe the amount of soy food you\u2019d need to eat on a daily basis to match the intake of the high soy consumers group \u2014 important info to include. But we were disappointed that the\u00a0story used relative risk figures to describe the benefits of increased soy intake on cancer survival. \u00a0It says that low soy consumers were \u201c1.8 times as likely to die\u201d\u00a0compared with the average and that \u201cThose who ate the most were about 11 percent less likely to die.\u201d It would have been more informative\u00a0and accurate to tell readers\u00a0the absolute percentage of subjects who had died at follow-up in the low,\u00a0average, and high soy consumption groups.", "answer": 0}, {"article": "Yorkshire Cancer Research; Prostate Cancer UK; The British Columbia Cancer Agency Strategic Priorities Fund.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\n\"Cancers that are contained in the prostate, however, have the potential to be 'actively monitored' which is not only cheaper, but has far fewer negative side-effects in patients with non-life threatening cancer.\"\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release tries to quantify benefits in two ways. First, it says that \u201cA recent study showed that more than 25 men were being unnecessarily treated with surgery or radiotherapy, for every single life saved.\u201d But how recent was this study? And who published it? Next, the release says that the news test \u201ccan pick out life-threatening prostate cancers, with up to 92% accuracy,\u201d although this is not technically correct. In the published study, the authors say that the algorithm resulted in \u201can AUC of 0.92.\u201d AUC stands for Area Under the Curve, which is not the same measurement as accuracy.\nThe AUC is considered the best measure of whether a test can distinguish between diseased and non-diseased people.\u00a0 In this case, the investigators used their test to differentiate between cancers that were confined to the prostate and those that had spread beyond the prostate among men who had undergone prostatectomy. \u00a0While these advanced cancers can be life-threatening, that\u2019s a bit of hyperbolic description. Metastatic cancers are clearly the most likely to be life threatening. \u00a0Additionally, estimates of AUC have 95% confidence intervals. \u00a0If the AUC, as it appears, was based on results from 4 patients, then 92% is a very imprecise estimate.", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nThat was longer than we expected, and it's great news for this group of women.\"\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers in this story attached to the benefits of less frequent bone density testing.", "answer": 0}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n\"The mounting evidence of caffeine consumption as a potentially protective factor against cognitive impairment is exciting given that caffeine is also an easily modifiable dietary factor with very few contraindications,\" said Ira Driscoll, PhD, the study's lead author and a professor of psychology at the University of Wisconsin-Milwaukee.\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that among older women in a large study, \u201cself-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\u201d\nThe release would have been better with some explanations of what the 36 percent reduction in risk of incident dementia actually meant.\nThe published study doesn\u2019t include any numbers in the primary tables to allow for a calculation of absolute risk reduction. The only statistics provided, even in the body of the paper, are the Hazard Ratios, including the 0.76, which gives rise to the 36 percent reduction for the higher caffeine consumers.\u00a0 In this instance, the release writer may have done their best with the available information from the paper, but the writer could have consulted with the study authors to provide this important additional detail. At the very least, providing some estimate of the baseline risk in the study would have helped put the 36 percent reduction in perspective. If that baseline risk was low to begin with, then a 36 percent reduction might not be very meaningful.", "answer": 0}, {"article": "The goal is to find what's right for you.\"\nThe short-term study-related reductions are comparable to results expected in clinical practice using psychotherapy or with that seen using antidepressant medication.\nBut participants robustly used the IntelliCare interactive apps as many as four times daily -- or an average of 195 times -- for eight weeks of the study.\nThe 96 participants who completed the research study reported that they experienced about a 50 percent decrease in the severity of depressive and anxiety symptoms.\nA novel suite of 13 speedy mini-apps called IntelliCare resulted in participants reporting significantly less depression and anxiety by using the apps on their smartphones up to four times a day, reports a new Northwestern Medicine study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release makes several claims but doesn\u2019t back them up with data. For example:\n\u201c13 novel mini-apps reduced depression and anxiety by nearly 50 percent in a preliminary research study\u201d\nWhat kind of depression and anxiety are we talking about here? Feeling a little blue or so severely depressed you can\u2019t get out of bed? Which tools were used to measure or rate participants\u2019 level of depression or anxiety?\n\u201cparticipants reporting significantly less depression and anxiety by\u00a0using\u00a0 the apps on their smartphones up to four times a day\u201d\nAgain, what does \u201csignificantly\u201d refer to?\n\u201cThe short-term study-related reductions are comparable to results expected in clinical practice using psychotherapy or with that seen using antidepressant medication.\u201d\nClaiming that using the apps for 8 weeks is comparable to a similar period of psychotherapy or antidepressant use is unfounded without a randomized clinical trial. The study itself notes that 64% of participants were taking antidepressant medication, and 22% were receiving psychotherapy, when they enrolled in the study.", "answer": 0}, {"article": "Some insurance plans cover EMDR.\nBut there is debate about whether the eye movement makes a difference, said Stephen Holland, founder of the Capital Institute for Cognitive Therapy and co-author of the textbook \u201cTreatment Plans and Interventions for Depression and Anxiety Disorders.\u201d \u201cThe question is whether stimulation adds to it.\u201d He does not use it in his practice because he considers it no more effective than cognitive behavioral therapy.\nEach time a particularly painful memory resurfaced, Henn said, \u201cyou have to go through it again until it has no meaning.\u201d By confronting the trauma head-on, she added, it became less powerful.\nBut Henn admitted she was worried that the speech would trigger an extreme emotional reaction, a fear shared by many who suffer from PTSD.\nThe idea is that reliving the memories helps remove the sting and that the urgency of the memories can be reduced as the brain begins to move them from short-term to long-term memory.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story provides vivid details of a patient\u2019s reactions to the intervention, the text makes little effort to describe the nature of the benefits that EMDR therapy might confer, much less quantify them.\nThe only reference is to the movement of traumatic memories from short-term to long-term memory.\u00a0 The individual who is the subject of the narrative never speaks to that; instead, she notes that the therapy made her trauma memories \u201cless powerful\u201d and that she is \u201cnot hurt by it anymore.\u201d\nIt\u2019s our opinion that much more should have been described about the benefits\u2013what percentage of people respond, and to what degree?", "answer": 0}, {"article": "This was unheard of.\nAverage disease specific survival at five years for the induction chemotherapy patients was 79 percent - equivalent to the results in patients with early stage disease, and significantly better than the 66 percent survival for patients who had chemo-radiation without the induction strategy.\nThe study did find lower functional preservation of the larynx in the induction chemotherapy group compared to those who elected chemoradiation.\nIf the tumor did not respond after that first dose, patients would likely fail on the chemotherapy and would do better going straight to surgery.\n\"In trying to match the biology of the tumor to the treatment, all of the patients get better outcomes,\" says study author Gregory T. Wolf, M.D., professor and chair emeritus of otolaryngology - head and neck surgery at Michigan Medicine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release explains the benefits for patients with stage 3 and stage 4 laryngeal cancer: \u201cAverage disease specific survival at five years for the induction chemotherapy patients was 79 percent \u2013 equivalent to the results in patients with early stage disease, and significantly better than the 66 percent survival for patients who had chemo-radiation without the induction strategy.\u201d However, there were some shortcomings here.\nAccording to the study, surgery achieved the best survival results. It may not be possible to conclude anything about the \u201cchemo trial\u201d group because the study was observational \u2013 taking a retrospective look at 10 years of patient charts \u2013 which does not prove cause and effect.\nIn each of the 153 cases, patients and doctors chose which treatment type they preferred; 71 were given a test dose of chemotherapy and then had further treatment decided based on the response. The release doesn\u2019t tell us how many were then treated with surgery due to lack of response and how many completed chemotherapy/radiation treatment.", "answer": 0}, {"article": "\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\nThe scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nWhat\u2019s more, that same group reported a 36% lower probability of suicide attempts in the past year.\nHe believes the data support the idea of demoting psychedelics to schedule 3 or 4, and that they can be used in controlled therapy situations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites \u201cabout 27,235 people\u201d who said they had used \u201cclassic\u201d psychedelics, which it identifies as magic mushrooms, DMT, mescaline and LSD. And it lists the reduction in the odds that these people had exhibited psychological distress in the prior month (-19%) or suicidal thoughts (-14%) or suicidal attempts (-36%) during the prior year. But it does not give total numbers of individuals for any of those categories.\nAs a side note, we\u2019d point out that the study technically reported on the \u201codds\u201d and not the \u201cprobability\u201d of exhibiting suicidal thoughts or attempts (the latter being language used in the story). A small point, to be sure, but we think these details matter.", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThere are several scientists who say this field is so new that it's lacking in good evidence that brain changes actually occur.\nSo some scientists believe that by playing this game \u2014 Project Evo \u2014 you can improve a range of cognitive skills and, by extension, relieve a range of symptoms associated with cognitive disorders.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\nIn fact, the creators believe their game will be so effective it might one day reduce or replace the drugs kids take for ADHD.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes claims that these games could be effective for a range of symptoms of cognitive disorders; that they could be as effective as drug treatment; and that they could cut the size and length of certain clinical trials in half. But there are no hard numbers that pin down what these claims mean.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\nKetamine \"helped me get my life back,\" says James, who asked that we not use his last name to protect his career.\nAnd that could explain why patients like James usually stop overheating once they are taking ketamine.\nSince then, doctors have prescribed ketamine \"off label\" to thousands of depressed patients who don't respond to other drugs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies largely on a single anecdote of a person who says ketamine \u201chelped me get my life back\u201d. The expert sources use only vague descriptions of ketamine as \u201ctransformational\u201d and that patients in one trial \u201cgot dramatically better.\u201d There are references to clinical trials, but none cites any specific results in quantified terms.", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nBut those studies were small and flawed, so no conclusions can be made about the technique, according to the new review.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\nFennel, an intestinal \"antispasmodic,\" may increase the speed at which food moves through the intestine, Brown said.\nThis may help if the underlying cause of colic is cramping or discomfort due to an immature digestive tract, although that is just a theory, Brown added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is about a review of several studies, and we don\u2019t expect the benefits to be quantified for each study reviewed.\u00a0Instead, the story used\u00a0vague phrases such as \u201cfound improvement.\u201d In on area, the story provides numbers, saying, \u201cA study of probiotics, which are reputed to help digestion, found that 95 percent of infants given L. reuteria probiotics seemed to reduce their average crying time compared to 7 percent of babies given simethicone, which is marketed to relieve gas under the brand names Mylicon and PediaCare Infants\u2019 Gas Relief.\u201d But even here, we would have liked to have seen some absolute numbers. We appreciate that it is difficult to tease these numbers out of the review, but, at a minimum, the small study size (90 children) would have been good context for readers.", "answer": 0}, {"article": "Both doctors improved their detection rates of potentially dangerous adenomatous polyps when they listened to music compared with their pre-study (\"baseline\") rates, the investigators found.\nThis was up from a baseline detection rate of 21 percent before the study began.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nWhile this is a small study, the results highlight how thinking outside the box -- in this case using Mozart -- to improve adenoma detection rates can potentially prove valuable to physicians and patients.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The absolute dfference in adenomas was not reported, only percentages.\u00a0 We\u2019re told it was a small study.\u00a0 How small?", "answer": 0}, {"article": "Standard therapies include over-the-counter pain meds, corticosteroid spinal injections, and/or invasive spine surgery that sometimes involves disk removal and vertebrae fusion.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story calls this treatment a potential \u201cboon to back pain patients for whom standard therapies have failed,\u201d and includes a glowing personal endorsement by the study\u2019s lead author.\nOnly near the end do we get a small amount of data:\n\u201cBy the one-year mark following either treatment, a full \u2018perceived\u2019 recovery was reported by 95% of the pRF patients, compared with just 61% of the steroid injection patients.\u201d\nThe story doesn\u2019t tell readers what \u201cperceived\u201d recovery means and how it was measured.", "answer": 0}, {"article": "Currently, lung cancer treatments rely heavily on chemotherapy, but doctors are shifting toward a more customized and precise way of treating each person\u2019s disease in order to improve their chances of survival.\nIn addition, \u201ca year after treatment, three times more people on immunotherapy were doing well compared to those who just got chemotherapy.\u201d\n\nThe results could play a role in changing standard treatments for people diagnosed with advanced NSCLC, by making a strong case for starting people immediately on the immunotherapy combination rather than giving them chemotherapy first, as many doctors currently do.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\nWhat\u2019s more, say the study\u2019s authors, doctors may also figure out which people are most likely to respond to the two-drug combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and which are not.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give absolute data for two of the three studies it mentions.\nIt says the two-drug combination of Opdivo and Yervoy found that after nearly a year, the lung cancer in people taking the immotherapy was \u201c42% less likely to have progressed than among people getting chemotherapy,\u201d and patients taking Keytruda with chemotherapy were \u201c51% less likely to die after 10.5 months\u201d than people getting just chemotherapy.\nAbsolute numbers would have given a clearer picture of what portions of patients saw a benefit. For example, in the Keytruda study, 69% of patients originally assigned to Keytruda were alive at the end of the study period versus 49% of those who received chemotherapy alone.\nFor the third study, the story says taking Opdivo before surgery \u201cshrunk those tumors drastically and lowered the chances for relapse\u201d and \u201cin about half of the people treated \u2026 the growths showed significant destruction by immune cells in the blood and certain targets on the tumor cells.\u201d\nHere the coverage could have been improved with a quantitative description of what\u2019s meant by terms such as \u201csignificant destruction.\u201d Also, this third study was very small and experimental, which we\u2019ll discuss under evidence quality below.", "answer": 0}, {"article": "(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\nTo investigate, Zheng\u2019s team followed 2,520 adults for eight years, testing their vision and cognitive status every other year.\n\u201cTaking care of your vision is important in order to maintain good cognitive function,\u201d she said in a telephone interview.\nA person\u2019s vision at their previous check-up was related to their mental function at the following check-up.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes a relationship between vision and cognition, but we never get a feel for how strong that link might be.", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\n\u201cPatients who were treated with surgery or radiation had side effects, while those who were managed with active surveillance, for the most part, did quite well,\u201d Barocas said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did not provide many numbers. For example, it reported erectile dysfunction and urinary incontinence as \u201cmore common\u201d in men treated with surgery than radiation, but did not give a quantity for the \u201cmore.\u201d\nThe release did include a numeral in this sentence, but it wasn\u2019t very enlightening: \u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\u201d", "answer": 0}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit mentioned is this:\n\u201cthe new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer, and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\u201d\nWe\u2019re glad to see it made clear that the blood test was increasingly positive for cancer in those women already known to have increasingly advanced cancer.\nHowever, it should have been made even more clear the overall study group is quite small (69 women), with only 23 women having known stage I/II disease; therefore, this study can not show if the blood test would be effective as a screening tool in healthy women.\nIt\u2019s very important to show how the test looks in populations with and without cancer \u2014 which will likely be done in the future. The public needs to know and be clear about that when a person has cancer, the test is positive and if we know there is no cancer the test is negative.", "answer": 0}, {"article": "tears.\n\u201cMost subjects can do in-line activities\u201d like running or biking \u201cwithout an A.C.L.\u201d He adds, \u201cOn the other hand, we believe that A.C.L.-deficient subjects that do return\u201d to sports involving cutting, pivoting or planting the leg \u201ccan consequently injure the meniscus\u201d or other cartilage in the knee and would benefit from a replacement A.C.L.\nHe points out that in The New England Journal of Medicine study, only 8 percent of the patients in the first surgical group subsequently tore a meniscus, a fragile pillow of cartilage that can rip if a knee gives way.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\nIn The New England Journal study, some of those assigned to physical therapy wound up requesting surgery, although they weren\u2019t experiencing any knee problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "(As noted, some of the measures in\u00a0these studies\u00a0can be considered either benefits or harms, depending on how you look at it.)\u00a0\nThis piece provides the absolute changes for each treatment group, and then tells us the key outcome: the results weren\u2019t statistically different and demonstrated non-superiority. The piece reports the relative proportions of each group who tore their meniscuses. Qualitatively, it tells us about stability outcomes. The controversy surrounding the importance of these measurements is explored and sometimes implied; it would\u2019ve been clearest for the author to explain (or wonder aloud) the meaning of increased mensical tears and instability in light of equivalent scores on the primary outcome. This story mentions that in the 2009 retrospective study, all subjects eventually developed similar and high levels of early-onset arthritis.\u00a0\nThe piece also provides some analysis of other outcomes, such as two \"almost identical\" results in the 2009 study. While quantified results are scant overall in this piece, that seems justified given that the comparisons between results often showed no statistical differences, which is clearly the important message. Of importance was the story\u2019s exploration of the controversy surrounding the meaning of outcomes in stability and meniscus tears.\nAs mentioned in our introduction, this study raises the question of treating all ACL injuries as if patients are pro athletes. On that note,\u00a0in an environment where we see pros jump at surgical therapy,\u00a0one facet of the decision that would\u2019ve been nice to raise is the recovery time. What are the outcomes, expectations, and/or trade-offs for getting back on the court sooner?\u00a0The piece reports study outcomes 2 years after surgery.\u00a0", "answer": 1}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\nWith statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nStein called the trial results \u201ca very important breakthrough,\" while being careful to note that they represent early science which should be confirmed through larger and longer studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that \u201cthe subjects who received REGN727 had a striking reduction of 60 to 65% \u00a0in LDL cholesterol,\u00a0according to (the lead researcher who characterized the results of the trial as \u2018pretty dramatic.\u2019 \u201d\nThe story also quoted an American Heart Association spokesman as calling this \u201cgame changing science\u201d \u2013 putting that phrase in the headline as well \u2013 and \u201ca very important breakthrough.\u201d\nTo describe results of potential efficacy from a small Phase I study this way without emphasizing to the general public that Phase I studies aren\u2019t designed to focus on efficacy is troublesome.\nNeither the Cardiobrief blog, nor MedPage Today, in reporting on the same studies, used any such hyperbole.\nIn fact, MedPage Today ended its story with the reminder: \u201cGiven the small number of subjects and the short duration of exposure, our ability to evaluate the safety profile of REGN727 in these trials was limited,\u201d the researchers cautioned.\nIf a Phase I trial, which is designed to measure safety and not efficacy, is too small and short to fully evaluate safety, then making bold claims about efficacy is even more of a reach at this point. A consumer-targeted story needs to make such points with emphasis.\u00a0 This story did not.\n\u00a0", "answer": 0}, {"article": "When ICI-associated colitis is severe, guidelines require a patient to stop ICI treatment until the colitis is in remission.\nBoth patients in the study had a complete resolution of their colitis following treatment with FMT.\nThe two patients included in the study were treated at MD Anderson between June 2017 and January 2018.\nThe research, led by Yinghong Wang, M.D., Ph.D., assistant professor of Gastroenterology, Hepatology & Nutrition and director of Medication Induced Colitis and Enteritis, was published today in Nature Medicine.\nWith endoscopic evaluation before and after treatment, both patients displayed significant improvements in inflammation and ulcerations, including a reduction of inflammatory immune cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly states the outcomes of fecal transplants in the two patients that constitute the study.", "answer": 1}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\nThat means that patients are tried on a succession of different drugs for 12 weeks or more and experience prolonged periods of ineffective treatment because their medication does not benefit them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about \u201cbreakthroughs\u201d and \u201choly grails,\u201d but doesn\u2019t provide any numbers to that effect.\u00a0The accuracy figures are included in the study\u2019s abstract and the story should have discussed them along with an explanation of what they mean.", "answer": 0}, {"article": "The 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\nThey found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\nThere was also an 18% reduced risk of dying from any cause over the 20-year period.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only told readers the relative risk improvements for taking a statin. It did not present the terms in absolute numbers. By the relative measure, taking statins seems very effective: 28% fewer men died from heart disease when taking statins compared to a placebo.\nBut the absolute risk is more sober and should always be presented along with relative numbers. Of the group taking statins, 6.69% of people with very high LDL died from cardiovascular heart disease within 20 years. Of the group taking a placebo (and it\u2019s not immediately clear to us what their LDL status was), 9.03% died from heart disease.", "answer": 0}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nHowever during the luteal phase -- after a woman ovulates and before her period -- only one area of the brain was activated by images of cigarettes and smoking.\nThe researchers tested 13 of the female participants twice to assess how their response changed at a different point in their menstrual cycle.\nAfter undergoing the brain scans they viewed the photos a second time and reported on a scale from zero to 100 if the pictures triggered cigarette cravings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In the original study that\u2019s being reported on, the authors state that they \u201conly observed subtle differences in brain activations between the follicular and luteal phases.\u201d But the article does not make clear that the findings were \u201csubtle.\u201d In fact, there was no discussion about the strengths of the relationships observed. In addition, the story states that other areas of the brain showed activity during certain phases of menstrual cycle. Do these areas of the brain also show activity for other responses? Are there other parts of the brain that are also associated with cravings that were not activated? The story could have done a lot more to describe what the researchers actually found in the study and why it might be relevant to readers.", "answer": 0}, {"article": "\u201cAre patients better off getting these much broader tests?\u201d he said.\nIncluding another 23 patients who were referred into the study at a late stage, there were 63 women positive for non-BRCA mutations.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nThe researchers found that 40 women, or 4 percent of the total group, did have potentially harmful mutations in other genes.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relays the benefits described in the study for the study population. It notes that 63 (about 4%) out of more than 1,000 women who test negative for BRCA mutations tested positive for non-BRCA mutations. \u201cOf those, the researchers decided that 33 would have been considered for additional screening or prevention measures based on their results.\u201d That description earns to the story a Satisfactory rating. Additional details on what screening and prevention measures might be recommended for which women \u2014 and some statement about whether those results are likely to apply to people outside of the study \u2014 would have been welcome.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "5-year estimated outcomes were given after only 2 years of data. No quantitative data on safety presented. Absolute numbers \nprovided. Limited long term data and small absolute benefit are key issues here. ", "answer": 1}, {"article": "Some studies, but not all, discussed side effects such as gastrointestinal discomfort, dizziness, mild pain and decreased libido.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\n\u201cWe need treatments to address it, and it should be treated with equal seriousness as erectile dysfunction.\u201d\n\nThe prevalence of premature ejaculation is difficult to measure because of the differing definitions of the problem and some men\u2019s reluctance to report it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While we don\u2019t really know what particular ingredients might be in the tested Chinese herbal treatments, the Ayurvedic herbal medicine or the Korean topical cream, we do learn that \u201cChinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\u201d \u00a0We would have benefited from knowing what the baseline times were, ie: if the two acupuncture studies were found to increase\u00a0intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo, how much additional time did the placebo provide?", "answer": 1}, {"article": "\"This is really something that is sort of common trade knowledge.\"\nTUESDAY, Feb. 2, 2010 (HealthDay News) --When a doctor wants to assess the condition of heart arteries without putting a gadget into those blood vessels, the X-ray technology called computed tomography -- more commonly called a CT scan -- is better than magnetic resonance imaging, or MRI, a German review of studies has found.\nDr. Ricardo Cury, director of cardiac MRI and CT at Baptist Cardiac & Vascular Institute in Miami and a consultant radiologist at Massachusetts General Hospital, said that the \"meta-analysis demonstrates a knowledge that we have accumulated for the past several years.\"\nThe German researchers looked at results of 109 published studies of noninvasive heart artery imaging, including 89 that used CT and 20 that used MRI and involving 8,505 people.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does provide some important details on the meta-analysis, including the number of studies and patients, as well as sensitivity results. However, we have two critiques:\n1) It notes that the sensitivity results, 97% and 87%, were for the studies of people with suspected coronary artery disease. We believe that\u2019s incorrect. According to the\u00a0published study, these figures are for the overall population in the meta-analysis, which includes those with suspected OR known disease, including those with heart attacks. For the analysis just of patients with suspected coronary artery disease, the results were different: 98% and 89%. But that\u2019s a minor problem.\u00a0 A bigger issue,\u00a0 to us, is the following. \u00a02) We would have liked to have seen the specificity results, too. We\u2019re unsure why they choose to report just sensitivity and not specificity. False positives are important, too, besides just false negatives.\n3) The study had clear limitations that were ignored in the story. \u00a0The authors of the study concluded, \"Randomized studies are\u00a0clearly needed to address the potential of coronary CT angiography for use in triage as a means of positively altering\u00a0management and outcomes in patients with suspected\u00a0CAD (coronary artery disease).\"\u00a0 The take home message for readers of this story may be that CT scans are \"Best for Checking Heart Arteries\"\u00a0 \u2013 as the headline states \u2013 a conclusion that has yet to be clearly demonstrated.", "answer": 0}, {"article": "Zeitzer said.\nThey found that exposing people to two millisecond flashes of light, similar to a camera flash, every 10 seconds elicited two hours of change in circadian timing, compared with 36 minutes for those exposed to continuous light.\nIn this latest study, Zeitzer and Raymond Najjar, a former postdoctoral scholar at Stanford now at Singapore Eye Research Institute, found that short flashes of light at night are more effective than continuous light exposure and could speed up the process of adjusting to a different time zone before a trip.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\nParticipants were able to sleep through the flashes of light without waking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Details on the benefits are minimal but we do get a sense that two different groups of volunteers were tested with different light exposures (continuous vs. intermittent flashing) and those with the intermittent flashing light had \u201ctwo hours of change in circadian timing, compared with 36 minutes for those exposed to continuous light.\u201d Changes in \u201ccircadian timing\u201d is not explained.", "answer": 1}, {"article": "\"That is a million-dollar question,\" he said.\nEven the study's lead author says the research should not be used to recommend chelation therapy, and he acknowledges that its findings could have been due to chance.\nEven more concerning, that benefit passed the bar for statistical significance \u2014 the standard for judging whether a result is real or a fluke \u2014 by only 0.001.\nThis study's findings are even more questionable, however, Kopecky says, because patients who got chelation had lower bad cholesterol levels than the placebo group at the start of the trial.\nThat large of a dropout rate \u2014 which is normally no more than about 3% \u2014 could skew the study's findings, Kopecky says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the\u00a0benefits were \u201cvery small, with 26.5% of those randomly assigned to chelation experiencing a cardiovascular problem, compared with 30% of those randomly assigned to a placebo infusion.\u201d That\u2019s\u00a0a satisfactory handling of the statistics.\nThe story could have\u00a0also pointed out that the primary outcome\u00a0was a so-called \u201ccomposite endpoint\u201d encompassing a lot of different results, including death, heart attack, stroke, referral for cardiovascular procedures, and others.\u00a0Most of the\u00a0benefit attributed to chelation was due to fewer cardiovascular procedures\u00a0being performed in that group, which is\u00a0an important detail.\u00a0Because this outcome involves some subjective determination about who should\u00a0and who should not be referred for\u00a0these procedures, it is considered a \u201csofter\u201d or less reliable\u00a0outcome than rates of death or heart attack, which are outside of the investigators\u2019 control. If chelation provided a substantial\u00a0benefit, we presumably would have seen\u00a0a larger difference on these other \u201charder\u201d endpoints.\nWe\u2019re also a little uneasy with\u00a0the\u00a0story\u2019s discussion\u00a0of\u00a0statistical significance, which it says is \u201cthe\u00a0standard for judging whether a result is real or a fluke.\u201d\u00a0It says it was \u201cconcerning\u201d that the results\u00a0of this study passed\u00a0the significance bar \u201cby only 0.001,\u201d implying that the results\u00a0would have been considered a \u201cfluke\u201d\u00a0if the results were a\u00a0few hundredths different. In fact, the results, taken at face\u00a0value, suggest that there was about a\u00a097%\u00a0probability that this result could not have\u00a0occurred by chance, and a change of .001\u00a0would not have altered that fact appreciably \u2014 even if it did mean that\u00a0the findings would no longer be considered \u201cstatistically significant.\u201d We think it\u2019s a stretch to question\u00a0this result \u2014 something which is almost never done\u00a0in coverage of\u00a0other studies that also \u201cbarely clear the bar\u201d for significance \u2014\u00a0\u00a0without a more complete discussion of what this means.", "answer": 1}, {"article": "\u201cCytokines are an alarm system in the body,\u201d said Dr. Curtis.\nNow, researchers at Jefferson (Philadelphia University + Thomas Jefferson University) have developed a test that could rapidly parse out infections of the brain from other diseases.\nChanges in cytokine levels of cerebrospinal fluid offer a very early measurable sign of infection.\u201d\n\nDr. Curtis and colleagues decided to see if they could detect patterns within the cytokines that might differentiate infections from other brain diseases or disorders.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nThe diagnostic could prove particularly useful in infants and young children.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits described are put in some numerical context. The results might show the presence of an infection, or something else (like tumors or autoimmune disease). It\u2019s seemingly innocuous, but for young children and babies, who can\u2019t describe their symptoms, such a tissue test could be beneficial, as the release explains.\nHowever, it would have strengthened this release to explain why some cytokine signals (and which ones) might be better indicators than others, and to what extent based on the small sample size.\nAnother thing that would have been helpful to explain is the fact that cytokines can also be inappropriately released (without infection, etc). This is a rare occurrence but we\u2019d still want to know that this distinction could be made as well.", "answer": 1}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\n\"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,\" added Alan Lotvin, MD, Executive Vice President, CVS Specialty.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We found the news release skimmed over giving crucial numbers and metrics for benefits. Separate from the cost benefit to home infusion versus hospital or clinic infusion, the release should have given us some numbers for safety.\nHere is what the release stated (emphasis ours):\n\u201cThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting. In addition, patients overwhelmingly preferred receiving their infusion therapies at home, reporting fewer disruptions in personal schedules and responsibilities.\nWe need numbers to demonstrate how \u201cas good\u201d the clinical outcomes were. We need numbers to represent \u201coverwhelmingly preferred.\u201d By what percentage did what number of patients demonstrate preference?\nThis is where the release could have taken some quantitative data from the study.", "answer": 0}, {"article": "\u201cWe find a clear benefit.\nA study of more than 60,000 adults in England and Scotland found that \u201cweekend warriors\u201d lowered their risk of death by a similar margin to those who spread the same amount of exercise over the whole week.\nPeople who cram all their exercise into one or two sessions at the weekend benefit nearly as much as those who work out more frequently, researchers say.\nIt\u2019s making them fit and healthy.\u201d\n\n\n\nThe UK\u2019s National Health Service recommends that to ward off an early death, people should spend 150 minutes a week performing moderate exercise, or 75 minutes a week doing vigorous exercise.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like the story in Newsweek, which we also reviewed, this story does not provide an adequate sense of the size of the potential benefits, stating:\nIn the study, those who met the physical activity target by exercising through the week had a 35% lower risk of death than the inactive adults, with cardiovascular deaths down 41% and a 21% lower risk of cancer death.\nUsing only relative risk rates such as these\u00a0doesn\u2019t tell the full story. \u00a0Read more on why absolute risk rates should also be included in news stories.\nIt also makes the study sound like it was experimental in fashion, conflating association with causation.\n\u201cPeople who cram all their exercise into one or two sessions at the weekend benefit nearly as much as those who work out more frequently, researchers say. \u00a0A study of more than 60,000 adults in England and Scotland found that \u201cweekend warriors\u201d lowered their risk of death by a similar margin to those who spread the same amount of exercise over the whole week.\u201d\nSee more on the importance of not overstating observational findings.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nAnalysis of images showed that the contrast used by the research team bound almost exclusively to the fibrin-fibronectin complexes, producing a strong and prolonged image enhancement of micrometastases and tumors compared with normal tissue.\n\u201cWe showed with this technique that we can detect very tiny tumors of just a few hundred cells,\u201d Lu said, adding that the study pushed imaging boundaries, revealing smaller cancers than can be detected with current clinical imaging modalities.\nUsing a microscopic imaging approach, called cryo-imaging, and MRI, the researchers verified that the MRI technique could detect micrometastases, even observing bone micrometastases that were less than 0.5mm \u2014 the diameter of a very fine pencil lead.\n\u201cThe technique used by researchers in this study enables very early detection of metastatic spread, which would allow adaptation of treatment more quickly and hopefully lead to better outcomes in the future.\u201d\n\nThe study, published online in the Aug. 12, 2015, issue of Nature Communications, was led by Zheng-Rong Lu, Ph.D., CWRU M. Frank Rudy and Margaret Domiter Rudy Professor of biomedical engineering and an expert in molecular imaging for cancer and other diseases.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t include information about how much better the enhanced MRI technology was shown to be (compared to MRI alone and cryo-imaging combinations)\u00a0in detecting metastases. The release does note that the investigators\u00a0\u201cverified\u201d that the new MRI method could detect micro metastases less than 0.5 mm, but offered no comparative measures of what other detection methods have to offer.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lacks precision in describing\u00a0the benefits of some products that have actually been studied in human tests (e.g. lactase and Bean-o), but then gives too much detail about products that have only been tested in lab studies. Does anybody care that a pill results in \u201c60% [of] large gluten molecules broken down in a half-hour and 75% at 90 minutes\u201d in a test tube? No. We care what happens inside people\u2019s bodies\u00a0and whether the products produce actual symptom relief.\u00a0It\u2019s particularly upsetting that the story concludes\u00a0with a plug for these test tube benefits, when a few paragraphs earlier we are told\u00a0that the products have never been tested in human trials.", "answer": 0}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\nMost patients don't even want to wait.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states the new procedure \u201crestored vision in babies for the first time\u201d but doesn\u2019t describe any quantified benefits of this newer method. At the end of the story, we are told the researchers claimed a \u201c100 percent\u201d success rate three months after surgery. However, that\u2019s not specific enough: Readers should be informed of how the researchers measured success\u2013what were the outcomes they measured?\u2013especially in such a young patient group where vision testing is tricky.", "answer": 0}, {"article": "Please see paper for the complete list.\nNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d Sixty-five percent of the Alzheimer\u2019s cases in this country involve APOE4; with seven million people carrying two copies of the ApoE4 allele.\n\u201cAll of these patients had either well-defined mild cognitive impairment (MCI), subjective cognitive impairment (SCI) or had been diagnosed with AD before beginning the program,\u201d said author Dale Bredesen, MD, a professor at the Buck Institute and professor at the Easton Laboratories for Neurodegenerative Disease Research at UCLA, who noted that patients who had had to discontinue work were able to return to work and those struggling at their jobs were able to improve their performance.\nAll but one of the ten patients included in the study are at genetic risk for AD, carrying at least one copy of the APOE4 allele.\nNewswise \u2014 June 15, 2016/Novato and Los Angeles, CA Results from quantitative MRI and neuropsychological testing show unprecedented improvements in ten patients with early Alzheimer\u2019s disease (AD) or its precursors following treatment with a programmatic and personalized therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research consists of 10 case studies in which all subjects showed some degree of improvement. But the news release gives information about only three patients \u2014 out of 10 in the study \u2014 who had the most dramatic improvements.It relates those patients\u2019 self-reported advances in functionality and gives measurements in memory improvement for two patients. It does not warn that self-reported improvements are likely to be biased by the patient\u2019s expectation of benefit from the program. It does not describe the specific interventions used for each patient. The news release doesn\u2019t tell us the total number of patients that were enrolled in this protocol. Were only the 10 that showed improvement included in the case study? What about the rest?\nThe release appears to cherry pick some data regarding risks and uses relative risks only, no absolute numbers. For example, you cannot tell from this release what your chances are of getting Alzheimer\u2019s if you have one or two APOE genes.\nClaims found in the release such as \u201cFollow up testing showed some of the patients going from abnormal to normal\u201d are both grandiose and unsubstantiated, but they could raise patient and caregivers\u2019 hopes that they or a loved one could reverse their Alzheimer\u2019s symptoms.", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nNow for the gene connection: Previous studies have linked macular degeneration to gene variations that remove some of that pathway\u2019s natural brakes, so it can become too active.\nWhile the study is too small to prove if lampalizumab really helps maintain vision, that\u2019s a bigger difference than the overall results suggested.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nThose are the only patients who appeared to benefit from the drug; they had 44 per cent less eye damage than the untreated patients, the Genentech team reported Wednesday in the journal Science Translational Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that patients who had the genetic variation and were treated with the drug had \u201c44 percent less eye damage than the untreated patients.\u201d However, since there is no information on what the baseline measurements were, we\u2019re not sure what that means. Is this a little or a lot in absolute terms? Did the treated group have noticeably improved vision?\nAs the study shows, all patients got worse after 18 months. But the lesions in the gene-carrier placebo group grew by about 4.2 millimeters, whereas the treated gene-carrier group\u2019s lesions grew 2.3 millimeters. It\u2019s not clear at all if that provides any actual vision benefit\u2013or is worth the risk of side effects, since presumably the patients will need to be treated indefinitely. We wish the story had explored this important aspect.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A clear and readable chart in the story quantifies\u00a0the apparent benefits of these text messages. But what\u2019s missing here is some nuance:\u00a0The control group saw a rise in blood pressure, whereas the experimental group remained relatively the same\u2013their blood pressure didn\u2019t actually get lower. So, does that even translate to an actual reduced heart disease risk?\u00a0And does any of this actually prevent heart attacks? These unanswered questions could have been better emphasized.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nThese trials form the basis of the Cambridge research that was published Tuesday in the journal Molecular Psychiatry\n\nBased on previous findings about depression, the team looked at the side effects experienced by patients given anti-cytokine drugs in 20 separate studies.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes\u2013and attributes\u2013statements saying studies showed the use of the anti-cytokines \u201cimproved symptoms of depression\u201d and \u201clessened symptoms of depression\u201d even in the absence of efficacy for reducing inflammation. But there are no statistics given to explain what \u201clessened\u201d or \u201cimproved\u201d means and very\u00a0little about the 20 studies\u00a0on which the researchers\u2019 conclusions about the potential anti-depressant benefits of the new drugs\u00a0are based.", "answer": 0}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nOverall, the studies involved nearly a million participants.\nIn the study, researchers analyzed information from 18 studies on coffee and diabetes and another 13 studies that included data on decaffeinated coffee and tea drinking and diabetes.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided several data points about potential benefits, but never discussed the limitations of drawing conclusions from observational studies.\u00a0 ", "answer": 0}, {"article": "\u201cIt\u2019s not a decision made on a single visit,\u201d she said.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nMost of the references to benefits are vague, such as, \u201cyou can save the majority of women who would have died of breast cancer.\u201d The story also does not make clear that the reduction in the risk of death was due entirely to removal of ovaries and that the researchers did not report that preventive mastectomy reduced the risk of death among these women. In addition, the factual errors in the description of cancer risks facing these women (described above) makes it impossible for readers to get an accurate understanding of the potential benefits of preventive surgery.", "answer": 0}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\nThey don\u2019t mention how many people actually suffered such a heart attack, but an earlier analysis of six of the trials showed that out of every 1,000 people, 18 individuals taking aspirin had heart attacks every year, compared to 23 individuals taking placebo pills.\nIn the current study, published in the American Journal of Cardiology, the researchers also report small decreases in stroke and death risks with aspirin, although those changes might have been due to chance.\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nThe researchers found a 19-percent reduction in non-fatal heart attacks among participants who took aspirin compared to those who did not.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Appropriate context.\u00a0 With a meta-analysis it is not statistically appropriate to pool absolute risk reductions, so the way the story treated the evidence is as good as can be done (showing the relative risk reduction and an \u201canchor\u201d in terms of absolute risk. Excerpt:\n\u201cThe researchers found a 19-percent reduction in non-fatal heart attacks among participants who took aspirin compared to those who did not.\nThey don\u2019t mention how many people actually suffered such a heart attack, but an earlier analysis of six of the trials showed that out of every 1,000 people, 18 individuals taking aspirin had heart attacks every year, compared to 23 individuals taking placebo pills.\nOn the other hand, that analysis also found aspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story adequately quantifies the survival benefit and at least mentions the improvements in quality of life and depression scores. It also provides some reasonable explanations as to why palliative care may be beneficial when administered early. Although we wish it had been more precise in its characterization of the depression and quality of life benefits (how big was the improvement? on which specific symptoms?), we feel there\u2019s enough\u00a0here for a satisfactory.\u00a0\u00a0", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nThe scientists then followed the people willing to continue the research for another 2 years, noting who developed new polyps, including advanced polyps with features that suggest they\u2019re more likely to become cancerous.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefits in appropriate statistical terms, noting that \u201cnew polyps were found in 58 percent of people on placebo, and only 51 percent on Celebrex.\u201d The story could also have given us the number of advanced polyps that were prevented in each group. And, as noted above under the \u201cEvidence\u201d criterion, the story should have explained that these differences in polyp incidence\u00a0might not translate directly to the number of actual cancers prevented. Since we\u2019ve already docked the points for this omission, however, we\u2019ll award a satisfactory here to recognize the appropriate use of absolute risk numbers.", "answer": 1}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n\u201cThis clock remains synchronized with the external day through regular exposure to light.\u201d\n\nNighttime flashes change the timing of the circadian clock, he said.\nArriving in New York, you would be synced to the local time after one day, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits of those who experience the flashing light therapy over those who have the continuous light therapy were\u00a0described this way: \u201cA series of flashes similar to a camera flash delivered every 10 seconds over a 60-minute period delayed sleepiness by two hours, compared to a 36-minute delay for those exposed to continuous light for an hour.\u201d\nThese quotes were also helpful in quantifying and understanding the benefits:\n\u201cIn essence, using the night before you traveled from California to N.Y. would move your circadian system two-thirds of the way there before you even left,\u201d Zeitzer said.\nArriving in New York, you would be synced to the local time after one day, he said.", "answer": 1}, {"article": "on Sept. 2.\nBut considering all the patients in the trial, only 12 percent had a reduction in tumor size that lasted for more than 14 weeks.\nIn the prospectus for that offering, the company said that one of the risks for investors was \u201cthe relative price of Folotyn as compared to alternate treatment options.\u201d It said there was a risk it might have to lower the price or offer discounts to successfully market Folotyn.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nSo the total cost of using Folotyn will be less than for many other drugs with lower monthly prices.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantitifes the benefits of Folotyn, which are not that impressive. The story provides the percentage of patients with reductions in tumor size and the median time that the benefits lasted.", "answer": 1}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\nNone of the low-dose supplements seemed to stave off such events in most of the patients.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nSUNDAY, Aug. 29, 2010 (HealthDay News) -- Most heart patients who take low-dose omega-3 fatty acid supplements don't appear to gain any additional protection against further cardiac trouble, new Dutch research cautions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate. The story mentioned that there did appear to be a subcategory of benefit in women who consumed the ALA fortified margarine. \u00a0It didn\u2019t to mention the benefits seen in individuals with diabetes from the use of fortified margarine.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\nHalf got the new gel and the other half received an inactive placebo.\nThe new findings are published in the New England Journal of Medicine.\nThe gel is derived from the sap of the Euphorbia peplus plant.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story delivers information on how the gel compared with placebo.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nFeb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate discussion of benefits as seen in the two published studies.", "answer": 1}, {"article": "FOR REPORTERS: Elias will be available for interviews today, and he\u2019ll be doing a Facebook Live broadcast at 3:15 Eastern.\nParticipants who received the sham procedure, on the other hand, showed no significant improvements.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\n\u201cFor the first time in a randomized controlled trial, we have shown that ultrasound can be precisely delivered through the intact human skull to treat a difficult neurological disease.\u201d\n\nPioneering Tremor TrialThe multi-site clinical trial included 76 participants with moderate to severe essential tremor, a condition that often robs people of their ability to write, feed themselves and carry out their normal daily activities.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this release credit for including numerical data on patient improvement during the study: \u201cthey found that mean tremor scores improved by 47 percent at three months and 40 percent at 12 months. Participants reported major improvements in their quality of life. People who couldn\u2019t feed themselves soup or cereal could again do so.\u201d\u00a0 Unfortunately, it omits a host of other numerical data contained in the NEJM paper that places the patient improvement in a less-glowing perspective, issues like the reduction in improvement over time experienced by some patients and the extent of adverse effects (see below). It\u2019s quantification data was based on relative rather than absolute improvements and it was not clear what those improvements meant functionally. The release could have described the range of the scale and given the actual tremor scores. This would have been more informative than describing a 47% reduction which could represent a very large or relatively small changedepending on what the baseline scores were.\nHad the release included some of the caveats pointed to in an editorial about the same study carried in the journal, readers would have a clearer picture of just how important this new procedure was.", "answer": 0}, {"article": "For more information on healthful eating for kids, visit the U.S. Department of Agriculture.\nConversely, every one point increase in healthy eating translated into a 1.2 point increase in IQ, the researchers found.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nFor every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nMONDAY, Feb. 7, 2011 (HealthDay News) -- Feeding children lots of fatty, sugary and processed foods may lower their IQ, while a diet rich in vitamins and nutrients appears to boost it, British researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although some data are presented, the results are not clearly explained. For example, the story says that \u201cfor every one point increase in processed foods consumption,\u201d the children\u00a0\u201clost 1.67 points in IQ.\u201d We are never given any explanation as to what a\u00a0\u201cone point increase in processed foods\u201d might mean. An extra hot dog each week? An additional serving of mac and cheese? There should have been some attempt to characterize these measurements in terms corresponding to actual food. Similarly, there\u2019s\u00a0also no discussion of what these IQ differences translate to in terms ability to read, write, and function in a classroom or in other aspects of life.\u00a0In\u00a0their study, the authors characterized the associations between\u00a0diet and IQ as \u201cweak.\u201d", "answer": 0}, {"article": "Why?\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nDr. Lawrence B. Goldstein, director of the Duke Stroke Center in Durham, North Carolina, and spokesperson for the American Heart Association said the results were not surprising, since \u201cno clinical trials ever showed that treatment with a (clot buster) improves survival.\u201d\n\nBut Kazley said that the additional deaths among patients who received tPA is likely because doctors are more likely to give the drug to those with severe strokes, who have a higher risk of death in any case.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes the vague claim that tPA\u00a0\"can improve patient outcomes following stroke.\" Some detail on what outcomes are improved, and by how much,\u00a0would have been useful for readers. The story also did not quantify the results of this study very well.\u00a0 It says there was a\u00a0\"20% difference\"\u00a0in the use of tPA between the groups, but fails to show that it is 1.1% vs 0.9% \u2014 a 2 in\u00a01000 difference in absolute terms. Given the relatively finely balanced benefit to harm ratio, this finding is not clinically important even though it is statistically significant due to the huge sample size.", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nThe test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\nStill, the test \"should be an important tool for an obstetrician who currently has no clue\" if premature birth is a possibility until it happens, said Brigham Young University (BYU) chemistry professor Steven W. Graves.\nThe false positive rate -- referring to tests that wrongly indicated premature birth -- was 20 percent.\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here.\u00a0 We\u2019ll give it a somewhat satisfactory grade. Here\u2019s why.\nThe story stated that the test \u201cpredicted 80 percent to 90 percent of the premature births at 28 weeks of gestation. The false positive rate \u2014 referring to tests that wrongly indicated premature birth \u2014 was 20 percent. The test wasn\u2019t as effective at 24 weeks of gestation.\u201d\u00a0 It didn\u2019t give any numbers to back up the experience at 24 weeks.\nBut we would have appreciated somewhere a note that it is the very early preterm births that are the most crucial to predict. The story fixates on 28 week testing. What\u2019s really needed are means to identify and study the 23 to 28 weekers. The story also doesn\u2019t acknowledge that we have no effective interventions to stop preterm birth and somewhat incorrectly explains how betamethasone for lung maturity works.\nIt also had an independent expert\u2019s quote: \u201cIf you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that\u2019s truly the case.\u201d\u00a0 That\u2019s a very important contribution to the story.", "answer": 1}, {"article": "The combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nStudy Limitations: The results apply only to pain after two hours.\nWho: 416 patients (ages 21 to 64 years) with moderate to severe acute extremity pain in two urban emergency departments were randomly assigned to receive\n\nWhat (Study Measures): The between-group difference in decline in pain two hours after taking the study drugs.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one, since the release does not quantify the extent of the pain reduction. The release notes only that \u201cAfter 2 hours pain was less in all participants, without any important difference in effect between the four groups.\u201d There were differences between the groups, but those differences were not statistically significant. However, given that we often call out news releases that make a big deal out of statistically insignificant differences, we approve of the way that issue is handled here \u2014 thus the satisfactory rating.", "answer": 1}, {"article": "In the absence of FY26, cancer cells switch from using their defective mitochondria to using metabolic activity in their cytoplasm to generate energy.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\nThe paper describes the comprehensive systems biology approach used to elucidate the mechanism of osmium action of FY26, led by PhD student Jess Hearn.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that FY26 is \u201c49 times more potent than Cisplatin\u201d \u2014 a statement that strikes us as hyperbolic. There\u2019s no explanation at all of how the researchers measured the \u201cpotency\u201d of the drug, and we\u2019re left wondering how they concluded that it was exactly \u201c49 times\u201d more potent. Rather than focus on this promotional-sounding claim, we\u2019d have preferred some description of what the researchers actually did in the experiment and what their results showed.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of treatment, immune responsiveness to bird flu, was accurately reported as occurring in 54% of those receiving the highest dose of the vaccine administered.", "answer": 1}, {"article": "For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nThis study evaluated 186 patients, comparing 94 Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse, and 92 healthy patients with no history of opioid use.\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the algorithm correctly identified patients with a history of opioid misuse nearly 97 percent of the time, rarely mis-classifying the healthy controls as being at high or even moderate risk of opioid misuse. One question that remains unanswered in the release is whether the POR test would successfully distinguish people with opioid use disorder from individuals who have used opioids without becoming addicted.", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nPBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy.\nUnlike conventional scattering technology, spot scanning technology delivers narrow beams to the tumor and the complex tumor shape can be irradiated through repetitive beam delivery with quick position change.\nGiven the growing demand for technical and clinical advancements in the treatment of cancer, interest in proton therapy is on the rise, with more and more hospitals and cancer treatment facilities venturing into this area.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "PBT\u2019s advantage over other types of radiation treatment is its ability to focus narrow beams of radiation onto tumors with reduced radiation spillover into other organs. That\u2019s why it\u2019s most beneficial for tumors of the CNS and in pediatric patients where oncologists strive to limit damage to surrounding tissues. Unfortunately, the news release didn\u2019t specify which types of cancers are good targets for PBT. There\u2019s the implication that PBT should be used in a wider number of cancers. However, there\u2019s ongoing disagreement over the evidence that PBT has a significant advantage over other types of radiation treatments in prostate cancer, for which it is coming into wider use.\nThere are two reasons PBT is becoming a common treatment for prostate cancer. With protons, only two fields (or radiation passes) are needed to cover the prostate compared with 7 to 9 fields using photon intensity-modulated radiation therapy (IMRT) in order to achieve an effective dose. The other reason is that clinics that have an expensive proton facility need to justify having it, and prostate cancer is very common. There is no shortage of available patients.", "answer": 0}, {"article": "Anyone remember fen-phen?\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nBut Ronald Evans, director of the institute's Gene Expression Laboratory and lead author of the new study, said in an interview that if it shows the same promise in primate studies, clinical trials on humans could begin in a couple of years.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the compound causes the body to burn fat to make room for new calories, relieves cellular inflammation, and reduces insulin resistance. Even though these benefits were only seen in mice, we\u2019d still expect to see some quantification of what was observed.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release refers to a multi-center prospective study of 1,947 blood samples, but does not tell us the citation for publication of that study. The blood sample tests were able to \u201cpredict the presence of intracranial lesions on a CT scan 97.5 percent of the time and those who did not have intracranial lesions on a CT scan 99.6 percent of the time. These findings indicate that the test can reliably predict the absence of intracranial lesions.\u201d\nThe release claims that the blood testing will rule out the need for a CT scan in \u201cat least one-third of patients who are suspected of having mTBI.\u201d This is the main purported benefit, along with reducing costs.\nThe Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5% of the time and those who did not have intracranial lesions on a CT scan 99.6% of the time. These findings suggest that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because this story reports on the risks of clots from hormone therapy, this criteria will be\u00a0judged against how well the story quantified the risks, not\u00a0the benefits, of\u00a0the treatment.\u00a0The story should have quantified the risk in absolute terms, not relative terms. The story states that \"women who took hormone pills were 4 times as likely to suffer a serious blood clot.\" 4 times higher than what? The story could have provided more context for the reader on these numbers by giving the actual risk of clotting from the pills compared to the patch.", "answer": 0}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThe results showed when they drank the milkshake with the inulin-propionate ester supplement they rated the high calorie foods as less appealing.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told by the release that participants who drank a milkshake with inulin-proprionate ester had \u201cless\u201d activity in areas of their brain linked to reward when shown pictures of high calorie foods. But no information is given about how much less, whether all of the participants experienced the same effect (or how many actually did and did not), or how many of the participants who drank the supplement ate 10 percent less than the control group that drank a shake with an apparently less concentrated\u00a0form of inulin (the fiber) alone. Similarly, the reader is told that \u201coverweight volunteers\u201d who got the ester supplement daily \u201cgained less weight\u201d over six months, but not how much less or how overweight they were. It\u2019s impossible to tell from the release (but it would have been very useful to know) the age and gender of the volunteers. If they were college students, for example, or mostly female, metabolic and hormonal factors might have played an outsized role in the results. Finally, references to \u201cprevious studies\u201d were nonspecific, and did not even mention if they were animal or human studies.", "answer": 0}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\nOverall, the investigators said, adding sestamibi SPECT/CT helped identify 7 of 9 benign tumors, and conventional imaging with added sestamibi SPECT/CT outperformed conventional imaging alone, as measured by a statistical analysis that measures tradeoffs between sensitivity and specificity.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases,\u201d and that \u201cConventional imaging combined with sestamibi SPECT/CT had a value of 0.85, while conventional imaging alone had a value of 0.60.\u201d The release offers that \u201ca value of 0.50 indicates that a diagnostic test is no better than chance,\u201d to give readers a benchmark for comparison.", "answer": 1}, {"article": "Enrollment ran from 1993 to 1998.\nOne possible explanation included in the study: The women with lower inflammation scores were more physically active as a group and therefore were at a slightly greater risk of falls.\nBut in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\nHigher scores were associated with an almost 50 percent larger risk of hip fracture in Caucasian women younger than 63, compared with the risk for women in the group with the lowest inflammatory scores.\nWomen with the least-inflammatory diets had lower bone mineral density overall at the start of the study, but lost less bone than their high-inflammation peers, the researchers found.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We were disappointed to see little actual quantification of the benefits found in the study. Most of the\u00a0numbers in the release were numbers quantifying the number of women being studied in different ways and the number of dietary components that were studied. One sentence said this:\n\u201cHigher scores were associated with an almost 50 percent larger risk of hip fracture in Caucasian women younger than 63, compared with the risk for women in the group with the lowest inflammatory scores.\u201d\nIt\u2019s very hard to know what to make of that sentence without knowing the actual number of women who saw a benefit or did not see a benefit. This is an issue of reporting relative risk (which this study did) versus absolute risk, which would give us actual numbers of women that were affected. (See our primer on writing about absolute vs relative risk.)", "answer": 0}, {"article": "They're forgetful,\" Ashare said.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nConsistent with these effects, clinical trial participants taking the AChEI, not the placebo, smoked 2.3 fewer cigarettes daily, a 12 percent decrease, and noted feeling less satisfied with the cigarettes they did smoke.\nThe rat component showed that pretreating the rodents with an AChEI decreased their nicotine consumption.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release may overstate things in the headline which claims, \u201cAn FDA-approved Alzheimer\u2019s drug could help smokers quit.\u201d The study didn\u2019t look at quit rates and lasted only 23 days, so the effect on quitting is entirely unknown. We\u2019ll give the benefit of the doubt here though since the release notes that\u00a0people involved in the trials (there was also an animal trial component) reduced their cigarette use by 2.3 cigarettes a day \u2014 a 12% decrease \u2014 after being on the drug for two weeks. The volunteers also related that they felt \u201cless satisfied\u201d with smoking after being on the drug, although this benefit was not quantified.", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story meets our standard by explaining that 1,000 milligrams daily of bergamot extract lowered cholesterol from an average of 278 milligrams per deciliter of blood to 191 in the study. But while\u00a0many readers with high cholesterol likely understand the significance of these numbers, readers without them (but who are nonetheless interested in the story) would benefit from a clear example or description of the risks posed by high cholesterol. The story would also have been stronger had it told us how this reduction in cholesterol would affect one\u2019s overall risk of a heart attack or stroke.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nBut until the vaccine is linked to an actual survival benefit or improvement in tumor status, Diamond said, no one can say if it helps the patients in a meaningful way.\nHow to explain the 27 percent who responded without the vaccine?\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article was vague in describing the results and did not elaborate on what the response was that those in the vaccinated group exhibited:\n\u201cThe investigators found that in the vaccinated group, 86 percent of patients showed a significant response, compared with 27 percent of those in the \u201ccontrol\u201d group who did not get the injection.\u201d\nTo its credit, the story included important caveats: the subhead of the story said \u201ctrue significance unknown\u201d and later in the story was this independent expert\u2019s quote, \u201cWhether it actually has an increase in survival remains to be seen.\u201d\nBut the vagueness on the main finding of the study leads us to give this an unsatisfactory score. What does \u201csignificant response\u201d mean?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe story does not cite the absolute benefit of vitamin supplements on weight control. The trial showed that women who took calcium and vitamin D were on average less than a third of a pound lighter (0.13 kg or 0.29 lbs) seven years later than women who did not. Despite the headline \u201cAdd bone, drop pounds,\u201d the story also fails to mention whether the dietary supplements influenced bone health or the incidence of fragility fractures. A closer reading of the trial could easily lead a postmenopausal woman to question both the accuracy of the article\u2019s headline and the clinical relevance of the study it reported.\n", "answer": 0}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nThe P-Cure Patient-Centric solution is a paradigm shifting change from the current method of treatment with the patient in the horizontal position.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nBecause of the high capital costs, proton therapy is currently only available to less than one percent of patients who could potentially benefit from it.\nAdult and pediatric patients who will initially benefit from this clinical breakthrough will be those treated for cancers of the lung, breast, chest, the head and neck, and lower torso.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are many claims of benefits in this release, none of them quantified:\nFor the patient, the real question is whether this device makes the treatment any better. If not, then does it make it any easier, more comfortable or shorter? There is no data provided. ", "answer": 0}, {"article": "The subjects were followed for 10 years.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that among study participants, those with a zero calcium score on a heart CT scan had only half the expected number of heart attacks or disabling chest pain over a 10-year period. That\u2019s a relative comparison, which as we frequently note does not provide the full picture regarding benefit. But the story goes on to give readers a better sense of what these numbers mean in absolute terms. It\u00a0explains the example of a person with a 12 percent risk of a heart attack over a decade based on the risk calculator recommended by the American college of Cardiology and others. That person actually turned out to have only a 4 percent 10-year risk, below the widely-used 7.5 percent risk threshold for recommending a statin.\nThe story makes clear that the scan does not provide a direct health benefit, but it provides information to people who are trying to decide about whether to start taking cholesterol-reducing statins. To help with that decision, it would have been nice for the story to include some discussion of the benefits associated with statin use, especially the\u00a0numbers needed to treat (NNT) with a statin in order to save a life.\nThe story includes only one patient anecdote, a woman who was feeling depressed and had trouble getting out of bed when she took statins, and then decided to stop taking the drugs after having a CT scan that showed zero calcium. We often find fault with stories that introduce readers to only one patient, who claims to have greatly benefited; however, the placement of the anecdote low in the story and the preceding context that included limitations and expert cautions mean this single patient story doesn\u2019t overwhelm the other information.\nLink to online Atherosclerotic Cardiovascular Disease (ASCVD) Risk Estimator: http://tools.acc.org/ASCVD-Risk-Estimator/", "answer": 1}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nNearly nine out of 10 strokes are caused by a blood clot that blocks one of the arteries supplying blood to the brain, the American Heart Association (AHA) said.\nThe tool, called an endovascular stent retrieval device, is made up of wire mesh that resembles a tiny ring of chicken wire, Powers said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is not about a single research study, so it is perhaps understandable that it remains general in its comments about benefits. But we found only statement from an expert that addresses the issue:\u00a0\u201cAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots.\u201d\nWhile stopping a stroke is clearly a benefit, that sentence does not tell us by what percentage of people randomly chosen to receive the new procedure have a better long-term outcome in terms of quality of life, or die less often of later complications, or any other measurable difference.\nThe outcome assessed in the studies, \u201cfunctional independence after stroke,\u201d is easy to understand. And the benefits were significant: 53-71% of treated patients were functionally independent following the stroke, compared to 29-40% of untreated patients.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story provides some quantification of benefits from screening, it\u00a0also exaggerates these benefits in qualitative terms. The story claims that the study is a \"shining light\"\u00a0and that screening\u00a0could \"cure or substantially lengthen the lives\" of lung cancer patients.\u00a0Unfortunately, the current study does not\u00a0prove that screening actually lengthens lives.\u00a0", "answer": 0}, {"article": "Tactics being tested include renal nerve ablation, a procedure that emits low-power radiofrequency along the nerves next to the kidneys, interrupting signals that trigger high blood pressure.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\n\"I thought it was compelling, though single cases are always questionable\" to generalize.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never actually describes how high this patient\u2019s blood pressure was prior to DBS, or how much it was reduced after treatment. Providing this data \u2014 limited though it may be \u2014 would have given readers a better idea of DBS\u2019s effects on blood pressure, at least for this\u00a0particular patient.", "answer": 0}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nSacco notes that both the AHA and the American Academy of Pediatrics now recommend cholesterol screening in children with risk factors for heart disease other than family history, such as obesity, high blood pressure and diabetes.\nRather than calling for all youngsters to have their cholesterol tested, which would entail considerable expense on the national level, Dr. Ralph Sacco, president of the American Heart Association (AHA), suggests looking more critically at current screening guidelines.\nA new study finds that current guidelines for cholesterol screening in children may miss nearly 10% of those who have high levels of LDL, or bad cholesterol.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThis story not only fails to question the assumption that treating children with elevated cholesterol can prevent heart disease, it allows a researcher to claim that screening children for cholesterol would help reduce the risk of diabetes. There is no reference to any evidence that cholesterol screening is a better predictor of diabetes risk than either other screening tests, obesity or other factors linked to diabetes. The statement also implies that identifying diabetes risk before symptoms appear is better than either recommending lifestyle changes to reduce diabetes risk for all children (regardless of cholesterol test results) or treating diabetes once symptoms appear.\n", "answer": 0}, {"article": "For more information on obesity, visit the U.S. National Library of Medicine.\nThe researchers came to their conclusions -- which should be considered preliminary until published in a peer-reviewed journal -- after following 13 men and 13 women of normal weight.\n\"If sustained, the dietary choices made by people undergoing short sleep could predispose them to obesity and increased risk of cardiovascular disease,\" the researchers wrote in an American Heart Association news release.\nIn addition, the researchers asked the participants questions about sleep time, depression, insomnia, screen time and stress.\n\"We found that people who got more than six but less than eight hours of sleep, and who reported the lowest levels of stress, had the most success in a weight-loss program,\" said study author Dr. Charles Elder.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented the outcome of 472 obese individuals and examined in more detail those who were able, on average, to loss 14 pounds over a period of 26 weeks. \u00a0The story did not provide any insight as to whether this amount of weight loss resulted in any health improvement in the obese individuals who were studied.\u00a0 So the true benefit \u2013 the true significance of the potential benefit \u2013 was not explained.\nFurther \u2013 while the study found that those who got an adequate amount of sleep were among the cohort of individuals who were found to lose the most weight, the story did not explicitly point out that the study does not inform us about whether enforced hours of sleep would impact weight loss and weight loss management. So, again, the headline, the story\u2019s first sentence, and the call to action by the researcher were not balanced.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThat would be one compassionate use of it, a very serious application.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story simply stated, \u201cno blood clots were reported among patients who were far enough along in testing to be evaluated.\u201d\nYet the first sentence says the device \u201chas proven safe and effective.\u201d\nThe story begs a much broader much discussion of what benefits one would hope for from device implantation \u2013 and how this study (as the Wall Street Journal reported) raises perhaps more questions than it answers.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only provides quantification of the harms of hormone therapy in relative terms. Because the incidence of stroke and breast cancer was very low in this population (particularly in the younger women), only presenting the risks in terms of\u00a0relative\u00a0risk tends to exaggerate the true risk to the patient. In this situation, presenting the harms in terms of absolute risk would be much more helpful to a patient trying to make a decision about whether to take hormone therapy. For example, the lifetime risk of breast cancer for a 50 year old woman is 13%. An increase of 19% in risk as cited in the article translates to a lifetime risk of about 15%. In this situation, a woman can decide if the tradeoff of increasing her risk of breast cancer from 13% to 15% is worth\u00a0the relief from\u00a0her menopausal symptoms.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on how these new techniques and technologies can address perceived shortcomings in conventional surgery. And it uses compelling language to describe these potential benefits: \u201cThe resulting real-time 3D visuals\u2014known as \u2018intraoperative imaging\u2019\u2014help surgeons excise tumors and tissue with greater accuracy, reducing risks, such as nicked nerves from an errant knife, and the potential need for repeat surgery. The images also help surgeons spot bleeding, blood clots or other unexpected complications outside their field of vision.\u201d\nHowever, the story doesn\u2019t offer any numbers to demonstrate whether that potential is being fulfilled. For example, the story notes that the Advanced Multimodality Image-Guided Operating Suite program at Brigham and Women\u2019s Hospital, which focuses on these real-time imaging techniques, has conducted 700 surgeries since 2011. Did those surgeries have better outcomes than comparable surgeries that didn\u2019t use these imaging technique? The story doesn\u2019t say.", "answer": 0}, {"article": "\"Children with sleep apnea and bedwetting should see an otolaryngologist first.\"\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nMONDAY, May 16, 2011 (HealthDay News) -- Half of children with sleep apnea who also wet the bed might stop their bedwetting if their tonsils or adenoids are removed, new research suggests.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\n\"If a child has bedwetting, pay close attention to their sleep patterns, and observe them while they are asleep and you can see whether they are breathing at a regular pace, and if not, seek additional help,\" Atala said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Right in the lead, the story quantifies the benefits, saying, \u201cHalf of children with sleep apnea who also wet the bed might stop their bedwetting if their tonsils or adenoids are removed, new research suggests.\u201d The story satisfies our criteria of absolute risk reduction. However, we would have liked to\u00a0have seen\u00a0more details, such as the average length of time it took for half of the 417 children to stop wetting. And, do the researchers\u00a0mean COMPLETELY stopped wetting, or went from wetting most nights to wetting rarely, for example. ", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately reported the benefits from the study of 861 patients that was released by the manufacturer and scheduled for presentation at a scientific meeting.Rather than falling victim to presenting the drug\u2019s benefits in relative terms (27% increase in median survival, more than doubling of the two year survival) the story provides the readers with absolute numbers.", "answer": 1}, {"article": "He noted that breast cancer deaths have decreased since mammography came into widespread use in the 1980s, though some of the decline, he said, was also due to better treatments.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\nThe guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of articulating the benefits of mammography screening for different age groups. For example, it notes that \u201cFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\u201d However, the story does not explain what it means to be \u201cscreened repeatedly\u201d \u2014 does that mean every year, or could it mean every other year? Still, we\u2019re very happy to see the story include numbers rather than referring solely to a general increase or decrease in benefits. The story also notes that the recommendations apply only to women with average risk of breast cancer. The story would have been significantly stronger if it had explained what \u201caverage risk\u201d means \u2014 most readers probably don\u2019t know.\nThe quote from the Susan G. Komen For the Cure Foundation demonstrates the importance of reinforcing that these guidelines apply to average risk patients \u2013 they express concern that \u201ca lack of coverage would hit \u2018high risk and underserved\u2019 women hardest\u201d \u2013 high risk women are not affected by these recommendations.\nA discussion on risk assessment is absent from most stories covering screening mammography, and has led to much confusion. One issue is that there are a variety of risk assessment models, and their use in particular patient populations is not always well understood by physicians. However, a brief discussion about how risk is assessed would be helpful for patients and others reading these stories.", "answer": 1}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\nSome experts said the results suggested that doctors might one day be able to custom-produce blood vessels for patients with circulatory problems in their hearts or legs.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that the experimental grafts made it \"easier and safer\" for patients to use kidney dialysis machines. However, the study did not actually compare the tissue-engineered grafts to standard artifical grafts. The story also stated that when the experimental grafts worked, those patients fared better than regular dialysis patients. But, again, the study did not include any such direct comparisons.", "answer": 0}, {"article": "The drug is Johnson & Johnson's abiraterone acetate.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "WebMD reports the data incorrectly\u2013it\u2019s median survival, not average survival. This implies that 50% of the patients had more than a 4-month survival, but the story (assuming that investigators provided data, which they might not have) should then provide the upper range of survival times (e.g., 11 months) to quantify \"better.\"\u00a0 They could also report that X% survived for 6 months, Y% for 12 months, etc. (though the latter may be 0).\u00a0\n This story seemed determined to put this study in the best possible light, reporting that \"The treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life. But there\u2019s more hope than that from the study\u2026\"\u00a0 What does that mean?\u00a0", "answer": 0}, {"article": "It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland -- and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nIn the new study, the researchers focused on well-known networks of activity that are observed when the brain is in a resting state.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\nAlthough effective drug treatments for mTBI await discovery, rest and counseling are known to be helpful for patients, Mukherjee said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release talks about the benefits of getting a fMRI early on \u2014 in this case, within the first two weeks of the mTBI. It states fMRI highlights abnormal patterns of brain activity, which helps physicians predict which patients are at a higher risk for post-concussive symptoms after six months.\nBut there\u2019s no mention of any quantitative data to help readers understand the scope of the benefit. How accurate was the fMRI in distinguishing patients who might later experience symptoms? Did all mTBI patients exhibit reduced connectivity in the \u201cdefault mode network?\u201d And how much worse did mTBI patients perform on cognitive and behavioral tests?\nSince only comparative words are used without any quantitative data, we give the news release a Not Satisfactory rating here.\nThe original journal article also doesn\u2019t give numbers so it falls on the shoulders of the writer to seek clarity from the researchers when benefits are being claimed. ", "answer": 0}, {"article": "But it didn't work for two of them.\nThe hazards of stem cell transplantation also raise questions about whether the study should have included children.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify benefits, e.g. 13 out of 15 patients were able to stop taking insulin.\u00a0 And even though these results look promising at first glance, the story provides cautionary statements that these are just preliminary results.\u00a0 ", "answer": 1}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nIn our first LIFE study, we confirmed that regular exercise can help improve physical function and prevent mobility loss.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provided only bare-bones results. We\u2019d have liked to see some indication of the changes in mobility \u2014 from what to what \u2014 following the exercise program.\nThe release says \u201cChanges in activity were significantly greater in the physical activity intervention group than the health education group from baseline through 24 months.\u201d What does that mean exactly? How much improved were those who took part in physical activity compared to those who didn\u2019t?\nIn addition, the headline and text refer often to reduced risks, but we\u2019re never told exactly what those risk factors are.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Look at the headline of this story: \u201cIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug.\u201d Now look at the first sentence: \u201cA little-known drug company announced modestly\u00a0encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\u201d We had to do a triple take because this level of reflection and circumspection is so rare and so welcome.\nThe story then goes on to spell out why the reporter used terms like \u201chints of modest benefit\u201d and \u201cmodestly encouraging\u201d and, if you read the links, the story also backs up the history of failure in this field.\nWhen it comes to quantifying the benefits, we\u2019re told, specifically, that \u201cthe patients who received all six low doses\u00a0did the best; their average improvement after the 12 weeks was 1.5 points on the 100-point cognitive test.\u201d It then says, \u201cPatients receiving a placebo (most were also on standard Alzheimer\u2019s drugs) lost 1.1 points.\u201d We\u2019re told the difference was not statistically significant.", "answer": 1}, {"article": "Six patients were given a full series of vaccinations, including five priming injections and two booster vaccinations.\nThe next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.\u201d\nHe added, however, that the studies confirm the potential of cancer vaccines.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that four of the six patients had no cancer recurrence after 25 months in the first study, and in the second study, eight of the 13 patients remained tumor free after 23 months.\nBut the studies cited are both phase I clinical trials designed to address safety, not efficacy. Any claims regarding the latter, especially given the limited number of subjects, would be highly speculative. Therefore, the headline is misleading. As noted in the final sentence of the article:\n\u201c\u2026\u00a0The next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.\u201d", "answer": 1}, {"article": "Keytruda \u2014 known generically as pembrolizumab \u2014 targets the activity of genes called PD-1 (anti-programmed-death-receptor-1) and PD-L1.\nSo it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\nIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits. We recognize this would be difficult given that the details around the study have not been released, but we also think that, because the details have not been released, more caution should have been used. It\u2019s unfortunate to see a statement like this, for example: \u201cIt helped patients live longer overall and helped them live longer without their tumors growing or spreading, Merck said.\u201d This is an unchallenged statement with no numbers to back it up, and it\u2019s not even attributed to a human. It\u2019s attributed to a company.", "answer": 0}, {"article": "In 1992, Harvard neuroscientist Richard Davidson embarked on an unusual research project to study the brains of Buddhist monks who spent thousands of hours meditating.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nThe results for both techniques were very positive.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers what percentage of study participants who got MBSR treatment reported improvement in pain, as well as what percentage of MBSR participants \u201creported improvement in the activities they could do.\u201d\nIt also offered the same numbers for participants who received CBT and for the control group, which received typical medical care for this condition. These details\u00a0deserve\u00a0a Satisfactory rating. But:", "answer": 1}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe Wisconsin Partnership Program is pleased to present its 2019-2024 Five-Year Plan, which was approved by the UW System Board of Regents in December, 2018 and goes into effect March, 2019.\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nThe Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health has awarded four grants through its New Investigator Program.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although we appreciate the release\u2019s attempt to quantify benefits in terms of ADAS-cog scores, these numbers lack any significance for those who are not familiar this particular scale. Is this a 10-point scale or a 100-point scale? The importance of the 3 and 4-point drops described in the release will be judged differently depending on this crucial context.\nIn addition, while the benefits were corroborated by mention of another study that showed \u00a0a reduction in the risk of developing Alzheimer\u2019s disease among men who receive Lupron, there is an important clinical difference between reducing risk of developing Alzheimer\u2019s disease and slowing progression of the cognitive deficits of Alzheimer\u2019s disease. The release didn\u2019t make this clear.", "answer": 0}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nAnd it's also important to note that this is not a cure.\n\"And MS is probably not a single disease.\nBut a 23 percent reduction is not a cure.\n\"We went 17 years with injectables before we got our first oral option, 'Gilenya', just last year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A general comment \u2013 not necessarily directed at this story nor at those responsible for it:\u00a0 We\u2019ve recently heard from some journalists that they can\u2019t or won\u2019t report on absolute risks or NNT (harms or conflicts of interests, either, for that matter) if the researcher doesn\u2019t provide that information.\u00a0 We have no patience for that stance or argument.\u00a0 That\u2019s akin to admitting that we\u2019ll only report what we\u2019re spoonfed.", "answer": 0}, {"article": "Type 1 diabetes, an autoimmune disease, occurs when the body's immune system cells mistakenly attack the insulin-producing (beta) cells in the pancreas.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\nIf we can control the autoimmunity, we may reverse the diabetes.\nStopping that autoimmune attack appears to be crucial to any treatment that hopes to cure or reverse type 1 diabetes.\n\"Our study brings a new hope for people with type 1 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does a good job reporting the results of this trial and it notes that patients in this trial reduced their use of insulin, but were not able to discontinue taking insulin shots. It includes cautionary statements from an independent expert who says that the trial didn\u2019t last long enough \u201cto declare victory over diabetes yet.\u201d\nBut we can\u2019t give it a passing score here because it misleads readers about the important long-term health outcomes that people with diabetes really care about. The story claims that the reductions in blood sugar levels seen in these patients \u201cwould\u201d reduce the risk of long-term complications. These researchers did not look at rates of complications. Indeed, the trial was far too short to produce meaningful results about rates of heart disease, blood flow problems, skin ulcers or other complications of diabetes, so any claims about reductions in complication rates are mere speculation.\nThis should have been framed as a preliminary safety study of a new approach that now needs to be tested in a randomized design with adequate numbers of subjects and duration to be able to truly say something about benefit or harm.\u00a0 Novel, promising, passed the first safety test.\u00a0 Period.", "answer": 0}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nBut, as the study's lead author Dr. Philip Kantoff acknowledges, \"It's not a home run; this is not going to cure prostate cancer.\"\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nIn the study, men with prostate cancer that no longer responds to hormone therapy (basically, chemical castration) lived about four months longer if they took Provenge than if they got placebo treatment.\nLongo, the NEJM editorialist, says he'd be more convinced if the placebo patients had received infusions of white blood cells that had been exposed just to the general immune-stimulating part of the Provenge treatment, without the prostate antigen part.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In a broad overview comment, it\u2019s sufficient for the story to have stated \"men with prostate cancer that no longer responds to hormone therapy (basically, chemical castration) lived about four months longer if they took Provenge than if they got placebo treatment.\"", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was a tricky one. The story certainly reflects the strong belief of two patients who were treated with eBx that their skin cancers were banished. \u00a0And it gives ample space to representatives of two companies that manufacture the radiation device, one of whom describes the treatment as a \u201cpainless alternative\u201d (a claim not supported by evidence in the story). The text also discusses findings from studies of older radiation techniques, but it rightly notes that these are not necessarily valid for judging the success rate of eBx. The story makes clear that skin cancer recurrences can take four or more years to appear, while the median follow-up time in studies of eBx to date can be measured in months.\nThe tiebreaker here for us is the headline and accompanying photos. Added to the anecdote-heavy text, these elements that radiate \u201cbenefits\u201d throw the story out of balance. We acknowledge that the reporter on this story may not have had any control over those elements.", "answer": 0}, {"article": "The F.D.A.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nMr. Girgus, 65, who also owns Dendreon stock, said patients like himself were \"looking into the abyss.\"\nBut Mitchell H. Gold, the company\u2019s chief executive, told analysts in a conference call that the outcome was \"unambiguous\" and met the goals the company and the F.D.A.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The drug maker\u2019s chief executive is quoted saying the results were \"an unambiguous hit on the primary endpoint of overall survival.\" It paraphrases his saying the outcome met the goals the FDA had previously set for the drug. \nThe story additionally paraphrases the chief executive verifying that the drug \"would have had to reduce the risk of death by 22 percent compared to a placebo\" to meet FDA requirements.\nThe chief executive is parsing his language very carefully, skillfully avoiding making an explicit claim about the drug\u2019s proven benefits.\u00a0\u00a0 \nRather than stating that the chief executive would not plainly describe the results, the reporter enables his evasion by connecting the dots between what the FDA said must be shown with the chief executive\u2019s assurances that it had been.\u00a0 \nFor context, see \"Relies on Press Release,\" below. ", "answer": 0}, {"article": "ET.\nTo minimize expectancy effects, the participants and the staff members supervising the sessions were told that the participants would receive psilocybin on both sessions, but they did not know that all participants would receive one high and one low dose.\nThe researchers assessed each participant's mood, attitude about life, behaviors and spirituality with questionnaires and structured interviews before the first session, seven hours after taking the psilocybin, five weeks after each session and six months after the second session.\nSix months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\n\"The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,\" says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tricky one. The release does tell us what percentage of patients benefited from psilocybin treatment, but does not explicitly quantify the extent of those benefits \u2014 which is what this category is designed to address.\nHowever, the release does address benefits in a meaningful way. Here\u2019s how: First, the release makes clear that all of the study participants had received a formal psychiatric diagnosis. That tells us that they were suffering from symptoms of clinical anxiety or depression. Second, the release states that six months after the treatment \u201cabout 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\u201d That language telling us that about 60 percent were in the normal range is important, because it means they were no longer exhibiting clinical anxiety or depression \u2014 and that is sufficiently meaningful to earn the release a satisfactory rating here.\nThe release would have been better if it had been more clear that this was a cross-over study so all participants received both the low-dose (placebo) and the full therapeutic dose in either the first or second treatment session. In addition, no comparison is given between the low-dose and high-dose therapeutic effects. Instead, the release describes benefits five weeks and six months after the second session, after all participants had received the strong dose.", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\nBy the third week, he said, both he and friends he asked for reactions were seeing results.\nThe company initiated a Phase 1 clinical study in August to determine whether bimatoprost can be used as a treatment in men and women suffering from hair loss (alopecia).\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify any of the benefits of Latisse or the other hair loss products.", "answer": 0}, {"article": "In its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nHe was not involved in the research.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study was not designed to compare CT with dog-sniffing, yet the researcher is allowed to say that the dog-sniffing \u201ceven surpasses the combination of chest computed tomography (CT) scan and bronchoscopy.\u201d", "answer": 0}, {"article": "When dentists administer lidocaine or another local anesthetic, they usually combine it with another drug called epinephrine, which acts to constrict the blood vessels.\nIn the clinical trials there were no serious side effects, Novalar said.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\n\u201cIt is reversing the epinephrine.\u201d\n\nThe label for the hypertension drug phentolamine contains warnings about heart attacks and occlusion of blood flow to the brain.\nIs a drug really needed for what seems like a trivial use?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a good job describing the clinical trials and the results.\u00a0 Kudos for including both relative and absolute differences. ", "answer": 1}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like a story in Reuters on the same study, this story uses the same dramatic relative reduction figure, but, unlike the Reuters story, it also provides the hard numbers. It says, \u201cDuring the entire 12 weeks, three of the patients taking dupilumab experienced a worsening of asthma compared with 23 on the placebo, a relative reduction of 87 percent.\u201d It also disclosed that there were 104 patients in the study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentioned that the study \"provided strong evidence that taking just one multivitamin a day did not cause harm.\", which could be considered a benefit of treatment.", "answer": 1}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nAfter five months, infants in the families in the video therapy group showed improvements in attention, engagement and social behavior, according to the study published Jan. 22 in The Lancet Psychiatry.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\nThe research involved 54 families of babies who were at increased risk for autism because they had an older sibling with the condition.\nSome of the families were assigned to a therapy program in which a therapist used video feedback to help parents understand and respond to their infant's individual communication style.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offered just one sentence describing the benefits of the study, but it included no quantification: \u201cAfter five months, infants in the families in the video therapy group showed improvements in attention, social engagement and social behavior, according to the study published Jan. 22 in The Lancet Psychiatry.\u201d\u00a0 How big were these improvements?\u00a0 How significant were they?", "answer": 0}, {"article": "Two had both inflammation and a malignancy.\nBut even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\nResearchers found 21 of the 27 participants had no or mild inflammation, but 15 had biopsy-confirmed malignancies.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The journal article that\u2019s the basis for the release provided quantitative data about the percentage of reduction of gum disease and PSA levels, as well as reports of reduced symptoms. The release, however, sticks to generalities, noting \u201creduced symptoms,\u201d quoting the principal investigator about \u201cimproved\u201d symptoms of prostatitis in those treated for gum diseases, and noting \u201csignificant improvement\u201d for those with the \u201chighest level\u201d of inflammation. The release includes no quantification.\nIn addition, the release mentions that PSA levels dropped in 21 of the 27 men who received periodontal treatment, but this is a misleading claim. A closer look at the study data shows that the reductions in PSA levels were not statistically significant. And\u00a0in the participants who had low levels of inflammation at baseline, the mean PSA level actually went up.", "answer": 0}, {"article": "They might be more health conscious or conscientious, or have other traits associated with longevity.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nSome experts in cancer screening and statistics said its novel approach was \u201con shaky ground\u201d and used a \u201ccompletely unverifiable\u201d methodology that they had \u201cnever seen before,\u201d but others praised its \u201cintriguing and innovative approach.\u201d There was one area of agreement, however: \u201cI imagine it\u2019s going to generate some buzz,\u201d said biostatistician Ted Karrison of the University of Chicago.\nThe new study lands amid another shift in how experts view PSA screening, which measures blood levels of a molecule sometimes associated with prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is good depth here discussing the benefits. Early in the story it indicates that \u201cfor a man in the U.S., the risk of dying of prostate cancer is about 2.5 percent. A mortality reduction of 30 percent would lower the death rate to 1.75 percent.\u201d \u00a0Later this is described in relative terms, saying that more frequent PSA screening \u201cmoved some prostate cancers from too-advanced-to-treat to treatable, reducing prostate cancer mortality by 27 percent to 32 percent over 11 years.\u201d", "answer": 1}, {"article": "ZURICH (Reuters) - Roche\u2019s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients\u2019 survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is essentially a data-free story, as noted above. How long does this drug cocktail help patients live compared to the other treatment groups? This critical question goes unanswered.", "answer": 0}, {"article": "\"Your eyes look like they're responding beautifully!\"\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nBefore the surgery, Manuela's pupil gave no response to or recognition of light.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\nBut the most dramatic result brought Manuela one step closer to her dream of reading.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This piece tugged at one\u2019s heart strings by presenting a young blind woman who could talk about her perceived visual improvement. Notwithstanding her experience, the story failed to communicate that not every patient in this small study showed even the small improvement of the woman featured in the story. \u00a0The study this story was built on reported that there was no clinically significant change in visual acuity \u2013 something this story didn\u2019t make clear at all.\u00a0 ", "answer": 0}, {"article": "WASHINGTON \u2014 Breaking a sweat?\nBut eventually with additional research, Rogers envisions more sophisticated use of such devices, such as real-time monitoring of how the body adjusts during military training, or even to screen people for diseases such as diabetes or cystic fibrosis.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nRogers, who did much of the research while at the University of Illinois at Urbana-Champaign, has long worked to develop electronic devices that can stretch and twist with the body.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t give quantified benefits because there aren\u2019t any\u2013and it should have made that point much stronger versus expanding on speculative uses for the device. We\u2019re told a study \u201cfound it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\u201d\u00a0 So what does that mean in clinical terms? Nothing yet. The purpose of the study was to show that the patch would stick and collect good data, not to show that it generates a health benefit.\nThe story also allowed speculation of benefits beyond electrolyte monitoring, too:\n(Researcher John A.) Rogers envisions more sophisticated use of such devices, such as real-time monitoring of how the body adjusts during military training, or even to screen people for diseases such as diabetes or cystic fibrosis.", "answer": 0}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nHowever, to make it applicable to prostate cancer a special probe had to be developed by the team.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\nThe new method aims to get round the problems by targeting the prostate with ultrasound.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lists the supposed benefits of this new approach, compared to existing methods used for detection and delineating prostate cancer.\u00a0 A source is quoted as saying, \u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\nBut the story offers no data or information that would quantify the supposed improvements over existing screening mechanisms.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits could have been stronger. The article states that researchers have found a way to identify the presence of a protein that indicates pancreatic cancer \u201cwith perfect accuracy and no false positives.\u201d That\u2019s technically true in this study, but it\u2019s only part of the story. As the story notes, the main benefit of the test would be its ability to detect cancer at an early, treatable stage. But the study included only 5 patients with such early stage cancers \u2014 something the story didn\u2019t explicitly tell us. While experts quoted in the article urge caution in reading too much into a small study, the claim of \u201cperfect accuracy,\u201d based on such a tiny sample, deserved a more aggressive and immediate challenge. It isn\u2019t until the very end of the story that any caveats are introduced. In addition, while patients who are able to undergo early treatment might be cured of the disease, the NCI cancer summary points out that the 5-year survival rate for patients who underwent complete resection for small tumors that were confined to the pancreas (the target for screening) was still only 18 to 24%. So, patients may still face long odds even when their tumors are caught early \u2014 context the story could have provided.", "answer": 0}, {"article": "He also keeps his blood pressure down by exercising and paying attention to his weight and diet.\nIts goal is to let people know that there is a link between high blood pressure, stroke and dementia.\nThe evidence is clearest for a type of dementia called vascular dementia.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nAnd he says other people with high blood pressure should follow his lead.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes several references to \u201cgreatly magnified\u201d and an \u201cincrease\u201d in risk of AD or vascular dementia among those with high blood pressure that goes untreated, but there are no solid data offered to support the claim, nor how treating blood pressure reduces that risk (and to what extent).", "answer": 0}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a major weakness of the news release. Both the headline and the accompanying text strongly suggest that ibuprofen can \u201cprevent\u201d or \u201cward off\u201d Alzheimer\u2019s disease. However, no data are included to support this.\nThe news release suggests that the way to diagnose AD early is by looking for elevated levels of Abeta42 in the saliva, thereby allowing early treatment with ibuprofen. However, no data on the accuracy of this screening method is included.", "answer": 0}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided information from a single study showing a dose response to the medications.\u00a0 This was a large study (750 patients).\u00a0 While providing information about the drug's effect on pain, the reader is not left with sufficient information about whether this amount of pain reduction was sufficient to change the quality of life for the patients studied. In addition, the story did not provide information about the length of time patients took the medication in order to obtain the benefit that was described.", "answer": 0}, {"article": "SOURCE: bit.ly/hBua85 Menopause: The Journal of The North American Menopause Society, online March 3, 2011.\nWomen typically suffer between 30 and 150 hot flashes a month, said Dr. Rafael Bolanos-Diaz, professor of health economics at San Marcos University in Lima, Peru, who co-authored the study.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained that \u201cwomen who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month.\u201d", "answer": 1}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nI didn\u2019t expect it to look like this.\u201d\n\nBut not everyone considers ataluren to be a miracle drug\u2014with good reason.\nTo Betty, the benefits are clear, even if they aren\u2019t easily quantified.\nAn approval is the FDA saying, \u201cthis drug is safe and effective.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Most of the \u201cbenefit\u201d information in this story is provided by the mother of the three boys with Duchenne muscular dystrophy, who reflects in detail on a level of activity among her sons that she feels demonstrates the drug\u2019s effectiveness. The reporter reflects briefly on clinical trial results that offered \u201csome slight positive results,\u201d but we never learn what those are.", "answer": 0}, {"article": "But most of the success so far has been with blood cancers like lymphomas and leukemias.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nBadie says it\u2019s not obvious why, but his analysis showed that these tumors did not contain much of the protein targeted by the CAR T cells that were injected.\nIt\u2019s also becoming clear that more than one type of modified immune cells may have to be enlisted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fairly describes the patient\u2019s course before and after the experimental treatment, and cites some data about the short life expectancy of patients with his type of brain cancer (glioblastoma). It could have done a much better job, however, of quantifying what actually occurred or is happening now in\u00a0the other eight people undergoing the same therapy at City of Hope, and of defining specifically what it means to say the patient in the story had his tumor \u201cunder control\u201d for \u201calmost\u201d eight months.", "answer": 0}, {"article": "\"Unfortunately, that is not the case.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nTypically, these \"fiducial markers\" are attached by an elastic headband and double-backed tape and are subject to jarring and slipping.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nThey determined that the cap outperformed the headband by 76 percent when the forces were applied to the headband and by 92 percent when they were applied to the markers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says that researchers \u201cdesigned three tests to determine how well this \u2018granular jamming cap\u2019 performed relative to the current headband in reducing targeting error:\nBut the release doesn\u2019t say how often these errors occur using the current headband method, so it\u2019s impossible to know whether this is an improvement that would amount to a significant advance.\nAlso, the news release does not explain how these tests translate to something meaningful for patients, such as fewer surgical errors, shorter procedure times, greater safety, or lower costs.\nIt does state that in about one operation out of seven, the target error is so large that the surgeon is forced to \u201credo the registration process,\u201d which orients the markers. But what that means is unclear. Does that prolong surgery to a significant extent? Does it result in greater risk or higher costs? The news release doesn\u2019t say.\nThe gold standard for fiducial (or placement) markers is the use of anchors for attachment to rigid structures such as the skull. This approach is routinely used in proton beam therapy, for example, where precise location and targeting is necessary. The coffee ground cap was not tested against the anchored\u00a0placement method but with what is recognized as a painless but flawed method.", "answer": 0}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nThe smaller studies in the analysis ranged in size from 36 to 484 patients, and most of them followed patients for as long as six to 12 months after surgery.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nOne limitation of the current analysis is that many of these smaller studies were not controlled experiments designed to prove whether or how transcatheter aortic valve replacement might improve quality of life, lead study author Nicola Straiton of the University of Sydney and colleagues note in Age and Ageing.\nAfterward, patients could walk significantly further in six-minute walking tests used to assess their functional capacity.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While it can be difficult to report on a complex synthesis of data, more numbers were needed to give readers a sense of the scale of improvements patients experienced.\nThe story says after patients \u201ccould walk significantly further in six-minute walking tests used to assess their functional capacity. On average, they added almost 42 meters (138 feet) to their performance before\u201d the procedure. But, according to the study appendix, this 6-minute walk statistic was based on only 4 studies and, more importantly, was not considered a clinically important difference.\nThe story also also says patients \u201creported clinically meaningful improvements in their quality of life and their ability to complete daily tasks after surgery.\u201d But there is no data to explain how that was measured.", "answer": 0}, {"article": "Researchers from the University of Pittsburgh Medical Center and Rutgers University studied 408 males from adolescence to their mid-30s.\nBechtold said the researchers wanted to \"help inform the debate about legalization of marijuana\" but that this is a very complicated issue and one, study, including his own, should not be taken in isolation and should be viewed in context of other studies on teenagers' marijuana use.\nHere's the scientific proof.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThe early chronic users smoked a great deal -- a peak of more than 200 days per year on average when they were 22 years old.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story is about research examining harms we think that a brief line or two\u00a0about the reasons for marijuana use would have been informative. \u00a0Especially when the author is allowed to say that he wanted to \u201chelp inform the debate about legalization of marijuana.\u201d \u00a0Debates involve tradeoffs of benefits and harms and we heard only one side of it in this story (and incompletely at that).", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- In women who have had breast cancer, annual mammograms help detect second breast cancers, but they're not as effective in women who have never had the disease, new research suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "By quantifying the benefits of screening mammography for women with a personal history of breast cancer in absolute numbers, the story presents this information accurately and in a useful, understandable way for women with breast cancer.", "answer": 1}, {"article": "Oxidative stress refers to a situation where levels of reactive oxygen species or \u201cfree radicals\u201d \u2014 damaging byproducts of energy use in cells \u2014 rise beyond the body\u2019s capacity to neutralize them.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\n\u201cIn our study the effect of yoga on BMI (body mass index) and blood sugar control was marginal,\u201d Hegde, the lead researcher on the work, told Reuters Health in an email.\nAmong the 60 study participants who took yoga classes several times a week, the average BMI \u2014 a measure of weight in relation to height \u2014 declined from 25.9 to 25.4.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided much discussion about the impact of the yoga on levels of \u2018oxidative stress\u2019. \u00a0Besides the fact that the link between oxidative stress and disease is tenuous at best, the story reported that those in the yoga group had a 20% reduction in oxidative stress when the study results showed that they had a 20% reduction in one marker of oxidative stress but at the same time showed reductions in two pathways form managing oxidative stress \u2013 which could be interpreted as increasing their risk from oxidative stress. Even the weight loss was not really quantified (the writer mentioned \u201ca handful of pounds\u201d lost).", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "About 3.3 million people are allergic to peanuts or tree nuts.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report includes sufficient detail about the studies\u2019 methodology and outcomes to help readers [eventually] understand the small numbers of children involved and the basic findings. \nThe story states that \"most\" of the 33 patients in the first test appeared to have improved resistance to peanut allergens, that 5 could tolerate peanuts without reaction, and that 4 had to withdraw because they could not tolerate the treatment.\u00a0\nThe story reports that the second test split the 18 subjects into treatment and placebo groups, and described approximate outcomes for each group.\u00a0 ", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\n\"\n\nA microchip to help someone see may sound more like a \"Star Trek\" device than legitimate science, but it is real.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nIn 2002, the first-generation artificial retina had only 16 electrodes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When a news organization decides to report on early Phase I research in 14 patients so far, it runs the risk of implying that benefts exist when, indeed, they have not yet been proven. \nThere are numerous studies of various artificial retina devices dating back at least 15 years, including those published by this device maker. A diligent story would have at least discussed those results to provide context.\u00a0 ", "answer": 2}, {"article": "TUHS neither provides nor controls the provision of health care.\nCompared with untreated animals, tau mice that had received zileuton performed significantly better on the tests.\nMicroscopic examination revealed vast differences in synaptic integrity between the groups of mice.\nTheir superior performance suggested a successful reversal of memory deficiency.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is light on data describing how much better at maze navigation the treated mice were compared to non-treated mice. \u00a0\u201c\u2026\u00a0significantly better on the tests\u2026\u201d and \u201c\u2026superior performance do not provide an adequate quantification of the test results. There is also a tacit and unfounded assumption that the reductions in leukotrienes and in tau are sustainable during prolonged treatment.", "answer": 0}, {"article": "About 29 million people in the United States have diabetes, according to the Centers for Disease Control and Prevention.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\nBut such evidence often does not pan out in human studies.\nBut the guidelines do recommend metformin first.\u201d\n\nFor patients with Type 2 whose doctor started them on a drug other than metformin, he said, \u201cI certainly would encourage people to talk with their doctor.\nBut Price, a science and medical reporter in Oakland, Calif., doesn\u2019t have Type 2 diabetes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The Not Satisfactory rating here stems in part from the prominent personal narrative that begins the story. In it, an individual begins taking metformin to help control her type 1 diabetes and reports a variety of positive outcomes, including becoming pregnant! This anecdote is far more vivid than the summaries of\u00a0studies that follow, and it is likely to color the reader\u2019s perception of the drug\u2019s benefits. The story also suggests high up that there are a litany of potential health benefits observed in studies \u2014 for example, \u201cthose who take metformin tend to have lower rates of cancer, heart disease and dementia, and to live longer overall than those who take other drugs for diabetes.\u201d Only\u00a0later does it proceed to highlight that overall, the evidence so far does not support any of the claims made in the article\u2019s title or the first few paragraphs. This framing, which front loads discussion of benefits and saves caveats and cautions for later, is unbalanced.", "answer": 0}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nSwaminath pointed out that even the new study found that \"low- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\"\nNow, researchers say a special scoring system might point to those people at highest risk for colon cancer, who may need the test the most.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a study that credits colonoscopy with reducing the risk of death from colon cancer by about 50 percent, by removing polyps. It would have been helpful for the story to explain what that relative reduction in risk means in absolute terms (e.g. did the rate of cancer death go from 50% to 25% or from 2% to around 1%?)\nThe story also notes that the study found that patients with a low to intermediate risk score \u201cstill have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\u201d\nWe\u2019ll give credit here for the story\u2019s provision of these key statistics, which do give a sense as how well the test accurately identifies truly low-risk individuals. However, we\u2019d note that the benefit here should ideally refer to the\u00a0ability of the algorithm to classify people at all risk levels (including high-risk), and therefore target the highest-risk patients for colonoscopy. The story doesn\u2019t really get into discussion of the predictive power of the test, referred to as a likelihood ratio, which is in the study manuscript. However, this is a difficult concept for most health care providers and patients, and we think it\u2019s understandable that the story did not include a full discussion of this topic.", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story uses only relative risk reductions to describe the impact of vegetarian diets, which provides readers with an exaggerated sense of the overall size of the benefit.\nLet\u2019s look at what is said in the story: \u201c\u2026researchers from Loma Linda University found that vegetarians were 22% less likely than meat-eaters to be diagnosed with colon cancer or rectal cancer.\u201d But here are the absolute numbers from the published article: During the 7.3 year follow up period, a total of 252 cases of colorectal cancer were identified in the 40,367 vegetarians studied (62.4 cases per 10,000) and 238 cases in the 37,292 non-vegetarians studied (63.8 cases per 10,000). That is a difference of 1.4 cases per 10,000 subjects. The relative reduction in risk does not play out to be very large in absolute numbers.\nAnd again the story says: \u201cLacto-ovo vegetarians (who eat eggs and dairy foods but not fish or other meats) came in second, with an 18% reduced incidence of colorectal cancer. They were followed closely by vegans (who don\u2019t eat eggs, dairy products or any kind of meat), who were 16% less likely to get a colorectal cancer diagnosis.\u201d But when we look at the actual study, we find that the confidence interval in both of these cases crosses 1, which means that the findings are not statistically significant (and would certainly be very small in absolute terms).\nWhen rolled up together, there does appear to be a slightly smaller risk of colorectal cancer associated with a vegetarian diet compared with a non-vegetarian one.\u00a0 Having said that, when you drill down into the different sub-diets, only the pesco-vegetarian diet was statistically significant on its own.\u00a0 None of the other diets are associated with a reduce risk of either colon or rectal cancer. Compared with the relative risks touted in the story, the absolute numbers derived from the study provide a somewhat different and less enthusiastic picture of the benefits.", "answer": 0}, {"article": "Get the facts.\nEven more frustrating about this vaccine is that it\u2019s being fought by an unusual group of people; while most anti-vax leanings are not affiliated with any particular political persuasion, Gardasil gets attacked additionally by conservatives who think that girls getting it will become more promiscuous, because HPV is a sexually transmitted disease.\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on safety to the exclusion of efficacy. It does not say which strains of HPV Gardasil protects against or how effective it is.at preventing the cancers those strains cause. It does not tell the reader that the more recently formulated vaccine, Gardasil 9, has expanded the protection conferred by the earlier version.", "answer": 0}, {"article": "Visit the American Heart Association for more on statins.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nPotluri cautioned, however, that this study can't prove that statins actually extended life in cancer patients.\nWhile it did not prove a cause-and-effect connection, the study of nearly 1 million cancer patients found that those taking statin drugs such as Lipitor and Crestor appeared to have:\n\u2022 and a 30 percent lower risk of dying from colon cancer.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states several times that there is no clinical benefit known, but only a correlation between people taking the medications and lowered incidence of certain cancers. Of course, based on the actual release, this is wrongly stated. The correlation is between high cholesterol levels and a lowered incidence of certain cancers.\nAlso, importantly, we\u2019re only given relative risk numbers here, not absolute risks, and that should have been explained. Also, we\u2019re told the \u201cstatin\u201d group lived longer overall, but that doesn\u2019t mean much without numbers.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nSiliq\u2019s safety and efficacy were established in three randomized, placebo-controlled clinical trials with a total of 4,373 adult participants with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not give any numbers to describe the magnitude of benefit shown in the three clinical trials. All we know is that \u201cmore patients treated with Siliq compared to placebo had skin that was clear or almost clear.\u201d But how many more patients and by how much? And how was this exactly assessed? The news release vaguely mentions a scoring system that looked at the \u201cextent, nature and severity of psoriatic changes of the skin\u201d without elaborating any further.\nIn a 2016 FDA briefing document online, there is some data related to the drug\u2019s effectiveness, but the number of analyzed subjects falls short of the total 4,373 trial participants cited in the news release.\nWithout any numbers describing the benefit, we have no idea how effective Siliq really is, which is why we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": ".\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\nIn their study, Lee and colleagues used both in vitro human models and in vivo rat models.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0briefly notes two findings: that human stem cells in petri dishes, prodded by proteins that promote inflammation, expressed genes involved in regulating inflammation, and that inflamed rat tendons exposed to stem cells demonstrated improvement.\u00a0 But without further study details, we have little idea of what to make of these results.", "answer": 0}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\nAnd he expects that at some point all dentists will follow a preventive protocol.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story includes links to some studies that report specific results, the only number reported in the story is a reduction in adult tooth fillings of 30 to 50 percent. But without any absolute numbers, this number isn\u2019t useful. Is it a cavity a year? A cavity a decade? The story refers to people at \u201chigh risk\u201d for cavities, but does not define what that term means. Without some anchoring in absolute numbers, all readers are left with is a vague sense that preventive treatment is \u201cbetter\u201d for some people, without pinning down how much better or for whom.", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nAccordingly, the 28-day \u201chealing\u201d diet he suggests consists almost entirely of natural, unprocessed foods, especially lean protein foods like light-meat poultry, fish, egg whites and low-fat dairy, beans (combined with whole grains), and nonacidic vegetables and fruits.\nDr. Aviv points out that many commercially produced foods and drinks are treated with acid-containing substances to enhance flavor and shelf life.\nA food does not have to be obviously acidic to be troublesome.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about a suite of lifestyle changes, from losing weight to quitting smoking to altering one\u2019s diet. However, the story does not make clear to what extent any of those things reduce the symptoms of acid reflux or GERD, as measured by clinical studies.\u00a0 And there\u2019s a lot of research out there on this subject. For example, this 2006 paper in JAMA Internal Medicine looks at 100 earlier studies related to lifestyle changes and GERD. The story also pays particular attention to the approach laid out in a book titled The Acid Watcher Diet, but offers no information about how effective the book\u2019s guidance may be in ameliorating symptoms or addressing underlying causes.", "answer": 0}, {"article": "Dextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nThen the researchers re-randomized those who did not respond to placebo to receive either drugs or placebo, and found similar encouraging results for the drug combination.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes an attempt to quantify the findings: \u201cAggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo,\u201d so we\u2019ll give the benefit of the doubt on the rating. But we think the story could have provided a lot more context. Is this a 10-point scale? What does this change represent in terms that would mean something to patients and caregivers? \u00a0The accompanying editorial provides some of the needed explanation when it notes that \u201ca minimum clinically important difference (MCID) has not been established\u201d for this scale and that \u201cThe apparently modest numerical benefit, as evidenced by the approximately 1.5-point between-group difference for the primary outcome measure, is therefore difficult to interpret.\u201d \u00a0The editorial also notes that there was no improvement in the quality of life measurement during the 10-week trial.\nAnother concern is the story\u2019s description of benefits from the study\u2019s lead author. He says\u00a0\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation.\u201d \u00a0Although this is accurate and the drug\u2019s benefits were significantly different from placebo, the placebo group also improved significantly. The story could have noted that there\u2019s a strong placebo effect happening here that accounts for some of the benefits.", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAhlquist called the 85% figure ''very high\" and adds: \"It would be very hard to find a noninvasive approach that could get that range.\"\n''One in every 17 of us will have colon cancer in our lifetime,\" says David Ahlquist, MD, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn., who presented his findings on the new colon cancer screening test.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave the same basic benefits data that the other stories gave, but it, too, didn\u2019t compare this data with any of the existing colon cancer screening methods, leaving readers with no good sense of the potential scope of the benefits suggested. There was only one vague reference to the new approach being able to find tumors on both sides of the colon, \u201ca feat that is not always accomplished by colonoscopy.\u201d", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThat hope is evident to other researchers, such as Dr. Ithaar Derweesh, a urologic oncologist and associate professor of surgery at the University of California San Diego Moores Cancer Center.\nWhile Derweesh agreed with Rosenstein that such a technique will take time to validate, and be used to steer patients toward a particular therapy -- something he called the \"holy grail\" -- he suggested that in the nearer term, such markers might be used as a trigger to pre-emptively begin erectile rehabilitation or to take measures that might lessen the potential damage.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nWhile some risk factors are well-known -- including age, diabetes and poor cardiovascular health -- whether a man suffers harsh side-effects is often chalked up to random luck.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Despite the headline that states that \u201cDNA markers may predict impotence after prostate cancer,\u201d the story correctly indicates that any benefit from the work is speculative; even if these markers are confirmed to be valid, there are currently no available treatments to target the genetic abnormalities. \u00a0However, another underlying issue, which was not addressed, is whether radiation treatment benefited men in terms of cancer control.", "answer": 0}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nThe study was presented in Chicago at the annual meeting of the North American Menopause Society (NAMS).\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "\"None of us had any indications,\" David said.\n\"Knowing how well the patients did in spite having a very high cardiovascular-risk burden opens up the door to thinking differently about how we might manage those patients.\nBut one Cleveland Clinic patient epitomizes a difference between CTAs and stress tests \u2014 and he does so just by being alive.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is an example of a story thrown off course by a single misleading anecdote.\nDiscussion of benefits is quite reasonable for 90% of the story, and we noted that the report offers specific information on the incidence of heart attacks or complications\u20143%\u2014in the course of making the point that the incidence does not differ between patients undergoing stress tests versus CTA. The story also notes that\u00a0CTAs \u201cresult in fewer instances of patients with suspected heart issues undergoing unneeded catheterization procedures.\u201d\u00a0That\u2019s all very well and good.\nBut at the very end, we learn of one patient who underwent CTA even though his stress test was normal, and whose life was apparently saved as a result. The man convinces his two brothers to get CTAs, which apparently reveal blockages that they were unaware of. \u00a0\u201cJust because I had a CTA, that had a domino effect to my brothers getting it, and it very well saved all three of our lives,\u201d the man says.\nUnless this man can predict the future, how could he possibly know that getting a CTA saved his life or those of his brothers? These men may have had blockages, but it\u2019s not at all clear that these blockages would have resulted in fatal heart attacks. In fact, a major concern with CTA is that it may reveal blockages that would never cause a serious problem, leading to unnecessary procedures. The point of the study is that there was no difference at all in the incidence of serious cardiac complications between those who undergo stress tests and those who get CTA.\nUnfortunately, that careful science-based message is badly undercut by the story\u2019s failure to push back against this anecdotal crystal ball-gazing. It\u2019s likely that any readers who make it to the end of this story will conclude that it\u2019s best to get a CTA, just in case.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\nIn a trial of 436 patients with the disease, 16 percent of participants who received Imlygic saw their tumors shrink for at least six months, compared with just 2 percent of those who received an older immune-boosting drug.\nIn one small study of 19 advanced melanoma patients treated with both Imlygic and a checkpoint inhibitor called Yervoy, nearly half of the patients responded.\nIt\u2019s being developed in combination with other immunotherapies, where we think there\u2019s a little more of a commercial opportunity, but we still need to see more data.\u201d\n\nImlygic is approved for skin tumors that are inoperable in patients whose cancer has returned following surgery.\nAmong those whose cancer had spread locally but not to internal organs, the response rate was better \u2014 33 percent.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicates that the treatment caused some tumors to shrink for at least 6 months, particularly in those\u00a0whose cancer had not yet spread to internal organs. But the overall discussion of benefits is lacking some important details. What does \u201cshrink\u201d mean? And when it says that 16% \u201cresponded,\u201d what exactly does that mean? (Of course, 84% did not respond \u2014 a statistic that was also worthy of comment in our view.) Finally, important outcomes, such as length of survival, are not presented or compared with alternatives. One study reported that median survival was 23.3 months with the new drug vs.\u00a018.9 months with the comparison treatment \u2014 a finding that would have been easy to include. The FDA cautioned in a news release that \u201cImlygic has not been shown to improve overall survival.\u201d", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\n\"More testing is not always more intelligent testing.\"\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story fails to quantify the benefits or risks of screening. ", "answer": 0}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research under consideration here involved 10 mice \u2014 and genetically bred mice at that \u2014 there\u2019s no way to determine whether increasing omega 3s in a woman\u2019s diet would have any benefit at all, let alone to quantify the likely benefits.\nThe story does explain that the mice bred to have higher ratios of omega 3 fatty acids seemed to produce more \u201cprecursors to egg cells\u201d and also produced higher quality eggs, meaning they would be more likely to have eggs that would be fertilized and develop into baby mice.\nThe bottom line, however, is that a woman reading this story and hoping to improve her fertility would find no information that would help her assess how much of an increase in omega 3s she might need, nor how much of an improvement in fertility this dietary change might produce.", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\nThree of the PSAPs were associated with improvements in speech understanding that were similar to results obtained with the hearing aid; one demonstrated little improvement; and speech understanding was worse with one PSAP.\nA comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release didn\u2019t dive into the PSAP versus hearing aid benefit numbers and this was a missed opportunity. According to the full study, hearing aids alone improved speech recognition by 12 percent. Meanwhile, the three most expensive PSAPs (all more than $300) improved speech recognition by at least 10 percent. It would also have been helpful to point out that the least expensive PSAP ($30) actually worsened speech recognition by 11 percent.", "answer": 0}, {"article": "\u201cI\u2019m amazed,\u201d she said.\nAs of March of this year, eight patients had no evidence of the tumors growing any more and two had no evidence of a brain tumor at all.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\nBut the 21 percent or so of patients helped by the vaccine all survived at least three years.\nIt\u2019s a hopeful enough finding to move forward and test the vaccine in more people, the team at the Duke University School of Medicine said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did give numbers, reporting that \u201c21% or so of patients helped by the vaccine all survived at least three years,\u201d while 4% of patients in the the historic control group were alive after three years. But in a small study, why not give readers the absolute numbers: how many out of how many? \u00a0Why make them do the math in their heads?\nSome of data were incomplete. For example, the story said of the 61 treated, \u201ceight patients had no evidence of the tumors growing any more and two had no evidence of a brain tumor at all,\u201d without indicating how much time had passed since those patients were diagnosed and treated.", "answer": 1}, {"article": ".\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nIn their study, funded by the Italian Ministry of Health, the investigators recruited three men and 11 women, ages 22 to 65, with obesity as shown by a body mass index (BMI) of 30 to 45 kg/m2.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the least straightforward ways to present research results is by stating changes in percentages rather than absolute differences between groups \u2014 and this release does exactly that. The release states, \u201cAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat \u2014 significantly more than controls did.\u201d And yet, the release doesn\u2019t report actual body weight or body fat data, leaving readers out in the cold as to what a 3 or 4% change in weight or fat loss really means. This is unintentionally misleading for people trying to assess the value of the treatment.\nCurrent guidelines for treating obesity recommend a 5 to 10 percent weight loss within one year for benefits to be clinically meaningful, and it\u2019s uncertain if participants would achieve this goal, given the short time frame of the study. Neither the release or the abstract it\u2019s based on addressed whether volunteers in the sham group (those who didn\u2019t receive dTMS therapy) also lose weight or fat mass. Without this comparison, it\u2019s difficult to understand the impact of dTMS itself or if the placebo effect played a role in these results.", "answer": 0}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some quantification of benefits of the device but leaves many questions unanswered. The story states that 80% of the patients experienced at least a 50% improvement in symptoms with the device. Compared to how many with conventional treatment? What does an \"improvement\" mean? In what symptoms? How was improvement measured?", "answer": 0}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nFor the eating out scenario, the average time good blood sugar control was increased was 28 percent on average.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nAn analysis of pooled data showed that the overall time that plasma glucose levels were in target \"increased by a median 28 percent\" with the artificial pancreas, said the study's lead author Roman Hovorka, a principal research associate at the University of Cambridge in the United Kingdom.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All benefits are presented in relative terms, which is misleading to readers. For example, the third sentence says, \u201cResearchers found that people who took statin medications had about a 16% reduced risk of renal failure and a 21% lower risk of dying after their surgeries, compared to people who weren\u2019t taking the drugs.\u201d What are the absolute numbers? Well, out of 67,941 people, 1,208 people suffered an acute kidney injury while not taking statins, and 1,039 suffered one while taking statins. That means 169 fewer people suffered an acute kidney injury, and this is making the big assumption that statins had anything to do with it.", "answer": 0}, {"article": "Among these adults, about 9 percent have resistant hypertension, which means that even taking three or more medications to control their blood pressure, it remains higher than 140/90 mmHg.\nThe procedure is safe as well as effective, the study authors said.\nThe findings were published Dec. 17 in the journal Circulation.\nSingh also noted that although this procedure is used in other countries it is not yet approved in the United States.\nAnother expert, however, said that scenario is likely overoptimistic.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately reports what the researchers reported about decline in systolic blood pressure.", "answer": 1}, {"article": "The most common side effects included upper respiratory tract infection, urinary tract infection, dizziness, drowsiness on waking, headache and vivid dreams.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\n\u201cForty milligrams looked like best dose on efficacy and tolerability,\u201d said David Michelson, Merck\u2019s vice president for neuroscience clinical research.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are 28 numbers in this 495-word story, not including the name of the drug. These numbers add up to very little. For one, there are a lot of comparisons of performance levels at different doses of drug. This seems to be aimed at scientists who may be working on similar drugs and are trying to come up with the perfect dose. Why would anyone else need this information? The absolute numbers are missing, as they often are, leaving us to wonder whether a 12.2% higher than placebo means much. Let\u2019s say you\u2019re an insomniac and you only sleep four hours a night. If you take this drug, you will have slept an extra\u00a029 minutes. At least that appears to be what this means. It\u2019s hard to say because of that odd caveat: \"larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment.\" When the second sentence in a story reads like that, you know you are in trouble.", "answer": 0}, {"article": "Psoriasis is an immune-mediated disease that causes itchy, dry and red skin.\nA significantly higher proportion of patients in the guselkumab group had a score of 0 (cleared psoriasis) or 1 (minimal psoriasis) in both the short and long term periods compared to the adalimumab and placebo groups.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nIn the multi-center trial, 293 adult patients with moderate-to-severe psoriasis (defined as covering 10 percent or more of the body) were randomly assigned to receive varying doses of one of the two drugs or a placebo over 52 weeks.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is fairly clear in this regard, reporting that 81 percent of patients taking a 200-milligram dose of guselkumab reported \u201cminimal\u201d or no psoriasis symptoms after 40 weeks of treatment, compared to 49 percent of patients taking adalimumab. The release doesn\u2019t note that patients taking 200-mg doses of\u00a0guselkumab did only slightly better than patients taking a 100-mg dose, and that the 100-mg dose fared slightly better at various points during the first 40 weeks of treatment. But that\u2019s a level of detail that perhaps we can\u2019t expect.\nThe release would have been better if it specifically noted that further study will be needed in order to find out if the observed benefits last longer than a year. The release also could have noted that the patients in this study were overwhelmingly white (91%) and male (71%), so it remains to be seen if a more diverse patient population would get similar benefits.", "answer": 1}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nOne year after migraine surgery, the patients had a very large percent improvement in average PSEQ score: on average, 112 percent higher than baseline.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\n\"The results also show that migraine surgery can lead to dramatic improvements in functioning and coping ability, even in patients who are very disabled before surgery.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits of this research is a bit cloudy, since it seemed to have two endpoints: first, the study attempted to quantify the extent of disability in migraine patients by using the\u00a0Pain Self-Efficacy Questionnaire (PSEQ). Second, it looked to see if PSEQ numbers improved following migraine surgery. The release says that the study found that after the migraine surgery, patients improved an average of 112% over their baseline PSEQ score. However, as we have pointed out on numerous occasions, these types of statistics often don\u2019t tell us much. We don\u2019t know if this means that migraine patients\u2019 self-efficacy went from \u201cbad\u201d to \u201cgreat,\u201d or just from \u201cterrible\u201d to \u201cless terrible.\u201d Did this improvement mean that patients were able to go back to work, or that they were able to get out of bed? Without concrete numbers, it is hard to tell.", "answer": 0}, {"article": "In 2008, a survey of more than 30,000 U.S. women in the journal Obstetrics & Gynecology found that nearly 40 percent reported that they'd had a sexual problem at some point in their lives, most often a lack of desire.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nShocked and not quite sure what to do, she turned to medical doctors, and found there wasn't much they could offer, as there's no prescription medicine like Viagra to help a woman when her sex life gets stuck.\n(CNN) -- Losing interest in sex would be unfortunate for most people, but for Linda Poelzl it was a professional hazard.\n\"But it took at least six weeks of almost daily practice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We can understand why this story was a bit short on data showing the benefits of these\u00a0treatments, since there really aren\u2019t\u00a0any. But that\u2019s no excuse to fill the void with\u00a0rosy anecdotes from patients and alternative medicine providers.\u00a0The story could have earned a satisfactory by seeking out a\u00a0skeptical perspective\u00a0and spending a bit more time on the\u00a0potential downsides of these approaches. Unfortunately, it didn\u2019t. \u00a0\u00a0", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nThe researchers conclude that \"these findings provide positive evidence for the benefits of physical activity in women attempting pregnancy, especially for walking among those with higher BMI.\nAmong a number of cautions the researchers point to in this work is that physical activity is related to other behaviors and lifestyle factors, and women who are more physically active may be different from women who are less active in many ways.\nFor the 1,214 women in the study, the association of walking with the ability to become pregnant, known as fecundability, varied significantly by body mass index, the authors report.\nThis is especially true for the results about walking for even limited blocks of time.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions two benefits of physical activity with regards to \u201cfecundability\u201d (the ability to become pregnant):\nSo the study put into context the amount of physical activity associated with an increase in fertility rates but it didn\u2019t tell us how much more likely vigorous walkers were to conceive compared to those who didn\u2019t walk, or those who walked only a little.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no mention of the size of the benefit observed.\nA STAT news story on this same trial noted that the study failed to meet its primary endpoint, which means the trial failed. As in many past Alzheimer\u2019s drug trials, the company found positive results only in a sub-group of patients. As we\u2019ve written previously, in larger subsequent studies, the drugs have all failed.", "answer": 0}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nMoreover, though resting energy expenditure varies with each individual, this increase would yield almost 1 lb.\nThe study showed that supplementing with this low dose of Capsimax increased metabolic rate which calculated to an equivalent to burning an extra 116 calories per day.\nThe MR Study was a placebo-controlled, crossover open label study with 40 healthy adults examining the effects of either 2 mg capsaicinoids from 100 mg of Capsimax or placebo on resting energy expenditure, heart rate and blood pressure.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that the supplement would increase a person\u2019s metabolic rate which would be equivalent to burning an additional 116 calories a day. The release further suggests that this could translate into 1 pound of fat loss monthly.\u00a0But it\u2019s important to note that as weight is lost, the metabolic rate decreases. What starts as 1 pound per month, regardless of the method used to lose weight, the metabolic rate would decrease with time and not remain linear. That should have been noted in the release.\nMore importantly, perhaps, the study lasted just two weeks. Participants received the active ingredient for one week and then crossed over to placebo. That\u2019s a very brief period of time from which to draw conclusions about benefit.", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nSome patients may require surgery to remove the uvula or the tonsils or excess tissue, or all of them, she says.\nThe apnea can probably be taken care of with these noninvasive techniques, she says, and invasive surgery can be avoided.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nThat meant Sheiner stopped breathing for at least 10 seconds about two times every minute.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag but we\u2019ll give the story the benefit of the doubt.\nIt said the CPAP \u201cworks for about half who try it\u201d \u2013 but we wish it had provided a source for that info.\nIt said surgery (apparently referring to non-robotic surgery) is effective only 20-30%\u00a0of the time.\nAnd it said that maxillomandibular advancement is effective more than 90 percent of the time.\nWe don\u2019t really know anything about the harms or benefits of the robotic surgery. The story could be more explicit about that.", "answer": 1}, {"article": "\u201cAnd it might be of some help.\u201d\nBut the new study, which mainly assessed full-term babies, found no cognitive difference at 18 months whether mothers received DHA supplements or placebos.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the \"smarter babies\"\u00a0issue, the story reported \"no cognitive difference at 18 months whether mothers received DHA supplements or placebos.\"\u00a0Perhaps that\u2019s sufficient on the one issue.\u00a0\nBut then it also reported \"the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\"\u00a0 What does \"small reductions\" mean?\u00a0 Did it make much of a difference in women\u2019s lives? \u00a0\nAnd which issue mattered more to women \u2013\u00a0\"smarter babies\" or postpartum depression?\u00a0", "answer": 0}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nBut he says by using an electroencephalogram and new, sophisticated computer programs to analyze the EEGs, he and his co-authors were able to correctly identify with 80% accuracy, which babies were at higher risk for autism and which were not.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nBosl acknowledges that if this is very early research, but he believes if the results are confirmed, it may lead to a safe and inexpensive way to detect autism, which would allow intervention before any autistic behaviors appear.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Nowhere does the story address the significance of this:\u00a0 that the main benefit of this test appears to be that it detected with 80% accuracy during a very small timeframe that a child had an older sibling with autism. This means that the study correctly identified most of the time a risk factor that was already known to the parents of the chlid and to the researchers. So, in effect, the study had no actual benefit for the kids or the parents. At least the HealthDay story paraphrased one independent expert who noted that\u00a0 \u201cthe study predicted who was at high risk of autism, but it\u2019s unknown if those babies actually went on to develop autism\u201d. This seems like a giant hole that should have been explored.", "answer": 0}, {"article": "Jennifer Corbett Dooren has details on Lunch Break.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nA study published in this month's issue of the Archives of Neurology found that the diet might protect against blood-vessel damage in the brain, reducing the risks of stroke and memory loss.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "When you find this story online on WSJ.com, it carries the banner:\u00a0 \u201cThe Diet That Saves The Brain.\u201d\nThere isn\u2019t any discussion in the body of the story to back up that bold claim.\nWe don\u2019t blame the reporter for this but someone at WSJ has to take responsibility for this hype.\nWe\u2019ll also add this to our wish list: an explanation that higher \u201cwhite-matter volume burden\u201d is a surrogate measure of health \u2014 i.e. it does not necessarily translate to more brain damage. These white spots are often found in normal people and might not mean anything. The differences the researchers found were statistically significant, but there\u2019s no attempt to sort out whether the changes observed are clinically meaningful.\n\u00a0", "answer": 0}, {"article": "Almost never?\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\nIn one of these studies it looks like running very intensely (faster than an eight-minute mile, more than four hours a week) increases your risk of death relative to not running at all.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The sole benefit discussed in the story is percent reduction in risk of death in a given year. The story explains this clearly, so it gets a satisfactory. It would have been more interesting \u2014 but significantly more complicated \u2014 if it had discussed the ways in which cardiovascular exercise reduces the risk of death. Which health risks are addressed here? Heart disease? Hypertension? Also, the story doesn\u2019t look at some of the other benefits of running or jogging, such as possible quality of life benefits. Most runners, for example, actually enjoy running. Still, that wasn\u2019t the focal point of the story.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presents the relative risk reduction of making the switch from tamoxifen to anastrozole. No absolute benefit provided.", "answer": 0}, {"article": "The Ava bracelet will launch this summer.\nThat\u2019s because resting heart rate data can be captured at its purest when a person is asleep and not moving.\nRegardless, Clue scientists say that they were more interested in the devices\u2019 ability to capture the day-to-day differences in someone\u2019s resting heart rate, which seemed to be consistent, and less interested in whether the devices could produce the exact values of resting heart rate.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nBut Don't Think Of This As Birth Control Even though Clue\u2019s marketing director happened to find out she was pregnant from her Fitbit, the point of the study was to demonstrate that it's possible to use Fitbit as a conception tool, not as a pregnancy test, H\u00f6gqvist Tabor said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would presumably be that women wishing to become pregnant would be more likely to become pregnant more quickly if they were using a Fitbit to track their ovulation cycles. To our knowledge, no study has been done to determine whether that\u2019s the case \u2014 and the story doesn\u2019t address this.\nWhat\u2019s more, it\u2019s not clear whether the 5 women studied are part of the 90% of childbearing-age women who would be able to become pregnant without resorting to this device.", "answer": 0}, {"article": "\"There's stigma, shame and embarrassment.\"\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\n\"The biggest problem we have in the field is that less than 10 percent of individuals with an alcohol use disorder get any treatment whatsoever,\" says George Koob, director of the National Institute on Alcohol Abuse and Alcoholism.\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks about a meta-analysis that looked at a large grouping of studies on the effectiveness of naltrexone and another drug, and it mentions general take-aways from the analysis. But, we\u2019re not given much\u00a0on what the evidence showed, such as how many people are helped by this drug, and to what extent they\u2019re helped.\nLooking at the meta-analysis cited in the story, one might be disappointed to learn that 9 people would need to be treated with naltrexone to prevent one additional person from returning to heavy drinking. The effects are modest, but real.", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nHowever, studies on humans have yielded inconsistent results on the association between postmenopausal estrogen-based hormone replacement therapy and dementia risk.\nShort-term use was not significantly linked to dementia risk, but in one cohort, dementia risk was higher among short-term users who had started hormone therapy in the late postmenopausal period.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides no numbers to back up the claims about the benefits of hormone replacement therapy.\u00a0 It references two studies, a case control study (one that starts with an outcome and then then traces back to investigate what the patient was exposed to) of 230,000 women and a prospective cohort study (one that follows people over time to determine how specific factors affect rates of a specific outcome) of about 8,195\u00a0women, both of which find very small decreases in Alzheimer\u2019s disease only in those women who had been taking estrogens for more\u00a0than 10 years. The decrease is barely significant in both case and could be due to unrelated variables\u00a0that are not discussed in the release.\nThe large case control study published in\u00a0Maturitas  concludes: \u201cOur findings do not suggest HT is an important determinant of AD risk.\u201d\nThe prospective cohort study published in Neurology concludes: \u201cOur results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.\u201d", "answer": 0}, {"article": "2.\nThat\u2019s comparable to the two \u201cscope\u201d tests on the USPSTF\u2019s list, flexible sigmoidoscopy and colonoscopy, which have the advantage of both detecting and removing precancerous polyps in one procedure.\nOf the two, Richard Wender, a physician and chief cancer control officer of the American Cancer Society, said the FIT is preferable, both because it\u2019s more accurate and because it requires only one poop sample and no changes in diet.\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story focuses on the\u00a0available methods of colorectal screening, comparing them based on available data, and points out that the two at-home screening kits are comparably effective to the two invasive procedures: sigmoidoscopy and colonoscopy.\u00a0 One of the at-home tests \u2014 the FIT, or fecal immunochemical test \u2014 when used, is estimated to prevent 20-23 deaths per thousand people screened, while estimates among those using colonoscopy suggest 22-24 deaths are prevented per thousand people screened.\u00a0 The story is clear in saying that there has been no head-to-head comparative study pitting the techniques against each other.", "answer": 1}, {"article": "Tissue that dies in the brain from stroke is absorbed, leaving a cavity, devoid of blood vessels, neurons or axons, the thin nerve fibers that project from neurons.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\nAfter 16 weeks, stroke cavities in mice contained regenerated brain tissue, including new neural networks - a result that had not been seen before.\nThis research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions:\n\u201cAfter 16 weeks, stroke cavities in mice contained regenerated brain tissue, including new neural networks \u2014 a result that had not been seen before. The mice with new neurons showed improved motor behavior, though the exact mechanism wasn\u2019t clear.\u201d\nAlthough we appreciate the inclusion of the caveat that the gel\u2019s mechanism of action is unclear, we\u2019re not given any sense of just how much of an improvement in the motor skills of the mice was observed. And can it actually be attributed to the new growth?", "answer": 0}, {"article": "\u201cEven if they live in the same city where they had their surgery, they might have to call an ambulance to pick them up, and the ambulance drivers don\u2019t understand how important it is to take them to the same hospital,\u201d he said.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n(Reuters Health) \u2013 Patients who need to be rehospitalized within a month after major surgery have a lower risk of death over the next two months if they return to the hospital where they had the surgery rather than going to a different facility, according to a new study.\nMore than nine million patients underwent one of 12 such surgeries during the study period, and between six and 22 percent, depending on the surgery, were readmitted to the hospital within a month.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the authors\u2019 finding of a 26 percent drop in 90-day mortality.\nBut it fails to mention that the authors\u2019 instrumental variable analysis \u2014 intended to reduce confounding \u2014 yielded just an 8 percent drop in mortality risk for those patients who were readmitted to the original hospital. Though less dramatic, it is still a potentially important finding.", "answer": 0}, {"article": "To learn more about ASTRO, visit www.astro.org.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\nIn this study, researchers found that patients who received a single fraction of 19 Gy HDR brachytherapy experienced similar clinical outcomes as with LDR brachytherapy, but with the convenience of a single visit.\n\u201cGiving the entire dose in a single treatment theoretically could have had a greater negative impact on the normal tissues in close proximity to the prostate\u2014meaning the bladder, urethra and rectum\u2014but this was not found to be the case.\n\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefit focused on a vaguely described \u201cbiochemical progression,\u201d which means that there was some evidence that prostate-specific antigen (PSA) levels increased.\u00a0 PSA is a protein produced by both cancerous and noncancerous tissue in the prostate. Determining PSA progression is more complicated following radiation because it takes time for the PSA level to stabilize (unlike following surgery to remove the prostate) before you can determine whether the PSA is rising. \u00a0Biochemical progression is also a surrogate measure and does not imply that the cancer is\u2013or will\u2013clinically progress.\nThe researchers did acknowledge that the actual benefits are unknown, saying that \u201cas the follow-up interval lengthens, 19 Gy dosing in a single fraction may or may not be sufficient to result in cure rates comparable to historical standards.\u201d", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly mentioned the reduction in hospitalization time, need for blood transfusions, and internal scarring were benefits of the procedure though it did not provide quantitative details. \u00a0In addition,\u00a0the story did provide quantitative data on the 30-day risk of\u00a0\u00a0sexual and urinary function complications.", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\nWhen Coleman's team looked at subgroups, however, they found the benefit among older women, a finding they say warrants more study.\n\"There is no overall difference in recurrence rates or survival rates [between patients who got the bone drug and those who did not], except in older patients, defined as more than five years after menopause.\"\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\nSince the current study was presented at a meeting, its findings should be considered preliminary until published in a peer-reviewed journal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article accurately framed the only potential benefit documented by the AZURE study: that it might provide a recurrence and survival advantage among a subgroup of post-menopausal women\u2026 and that this results is something to be studied further. ", "answer": 1}, {"article": "Uterine fibroids, abnormal masses of fiber and muscle tissue in the wall of the uterus, are considered one of the most common causes of infertility and complications related to pregnancy.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\n\"Women who had been unable to conceive had normal pregnancies after UFE and similar complication rates as the general population in spite of being in a high-risk group.\"\n\"Our findings show that UFE is a fertility-restoring procedure in women with uterine fibroids who wish to conceive, and pregnancy following UFE appears to be safe with low morbidity,\" Dr. Pisco said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job providing absolute numbers in describing the trial results:\nAfter an average follow-up of almost six years, 149 of the 359 women, or 41.5 percent, had become pregnant one or more times, and 131 gave birth to a total of 150 babies. It was the first pregnancy for more than 85 percent of the women who gave birth.\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nHowever, to understand the actual benefits, we\u2019d need to know more about the women who were treated with UAE.\u00a0 This study enrolled women who had fibroids and/or\u00a0adenomyosis (a different condition)\u00a0that apparently caused symptoms, and had not become pregnant after a year of unprotected sex; it offered them the option of UAE, even though its fertility effects were not well understood at the time of the study. There is no information on whether these women had fibroids as the cause of their failure to conceive after a year.\u00a0\u00a0Thus, the pregnancy rates achieved after UAE are difficult to interpret.\nThe release would also have been more informative had it broken down pregnancy rates by full or partial UAE.", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nTHURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes benefits in qualitative terms, \u201cthat mice who received the compound had slower blood clot formation than untreated mice.\u201d However, it provides no specifics on how this was measured or how this might or might not translate to humans. While there was one cautionary statement near the end of the story about the limitations of mouse studies, the story\u2019s headline and first paragraph emphasized claims that the compound might work for \u201chuman heart patients.\u201d That\u2019s unbalanced.", "answer": 0}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nThe American College of Rheumatology is rewriting its guidelines for osteoarthritis management and will include topical Nsaids in the recommendations, said Dr. Altman, who is on the guidelines committee.\n\u201cFuture research needs to be done using patients with co-morbidities to know that these agents are safe in the highest-risk population,\u201d said the author of the analysis, Dr. Una Makris, an associate research scientist at the Yale School of Medicine.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\n\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough the story explains the available evidence comparing topical NSAIDs to oral pain relievers, highlights the limited number of direct comparisons, and carefully states the general consensus of experts, all of this solid reporting is undermined by a focus on personal anecdotal evidence over quantifiable benefits. Indeed, the reporter claims one medication provided immediate relief, a statement at odds with clinical trials that conclude that it usually takes hours for patients to feel the pain-relief effects of topical NSAIDs. ", "answer": 0}, {"article": "All rights reserved.\nApproval as an initial treatment likely would boost that sharply.\nTykerb had sales of $189 million last year.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefit in the story \u2013 strange when the entire story is about the drugmaker seeking new approval for the drug.\u00a0 Upon what evidence is that request based? ", "answer": 0}, {"article": "CNN Films Presents:\" Glen Campbell ...\nMuch more research is needed\n\nThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\n\"The study is encouraging enough that we should certainly go ahead and do a [larger] clinical trial because we showed that it is safe and does have significant effects on Alzheimer's biomarkers,\" said Dr. R. Scott Turner, professor of neurology at Georgetown University Medical Center and lead investigator of the study, which was published on Friday in the journal Neurology.\nAntioxidant may be most effective in combination\n\nThis is one of the first studies to look not only at these biomarkers, but also the metabolites of resveratrol in spinal fluid, to show that resveratrol is probably getting into the brain, said Dr. Giulio M. Pasinetti, who is the Saunders Family Chair and professor in neurology at the Icahn School of Medicine at Mount Sinai.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The key finding of the study is that high doses of resveratrol can have an effect on the production of amyloid-beta40, a biomarker that declines in spinal fluid as Alzheimer\u2019s disease advances. The story describes these effects, but doesn\u2019t provide specifics. Similarly, the story mentions that some patients \u201chad slight improvements in their ability to carry out a daily task,\u201d but \u2014 again \u2014 doesn\u2019t give readers any way to quantify what \u201cslight improvements\u201d means (more on this under \u201cQuality of Evidence\u201d).\nAnother problem is the statement that resveratrol \u201cmay actually have benefit in slowing progression of this disease,\u201d which is not consistent with the findings of the journal article. In fact, the journal article specifically states that\u00a0\u201cThe altered biomarker trajectories must be interpreted\u00a0with caution. Although they suggest CNS effects, they do not indicate benefit.\u201d\nWhile we have to rate the story Not Satisfactory for those concerns, the story does a good job of noting that the real goal of the study was to determine whether high doses of resveratrol are safe, so that more research can be done. That\u2019s an important point, and one worth making. Similarly, the story makes clear that: \u201cThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\u201d That\u2019s crucial, and the story is clear on the point.", "answer": 0}, {"article": "Most recently, the F.D.A.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nThe current study will test vaccine dosages and sequences of four or five shots; some subjects will get a placebo.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nPrevious NicVax trials were intended to assess vaccine safety and dosing levels rather than efficacy, but researchers reported high short-term rates of quitting.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story claims that this vaccine will help smokers quit by producing antibodies that attach to nicotine molecules and prevent them from reaching the brain, thus reducing the pleasure associated with smoking. The story notes that \u201cresearchers report high rates of quitting in early studies\u201d, but there is no data provided to support this statement. It is not enough to say that there is excitement about the vaccine\u2019s approach. Some data are needed to judge whether excitement is warranted. The drug company website provides some preliminary short term results from former trials, and there was a 33% 30-day abstinence rate for active vaccine versus 9% for placebo, but the duration and size of this trial were not mentioned. Would the article\u2019s optimism be dampened by inclusion of this rate?", "answer": 0}, {"article": "In North America, we don't get enough omega-3s from seafood, so there lies an opportunity to improve our diet and help prevent the risk of breast cancer.\"\n\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nOmega-3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a first-ever University of Guelph study.\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nPublished in the Journal of Nutritional Biochemistry, the study involved feeding the different types of omega-3s to mice with a highly aggressive form of human breast cancer called HER-2.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There aren\u2019t benefits to quantify, only results, but the news release reports even those in confusing fashion. It states in the second paragraph that \u201cmarine-based omega-3s are eight times more effective at inhibiting tumor development and growth\u201d without giving any sort of baseline for what\u2019s being measured. Further down it states that \u201cexposure to marine-based omega-3s reduced the size of the tumors by 60 to 70 percent and the number of tumors by 30 percent\u201d without saying how much omega-3s the mice consumed or giving the sizes or frequency of tumors. Also, there\u2019s no data on how many mice died.\nThe Cochrane Collaboration (a non-profit that researches and reports on evidence-based medicine) looked at many different human studies and says that so far there is no proof fish oil can treat or prevent cancer-related weight loss, depression, dementia and many other conditions.", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\nHe called the results \"striking,\" even though the experiment was only a pilot study for a two-year trial of calorie restriction due to begin in the fall.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t quantify the suggested benefits (decreased insulin level, decreased body temperature, drop in thyroid hormones, and decline in DNA damage) gained by the study participants. And the study didn\u2019t mention the parameters that failed to demonstrate change during the study (protein carbonyl, glucose, and dehydroepiandroestrone sulfate (DHEAS).", "answer": 0}, {"article": "They end up staying close to home and avoiding travel, shopping and visits.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are stated as such:\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\nand\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\nThis is sufficient for a Satisfactory rating on this criterion. We would have liked to have seen more discussion about actual improvements (perceived and otherwise) to patient quality of life. The closing line of the study brings this into question, i.e. how the work is of \u201cuncertain clinical importance,\u201d and good interview questions with both a study author and independent expert source could have greatly clarified the issue.", "answer": 1}, {"article": "Drs.\nAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion--compared with gaining an average of 4.6 pounds on fluoxetine (Prozac).\nSo those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.\nResearch at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression\n\nSEATTLE--Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.\n\"Our study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese,\" said study leader David Arterburn, MD, MPH.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion\u2013compared with gaining an average of 4.6 pounds on fluoxetine (Prozac). So those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.\u201d", "answer": 1}, {"article": "\"A year would give us even more data and ideas,\" Raed adds.\nAt 600 IUs, arterial stiffness actually increased slightly - .1 percent - and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.\nSo researchers looked at baseline and again 16 weeks later in 70 African-Americans ages 13-45 - all of whom had some degree of arterial stiffness - taking varying doses of the vitamin best known for its role in bone health.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nIn what appears to be the first randomized trial of its kind, they found that arterial stiffness was improved by vitamin D supplementation in a dose-response manner in this population, they write in the journal PLOS ONE.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quantifies the benefits in each group with this statement: \u201cTwo thousand IUs decreased stiffness by 2 percent in that timeframe. At 600 IUs, arterial stiffness actually increased slightly \u2013 .1 percent \u2013 and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.\u201d\nBut we\u2019re concerned that the release did not describe any of the statistical testing results. The 2% decrease seen by the group that got 2,000 units per day was not statistically significant. Nor was there a statistical significance in any group that received smaller doses. A difference was only seen in the group that got the highest dose of 4,000 units per day. That distinction was not made clear.\nFurther, what does a 2% decrease in arterial stiffness mean in terms that would matter to a patient? The 2% decrease in reduced stiffness is a proxy or surrogate marker for a health outcome, but not one that tells us the actual impact on patient health.\nOn the plus side, the release explains that the study consisted of 70 participants, and that those taking the most vitamin D showed the greatest reduction in arterial stiffness \u2014 10.4 percent in 4 months \u2014 but it does not say how many participants that was. The study does make it clear, however. The high-dose group included 18 people.", "answer": 0}, {"article": "According to World Cancer Research Fund International, 84 percent of cervical cancers occur in less developed countries, with the highest rates in Africa, Latin American and the Caribbean.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThe new urine test, they say, is different because it analyzes not only multiple sources of human cellular DNA altered by precancerous changes, but also DNA from HPV that is sexually transmitted and causes virtually all cases of the disease.\nUsing all four genes, the test now had a sensitivity of 90.9 percent and a specificity of 60.9 percent.\n\"If further studies confirm these findings, we see a significant use of urine screening as a way to quickly and inexpensively determine if a biopsy is warranted, or if physicians can use a 'watch and wait' approach before intervening,\" says Guerrero-Preston.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We rate this a borderline satisfactory.\u00a0 On the one hand, the release offers numerical summaries of the test\u2019s abilities to both correctly detect cancer (sensitivity) and correctly identify someone who does not have the disease (specificity).\u00a0 But the text does a relatively dense job of explaining how the investigators reached the urine-test stage, creating a narrative that will require a determined reader and could thwart\u00a0someone giving the text a more cursory view.", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nThe very different experiences of the two sisters illustrate the paradox at the heart of screening recommendations: What matters is not whether screening is done but how it is done and how screening information gets used.\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide any information about the success rates associated with any of the treatments discussed.\u00a0 A number needed to screen should be available.\u00a0\u00a0 Is it 100 that need to be screened to achieve one additional depression remission?\u00a0 Or what is it? ", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A couple of problems here. First, the story describes the overall cancer prevention benefit for Avodart\u00a0in relative terms (\u201ca 23% reduction\u201d) but never gives us the absolute numbers. It would have been much more meaningful if the story had told us, as the original study did,\u00a0that\u00a0 \u201c659 of the 3305 men in the dutasteride [Avodart] group (19.9%) and 858 of the 3424 men in the placebo group (25.1%) received a diagnosis of prostate cancer, representing an absolute risk reduction with dutasteride of 5.1 percentage points.\u201d\u00a0(As noted above, even these absolute risk data are somewhat misleading.)\nSecond,\u00a0a Glaxo representative\u00a0makes the reasonable point that although the cancers prevented by Avodart may be slow-growing, many men with\u00a0these kinds of cancers undergo\u00a0invasive surgery that reduces\u00a0their quality of life. To understand the scope of this benefit,\u00a0however, it is important to know just\u00a0how many men with these lower-risk cancers go on to receive surgical treatment, and what kinds of consequences\u00a0they might\u00a0avoid by\u00a0taking the drug.\u00a0Otherwise there\u2019s\u00a0no way to measure this benefit against the\u00a0potential harms of treatment, such as increased risk of aggressive cancer and\u00a0sexual dysfunction. ", "answer": 0}, {"article": "JACC is ranked No.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does quantify benefits \u2013 but it leaves readers a bit underwhelmed. The numerical differences shown are rather small for the conclusion that the release trumpets. We would have liked some context to justify the excitement about this study.\nChildren who received intervention scored 5.5 percent higher in \u201cknowledge, attitude and habits\u201d than the controls, after the first year. However, that difference lowered to just 4.9 percent after the third year of intervention. We suspect that quantifying the \u201cknowledge\u201d of a 4-year-old is tricky and perhaps a bit more subjective than a blood test or other study data.\nChildren who received the intervention had obesity rates of 1.1 percent in the group compared to 1.3 percent in the control group. The release should have explained why the authors believe the difference of only 2/10 of a percent qualified as \u201cgroundbreaking.\u201d\nIn addition, we\u2019d note that the release touts reductions in body fat, measured through skinfold measurements, as a positive outcome. But skinfold measurements are a questionable marker of body fat given not only risk of inter-, but intra-operator error in terms of landmarking the exact same skinfold location for repeated measurements.", "answer": 1}, {"article": "\"That's the main natural compound in unroasted coffee, and roasted coffee has much, much less of it than unprocessed coffee,\" Vinson said.\n\"Those studies demonstrated that patients experienced somewhat mild weight loss.\nTUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nLona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern in Dallas, cautioned that the study is short on specifics, making it difficult to draw any conclusions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the patients lost an average of 17 pounds or 10.5 percent of their bodyweight after 6 months. Ok, but the story also says that the study involved three distinct phases where subjects were taking different doses of the coffee extract or a placebo. Was the weight loss seen only while the subjects were taking the active extract, or did it also occur when patients were taking the placebo pills (indicating that the weight loss was due to some other factor, such as their overall diet or exercise levels)? The story doesn\u2019t tell us. To score a satisfactory here, we\u2019d need to see a more thorough reporting of how much weight was lost during the three trial periods.", "answer": 0}, {"article": "The caveat is that VX-770 is designed to counter one specific genetic mutation that accounts for about 4 percent of cases of cystic fibrosis.\nmay have a profound effect on the disease.\u2019\u2019\nMany do not live past age 40.\nShe said other results of the trial were encouraging.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": ".\nThe other sample received a lower, more conventional biologically effective dose (maxBED10 <90), using non-adaptive therapy.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nOne sample received a higher biologically effective dose (maxBED10 >90), primarily enabled by MRIdian MR-guided on-table adaptive radiotherapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides exact information about increased survival rates in the cohorts of individuals treated with the adaptive versus the convention radiotherapy techniques.\n\u201cThe cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months).\u201d", "answer": 1}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\nVincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nBy the end of six weeks, there was no difference between the groups: 61 percent of the sham group was experiencing hot flashes, while 62 percent who got actual acupuncture reported them.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes how many women in the acupuncture and sham treatment groups were still having hot flashes at the end of the active treatment part of the trial. ", "answer": 1}, {"article": "A systematic review of C.B.T.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nOn average, treated patients fell asleep almost 20 minutes faster and were awake in the night almost half an hour less.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nMy experience is consistent with these averages.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story carefully lists several benefits from the Annals study: patients treated with CBT fell asleep almost 20 minutes faster and were awake in the night almost half an hour less and their total time \u201csleeping in bed\u201d was increased by 10 percent.\nWe have only two minor quibbles. One is that the writer compares himself to the study participants, and he may not meet the same criteria as they did.\u00a0\u201cFor me, and many patients, C.B.T. works. And as studies show, it works better than drugs,\u201d he wrote. But the Annals study had \u201cnarrow inclusion criteria\u201d that perhaps deserved some comment.\nThe second is that total sleep time gain is described in relative terms with a figure of 10%. The absolute increase in sleep time was 7 minutes, according to the study.", "answer": 1}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\nHowever, a new study shows the use of novel anticoagulants for AF prescribed on an \"as-needed basis\" guided by diligent pulse monitoring, can be a safe and effective alternative to lowering overall risk of stroke.\n\"While this is an observational study with a relatively small patient sample, further research is certainly needed to better understand alternate treatment options,\" said Pammer.\nWe call them \"highly motivated patients,\" said lead author Monica Pammer, PA-C, a physician assistant in Electrophysiology at the Hospital of the University of Pennsylvania.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that 100 participants were followed for 23 months and of those hundred, 28 \u201cstarted taking the blood thinner at least once for a suspected or detected AF episode, and only 10 patients transitioned back to chronic oral anticoagulation therapy for recurrent AF.\u201d \u00a0What is missing from this is any detail on what kind of stroke or ischemic attack that could have been present in a control group. In other words, we have no idea if this\u00a0is a meaningful result or not. \u00a0Interesting, yes. Meaningful? \u00a0Not so much.\nThe headline claim, \u201cBlood thinners on \u2018as needed\u2019 basis is safe and effective for lowering stroke risk as compared to long-term use,\u201d isn\u2019t borne out by the reported research results.\nTo get credit here, one would need information on what one would have expected if they had not received this treatment. The goal of anticoagulation is to prevent stroke. Would we have expected strokes in this population if it hadn\u2019t been treated this way? While the results are reassuring, the risk of stroke in AF is small and accrues over time.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that after 28 weeks of treatment, 25 percent had a \"sustained virologic response\" (SVR) and after 48 weeks 55 percent did.\u00a0 \nBut why not use absolute numbers \u2013 how many out of how many?\u00a0 It tends to gloss over the fact that was mentioned but not emphasized \u2013 that this was only in 50 patients.\u00a0\nThere was also no attempt made to explain what a change in virologic response actually meant in peoples\u2019 lives.\nFinally, the story doesn\u2019t challenge the researcher\u2019s use of the term \"cure.\"\u00a0 What does that mean to him? And what does it mean to readers?\u00a0 \n\u00a0", "answer": 0}, {"article": "Recipients were at most seven years older or younger than the donors.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies benefits here:\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent. With donors over 80, survival outcomes were similar, but the discard rate increased sharply to 48 percent.\nHowever, the\u00a0story appears to make a jump in correlation about the benefits that isn\u2019t supported by its own facts.\nAt the beginning the story makes this claim: \u201cA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\u201d But the researchers never compared a 79-year-old kidney to a 49-year-old kidney in similar recipients \u2014 which is what many readers may assume the story is talking about. The story later says the researchers only transplanted kidneys at most seven years older than the recipient.", "answer": 1}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits. It says that \u201clevels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\u201d Did this happen every time the scientists blocked the gene? How many times did they repeat this exercise? Did their actions ever make the cancer worse?", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports only the study\u2019s estimate of a relative risk reduction of 25 to 32 percent. This figure is meaningless without reporting the underlying absolute risk of dying from prostate cancer. The American Cancer Society states that \u201cAbout 1 man in 39 will die of prostate cancer.\u201d To put it another way, of every 100 men in the US, fewer than 3 will die of prostate cancer and more than 97 will die of something else. The study\u2019s estimate of relative risk reduction might translate into fewer than 2 men dying of prostate cancer and more than 98 dying of something else. However, since many men are already screened with PSA tests, the actual reduction in deaths is likely to be smaller than that. For a more accurate way to capture the measured benefits, see STAT\u2019s story.", "answer": 0}, {"article": "They're on the rise in the United States and no one knows why.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nBut tree nuts may be harder to treat, Wood said, because tree-nut allergic individuals often have multiple kinds of nuts they can't eat.\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported benefits in this way:\nThe results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy. Still, it did not eliminate all symptoms.\nWhy not quantify/specify what terms like these really mean:", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits aren\u2019t quantified at all. The story simply tells us that patients who played the game \u201cmade significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\u201d This is somewhat understandable, since the paper itself offers no specific numbers, and includes a graph that makes it difficult to assign numbers to patient performance. However, one way to address this would have been to ask one of the researchers.\nIt\u2019s\u00a0questionable whether a 7.9 change on the Functioning scale (100 points total) translates into improved functioning in the real world. On the cognitive tasks, pretty much anyone who does cognitive tests (even some with\u00a0dementia) get better over time, whether they are aware they are going testing or not. It\u2019s a practice effect.", "answer": 0}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\nIt is hard to know who will be able to improve reading skills over time, and how much extra help is necessary.\n\"\n\nAbby and Davis, like an estimated 5 percent to 20 percent of the population, have struggled with dyslexia, a condition that, broadly speaking, hinders a person's ability to interpret language.\nScientists have recently made headway in understanding what's going on in the brain of a person with dyslexia, which has not been well understood.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWe will give this story a satisfactory rating because it portrays this research as providing information for researchers seeking to understand dyslexia, rather than offering important direct benefits to individuals. However, most of the story is about what it is like to live with dyslexia. These anecdotes have little or nothing to do with the research. The list of celebrities who may have or had dyslexia also seems irrelevant and distracting. Then the story tosses in discussion of a study that looked at correlations between dyslexia and spatial skills; again, unrelated to the topic of the primary study reported here. The jumble of extraneous personal tales and other research muddles the point of the story.", "answer": 1}, {"article": "Soon after Zane relapsed, he and his father bumped into friends in a local doughnut shop who told them about a TV segment on CAR T-cell therapy.\n\u201cThere\u2019s a lot that still needs to be worked out.\u201d\n\n[Here\u2019s what you need to know about immunotherapy]\n\nComplications can be lethal; one clinical trial was briefly halted in July after three young adults died of brain swelling.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\n[Brain cancer now the leading cause of cancer deaths in children]\n\nAt a six-month checkup, tests showed that the leukemia was back again.\n[For a 6-year-old with cancer, a future staked on medicine\u2019s hottest field]\n\nThe clinical trial already has treated nearly two dozen leukemia and lymphoma patients through age 30.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a broad overview of multiple trials, rather than spending a lot of time on any specific study. That can be dicey, given variability between trial results. However, the story still manages to offer some real numbers \u2014 and grounds the benefits with qualifiers. For example, in referring to multiple trials in both adults and children, the story says that some trials have reported \u201cremission rates of up to 90 percent.\u201d The story then notes that \u201crates in other trials are considerably lower, and many patients relapse.\u201d\nElsewhere, the story quotes one researcher as saying \u201cThe treatment is great about getting people into remission but not at keeping everyone in remission.\u201d The story then offers some information on one study by the same researcher, stating \u201c39 of 42 patients went into complete remission. By a year, about half had relapsed.\u201d That combination of real numbers, with a sobering qualifier, is important.\nWhat we would have liked to have seen: Along with remission discussion, some\u00a0extra\u00a0assessment of what the research shows on overall survival rates, and how long people on the drug can be expected to live.", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story just squeaks by on this, but we want to especially compliment the story for pointing out that the benefits are short-lived. While the story does not use a lot of numeric quantification, it does provide important context for how to view the study results.\nHere\u2019s what it says about benefits: \u201cTheir work confirmed that sleep deprivation \u2014 anything from three to four hours of sleep followed by 20 to 21 hours awake to no sleep for 36 straight hours \u2014 is indeed a powerful antidote to depression.\u00a0In the 66 studies they analyzed,\u00a045 percent to 50 percent reported feeling less depressed.\u201d\nBut this is the part that puts a context around that for readers:\n\u201cThat sounds great, but there\u2019s a huge problem: For more than 80 percent of patients, the antidepressant effects are lost as soon as they get a good night\u2019s rest. Repeated exposure to sleep deprivation has had mixed results.\u201d", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t include any statistics on the benefits of the treatments but does make strong pitches on their effectiveness:\n\u201cCompared to standard therapies alone, the drugs tested in the trial substantially reduced the presence of residual disease in the breast tissue and lymph nodes (known as achieving pathological complete response, or \u201cpCR\u201d) when administered before surgery,\u201d according to a co-investigator.\n\u201c\u2026 when added to standard, neoadjuvant chemotherapy, the combination of the molecularly targeted experimental drug veliparib plus carboplatin showed sufficient improvement to meet the pre-specified threshold for \u201cgraduation\u201d from the trial, signifying a high likelihood for success in a modest, confirmatory phase 3 neoadjuvant trial in the triple negative subset. Likewise, the experimental drug neratinib was found to have sufficient improvement in the pCR rate for patients in the HER2-positive/HR-negative subset, that it too was \u201cgraduated\u201d from the I-SPY 2 trial.\u201d\nThis is a close call. These are small, phase 2 trials, and therefore not designed to provide clear data on drug efficacy. And had the release made that point explicitly, perhaps we\u2019d be more inclined to rule this Satisfactory. However, we think that readers deserve to know what \u201csubstantially reduced\u201d and \u201csufficient improvement\u201d refer to, particularly when the researchers are making strong claims about potential efficacy. How many patients benefited? What is meant by \u201chigh likelihood of success\u201d in a future trial? We wished for some numbers to make this clearer.", "answer": 0}, {"article": "Amgen shares rose $1.57, or 2.6 percent, to close at $62.81.\nOne study included 7,868 women, aged 60 to 90, with moderate to severe osteoporosis.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nA first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest, and could soon add a more expensive but easier to manage treatment option to the booming market.\nThe effectiveness of denosumab and existing drugs appears to plateau after two or three years, she added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The relative risk reduction for each of the trials is provided, but the story fails to provide the absolute risk reduction (62% of what?).\u00a0 The writer also mentions that spine bone density loss in the men receiving denosumab was \u201cfar smaller\u201d compared to the placebo group; however, the reader is not given any quantitative data to determine the clinical significance of this.\nIn addition to\u00a0comparing the absolute risk reduction observed in the denosumab group to the placebo group, it would have been helpful to the reader to know what the risk reduction was for approved and potentially more affordable medications.\u00a0 ", "answer": 0}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\nHowever, among the women who did have invasive cancer, computer-aided detection was linked with a greater likelihood of finding the cancer while it was stage 1 or 2 compared to stage 3 or 4, they found.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story pointed out that CAD use did increase the likelihood that a woman\u2019s cancer would be diagnosed at an earlier stage. \u00a0Readers should also have been told that the study found the increased association between using CAD & an earlier stage of cancer diagnosis may be stronger among women older than 75.\nThe endorsement of the use of CAD & minimization of its problems by Dr. Daniel Kopans, should have been balanced by comments from another expert not connected with the study.", "answer": 1}, {"article": "The Lancet.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\n\"If the SCOOP screening strategy was taken up in exactly the same way as in the study in all UK women aged 70-85 years, we estimate that the strategy could prevent up to 8000 hip fractures per year in the UK.\nThis recommendation was acted upon by the women and their GPs so that over three quarters of the women at high risk were on osteoporosis medications within six months of screening.\nIn the screening group, there were 54 fewer women who suffered one or more hip fractures compared to the routine care group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are quantified. We learn how many women in the treatment arm of the study were placed on osteoporosis medication following screening and how many hip fractures were potentially avoided among the women who received the screening procedure. The release reports both the relative and absolute risk reductions associated with screening. It also projects how many hip fractures might be prevented in Britain on an annual basis if the screening procedure were adopted nationwide.", "answer": 1}, {"article": "COLUMBIA, Mo.\n\"The patients who took statins and had endovascular repairs had a 26 percent decrease in mortality up to one year after surgery.\nPatients who took statins and had traditional open procedures also did better, but the difference was not nearly as significant as with endovascular repair.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"Although this condition usually occurs in men older than 50 with a family history of the disease, anyone can have an abdominal aortic aneurysm,\" said Todd Vogel, associate professor and chief of the Division of Vascular Surgery at the MU School of Medicine, and lead author of the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are giving this a failing grade because there are no absolute numbers in the release. It describes a 26% reduction in mortality, but we have no idea how many patients that actually represents. If there were 20,000 records reviewed, how many died? We don\u2019t know. How many who did not die were taking statins? We don\u2019t know. There are ample data in the paper, none of which is in the story. When you read the study, you see that \u2014 depending on the group being compared \u2014 the mortality rates were quite close. For example, in the group of patients studied who underwent an endovascular surgical repair for their aortic aneurysm, 1% of those who took statins died. And 1.45% of those who did not died.\u00a0Both of these are very low rates.", "answer": 0}, {"article": "\"That's what we are striving for with this project.\"\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\nCurrently, almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or balance problems, or symptoms that are reported by the child, like headaches, blurred vision or feeling groggy.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that the study correctly identified the presence of traumatic brain injuries 94 percent of the time, and that the levels of GFAP in the blood corresponded to the severity of the injuries. However, the release emphasizes only one side of the biomarker story, focusing entirely on the positive predictive value. While important, we think that the other side of the coin should have been addressed as well. Another presumed benefit of an easy-to-use biomarker blood test to detect concussion would be eliminating the necessity of a CT scan if, in fact, the biomarker had a high negative predictive value. \u00a0The study notes a 98% negative predictive value. That means if the test comes back negative, there is a very low likelihood that the person has suffered a concussion. This could eliminate the need for a CT scan and any additional treatments. In reality, it is unlikely that a positive test would obviate the need for a CT scan. In fact, one could argue that the presence of a positive result would require a CT scan. \u00a0The 94% accuracy notation in the press release is incorrect. \u00a0It should have noted a 94% sensitivity (true positive) and a 47% specificity (true negative). The low specificity means that many positive results will be wrong (see more below under \u201cHarms\u201d).", "answer": 0}, {"article": "Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n\"The Decipher test's tendency to make the two specialties more concordant in their treatment recommendations provides significant value toward standardizing care for patients.\"\n\"As genomic tests like Decipher become used more routinely in urologic cancer patient care, they will have a greater impact on treatment recommendations in clinical practice and allow for better personalization of therapy.\"\nSAN DIEGO, July 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that a study featured on the cover of Urology demonstrates that Decipher\u00ae Prostate Cancer Classifier significantly influenced treatment recommendations following prostate surgery, reducing disagreement between urologists and radiation oncologists, and has the potential to enhance personalization of patient care.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, according to the latest study, Decipher has the ability to change the minds of both urologists (45%) and radiation oncologists (35%), and get more of them to agree what or what not to do with a patient after removal of his cancerous prostate gland.\nWe\u2019ll give the release credit here for quantifying the main findings of the study. But we\u2019d note that there was potential to go deeper. We\u2019re never told how many patients have issues with recurrent cancer or metastasis. (The Centers for Medicare and Medicaid Services suggests about 40,000 men each year face a high risk.) We also\u00a0aren\u2019t told\u00a0how effective radiation or other therapies are after a prostatectomy, nor\u00a0how effective Decipher might be in saving lives.\u00a0Most of the clinical trials cited in the article mention only reductions in biochemical progression\u2013a surrogate endpoint.\nMost of what\u2019s found in the release are rather general statements from doctors who have financial relationships with GenomeDx Biosciences, e.g. \u201cit helped ensure that the ones selected for adjuvant therapy are the ones most likely to benefit from it.\u201d", "answer": 1}, {"article": "Why didn't they all get better vision immediately without the contact lenses?\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\n\"The patients' own cells and nerves grew back, and there was an overall improvement in vision,\" said study co-author May Griffith.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\nAs for side effects, Griffith said the patients didn't report any pain or discomfort, and there were no signs that their bodies tried to reject the corneas, a risk that people face when they get transplanted organs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are quantified about as well as in the other two stories, and the story avoids putting the benefits in relative terms. The one big advantage of this story is that it puts a number to the vision improvement. \"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.", "answer": 1}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThey found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes many sketchy statements about DHA, citing benefits for \u201cimproving mood\u201d and \u201creducing symptoms of depression.\u201d The story made these as flat statements of fact, but this is far from established science.\nIt also failed to provide quantified benefits from the study in question. Where are the absolute risk reduction figures?\n\u201cThey found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking\u2026..The MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\u201d", "answer": 0}, {"article": ".\nPeople taking the Arena pill experienced significantly more weight loss, at least 5 percent of their weight over 12 weeks, than people taking a placebo, according to the report filed in the journal Obesity.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nShares of Arena Pharmaceuticals rose almost 7 percent yesterday after the San Diego company released positive mid-stage trial results of its obesity drug, lorcaserin.\nprovide reason for optimism for the millions of Americans struggling with the obesity epidemic,\u201d said Dr. Steven Smith, the study's principal investigator at the Pennington Biomedical Research Center in Baton Rouge, La.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story detailed that individuals taking lorcaserin lost more weight in 12 weeks than did the individuals who were taking the placebo. \u00a0However the story did not provide any information about the magnitude of the difference between the groups, nor did it actually provide absolute quantitative information about the actual amount of weight lost.\u00a0 The phrase \"significantly more weight loss, at least 5 percent of their weight\" doesn\u2019t tell readers how much.\u00a0 ", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article carefully reminds readers that both devices need further testing. Under \u201cVerdict,\u201d the article reads\nSo far there haven\u2019t been any scientific publications detailing lives saved with the LifeVac or another device, from Dechoker LLC, of Salisbury, N.C.\nIn particular, we understand from the article that\nOn the market less than two years, neither LifeVac nor Dechoker has published evidence of successful uses in humans.\nThe successes of LifeVac have been studied only in cadavers where success was observed \u201c49 out of 50 times.\u201d", "answer": 1}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone.\nNearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does quantify the benefits, but we have concerns with how the release states: \u201cAt about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts\u2026\u201d This is a difficult sentence to follow since 40 months was the median\u00a0survival (with a range of 20-51 months). The sentence might be interpreted by some readers that most women lived to at least 40 months, which was not the case.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nAll three drugs improved vision substantially, with aflibercept showing more visual gains in patients with worse vision at the start of the trial.\nFor participants with more severe vision loss (20/50 or worse), aflibercept improved vision on average nearly four lines, bevacizumab about 2.5 lines, and ranibizumab almost three lines.\nParticipants on bevacizumab and ranibizumab received, on average, 10 injections, versus nine for those on aflibercept.\nHowever, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "These drugs are already used for treatment of macular edema and the purpose of the study was to compare the three. In general, all three show good results, with aflibercept producing slightly better results for those initially exhibiting poorer vision. The release quantifies this clearly in terms of improved ability to read an eye chart.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nThe study is preliminary and doesn't prove cause and effect.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study reported on failed to find a statistically significant improvement in psoriasis. \u00a0Despite this, the story headline, first sentence and overall tenor report about benefit even though this is inappropriate given the study results. \u00a0\u00a0", "answer": 0}, {"article": "\"I can do what everybody does.\"\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an adequate job of quantifying the benefits, using hard data to indicate the duration of the study, the number of patients involved and the most signficant outcome. \nThe reporter also does a good job of quantifying the side effects, which it does with even more specificity.\u00a0\n\u00a0", "answer": 1}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nThe results were that patients positive for AR-V7 who were treated with taxane-based chemotherapy had superior overall survival (OS) relative to those treated with ARSI therapy (median OS, 14.3 vs. 7.3 months).\nThis question weighs heavily on doctors and patients, but now, with the Oncotype DX AR-V7 test, we can provide them the confidence to know whether continuing with hormonal therapy or switching to chemotherapy will result in better survival outcomes,\" said Ryan Dittamore, chief of medical innovation at Epic Sciences and a co-author on the study.\nImportantly, patients negative for AR-V7 who were treated with ARSi therapy had superior OS relative to those treated with taxanes (media OS, 19.8 vs. 12.8 months).\n\"This liquid biopsy test addresses a critical unmet need at a decision point in management to predict and select the therapy that is most likely to extend a patient's life,\" said Howard Scher, M.D., who led the study and is the co-chair, Center for Mechanism Based Therapy and Head of the Biomarker Development Initiative at MSK.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated that \u201cThe results were that patients positive for AR-V7 who were treated with taxane-based chemotherapy had superior overall survival (OS) relative to those treated with ARSI therapy (median OS, 14.3 vs. 7.3 months). Importantly, patients negative for AR-V7 who were treated with ARSi therapy had superior OS relative to those treated with taxanes (media OS, 19.8 vs. 12.8 months).\u201d\nBut in the published paper, the results state: \u201cThe median survival of patients negative for AR-V7 was 19.8 months for those treated with an ARS inhibitor and 12.8 months for those treated with a taxane (hazard ratio, 1.67; 95% CI, 1.00-2.81;\u00a0P\u2009=\u2009.05) (Figure 2A). In contrast, for patients with AR-V7\u2013positive CTCs, those receiving taxanes had longer observed median survival times relative to those treated with ARS inhibitors (14.3 vs 7.3 months; hazard ratio, 0.62; 95% CI, 0.28-1.39;\u00a0P\u2009=\u2009.25)\u201d\nSo, for those with a negative test, the androgent (hormone) therapy had improved survival. However, for those with a positive test, there was a trend but the sample size was very small and the p-value was >0.05 (indicating weak evidence), so the results could have been due to chance. As such, we rate this unsatisfactory since the piece provides misleading information for part of the results.", "answer": 0}, {"article": "Canada is one of the top five world producers of barley -- almost 10 megatonnes per year -- but human consumption accounts for only two per cent of the crop yield, with livestock making up the other 98 per cent.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\nMeasuring non-HDL and apoB provides a more accurate assessment for cardiovascular risk, as they account for the total 'bad cholesterol' found in the blood.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits. You have to go back to the original study to learn this: \u00a0\u201cA median dose of 6.5 and 6.9 g/day of barley \u03b2-glucan for a median duration of 4 weeks significantly reduced LDL-C (MD = \u2212 0.25 mmol/l (95% CI: \u2212 0.30, \u2212 0.20)) and non-HDL-C (MD = \u2212 0.31 mmol/l (95% CI: \u2212 0.39, \u2212 0.23)), respectively, with no significant changes to apoB levels, compared with control diets.\u201d \u00a0It would have been nice to have had these reductions contextualized in a form that makes sense to the readers.", "answer": 0}, {"article": "Moffitt is the No.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nMoffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nTheir study, published in the June 30 issue of Breast Cancer Research, found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site.\nThe researchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any numbers to support the benefit claims. It states, \u201cResearchers discovered that among the breast cancer patients who tested positive for the estrogen receptor (ER) biomarker, patients who had neoadjuvant radiation therapy had a significantly lower risk of developing a second primary tumor than patients who had adjuvant radiation therapy.\u201d\nHow much lower was the risk? Some absolute risk numbers should have been included here. They were available in the published study.", "answer": 0}, {"article": "This is relatively new thinking.\n\u201cIt is not clear that it is the specific early introduction of an allergenic food that renders immunological protection, rather than the accompanying increased diversity in the diet that occurs as a by-product,\u201d writes Dr. Matthew Greenhawt, an allergy and immunology specialist at Children\u2019s Hospital Colorado, in the accompanying editorial.\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nThey found evidence of \u201cmoderate certainty\u201d that introducing peanuts early, between ages 4 and 11 months, is linked to a reduction in the risk of developing a peanut allergy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even in this short story, we need some metric for measuring the benefit. The story says there was evidence that introducing peanuts earlier to infant diets provided a \u201crisk reduction\u201d of later allergy. How much of a risk reduction? Was the reduction similar between eggs and peanuts?\nThe journal article itself gives some absolute risk numbers. For egg allergy, the study shows a reduction of 24 cases per 1,000 children. For peanut allergy, the risk is reduced by 18 cases per 1,000 children. But the authors warn that the \u201ccertainty of the evidence\u201d was downgraded due to some gray areas in how the studies were done.", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\nIt could take up to nine months before agency scientists can draw any conclusions, FDA said in a posting to its Web site.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment specifies that four suicides, and a higher number of other mental health effects, have been reported to the FDA. \u00a0\nIt also specifies that 11,000 patients participated in the pre-approval clinical trials and with no reports of similar incidents.\u00a0 \nBut it fails to make clear to viewers the important differences between data from clinical trials and from post-surveillance voluntary reports. \u00a0\nThe story didn\u2019t quantify potential benefits.\u00a0 ", "answer": 0}, {"article": "Naloxone is a prescription drug that can reverse the effects of prescription opioid and heroin overdose, and can be life-saving if administered in time.\nThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\n\u201cNaloxone is non-addictive, and expanding training on how to administer the drug can help basic emergency medical service staff reverse an opioid overdose and save more lives.\u201d\n\nNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\nAccording to the study findings, advanced EMS staff were more likely than basic EMS staff to administer naloxone.\nIn general, the rate of opioid overdose death was 45 percent higher in rural areas compared with urban areas.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not quantify the benefits of allowing staff with less experience to administer this drug. It says only that, \u201cadvanced EMS staff were more likely than basic EMS staff to administer naloxone.\u201d\nIt kind of quantifies some other things in relative terms. It says, for example, that \u201cthe rate of opioid overdose death was 45 percent higher in rural areas compared with urban areas.\u201d OK. That\u2019s a measure of the problem, although it would be nice to know how many deaths in absolute terms happened in rural areas in the year studied. It also says that \u201cThe use of naloxone by rural EMS staff, however, was only 22.5 percent higher when compared with urban EMS naloxone use.\u201d But\u00a0it is not known whether the rate of death was higher or lower in those patients who received or did not receive naloxone. Not knowing the absolute numbers here and not knowing whether naloxone actually made a difference in health outcomes when comparing rural areas to urban areas makes this number difficult to interpret.", "answer": 0}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nWhat's unique about the drug is it is very selective; it only blocks TRK receptors,\" said lead author Dr. Ted Laetsch, Assistant Professor of Pediatrics and with the Harold C. Simmons Comprehensive Cancer Center.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary endpoint of the phase 1 study was safety and tolerability of the drug among a small number (17) of pediatric patients with and without specific genetic mutations. These results are essential to demonstrate before larger trials to demonstrate clinical effectiveness can commence.\nThe release presented the anecdotal story of one patient\u2019s tumor response and claimed a \u201c93 percent tumor response rate\u201d in the headline. With so few patients, this is just a rough estimate and very misleading.\nIn addition, the release reports that the \u201cresponse was long-lasting for most patients\u201d without clarifying that the median follow-up period for the trial was just 8.2 months.", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release includes next to nothing in the way of numbers to back up its claim. It includes only one measured benefit: the majority of around 700 women or \u201c(85.4 \u2013 92.1 percent) found the product easy to use.\u201d This was based on a post-trial survey, according to the release.\nAn interesting finding of the survey not mentioned in the news release was that 57% of women were satisfied with the placebo, compared with 69% to 76% of those treated with the active drug. While it is not surprising that the study, which was supported by the pharmaceutical manufacturer, chose not to focus on this result, it would have provided useful context for understanding the product\u2019s impact on symptoms.", "answer": 0}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main investigator states, \u201cSaliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline,\u201d which gives readers a sense of the potential benefits. But that\u2019s only a partial account of what readers need to know.\u00a0We think any story about diagnostic testing or screening should discuss the sensitivity and specificity of the test \u2014 numbers which tell us about how well the test finds people who actually have the disease and rules out people who don\u2019t have it.\u00a0But the closest the story comes to this is the following: \u201cThey found that the saliva of people with Alzheimer\u2019s had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\u201d\nWe\u2019d note that another story about this study from the Wall Street Journal (which we didn\u2019t review) had most of the details we were looking for here. It said, \u201cSome 80% of the sample predicted by the biomarker combination to go on to develop abnormal memory problems truly went on to develop them, while 20% would have been classified as a false negative. The algorithm, 75% of the time, correctly predicted who wouldn\u2019t go on to develop memory problems.\u201d", "answer": 0}, {"article": "Each stage was 15 minutes.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\nCraig Horswill, clinical associate professor of kinesiology and nutrition at the University of Illinois at Chicago, says the study adds to the growing body of evidence that suggests strategies for increasing non-exercise active thermogenesis \u2014 defined as spontaneous activity unrelated to a fitness routine \u2014 are needed to help overcome the detrimental effects of prolonged sitting.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nHorswill and his colleagues compared the metabolic rate produced by three workstations: seated at a desk, seated at a desk equipped with a device that stimulates leg movement and standing at a desk.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did briefly mention the benefits found in the study: \u201cmodest movement while seated elevated the metabolic rate more than sitting and more than standing, by 17 and 7 percent respectively.\u201d But it gives us no context for these numbers \u2014 in terms of metabolic rate variability, is 7% a lot? A layperson reading this news release has no frame of reference to determine if these numbers are significant. Would 7% increase over the course of a lifetime reduce sitting-attributed mortality?", "answer": 0}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\nThe Tecos heart safety study was conducted by an independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The focus of the story is on the drug\u2019s risk profile, but we think the story should have provided at least some information about whether this drug has been shown to be more efficacious than other therapies. The story missed what was in our view one of the most important points of the study: the practically nonexistent benefit in reducing blood sugar compared with existing therapy. And, while the drug did not increase rates of cardiovascular disease, it also did not reduce them. Also, the study followup was relatively short; median follow up of 3 years. That could have been mentioned somewhere.", "answer": 0}, {"article": "\u2022 Khin NA, et.al.\nWhat makes this even more significant is that the response was rapid and this milestone was achieved in patients deemed to be treatment-resistant.\nTo put this into context, an analysis of placebo-controlled data from three prior studies conducted by Duru and Fantino determined that a minimum change in MADRS of 1.9 was clinically meaningful.2 In addition, the average difference is between 2-3 points for currently approved antidepressants vs. placebo.3\n\nSafety results were consistent with previous studies of esketamine in younger adult populations.\nThe primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does include numbers for the one trial that produced statistically significant benefits, but it\u2019s a very technical explanation and probably too difficult for most lay readers to interpret. It states:\n\u201cThe primary efficacy endpoint, change from baseline in the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score, demonstrated the statistically significant clinical improvement in patients\u2019 depressive symptoms for esketamine nasal spray plus an oral antidepressant at day 28 (Least Squares Mean Difference Standard Error from placebo nasal spray plus a newly initiated oral antidepressant: -4.0 [1.69], 95% Confidence Interval [CI]: -7.31, -0.64; one-sided p=0.010).\u201d\nThat gets it a satisfactory rating here. However, it\u2019s worth noting that a news release (or a news story) should be expected to provide some context and to help non-experts grasp technical concepts in real terms. How big a difference would these numbers make? An expert may be able to tell readers that, but that expertise is missing from the release. It would have been much stronger if it had provided even a concise explanation of what these numbers mean.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify any benefits. What\u2019s more, the story doesn\u2019t give any idea what the benefits might be or what improvemements might be expected. See comments in \u201cEvidence\u201d section. ", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\nAt a meeting last fall, FDA scientists said Mela Sciences had not shown how its device would influence day-to-day decisions by doctors.\nIn a company-sponsored study published last year involving around 1,300 patients, some with multiple growths, doctors reported that MelaFind correctly suggested biopsies on 125 of 127 melanomas that doctors had removed.\nThe device is approved only for dermatologists and only for use on growths that don't have obvious signs of cancer but still have one or two worrisome traits.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story shows that the device is fairly effective at finding cancerous lesions. \u201cIn a company-sponsored study published last year involving around 1,300 patients, some with multiple growths, doctors reported that MelaFind correctly suggested biopsies on 125 of 127 melanomas that doctors had removed.\u201d", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nIn the new study, most of the walnut eaters snacked on the shelled whole nuts straight out of the package, Robbins says.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make over-the-top claims about the benefits of walnuts, but it also doesn\u2019t provide enough info to allow readers to judge the signficance of the research. The story says that eating walnuts \u201cimproved sperm quality,\u201d but it doesn\u2019t\u00a0say by\u00a0how much. A look at the original paper shows that sperm vitality and motility increased by about 5%, while the percentage of sperm with normal size and shape\u00a0increased by 1%.\u00a0We\u2019re not expert enough to know if these are clinically meaningful changes, but the point is that news consumers shouldn\u2019t have to be. The story should have clued them in\u00a0to what these changes mean, perhaps by including some more pointed feedback from an independent source.", "answer": 0}, {"article": "\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nThe idea that this clustering effect is controlled by how fast or slow a protein reconfigures itself is typically not a standard way of thinking in research on proteins, but our work has been able to show these changes.\"\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\n\"We found that those on a certain class of antidepressant, called tricyclics, didn't need the levodopa therapy until much later compared to those who weren't on that type of antidepressant medication,\" Collier said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No numbers are offered in the release. We don\u2019t know how many patient records were examined. We don\u2019t know the number of rats in the animal studies. We don\u2019t know the number of test tubes in the cell-only stage of this early proof-of-concept study.\nThe release includes this statement on benefits:\n\u201cIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\u201d\nWhat does \u201cstopped the growth\u201d mean if we don\u2019t have a measurement of growth in the absence of nortriptyline? For how long was the growth stopped? Was the impact temporary or permanent?The release doesn\u2019t say.\nThe research was not done in humans but only in rats and in cells. The release should have included this information early in the text and in the headline.", "answer": 0}, {"article": "In men, T plays a key role in the development of male reproductive tissues as well as promoting secondary sexual characteristics such as increased muscle and bone mass and growth of body hair.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nFor this study, they sought to compare its effects on a host of parameters (obesity, cholesterol levels, diabetes, liver function) considered to contribute to cardiovascular disease.\nTo date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.\n\nResearchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The text does a good job of describing the differences in cardiovascular outcomes between men receiving testosterone treatment and those who chose not to. But the release never tells us how many people were in each group or what the event rate was, which makes it difficult to make a comparison. And, as the release alludes, the observational design of the study means the cardiovascular outcomes\u00a0are not conclusive.", "answer": 1}, {"article": ".\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release tells readers that within six months of having a TAVR procedure, patients had quality-of-life measurements that were \u201cconsiderably better\u201d than they had been before the surgery. Unfortunately, the release doesn\u2019t offer any specific information about how much the quality-of-life measurements improved or which quality-of-life metrics were being used. The release would have been stronger if it had backed up qualitative terms like \u201cconsiderably better\u201d with quantitative information. Given the risks associated with the procedure, one would be interested in demonstrating that this procedure improved quality of life in individuals who, given their age, have limited life expectancy.", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of PET scanning. The story states, \u201cseveral studies suggest it can effectively provide an early warning\u201d, but does not give any quantification for the magnitude of effects observed in these studies. Most importantly, the story does not mention that even if Alzheimer\u2019s is detected early, there is not much that can be done for it. Aricept has only minor affects on the progression of the disease.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nBut a significant portion of parents will feel good about this and watch this with incredible interest.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article did not present the details of any specific benefits, only speculation regarding potential benefits on the part of the project\u2019s lead pediatrician. What evidence of benefit is there to warrant the million-dollar-plus investment?\u00a0 ", "answer": 0}, {"article": "RotaTeq contains live, but weakened, strains of rotavirus designed to build immunity without causing illness.\nThe federal Centers for Disease Control and Prevention and the manufacturer, Merck & Co. Inc. of Whitehouse Station, N.J., have promised elaborate studies to catch any safety problems.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nBut it is also drawing new manufacturers into the vaccine market, which many drug companies had abandoned in the 1980s and 1990s, citing too little profit.\nFifty to 60 of them die, but it is a different story overseas, where babies often do not receive good medical care and hundreds of thousands die every year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantitative estimates of benefit are provided. How well does the vaccine work?", "answer": 0}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nThese results were similar to findings in children where the system extended the amount of time spent at target blood sugar levels, he added.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nSUNDAY, June 27, 2010 (HealthDay News) -- New research suggests that artificial pancreas technology can help diabetics gain greater blood sugar control overnight, even when they have eaten a big meal or had wine for dinner.\n\"The promise in the near term of these technologies is not only to help us reduce significantly the risk of long-term diabetic complications, but also to reduce the risk of having a catastrophic hypoglycemic event, and further help people with diabetes live easier,\" Aaron Kowalski, research director of the JDRF's Artificial Pancreas Project, said during the teleconference.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We do receive one set of data on benefits, the 70% vs. 47% for time spent in target blood glucose. We\u2019re unable to verify these numbers, as the\u00a0abstract\u00a0available online and MedPageToday coverage both cite \"Time in Target\" as 72% and 50%. Perhaps 70% and 47% come from a different source, such as the press teleconference or presentation. We cannot verify it.\nRegardless, as we said for the harms, the comparative benefits are not meaningful if we don\u2019t know who the comparator group was. Furthermore, we feel than an independent voice should\u2019ve been provided to tell us the meaning of the benefits. According to the abstract, the key benefits were a) reduced variability and\u00a0b) reduced time duration and severity of hyperglycemia. What does that mean for patients, or even doctors? Why does glucose deviation matter if, as the abstract says, the average glucose levels\u00a0were the same in both groups? Just giving us \"70%\" next to a lower number, without an explanation or an identity for the comparator group, says zilch about the value of this research.", "answer": 0}, {"article": "Well, maybe not.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\nThe researchers found that the specific markers they were looking for in the extracted synovial fluid--two cytokines named GM-CSF and IL-15--decreased in concentration in the subjects after 30 minutes of running.\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\n\"What we now know is that for young, healthy individuals, exercise creates an anti-inflammatory environment that may be beneficial in terms of long-term joint health,\" said study lead author Robert Hyldahl, BYU assistant professor of exercise science.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of this approach are in no way quantified. The news release states that the amounts of inflammation markers decreased, but does not say by how much although the published study includes this information. It should be kept in mind that the inflammation markers are a proxy for what we really care about \u2014 actual rates of osteoarthritis. It is doubtful that measuring two biomarkers after a 30-minute run can tell us much about the impact of running over a lifetime.\nIn addition, the release does not mention that this is a pilot study and that only 11 subjects were used and only 6 actually completed the tests because synovial fluid is difficult to obtain from a healthy joint. The paper does include statistics, but the p values (the probability of obtaining a result equal to or exceeding what was actually observed) may not be of any use when applied to only 6 subjects. This does not seem to be a statistically valid study. The release was probably premature.", "answer": 0}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nMore studies will be needed to determine whether this method can be used as a widespread treatment for other brain-related disorders, but if today\u2019s research is any indication, TMS could be a key to improving the lives of Americans suffering from a multitude of disorders.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only notes that studies employing TMS sessions to treat Parkinson\u2019s and autism \u201chave seen some success,\u201d but the reader will find no specific information about what that means. Also missing: What percentage of patients with depression respond to treatment, and if the effects are short-term or long-term.", "answer": 0}, {"article": "While the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nThat growth also resulted in larger internal organs, particularly the lungs, making breathing easier.\nThe study, published Monday in the journal Pediatrics, was produced by the UConn/Hartford Hospital Evidence-based Practice Center and was funded by the U.S. Department of Health and Human Services.\nLungs are clogged with a thick mucus, which can lead to lung infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nThree years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nIn a bid to make cancer immunotherapy more effective, researchers report they have succeeded in halting the progress of aggressive melanoma in its tracks \u2014 at least briefly \u2014 in seven patients treated with an army of cloned cancer-fighting immune cells.\nThe approach outlined in the new study by researchers from the Fred Hutchinson Cancer Research Center in Seattle identifies several ways to make it better, said Dr. Cassian Yee, the study's senior author.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt for reporting:\n\u201cIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks. Another patient was declared in remission because his cancer ceased to spread and, after several months, disappeared altogether. Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient\u201d", "answer": 1}, {"article": "Lung cancer is the No.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article presents the rates of metastatic disease for each group in the study. That said, we suggest some areas where we believe it could\u2019ve been stronger.\nWe would\u2019ve liked to have seen absolute quantities here. We would have liked to see the number of subjects in each treatment group (the \u201clittle n\u2019s\u201d) in addition to the study\u2019s total headcount (the \u201cbig N\u201d). What if 150 people were in one group and 7 in the other? It\u2019s necessary to evaluate the quality of the study and add meaning to the 20% and 42% statistics.\nSeveral more benefits were summarized in prose without quantities, including claims about the comparative superiority of metformin to TZDs. While space would not permit all the numbers, surely there was space for more than one. \nNow, we know that the abstract itself didn\u2019t quantify these other benefits, present the little n\u2019s, include absolute quantities, or explain the evidence behind the trend of metformin superiority over TZDs. (By the way, the term \u201cinitial trend\u201d suggests the result may not have been statistically significant.) While true, these facts aren\u2019t in the abstract or ACCP statement, but we think that\u2019s not a suitable reason for not acknowledging at least the importance of missing context\u2013 it\u2019s instead a known peril of reporting on unpublished research. Before research goes through peer review and full publication, it has more inherent unknowns, both in the science,\u00a0the vetting of quality and conflicts of interest, and\u00a0the final level of information that the public gets to see. Thus, we think,\u00a0when the decision is made to report on preliminary research,\u00a0those unknowns need to be acknowledged to distinguish it from more mature research.\n Dr. Gutterman says that more research is needed before the preventative use of metformin in smokers \u201ccould be proposed.\u201d It balances Dr. Mazzone\u2019s proposal of the same potential benefit; but is the cat already out of the bag since Dr. Mazzone (and Reuters) have, at this point in the article, already proposed this potential benefit? As the proposal is one with a broad audience, and broad appeal, more caveats about the status of this hypothesis would\u2019ve been ideal.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nThere were no serious adverse events across any of the treatment groups.\nThe primary outcome was the proportion of subjects with an endoscopic visibility rating of excellent or good based on the Aronchick scale.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides a modest amount of information on the results of the study providing both percentages and actual numbers on the success and acceptability of the comparisons. We would have liked to have seen an acknowledgement that the sample size is rather small and while the percentages seem impressive, they may not be clinically or statistically significant.", "answer": 1}, {"article": "\"We always assume there's luxury,\" Wright said.\nBlood test accuracy is defined based on sensitivity, the percentage of positives that are correctly identified, and specificity, the percentage of negatives that are correctly identified.\nThis is true even of Parkinson's, which is diagnosed based on symptoms, a patient's history, neurological exams, a patient's response to medicine and, in some cases, brain imaging tests.\nUp until now, many diseases have been diagnosed based on symptoms, with patients asking, \"How do you know I have this?\"\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Atypical for many news stories like this, this one provided the actual specificity and sensitivity numbers for the blood test, and how that compares (in general) to the typical spinal fluid test.\nThat said, the story could have been a little more thorough in its discussion of what sensitivity and specificity mean. It says sensitivity is \u201cthe percentage of positives that are correctly identified, and specificity, the percentage of negatives that are correctly identified.\u201d That\u2019s accurate, but the story could have gone further to explain, for example, that a low specificity test means it will have a high false-positive rate (more people who don\u2019t have the disease are erroneously told that they have it). A low-sensitivity test, by contrast, will have a high false-negative rate (more people who actually have the disease are falsely reassured by a negative test result).", "answer": 1}, {"article": "Melatonin significantly reduced BP.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nThe present study was aimed to investigate whether such changes can be reversed by daily melatonin ingestion.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We rate this a\u00a0Satisfactory because the release provides the absolute decrease in BP that was achieved in 63 participants. However, the way the benefit was quantified may not be useful to readers. The statement: \u201cNighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SDP/DBP, respectively\u201d may be too technical for most readers.", "answer": 1}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The first paragraph says the drug BYL719/alpelisib can \u201ccut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\u201d\nIn the second paragraph we learn this effect was seen when BYL719/alpelisib was combined with Faslodex, a drug currently used to treat advanced breast cancer. In patients who received both drugs, the median progression-free survival was 11 months. It was 5.7 months for patients on Faslodex alone.\nIn the next paragraph, we are told the drug combination cut the risk of death or progression by 35 percent, but there are no statistics about the absolute number of people who died included in the story.\nTo learn more, we looked at the news release and study abstract put out by the organizers of the European Society for Medical Oncology (ESMO) 2018 conference in Munich, where the study was presented. This allowed us to discover that the study randomized 572 postmenopausal women or men with hormone-sensitive, HER2-negative advanced breast cancer. Of these, 341 were found to have the PIK3CA mutation when their tumor was tested. The findings reported from the study were specific to that group of patients who had the mutation. The news release explains that 36% of 262 patients with this mutation responded to the combination.\nWe also learn, in a quote from the study\u2019s lead author, that \u201cthe follow-up is short so we cannot say whether there is a long-term survival benefit.\u201d They hope that the progression-free survival will translate into an overall survival benefit\u2013but they don\u2019t know.\nIn short: There is no data to support the headline\u2019s claim that BYL719/alpelisib reduces the risk of death from breast cancer by 35 percent.", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nThe new trial looked at a type of lung cancer called squamous cell non-small cell lung cancer, which accounts for about 20%-30% of lung cancers.\nMerck is also studying Keytruda in people with advanced lung cancer to better understand how they are responding to treatment, what determines how well a patient will respond, and how to get good results for more patients, Perlmutter said.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says only that Opdivo \u201cis working so well that pharmaceutical giant Bristol-Myers Squibb announced Monday it is stopping a trial in lung cancer two years ahead of schedule.\u201d But \u201cworking well\u201d doesn\u2019t give readers any idea of the scope of potential benefits. The story also calls Opdivo a \u201cbreakthrough\u201d \u2014 how we can we know that if we don\u2019t know anything about what happened in this study? Even the relevant news release offered more information, stating that \u201cthe study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm\u201d (i.e., those patients receiving docetaxel). Even if Bristol-Myers Squibb chose not to release any numbers, it may still have been possible to find and discuss survival rates for squamous non-small cell lung cancer patients outside of the study who are treated with docetaxel. Failing that, the story could have noted the lack of quantifiable benefit information provided by Bristol-Myers Squibb.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not include information for the reader that the observed association between bone mineral density and cola consumption exhibited a dose response. In addition, since there is no known biologic basis for finding this association in women but not men, the relationship needs to be examined further to be sure that the association is real and robust, and that other confounding factors aren\u2019t at play. ", "answer": 0}, {"article": "For more information on asthma, visit the U.S. National Library of Medicine.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nIn addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits observed in the study were not quantified. As with harms, the story didn\u2019t tell readers how often events occurred. ", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided comparative quantified specifics on the benefits of sulforaphane in the three groups of rabbits, in the form of percentage decrease in lipid levels.\u00a0We\u2019ll call that good enough for a Satisfactory rating, although ideally we\u2019d like to see some discussion of what the results might mean for cardiovascular risk in a human. We\u2019ll address that deficiency below under the Evidence criterion.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nNeurologists can get a ballpark estimate of a patient's risk of Alzheimer's dementia using the Mini-Mental State Examination questionnaire, or by testing for the high-risk form of the gene ApoE, which increases a person's risk of Alzheimer's by up to 12-fold.\nOne day, MRI brain scans may help predict whether older people will develop dementia, new research suggests.\nIn a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release said MRIs \u201cpredicted with 89 percent accuracy who would go on to develop dementia within three years\u201d when looking at the whole brain, and accuracy rose to 95% when researchers focused on \u201cspecific parts of the brain most likely to show damage.\u201d\nThose percentages might sound impressive. However, the news release didn\u2019t say how many people might benefit from a scan to detect Alzheimer\u2019s early, and how many might be subjected to testing that doesn\u2019t help them but could cause harm (see \u201cExplain Harms,\u201d below).\nFor example, the lifetime risk of developing Alzheimer\u2019s has been estimated at around 10-20%. According to our back-of-the-napkin calculations, if 100 older people were regularly screened using MRIs, as many as 19 might benefit from an early warning. The other 81 or so would not benefit or might be harmed.\n\u00a0", "answer": 0}, {"article": "\"They should have a role to play in cancer treatment.\"\nNext, the team will work with clinicians to develop safety tests of the ZIKV-LAV in glioblastoma patients.\nNext, the team wanted to show whether the ZIKA-LAV could work to infect and kill human patient-derived GSCs in a mouse model.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nFinally, the team investigated the cellular mechanisms that the modified Zika virus used to kill the GSCs.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn from the release that mice with the attenuated zika virus lived 50 days, in comparison to mice in the control group that lived 30 days.\nWe\u2019ll award a marginal satisfactory grade for this description, but we emphasize that it\u2019s a huge leap from mice to humans. We\u2019ll address that issue in more detail below under the evidence criterion.", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The proposed benefit is to find people at increased risk of heart disease with a bone density scan and treat them.\nOne of the authors is quoted:\n\u201cWe found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\u201d\nHowever, the release doesn\u2019t provide numbers that put the presumed benefit in context.", "answer": 0}, {"article": "For clinical or PR inquiries, please call (405) 400-0680.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nIRAPjoint\u2122 is produced through a single blood draw which is enough for a full year's treatment of up to 12 injections.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives no numbers to help readers assess the new therapy\u2019s benefit. In fact, it says very little about the therapy benefit at all besides the fact that \u201csuccess has been achieved\u201d by using the treatment, and that the new treatment is \u201csignificantly better\u201d than a rival European treatment.\u00a0\nThere was no study mentioned in this news release. On the website of Arthokinex, the joint pain clinic that has released the new treatment, there is a link to a 2015 study published in the journal Cytokine by one of the clinic\u2019s doctors. The study looked retrospectively at the charts of 53 of the clinic\u2019s patients who had undergone this treatment, and concluded that the treatment was effective in treating mild to moderate osteoarthritis.\u00a0\nAs noted in this news release, the use of a patient\u2019s own blood as a treatment option has been available for some time. However, evidence demonstrating its benefit compared to placebo or other injections is very limited. Instead, the release implies benefit by referring to the use of this type of treatment by professional athletes.", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThe study shows that receiving little to no nutrition during the first week in intensive care makes children recover faster.\nAn international team of researchers from University Hospitals Leuven (Belgium), Sophia Children's Hospital Rotterdam (The Netherlands), and Stollery Children's Hospital Edmonton (Canada) has now challenged the validity of this common practice.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quotes the lead coordinating investigator saying \u201cthe current practice of feeding children in an early stage does not contribute to their recovery,\u201d but it offers not a single data point. There is no information provided other than the number of total participants, and no mention of the makeup of the randomized groups, the specific findings, or the comparative rates of new infections and lengths of ICU stay (the two endpoints of the study overall). The release does note more correctly at one point that the study was designed to \u201cchallenge the validity\u201d of early parenteral feeding, but it never explains the details or context of those feedings. The absolute difference in the outcomes between groups is left unanswered.", "answer": 0}, {"article": "The Western Eye Hospital is a specialist eye hospital in West London with a 24/7 accident and emergency department.\nWhile we cannot cure the disease, our test means treatment can start before symptoms begin.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nIn the future, the test could also be used to diagnose other neurodegenerative diseases.\"\nA SIMPLE eye test could help solve the biggest global cause of irreversible blindness, glaucoma.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release claims that \u201cour developments mean we could diagnose patients 10 years earlier than was previously possible\u201d but what does that mean in terms of disease prevention or reversal?\nThe release could have put the benefits in context by telling us more about what was involved with the test and how many people were diagnosed with early signs of glaucoma. What were these signs?", "answer": 0}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was clear that outcome studied was the duration for a bout with acute diarrhea. \u00a0However by opening the story with mention of possible ability to \u2018soothe fickle bowel\u2019, this piece plays into the marketing of benefit from probiotics beyond treating the condition studied. In addition, the story gives only relative risk reduction for the risk of prolonged diarrhea \u2013 reduced by 59%.\u00a0 But 59% of what?", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reader is left to ponder statements such as \u201cmice that\u00a0got night milk were significantly less active\u2026\u201d But how much less active?\nThe story does make a good faith effort to report some number-based outcomes from the study. It says, for example, \u201cBalance and coordination were measured by the number of falls from a rotating bar during a 20-minute period: Mice fed night milk on average fell four to five times, about twice as often as mice given day milk. Diazepam-treated controls fell about nine times, while the water-fed controls fell twice.\u201d But then again, it\u2019s not exactly made clear\u00a0how this result relates to the outcomes that readers are interested in such as sleep or anxiety. We\u2019ll reluctantly rate this Not Satisfactory.", "answer": 0}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nWhen they would open me up [the aorta] could just blow.\u201d\n\nThe bulge in the large artery that carries blood away from the heart can be immediately life-threatening if it grows large enough to rupture.\nIf not for a new surgical technique, a minimally invasive procedure which uses 3-D printing technology, the adventurous Berg might never have been able to return to her passions of traveling, snorkeling and cooking.\nAnd even if the stent does fit, patients often undergo a long, painful recovery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Actual data is nowhere to be found to back up the assertion that this technique saves lives and results in quicker recoveries than other treatments, and it\u2019s not clear what the procedure is being compared to. Instead, there\u2019s one patient anecdote with an unsubstantiated statement that her condition \u201cnearly killed her.\u201d\nIdeally, the story should have made clear what data, if any, compares these customized stents to standard stents.", "answer": 0}, {"article": "He wasn't doing his homework.\nEven though there are studies now showing that neurofeedback works for ADHD, all of these studies have serious limitations, researchers say.\nNeurofeedback is expensive, time consuming and still scientifically unproved.\nSo the approach remains promising but unproved, says David Rabiner, a researcher at Duke University who writes a newsletter about treatments for ADHD.\nNeurofeedback is better for people with ADHD, she says, because it provides constant feedback during a session, which is usually done in a therapist's office.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was the biggest hole in\u00a0an otherwise reasonably solid story. The article claims that there is \u201cgrowing evidence\u201d that neurofeedback can help treat people\u00a0with ADHD. However, the story never describes any of the results of this purported increase in research that supposedly documents these benefits.\u00a0The closest we come is the description of a study which hasn\u2019t even been published yet.\nThe story also suggests that neurofeedback\u2019s benefits might last longer than those of medication. Again, however, we are never given any sound basis to believe that neurofeedback works at all \u2014 let alone better than other treatments.\nAt the same time, the story leans heavily on testimony from a journalist who has written a book about ADHD and claims neurofeedback worked for her and her son.\u00a0\u00a0We are told that the primary improvement she saw with\u00a0her son\u00a0was that he was \u201ceasier to live with.\u201d\u00a0Although this kind of anecdotal report\u00a0can be useful\u00a0to add context to scientific findings,\u00a0it is\u00a0certainly no substitute for reporting on the actual clinical outcomes\u00a0of research.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\n\"He did not want to go on the ventilator,\" she said, adding that many people prefer a \"natural death.\"\n\"Ethical review happens at several levels: at the NIH, at the Food and Drug Administration and most importantly at University Institutional Review Boards at each institution where a faculty member is participating in a trial,\" Glass explained.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since this was primarily a safety study, there are no measurable benefits to quantify, and the story lets us know with this statement:\u00a0\u201cUnfortunately, the procedure provided no benefit to patients.\u201d\nWe\u2019ll count this as sufficient for a Satisfactory rating.\nHowever, we encourage journalists to think twice about giving air time to early-phase trials, especially for stem cells. In many cases, there isn\u2019t a lot to report yet, since benefits haven\u2019t been established in any meaningful way. Better to wait until bigger trials are conducted, which was even implied with this ending quote in the story:\n\u201cWe are just now getting started with testing our hypotheses about using stem cells as therapeutics,\u201d Glass said. \u201cWe do not know if these treatments will work, and it will take time to test these therapies in a systematic and safe way.\u201d", "answer": 1}, {"article": "About the American Academy of OphthalmologyThe American Academy of Ophthalmology is the world\u2019s largest membership association of eye physicians and surgeons.\nDuring the baseline measurement, diets rich in vitamin C were associated with a 20 percent risk reduction for cataract.\nAfter 10 years, researchers found that women who reported consuming more vitamin C-rich foods had a 33 percent risk reduction of cataract progression.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news releases notes that, \u201cDuring the baseline measurement, diets rich in vitamin C were associated with a 20 percent risk reduction for cataract. After 10 years, researchers found that women who reported consuming more vitamin C-rich foods had a 33 percent risk reduction of cataract progression.\u201d\nThe release would have been stronger if it had used absolute numbers (the actual total rate of cataracts in women with vitamin C-rich diets vs. those with diets low in vitamin C) in addition to the relative risk figures.", "answer": 0}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us how much the diet reduced cholesterol, providing the actual\u00a0values from the lab report.\u00a0It could have also\u00a0estimated the expected reduction in 10-year cardiovascular risk that this would\u00a0correspond to.", "answer": 1}, {"article": "And sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nRead the full guideline at the American Society of Clinical Oncology.\nThe new guidelines replace previous guidelines issued in 2002, and subsequent updates in 2003 and 2004.\nAromatase inhibitors are not effective in this age group, the experts note.\nCrystal Denlinger, assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "\u201cI was cute as button \u2014 and there was my double chin,\u201d she said.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a good deal more information on the benefits seen in the clinical trials than does the corresponding Washington Post coverage. We are told, \u201cThe pooled results from both trials found that 68.2 percent of patients who got the drug saw at least a one-grade reduction in fat, compared with 20.5 percent of patients who got sham injections. Grading was determined by clinical examination and answers on a standardized form. Sixteen percent of patients who received the real injections saw a reduction of two grades in under-chin fat. Only 1.5 percent of the placebo group saw that level of improvement.\u201d\u00a0We would have liked to have seen some detail about what a two-grade change in under-chin would look like, however.\nAnd while the story does focus extensively on one patient\u2019s anecdotal success story, it also notes that not every patient is a good candidate for treatment. Example: \u201cIf a patient has excess fat and loose skin, Dr. Rohrich said, \u2018you\u2019ll have a crepey neck and need a neck lift\u2019 after fat is reduced with the shot. Neck lifts can cost $5,000 or more.\u201d", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits, instead focusing on one patient\u2019s experience with the technique and noting that it \u201chas been getting positive reviews so far\u201d in a U.S. clinical trial. The story also notes that Sonata was approved in Europe. A 2015 paper in the journal Gynecological Surgery offers information on\u00a0outcomes for 50 patients in a \u201cFAST-EU\u201d trial for Viz-Ablate (which appears to be another name for Sonata). For example, 12 months after the procedure, 38 of 48 patients had reduced menstrual bleeding by at least 22 percent (which study authors described as the threshold mark for being \u201cmeaningful\u201d to most women).\u00a0 The Sonata trial is designed to measure effectiveness (defined as more than 50% reduction in blood loss) and safety in a U.S. population.", "answer": 0}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nTesting in mice showed that the vaccine safely prevents the buildup of substances in the brain associated with the fatal disease, the team reported this week in the journal Alzheimer's Research & Therapy.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\n\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives no data to describe the differences in the buildup of amyloid in the brains of mice given the vaccine versus those not given it.\nA news release stated: \u201cThe latest study \u2013 consisting of four cohorts of between 15 and 24 mice each \u2013 shows the vaccine prompted a 40 percent reduction in beta-amyloid and up to a 50 percent reduction in tau, with no adverse immune response.\u201d\nAlso, the story doesn\u2019t explain whether there\u2019s any data behind these speculative comments about potential human benefits from a researcher:\n\u201cIf the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families. \u2026 The number of dementia cases could drop by half.\u201d", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mentioned lack of \nbenefit from statins for this purpose; also provided some details of side effects of statins", "answer": 1}, {"article": "This early detection is key because early treatment is more effective.'\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\nFor that reason, tests that spot antibodies to citrullinated proteins are already used to diagnose the disease.\nFurthermore, current tests for rheumatoid arthritis are limited in their ability to diagnose disease in different patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release asserts that the key benefit of the test for tenascin-C protein is early detection of RA that can be used to initiate early treatment. After looking at results from 2,000 patient volunteers, the lead researcher was quoted saying the test \u201ccould diagnose RA in about 50% of cases\u201d and that the test was 98% accurate in ruling out RA. It isn\u2019t clear from the release if all 2,000 patients started out healthy and half went on to develop RA, or if the test accurately detected the RA precursor protein in only half the patients that went on to develop RA.\nOverall, the release provides insufficient information to quantify the benefits. Accuracy is a reflection of both sensitivity (diagnosing the condition when it really exists) and specificity (not diagnosing the condition when it doesn\u2019t exist). The very high accuracy implies the test is both sensitive and specific. However, this may be misleading depending on the nature of the population studied. If the population includes patients with established rheumatoid arthritis it may make the test look better than studying a population of individuals who don\u2019t have the condition or may have a different condition.", "answer": 0}, {"article": "To learn more about deep brain stimulation, visit the American Association of Neurological Surgeons.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nFor five patients, navigation to each of the three stores learned during stimulation was faster and shorter than navigation to the three stores learned without stimulation, indicating a consistent effect, the study said.\n\"Critically, it was the stimulation at the gateway into the hippocampus, and not the hippocampus itself, that proved effective,\" senior study author Dr. Itzhak Fried, a professor of neurosurgery at the David Geffen School of Medicine at UCLA, said in a university news release.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that the test looked only at a simulation of learning how to navigate a virtual city. It points out that this test does not prove that electrical brain stimulation can overcome memory problems caused by Alzheimer\u2019s disease or other types of dementia. An independent source quoted in the story points out the experiment did not show if the effects last.", "answer": 1}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nPodiatrists have begun using a laser treatment that combats the infection \u2014 or wastes their patients\u2019 money because it doesn\u2019t work, depending on whom you ask.\nIt tends to be a cosmetic issue for the younger set and a pain issue for older folks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are not well quantified. The FDA approved the Pinpointe FootLaser noting it is, \u201csubstantially equivalent to the predicate devices and is safe and effective for use for the temporary increase of clear nail at 6 and 12 months following treatment in patients with onychomycosis.\u201d We are unable to locate any studies comparing it or any laser to prescription drugs in the treatment of toenail fungus. We think that the story was a bit over the top in its enthusiasm.", "answer": 0}, {"article": "All were between 12 and 30 weeks of gestation.\nBut, she added, because this is the first study of its kind, and the acupuncture protocol used was specifically designed for this study, \"you always need replication of the findings.\"\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nBut, she cautioned that \"acupuncture is not a substitute for the appropriate use of antidepressant therapy especially in women with a prior history of response to antidepressants.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only reported benefits in relative terms, but those percentages were juxtaposed to the actual numbers of women assigned to the three study groups \u2013 so it\u2019s possible for readers to do the math.\u00a0 Nonetheless, why make them do the math?\u00a0 Why not just give the absolute numbers of how many in each group responded? \nOne thing we did like is that the story explained that the study defined a \"positive response\" from treatment as an improvement of more than 50% in depressive symptoms. It would be interesting to know if the women in the study would self report this amount of improvement as a significant improvement in how they were feeling.", "answer": 1}, {"article": "A stroke occurs when a clot cuts off blood flow to parts of the brain.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No, as in \u201cevidence\u201d above, the benefits in the 4 patients are really never explained.", "answer": 0}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nA recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.\n\"Given comparable effectiveness, doctors need to discuss advantages and disadvantages of both treatment options with their patients.\nThey found that symptom improvement and rate of remission were similar between the two options, whether used alone or in combination with each other.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of benefits. That\u2019s a big omission considering people with major depressive disorder are being told that talk therapy and medications yield the same outcome.\nSome of the important quantifiers missing include:\nHow long was the treatment? What percent improved after treatment? How much did they improve? What was the rate of relapse? How long did they improve?", "answer": 0}, {"article": "Women whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted.\nThe new study, like previous ones, re-ignites the ongoing debate about the best age to start routine mammograms and the best screening interval.\n\"The findings make sense,\" she said.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt for presenting lots of numbers \u2013 in contrast with the WebMD story that included NONE.\nHowever, more critical analysis would have been appreciated.", "answer": 1}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\n\"I have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\" Calder-Becker said.\nNone of the participants in either group had heart abnormalities, but the SIPE-susceptible athletes had higher pulmonary arterial pressure and pulmonary artery wedge pressure during the underwater exercise, confirming that SIPE is a form of pulmonary edema caused by high pressure in the blood vessels within the lungs.\nDURHAM, N.C. -- Swimmers and divers who are prone to a sudden and potentially life-threatening form of pulmonary edema in cold water could benefit from a simple and readily available dose of sildenafil, according to findings from a small study by Duke Health researchers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the press release indicates that measures of pulmonary arterial pressure \u201cwere no longer as elevated\u201d in individuals who received sildenafil, the document got no more specific than that. The author described the benefit very vaguely in this statement:\n\u201cIt appears that the drug, which dilates the blood vessels, could be creating more capacity in the blood vessels in the arms and legs, reducing the tendency for blood to redistribute to the thorax, and therefore reducing the high pressure in the pulmonary vessels.\u201d\nWe\u2019re also concerned with the glowing anecdote that the release uses to illustrate the drug\u2019s benefits. The study itself looked at pulmonary arterial pressure and had nothing to say about sildenafil\u2019s ability to prevent bouts of SIPE during competition. Nevertheless, this study participant gushes,\n\u201cI have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\u201d Calder-Becker said. \u201cI have not had an incident since then. I didn\u2019t want to give up racing \u2014 this is something my husband and I do together, and we travel together to competitions \u2014 so it has meant everything to me to continue.\u201d\nThe anecdote goes well beyond the limited parameters of the study and overwhelms any cautions regarding the limitations of current evidence.", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\nThey reported that patients who had the round window approach had a much better chance of keeping their residual hearing in the long term.\nThey found that electrodes designed with no wire (called lateral wall electrodes) performed the best in maintaining residual hearing in the inner ear, compared to electrodes made with wire.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Two types of benefits are discussed in the news release.\nThe study looked at 230 patients (it was actually 196 patients but 225 implants) \u00a0with \u201cevery type of cochlear implant, including three FDA-approved implants that use different types of electrodes to stimulate the auditory nerve.\u201d \u00a0The benefits were not quantified but we are told that the researchers \u201cfound that electrodes designed with no wire (called lateral wall electrodes) performed the best in maintaining residual hearing in the inner ear, compared to electrodes made with wire.\u201d \u00a0How much better? We don\u2019t know.\nThe other benefit compares \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear) versus the \u201cround window\u201d approach and \u201cthe round window approach had a much better chance of keeping their residual hearing in the long term.\u201d\nHow much better? \u00a0We aren\u2019t told.", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma.\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the questions the study attempted to answer was whether ibuprofen is a safer drug than acetaminophen in children with mild persistent asthma. This release does a laudable\u00a0job laying out the figures for the number of asthma exacerbations for each group. It\u00a0also includes quantitative data for the percentage of days with full asthma control, use of \u201crescue medication\u201d and unscheduled healthcare visits. It also used the term \u201csignificant\u201d correctly, stating that there \u201cwere no statistically significant differences between groups\u201d (a common mistake we\u2019ve seen in other releases).\nDue to all these factors, we give the news release a Satisfactory rating here.", "answer": 1}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only provides relative risk reductions when absolute risk reductions are best (and are provided in the study findings).\u00a0 The article also claims that the study findings \"indicate that treatment offered a clear advantage,\" which is premature since this is not a randomized trial. The quote from an \"expert\" (the story gives no information about his expertise)\u00a0 is misleading:\u00a0 \"This debunks the idea that older men do not benefit from treatment.\"\u00a0 Clearly, the study is completely insufficient to 'debunk' watchful waiting as a treatment option for prostate cancer, especially in older men. ", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nIt also warned that women who are pregnant or trying to conceive should avoid melatonin \u201cbased on possible hormonal effects.\u201d (Drank\u2019s bottle now say it is a dietary supplement.)\nThat said, he would not advise eating Lazy Cakes, partly because he was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear that \u2013 despite the claims made by some who stand to profit \u2013 there is no quantifiable information about benefits documented about these products.\u00a0 And there\u2019s this closing skepticism from Dr. Lewy: \u201che was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\u201d", "answer": 1}, {"article": "J Nucleic Acids pli:725071. doi:10.4061/2010/725071.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\nThese trials employed a simple, economical design in which participants acted as their own controls (i.e., change in metabolic markers was measured before and after eating the bar).\nThey are currently conducting experiments to better understand which ingredients in the bar are most important in the complex mixture for the observed effects.\nThese trials were conducted over a 4-year period using very similar bar formulations.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The peer-reviewed article on which the news release is based quantifies the results of the study, which don\u2019t seem to square with a claim of \u201cbroad scale health improvement.\u201d According to the study abstract, a group of \u201cless-inflamed\u201d participants lost 2.4 pounds of body weight over the course of 2 months while eating the bars. But the news release refers generally only to such things as \u201cimproved metabolism\u201d and \u201creduction in weight and waist circumference,\u201d offering no specifics.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nOther estimates are far higher.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear there was no significant difference between a sham procedure or stent insertion, but it only describes the benefit as \u201cless pain.\u201d We would like to see how the pain was measured, some numbers on how much pain was reduced, and how many patients benefitted in each group.", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\nThis is one of very few studies that looks at olive oil intake and risk for neurologic diseases, including stroke, Nikolaos Scarmeas, MD, of Columbia University in New York City, says in an email.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only cited a 41% lower risk of stroke but didn\u2019t give the actual numbers of how many versus how many in the different groups. That may give an inflated sense of benefit or risk reduction.", "answer": 0}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nAnd while the participants in both groups exercised more and cut back on alcohol during the study, they did so at similar rates, making these changes unlikely to be responsible for the differences in health outcomes either.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us there was a \u201c48%\u00a0reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\u201d However,\u00a0the absolute difference in outcomes between groups was not quite as striking as this figure would suggest. There were 20 events in the meditation group and 32 in the control group \u2014 data the story easily could (and\u00a0should) have provided.\nThe story did not provide any information on cardiovascular endpoints which were secondary outcome measures.\u00a0 There were 4 deaths from cardiovascular disease in the meditation group and 5 in the health education subjects.", "answer": 0}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided no insight about the amount of circumference that could be reduced with the use of these devices or whether the reduction was predictably long term or not.", "answer": 0}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\nMONDAY, Jan. 4, 2016 (HealthDay News) -- Newer blood pressure drugs are as safe and effective as older medications, new research suggests.\n\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never says what outcomes exactly we\u2019re talking about \u2014 deaths, heart attacks, blood pressure? Nor does it say how effective these medications were at improving these outcomes \u2014 merely that they are equivalent. We think both of these issues should have been addressed in order to earn a Satisfactory rating here.", "answer": 0}, {"article": ".\nAccording to Ana Isabel Jim\u00e9nez, Director of R&D at Sylentis, \"we trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world.\"\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nTivanisiran is a product under development for the treatment of signs and symptoms related to dry eye syndrome and has the potential to be developed for other pathologies that cause ocular pain (corneal lesions, refractive surgery, etc.)\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no effort made in this release to provide any numbers that would put the benefits of using tivanisiran in context. It does quote a scientist working on the treatment endorsing the drug:\nAccording to Ana Isabel Jim\u00e9nez, Director of R&D at Sylentis, \u201cwe trust in our technology, innovative in this field, and we hope that tivanisiran will soon become a real alternative for the treatment of millions of people that suffer dry eye disease around the world.\u201d", "answer": 0}, {"article": "\"We have a lot of kids skipping meals for a whole bunch of reasons,\" he said.\nAt the end of the period, those students who received the snack more regularly experienced a decrease in their overall BMI (-.7kg/m2) compared to those who did not receive the regular peanut snack (-.3kg/m2).\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nThe study acknowledged that snacking is more common during the adolescent years and that the unhealthy eating habit can lead to an unhealthy weight.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release confuses or misses some key points about the study and the data it obtained and set out to measure. The intervention was not a \u201c12-week\u201d study, but lasted six months overall. Moreover, the goal of the study was not to measure the impact of eating peanuts on weight loss. It was to compare the weight loss or BMI-reduction outcomes in Mexican-American children who were either high adherents or low adherents to a suggested (and freely offered) snack of peanuts or peanut butter on a daily basis at the end of the school day. And the study also included educational and physical activity components. The release is unclear about the actual number of students in the comparison groups who lost weight. It is silent on how much the teens weighed on average or across a range at the start and end of the study in the comparison groups, and it tells us nothing about the number of calories in the snacks or how much physical activity was involved. The published abstract did not either, but presumably the full study was available in the preparation of the release. The release does note that students who got the snack more regularly decreased their overall BMI by .7kg/m2 compared to those who did not get the snack regularly, but most readers will not do the math or understand what the figure means. It needs to be pointed out that the 0.7kg/m2 drop was not deemed statistically significant, even by way of the often-denigrated p value where it was found to be 0.21 (a value less than .05 is traditionally deemed \u201csignificant\u201d). It\u2019s also worth noting that the absolute difference in weight between the two groups was the high adherence kids GAINING\u00a01.54 pounds less than the low adherence kids \u2014 a difference deemed not to be statistically significant either (P 0.63).", "answer": 0}, {"article": "Melbourne based start-up Atmo Biosciences is set to commercialise this revolutionary technology.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nThis second paper made a direct comparison between measuring hydrogen production within the gut via the gas-sensing capsule and indirect measurement through breath testing.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main benefits touted are:\nUnfortunately, we\u2019re not given any supporting data, or context to place these results in perspective.\nAre readers expected to know what high sensitivity and signal-to-noise ratio are?\nWe\u2019re told the capsule measures gases, but how do those relate to disease?\nFurthermore, where\u00a0exactly\u00a0did the\u00a0\u201c3000 times more accurate\u201d figure come from and what does it mean? Based on our analysis of the study itself, it seems that the\u00a0capsule detected about 12 times as much hydrogen as the breath test in the point of the intestine with the greatest difference.\nAnd \u201csensitivity\u201d (the ability to correctly identify patients with disease) cannot be measured since there are no patients with confirmed disease in this study. (We provide an overview of sensitivity and other issues related to medical testing in our primer: Understanding medical tests: sensitivity, specificity, and positive predictive value.)", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story mentioned weight loss, health improvement, and longer life, it failed to provide quantitative estimates for these. \u00a0\nThe story provided quantitative information on the disease reduction obtained with the use of this device in individuals with type II diabetes. \u00a0 Although the story did mention that weight loss is slower with gastric banding than with gastric bypass, it\u00a0failed to provide quantitative information about the amount or rate of weight loss attained with banding. \u00a0The story should also have mentioned that long-term followup finds for those whose diabetes resolves following gastric banding, about half re-develop diabetes at 10 years. \u00a0\n\u00a0", "answer": 0}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nAlthough capturing specific numbers related to cost-savings was not part of this study, Dr. Gunter said it is an important area of focus for future studies.\n\"We have demonstrated that a population of complex and high-risk patients, many of whom are older adults and novice smartphone users, can complete this protocol with high fidelity and satisfaction,\" the researchers concluded.\nThe WiSOR research team addressed this issue by having participants undergo tailored training to learn to use the WoundCheck app.\nShe said this is a model easily adaptable to other medical centers, whether through providing participants with a phone, having a rotating supply of phones at the hospitals for patients to borrow, or relying on a patient's personal device.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports \u201can overall data submission rate of 90.2 percent among participants, and submissions were reviewed within an average of 9.7 hours. During the study, seven wound complications were detected and one false negative was found.\u201d\nBut with no control group and no long term outcomes studied, it\u2019s likely the benefits of the app are much more modest than these numbers suggest.  ", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nIn addition, the study looked at the whole fruit, not individual nutrients.\nThe study was to be presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla.\n\nCardiologists were quick to caution that there is no single magic food or ingredient that is the key to heart health, but they all agreed that kiwi may have a place in the five daily servings of fruit and vegetables that are currently recommended as part of a heart-healthy diet.\nSo, is kiwi the new \"wonder\" fruit?\n\"When we say 'eat more fresh fruit,' we stick to the tried-and-true or anything that is handheld and peeled, but these findings suggest that a kiwi can be part of a heart-healthy diet,\" he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits but didn\u2019t put them in any meaningful perspective. What difference does it make to lower systolic blood pressure by 3.6 points?\nIs this truly newsworthy?\nEnough to raise the question in the story, \u201cSo is kiwi the new \u2018wonder\u2019 fruit?\u201d", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nThe problem in bipolar illness and depression, he explains, doesn\u2019t appear to be that a person has too much or too little glutamate; instead, it\u2019s likely that the way their neurons release and take up the chemical is out of whack.\nThe 18 patients in the study had tried an average of seven different drugs for treating their bipolar illness, and were still severely depressed; 55 percent had failed electroconvulsive therapy (ECT), or shock treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tosses in a few numbers, but it uses them in such a way that they make the benefits seem more impressive than they really are. An honest approach would have been to start with the 18 patients and then give the absolute number of all patients who benefited, did not, or suffered side effects. Instead, the story says, for example, that \" Six percent responded to placebo.\" That\u2019s roughly\u00a0one person. One person versus the 12 who responded to the drug. Whether this ratio would shrink or expand in a larger, controlled study is never discussed with any other scientists.", "answer": 0}, {"article": "The vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\nThis finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This release describes the weight loss benefits of a vegetarian diet in terms of average weight lost. It states that participants in the vegetarian diet group lost an average of 6.2 kilograms in comparison to participants in the conventional diet group who lost an average of 3.2 kilograms. It also claims those on the vegetarian diet lost more subfascial and intramuscular fat than those on a conventional diet.\nThe release never tells us how long the study lasted, you have to go to the published report for that. When we did, it wasn\u2019t clear whether the weight loss was maintained at 6 months and beyond. It is very common for weight-loss studies to show that initial weight loss is greater than later weight loss, especially when there is no blinding involved.\u00a0", "answer": 1}, {"article": "Not only have the number of women choosing breast implants for augmentation risen by nearly 40 percent in the last decade, Schulman says that in his practice, 80 percent of them are choosing silicone over saline.\nBack then they contained a runny liquid silicone.\nDoctors reassured her it wasn't her implants.\nBut ultimately she decided she didn't want to go through more surgery.\n\"A little tooty noise.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 This was about safety.\u00a0 No good way to quantify benefits.", "answer": 2}, {"article": "\"The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries,\" Webster said.\nTUESDAY, March 13, 2018 (HealthDay News) -- A pill that combines three blood pressure-lowering drugs improves people's chances of lowering their high blood pressure, researchers report.\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\n\"Most hypertension guidelines in these countries do not recommend combination blood-pressure-lowering therapy for initial treatment in all people.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Among those who took the so-called \u201ctriple pill\u201d for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care. The story doesn\u2019t state this, but we found via the news release that \u201cusual care\u201d meant taking whatever blood pressure medicine their doctor prescribed.\nAlso, there was no information in the news story about what the blood pressure targets were. According to the release, the blood pressure target was 140/90 mm Hg or less, with a lower target of 130/80 mm Hg or less for those with diabetes or chronic kidney disease.\nLastly, the story should have cautioned that lowering blood pressure might not reflect benefits on patient-centric outcomes like heart attacks and strokes. It is a surrogate marker.", "answer": 0}, {"article": "\"Hopefully, there will be less anxiety about getting a recall.\"\nThe frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\nMeanwhile, the American Cancer Society continues to recommend that women get mammograms every year beginning at age 40.\nWomen can halve their risk of a call-back for a false-positive if the interpreting radiologist has previous mammograms for comparison, the researchers found.\nOct. 17, 2011 -- Getting screening mammograms every two years instead of annually reduces the chance of a false alarm, a new study shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This article leads with valuable information for all women over age 40 by stating \u201cGetting screening mammograms every two years instead of annually reduces the chance of a false alarm, a new study shows.\u201d\u00a0 Unfortunately the writer doesn\u2019t quantify or elaborate adequately on that reduction.\u00a0 Instead, the writer later focuses on how women undergoing screening mammography shouldn\u2019t be anxious if they experience a recall because over half of women who have screening mammograms for 10 years will be recalled.\nReaders would have been better served if the writer had emphasized the significant reduction in both recall mammograms & false-positive biopsies in women who are screened every two years rather than annually.\u00a0\u00a0Part of the continuing controversy\u00a0over screening mammography\u00a0focuses on\u00a0annual versus biennial screening.\u00a0 Because this\u00a0study showed a significant reduction in the percentage of those recalled & needing biopsies among women who are screened\u00a0every other year, with no\u00a0statistically significant increase in late-stage diagnosis of breast cancer, the article should\u00a0have emphasized those important findings.", "answer": 0}, {"article": "\"We should offer all women the possibility of a cure.\"\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\u2022 The surgery should be aggressive in an attempt to remove all visible signs of the tumour, and to avoid leaving any residual disease.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The key benefit here is the survival rate and, on this point, the release is fairly clear. It notes that the current survival rate for advanced stage ovarian cancer is 20%, and that adopting a new standard of treatment could increase that survival rate up to 50%. The release would have added clarity by including an explanation of what is meant by \u201cup to 50 percent\u201d survival. It\u2019s a bold claim about a devastating disease so precision is desirable. The reviewer uses 12-year survival as a proxy for cure in the original article but the release equates this to being \u201ccured\u201d of ovarian cancer. Some might debate that long-term survival equates to a cure \u2014 we\u2019ll give the benefit of the doubt here and dock points below under the \u201cUnjustifiable Language\u201d criterion.", "answer": 1}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nTo learn more about the research, please contact Kara Yacovone at kyacovone@kellencompany.com.\nAnd now, even more good news: new research shows that pasta consumption in children and adolescents is associated with a better diet quality than that of children who do not eat pasta.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not give us any numbers that allow us to see the proof of the association described. Here is one statement from the release.\nThe study \u201cdemonstrated that young pasta-eaters have greater intakes of important vitamins and minerals and lower intakes of saturated fat and total fat in the diet compared to their peers who do not consume pasta.\u201d\nReaders need to see definitions of greater, lower and important in that paragraph. Without numbers and definitions, there is no context for the reader.\nFor more discussion on pasta association research, see this blog post, \u201cEat Pasta, Lose Weight,\u201d published here in 2016.", "answer": 0}, {"article": "Micro-RNA are small non-coding RNA that control many genes and processes vital for cellular life such as metabolism, development and the immune system.\nThe team also validated eight out of nine micro-RNA molecules in an independent group of progressive MS cases, confirming the reproducibility of the findings.\nUsing next generation sequencing and integrative bioinformatics they found that serum exosome micro-RNA profiles not only distinguish MS from healthy controls, but also distinguish relapsing-remitting MS (RRMS) from progressive MS with high accuracy.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nIn addition to identifying biomarkers that distinguish healthy people from those with MS, the researchers identified nine unique micro-RNA molecules that differentiate between two MS sub-types: relapsing-remitting MS (RRMS) and progressive MS.\n\nRelapsing-remitting MS (RRMS) affects 70 percent of people and often evolves into a secondary progressive form of MS. 10-15 percent of people with MS are diagnosed with a progressive form of the disease from the outset known as primary progressive MS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "A source describes possible benefits stemming from earlier and more accurate MS diagnosis \u2014 but these benefits from earlier and more accurate diagnosis are hypothetical. There was no discussion or numerical context relating to the differences in the RNA levels between MS patients and controls. Benefits of the test were not quantified. ", "answer": 0}, {"article": "\u201cI don\u2019t know why it is not being incorporated in the US,\u201d she said.\nSome European hospitals already rely on the method, called cell-free fetal DNA, although it\u2019s not available from doctors in the U.S.\n\n\u201cWhat they are finding in England is that many women are not going on to have the invasive tests,\u201d Bianchi told Reuters Health.\nThat leaves some room for error, which could be important if parents are making medical decisions based on the results \u2014 such as whether or not to get an invasive procedure to look for genetic disorders.\nNEW YORK (Reuters Health) - Blood drawn from expectant mothers could offer parents an earlier sneak peek at their baby\u2019s sex than methods currently used in the U.S., researchers said Tuesday.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Reuters examines how parents may benefit from earlier results in pregnancy if their unborn child is at risk of a serious genetic defect that is sex-linked. However, the story also points out that there is some chance of mistakes with the early testing.\nWe\u2019re just surprised that neither Reuters nor the NY Times pointed out in absolute terms that 5 out of every 100 tests of girls and 1 of every 100 boys will be wrong \u2013 6 out of a hundred multiplied by millions of pregnancies a year is a lot of errors even if uptake is small.\nIt\u2019s also worth noting that most research achieves better performance results than when the tests are used in the real world.", "answer": 1}, {"article": "\"This is an important area of research.\nThe study found that the advanced version of TCD ultrasound was able to differentiate between healthy and concussed athletes 83 percent of the time.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\n\"There is growing evidence that concussions can change the blood flow in the brain,\" said study author Robert Hamilton, PhD, co-founder of Neural Analytics in Los Angeles, Calif., and a member of the American Academy of Neurology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the TCD ultrasound device \u201cwas able to differentiate between healthy and concussed athletes 83 percent of the time\u201d compared to lower success rates for other procedures. But that is not the only important statistic.\nWhile the concordance between the clinical criteria and the ultrasound was 83 percent, the test has a sensitivity of only 70 percent, suggesting that 30 percent of concussions are missed. In addition, there is a 17 percent false positive rate, It was not made clear by the news release when the test was performed. It appears that the test was well after the traumatic event, so we do not know what the test performance is at the time of injury.\nThe release also makes clear that physicians do not yet know\u00a0what to \u201cmake\u201d of this ability when it comes to clinical care.", "answer": 0}, {"article": "\"It's not far-fetched that the pharmaceutical industry will try to create a supplement of these microbiomes, much like was done with probiotics,\" she said.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn from the release: \u201cThe abundance of these two bacteria were increased twofold when there was a pet in the house,\u201d and those effects take place \u201cduring pregnancy as well as during the first three months of the baby\u2019s life.\u201d\nBut we\u2019re left wondering, twofold of what? \u00a0And what kind of effects are related to a twofold increase in these two bacteria? The release doesn\u2019t tell us.", "answer": 0}, {"article": "Furthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nCurrently, the team is randomizing prostate cancer patients to participation vs. no participation in this structured yoga program in order to further characterize the potential benefits of yoga in this population.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Numbers might have helped the reader decide whether, in fact, the news release was really about how yoga may lessen the side effects associated with prostate cancer treatment, or whether it was about the feasibility of such a study.\nBut numbers were lacking. \u201cMost yoga participants reported a sense of well-being at the end of each class, and upon finishing the yoga program and concluding their study involvement, many patients requested and received an at-home practice routine to fit their needs,\u201d one researcher says.\nMost? 51%? 99%?\nMeasuring how someone feels is often subjective and can be difficult. In this case, yoga\u2019s effect was measured by participants\u2019 responses to questions about quality of life, cancer-related fatigue and the prevalence of impotence and urinary incontinence.\nThe comment that scores were variable but then improved suggests that they did not achieve statistical significance. \u00a0Even if they did, the question would be whether the differences were considered clinically important \u2014 and how they would compare versus other interventions. There was a\u00a0substantial loss to follow-up (40%), but the investigator seemed most pleased that 27 men completed the study (and that 45 out of 68 eligible men agreed to participate). We would like to have known what the criteria were for eligibility. This is where it would be be wonderful to have a study to look at. Unfortunately, we\u2019re told only that the study will be published sometime in 2016.", "answer": 0}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nBut sexual health organisations are warning that being classed as a medical device does not guarantee that the app will effectively prevent pregnancy.\nAlong with her husband and co-founder Dr Raoul Scherwitzl, Berglund created the algorithm used in the app for personal use, before deciding it was something she should share with the rest of the world.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites a study that the app, when used precisely as directed\u2013or so-called perfect use\u2013has a failure rate such that 0.5 in 100 women will get pregnant over a year of use. People aren\u2019t perfect, so with so-called typical\u00a0use, 7 people will get pregnant out of 100 users over a year. The pill by comparison, results in 0.3 out of\u00a0100 people with perfect use, and 9 out of 100 with typical use.\nIn addition, the writer makes clear that the method requires abstaining from sex or using other protection for as many as 10 day per cycle, although that interval may decrease with longer use.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story lists these benefits:\nBut these benefits are presented anecdotally. This is unsatisfactory because \u2014 as the story rightly points out \u2014 there is extensive experience with the obstetric use of nitrous oxide in Great Britain, Finland, Canada, and Australia. Providing supportive evidence from this international experience is highly relevant.", "answer": 0}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nNineteen patients (53 percent) in the YAG group reported significantly or completely improved symptoms, compared with none of the patients in the placebo group, the researchers added.\nSix months after treatment, 54 percent of patients in the YAG group reported significantly greater improvement in floater-related visual disturbances, compared with only 9 percent of those in the placebo group.\nThere were no differences between the two groups in harmful side effects, according to the study, which was published July 20 in JAMA Ophthalmology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits of the procedure in question, saying, \u201cSix months after treatment, 54 percent of patients in the YAG group reported significantly greater improvement in floater-related visual disturbances, compared with only 9 percent of those in the placebo group.\u201d\u00a0 It goes on saying, \u201cNineteen patients (53 percent) in the YAG group reported significantly or completely improved symptoms, compared with none of the patients in the placebo group.\u201d", "answer": 1}, {"article": "People rightly have suspicions about it.\nWhile 15%-20% of those on the three other drugs were more likely to gain more than 15% of their body weight, just 10% of those on lithium put on the same amount of extra pounds.\nThe new research, published in the medical journal PLOS Medicine, found that the side-effects of the mood-stabilising alternatives used by most patients are either the same as or worse than lithium, Hayes said.\nThey found that patients on lithium had a higher risk of suffering kidney function problems and developing hypothyroidism or hyperthyroidism and also hypercalcemia.\nThey have prompted calls for a rethink about attitudes towards lithium, given that only an estimated 10% of those with bipolar disorder use it, mainly because patients fear it will cause loss of personality, weight gain and other problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research examined the side effect profiles of\u00a0\u00a0lithium, valproate, olanzapine, and quetiapine and provided hazard ratios for the most commonly recognized side effects.\nThe Guardian story reflects those findings in a qualitative way with some quantitative details, such as: \u201cMeanwhile, lithium patients were less likely to put on weight than patients on the other drugs. While 15%-20% of those on the three other drugs were more likely to gain more than 15% of their body weight, just 10% of those on lithium put on the same amount of extra pounds.\u201d", "answer": 1}, {"article": "For more information about McLean, visit mcleanhospital.org or follow the hospital on Facebook or Twitter.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\nThis research builds upon previous studies demonstrating that art, music, and other similar therapies can effectively reduce symptoms of dementia without medication.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We applaud the release writers for noting this was a \u201cpilot\u201d study only, and just intended to get the research started. But we have to quibble with this statement about benefits because it has no quantifiable metric.\n\u201cThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly\u2013but not exclusively\u2013among patients with milder forms of dementia.\u201d\nWe aren\u2019t given any metric for \u201csignificant\u201d \u2014 did it cut symptoms of agitation by half? And when they call out \u201cmilder\u201d dementia, why aren\u2019t we given a definition for that? In the published study the authors clearly state: \u201cWe did not perform standardized diagnostic assessments or use objective measures of agitation before and after each episode of tablet use.\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although one source quoted in the story quantifies the potential harm of improper use of sunscreen\u2014 inadequate skin coverage causes \u201c25% less value\u201d\u2014there is no attempt to quantify the reported benefit of slathering up with new, specially formulated sunscreens. ", "answer": 0}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThese findings illustrate how use of the I-Portal goggle can better identify oculomotor, vestibular and reaction time (OVRT) differences between those with mild traumatic brain injury (mTBI) and non-affected individuals.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Besides stating the sensitivity and specificity figures, the news release does not provide any additional information on the meaning behind these numbers. These are technical terms that can easily be confused with accuracy.\nSensitivity, also called the true positive rate, refers to the rate at which the test correctly identifies those who do have the condition.\nSpecificity, also called the true negative rate, identifies the correct proportion of negatives in a test (i.e. its ability to rule out those who do not have the condition).\nAlthough 89% sensitivity and 95% specificity sound as if the test is quite accurate,\u00a0it misses the main point, which is that the test performs less well than looking at symptoms. The study compared the new \u201cobjective test\u201d to standard criteria for diagnosing TBI. What the study showed was that compared to standard methods, this new one missed 11% of those with TBI and over-diagnosed it in 5% of the non-TBI controls.\nAlthough the sensitivity and specificity figures were given in the news release, none of these terms were explained for reporters and general readership. This is why we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\"I refuse to believe that there's going to be any other outcome than 'it's all going to be okay' because the alternative is unfortunately not something I want to think about.\"\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nWhen Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\nRecent research from Tufts Medical Center found evidence that these prenatal tests can detect cancers in pregnant women.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The CBS story says that the study \u201clooked\u201d at eight women. But this is an incomplete description. The study involved\u00a0125,426 samples from which abnormal results (typically indicating a chromosomal disorder in the fetus) were detected in\u00a03757 (3%). Ten cancers were subsequently identified in women whose babies were found to be normal despite an abnormal test result, with further analysis done on the eight women mentioned in the story. Without this\u00a0quantitative data, readers have no sense of the rarity of the eight cases described or of the scope of the benefit that might be realized if such testing were offered more widely.", "answer": 0}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nThe researchers also cautioned that the process is not without risk, with patients vulnerable to infection during part of the therapy.\nAfter the stem cell treatment, \"patients are absolutely medication-free; they're off insulin,\" said Dr. Richard Burt, chief of the division of immunotherapy at Northwestern University's Feinberg School of Medicine and senior author of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the new therapy eliminated the need for injections for months or years in 14 of 15 patients, thereby describing absolute benefits. ", "answer": 1}, {"article": "The average age of children in the study was 7.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release mentions a diagnostic accuracy rate of 81%, but where exactly does this number come from and what does the term \u201caccuracy\u201d mean here? We\u2019d prefer a more detailed discussion that includes an explanation of the sensitivity and specificity of the test. Or at least a mention of false positive and false negatives. The study that\u2019s the basis for the test told us there was 1 false positive and 6 false negatives out of the 18 people in each group. But later on in the release, we learn that the researchers aren\u2019t sure yet if the test can distinguish between autism and other similar neurodevelopmental conditions, so the low number of false-positives reported may not hold up with additional research. In addition, the release says that while typical children adjusted their sniffing almost instantly when smelling an odor, \u201cchildren on the autism spectrum showed no such response.\u201d If that\u2019s the case, why wasn\u2019t the test 100% accurate?\nThe release did a reasonable job here and emphasized that the study isn\u2019t ready for clinical use. But we don\u2019t think it quite met our standard for reporting on the complex issue of diagnostic accuracy.", "answer": 0}, {"article": "What does that mean for men today?\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\nPerhaps more important, it suggests a more in-depth evaluation of the common blood tests could better predict who needs aggressive treatment and who has a slower-growing tumor that may be OK to monitor instead.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides survival rates for men with high PSA velocities\u00a0and low PSA velocities (although the time period for the estimates is not so clear).\u00a0 Because this is an observational study, absolute risk reductions are not possible.\u00a0 While this is adequate, the story overstates what the findings mean.\u00a0 A quote from the lead author stating,\u00a0\"It doesn't just diagnose prostate cancer, it diagnoses prostate cancer that's going to actually cause harm,\"\u00a0is unfounded and not supported by the\u00a0evidence.\u00a0\u00a0Additionally, the story's inclusion of a recommendation from the lead author that men have \"baseline\" PSA tests at 40 to use as a comparison for future changes is another example of enthusiasm despite evidence. \u00a0 ", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article states that pomegranates produce cardiovascular benefits through decreased blood pressure (unquantified), decreased oxidation of LDL cholesterol (unquantified), improved coronary blood flow (unquantified), and reduced PSA (unquantified).", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\n\u201cAnd certainly there's an emerging research base showing that some of these bioactive components may affect another lipoprotein particle favorably, like high-density lipoprotein.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\nJust an avocado a day can significantly lower your cholesterol and reduce the risk of heart disease, a new study shows.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story accurately compares the reduction of LDL cholesterol in study participants who ate avocado to reductions in LDL among study participants who did not \u2014 the avocado group\u2019s LDL levels dropped by just over 13 milligrams per deciliter of blood (13.5 according to the news release), compared to reductions of 8.3 and 7.4 for two other groups. The story also provides readers with a frame of reference for those numbers, noting that overall LDL levels should be below 100 (which makes a difference of 5 or 6 mg/dl fairly significant). The story also explicitly makes the connection between LDL cholesterol and human health, noting that it is a significant risk factor for heart disease.\nWe wish the story had explained how the changes observed in the study would affect someone\u2019s risk of a heart attack or stroke. In addition, there\u2019s a reference to the \u201cplaque-busting\u201d properties of monounsaturated fatty acids that is a bit of unnecessary hype. There is no medication or nutrient that \u201cbusts\u201d plaque, but rather a healthy lifestyle, diet, and medications for some will help prevent its accumulation. Given the other strengths discussed above, we don\u2019t think these problems are sufficient enough to warrant an unsatisfactory rating.", "answer": 1}, {"article": "\"It's clear we need more efficacious drugs with milder side effects.\"\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nFrom 20 to 45 percent of people who score high on the scale go on to develop full-blown psychosis, in which these symptoms become extreme, researchers have found.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides some quantification of the benefit of taking Zyprexa to delay psychosis after one year of treatment, but this difference was marginally statistically significant, which is also mentioned. What the story does not report: After the medication was stopped, these patients showed more severe psychotic symptoms than when they were first recruited for the study, suggesting that while symptoms were blunted, the disorder progressed despite the use of anti-psychotic medication. ", "answer": 1}, {"article": "But you may not want to start a raucous celebration just yet.\nAn analysis of 10 human studies of the supplement presented at the American College of Sports Medicine annual meeting in June concluded that quercetin supplementation \u201cis very unlikely to provide an endurance performance advantage.\u201d\n\nBut the beer experiment did not begin by looking at mice.\nThese effects matter, said Dr. Johannes Scherr, lead author of the study, because if a marathon runner\u2019s body is less sore and inflamed after a race, and he doesn\u2019t develop the sniffles, he can recover and return to training more quickly than he otherwise might have been able to.\n\u201cIt can be speculated that the training frequency could be higher (with shorter breaks after vigorous training sessions)\u201d in those drinking beer, he wrote in an e-mail response.\nBut, said Dr. Scherr, it almost certainly involves the beverage\u2019s rich bouquet of polyphenols, chemical substances found in many plants that, among other things, \u201csuppress viral replication\u201d and \u201cinfluence the innate immune system positively,\u201d all beneficial for fighting off a cold.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did quantify the benefits of one parameter by quoting the abstract \u201cincidence of upper respiratory tract infections was 3.25-fold lower\u201d \u2013 but it was not mentioned that these were self-reported upper respiratory tract infections.\nThe story mentions that there was \u2018significantly less evidence of inflammation\u2026.and lower counts of white blood cells than the placebo group\u201d but does not provide numbers. The story also states that the \u2018beer experiment\u2019 showed benefits of minimizing post-race damage. But the study didn\u2019t measure damage, it measured blood markers of immune function.", "answer": 0}, {"article": "\u201cOur clinical trial participants were overwhelmingly receptive to this new technology,\u201d Pillsbury said.\nThe EAS System FDA approval is for candidates who are 18 years old and older who have normal to moderate sensorineural hearing loss in the low frequencies, sloping to a severe-to-profound hearing loss in the high frequencies.\nNinety-two percent of participants reported an improvement in their ability to hear even among background noise, one of the most challenging listening environments for people with hearing loss.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release claims that 97 percent of participants in the clinical trial at UNC \u201creported a benefit\u201d from the device within the first year and 90 percent reported overall satisfaction. It says \u201con average, patients performed more than twice as well on tests of speech understanding\u201d compared to those without the implant.\nIt is not clear if the benefit experienced by 97 percent of participants translated into clinical (real-life) significance for patients. What exactly does \u201csatisfaction\u201d represent in this context? The release doesn\u2019t specify. And how big a benefit is performing \u201ctwice as well\u201d as patients who didn\u2019t get the device? The answer depends on what the baseline hearing losses were for each group of participants \u2014 something not discussed in the release. There are no data at all on failures, removals, infections, etc. They are not mentioned.", "answer": 0}, {"article": "The drug has not yet been approved by the U.S. Food and Drug Administration.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\n\"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the benefits, albeit only in relative terms. The story says, \u201cApixaban showed a 21 percent relative reduction in the incidence of strokes or systemic embolisms (clots) when compared to warfarin, a 31 percent relative reduction in major bleeding and an 11 percent relative reduction in overall mortality, the researchers found.\u201d We would have liked to have seen these comparisons in absolute terms. When you read in the story, for example, that 18,000 patients were studied, you might assume that a huge number of them died, meaning that 11% percent difference represents hundreds of people. In reality, the differences were quite small.\u00a0 For example, the 21% relative reduction in stroke or embolism is an absolute difference of 1.27% with apixaban as compared to 1.6% with warfarin. The 31% relative risk reduction in major bleeding is an absolute difference of 2.13% with apixaban and 3.09% with warfarin.\u00a0 This is a great example of why absolute numbers are so important in this type of story.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification here was presented in such a way to make it clear to readers that there was no significant benefit found to surgical intervention, which is a fair conclusion to draw from the study. The story says, \u201cIn the Stich study, 41% of patients assigned to treatment with drugs alone died during the follow-up period, which averaged five years. That compared with a mortality rate of 36% among patients who received bypass surgery plus medication. Although the relative reduction in risk of death was 14%, the result didn\u2019t meet tests for statistical significance, meaning it could have resulted from chance alone.\u201d\u00a0That\u2019s a great way to describe the lack of statistical significance. It would have been even more powerful to show readers the actual number of patients who died in each group.", "answer": 1}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Quantifying changes in cognitive function for readers is a challenge.\u00a0 Exactly what does a long term memory performance of 46% of normal mean?\u00a0 Are these changes important for daily living or are they statistically significant but clinically irrelevant?\u00a0 The story included that important caveat from the researchers:\u00a0 \u201cwhether these effects are clinically important will require larger studies.\u201d", "answer": 1}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story really does not provide a crisp rationale for a bioabsorbable stent.\u00a0An important limitation of existing stents is that they are associated with increased risk of clots. The absorbable stents are designed to\u00a0help with this problem, but the story doesn\u2019t communicate this. It only\u00a0refers to the\u00a0possibility that the\u00a0new stents may also cause clots in some people.\u00a0The comments of the Abbott spokesperson aside, the reader is not provided with any idea of how often the existing stents create difficulties and why the Abbott stent will alleviate the problem.", "answer": 0}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nBut they do focus on the group of women for whom there is the most debate about the value of radiation.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\nWEDNESDAY, Sept. 21, 2016 (HealthDay News) -- New guidelines issued by three leading cancer organizations suggest that more breast cancer patients should consider radiation therapy after a mastectomy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits aren\u2019t quantified in the story. In fact, benefits are barely discussed in the story. The story simply notes \u201cthe guidelines say there\u2019s enough evidence to show radiation treatment after a mastectomy decreases the risk of breast cancer recurrence.\u201d But how much does it decrease the risk of breast cancer recurrence? \u00a0If the benefits aren\u2019t clearly defined, it\u2019s virtually impossible to determine if the costs and risks outweigh them. Granted, the decreased risk of recurrence likely varies widely based on the patient and type of cancer (a point the story makes). But the story would have been much stronger if it had tried to offer more detail on benefits for readers.", "answer": 0}, {"article": "Autistic children are prone to seizures.\nOther doctors said Geier's studies were small, were not scientifically sound and were published in journals that do not follow the standard practice of having experts review the methods.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nThese experts contend that Lupron, costing about $5,000 a month but seldom covered by insurance, is one of many treatments that cash in on the desperation of parents trying to cope with an incurable condition for which medicine has few good answers outside of painstaking behavioral therapy.\nThe area's largest autism treatment center jointly run by the University of Miami and Nova Southeastern University, as well as another at Florida Atlantic University, frown on Lupron and other untested therapies, officials at the centers said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story, as noted, cites the Maryland researcher\u2019s claims from small published studies, but also states: \"      \nnumerous physicians, researchers and therapists insist there\u2019s no proof mercury causes autism, that Lupron removes mercury or that autistic kids have excessive testosterone.\"", "answer": 1}, {"article": "Amgen reported just $40 million in third-quarter sales.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the drug \u201csignificantly reduced the risk of heart attacks, strokes and death in patients with heart disease\u201d and quotes an Amgen officer as saying, \u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction.\u201d\u00a0 Unfortunately, the story fails to provide any actual data that would support those claims. It does at least explain that this is because Amgen hasn\u2019t released any details yet on the magnitude of benefit. We\u2019d argue that it\u2019s better journalism to wait until that data is in hand, and can be assessed by independent experts.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Another mixed bag.\nBut if we gave a barely satisfactory grade on \u201cevidence,\u201d we must balance the scale here and render this unsatisfactory.\u00a0 Why?", "answer": 0}, {"article": "Systolic blood pressure (the upper number in blood pressure readings) indicates how much pressure your blood is exerting against your artery walls when the heart beats.\nFollowing the 14 days of mango consumption, the study participants resumed their normal daily diet but eliminated mango intake for 13 days.\nYet once mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\nSix of the 24 participants produced methane, and of these six, three shown significant reduction after consuming mango, which is considered a favorable outcome for gut health.\nAdditionally, some of the participants showed favorable changes in the production of breath methane, an indication of the potential influence on gut fermentation.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t quantify the benefits, instead noting that \u201conce mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\u201d The release described benefits \u2014 all surrogate markers for health \u2014 in a similar way for reduced pulse pressure and reduced methane levels in the breath of three of the six patients who produced methane. What does \u201csignificantly lower\u201d mean? And since all of the patients were described as healthy, do the reductions actually matter?", "answer": 0}, {"article": "Researchers found that more patients taking Prozac or Effexor had a substantial improvement in their symptoms than those taking a drug-free placebo pill, regardless of how severe those symptoms were to begin with.\nStill, Gibbons said that the improvement in symptoms for the average patient wasn\u2019t insignificant.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\nWhat\u2019s more, one researcher not involved in the study said its findings still don\u2019t mean the drugs are any better than non-drug methods of treating depression, such as talk therapy and being more physically active.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gave detailed breakdowns of percent improvement in scores on depression tests and provided an estimate of the number needed to treat in order for one to benefit.\u00a0 The difference in benefits between older and younger patients was highlighted.", "answer": 1}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nBoth acupuncture and Alexander Technique prove effective for long-term relief of chronic neck pain\n\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that both acupuncture and the Alexander Technique led to a significant reduction in neck pain at 12 months, as determined by the Northwick Park Questionnaire (NPQ). Statistical significance does not, however, necessarily indicate strong treatment effects. For instance, with enough data in hand, we can discover that minute differences between treatment and control can\u00a0have very significant p-values (calculated probability), although we are not claiming this is the case here. From the original study, we learn the\u00a0treatment effects of 3.92% reduction in NPQ versus usual care for acupuncture, and 3.79% for the Alexander Technique.\nEven with these numbers, the information is still lacking in interpretability. What does a 3-4% reduction in NPQ score really mean? Is the benefit worth the number of sessions of each therapy?", "answer": 0}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nSuvorexant works differently from those drugs, zeroing in on specific brain chemicals involved in the ability to sleep, explained study author Dr. William Herring, executive director of clinical research at Merck.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nA drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The following paragraph is a confusing, convoluted presentation of numbers:\n\u201cAt the outset, when patients spent eight hours in bed, they were typically asleep for 66 percent of that time. One day on suvorexant boosted that by anywhere from 5 percent to 13 percent, relative to the placebo. Between 21 and 37 fewer minutes were spent awake during those sleep periods.\u201d\nFirst, percentages of time asleep were used, then minutes of wakefulness.\u00a0 So the descriptors are switched, leaving readers like us losing sleep.\nSuggestions:\nWe were also troubled by a couple of comments:\n\u201cThere are sleep aids on the market, but they do not work for everyone and they can have side effects that include sleepwalking, daytime drowsiness and confusion.\u201d\u00a0 There is an implied suggestion that Suvorexant will not have these side effects but no data is provided\n\u201cSuvorexant works differently from those drugs, zeroing in on specific brain chemicals involved in the ability to sleep, explained study author Dr. William Herring, executive director of clinical research at Merck.\u201d\u00a0 Yes, indeed Suvorexant does work differently than the currently available drugs but suggesting that \u201czeroing in\u201d on sleep is a bit of an overstatement.\u00a0 The orexin 1 and 2 receptors have been shown in previous studies to effect energy, fluid homestasis, emotion regulation and stress responsiveness to name a few non-sleep effects (Vitamins & Hormones. 89:19-33, 2012)", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story does state that the vaccine could reduce HPV-related cervical cancer by 70%, this is not adequate quantification of the benefits. 70% of what? The reader should be informed\u00a0whether HPV-related cancer accounts for a small or large amount of cancer cases.", "answer": 0}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nEven with detailed template biopsies there is a risk that we may fail to detect prostate cancer in some cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nCurrently indicators such as diagnosed prostatomegaly (enlarged prostate) and unusually high PSA levels can lead to recommendations for biopsy if there is a concern that cancer may be prevalent.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no quantification of the benefits. An allusion is made to the necessity of early diagnosis and the eventual ease of testing, but there is no quantification of how this test compares to other tests. It is unknown how accurate the test might be when used in the general population (no discussion of sensitivity or specificity) or if a biopsy will be needed if the test is positive or if the test will detect cancer at a stage that can be cured nor if it will lead to a decline in mortality. Thus, benefits cannot be quantified and they release should have made that clear.", "answer": 0}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nOn average, she stops breathing 53 times an hour, that's nearly once every minute during a night's sleep.\n\"And as far as I'm concerned, this is a cure.\nA study published in the New England Journal of Medicine found that 68 percent of patients experienced less sleep apnea after getting the implant.\nA treatment is offering hope for millions of patients with sleep apnea, a disorder that causes people to stop breathing when they're asleep.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. Beyond one patient\u2019s anecdotal experience, the story refers to a study that found \u201c68 percent of patients experienced less sleep apnea after getting the implant.\u201d How bad was the apnea before? How did the compare against a control group (if there was one)?\nBut there is virtually no information about the study, the extent of the improvement, how long it lasted, etc. More detailed information is needed here. However, the biggest concern here is that the story doesn\u2019t make sufficiently clear that Inspire is designed to address just one particular type of sleep apnea. It does say that Inspire is for \u201cmoderate to severe cases,\u201d but that\u2019s pretty vague \u2014 and doesn\u2019t address the core problems here. First off, there are two large classes of sleep apnea: obstructive (in which the airway becomes blocked) and central (in which the brain doesn\u2019t send the appropriate signals for normal breathing). Inspire can only address obstructive sleep apnea. What\u2019s more, it can only address some types of obstructive sleep apnea. For example, Inspire\u2019s website notes that \u201cInspire therapy is not intended for patients with a complete concentric collapse at the level of the soft palate.\u201d What exactly does that mean? How common is that condition? I wish the story had told us. What\u2019s more, Inspire\u2019s website also notes that \u201cInspire therapy has not been clinically tested in patients with a body mass index greater than 32.\u201d In other words, no one knows whether Inspire would work on one of the groups of people at greater risk of sleep apnea.\nThere\u2019s also this hyperbolic quote:\u00a0\u201cThis has been revolutionary. It\u2019s been a game changer,\u201d Dr. Maurits Boon said. Considering the device doesn\u2019t work for everyone, is expensive, invasive, and may cause side effects, it doesn\u2019t seem revolutionary.", "answer": 0}, {"article": "Rheumatoid arthritis affects about 1.3 million people in the United States, while osteoarthritis affects 27 million Americans aged 25 and older, according to the American College of Rheumatology.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011.\n\"Joint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\" study author Dr. Bheeshma Ravi, from the University of Toronto and Women's College Research Institute, said in a journal news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes a quote pulled from a news release that says, \u201cJoint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\u201d without any details about how successful or any of the specific characteristics of the patients.", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nBy the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nAddiction specialists not involved in the study said the findings are promising, although side effects such as trouble concentrating, tingling and itching caused about one in five people to drop out of the study.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\n\"You can come in drinking a bottle of scotch a day and get treatment without detox,\" said Dr. Bankole Johnson of the University of Virginia, who led the study, which was conducted at 17 U.S. sites from 2004-2006.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided some idea of the magnitude of benefit from the use of this drug \u2013\u00a0significantly more people using this medication\u00a0were able to abstain from drinking entirely for at least 28 days out of the 98 days of the study.\u00a0 Similarly, there was also a reduction of the average 11\u00a0 drinks per day to 6 1/2\u00a0drinks per day for those using this medication as compared with 7 1/2 for those in the placebo group.\nThe inclusion of the anecdotal report of someone who remained sober years after taking the drug implies a duration of effect well beyond the duration of this study: 3 1/2 months.\u00a0 While there is no formal exaggeration of the effect, a cheery anecdote may falsely raise expectations in the reader.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nThe International Society for the Study of Women's Sexual Health went even further, calling the study \"a great disservice to the millions of pre-menopausal women suffering from (hypoactive sexual desire disorder).\"\nStreicher, an associate professor of clinical obstetrics and gynecology at the Northwestern University Feinberg School of Medicine, said the study drew \"erroneous conclusions.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This rating is borderline as the article noted: \u201cThey said for women using the drug, the number of additional \u2018satisfying sexual events\u2019 averaged out to about 0.5 per month.\u201d \u00a0What would give this increased meaning is what the baseline was. If the baseline is zero or 0.5, maybe increasing that by half a satisfying sexual encounter might be meaningful. If the baseline is 10, does half an additional encounter make any difference? \u00a0Later in the article we learn that \u201c10%\u00a0more patients\u201d had meaningful sexual encounters, but what exactly does that mean? \u00a0\u201c10%\u201d of what? The article tips decisively into Not Satisfactory territory with its unbalanced focus on unrepresentative anecdotes depicting women who had \u201clife-changing\u201d improvements.", "answer": 0}, {"article": "Before treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nEven so, Andriole says, the findings may not make too much difference in the real world.\nThat's according to a study just published in the journal CANCER.\nDr. Gerald Andriole of Washington University, who was not involved in the study, told Shots he wasn't surprised by the results.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story covered a study that raised questions about clinical staging being \u201cworthless.\u201d\u00a0 The story made clear that there were serious new questions about the absence of benefit.", "answer": 1}, {"article": "\"It's bad science, good publicity,\" said the Zone's Sears.\nThe study found that while LDL rose slightly for those in the Atkins group, their blood levels did not differ statistically from the other groups.\nAll the participants reported eating about 2,000 calories a day when the study began.\nA year-long, head-to-head study of four widely used diets found that overweight women who followed the very low-carbohydrate Atkins diet had no adverse health effects and lost slightly more weight than women on the other three.\nAfter a year, women in the Atkins group averaged a modest 10-pound loss compared with about six pounds for those in the other groups.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary outcome of the study was weight loss; after a year, individuals on the Atkins diet were reported to have lost about 10 pounds\u00a0as compared to about a six pound loss on the other four diets.\nThe quantitative\u00a0information on the other clincial parameters measures\u00a0were not reported.", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story posits a cognitive benefit for older adults with more fulfilling sex lives. However, it never quantifies that benefit. It says the sexually less-fulfilled had \u201clower average cognitive scores compared with those who felt sexuality was important and were satisfied with their current sexual activity. The association between lower cognitive functioning and the belief that sexuality was unimportant was significant in both sexes, but seemed stronger in women.\u201d\nHow significant was the difference here, and would it matter to people in their daily lives? Or is it just a statistically significant difference that has no real-word meaning? How much stronger was the association in women? The story doesn\u2019t tell us.\nWe\u2019d also note that this is a cross sectional study that took a snapshot of participants\u2019 cognitive ability at one point in time. The study tells us nothing about potential for sex to prevent cognitive decline, just its association with cognitive abilities at one particular moment.", "answer": 0}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\n\u201cThis suggests that being reassured that all is normal is highly valued by patients and CTCA really helps provide this reassurance.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n\u201cPatients with normal coronary arteries or those with severe coronary artery disease seemed to get the most benefit in quality of life and did best,\u201d senior study author Dr. David E. Newby from University/BHF Center for Cardiovascular Science in Edinburgh, told Reuters Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is about how patients felt and the symptoms they reported, not purely medical outcomes. It notes that the benefits vary from person to person and makes no claim of dramatic benefits. But we\u2019d like to see the claim that was made backed by some numbers. It says \u201c\u2026 patients\u2019 quality of life got worse in the following weeks and months.\u201d How much worse?", "answer": 0}, {"article": "1.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\nMoreover, the consumption of one medium fresh pear per day had a positive effect on nutrient intake since consumers had higher usual intakes of dietary fiber, vitamin C, magnesium, copper, and potassium, and higher mean intakes of total sugars; consumers of fresh pears also had lower intakes of total, monounsaturated fatty acids, saturated fatty acids, and added sugars.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release, as noted above, says pear consumers had a lower body weight and were \u201c35 percent less likely\u201d to be obese compared to non-pear consumers, but there is no hint of context. Was this over time? Did the correlation vary according to age groups? (The age ranged from 19 years old to senior status.) What were the absolute numbers? The release does state that the study found no differences in calories (energy) intake and physical activity between the pear eating and non-pear eating group. And while it mentioned that the analysis looked at cardiovascular risk factors, it was silent about\u00a0any differences (or lack thereof) in cardiovascular disease (CVD) or CVD risk in pear eating and non-pear eating subjects.\nAside from the poorly quantified main point about the association between pear consumption and body weight, the release did mention some of the dietary benefits of pears: \u201cPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories. They are sodium-free, cholesterol-free, fat-free and contain 190 mg of potassium.\u201d", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\nIt compared outcomes of patients who actually received the magnetic pulses against patients in a \"sham\" group, who sat down in the treatment chair for fake sessions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes a single patient anecdote and does provide us with some information about the NIMH sponsored clinical trial: \u201cBoth Cochran and West cite high patient response rates. A clinical trial funded by the National Institutes of Health revealed a \u201csignificant effect of treatment\u201d when patients received TMS treatment. It compared outcomes of patients who actually received the magnetic pulses against patients in a \u201csham\u201d group, who sat down in the treatment chair for fake sessions.\u201d \u00a0\nHere is what the lead author of the NIMH funded study said about the results (http://www.nimh.nih.gov/science-news/2010/magnetic-stimulation-scores-modest-success-as-antidepressant.shtml) performed in 190 patients with depression who failed standard drug therapy::\nHardly the results suggested by the story", "answer": 0}, {"article": "Enter EllaOne, a member of a new class of drugs called selective progesterone receptor modulators.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\nJune 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nSurgery is often the only way to treat painful, bleeding fibroids, but surgery too can sometimes compromise fertility.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that 80 to 95% of women have no bleeding after taking the drug. However, that leaves a lot of open questions about the effectiveness of the drug. For example, how long does this benefit last? What about other symptoms of fibroids like abdominal pain and pressure? The story repeatedly mentions that the drug shrinks fibroids. By how much? Is that difference clinically meaningful? In other words, can women perceive an improvement in bulk symptoms\u00a0(pain, pressure) as a result of the decreased fibroid size? Do the fibroids grow back?", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nProton therapy did not make a difference in all of these side effects, but had significant effects on several.\nThe researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite.\nThe results were presented on May 22 at the annual conference of the Particle Therapy Cooperative Group, held in San Diego.\nThe results have particular relevance for the University of Maryland School of Medicine; this fall the school will open the Maryland Proton Treatment Center (MPTC).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states in the opening paragraph that \u201cpatients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\u201d But it never offers detailed information on what that means. For example, the release later states that proton therapy resulted \u201ca significantly lower number of side effects, including nausea, blood abnormalities, and loss of appetitite.\u201d How much less likely were patients that received proton therapy to experience these side effects? Did they not experience any of these side effects, or did the benefits vary from patient to patient? What type of blood abnormalities are they talking about? Frustratingly, the release goes on to list a wide range of possible side effects from radiation therapy, but then says that \u201cproton therapy did not make a difference in all of these side effects, but had significant effects on several.\u201d Which ones?", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of discussing the manufacturers\u2019 claims of their products\u2019 effectiveness through tests in the lab, including the removal of micro-particles and \u201cclearing\u201d smoke close to the wearer.\u00a0 But more importantly, the story is specific in pointing to the difference between supposed \u201cair-quality\u201d measurements in the lab and any thwarting of the transmission of actual pathogens which would lead to real infections.\u00a0 The story also points out that much of the transmission of cold and flu viruses occurs when hands touch contaminated surfaces, something these devices have no effect upon.", "answer": 1}, {"article": "Soy has been touted as an alternative treatment to hormone replacement therapy after HRT was linked to an increased risk of breast cancer.\nAlthough all the studies looked at soy supplements, Melby says that getting soy from food is a better bet.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n\"I personally think foods [containing soy] are better.\"\nTwo co-authors, not including Melby, have ties to the soy industry.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story dances all around \u2013 but never delivers specific data on the absolute benefit seen in the meta-analysis.\nThe closest it comes is this:\u00a0 \u201csoy supplements with higher amounts of the isoflavone called genistein were more than twice as good at reducing hot flash frequency than those with low amounts.\u201d\nAnd this non-evidence statement from one of the author-researchers: \u201cWhat this study shows is that ingesting soy isoflavones will help you. I personally think foods [containing soy] are better.\u201d", "answer": 0}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\nResearchers say a new way of analyzing genetic test data may one day help identify people at high risk of having a heart attack at a young age in time to help.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story has the researchers estimating that as many as 25 million Americans may have three times the average risk for coronary artery disease, even though their research used \u201ca DNA database from Britain.\u201d\u00a0 The story also says that the \u201cscoring system also can predict an increased risk of Type 2 diabetes, inflammatory bowel disease, breast cancer and an irregular heartbeat called atrial fibrillation,\u201d but doesn\u2019t offer what those increases might be.\nThe big question goes unaddressed and unanswered: Is there proof this test will help anyone?", "answer": 0}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\nIn this study, Greek researchers from Aghia Sophia Children's Hospital in Athens compared the hormones of 23 teenagers with PCOS with 17 healthy teenagers of the same age and BMI.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\n\"Teenagers who get an early diagnosis of PCOS can sooner start to deal with the physical and psychological symptoms caused by this lifelong condition,\" said lead researcher Dr Flora Bacopoulou.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit here would be identifying levels of irisin found in patients with PCOS that are distinct from irisin levels in the control group of study participants who do not have PCOS. So, what we were looking for here is quantification \u2014 what were the irisin levels in the PCOS patients? And what were the irisin levels in the control group? The release doesn\u2019t tell us. Instead, it says only that \u201cteenagers with PCOS had significantly higher irisin levels compared to the control group.\u201d\nEstablishing the superiority of a diagnostic test requires comparisons in much larger populations than were enrolled in this study.", "answer": 0}, {"article": "\"This might also improve the efficiency of reporting,\" he said.\nIn an independent test set of 127 women, the radiomics analysis reduced false-positive findings by 70 percent, while detecting 60 of 61 malignant lesions, or 98 percent.\n\"The model might help to lower the number of BI-RADS 4 lesions suspected of being cancer on the basis of screening mammography while retaining a high sensitivity similar to the sensitivity reported for biopsies themselves,\" Jaeger said.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers learn that after the technique was developed, the radiomics analysis reduced false-positive findings by 70%, while detecting 60 of 61 malignant lesions in a test set of 127 women, or 98%. In order to give full meaning to these statistics, we need to know what the number of false positives was in the comparison group, rather than being given only the percentage of change.\nSimilarly, a brief statement is made about the advantage of the consistency provided by a software algorithm in comparison to readings of images by human technicians. That statement, too, is not quantified. How much error does result from the variability introduced by human reading of images? To what extent is that a problem?\nAlso, the publication stated that the rate of malignant lesions was higher than expected in this group so they would need to replicate this technique to make sure they didn\u2019t have bias within their sample.", "answer": 0}, {"article": "(See below for more information.)\nThe Standardized Assessment of Concussion had performed rather miserably, correctly identifying only two of the concussed athletes, missing 10, and finding that three of the uninjured control athletes had supposedly sustained a concussion, since their scores had declined compared with their baseline (almost certainly, the study\u2019s authors believe, because these young athletes were physically tired).\nThe King-Devick test did much better, correctly assessing concussion in 75 percent of the young injured players and inaccurately identifying it in only one.\nresearchers knew that in recent years, trainers working with athletes in sports such as boxing and mixed martial arts, where concussions are common, had begun supplementing the Standardized Assessment with a simple vision exam, known as the King-Devick test, during which someone reads slightly jumbled lines of numbers printed on three cards as quickly as possible.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides a good discussion of how the vision test compared in reliability with the standard testing protocol including a cognitive test and a balance test. The tests were applied to 243 young (age 5-18) and 89 college athletes playing a season of hockey or lacrosse.\nAmong the 12 students that sustained head injuries, the researchers found the King-Devick test correctly assessed concussion in 75 percent of the injured players and misidentified one. In comparison, the standard testing protocol accurately assessed only two of the concussed athletes and missed 10. The standard tests also misidentified three athletes as having sustained a concussion, according to the study. The study authors concluded that the vision test was the more sensitive, accurate test.", "answer": 1}, {"article": "\"Now I feel relieved.\"\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\nBecause shingles is not contagious and doesn't present a risk of death, Hirsch said he would recommend the flu vaccine and the pneumococcal vaccine over this one for uninsured patients who would have to pay out-of-pocket.\nWhile less reliable than some childhood vaccines, which are usually 90 percent effective in preventing certain illnesses, the shingles vaccination is still worthwhile, said Dr. Ciro Sumaya, professor of health policy and management at Texas A&M Health Science Center School of Rural Public Health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nInterestingly, while other stories about this study touted the finding that vaccination cut the risk of shingles by more than half, this story points out that compared to many other vaccines, a 55 percent reduction in relatively risk is a weak performance. The comment from one individual that the vaccine is \u201cbetter than nothing\u201d also helps readers put the benefits into perspective. The story does include endorsement of vaccination and descriptions of the terrible pain shingles attacks can inflict. It also points out that this study provides information about a reduction in the risk of serious eye problems caused by shingles that was collected by the clinical trial that led to the vaccine\u2019s approval.\nThe story reports the absolute annual shingles attack risk figures of 6.4 per 1,000 among the vaccinated participants versus 13 per 1,000 among those not vaccinated. We would have like to also see the story mention that the results indicate that about 71 people need to be vaccinated to prevent one from suffering a shingles attack. And since the story reported relative risk reduction statistics for ophthalmic herpes zoster cases, it should have also told readers the absolute numbers.\nThe story should have pointed out that the study looked at a limited time span and that the researchers can\u2019t say whether the effects of the vaccine persist through later years. That\u2019s an important caveat, since a 60-year-old who had chicken pox as a child is at risk for a shingles attack for the remaining decades of life. If the vaccine cuts the risk of attacks in half, but only for the first few years after vaccination, then the lifetime reduction in risk would be much smaller.\n\nAlso, the final quote from an expert saying \u201cthe benefit, I think, is overwhelming\u201d may overpower all the statistics, leaving readers with an unbalanced summary of the benefits of this vaccine.\nSo, while overall the story had a mixed performance on this criterion, we\u2019ll give it a satisfactory score.", "answer": 1}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nBut help could soon be at hand in the form of a nasal spray, new research suggests.\nThat uninterrupted sleep period extended to more than four hours, Kaminetsky said.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re giving the benefit of the doubt on the rating, though we wish the story were more precise. The story says the results showed\u00a0\u201ca significant decrease,\u201d and the average was \u201ctwo fewer episodes\u201d per night,\u00a0but a reduction from how many episodes total is unclear. \u00a0 The same lack of\u00a0details complicate the discussion of the measured increase in uninterrupted sleep and quality of life. The numbers in the story, though a little vague, at least give some sense of the magnitude of the benefit in terms that are meaningful to people with this condition.", "answer": 1}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cNot only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well.\u201d\n\nBy testing cancer DNA in the bloodstream, the researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with the drug.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\nThe liquid biopsy, less invasive than a tissue biopsy, also detects early signs of resistance to olaparib and monitors the cancer\u2019s evolution over time, according to the paper, published in Cancer Discovery on Monday.\nThey also used the test to analyse DNA in the blood after treatment had started, so people who were not responding could be identified and switched to alternative therapy in as little as four to eight weeks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the benefits of using the three-in-one liquid biopsy. Readers learned that results of the biopsy were used to initiate (or not) and continue (or not) treatment with a cancer therapeutic drug that targets certain types of prostate cancers in men. Readers did not learn anything about the trial design or how effectiveness of the biopsy was measured. At the very least, it would have\u00a0been helpful to know what proportion of patients \u201cbenefited\u201d (changing drug vs. initiating drug).", "answer": 0}, {"article": "The armpits, palms, and soles are often affected.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\nThe study was small and the findings are preliminary.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are given relative estimates of sweat reduction after treatment \u2013 but no context to judge the scope.\nWhat does an 80% reduction of sweat in a person with excessive sweating amount to?\u00a0 Does that bring them back to near \u201cnormal\u201d?\u00a0 \u2013 Which, of course, raises questions about \u201cWhat is normal?\u201d\n\u00a0", "answer": 0}, {"article": "That confirmed what researchers had believed for several years.\nPaul Workman, professor and chief executive of the Institute of Cancer Research in London, said in a statement accompanying the publication of the journal article that \"the evidence on aromatase inhibitors has been accumulating for well over a decade, but it has taken this huge and complex study to make sense of all the data, and provide a firm basis for clinical guidelines.\u201d\n\n\"It tends to be the discovery of new treatments that grabs the headlines, but it is just as important to maximize the benefit patients get from existing treatments through major, practice-changing studies like this,\" Workman said.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nRichard Gray, a professor at the University of Oxford and who served as the lead statistician for both studies, said that half of all women with breast cancer are postmenopausal with hormone-sensitive tumors and could potentially benefit from both drugs.\nA separate analysis by the same group, also published in The Lancet, looked at bisphosphonates, which are typically used for osteoporosis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reports risk reduction of dying from breast cancer in relative numbers, but we think benefits of an intervention should always be stated in absolute figures when possible. We believe relative risk numbers tend to inflate the impression of how much impact the drug really has. For example, the story states that bisphosphonates could reduce the risk of death by 18% over 10 years. It would be more informative to note that the 10-year risk of death was 14.7% for women who took bisphosphonates vs 18.0% for women who did not receive bisphosphonates \u2014 a 3.3% absolute reduction.\nAnother issue here is that\u00a0aromatase inhibitors are only used in postmenopausal women \u2014 either natural menopause or induced. The story doesn\u2019t explain this.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Provides relative risk reduction of chemoprevention with hormone therapy for high-risk women, however, no absolute risk reduction provided. No quantitative risks mentioned for taking hormone therapy for chemoprevention. Incomplete discussion of reduced rate of side effects in raloxifene group. ", "answer": 0}, {"article": "The woman would then be taken to the operating room area,\u201d Madrigrano said.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\n\u201cThe radar reflector is a replacement for the wire and is essentially a little marker.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although there are theoretical advantages to the Savi Scout device, the news release takes that speculation one step further suggesting not just convenience for the patient but also implying superiority: \u201c\u2026surgeons can target the affected tissue within 1 millimeter of the reflector,\u201d and \u201c\u2026the more precise localization of the surgical site enable surgeons to plan the procedure better.\u00a0That advantage may lead to less tissue needing to be removed and a better appearance of the breast after surgery.\u201d\nSince the Savi Scout has not been compared to the standard approach these are unvalidated statements.", "answer": 0}, {"article": "...\nBE days per week decreased in the 50-mg/d and 70 mg/d treatment groups but not in the 30 mg/d treatment group compared with the placebo group, according to the study results.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While some quantification is given for a secondary study outcome (the proportion who stopped binge-eating for four weeks), no specific numbers are given for the primary study outcome (binge-eating days per week). Since this was the main measure of the success of the study, we think this result should have been described more thoroughly.", "answer": 0}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n\u201cExercising, eating healthy and trying novel ways to improve your health is something you should definitely explore and bring up with your physician.\u201d\n\nEnvironmental factors could play a role in glaucoma risk as well, said Dr. Ahmad Aref at the University of Illinois at Chicago.\nOverall, both medical and non-medical approaches are key to treating the disease in the future, Aref added.\nCoffee, or caffeine in general have previously been linked to increased glaucoma risk, although recent studies don\u2019t agree, Coleman and her colleagues write.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions that study participants who drank one cup or more of hot caffeinated tea daily \u201chad 74 percent lower odds of having glaucoma\u201d compared to those who don\u2019t drink hot tea.\nOur standard response to a statement like this is to ask, \u201c74% lower than what\u201d? A 74% reduction from an already-small number might not be very meaningful.\u00a0Absolute numbers would have helped\u2013here\u2019s more about how to provide them and why this is important.", "answer": 0}, {"article": "An Australian study called the Tasmanian Healthy Brain Project recruited 359 participants ages 50 to 79 who took a series of cognitive tests before completing at least a year of full-time or part-time study at the University of Tasmania.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\n\"The study findings are exciting because they demonstrate that it's never too late to take action to maximize the cognitive capacity of your brain,\" said lead researcher Megan Lenehan, PhD.\nFull text of the article is available from the APA Public Affairs Office and at\n\nThe American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The authors report the proportions in each group for whom cognitive capacity, or actually \u201ccognitive reserve\u201d improved. It\u2019s difficult, though, to evaluate the magnitude of the change from either the news release or the article. It would have been helpful if the author of the news release pressed one of the scientists to translate this into English. We also don\u2019t know whether the increase the scientists measured has any clinical significance. Contrary to what the title of the press release implies, the findings are a long way from saying dementia risk may be reduced by the university studies intervention. The scientific article authors make this clear by saying in their last paragraph that this question is one for further study.", "answer": 0}, {"article": "Researchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\nMore than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\n\"Conventional radiotherapy fails to durably control the primary lung tumor in 60 percent to 70 percent of patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately quantifies the benefits of treatment by providing the number and percentage of participants who had complete or partial response to the therapy. However, the story should have defined what \"complete\" or \"partial\" response means. More importantly, the story was not explicit about the fact that the observed results can only be compared to historical data, not concurrent\u00a0\"best\" standard care. We know what happened to the study patients, but what would have happened if they got standard therapy can only be speculated on.", "answer": 0}, {"article": "\u201cOur lab is on an island in the South.\nBut [by] bringing Omega-3 and -6 and antioxidants to the skin, we\u2019re giving it more of the tools it needs to handle sun exposure.\u201d\nNow, a new study by Yale University cancer researchers, published this year, shows that the cell-damaging effects of ultra-violet rays may continue for some time after you seek cover.\nMs. Peterson, a former marketing executive, began to explore the use of all-natural products several years ago after surviving melanoma, the most serious type of skin cancer.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that \u201cProduct formulators are now seeing after-sun care as another line of defense to stop cell mutations and aging in its tracks.\u201d But the story does not cite evidence to show whether their products do that.\nIn the accompanying video, the reporter is more blunt about the uncertainty:\n\u201cWe don\u2019t really know how long it takes for antioxidants to act on the skin,\u201d says the reporter, who then cites several products. \u201cThey feel great and they smell great and they feel good on your skin after it\u2019s been sun-parched. As to whether it\u2019s helped my skin defend itself from the sun, it\u2019s too soon to say. I\u2019ve only been using them for a couple of weeks, but I think it\u2019s worth a try.\u201d", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nSo \"low risk\" in the Swedish study means higher-risk than the current \"low risk\" men diagnosed in the United States.\nIn an editorial accompanying the study, Dr. Dr. Matthew Smith of Massachusetts General Hospital makes some important points.\nFor this group, surgery saved one life for every seven men who had prostatectomies \u2014 considered a favorable ratio.\nFirst, only about 1 in 20 men in the Swedish study had a prostate cancer diagnosis based on a high PSA level.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported only the relative difference in the number of men in each treatment group who died during the follow-up period. \u00a0For readers to understand what the real difference in risk is, information about the absolute difference in risk needs to be reported. See the AP story for comparison. ", "answer": 0}, {"article": "Both cause uncontrolled daily seizures and put patients at high risk for other physical and intellectual disabilities, injury and early death.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nThe agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nMany parents already are giving children unregulated CBD formulations that are available in medical marijuana dispensaries in the many states where such operations are legal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Some would argue that FDA approval automatically means that benefits and risks of a new drug have been quantified to experts\u2019 satisfaction. But that is not necessarily the case and readers with an interest in this drug would be better informed if some of the clinical trial evidence had been included in the story. As it stands, the article offers no information at all about reduction in seizures of those who take the drug, or a basis for which to compare its value to other treatments for severe epilepsy.", "answer": 0}, {"article": "To find out whether the movements and static poses associated with yoga could make a difference, as earlier research had suggested, Dr. Sherman and her colleagues recruited 228 people with chronic low back pain in the Seattle area.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\nDr. Sherman recommended taking an intensive stretching class, then establishing a routine at home.\nThe improvements remained when the researchers checked with them 26 weeks after the start of the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The journalist adequately framed and quantified the benefits in terms of both primary and secondary outcome measures.\n\n\n\n ", "answer": 1}, {"article": "Median length of stay was 6 days (range, 4-58) with a median follow-up of 25 months.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nSAN DIEGO, April 24, 2015 /PRNewswire/ -- University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife\u00ae System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.\nIRE overcomes rapid growth of the tumor by killing all malignant cells at once so they cannot continue to grow and spread.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly states that nearly three-quarters of pancreatic cancer patients die within a year of diagnosis and 94 percent die within\u00a05 years. It then goes on to\u00a0say the NanoKnife IRE treatment doubles overall survival to 24 months. But the release never provides the absolute numbers from either the treatment or control group to substantiate this. The percentage of patients alive at 24 months may be higher in one group or the other, but the data are not there to tell. In addition, the release states that existing treatment \u201cwill only stabilize the disease and not destroy the tumor,\u201d whereas the new treatment \u201covercomes rapid growth of the tumor by killing all malignant cells at once so they cannot continue to grow and spread.\u201d But it\u2019s not clear that the new treatment does, in fact, do more than \u201cstabilize the disease\u201d or that the cancer won\u2019t \u201cgrow and spread\u201d with the new treatment, since a chart in the abstract suggests that the disease unfortunately remains uniformly fatal even with the new treatment.", "answer": 0}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Deep in the story, a company-funded study of 10 (!) women was discussed \u2013 resulting in \u201cskin that was 25% thicker after a year.\u201d\u00a0 What does that mean? What is the true benefit of that?\u00a0\u00a0 The story says doctors graded cellulite reduction as \u201cgood to excellent.\u201d\u00a0 In all 10 women?\u00a0 Was this a subjective judgment?\nThen the story cites unpublished data from a company-financed trial trial.\u00a0 Might as well have been a news release.\u00a0 Hardly a good source of evidence to cite at this point.\nBy the end, there really was no good quantification of benefit.\nInterestingly, the story provides no information about what the subjects thought about the results.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article assumes Botox reduces the appearances of wrinkles. But it provides no data to verify this. ", "answer": 0}, {"article": "For further information or interview requests contact Sandy Fleming at the University of Kent Press Office.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nIn a report titled Return to running following knee osteochondral repair using an anti-gravity treadmill, published in the journal Physical Therapy in Sport, Dr Hambly demonstrates how a graduated return to running using an anti-gravity treadmill can help to reduce fears about re-injury and increase self-belief in being able to run on the injured knee.\nWhen people run, the load on their knee joints can be up to five times greater than when walking.\nThe cartilage covering the bone surface is not able to heal itself when it is damaged and this is why surgical procedures are available to repair the damaged area.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not offer any units of measurement to describe the benefits. The descriptions of benefits also lean pretty heavily on abstractions that are tricky to measure.\nIn the following example, the benefits are \u201ca great environment for healing\u201d and \u201cbelief\u201d that a patient can make a successful return.\n\u201cNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\u201d\nIn another example, the researcher is paraphrased as saying the machine could be helping to \u201creduce fears about re-injury and increase self-belief.\u201d Basically they are saying that the runner re-gained some confidence in running. This cannot be extended to generalizations about health outcomes.", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nThe evidence is strongest for colorectal cancer, she says.\nThe fact that the government is funding the study is an indicator that the idea has traction.\nNeither study subjects nor investigators will know until the end which regimen they are on.\nBut these studies, she points out, are fraught with possible error.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story did not contain any quantification of the potential benefits from vitamin D.\u00a0 On the one hand, the story mentioned about 12 conditions that might be helped.\u00a0 On the other hand, JoAnn Manson basically said we don\u2019t really know where the true benefits will be until after the clinical trial is done. That was an appropriate balance or the story. ", "answer": 1}, {"article": "\u201cIt\u2019s a survival thing,\u201d she said.\nNearly 5 percent of women with cancer in a single breast had a double mastectomy in 2003, compared with 1.8 percent of women who made that choice in 1998.\nOf the women in Tuttle\u2019s study who received mastectomies in 2003, 11 percent chose to have both breasts removed.\nSuch scans are becoming standard for women who appear to have cancer in one breast, and half the time they raise suspicions about the other breast.\nThen the women can have genetic tests and assess their risks for follow-up cancers before deciding whether to have one or both breasts removed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Generally the article does a good job of using data to show how the number of double mastectomies has increased over six recent years.\u00a0 \nBut there is one serious flaw: The report states that, \"Women removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\" That sounds fearsome, and like a reasonable motivation to undergo double mastectomy. But we have no idea how that 1 percent compares to a woman of a similar age who has not been diagnosed, to a woman with high risk who has not been diagnosed, etc.\nIn addition, the reporter is rounding up from a recurrence rate of between .5 percent to .75 percent, as stated in the research article. The average reader may estimate a 40 year old woman with 40 more years life expectancy has risk of recurrence in other breast of 40 percent; but data suggest it is closer to 20 to 30 percent. \nThe article is also unclear about the evidence regarding mortality: Have no studies looked into the question of whether a double mastectomy increases lifespan, or are there studies that show no difference?\u00a0 ", "answer": 0}, {"article": "All rights reserved.\nIn a meta-analysis by Dr. Enck, entitled \"Therapy Options in Irritable Bowel Syndrome,\"3 published in The European Journal of Gastroenterology & Hepatology, Dr. Enck and the authors concluded that the highest efficacy in the management of IBS is currently found in peppermint oil.\nThe data showed that IBgard\u00ae demonstrated a statistically significant reduction in the Total IBS Symptom Score (TISS) in as early as 24 hours and at four weeks.\nAmong the thirteen IBS options that Dr. Enck and the authors reviewed, only peppermint oil had the lowest NNT (number needed to treat) of 2-3 patients needed for one patient to benefit from the therapy.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not quantify the benefits of IBgard or generic peppermint oil. It makes vague statements about benefits or effectiveness without specifying what they are:\n\u201cThe published data showed that IBgard\u00ae demonstrated a statistically significant reduction in the Total IBS Symptom Score (TISS) in as early as 24 hours and at four weeks. The TISS represents a composite score of eight individual IBS symptoms.\u201d\nWhich symptoms were reduced? By how much were they reduced? How many patient volunteers were involved in the study? The release doesn\u2019t say.\nA strength of the release is the inclusion of information on number-needed-to-treat (NNT). But lack of comparability in the outcomes measured in different studies makes comparison of NNT across treatments difficult. The release tries to make such comparisons nonetheless.", "answer": 0}, {"article": "Patients with chest pain symptoms require multiple blood tests over several hours before a diagnosis is reached.\nA negative (or low-risk) clinical chemistry score at emergency department presentation missed only one of these events compared with up to 25 missed heart attacks/death when using a high-sensitivity cardiac troponin test alone.\nA positive (or high-risk) clinical chemistry score also identified about 75% of patients at high risk of heart attack or death when positive compared with a low of 40% detected when the high-sensitivity cardiac troponin test alone was positive.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The text gets specific about more accurate predictions stemming from the scoring system.\u00a0 But other benefits are not well explained.\u00a0 For example, although the lead of the news release describes the proposed laboratory score as \u201csafer,\u201d it clarifies that statement in a rather murky way lower in the release by noting that the use of an existing diagnostic test, high-sensitivity cardiac troponin, has not been demonstrated to be safe. Why that is the case is never explained.\nAlso, the study design was not reported in the release. In fact, the study was retrospective, so investigators don\u2019t actually know whether outcomes were better among those who underwent the new test vs. the standard troponin.", "answer": 0}, {"article": "Source: Brightling C, et al.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that the study involved 61 participants, about half of whom were given fevipiprant and half were given a placebo. It accurately reports that over the course of 12 weeks, researchers found that those taking the drug saw a decrease in their level of sputum eosinophil, a marker of white blood cells associated with asthma symptoms, from an average of 5.4 percent to 1.1 percent, which is close to that of a person without symptoms.\nHowever, importantly, the news story stated that the drug\u00a0\u201cwas shown to reduce asthma symptoms as well as inflammation.\u201d But the researchers specifically stated that future studies would have to be done to see if the decline in eosinophil counts resulted in improved symptoms. Right now, no one knows if it will help symptoms. For this reason, we\u2019re rating this Unsatisfactory.", "answer": 0}, {"article": "When roasted at 475 degrees, coffee beans are sometimes described as rich and full-bodied.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\nThe study used a \"cross-over\" design, which allowed each subject to serve as his or her own comparison group.\nSubjects did not change their calorie intake over the course of the trial.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the competing Health Day story, this story didn\u2019t provide some key details of the \u201ccross-over\u201d study.\nWas the weight loss seen only while the subjects were taking the active extract, or did it also occur when patients were taking the placebo pills (indicating that the weight loss was due to some other factor, such as their overall diet or exercise levels)? The story says that weight loss \u201cappeared to be greater while subjects were taking the pills than when they were on the placebo\u201d but offers no specifics. To score a satisfactory here, we\u2019d need to see a more thorough reporting of how much weight was lost during the three trial periods.", "answer": 0}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThey are also 16 times more potent than a clinically-used antibiotic in killing the superbug MRSA, and they were also highly potent against other antibiotic-resistant infections, such as vancomycin resistant enterococci, and tuberculosis.\"\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nTeixobactin is a recently discovered natural antibiotic which many in the international scientific community believe could lead to creation of the first commercially viable new antibiotic drug in 30 years.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says the simplified versions of teixobactin \u201chave identical potency\u201d to the natural form. A quote also claims teixobactin \u201ckills bacteria without detectable resistance including superbugs such as MRSA.\u201d But nowhere are readers told that teixobactin has yet to be tested in people. All the claims of benefits are based on laboratory tests. Readers should be told that the benefits for patients have not yet been tested.\nAs one commentary about new antibiotics published last spring noted, \u201cResistance development may not have been observed in initial experiments yet, but similar beliefs for e.g. vancomycin, have been proven wrong. As of yet, teixobactin has not yet reached testing in clinical trials.\u201d", "answer": 0}, {"article": "Too many people give up on treatments like Rogaine and low-level-light devices before they\u2019ve had a chance to work, Dr. Senna said.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The company doesn\u2019t give detailed data on how much hair growth their customers experience and what types of people benefit, and there\u2019s no independent analysis of its product. That\u2019s a problem, and the story should have pointed out this lack of reliable data. Instead, the story says its \u201cresults are certainly compelling.\u201d\nThe story does attempt to give readers an idea of the scope of the claimed benefits, modest as they may be. It states:\nAfter four months of daily application \u2014 that is, working the tea-colored tonic into the hair section by section, then letting it sit on the scalp for six hours \u2014 most users regain at least 30 percent of lost density, and some as much as 60 percent, according to company figures.\nBut the story relies heavily on two anecdotes: a 42-year-old woman who replied that after three months of use, \u201cYou can\u2019t see holes in my hair anymore.\u201d Another user, a 35-year-old man, said he \u201cstarted seeing peach fuzz after four months.\u201d There\u2019s no interview with someone who didn\u2019t achieve a benefit.", "answer": 0}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\n\u201cThe difficulty is identifying which patients will benefit from these drugs,\u201d said Professor Robert Coleman, emeritus professor of medical oncology who led the new study.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did not provide numerical context for the specific benefits of having the MAF amplification genetic testing nor of taking a bisphosphonate drug. \u00a0All readers, but especially those diagnosed with breast cancer, deserve to know specific benefits of testing and treatment. General statements such as \u201c\u2026could benefit thousands of breast cancer patients\u2026\u201d and \u201c\u2026can help prevent the disease from spreading to the bone\u201d do not inform decisions.\nThe published study used invasive disease-free survival as the outcome. \u201cDisease-free survival\u201d is a surrogate or proxy for overall survival \u2014 which is the outcome that patients care about most. To learn more see our toolkit page on the use of surrogate markers in clinical trials.\nFinally, readers should have been provided some context as to what extent the researchers found positive outcomes.", "answer": 0}, {"article": ".\nThis study would also suggest that humans lost something when we rid ourselves of the microbes and parasites that had evolved alongside us for tens of thousands of years.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nShould that work, it has the potential to help the 235 million people around the world who suffer from asthma.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The heading of the article is eye catching: blood-sucking parasitic worms! The health of millions improved! It\u2019s not until about two-thirds of the way\u00a0through the article that it becomes clear these claims are based on the findings of a laboratory study of asthmatic\u00a0mice, and so there are no actual benefits to report on. The treatment hasn\u2019t yet been tested in humans. The article does make an attempt to explain how similarities in mouse and human anatomy suggest that humans might benefit from the same treatment. It also notes that \u201ctheir [the researchers\u2019] next step is a phase one clinical trial, which would test the effectiveness of an AIP-2 pill.\u201d Actually, phase I trials assess safety and appropriate dosage for new medications. Final effectiveness of new treatments is not assessed until much later, in phase III trials. Any\u00a0possible benefits of this treatment to the public, therefore, are considerably farther down the road than the article implies. Furthermore, findings from other studies in the line of research are mixed. All in all, the statement\u00a0that AIP-2 \u201cmay make millions of people healthier\u201d is premature.\nAs we\u2019ve stated many times, mouse research is usually not newsworthy because of these challenges.", "answer": 0}, {"article": "The study appeared online May 13 in The Annals of Rheumatic Diseases.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nResearchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nA Swedish study suggests yet another health advantage of breast-feeding, this time for the mother: it reduces the risk of rheumatoid arthritis.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\nThe news brief says women who breast-feed reduce their risk of rheumatoid arthritis by 25% to 50%. But ideally, readers would also learn the absolute numbers on which these estimates of relative benefits are based. However, the published study also failed to report the reduction in absolute numbers. What\u2019s a reporter to do? Run the numbers on a calculator? Ask the researchers for more information? If the estimated prevalence of RA is 72/100,000, a 25% reduction might be somewhere in the neighborhood of 18/1000,000 or about two-hundredths of one percent (0.02%), and a 50% reduction might be an absolute reduction of 0.04%\u2013a small number any way you look at it. At the least, readers should be made aware that the true meaning of these numbers is uncertain. \n", "answer": 0}, {"article": "The median age was 75 years (range 41to 94).\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\nThe results, which were based on data from more than 1,000 patients across five institutions that comprise the Elekta Lung Research Group, are available online and will be published in the July 15 print issue of International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics.\nThe ELRG includes participants from William Beaumont Hospital in Royal Oak, Michigan; Princess Margaret Cancer Centre; Thomas Jefferson University in Philadelphia, Pennsylvania; Julius-Maximilians University of W\u00fcrzburg in W\u00fcrzburg, Germany; and The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital in Amsterdam, The Netherlands.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No where in the release does it back up the claims made in the headline and the lead that SBRT that the research supports use of SBRT on those 80 and older. Where are the data to support this? The release says:\nStudy results show no significant differences among the three age groups with respect to 2-year local recurrence, regional recurrence, distant metastases or the incidence of grade 3 or higher toxicity. Cause-specific survival was similar among all three age groups (90.3 to 90.6 percent). Two-year overall survival was lower in older patients, which is likely related to other medical issues.\nSo we are apparently to take this to mean that because cancer recurrence in older patients was no different than in younger patients that the treatment was successful? We need numbers to back up these claims.\nWe\u2019d also like the release to be transparent about the fact that the treatment was not compared with any others.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Colonoscopy may miss as many as one in every 13 colon cancers, suggests a new study.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\nBut he added that the risk factors identified match those in the earlier studies.\nWomen were a third more likely to have had their cancer missed, report the researchers in The American Journal of Gastroenterology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story includes a lot of numbers and, for this reason, we\u2019ll give it the benefit of the doubt on this criterion although we would have liked to have seen more numbers in absolute terms. Saying that women had a 30 percent higher chance of having their cancers missed, for example, sounds like cause for a significant health policy overhaul. But what does that mean in hard numbers?\u00a0How many women were included in this study, for one. And what was the ratio of missed cancers for them? We\u2019re told 1 in 13 overall, but what was the breakdown for men and for women? It also would have been helpful to see the absolute numbers by gastroenterologist versus primary care physician, as the skill set of the person operating the colonscopy also appears to be a factor.", "answer": 1}, {"article": "Hupin D, Roche F, Gremeaux, et al.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\nThere were other significant findings too - notably that starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release started off strong by giving the absolute death rate, but thereafter cited relative risk reductions.\nFor example, the release states: \u201c\u2026starting or restarting physical activity during retirement reduced the risk of death by two-thirds, but in contrast any reduction, even in low levels of activity, exposed the elderly to a higher risk of death.\u201d\nBut two-thirds of what? And exactly what figure corresponded to a higher risk of death?\nBenefits reported as relative risk reductions may inflate the impression of how effective the intervention really is. This is why we give the release a Not Satisfactory rating here, since we prefer news releases to report benefits data in absolute numbers.", "answer": 0}, {"article": "S. Raman; M. Pless; A. Cubillo; A. Calvo; R. Hecht; C. Liu; E. Chan; J. Chesney; A. Prat; David Geffen School of Medicine, University of California, Los Angeles, CA;, Department of Oncology, Kantonsspital Winterthur, Winterthur, Switzerland; HM Universitario Sanchinarro, CIOCC, Madrid, Spain; Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain.\nAmgen, the pharmaceutical company that makes T-VEC, was a sponsor of the trial.\nThe authors note several limitations of the current study, including the preliminary nature of the results, as well as the number of patients tested.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The trial was not designed to test the effectiveness of this therapy, so we don\u2019t expect the news release to describe any benefits.", "answer": 2}, {"article": "Whether I\u2019m actually going to take it, well, we\u2019ll see.\u201d\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\nIn addition, some studies might not use large enough doses of the herb; others might use a species of echinacea that is less effective.\nDr. Barrett said there was probably little harm in using echinacea, and he was cautiously optimistic that the herb does have a very small positive effect.\nJ. David Gangemi, director of the Institute for Neutraceutical Research at Clemson University, said he found the study interesting, but added, \u201cI think that many of the people who have dedicated their careers to clinical trials in studying these effects are not at all convinced from this analysis that there is this large reduction in incidence and duration of disease.\u201d\n\nDr. Gangemi is the senior author of a 2005 study, published in The New England Journal of Medicine and included in the review, that found no benefit in the herb.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reporter says the study showed a 58 percent reduction in cold risk, and some unspecified ability to shorten duration.\u00a0It would be useful to know how likely an average adult or child is to get a cold each year, and how long it lasts.\u00a0This would also help\u00a0people understand the possible payoff of taking echinacea\u2013and compare it to the costs. \u00a0", "answer": 1}, {"article": "Separate strands of material become stronger when they link up.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nThey demonstrate it in this video.\n\u201cSuch a result has been previously achieved only by a lower lid blepharoplasty, an invasive surgical procedure,\u201d they wrote.\nThe research was led by Robert Langer, a prolific inventor who heads a biological engineering lab at MIT.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlines the improvements arising from the use of this material, but no numerical\u00a0data was offered.", "answer": 0}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece does a nice job of presenting the results of the initial report in terms of absolute and relative risk reduction; however, absolute data is not provided for the secondary analyses. \u00a0To its credit, the story clearly and effectively explained statistical significance as it relates to this research. \u00a0As stated in previous coverage, the story reiterates that the benefits of the vaccine are modest and additional research is needed. ", "answer": 1}, {"article": "Check back soon for further information.\nCSL, which is one U.S. vaccine supplier, found the same side effects in its study that people experience with regular flu vaccine, which is no surprise since this shot is merely a recipe change from the annual standby.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nBut different manufacturers make different formulations of the vaccine, so more evidence was needed.\nThe dose question has an important ramification: It means people will have to line up for influenza vaccinations twice this year instead of three times \u2013 once for the regular winter flu shot and a second time to be inoculated against swine flu, what doctors call the 2009 H1N1 strain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nNear the top, the story notes that the new trials indicate the H1N1 flu shots appear to be as effective as seasonal flu shots. However, there is no explanation of the phrase that \u201c75 percent and 96 percent of vaccinated people should be protected with one dose.\u201d Does it mean that that percentage of people won\u2019t get sick? This story uses the term \u201ceffective\u201d without defining just what it means for individuals or society.", "answer": 0}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nHowever, this study provides additional evidence on top of prior work from Dr. Andersen's lab and others that lithium may have therapeutic potential in PD, which is a hypothesis that should be tested in clinical trials,\" he said.\n\"The treatment also protected the area of the brain that is normally damaged by Parkinson's.\"\n\"We clearly saw a prevention of the motor difficulties we would expect to see in the animals,\" said Andersen.\n\"For patients these side effects are just as devastating as the freezing that is associated with PD.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We aren\u2019t really provided with much in the way of information here \u2014 the number of animals involved or how they measured the actual improvement in abnormal movements or what the results were. One of the researchers talks about \u201csignificant behavioral improvement,\u201d but is that \u201csignificant\u201d only in a statistical sense or something that would be noticeable to an average person? We are also told, \u201clithium boosted the expression of tyrosine hydroxylase which increases dopamine synthesis via the inhibition of calpain-1, an enzyme that normally reduces dopamine synthesis\u201d but without really informing the reader with why this is important. We are also told about findings from two earlier studies,\u00a0\u00a0\u201cWe clearly saw a prevention of the motor difficulties we would expect to see in the animals,\u201d said Andersen. \u201cThe treatment also protected the area of the brain that is normally damaged by Parkinson\u2019s.\u201d It would have been helpful to have some numbers here, or a more thorough description of what the study actually showed.", "answer": 0}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nDr. Jenkins, who is not affiliated with the company, has continued to monitor Mason.\nMason believes the stem cells accelerated his recovery.\nResearchers have followed Mason and five other patients -- all with the most severe spinal cord injuries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies on comments from the patient, James Mason, and his doctor, Arthur Jenkins, M.D., a neurosurgeon at Mount Sinai Hospital in New York City. Mason is shown in video footage moving his arms and legs in physical therapy. Three months after surgery, he reports that his wrists have become stronger. Six months post-surgery, he says his improvement has \u201cdoubled,\u201d sensation has returned to his feet and legs, and there\u2019s slight movement in his hips. The physician, Jenkins, says: \u201cMy two cents is it worked that this actually changed his neurological recovery and function, that his actual functional improvement is from the stem cells that were injected.\u201d\nNo data is presented to back up these statements. The narrator, CBS chief medical correspondent Jonathan LaPook, M.D., says the company sponsoring a trial of this therapy, which isn\u2019t named, reported that four out of six patients it was following experienced improvement in motor strength and function. However, there are no measurements provided for any of these observed improvements.\nIf these patients are being followed as part of a trial, readers ought to know what outcomes the researchers are looking for (even if the trial isn\u2019t complete as yet) and how they would objectively measure their improvement.", "answer": 0}, {"article": "It may also prevent infections and exacerbations of Chronic Obstructive Pulmonary Disease (COPD) like emphysema.\nThey also had over double the incidence of falls, the study said.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nThe falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did\u00a0not provide adequate\u00a0quantification of benefits. It said that of the 55 elderly people who received high doses of vitamin D, \u201cthose with higher doses saw ARIs cut nearly in half.\u201d That\u2019s quite vague. What was the rate before? Would all 55 have developed ARIs or only two?", "answer": 0}, {"article": "\"It's phenomenal.\"\nAnd starting at two years after treatment, the two groups' survival rate began to diverge, the researchers reported.\nBut some cancer doctors caution that comparing the outcomes for patients receiving the virus treatment to what would have happened to similar patients in the past could produce misleading conclusions.\nAfter 24 months, 21 percent of the patients treated with the virus had survived compared with 14 percent of the historical comparison group.\nThe experimental treatment seems to have extended survival in a small group of patients with glioblastoma who faced a grim prognosis because standard treatments had failed, Duke University researchers say.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job of reporting the scope of the observed benefit, stating that 21% of patients \u201cexperienced a prolonged survival\u201d and then breaking down that number with more specifics. For example, it reported that after three years, 21% the treated patients survived versus 4% of a historical control group.\u00a0But in a small study, why not cite the actual numbers \u2013 how many out of how many? \u2013 rather than make readers do the math in their heads.", "answer": 1}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Consider this rating a partial credit. We were happy to see some results in absolute terms and the important subgroup result for babies with type 1 disease. But the article gets enough dings to withhold a satisfactory grade.\nFirst are the qualitative summaries. \u201cAn injection of Avastin stopped blood-vessel growth.\u201d That\u2019s a bit vague for such a zinger. For one thing, one of Avastin\u2019s apparent advantages was that it doesn\u2019t stop vessel growth in the peripheral retina. For another, does this sentence mean Avastin cured all babies? (Retinopathy came back in 4 of 70.) Or does it mean Avastin universally stopped vessel growth at the outset? (The main endpoint of the study was recurrence of disease. Maybe the laser also stops vessel growth at first.)\nAnd we think the story could set a neater table before comparing the benefits of Avastin and the laser therapy. It names 3 downsides of laser therapy, but efficacy (50% recurrence in zone I disease) wasn\u2019t one. Since the study was designed to compare recurrence rates, we assume this downside of the laser is prominent. Another downside of the laser was given: some babies need several treatments. But, in comparison, we\u2019re told that \u201cin many cases\u201d Avastin only needed one treatment. \u201cSome do\u201d means the same thing as \u201cmany don\u2019t,\u201d so a\u00a0cleaner comparison would\u2019ve been nicer.\nHere\u2019s a final aside, not of the same magnitude as the prior comments. In an ideal world,\u00a0the article could\u2019ve addressed the different types of retinopathy of prematurity. Indeed Avastin was superior in the overall cohort, especially in Zone I disease, and the article accurately quotes the editorial as suggesting Avastin should become the treatment of choice in Zone I. But absent is the fact that this study showed no significant benefit in Zone II disease, the larger group of enrolled babies. There was a trend towards benefit, but it wasn\u2019t statistically significant. The message from the editorial is that Avastin is possibly superior in Zone II, but we\u2019ll need more studies. This thread would\u2019ve added some nice balance to the story\u2019s conclusion that Avastin \u201cfar surpassed\u201d laser therapy in treating this disease, and would allow them to be more specific about the 15 hospitals that stopped using the laser (for whom? all zones?).", "answer": 0}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nTwenty more patients will be treated to assess the best dose of the virus, the goal being the highest dose that does not set off an immune system attack, Dr. Tuddenham said.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that six patients were \u201csuccessfully treated\u201d and explained that treated patients \u201ccontinued to produce their own Factor IX for up to 22 months,\u201d and notes that one patient had an initial good response but his Factor IX levels declined.\u00a0 It also points out that because his immune system recognized the viral vector, it is now sensitized to respond in the future and he now can\u2019t be treated again.\u00a0 That would mean that five of six \u2013 not six of six \u2013 were successfully treated.\nThere was also no comment about what difference these blood test changes made in patients\u2019 lives \u2013 how they felt.\nNonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states:\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\nWhile it\u2019s good to see some numbers, we have concerns about the \u201cradical therapy\u201d statistic and what it means, which we\u2019ll address below in the \u201cEvidence Quality\u201d criterion.\nWe also call foul on a quote by the researcher who says the treatment represents \u201ca huge leap forward,\u201d which is an exaggeration. It\u2019s too soon to say if this is a real advance or merely a costly and ineffective treatment that exposes patients to potential harm for no reason.\nHere\u2019s one reason why readers would do well to temper their enthusiasm: The study follow-up was\u00a0too short to show a survival benefit\u2013which is the ultimate goal of treating prostate cancer. We wish the story had called attention to that limitation.", "answer": 0}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\nThere were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nA two-thirds dose reduction increased the odds of a flare occurring by four times compared with a one-third dose reduction, with flares occurring in 37% of patients.\nFor those patients who either fail to respond, or who develop an inadequate response to these drugs over time, a biologic DMARD is an effective add-on treatment option.2 The first choice of biologic therapy is usually a TNFi2 and currently identical dosing regimens of TNFi are used both to induce and then maintain a clinical response.1\n\nOver the first six months of the study, flares (exacerbations of symptoms and signs) occurred in 14% of patients who stayed on the same TNFi dose, compared to a similar figure of 13% in those patients for whom the dose was reduced by one-third.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release notes that there was no significant difference in outcome between those who got the standard dose and those who got the dose that was reduced by a third. It gives the absolute percentage of patients experiencing flares in both groups.", "answer": 1}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nBut the vast majority of patients, 86 percent, did not have an allergic reaction.\nResearchers studied the results of about 6,300 food challenges.\nNow, a new study sheds light on the effectiveness of a test called a food challenge to determine whether a person can tolerate a food they once reacted to.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides the percent of patients who were categorized as having no response, mild allergic response, and anaphylaxis. Because this wasn\u2019t a randomized controlled trial, those numbers summarize the important findings of the study.", "answer": 1}, {"article": "The condition is treated with a range of different medications, including drugs usually intended for people with depression and epilepsy.\nIn the second, third and fourth rounds of treatment, most - but not all - patients were able to tell when they had been on either the highest THC dose or the placebo.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Both stories did a decent job of quantifying the benefits.This story provided more details, though, including the differences in patient experiences between the three different concentrations of marijuana. It also repeated this important bit of information:\u00a0\"There was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\" The story also does a great job of pointing out that the treatment duration of five days in each dosage phase is too short to judge utility for chronic pain, which is\u00a0a long-term affliction.", "answer": 1}, {"article": "The results appear in Nutrition Journal.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\nBut when researchers limited their analysis to men only, they found a significant reduction of about 4.7 points among those who drank the beetroot juice.\n\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story selectively reported the outcomes for a subgroup of men, and did not report that there was no significant effect in the study as a whole.\nIn addition, it\u2019s important to note that these results are based on findings for one day after a single dose of beet juice.\u00a0One of the study authors speculates that the effect\u00a0\u201cmight be even greater over the long term if they are drinking it day upon day,\u201d but it\u2019s perhaps just as likely that the effect will dissipate over time. It\u2019s also possible that the \u201cbenefits\u201d are due to chance, a poorly conducted study, or data mining. The truth is we don\u2019t know, but this story reported\u00a0only on the optimistic interpretations of this research.", "answer": 0}, {"article": "According to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\n\"Our new findings suggest that black tea, through a specific mechanism through the gut microbiome, may also contribute to good health and weight loss in humans.\"\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\n\"The results suggest that both green and black teas are prebiotics, substances that induce the growth of good microorganisms that contribute to a person's well-being,\" she said.\n\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s disappointing that we are left without any idea of the magnitude of the findings. We are told merely that \u201cthe weights of the mice that were given green or black tea extracts dropped to the same levels as those of the mice that received the low-fat diet throughout the study.\u201d", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nHer task force recommended that an international registry be created for tracking such cases to help researchers better pinpoint which patients might be at risk.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nThe report identified possible benefits of screening, but noted that there is no solid evidence \u2014 in the form of randomized trials, medicine\u2019s gold standard \u2014 comparing fracture rates of patients who have been screened with those who have not been screened.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provided adequate discussion of the relative benefits of the treatments and screening methods under discussion. \n\u00a0\n ", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nNew blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of these tests would be a clear and early diagnosis, allowing patients to receive relevant treatment earlier. But the release\u2019s statement that the blood tests identify these antibodies with 90% certainty is at best misleading. The story never points out that only 33% to 44% of patients with diarrhea-predominant IBS tested positive \u2014 suggesting that most people with IBS will test negative (even though they do, in fact, have IBS). Any release about a new test should explain both the sensitivity and specificity of the test.\nMoreover, the release doesn\u2019t tell readers that there is no cure for IBS. Instead, as the NIDDKD notes on its site, doctors \u201ccan manage the [IBS] symptoms with a combination of diet, medicines, probiotics, and therapies for mental health problems. You may have to try a few treatments to see what works best for you.\u201d Or, as the Mayo Clinic summarizes, \u201ctreatment focuses on the relief of symptoms so that you can live as normally as possible.\u201d Even without a confirmed diagnosis of IBS, patients would be able to share symptoms with their doctors. As a result, the physical health benefit here may be negligible.", "answer": 0}, {"article": "According to the World Health Organization's 2008 figures, at least one in three of the world's adult population is overweight, and almost one in 10 people is obese.\nTake this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nThe researchers say what's responsible are the antioxidant and anti-inflammatory effects.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story described the health benefits associated with consumption of a\u00a0\u2018Mediterranean diet\u2019\u00a0\u00a0in the broadest of terms. \u00a0It was not clear from this story the extent to which improvements in the parameters mentioned would impact health or even the obesity epidemic described in the second half of the piece.\nWhat were the data results of the meta-analysis?\u00a0 That\u2019s what supposed to be news here.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nBut that decision does remain a judgment call.\nStill, the real crux of the debate on PSA testing is the second issue: the possible negative effects of screening.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the purported benefits of PSA screening as described in this recent study. And it at least made a stab at questioning the basis of these projected benefits \u2013 and the statistical modeling study that was just published.", "answer": 1}, {"article": "\"Today, we know that all chocolates are not the same.\"\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\n\"Several studies indicate that even a little chocolate can help reduce blood pressure and increase blood flow through the arteries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Used only relative risk reduction, not absolute. We have a primer on this as well. So when it talked about 22% lower stroke rate or a 46% lower stroke death rate, we\u2019re not told 22% of what?\u00a0 Or 46%\u00a0of what?\u00a0 \nLater there\u2019s mention of chocolate helping to reduce blood pressure or increase blood flow but no data are provided. ", "answer": 0}, {"article": "\"That's what we set out to answer.\"\nCases of high school athletes collapsing and dying on sports fields most often result from undiagnosed heart defects, says Dr. Jeffrey Towbin, co-director and head of clinical care at the Heart Institute.\nSince the study began about a year ago, 500 local teens have been screened and 26 diagnosed with heart abnormalities.\nFewer Italian athletes died after the testing began, but the tests also had a relatively high rate of falsely reporting medical problems.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story reports that false positive results in an existing screening program in Italy unnecessarily restricted sports participation and quotes a researcher as saying that \u201cThere\u2019s got to be a better way,\u201d the story presents the methods being used in this screening research study as clearly beneficial, even though the study has not even finished collecting data. Readers are not given any information about the numbers of deaths that proponents say screening might prevent; indeed the story does not even provide an estimate of the number of teens who collapse and die on sports field, so readers are unable to judge the size of the health threat.\nSome of the statistics presented seem inconsistent. In one place, the article says \u201cheart conditions that put one in 10,000 people at risk when doing top-level physical activities.\u201d Then later, the story says one person in 100 is \u201cborn with potentially life-threatening heart defects.\u201d The researchers say they recommended that 4 out of 500 students tested stop playing sports, close to the one in 100 figure, but then they also said another 22 teens (or more than 4 out of every 100) had some sort of abnormality requiring lifelong monitoring. The discrepancies are not clearly addressed.", "answer": 0}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cClearly in aging something is breaking down, and we become less effective at managing this inflammation,\u201d says Mark Davis, director of the Stanford institute.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides no numbers that would help readers grasp the size of the benefit offered by coffee. Instead, the story uses sweeping language that offers readers little real insight. For example: \u201colder people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\u201d Or: \u201cPeople who drank more than five cups of coffee a day showed extremely low levels of activity in the inflammatory gene pathway.\u201d That second line is particularly unusual, since it\u2019s not clear where it came from \u2014 the journal article doesn\u2019t mention how many cups of coffee study participants drank per day. In fact, the closest the journal article comes is to note that \u201cmoderate coffee consumption may suppress systemic inflammation that is caused by inflammasome activation, which may account for its correlation with decreased mortality.\u201d ", "answer": 0}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nAt 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1).\nISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It\u2019s impossible to judge the potential benefits because basic information is missing. For example, the release does not define what it means by \u201chigh-grade\u201d prostate cancer. It says it used the Gleason Score, but not what cutoff the company used in this analysis. Did they consider a Gleason score of 7 to be high-grade? Without such specifics, it is impossible to interpret the meaning of \u201c94% accuracy.\u201d\nThe release states:\n\u201cAt 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). This compares with just 33% identified by Prostate-Specific Antigen (PSA) alone.\u201d\nThere are problems with this data on several levels. First, they refer to the 94% as accuracy. But the description implies something else. The 94% refers to what sounds like the sensitivity of the test, not its accuracy. Sensitivity is the number of true cancers (a gold standard defined based upon the biopsy result showing a \u201chigh-grade\u201d cancer) picked up by the test. So the 94% implies sensitivity or that 6% of patients with true cancers were missed by this new test. What is confusing is that this is compared to a 33% accuracy of the PSA test.\u00a0And here also the new test is stated to have a specificity of 88%. So we\u2019re left wondering if the 33% refers to the PSA\u2019s specificity, and not the accuracy. If it\u2019s not clear to us, it may not be clear to lay readers either.\nFor more explanation on sensitivity\u00a0and specificity see our toolkit article on the topic.", "answer": 0}, {"article": "Their conclusion?\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\nAs Shots reported last week, a lot of state Medicaid programs have stopped covering circumcision.\nFor one thing, the studies about HIV have only been done in Africa, where AIDS is much more common among heterosexuals.\nFor its part, the pediatricians group hopes the new recommendations will encourage more parents to circumcise their sons \u2014 and more insurance plans to pay for it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Only relative risk reduction figures were given for UTI and HIV risk reduction.\nThe AAP website notes: \u201cA slightly lower risk of urinary tract infections (UTIs). A circumcised infant boy has about a 1 in 1,000 chance of developing a UTI in the first year of life; an uncircumcised infant boy has about a 1 in 100 chance of developing a UTI in the first year of life.\u201d\u00a0 This would have given readers a bit more of an idea of what the numbers are.\nNonetheless, the NPR story did a better job on this by giving some numbers than did the competing AP story, so we\u2019ll give it a pass.", "answer": 1}, {"article": "\"It's really mild,\" said Bardwell.\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story frames the research through the experience of Mr. Hollis Bardwell, the first patient in the study to have a neurostimulation device implanted. The\u00a0story tells us\u00a0Mr. Bardwell\u00a0is \"looking forward to rocking and rolling again\" \u2014 an optimistic outlook that will no\u00a0doubt serve him\u00a0well as a patient. But as\u00a0readers, we want to and\u00a0deserve to\u00a0know whether Mr. Bardwell\u2019s\u00a0enthusiasm is justified, and unfortunately this story doesn\u2019t provide a balanced perspective. As discussed above, the objectives of this phase 1 study are modest and include mostly safety-related assessments. And even if the study does report dramatic benefits for the device on heart function, we won\u2019t know until larger studies are performed\u00a0whether the results are broadly applicable to\u00a0other patients with heart failure. By focusing on the experience of one patient\u00a0and failing to mention the many hurdles that that lie ahead in the development of this\u00a0device, the story paints an\u00a0unacceptably rosy portrait of\u00a0the technology.", "answer": 0}, {"article": "However future studies will include girls too.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nThe scans revealed that the wiring of the brains of those with autism was disorganized compared with the brains of a typical person without autism.\nBy scanning the brain for 10 minutes using magnetic resonance imaging, researchers were able to measure six physical differences of microscopic fibers in the brains of 30 males with confirmed high-functioning autism and 30 males without autism.\nThis is how they could determine which brains scans belonged those study participants with autism.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story and the Reuters story use the 94 percent accuracy figure with no context. \u00a0\u201cBy scanning the brain for 10 minutes using magnetic resonance imaging, researchers were able to measure six physical differences of microscopic fibers in the brains of 30 males with confirmed high-functioning autism and 30 males without autism.\u00a0The images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\u201d What exactly does this mean? Was autism found in all of the 30 who had autism and none of the 30 who did not? Were there any false diagnoses?\u00a0", "answer": 0}, {"article": "The \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\nIn the new study, 15 of 28 teens with type 1 diabetes who got an experimental treatment using their own stem cells went into remission and did not need insulin injections for an average of about 1.5 years.\nEight teens who took part in the study have remained insulin-free for two years, on average.\nOne patient has gone without insulin injections for 3.5 years.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that \u201cEight teens who took part in the study have remained insulin-free for two years, on average. One patient has gone without insulin injections for 3.5 years.\u201d\nA significant limitation of this report is that it fails to note that this procedure (at least in the previous literature) is only effective immediately after the diagnosis of Type 1 diabetes, generally in the first six weeks or so.\u00a0 The procedure works by dampening the immune response that is destroying pancreatic insulin-producing cells, and after about six weeks the great majority of these cells are already destroyed, so treating the immune system will have little effect. Were the patients in the current study identified very early after diagnosis, as has been described in the previous literature (e.g., Couri et al. JAMA 2009)?\nThe problem is that the article implies that this approach could potentially be beneficial for the millions of existing patients with Type 1 diabetes, rather than merely future patients identified very early after disease onset.", "answer": 0}, {"article": "For more information about our products and organization, visit http://www.\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe randomized controlled trial shows superior outcomes in patients undergoing minimally invasive sacroiliac joint (SIJ) fusion using triangular titanium implants, compared to nonsurgical management, according to the new research overseen by Dr. Daniel J. Cher of SI-BONE, Inc., in San Jose, Calif. (The study was sponsored by SI-BONE, manufacturer of the SIJ implants.)\nSeventy-three percent of subjects undergoing the implant procedure had \"clinically significant\" reduction in disability scores, compared to just 14 percent in the nonsurgical group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release cited the primary outcome of the implant procedure in terms of an absolute percentage.\nUsing reduction in pain and absence of complications at 6 months as the primary outcome, \u201ctreatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment,\u201d according to the release. In addition, the average pain score decreased to 30 in the surgical group versus 72 in the nonsurgical group. \u201cSeventy-three percent of subjects undergoing the implant procedure had \u201cclinically significant\u201d reduction in disability scores, compared to just 14 percent in the nonsurgical group.\u201d\nWe thought that the release\u2019s implication that it is easy to figure out who has chronic pain due to\u00a0SI joint inflammation was inadequate. In practice, it is very difficult to diagnose patients with sacroiliitis and it\u2019s often mistaken for other types of back pain, as the study itself indicates.", "answer": 1}, {"article": "\u201cWe hope this can be used as one of the tools to identify children at risk,\u201d he said.\nCortisol levels fluctuate during the day meaning results were not always accurate, and only revealed cortisol levels at a single point in time.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\nSimmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The magnitude of the correlation or association between cortisol and traumatic events was not mentioned, and it is very small. As per the scientific article, the history of traumatic events accounts for only 5 to 13% of the variance in the cortisol levels; the biggest effect on those levels was male or female sex, with boys having about two times higher levels than girls. So many, many other factors are influencing cortisol levels besides these reports of traumatic events.", "answer": 0}, {"article": "+ Loss of fat was associated with faster walking speed, while loss of muscle was associated with reduced knee strength.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\n\"A lot of older adults will walk as their exercise of choice,\" said Kristen Beavers, assistant professor of health and exercise science at Wake Forest and lead author of the study.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release did a nice job at citing statistics from the study, especially at the end of the release. It rephrased some of the statistics to make them easier for a general audience to understand such as with the percentage of weight loss coming from muscle mass.", "answer": 1}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\nThey measured the level of inflammation in the participants' intestines before and after the test period.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What does a decrease in inflammation level of 28% mean?\nNo context is given for the scope of this effect.", "answer": 0}, {"article": "\"The pace is unbelievable.\"\nAt the cancer meeting, featured presentations include a study by researcher Mario Sznol, of the Yale Cancer Center, who will discuss long-term results of nivolumab.\nThe most noticeable side effects from nivolumab have been moderate fatigue and vitiligo, a loss of pigment on some areas of her hands and arms, says Herry, 57, from Santa Cruz, Calif. She's been able to continue working as a registered nurse throughout these latest treatments.\nUnlike traditional chemo, which indiscriminately kills growing cells, the new generation of melanoma drugs work in a precise way, based on a better understanding of the specific genes and proteins that drive cancer growth, says Timothy Turnham, executive director of the Melanoma Research Foundation.\nPatients with a limited time to live may not be so positive, Turnham says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "With so many different drugs discussed in one overview story, it\u2019s difficult to give complete data on all. And, while we had some reservations, we give the story the benefit of the doubt on this criterion.\nIn general terms the story states, \u201cNo one can claim to have cured melanoma.\u201d Also in general terms, it stated, \u201cWhen the new immune therapies work, they often keep cancer at bay for a long time.\u201d\nIt gave specific details on two studies released in advance of the upcoming ASCO meeting \u2013 what percentage of patients had what percentage of tumor shrinkage. But we would have liked to have seen additional comments on why this level of tumor shrinkage is important to the patient. Tumor shrinkage may be a surrogate outcome that doesn\u2019t translate into a meaningful improvement in a person\u2019s life. Was there an improvement in survival or quality of life? \u00a0How long were the subjects followed in the studies?\nIt also included this quote from the executive director of the Melanoma Research Foundation: \u201cDrugs such as ipilumumab can seem like breakthroughs to doctors because they help 15% of patients. Patients with a limited time to live may not be so positive.\u201d", "answer": 1}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story said that the risk of strokes was reduced by 55% in men with the highest lycopene levels, a relative comparison. But it also gives readers a look at what the absolute risks looked like: \u201cThere were 25 strokes among 258 men who were considered to have the lowest levels of lycopene while there were 11 strokes among men with the highest lycopene levels.\u201d It was the only one of the three stories we reviewed that included the absolute risk figures.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The \"paint\" was touted as having use for identifying \"the micrometastases that can make breast cancer so dangerous\" although it is not clear that it would be sufficiently sensitive for this purpose.\u00a0 More importantly, the implication is that detecting these would automatically mean a difference in terms of outcome (decreased morbidity or increased mortality) \u2013 however there is no evidence to suggest that this is the case.", "answer": 0}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nHe found that when healthy newborns had kangaroo care, there was less facial grimacing and crying suggesting pain, compared to babies who had been swaddled and had the procedure in their bassinets, \"sort of alone.\"\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nThere, hospitals with no access to incubators and other equipment often sent home preemies with no expectation that they would live.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story consistently suggests that this practice is beneficial, there is no quantification of benefits.\nBut data isn\u2019t hard to find. For example, the news release from the 20-year follow-up study contains a wealth of statistics, including details like:\n\u201cLooking at mortality, the research found that Kangaroo Mother Care offered significant protection against early death. The mortality rate in the control group (7.7 percent) was more than double that of the KMC group (3.5 percent).\u201d\nThe study also included this information using absolute terms: 8 deaths (3.5%) of 229 children in the kangaroo group and 16 (7.7%) of 204 in the control group.", "answer": 0}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\nThen they waited for the brain to heal, as it adjusted to the presence of the electrodes.\nThe scientists published details of their work online Thursday in the journal Science Translational Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t overstate the benefits to this one patient. It explains\u00a0that the benefits seen here\u2013the sense of \u201ctouch\u201d provided to this paralyzed individual through a brain-computer interface\u2013does not replicate what most of us might think of as a complete sense of touch. For example, one quote says\u00a0\u201cwe\u2019re really not at the point where we could, say, get him to feel the difference between silk and burlap.\u201d We did feel\u00a0the headline strays over the line a bit, by claiming \u201cimplant restores sense of touch.\u201d\nWhat is needed here is more qualification that this is just one patient, and given the variability in spinal cord injuries, it\u2019s really unknown how this will play out for other people. We also\u00a0took issue with the ending quote of the story that states we\u2019re \u201con the verge of something here that\u2019s going to transform lives.\u201d This needs to be hedged with the reality of the slow pace of the scientific and medical research process.", "answer": 1}, {"article": "She is a bacterial infectious disease expert at the Emory University School of Medicine.\nAdvocates are recommending the vaccine be given to 11- and 12-year-old girls before they become sexually active, but argue that it is not a license to behave promiscuously, Kaledin reports.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nOne agency reviewer, Dr. Nancy Miller, told the advisory committee that Merck submitted data to support the use of the vaccine in females 9 to 26.\nMiller said Gardasil does not necessarily protect against one or more of the four viruses in people already infected before they get the vaccine, and can increase their risk for precursors to cervical cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does explain that the vaccine is effective against 70% of HPV infections, potentially saving 3,500 deaths from cervical cancer per year. The story should have provided more context. In order to realize the purported benefits, every eligibile individual would need to be vaccinated and the vaccine would have to be 100% effective. These are both unrealistic because women in lower socioeconomic groups have a higher incidence of HPV and lack access to healthcare.", "answer": 1}, {"article": "The drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nSo it\u2019s not really controversial to conclude that simultaneously using opioids and benzodiazepines dramatically increases the risk of drug overdose \u2014 or, conversely, that stopping the concurrent use of these two drugs could reduce the risk of overdose.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job conveying the risk increase of combining drugs versus using opioids alone, and we especially like its use of a bar graph to give a visual representation of the added danger. The story states that eliminating concurrent benzodiazepine and opioid use could reduce the risk for an opioid overdose\u2013related emergency room or inpatient visit by 15 percent. Further, it says the study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an ER or inpatient visit for a drug overdose.\nOne quibble: It wanders into sketchy territory by extrapolating deaths: \u201cIf that reduced risk applies to overdose deaths as well, eliminating concurrent opioid and benzodiazepine use could have prevented up to 2,630 opioid painkiller\u2013related overdose deaths in 2015.\u201d This is an interesting perspective, but we\u2019re wondering if it\u2019s valid to assume that deaths would decline proportionally to hospital visits. An independent expert source would have been helpful here.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The column allows promoters of products to make their claims, but then quotes an independent professor of pharmacy saying that, to his knowledge, there are no well-designed studies showing that caffeine works better than placebo for weight loss.", "answer": 1}, {"article": "\"They got it completely wrong,\" he said.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nAt issue is whether virtual colonoscopy will enhance quality or whether it is, in the words of one physician blogger, \"a proxy for high-tech excesses.\"\nIts supporters, many of them radiologists who read CT scans, tout virtual colonoscopy as a more palatable alternative that has the potential to boost low rates of screening.\nUnlike standard colonoscopy, generally performed under anesthesia, in which a long, flexible scope is inserted into the rectum and snaked through the large intestine to find and snip out polyps, the new procedure doesn't require a ride home or a day off.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of virtual colonoscopy. While it does provide the frequency of incidental findings, it does not indicate what percentage of polyps are found relative to standard colonoscopy.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly explains that the eight cases of maternal tumor DNA findings came from a collection of more than 125,000 blood samples submitted to one of the companies over a two-year period, and that about 3 percent were positive for one or more chromosomal abnormalities. It also points out that follow-up tests showed the fetus was normal in a \u201cvery small number of instances\u201d and that among those just 10 cases of maternal cancer were suspected. Further, of the eight women featured in the published report, just three had their cancers diagnosed because of the findings.\nThe story earns a Satisfactory grade here. Some additional questions that could have been addressed by the coverage include:", "answer": 1}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\nWe need more human studies of this HIV vaccine\n\nBut we still don\u2019t know if the vaccine will protect humans from the virus, since the studies so far have only looked at safety and immune responses, not efficacy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The APPROACH trial randomly assigned 393 volunteers from five countries to receive one of seven experimental vaccines or a placebo. \u00a0While the report notes that \u201cthe mosaic vaccine was the best tolerated and also capable of generating anti-HIV immune responses in all the people who received the shots,\u201d one is tempted to ask: Compared to what? How is it possible to determine the benefits of the vaccine when we don\u2019t have any quantitative sense of how the vaccine/ comparators performed?\nThat being said, the story makes it clear that these immune response results, interesting though they may be, are not the outcome that matters \u2014 and this is a very important qualifier. It also uses results from previous animal studies to suggest how the vaccine might ultimately perform in people. It does this in a way that isn\u2019t inappropriately optimistic.\nWe\u2019re on the fence with this rating but will give the benefit of the doubt.", "answer": 1}, {"article": "The results have not previously been published or presented.\nThe impact of age and HIV infection on C-Tb, TST and QFT reactivity was assessed in 1090 individuals with symptoms suspect of TB disease, analysis is ongoing and will be included in the presentation.\nThe test, known as C-Tb, combines the \"field friendliness of the PPD-based tuberculin skin test with the high specificity of interferon gamma release assays, or IGRAs,\" said lead researcher Morten Ruhwald, MD, PhD, head of human immunology at Statens Serum Institut in Denmark, which developed the test.\nDr. Ruhwald said another advantage of C-Tb is that the measurement of infection, a 5mm or larger induration, is universal across patients with different risk factors, including HIV infection.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides information that the new test \u2014 the C-Tb \u2014 is almost as effective as the IGRA, or interferon gamma release assays, which are more expensive, require blood samples and complicated lab work. It also explains that C-Tb is less prone to produce false positives than the TST in BCG-vaccinated individuals. News releases on diagnostic tests should also address the balance between sensitivity \u2014 which is how good the test is at positively identifying people who actually have the problem \u2013 and specificity \u2013 how good the test is at ruling out people who don\u2019t have the problem. This release addresses the specificity issue, stating \u201cThe specificity of C-Tb, unlike the TST, was not impacted by the BCG vaccine, the partially effective vaccine that many residents in the developing world receive. TST specificity in this group was only 62 percent. The sensitivity of C-Tb was comparable to the IGRA in confirmed TB cases (77 percent vs. 81 percent), indicating similar abilities to detect infection.\u201d", "answer": 1}, {"article": "Some of the complaints related to the placement of the device.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nIn a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article raises questions on how the TVU improves outcomes for women undergoing Essure device placement. How is the test an improvement over HSG, the current test? \u00a0Though invasive, as suggested by its name (transvaginal), the procedure is less involved, invasive and painful than a HSG (which requires the injection of dye directly into the cervix/uterus \u2014 \u00a0and which frequently causes pain and cramping). However, this fact is not mentioned in the report at all. Also not mentioned is the benefit of using ultrasound to minimize exposure to radiation vs. the x-rays needed for an HSG (which do emit radiation). \u00a0Readers are not given any description of the potential benefits of TVU over HSG, or how they compare vis-a-vis the visualization of Essure placement. Was there a study that looked at the accuracy of TVU in determining the correct placement? \u00a0And if the device is found through TVU to be improperly placed, or it\u2019s determined through the exam that the device has broken or migrated, what are the next steps?", "answer": 0}, {"article": "\"It makes you feel so much better,\" Wade says.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\nBut some say the agency's aversion to accepting any risks is outdated.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Here\u2019s the good part. \u00a0 The story focuses on the regulatory hurdle.\u00a0 We appreciate the sidebar that includes a link to FDA\u2019s 200-page review documents.\u00a0 From those documents, the story notes that \u201cmany people lose 5% of their body weight\u201d after using the drug. And there was reference to some data on lowering blood pressure.\nBut here\u2019s where we yearned for more/better info: Instead of riding the patient anecdote, the story could have provided some real data.\u00a0 The past proceedings of the Advisory Committee are readily available.\u00a0 The biggest issue with \u201cdiet pills\u201d is that if you have not altered your lifestyle, you will gain the weight back again. As noted in our summary above, the story could have directly included \u2013 even at a high level \u2013 some of the data from the clinical trials so that readers could have an appreciation for the magnitude of the weight loss seen. The one line \u2013 \u201cQnexa does appear to help many people lose at 5 percent of their body weight\u201d \u2013 just doesn\u2019t tell the story.", "answer": 0}, {"article": "\"And for those people, medication can help.\"\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\nAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\nPatients who took 400 milligrams of the anti-seizure drug zonisamide daily for a year lost nearly 7.5 pounds more on average than those assigned to dietaryand lifestyle changes alone, the new study found.\n\"But for about a third [of patients], biological issues are at play, such as not easily experiencing satiety signals from the gut to the brain, which senses what your energy intake has been,\" he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We weren\u2019t very happy with the headline and lead of this story, because they make the benefits sound more spectacular than they really were. The story goes on to explain, though, that a larger percentage of the study participants who took the highest does of the drug managed to lose 5 percent of their weight. The story says, \u201cAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\u201d", "answer": 1}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\nMONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\nOne expert said the new information is valuable.\nThe data and conclusions of the research should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We have a few suggestions here. Most importantly, we think the take-home message of the study was too oversimplified. The headline claims that Brilinta \u201cBeats Plavix When Paired With Low-Dose Aspirin.\u201d In fact, this study was a geographic analysis to explain why Brilinta wasn\u2019t better than Plavix in the US, unlike in other countries, and the lead conclusion was: \u201cThe regional interaction could arise from chance alone.\u201d Next, it says that the aspirin dose was \u201ca possible explanation.\u201d In fact, since last year the dose of\u00a0aspirin has been suggested\u00a0as a possible explanation for the regional differences in Brilinta\u2019s effects, and that hypothesis has generated controversy. This new study is important to raise our antennae and spur new research, but it wasn\u2019t designed to prove the effect of aspirin.\nOf course, the article\u2019s take-home message is the same one that many in the field (including the FDA) may derive from this study. The aspirin finding is most relevant to current practice, both for the use of ticagrelor globally now and perhaps soon in the US. It\u2019s also valuable for thinking about aspirin in this setting in general. However, we think the \u00a0context should not be boiled off from the message. \nIt\u2019s important to keep in mind the limitations of this reported benefit, as we discussed under Evaluate the Quality of Evidence. The details are statistical, such as the weakening of a study\u2019s power by repeatedly slicing and dicing the same data, which is beyond the scope of this article. But we think more of the big picture would have been appropriate.\u00a0For journalists, the big picture is a question of tone, of conveying the caution urged by the researchers, For doctors, the big picture is that only future randomized trials can investigate whether the pattern observed in this study with aspirin dose is a true effect, a red herring resulting from chance, or a surrogate marker of another factor that\u2019s more important to target.\nAdditionally, the benefit is quantified as a relative risk reduction. If you\u2019re a regular here, you know\u00a0how we feel about relative risks vs absolute ones. In absolute terms, the difference between the two drugs was about 2% for heart attack, stroke, and death.\u00a0", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nThe findings show that HIF-2 is a promising target to combat kidney cancer, said Dr. Brugarolas, senior author and a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.\nWe want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials,\" said Dr. James Brugarolas, Director of the Kidney Cancer Program, who is leading an $11 million SPORE grant from the National Cancer Institute seeking to translate new discoveries into novel therapies for kidney cancer patients.\n\"The approaches we have taken pave the way for identifying drug candidates for other proteins that have traditionally been considered undruggable.\"\nHIF-2 inhibitors, which grew out of research begun more than 20 years ago at UT Southwestern Medical Center, work by interfering with processes that fuel the growth of cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are told that \u201cmice transplanted with kidney cancer from over 20 patients\u201d found that \u201cthe HIF-2 inhibitor PT2399 controlled cancer in half of the tumors.\u201d\u00a0 This is unsatisfactory on a number of levels. How many mice? \u00a0How well did the comparator mice do? \u00a0What does \u201ccontrolled cancer\u201d mean? \u00a0Were the differences statistically or clinically meaningful? \u00a0These are, admittedly awkward questions, but the kind of questions that need to be explained in a press release that claims \u201cNew HIF-2 kidney cancer therapy more effective than current treatment, study shows.\u201d", "answer": 0}, {"article": ".\nIn addition, she said, beta amyloid, a toxic protein that accumulates in the brain of Alzheimer\u2019s patients, seems to tie up insulin in the brain.\nCraft reasoned, perhaps if more insulin could be put into the brains of people with the degenerative brain disease, their memories and ability to function might improve.\nIn the four-month study, the group randomly assigned to receive intranasal insulin twice a day either improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\nBut, she added, if her study goes forward, many will be able to participate in it.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that insulin-treated patients \u201ceither improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\u201d The statement is not misleading, but\u00a0it is\u00a0not\u00a0detailed enough to satisfy\u00a0this criterion. Unfortunately the story did not place the study results into context. How relevant to the patient were the changes seen and would they or their family members notice the improvement? The story could have described the scales that researchers used to\u00a0measure function, and provided the actual values for the treatment and placebo groups. This would\u00a0have given readers a more objective accounting of how \u201cslight\u201d the improvement was.\u00a0Notably, the researchers acknowledge in their paper that \u201calthough we achieved statistical significance for our primary outcome measure, the observed effects were small in absolute terms, and thus their clinical significance is unclear.\u201d", "answer": 0}, {"article": "\"Some will benefit in a very large way.\n...\nHow many lives?\nThis means some women will undergo needless surgery, radiation, or chemotherapy.\nSo should U.S. women continue to get routine mammograms?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The machine, which is made by the Bedford company Hologic and developed partly at MGH under Rafferty\u2019s supervision, produces images that are so vivid and clear they seem to speak out loud: \u201cHey, right here!\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\nThere are also costs in the sense of risks: Women who get a combo 2-D and 3-D mammogram, the protocol that confers the most dramatic jump in benefits, are exposed to twice as much X-ray radiation as the norm (albeit still an amount that\u2019s under the FDA\u2019s permitted limit).\nBut 3-D mammography could become its flagship, because for the moment it owns the entire market \u2013 although other companies, including powerhouse GE, are developing their own 3-D machines, Hologic is the only one with FDA approval thus far.\nIn fact, technology developers had been trying in various ways for years to increase mammography\u2019s sensitivity (its ability to flag possible cases of cancer) while also increasing its specificity (its ability to filter out the false positives).\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The author fails to quantify the potential benefits of 3-D mammography.\u00a0 Dr. Rafferty, a consultant on the development of 3-D imaging, and Andy Smith, vice-president of Hologic, sole provider of FDA approved 3-D imaging equipment, provide very positive, glowing quotes about the benefits of 3-D imaging but the story provides no independent, evidence-based information to support these claims of benefit.\nThe author refers to 3-D mammography trials that Dr. Rafferty has been running since 2007 but there is no specific information about the type of trials, how many women are in the trials, the specific focus of the trials (2-D imaging vs 3-D imaging?), the source of funding for the trials, and the designated endpoint for the trials.", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article notes that the patient was in remission for seven months, but like the TIME article, says nothing specifically about what the patients tumor status was during those seven months. If the tumors shrunk, it would be at least useful to know the baseline measurements and degree of shrinkage and disappearance, as well as any improvements or (setbacks) in quality of life.", "answer": 0}, {"article": "Currently, an early Alzheimer's diagnosis requires complex brain scans.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not provide any means for assessing benefit of advanced knowledge about whether one were to develop Alzheimer\u2019s disease. The enthusiasm for the test should be limited to its role as a research tool.\u00a0 The tone of the broadcast implied that knowing about the disease early would allow for treatment to benefit the patient when this is not the case.\u00a0\u00a0\u00a0 ", "answer": 0}, {"article": "I'll keep going as long as I can enjoy what's to be enjoyed.\u201d\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We appreciate that this is the rare story to point out that clinical significance was not considered, but we think the story leads readers down the wrong path by comparing a 25% reduction to a 5% reduction and not providing the absolute numbers.\u00a0In addition, the story should have pointed out that the reduction was measured by comparing the patients\u2019 baseline volume to their volume at the end of the study, as opposed to comparing their results to a similar group who did not receive the therapy. \u00a0", "answer": 0}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article reported that the FDA found no evidence of heart disease benefit associated with consumption of green tea.", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0There was no real discussion about the potential benefits to be derived from early and accurate diagnosis of Alzheimer\u2019s disease. Ideally, a diagnostic test should reliably distinguish between those with and those without the disease. \u00a0In addition the test should have a low incidence of side effects. \u00a0The potential benefits of the use of florbetavir are noted as a strong association. \u00a0The strength of the association is not provided leaving the average reader (amplified in the headline) with the impression that the test works and can distinguish between those with and without Alzheimers.\nThe story did explain that \"Another study presented at the conference looked at people with mild cognitive impairment, which can precede Alzheimer\u2019s. It found that 22% of patients with plaques identified using florbetapir (vs. 3% of those without plaques) progressed to full-blown Alzheimer\u2019s within a year.\u2019\u00a0 But it didn\u2019t comment on the quality of that evidence.\u00a0", "answer": 0}, {"article": "They lower blood sugar by inhibiting reabsorption of glucose in the kidneys.\nIn calculating the combined number of cardiac deaths, non-fatal heart attacks and non-fatal strokes, 14 percent fewer events were seen in patients taking Jardiance in combination with standard treatments, compared with patients who took standard treatments alone, meeting the study\u2019s main goal.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nLilly shares jumped as much as 9 percent after data from the trial was released Thursday at a medical meeting in Stockholm.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story relies entirely on relative risks to convey the benefits found in the study \u2014 most notably in the headline. We think that estimates based on relative risk can be misleading in isolation, and so we always prefer for stories to include a measure of absolute risk reduction as well. \u00a0For example, the abstract of the study explains that the \u201cslashing\u201d of deaths mentioned in the headline means that the death rate was 5.7% in the Jardiance group compared with\u00a08.3% in the placebo group.", "answer": 0}, {"article": "They have gained nearly 8 percent since December 18.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits was vague, with no quantification.\nFor example, the story reported: \u201cThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\u201d\nMaintained what clinical benefits? What was the actual comparison with the placebo group?", "answer": 0}, {"article": "Aug. 30, 2010 -- Three puffs a day of cannabis, better known as marijuana, helps people with chronic nerve pain due to injury or surgery feel less pain and sleep better, a Canadian team has found.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\nIt\u2019s the same kind of growth,\u201d says study researcher Joao Martins Pisco, MD, chief radiologist at Hospital Pulido Valente and director of interventional radiology at St. Louis Hospital, both in Lisbon, Portugal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on the technical success of the procedure but more importantly reported on the percentage of men who reported experiencing \u2018excellent\u2019, \u2018slight\u2019 or \u2018no\u2019 improvement. \u00a0Although the starting score of the patients was reported, it would have been valuable to translate this into information that readers could grasp. \u00a0The story should have mentioned whether the difference in symptom severity was something that the patient could detect or simply a change in a clinical score. \u00a0And to be comprehensive, the story should have provided information about the benefit that might be expected from other treatment options (e.g. TURP) for comparison.\nWithout a clear context about what was \u2018improved\u2019 and whether it was sufficiently better than what is was noticed by the patients themselves \u2013 it is not possible for readers to know how much value to put on what the new technique has to offer.\n \n \n", "answer": 0}, {"article": "Visit the Mayo Clinic News Network.\nDr. McBane says quality of life surveys, which were taken monthly throughout the six-month trial, showed that patients markedly preferred oral apixaban over injectable dalteparin.\nTheir findings were presented at the annual meeting of the American Society of Hematology by Robert McBane II M.D., a Mayo Clinic cardiologist.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release was vague and did not include any absolute numbers. The lead author said that quality of life surveys showed that patients preferred apixaban over heparin, but there was no information about whether the medication was equally effective at preventing blood clots. The abstract of the conference presentation actually does show that apixaban may have been more effective than heparin; none of the patients that received apixaban had major bleeding, and fewer had deep vein blood clots than those that received heparin. These concrete numbers should have been included in the news release.", "answer": 0}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\n\u201cManaged care pharmacy, indeed the health care system, has never seen a challenge like this to our resilience in absorbing costs,\u201d they wrote in the Health Affairs blog.\nThe study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\nIn many cases such big reductions were achieved even though the patients were already taking statins.\nIn the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job of clarifying the risk of cardiovascular events in each study. For evolocumab, the article said, \u201cAfter one year, 0.95 percent of those in the group that received the drug had suffered a heart attack, stroke or other cardiovascular problem, compared with 2.18 percent in the group that did not take the drug.\u201d The article went into the same nitty gritty for alirocumab: \u201cAfter one and a half years, the rate of cardiovascular events was 1.7 percent in those who received the drug, versus 3.3 percent in those who received a placebo.\u201d\nWe applaud that the piece reported the raw percentages, since it puts the benefits into perspective. But high up in the story, it cites the figures in terms of relative risk reduction, making the benefits sound more impressive: \u201cBoth drugs reduced the rate of such cardiovascular problems by about half.\u201d\nWe encourage stories to report benefits in absolute terms so that readers have a clearer idea of what \u201crisk reduction\u201d really means. And since many readers will not read a long story in its entirety, we encourage journalists to put that information somewhere that readers are likely to see it. If an eye-popping relative risk figure is mentioned high up in the story, it should be accompanied by immediate discussion of what that means in absolute terms.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of adding MRI for diagnosis of clots was reported this way \u2013 that the \"MRI detected more clots and heart damage that could lead to them.\"\u00a0 How much more?\u00a0 In another place it said nearly twice as many, but twice as many as what baseline? \u00a0 \n\u00a0The success of the Angiojet was reported as 83%; however there was no estimate of 'success' in patients who were not treated with the Angiojet.\u00a0 The measure of success was defined in the story as getting patients \"back in the flow\".\u00a0 This\u00a0is not a quantitative measure.\u00a0 Further \u2013 it is not even clear what it means.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story does state the \"accuracy rate\" for the new twofold screening protocol with and without the addition of the quadruple screen, there is no comparison to existing screenings such as amniocentesis. Furthermore, the more important information to give consumers would be the positive predictive value of the screening, or the probability of Down syndrome given a positive test result. This is especially important when the prevalence of Down is so low, causing most\u00a0positive test results to be false positives.", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\nAmong the 88 participants with moderate-to-severe disease who were given intravenous infusions of either teprotumumab or a dummy drug every three weeks for eight treatments, 43 percent who got the real drug had a reduction of at least 2 millimeters in eye protrusion by the sixth week compared to 4 percent in the placebo group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story clearly states that 43 percent of the patients who were given teprotumumab\u00a0in this trial experienced a reduction of \u201cat least 2 millimeters in eye protrusion by the sixth week compared to 4 percent in the placebo group.\u201d\u00a0 One of the researchers is quoted as saying, \u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study.\u201d\u00a0 The story also points out that this level of reduction \u201cis similar to that reported after decompression surgery.\u201d", "answer": 1}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\nThis test, which is noninvasive, could be wake-up call for some.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nBut there is not a strict cutoff point between normal or abnormal, Brannigan said.\nScott said she was surprised by the number of steps involved, although none were very difficult.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This was the story\u2019s one big failing. There is no attempt in the story to actually quantify how well the test works. What\u2019s the sensitivity?\u00a0 What\u2019s the specificity?", "answer": 0}, {"article": "6 Kowdley KV, et al.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nAround 180 million people globally have chronic HCV infection,1 including approximately 15 million people in the EU.2 The prevalence of HCV infection in children varies from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.3 While direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.8\n\n\"Direct-acting antivirals have transformed the treatment of adults with chronic HCV, however, studies of these new therapies in children are required,\" said Dr Karen Murray, University of Washington School of Medicine and Seattle Children's, Seattle, United States, and lead author of the study.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that 99 percent, or 89 out of 90, children treated with the ledipasvir/sofosbuvir combination had undetectable levels of hepatitis C virus 12 weeks after treatment.\nWe do caution that sustained virological response (SVR) and the reduction in viral load, which is what this study measured, may or may not reflect outcomes that people care about. As discussed in another review on a different hepatitis C drug announcement, \u201cPatients care most about conditions that affect them and not how many virus particles are in their blood.\u201d", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story mentioned the number of people in the two study groups who had heart-related death, heart attacks and other serious cardiac problems during the course of the study, it could have a done a better job at clarifying that this represented a small percentage of affected individuals.\u00a0 A more direct statement an juxtaposition of absolute versus relative risk reduction would have been helpful. ", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nOne possible reason, as the report noted, was that many children refuse to continue taking medication after a year or so, something most parentsof such children well know.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nIf the pills can truly produce long-lasting benefits, more parents might be encouraged to start their children on these medications early and continue them for longer.\nmedication is that a \u201cgold-standard\u201d study would require researchers to assign children randomly to groups that either received medication or didn\u2019t.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story seems to assume that readers are familiar with ADHD and the common range of treatment effects in children. It would have been nice to see more background, including specific numbers, rather than vague references to how children may feel \u201cmore focused and in control\u201d or \u201cimpressive short-term relative benefits of medication.\u201d Different people may have different definitions of \u201cimpressive.\u201d Numbers would help.", "answer": 0}, {"article": "While Avastin, which is a cancer drug, has not been approved for use in treating macular degeneration, it has the same mechanism of action as Lucentis.\nIf this finding is considered valid, it could render the results of the National Eye Institute trial somewhat moot by raising safety questions about Avastin.\nSales of the drug for each company were about $1.5 billion last year.\nBut there has never been a definitive trial to compare the two drugs.\nStill, doctors will be looking closely at details of the data.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It did as much as it could given the lack of data, detailing the noninferioirty criteria and describing how the results are expected to fall. We think the blog is clear that peer-reviewed benefits data will be available upon publication. While in many cases we\u2019d ding this approach, since this study was of the noninferiority variety, the \u2018quantity\u2019 of primary interest is a binary, yes or no, and it is explored. The study also hints at another endpoint of interest, retinal thickness. Although some seems speculative or hearsay, there\u2019s much more here than about the harms.\nOn a sidenote, we would\u2019ve liked some exploration of the clinical significance of either drug\u2019s benefits. We understand business concerns about how the drugs stack up to each other financially, but it\u2019s of interest to patients how well they fight this disease at all. And a blog piece like this reaches all readers, not just the business community.  \n", "answer": 2}, {"article": "\u201cWhat makes our study stronger than those others is that we used a device that was able to measure all of the movements we do in our daily lives,\u201d she says.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that engaging in light activity for 30 minutes per day reduced relative risk of mortality during the study period by 12 percent. It also noted that engaging in moderate activity for 30 minutes per day reduced that risk by 39 percent. But what about the absolute risk reduction?\u00a0", "answer": 0}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nIn fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\nBut no matter where you live, surgery is not necessarily the best or only option.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment and presents qualitative results only.", "answer": 0}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nHarrington expects the FDA to clear T-VEC within the year, and it could potentially be available to patients right away.\nThe results of the trial were published Tuesday in Journal of Clinical Oncology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Melanoma is a cancer on the rise and a treatment for inoperable melanoma that increases survival rate is beneficial. But we\u2019d prefer a bit more precision in the way the statistics were handled and communicated. The 16.3 vs. 2.1% comparison is accurate, but the story could have done a better job explaining what \u201cshowing results\u201d means and how the outcome was measured.\nMore problematic is the story\u2019s description of survival benefit, which suggests an average survival of 41 vs. 22 months in the treatment vs. control groups. The more appropriate outcome to report is median overall survival. The difference for that outcome was 23 vs. 19 months. This is a statistically and clinically meaningful difference, but isn\u2019t quite as stellar as what is reported by the story. Average survival could be misleading because it can be affected by outlier patients who do very well on the drug but are not representative of typical outcomes. Median survival\u00a0is the time at which an equal number of patients do better and an equal number of patients do worse. It\u2019s the standard outcome for such studies and what was reported in the abstract of the paper being covered.", "answer": 0}, {"article": "General.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nIn the vaccinated patients, A1c levels fell from an average of 7.36 before the first dose to 6.18 after five years, holding almost steady at 6.65 in the eighth year.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\n\u201cThe clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system,\u201d said Dr. Mihai Netea of Radboud University Medical Center in the Netherlands, who was not involved in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Wisely, the story quantifies reduction in absolute terms: \u201cIn the vaccinated patients, A1c levels fell from an average of 7.36 before the first dose to 6.18 after five years, holding almost steady at 6.65 in the eighth year. In patients receiving a sham injection, levels showed almost no change from their initial levels of 7.10: 7.07 in the fifth year and 7.22 in the eighth.\u201d\nThe story also explains exactly how much the drop in hemoglobin A1c was (9-16%) and how that compared to the levels in patients receiving the placebo injections and to normal A1c levels. The story also noted that a 10% drop in A1c levels reduces the likelihood of complications such as stroke and heart attack by a third. In addition, the story explained that the patients treated with the BCG vaccine now need one-third less insulin than they did before the treatment, \u201creducing their risk of hypoglycemia, in which insulin lowers blood sugar to dangerously low levels.\u201d One relatively minor shortcoming is that the story did not explain that the reduction in hemoglobin A1c levels didn\u2019t occur until the third year after the vaccinations had been given.", "answer": 1}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nAt the end of the study, the men following the intermittent diet plan lost 47 percent more weight than the control group.\nFor the small study just published in the International Journal of Obesity, the team enlisted 51 obese men from the ages of 25 to 54 years old.\nAll participants had maintained their current weight for six months leading up to the study and did not exercise regularly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that the men following the intermittent diet plan lost 47percent more weight than the control group, but not what the study group participants actually weighed before and after. It also notes that the intermittent dieters maintained an 18-pound loss six months after the study, but not whether they stayed on the diet or what other factors may have accounted for that outcome. Readers also won\u2019t learn how many calories were consumed in each cycle of the study or what foods were involved.", "answer": 0}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nSage Therapeutics, based in Cambridge, Mass., reported on Tuesday that 7 of the 10 women who took the drug in the trial experienced significant improvement in their depression within 60 hours of the injection.\nInterestingly, none of the patients who took the drug reported psychiatric side effects, such as abnormal dreams, insomnia, and anxiety \u2014 but 5 of the 11 women on the placebo reported such symptoms.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We will give the story a satisfactory rating because it specifies that 7 of 10 patients given SAGE-547 reported significant improvement in their depression within 60 hours, which persisted for up to 30 days.\nHowever, the story did not tell readers that the depression questionnaire used in this study, Hamilton Depression Rating Scale (HAM-D), has been criticized as placing greater emphasis on sleep than on suicidal thoughts, so that the scores of some patients may improve even if their thoughts of suicide increase.\nReaders should have been told that the form of the drug used in this trial is given as an IV solution and that it will not be known if a pill can produce similar results until separate trials are completed.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\nAnd the potential effect was \u201cvery small,\u201d Dr. Eleni Linos of Stanford University, who wasn\u2019t involved in the research, told Reuters Health in an email.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt, although suggest a minor change in the future.\nThe story only used relative risk reduction figures. It could have included just a line to explain why it may not be statistically appropriate to pool absolute risk reductions in such a meta-analysis.", "answer": 1}, {"article": "No serious adverse events were reported.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nThe Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported that fevipiprant \u201creduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients.\u201d It states: \u201cThe Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.\u201d", "answer": 1}, {"article": "ET.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release notes, \u201cMen who filled prescriptions for erectile dysfunction drugs in the years following a heart attack had a substantially lower risk of dying or being hospitalized for heart failure than men who did not use these drugs.\u201d And it states there was a 33% reduction in death and a 40% reduction in hospitalization for heart failure among patients prescribed ED drugs. But these are relative risk numbers and we think absolute risk numbers are more useful for readers.\nA quote from Dr.\u00a0Andersson;\u00a0\u201cThis type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death\u201d is a bit of a stretch given the study was observational and does not prove cause and effect.", "answer": 0}, {"article": "Lung cancer is the leading cause of cancer death in the United States.\nThe study reports that in both tissue culture and in a mouse, tumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2.\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nThat was the conclusion of a new study published today in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.\n\"Our goal is to see if CRISPR can be used with chemotherapy to provide a safe, affordable way to give patients who are not responding to treatment at least a fighting chance against this very challenging cancer,\" said Eric Kmiec, Ph.D., the principal author of the study and the director of the Gene Editing Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is unable to claim a benefit in humans since the study was done in cell cultures and mice models and findings in the lab don\u2019t always translate to similar outcomes in humans.\nBut even in describing the benefits in animal models and cell culture, the release fell short. It says, \u201ctumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2.\u201d\nBut there\u2019s no data to give readers a sense of the scope of this potential benefit, such as how much the volume decreased, for what period of time, and in what percentage of the tested samples.", "answer": 0}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nThat's promising, because there's evidence that a 7 percent body weight loss cuts the risk of developing diabetes by about 60 percent.\nThere is some evidence that these kinds of programs are working.\nNot every Omada Health participant makes the progress they're aiming for.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantified the benefits of the treatment program in one study, informing readers that in a study of 200 people at risk for developing diabetes, \u201c75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight. And about 1 in 4 participants lost 7 percent of their body weight or more.\u00a0\u201d\nWell give this a barely passing satisfactory, though we also wanted to know: What was the average weight loss? How long did it take to lose the weight? How successful are people at keeping the weight off? It\u2019s also useful to point out that there was no control group to measure this program against.", "answer": 1}, {"article": "Statins such as Lipitor, Crestor, and a generic called simvastatin are widely prescribed to lower so-called \u201cbad\u201d or LDL cholesterol \u2014 a risk factor for heart disease \u2014 and are credited with being among the most successful drugs in helping to prevent heart attacks and strokes.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\nThey then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "To its credit, the story presents the benefits in appropriate statistical terms when it says, \u201c13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\u201d This is better than saying statin users had a 35% lower risk of dying from pneumonia, which is how many stories would have put it. Nevertheless, many readers will probably come away from this story with an exaggerated sense of the benefits, as the story never provided the absolute death rate due to pneumonia among all statin users compared with non-statin users. Since pneumonia is not very common,\u00a0any benefit according to this measure would have been much smaller than the 7%\u00a0reduction mentioned in the story. Even if this statistic was not available, the story could have provided some data about the likelihood of developing pneumonia, which would have put the findings in\u00a0perspective. It\u2019s important for people to understand that statins won\u2019t reduce their chances of dying by 7% compared to people who don\u2019t take statins. \u00a0", "answer": 0}, {"article": "This was definitely worth it.\u201d\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\n\"It gave us an answer \u2014 that this was her physiology and her genetics and not something in her head.\u201d\n\nThe Avera Institute for Human Genetics (AIHG) in Sioux Falls, South Dakota is among several institutions exploring the role of pharmacogenomics \u2014 the science of how our inheritance and genetic makeup influences the way we metabolize medications.\nDNA Tests May Be a Guide\n\n'One piece of the puzzle'\n\nAIHG\u2019s pharmacogenomics research has led to the development of Genefolio, a genetic test that uses an individual\u2019s unique DNA to predict how that individual will respond to medications.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article is nominally about the\u00a0Genefolio test that\u2019s offered by the Avera Institute for Human Genetics. But the only specific numbers provided in the story pertain to a different test called GeneSight. That\u2019s misleading, since it suggests that the two tests are interchangeable. These are two different products looking at different genetic profiles to make recommendations. It\u2019s like using data from the AT&T cell network to show how great T-Mobile\u2019s coverage is.\nThe story also doesn\u2019t do enough to explain what the numbers provided mean. Does the 70% reduction mean that patient symptoms went from a 10 out of 10 to a 3 out of 10? Or from 2 out of 10 to 0.6 out of 10? Both are possible and the story should have clarified the difference between relative and absolute numbers.", "answer": 0}, {"article": "\u201cI ran a treatment program for years, and we invested\u201d millions in treatment services.\nAt each stage, about one-third of the people trying to quit had relapsed, the study found.\nDr. Fiore, who has reported receiving payments from drug makers, said that \u201cthere are millions of smokers out there desperate to quit, and it would be a tragedy if they felt, because of one study, that this option is ineffective.\u201d\n\nIn the new study, conducted in , the researchers followed a representative sample of 1,916 adults, including 787 people who said at the start of the study that they had recently quit smoking.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nThey interviewed the participants three times, about once every two years during the 2000s, asking the smokers and quitters about their use of gum, patches and other such products, their periods of not and their relapses.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was less successful than the other two in quantifying the benefits. It did not put any hard numbers to the findings, saying instead, \u201cAt each stage, about one-third of the people trying to quit had relapsed, the study found. The use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor. One subgroup, heavy smokers (defined as those who had their first cigarette within a half-hour of waking up) who used replacement products without counseling, was twice as likely to relapse as heavy smokers who did not use them.\u201d While using vague terms like \u201ctwice as likely\u201d may make the story a little less daunting for some readers, we think that a story on a scientific study, especially a study as controversial as this one, should provide the actual numbers from the study as much as possible. Also, all three stories failed to make it clear whether the same 30% or so of people continued to relapse throughout the study or whether a total of two-thirds of the participants fell back to smoking.", "answer": 0}, {"article": "As rates of sugar-related disorders such as diabetes, obesity and heart disease climb, many experts believe that when Americans rid themselves of fat, they simply replaced it with sugar in all its forms.\n\u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d\n\nAfter nine days of having their total dietary sugar reduced to 10% of their daily calories, however, they showed improvements in all of these measures.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\nBut that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The quantification of the results does not quite clear our bar here. The story says this:\nOverall, their fasting blood sugar levels dropped by 53%, along with the amount of insulin their bodies produced since insulin is normally needed to break down carbohydrates and sugars. Their triglyceride and LDL levels also declined and, most importantly, they showed less fat in their liver.\nWe would have preferred more numbers documenting the changes for each outcome, in absolute terms (the \u201c53%\u201d figure is a relative reduction), along with a comment or some description of how meaningful the changes were clinically.", "answer": 0}, {"article": "The W.H.I.\nIn a Danish randomized controlled trial of 1,006 women entering menopause, among those given hormones for 10 years, \u201cthere was a reduction in cardiovascular disease and breast cancer \u2014 a clear benefit with nominal risk,\u201d Dr. Hodis said.\n\u201cThe cardiovascular protection found in observational studies involved women who were younger and within a few years of menopause when they started taking H.R.T.,\u201d he said.\nfindings, many new analyses and studies have prompted experts to rethink the wisdom of avoiding hormone replacement, especially for women within a few years of menopause whose personal and family history do not place them at high risk of breast cancer.\n(Those without a uterus, who were randomized to take conjugated estrogens alone, had no increase in breast cancer; in fact, they had a slight decrease over all.)\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story is about risks and benefits, and about the misunderstandings that can result. But we did not find the absolute risk and benefit numbers that would have helped to clarify.\nHere is a benefit statement, which we found incomplete. We would have preferred some absolute numbers.\n\u201cIn a Danish randomized controlled trial of 1,006 women entering menopause, among those given hormones for 10 years, \u201cthere was a reduction in cardiovascular disease and breast cancer \u2014 a clear benefit with nominal risk,\u201d Dr. Hodis said. These benefits persisted after 16 years of follow-up, according to the study, which was published in 2012.\u201d\nHow big was the \u201cclear benefit?\u201d What does Dr. Hodis consider a \u201cnominal risk?\u201d Readers may look at these issues differently than Dr. Hodis does, so it\u2019s important to clarify.", "answer": 0}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nThe findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Probably the weak point of the story.\nThe story only says \u201cTheir reported levels of hot flashes dropped markedly.\u201d\u00a0 What does that mean?\u00a0 From what to what?\u00a0 Measured how? And in how many of the men?\u00a0 With no indication of what their baseline symptom severity was, there\u2019s no way to interpret the sketchy results reported in the story.\nThe story also throws in a tag line that the same study \u201calso found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\u201d\u00a0 But no data were given to back up these claims.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies results appropriately. It notes that in one test, \u201c67% of the patients were judged \u2018very good\u2019 or having \u2018marked improvement\u2019 after they took the expensive placebo, compared with 58% of patients after they took the purportedly cheap placebo.\u201d Readers can tell from the story\u2019s numbers that we\u2019re talking about a relatively modest amount of improvement.", "answer": 1}, {"article": "A treatment for obesity could be on the horizon as scientists have discovered an antibody that reduces body fat.\nThat would then lead\u2014if all goes well\u2014to the first human trials in three to four years.\u201d\n\nAt present, the researchers are focusing on the adiposity, rather than bone loss, for drug development: \u201cI think obesity is a more prevalent disease\u2014but osteoporosis at the tail end can be tagged on.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nBut how do mice models translate to human treatments?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research was on mice, there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to determine the scope of\u00a0the likely benefit. The story should have made this point before it starts discussing benefits like \u201cthe antibody caused significant weight loss and gains in bone mass.\u201d The story tells readers that \u201cMice [sic] a fairly close genetic match to [h]umans, and\u2026[the corresponding author] is hopeful there will be similar effects in humans.\u201d That doesn\u2019t give readers much insight. In short, readers don\u2019t get a very good idea of what the antibody did to the mice, nor how relevant that is to human biology.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story does not quantify the benefits at all except for saying that the safety and efficacy was tested on over 400 patients.\u00a0 What benefits they received from the treatment are totally omitted from the story. This is unacceptable, especially as the FDA provided some quantification in their news release.", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\n\u201cThis may also be why the rate of major cardiovascular events during follow-up was no lower in the fatty acid groups than in the placebo group.\u201d\n\nAll the men and women in the Dutch study were aged between 60 and 80 and had suffered a heart attack roughly four years previously.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re going to be a bit tougher on this one. The story failed to mention the benefits reported in the results section of the paper demonstrating that\u00a0for those who had diabetes in addition to having had a heart attack, there did appear to be some benefit in terms of reduced incidence of coronary artery disease, death from coronary heart disease and incidence of arrhythmia.", "answer": 0}, {"article": "The study was funded by the P.J.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does a good job of explaining the findings with numbers. It says the study shows \u201cheart CT scans can help personalize treatment in patients whose blood pressure falls in the gray zone of just above normal or mild high blood pressure.\u201d It says the study suggests \u201cpeople with the highest calcium levels would benefit most from aggressive blood pressure treatment, whereas those with little or no calcium may not need to be treated as intensively, depending on their other heart disease risk factors.\u201d\nIt gives some detailed numbers to show the risk differential between people with no calcium buildup and those with a lot of calcium. To paraphrase the release, among participants with borderline blood pressure readings, those with calcium scores of zero and high predicted risk of heart disease had a low actual event rate, of 12.7 events per 1,000 person-years. Those with calcium scores over 100 but a low predicted risk of heart disease ended up with a higher rate of actual cardiac events, 19.7.\n\u201cThus,\u201d the release says, \u201ceven though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nGiven that the difference in cardiac event rates between people with low calcium scores and those with high calcium scores isn\u2019t extreme, this might amount to a marginal benefit; we would have liked some discussion of how many patients might fall into this \u201cgray zone\u201d and thus benefit from this approach.\nBasically, the benefits, including the number needed to treat (NNT), cost-effectiveness, as well as harms and costs of obtaining these calcium scores are unknown. All we know is the magnitude of the increased potential risk associated with higher calcium scores, not whether this risk can be reduced.", "answer": 1}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\nBut nearly 40% have headaches that are so frequent (at least once a week), severe or hard-to-treat that they qualify, Silberstein says.\nStudies find that just 3% to 13% use the treatments.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes one of the guideline authors who says that \u201cabout 80% will get relief \u2026\u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\u201d\nThis may well be true, but we think the 80% figure puts the benefits in the best possible light and misplaces the emphasis. If it takes 3 or 4 drugs, alternative remedies and lifestyle changes to achieve a benefit for 80% of people, clearly a much smaller number of people are likely to experience a clinically significant benefit from any individual treatment.\nA close call here, but the story does mention that treatment can \u201ctake a lot of trial and error and careful dosing\u201d \u2014 enough context to merit a satisfactory rating.", "answer": 1}, {"article": "U.S. guidelines recommend Americans consume less than 2.3 g of salt daily, or 1.5 g for certain people who are more at risk for high blood pressure or heart disease.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nBut even so, the scientists think they would need to have data from at least 18,000 people before they could expect to identify any clear health benefits.\nFrancesco Cappuccio, head of the World Health Organization\u2019s collaborating center for nutrition at Warwick University, said it was \u201ca surprisingly poor piece of work.\u201d\n\n\u201cThis study does not change the priorities outlined worldwide for a population reduction in salt intake to prevent heart attacks and strokes, the greatest killers in the world,\u201d he said in an emailed comment.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news of this piece is that, not withstanding the recommendations of many guidelines and experts, \u00a0the recently published Cochrane review failed to demonstrate that a small reduction in dietary salt intake decreased the chance of developing heart disease or dying prematurely.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not mention the number of adult smokers under age 65 who would need to be vaccinated to prevent one case of pneumonia.\u00a0 There was little data on this point in the source material, which the story should have noted.\u00a0 ", "answer": 0}, {"article": "Anderson Cancer Center in Houston.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n\"For women with metastatic breast cancer and a BRCA mutation, PARP inhibitors may be considered for their treatment,\" said lead researcher Dr. Jennifer Litton, an associate professor of breast medical oncology at the University of Texas M.D.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nIn addition, 32 percent of the women receiving talazoparib had other side effects, compared with 38 percent of those on standard chemotherapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the drug\u2019s benefit in terms of \u201cprogression-free survival.\u201d Women who took\u00a0talazoparib went three months longer without their cancer progressing, on average, as compared to women on standard chemotherapy. However, it did not give us precise numbers on this: What was the total, in months, before cancer progressed, in both groups?\nAccording to OncLive, \u201cat a median follow-up of 11.2 months, the median progression-free survival (PFS) was 8.6 months with talazoparib compared with 5.6 months\u201d for the control group.\nThe HealthDay story also said women on talazoparib had a \u201chigher response rate\u201d than women on standard chemotherapy, but never explained what that means.\nMost importantly, the story didn\u2019t address the most important statistic: overall survival. Does the drug help women live longer? As we\u2019ve explained, PFS is what\u2019s known as a \u201csurrogate marker\u201d and is no guarantee of a longer life.\nDrugs are frequently approved on the basis of uncertain markers such as \u201cprogression free survival,\u201d which is the amount of time between treatment and worsening of symptoms. The drug Avastin won accelerated FDA approval to treat metastatic breast cancer based on its ability to delay tumor growth, but that approval was revoked when multiple randomized trials showed the drug didn\u2019t improve survival and had significant side effects.", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nThis gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\nBut tailoring those guidelines to better fit individuals could prevent many more heart attacks and strokes, say developers of a computer model that makes those calculations.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Mixed bag here, but we\u2019ll give the story the benefit of the doubt.\nThe benefits from the use of models to better fit treatment recommendations were described as relative improvements rather than absolute benefits.\u00a0 That\u2019s how the data were described in the abstract of the paper reported on; the predicted numbers were contained within the body of the article. Given the size of the population in question, we can look the other way on the use of relative risk reduction figures.\nAnd, as already noted, the story injected some caution about real world benefits by quoting an independent expert:", "answer": 1}, {"article": "\"We recognized that it may have curative potential.\"\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\nThat compared with the 74 percent survival at ten years in the group that received only radiation plus hormone therapy, amounting to a 15 percent survival advantage in the group that was treated with prostate removal.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated the survival difference in clear, absolute terms: \u201cThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive. That compared with the 74 percent survival at ten years in the group that received only radiation plus hormone therapy, amounting to a 15 percent survival advantage in the group that was treated with prostate removal.\u201d", "answer": 1}, {"article": "FODMAPs are a group of carbohydrates that don\u2019t get broken down and absorbed in the small intestine.\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nThey may assume that they have gluten sensitivity, but some researchers believe that it\u2019s not the gluten they\u2019re sensitive to.\nA low-FODMAP diet eased their symptoms, as it does for about 70 percent of people who suffer from irritable bowel syndrome, a condition that causes abdominal pain and bowel changes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article only provides us with a glimmer of understanding concerning the perceived benefits of a low-FODMAP diet in people with non-celiac gluten intolerance. There is no quantification of the benefit. \u00a0The story says, \u201cA low-FODMAP diet eased their symptoms, as it does for about 70\u00a0percent of people who suffer from irritable bowel syndrome, a condition that causes abdominal pain and bowel changes.\u201d \u00a0How much were their symptoms reduced? Was the reduction clinically important or statistically significant but unimportant? \u00a0Did everyone fare equally as well with the diet change?", "answer": 0}, {"article": "\"And a well designed instrument will push back.\"\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\nHe led a study of some 460 patients who were given Alexander lessons, massage, or the usual care of pain killers and exercise.\nAnd although the teacher will put her hand on your neck or shoulder, it's more to bring awareness than to make adjustments.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article provided skeletal information on only one of two primary outcome measures in the study, the one that cast the Alexander Technique in the most positive light. The article noted that subjects who had 24 lessons in the Alexander Technique went from 21 days of pain to 3 days of pain without ever mentioning what this means in real life terms. This statistic referred to the number of days in the last month during which the study subjects experienced any back pain. Without information on back pain intensity, or disability attributed to back pain, this statistic is difficult to interpret. So this article did not adequately frame this benefit.\nThe results of this study are not easy for journalists to characterize or present\u2014given the way the study was conducted and reported. The journalist did a better job of attempting to quantify the benefit of the Alexander Technique than she did in evaluating the quality of the evidence. \n\u00a0\n", "answer": 0}, {"article": ".\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\nHowever, the study did not compare patients with unknown stroke onset who received tPA to those who did not, Oppenheim said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported that the test was 90% accurate, but it could have provided more insight to readers about what this \u00a090% means.\nThis study is really just about predicting whether the stroke was in the past 3 hours or not. It would have been helpful to show the net effect size for strokes within 3 hours vs. those > 3 hours \u2013 it is not a very big absolute difference, but that is the cut-point that has been used.\nIt also could have included some information about how the rates of complication change when tPA is given to patients beyond this 3 (or 4.5 even) hour window.\nNonetheless, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "\"I'm keeping things ready for when they get the green light,\" he said.\nIn each patient, \"the pulses are sent in a pattern that is close to how normal muscles work,\" said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center.\nOther researchers who contributed to the two studies are the APT Center's Lisa Lombardo, physical therapist; Kevin Foglyano, biomedical engineer; and Gilles Pinault, MD, a surgeon and co-director of the center.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\nNathan Makowski, an investigator at the Cleveland FES Center, created by Case Western Reserve and the Cleveland VA, said that FES technology has been used primarily for therapy in stroke patients in the past.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release describes both men\u2019s improvement in terms of distance walked with the aid of electronic nerve stimulation. For example, the stroke patient\u2019s ability to move \u201cwithout the system was about 19 yards per minute; with the system, 47 yards per minute,\u201d the news release states, while training improved his speed with the system turned off to \u201c23 yards per minute, indicating therapeutic benefit.\u201d His distance improved from 83 yards to 1,550 yards, almost a mile.\nIt states that the multiple sclerosis patient \u201cwent from the two steps to consistently walking more than 30 yards during the (90-day) trial. In that time, he used a walker to help maintain his balance.\u201d\nThe news release also provides quotes from the men and links to videos that show the men\u2019s abilities to walk with and without electronic stimulation.", "answer": 1}, {"article": "Then, you take it at home every day. \"\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\nAmong children receiving the treatment, 10% required rescue epinephrine during the exit challenge, compared with 53% in the placebo group.\nA little more than 11% of the children dropped out of the study due to severe side effects.\nTo test the experimental therapy, 66 research centers in 10 countries recruited 551 participants who ranged in age from 4 to 55 and who all had a peanut allergy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that two-thirds of people who underwent months of treatment were able at the end of the study to tolerate the equivalent of two peanuts.\u00a0\u00a0\nUnlike the Fox News story, CNN reports on how the control group fared, saying that 53% of those subjects required rescue epinephrine with the final peanut challenge test compared to 11% of subjects in the treatment group. ", "answer": 1}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\n\"This study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\"\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The patients\u2019 response was modest and the news release reflects that. The release quotes a researcher saying, \u201cThis study demonstrated responses in five of 18 patients treated at MD Anderson, and many of the patients had significant reductions in their tumor size.\u201d It also gives details of some of those treatment responses.", "answer": 1}, {"article": "GammaCore is hand-held.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nThis went up to about a third of patients with so-called episodic cluster headaches.\nIt does not have the side effects or dose limitations of commonly prescribed treatments or the need for invasive implantation procedures, which can be inconvenient, costly and high-risk.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article uses percentages to vaguely describe the benefits (\u201cappeared to help\u201d) in the treatment vs sham treatment groups, but it does not\u00a0mention the absolute number of patients in the two arms of the study, or what \u201chelp\u201d meant. It relies mostly on complimentary statements by one of the investigators who conducted a study of the device, and by the company.\u00a0But the major lapse in full disclosure comes with the absence of information about the failure of the clinical trial to reach its statistical goal. The apparent benefit of the device over the sham device was only seen after a pre-specified subgroup analysis. As noted in the accompanying editorial: \u201cThe primary endpoint was not achieved in this study \u2013 ie, differences in reduction in pain severity between active and sham groups were not significant\u2026..conclusions drawn in this way are notorious for failing to replicate.\u201d", "answer": 0}, {"article": "\u201cThose are the three big killers of older people.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\nThe study, called the National Lung Screening Trial, was conducted by the American College of Radiology Imaging Network and the cancer institute.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\nThis study suggests that, at least in lung cancer, spending more on tests saves lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story might have met this criterion if not for a misleading lead sentence. Researchers did announce that the heavy smokers in this trial who were offered CT scans had a 20 percent lower rate of death from lung cancer than those offered chest x-rays. The story does report the total number of deaths in the body of the story (354 vs. 442), but it does not point how that because so many smokers were in this trial, the lung cancer death rate in each group was less than 2 percent. That context is important, because while the relative difference in death rates is indeed 20 percent, the absolute difference is less than one-third of one percent (1.32% vs. 1.65%). A letter sent by the National Cancer Institute to trial participants points out that based on these results, 300 heavy smokers would have to be screened in order to extend a single life. Those statistics would have helped readers put the results in perspective.\nThe story does include valuable comments from one of the researchers about how much more analysis and study is needed in order to understand whether and for whom this sort of screening might be beneficial.\nAnother problem with the lead sentence is that it is not quite accurate to say that \u201cannual CT scans\u201d produced this result, since the trial didn\u2019t offer ongoing annual screening, but rather three scans done at one-year intervals and then no more.\u00a0 ", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nThis research is exciting as it suggests that an activity as simple as singing could reduce some of this stress-induced suppression, helping to improve wellbeing and quality of life amongst patients and put them in the best position to receive treatment.\"\nThe study tested 193 members of five different choirs.\nWith the choir, you can share experiences openly and that is hugely important.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The actual benefits in the results section of the manuscript were very modest, albeit statistically significant. This needed attention in the news release. The release does not use any numbers to give us a firm grasp on benefits for the study group. The release claims study participants had \u201csignificant reductions in stress hormones,\u201d but does tell us the significance. Here is an excerpt that tantalizes but disappoints:\n\u201cThe study tested 193 members of five different choirs. Results showed that singing for an hour was associated with significant reductions in stress hormones, such as cortisol, and increases in quantities of cytokines \u2014 proteins of the immune system \u2014 which can boost the body\u2019s ability to fight serious illness.\u201d\nWe wish this paragraph \u2014 explaining how samples were taken \u2014 had included some numbers for at least one of what it calls the \u201cchanges:\u201d\n\u201cChoir members gave samples of their saliva before an hour of singing, and then again just after. The samples were analysed to see what changes occurred in a number of hormones, immune proteins, neuropeptides and receptors.\u201d\nWe\u2019d also like to see the findings put into context. Since these biomarkers have been studied for many years by others, it would be appropriate to explain how the research community agrees on the significance of a change. What level of cortisol change, for example, is considered \u201csignificant?\u201d", "answer": 0}, {"article": "Drs.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nWomen getting the faster fluid rate (250 milliliters per hour) were less likely to get a cesarean section.\nBy pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase.\nEven low levels of dehydration can seriously compromise normal physiological function, yet recent studies looking at hydration in laboring women via the rates of intravenous (IV) fluid showed conflicting results.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release offers a clear, succinct statement of the benefits provided by increased IV fluids, it provides no numbers describing the magnitude of those benefits. The research report on which the release is based found that the differences in number of cesarean procedures and in the duration of labor were real but relatively modest.\u00a0 For example, a c-section\u00a0was deemed necessary for 12.5% of women who got higher levels of hydration and for 18.1% of those who received lower levels of fluids during labor. Length of labor declined by about an hour, a statistically significant but still modest clinically significant outcome.", "answer": 0}, {"article": "\u201cMonitoring viral load is crucial to the success of HIV treatment.\nPublished in the journal Scientific Reports, results showed the stick test was 95 percent accurate over 991 blood samples, and the average time to produce a reading was 20.8 minutes.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t correctly report the sensitivity of the lab-on-a-chip method, and an Imperial College London (ICL) news release (which the Reuters story seemed to rely on heavily) gets this wrong, too. The key thing each piece missed: There were two tests. The study used a scaled-up and better-understood test tube assay (which indicates a positive through a\u00a0fluorescence reaction)\u00a0to\u00a0validate and compare to the lab-on-a-chip test (which uses acidity/pH). The researchers ran biological samples through each test to cross-reference them.\nHere\u2019s how the numbers break down: The tube assay was 95% sensitive (meaning it missed 5% of HIV-positive samples) when more than 1,000 copies of HIV-specific RNA were present per milliliter \u2014 a limit WHO says is an acceptable sensitivity. Between 50-1,000 copies, the tube assay dropped to 88.75% sensitivity. (We\u2019ll note here that some lab-grade tests can detect 100 times fewer copies with close to 100% sensitivity.)\u00a0The pH-based lab-on-a-chip test, meanwhile, was 88.8% sensitive at more than 1,000 copies and 76.1% with 50-1,000 copies. That\u2019s a far cry from 95% accurate.", "answer": 0}, {"article": "Giving school children access to chilled, self-serve water may help chip away at childhood obesity, a new study of more than one million New York City school students suggests.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nWater jets also were linked with a decrease in the amount of half-pints of milk students bought, which could be a potential mechanism of weight reduction, the researchers found.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The CBS story does a good job quantifying the benefits in absolute terms, when the lead researcher points out that water dispensers were associated with \u201ca one percentage point reduction in the likelihood of being overweight for boys and a little over half a percentage point reduction for girls.\u201d The article translated this for readers as \u201ca modest weight drop among students.\u201d\nThe piece also notes that water jets were linked with \u201ca decrease\u201d in the amount of half-pints of milk students bought, but it does not give any specific numbers. Specifically, researchers found a 12.3 decrease in the number of all types of milk purchased per student per year.\nWe think the quantification of benefits in absolute terms is enough to merit a Satisfactory rating here.", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nAll but one had a successful transplant, and none had detectable antibodies immediately afterward.\nCritically, the enzyme does not banish the antibodies forever.\nThat means antibodies started to attack the new kidney.\nIt's almost impossible to find a compatible donor for those patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an adequate job of noting the actual numbers of patients in the study group, the absolute number that were able to have a successful transplant and the absolute number who later had a rejection episode that required standard anti-rejection therapy.", "answer": 1}, {"article": "It only finds the damage already done.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nNationally, deaths from this operation run two to four times higher, and they increase with the patient\u2019s age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does an admirable job of explaining the modest benefit of these scans. The story\u2019s effort to explain the statistics in several ways, including the use of absolute numbers, could serve as a model for other journalists. Example: \u201cIn the national trial, those screened with chest X-rays had about a 1.7 percent chance of dying from lung cancer during the study period; in the CT scan group, it was about 1.4 percent.\u00a0For every thousand people screened with a low-dose CT, three fewer died of lung cancer.\u201d\nAnother way to express this benefit would be the number need to treat (NNT) \u2014 the number of patients screened to prevent one lung cancer death. In this case, the NNT appears to be around 1 in 400. This is considerably better than other screening programs such as breast or prostate cancer.", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\nIn addition, a pooled analysis of data from the ZOE-70 and ZOE-50 trials showed that the candidate vaccine effectively reduced the risk of subsequent chronic neuropathic pain, also known as postherpetic neuralgia (PHN)1 which is the most common, and often severe, complication of shingles3,4.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release, like the original\u00a0article on which it reports, states that the vaccine effectively prevented shingles in 90% of participants, including preventing the pain often associated with shingles.\nAbsolute numbers in addition to or rather than relative reductions would have been a more meaningful quantification for readers.", "answer": 1}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nStatins are not risk-free.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presented relative risk of being diagnosed with colon cancer (i.e. \u2018patients \u00a0who took statins had a 12 percent lower risk of being diagnosed with colon cancer than people who did not take the drugs\u2019) rather than the absolute risk of being diagnosed with colon cancer in the two groups. Readers should ask, \"12% of what?\"\u00a0 See our primer on this topic. ", "answer": 0}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nBut, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story provides a more nuanced look at potential benefits of TMS than the competing WebMD coverage. In addition to providing statistics on the amount of improvement seen in the stimulation group, the story notes that\u00a0\u201cit\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\u201d \u00a0It also explains that the benefits were more pronounced among those with more serious symptoms. This is important context for patients or caregivers who\u00a0want to know how the research findings might apply to them.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nAccording to the best research, the drug reduces the risk of premature birth by one-third among women who are at high risk because they had a previous preterm birth.\nThe study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As already noted, the story explained that the drug \u201cisn\u2019t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.\u201d", "answer": 1}, {"article": "\u201cI keep waiting for the day when I have shortness of breath,\u201d he said.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nThe researchers are now searching for culprits among genes that remain \u2014 a search that could take years.\nTo keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story suggests that the purpose of this research is to\u00a0\u201csee if genetics can explain why heart disease strikes apparently healthy people.\u201d\u00a0But how many people are we talking about who might benefit from this information? The story doesn\u2019t say.\u00a0And even if we can identify these \u201capparently healthy\u201d people, will treating them with existing medications (which mainly target the traditional risk factors) improve their outcomes? Or will new medicines be developed that can treat them? Again, the story does not address the issue.The story should have explained that\u00a0for most of us, traditional risk factors are very effective\u00a0at predicting who is at increased risk of heart disease and should receive preventative\u00a0treatment. It\u2019s only toward the end of this long story that we learn that this family must have a \u201crare\u201d mutation that causes their\u00a0disease through some other pathway.\u00a0This information should have come much sooner, and with more detail.", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the article provides data about the total number of people randomized to the two arms of the study, it does not go beyond what the news release offers about the percentage/relative increases in remission of symptoms and response to drugs. No absolute numbers are given, so it\u2019s impossible to know how many of the patients in each arm actually benefited and to what extent. All it provides is the relative improvement in \u201cresponse\u201d to medication: \u201cresearchers found a 30% greater response to the medicine when the test was applied.\u201d No data is provided for remission.\nBut when you look at the raw numbers regarding remission rates, and compare the results of both groups, they don\u2019t look as impressive: Of those who didn\u2019t receive genetic testing, 10% reached remission. With the tests, it was 15%. This gives the reader perspective that the absolute difference was 5%.\nAlso, the news release hints that at least some of the results might not have been statistically significant, and we\u2019re curious about that and think it should have been explained in the story:\n\u201cThe GeneSight-treated cohort also demonstrated higher symptom improvement which approached statistical significance (Chart 1).\u201d", "answer": 0}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\nPublished in the New England Journal of Medicine, the study found that, among uninfected women, Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nThe findings indicate that if uninfected populations are vaccinated with Gardasil 9, approximately 90 per cent of all cervical cancers worldwide could be prevented.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release headline says the new version of the vaccine is \u201cbetter\u201d than the existing version, and the study backs this up. As the release notes, \u201c\u0085Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\u201d\nBut while \u201c97 percent effective\u201d sounds very impressive, what exactly does that mean? \u201c97 percent effective\u201d compared with what? The study published in the NEJM has the statistics that can put this into perspective. The paper notes the exact rate of disease that was observed in both the old and new vaccine groups: \u201cThe rate of high-grade cervical, vulvar, or vaginal disease related to [various HPV subtypes] \u2026 was 0.1 per 1000 person-years in the 9vHPV [new vaccine] group and 1.6 per 1000 person-years in the qHPV [existing vaccine] group.\u201d \u00a0For a more reader-friendly description, the release could have said the rates were 0.1 vs. 1.6 cases per thousand people in the study annually.\nIn addition, the accompanying editorial in the NEJM rightly points to the less than spectacular successes to date in actually immunizing young and adolescent girls with three doses over 6 months. \u201cAt 57%, coverage for the first dose of HPV vaccination among girls 13 to 17 years of age lags behind coverage for other vaccines recommended for children 11 to 12 years of age by approximately 20 to 25 percentage points.\u201d Greater emphasis on the need to follow through with all three doses would have been welcome.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided no information about how effective the radiation from this device is in the treatment of prostate cancer. \u00a0How do the lifespans of men treated with the RapidArc compare to men receiving radiation treatment from other devices? \u00a0How about those having surgery?\nThe major cited benefit is that treatment time is reduced from 5 to 10 minutes to less than 2. \u00a0It does not reduce the number of treatments.\u00a0", "answer": 0}, {"article": ".\nIf the test is negative, its accuracy will allow doctors to wait and watch a lesion.\n[Breast cancers predicted to rise by 50 percent by 2030]\n\nThe study released Sunday showed that the tests were about 97 percent accurate on 639 subjects.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nIf it shows a malignancy, a biopsy still would be needed to confirm the cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Overall, the benefits of the new test appear to be potentially substantial, but the article should\u00a0have quantified them with a bit more precision. For example, the \u201c97 percent\u201d accuracy rate used to describe the study results refers to the combined use of bronchoscopy and the new test \u2014 not the test by itself. Bronchoscopy alone is still accurate 75 percent of the time, and the test alone had an \u201carea under the curve\u201d of 0.74 \u2013 0.78 \u2014 meaning that 74-78% of the time it could correctly classify whether or not a patient had cancer. It\u00a0also would have made more sense, and brought more important context to readers, if the article had noted that the new test was able to reclassify a particular group of people at risk\u00a091 percent of the time. This group is composed of those considered at intermediate risk. The ability to place them in a \u201cwatch and wait\u201d or \u201clow-risk\u201d category is important because for some that will bring reassurance, but for others more anxiety and more tests.", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\nPublished in the Journal of Psychopharmacology online Dec.1, the study showed that one-time treatment with the hallucinogenic drug psilocybin \u2014 whose use required federal waivers because it is a banned substance \u2014 quickly brought relief from distress that then lasted for more than six months in 80 percent of the 29 study subjects monitored, based on clinical evaluation scores for anxiety and depression.\n\u201cOur study showed that psilocybin facilitated experiences that drove reductions in psychological distress,\u201d says Bossis.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does tell readers what percentage of patients benefited from psilocybin treatment, but does not explicitly quantify the extent of those benefits \u2014 which is what this category is designed to address. Instead, readers are given qualitative assessments of the treatment \u2014 that it \u201csignificantly lessens mental anguish\u201d and brought \u201crelief from distress.\u201d But those terms are vague. What does \u201csignificantly lessens\u201d mean? For example, did patients return to clinically normal levels of anxiety?", "answer": 0}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nMerck said trial results would be presented at an upcoming medical meeting.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Passing along the drug company\u2019s announcement that a drug \u201cmet the main goal of a late-stage trial\u201d doesn\u2019t come anywhere close to explaining what was found in that trial.\nThe story said \u201cKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer.\u201d\nBut what percentage of patients lived longer? And by how much? How did the drug affect their quality of life? Those questions weren\u2019t addressed.", "answer": 0}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\nIt's the most expensive device in medicine today.\nAt double the cost of standard treatments, many experts say it's being used without proof it's more effective.\nThe technology is two decades old, but Mass.\nIs this a better treatment for adults than conventional?\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "The oral drug targets an enzyme called Syk.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nFor now, R788 looks very promising, the researchers report.\nBut there's an overabundance of Syk in the fluid of arthritic joints, and the enzyme is part of the runaway immune machinery that increases joint inflammation.\nFor patients treated with the more active twice-daily dose of 100 milligrams of R788:\n\u2022 67% had at least 20% fewer arthritis symptoms, compared to 35% of patients getting a placebo.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As with the harms, the story provides a long list of comparisons in relative terms to tout the benefits of the drug. This is more helfpul than most stories, but the story could have done a better job by providing some numbers in absolute terms. The first comparison, for example, says, \"67% had at least 20% fewer arthritis symptoms, compared to 35% of patients getting a placebo.\" It\u2019s hard to know how big of a benefit this really is.\u00a0We tried to do the math\u00a0using the number of people in the study and quickly realized\u00a0that without the number of symptoms,\u00a0there\u00a0is no way to calculate the true size of the benefit here.\u00a0", "answer": 0}, {"article": "For more information, please visit www.alzheimersprevention.org.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\nThe article reviews decades of research into the impact that various meditation techniques have had on the prevention of Alzheimer's disease, focusing on one evidence-based practice that Khalsa says can be a powerful part of any Alzheimer's prevention and spiritual fitness program, Kirtan Kriya (KK), a meditation technique which has been successfully used to improve memory in studies of people with subjective cognitive decline and mild cognitive impairment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release claims that the 12-minute meditation has been successfully used to \u201cimprove memory\u201d in people with subjective cognitive decline and mild cognitive impairment. There\u2019s no quantification offered.\u00a0 What was the health status before and after performing the meditation exercises?\nThe headline is particularly concerning, suggesting that a research journal article finds meditation and spiritual fitness beneficial in preventing Alzheimer\u2019s. But the news release mainly focuses on vague claims and a description of the technique without explaining \u201chow\u201d the technique benefits the brain other than activation of a certain area.\nWhen we looked at the review article that the release is based on, we found that the few actual studies cited on meditation were very small. There was no mention of randomization, and again no design where development of dementia was compared between those practicing meditation and not. The studies themselves mentioned they were \u201cpilot\u201d or \u201cpreliminary.\u201d", "answer": 0}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nThey identified 86 patients who had psoriasis before their operation, 21 of whom were also diagnosed with psoriatic arthritis, and compared their symptoms before and after undergoing bariatric surgery.\nFor the study, Reddy and colleagues reviewed the medical charts of 9,073 weight-loss surgery patients who were treated between 2002 and 2013 at NYU Langone's Weight Management Program.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although it is hard for a reader to picture what a severity score of 5.6 for psoriasis would actually look like, the news release at least gives us the range of possible scores (0-10) and the absolute reduction in scores for disease severity. It would have been helpful to know if such a reduction would allow a psoriasis patient to stop using one of their medications or need fewer interventions. We assume that these are the averages of the scores of the 86 patients who underwent surgery (the \u201csignificant reductions in their \u201cdisease severity scores dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\u201d)\nThe study monitored patients on average for\u00a0more than six years, \u201cwith an average excess weight loss of 46.2 percent body weight.\u201d \u00a0It would have been helpful to also include the average pre-surgery starting weight of the volunteers.", "answer": 1}, {"article": "The altered T-cells \u2014 called chimeric antigen receptor cells \u2014 are then dripped back into the patient\u2019s veins, and if all goes well they multiply and start destroying the cancer.\nBut such drugs tend to be extremely expensive.\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nShe wound up on a ventilator, unconscious and swollen almost beyond recognition, surrounded by friends and family who had come to say goodbye.\nThe researchers were presenting their results on Sunday and Monday in at a meeting of the American Society of Hematology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We think the story leaves readers with an improbably rosy portrait of the experimental treatment\u2019s benefits. Here\u2019s why:", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThat kind of analysis is not the strongest type of research, but the authors took extra steps including examining raw data from the original studies.\nThe authors explained their statistical findings by using a pain scale of 0 to 100: The patients' average baseline pain measured 60; it dropped to 30 on average in those who got acupuncture, 35 in those who got fake acupuncture, and 43 in the usual treatment group.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are clearly explained by the story: \u201cThe patients\u2019 average baseline pain measured 60; it dropped to 30 on average in those who got acupuncture, 35 in those who got fake acupuncture, and 43 in the usual treatment group.\u201d It would have been helpful to include some comparison here.\u00a0 For example, how well do NSAID\u2019s work for these conditions?", "answer": 1}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\nResearchers compared data on 6,684 women and girls taking spironolactone to 31,614 who were prescribed antibiotics.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\n\"It's clear that a safe alternative to oral antibiotics could have a huge benefit, and our data show spironolactone may be that alternative,\" said the study's lead author John S. Barbieri, MD, MBA, Dermatology chief resident at Penn.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This criterion rates a Not Satisfactory because the study did not set out to quantify benefits of a specific drug or drugs and yet the release makes numerous claims about one drug\u2019s benefits while calling for a change in practice. The study that was undertaken can not tell us how well the drug worked or which factors contributed to discontinuance of any of the drugs.\u00a0The release provided the absolute numbers of women who stopped taking a drug and switched to an alternative drug but the measurement of switching drug therapies was only a proxy for effectiveness.", "answer": 0}, {"article": "This is not only time inefficient, it's costly.\nCompared with patients receiving usual care, a significantly higher proportion of patients receiving the Triple Pill achieved their target blood pressure of 140/90 or less (with lower targets of 130/80 for patients with diabetes or chronic kidney disease).\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nAt six months, 83 percent of participants in the Triple Pill group were still receiving the combination pill compared to the majority of patients in the usual-care group still receiving only one and only one third receiving two or more blood-pressure-lowering drugs.\nThe trial, which was conducted in Sri Lanka, enrolled 700 patients with an average age of 56 and blood pressure of 154/90 mm Hg.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The target blood pressure (BP) for this study was below 140/90 (or below 130/80 in patients with diabetes or chronic kidney disease).\nThe news release states that: \u201c70% (of subjects) reached blood pressure targets with the \u2018Triple Pill\u2019, compared to just over half receiving normal care.\u201d (Normal or usual care is defined in the release as \u201ctheir doctor\u2019s choice of blood pressure lowering medication.\u201d)\nIt should have been made more clear this was measured after 6 months in the study.\u00a0And as a result, the effect on cardiovascular (CV) risk reduction of the combination is unknown.", "answer": 1}, {"article": "\u201cStatins don\u2019t cut out all of the unhealthy effects of a burger and fries.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "        \nA balance was struck between the claims of the study author and those of several unaffiliated experts.\u00a0 While the study centered on the cholesterol lowering effects of a statin condiment, the negative effects of a high fat, high sodium, high calorie diet were highlighted providing a balance to the story.\u00a0 \nThe story mentions\u00a0that\u00a0\"A study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\" But this wasn\u2019t the only study to come to that conclusion, and, in fact, the drug company\u2019s own research backs this claim up, as has been well documented in previous news stories.\nWe wish the story had clarified whether the research team was suggesting popping a single statin pill in response to a single cheeseburger, or whether they were suggesting a regular regimen of statin use.\u00a0 This is a key point, and is relevant to any discussion about the quality (or lack) of evidence, and about potential harms and benefits.\u00a0 ", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did a pretty good job of presenting the complicated data modeling and reasons for the recommendations regarding breast density risk calculations and screening intervals. But it needed some actual numbers to quantify the benefits. In this case, it\u2019s the number breast cancer deaths averted.\nAs the study abstract stated,\u00a0\u201cbreast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted).\u201d", "answer": 0}, {"article": "Treatment usually involves surgical removal of the uterus, known as hysterectomy.\nFurther, the average number of lymph nodes removed was about the same in the robotic and open procedures, suggesting that both approaches result in about equal surgeon accuracy in staging endometrial cancer.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\nNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\nBased on their review, the researchers found that minimally invasive surgeries done with a human hand and instruments or with robotic assistance equipment took around the same time and resulted in similarly long stays in the hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story summarized the findings succinctly: the robotic and laparascopic surgeries: \u201ctook around the same time and resulted in similarly long stays in the hospital. However, about half as much blood was lost when robots were enlisted than with standard laparoscopy. Both minimally invasive techniques resulted in longer-duration operations than open surgery. But both also led to shorter hospital stays and, in the case of robotic surgery, less blood-loss. Further, the average number of lymph nodes removed was about the same in the robotic and open procedures, suggesting that both approaches result in about equal surgeon accuracy in staging endometrial cancer.\u201d\nHowever, we would have liked to have seen a bit more discussion on the issue of blood loss. Although the amount of blood loss seen in the patients who underwent a robot-assisted procedure was statistically lower, there was no difference in the patients\u2019 need for a transfusion. The 8 studies also had dramatically different blood loss in all three groups. The range of blood loss in patients undergoing a robot-assisted procedure was almost 3 fold (66.6ml in the Veljovich study as compared to 166 in the Bell study).", "answer": 1}, {"article": "The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world.\n\"In a cohort of emergency room patients with suspected sepsis, we saw that the assay picked up infection within an hour in 85% of patients who exhibited clinical symptoms of sepsis, and equally importantly, it did not falsely predict infection in healthy subjects or patients with inflammation triggered by other causes, such as trauma.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\nAnd it can more specifically identify patients who have excessive inflammation due to systemic infection, rather than other causes,\" said Donald Ingber, M.D., Ph.D., the Wyss Institute's Founding Director, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The published study has substantial quantification of its findings, and the range of pathogens detected. The release notes that the assay \u201cpicked up infection within an hour in 85 percent of patients who exhibited clinical symptoms of sepsis,\u201d but offers no actual number of patients. The release states that the Wyss team \u201csuccessful tested the assaying rat and pig models\u201d of E.coli infection, but left out any data about the strength or accuracy of the experiments in pigs.\nThe sensitivity and specificity of the test in the emergency department patients studied is key. The release quantifies the sensitivity, but only mentions specificity in a qualitative way. The published study, by contrast, notes:\n\u201cIn patients with suspected sepsis, the FcMBL ELLecSA detected infection in (55 of 67 patients) with high sensitivity (>81%), specificity (>89%), and diagnostic accuracy (0\u00b787). It also distinguished infection from trauma-related inflammation in the same patient cohorts with a higher specificity than the clinical sepsis biomarker, C-reactive Protein.\u201d", "answer": 0}, {"article": "Kilmer McCully of the V.A.\n\"These studies did not test whether B vitamins used by healthy people can help keep them healthy.\nIn the second study, Kaare Harald Bonaa of the University of Tromso in Norway and colleagues researchers gave 3,749 patients who had had a heart attack within the previous week the vitamins or a placebo for more than three years on average.\nAnother study presented at the cardiology meeting did surprise researchers when it did not find any benefit to combining the blood-thinner Plavix with aspirin for preventing heart attacks, strokes or deaths in heart patients.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We give this story a satisfactory score, but the story could have helped readers understand why measuring surrogate markers such as homocysteine levels can be different than tracking true outcomes such as heart attack or stroke. Here, the surrogate endpoint (homocysteine levels) \u201cimproved,\u201d but the real endpoint \u2013 heart attack and stroke \u2013 did not. ", "answer": 1}, {"article": "The effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\n\u201cWhat we are hoping for with this device is to find a treatment for movement disorders where Levodopa, Parkinson\u2019s disease where Levodopa is not enough.\nBut I still believe that something will be found at some point which could be useful.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\nIt is a current device which is very similar to the ones that people use for pain relief with electrical stimulation of muscles and nerves, what\u2019s called TENS.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019d like to point out this story\u2019s reporting on a patient who didn\u2019t receive any benefit from the device. These kinds of anecdotes are rare and valuable in health stories, which too often focus on patients who achieve spectacular, unrepresentative results. The reality for many patients is often more prosaic, as this quote nicely conveys: \u00a0\u201cI have become hardened in the sense that I do not have too great expectations. But I still believe that something will be found at some point which could be useful. There is extensive research in this field and I hope that it eventually will come up with a result.\u201d\nThat being said, we have to rate this story Not Satisfactory because it never quantifies the apparent benefit, summarizing it instead in general terms: \u201cAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\u201d Patients need to know something about degree of benefit to determine if this is something that may be worth exploring.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\nDr. Susan V. Bukata, associate professor of orthopaedic surgery at the University of Rochester Medical Center, said that the study really doesn't provide enough information to make a definitive conclusion.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because this study was focused on avoiding the risk of heart attack and stroke, we think that the benefits category is not applicable here.\n", "answer": 2}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nIn contrast, a concussion survey commonly used by doctors was right less than 70 percent of the time.\nAnd microRNAs offer a promising way to assess concussions in adults as well as children, says Bhomia, whose research involves a range of \"biomarkers\" for traumatic brain injury.\nHicks and a team of researchers have been looking for an objective test that might help.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify benefits with this statement:\nA test that measures fragments of genetic material in saliva was nearly 90 percent accurate in identifying children and adolescents whose symptoms persisted for at least a month, a Penn State team told the Pediatric Academic Societies Meeting in San Francisco, Calif.\nThe story overstates both the accuracy of the test and the meaning of the study results. First, regarding the accuracy, while it is technically correct that the researchers reported their spit test \u201cwas nearly 90 percent accurate in identifying children and adolescents whose symptoms persisted for at least a month,\u201d that statement is likely to give most people an inflated sense of what test results would mean in the real world.\nThe researchers reported in their conference abstract\u00a0(see session ID 255639) that the test had a sensitivity (ability to detect true cases) of 90 percent and specificity (ability to rule out non-cases) of 87 percent. But the lead researcher estimates that only 25 percent of children have prolonged symptoms after a concussion. Putting those numbers into a statistical calculator indicates that in a typical group of patients, a positive result would mean the likelihood of prolonged symptoms would be actually less than 70 percent. Still, a negative result would be correct more than 96 percent of the time.\nAlso,\u00a0where is the evidence that predicting symptom duration improves outcomes? Would the test result change treatment? Would it alter decisions about when it is safe for a child to return to sports? Of course, parents want to know \u201c\u2019When is my child going to be back to normal again?,\u2019\u201d but most readers would infer that the test must have some value beyond making predictions that don\u2019t change how the child is actually treated.\nWhat\u2019s more, the story includes a claim that doesn\u2019t make sense based on the evidence the researchers presented. It paraphrases an expert who says \u201cA saliva test could greatly improve care for young people who don\u2019t have obvious symptoms of a concussion.\u201d But that\u2019s not what the researchers looked at\u00a0\u00a0They reported that the saliva test was able to predict the duration of symptoms, which doesn\u2019t reveal anything about its ability to detect brain damage that does not produce symptoms. That is an important question that still has to be tested.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nRobert Nagele, PhD, presented his team's most recent findings October 18 at OMED 15 in Orlando.\n\"As osteopathic physicians, we constantly tell patients that a healthy lifestyle is the best medicine for preventing disease.\nThe blood test developed by Dr. Nagele has also shown promise in detecting other diseases, including Parkinsons's, multiple sclerosis and breast cancer.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No details are given about how the test has performed. \u00a0Nothing about sensitivity or specificity. \u00a0If the test is \u201cnearing development,\u201d the researcher should be able to provide positive and negative predictive values \u2013 the best measures to judge the performance of such a test. \u00a0How many people who test positive really have the disease, and how many who test negative don\u2019t?\nThen, in this data-free zone in which this news release resides, it goes even further\u00a0beyond Alzheimer\u2019s to say that \u201cthe blood test has also shown promise in detecting other diseases, including Parkinson\u2019s, multiple sclerosis and breast cancer.\u201d \u00a0Again, without a shred of evidence provided.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release merely says \u201cit works.\u201d The release notes that the author lost 70 pounds 12 years ago, although it appears that his personal weight loss was the result of applying techniques discussed in an earlier book, not the specific methods pitched in this release.\nAnd, while Lou Piniella is trotted out of the bullpen to impress with his name, no data about his results are provided in the news release.\nIt is important to note that while the release claims that \u201cThe Baseball Diet\u201d will produce results within nine weeks, in order to improve health a diet plan must help people maintain lower weight indefinitely.", "answer": 0}, {"article": "Sanofi said this was mainly due to neutropenia, a blood disorder people can get from chemotherapy treatment, and its complications.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\nPARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story included the mean overall improvement in survival. But it didn\u2019t comment at all on the tradeoff of 2.4 months in improved median survival versus a 3% higher risk of death from side effects.\u00a0 A barely satisfactory grade on this. \n", "answer": 1}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe study had some limitations, the authors acknowledged.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\nFor example, only about 70 percent of people who were taking drugs to lower cholesterol were actually on statins at the study's start.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story nicely summarizes what researchers did in the study, but it does not provide any numbers for the benefits found in the study. This is unfortunate because it would have given readers a better sense of what \u201cslightly lower risk\u201d meant in the lead.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\nDupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In terms of benefits, the release offers the following: \u201cOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\u201d But readers are left to interpret on their own what \u201cgreater response\u201d and \u201ca reduction in itch\u201d mean.\nThe release would have been better if it had told readers how the improvement was measured and how many patients experienced improvement rather than using the term \u201coverall.\u201d", "answer": 0}, {"article": "Cardiac arrest involves the abrupt loss of heart function, breathing and consciousness.\nWhen the ambulance arrived within five minutes, 14.5 percent of patients in the bystander CPR group survived at least 30 days, compared with 6.3 percent in the group that didn\u2019t get this help.\nWhen ambulances took up to 10 minutes to arrive, bystander CPR was associated with tripled survival odds, the study also found.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\n\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of giving exact numbers of survivors who did and didn\u2019t receive CPR in the study. It provides exact survival times for ambulance arrivals\u00a0at 5, 10, and 13 minutes. These statistics are provided both in terms of percentages\u00a0and ratios.", "answer": 1}, {"article": "Anderson Cancer Center.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\n\"This presents an unprecedented opportunity for informative early detection of pancreatic cancer and in designing potential curative surgical options.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits of the tests are presented only in vague terms. The expert quoted claims that earlier diagnosis of pancreatic cancer would reduce death rates, but in the next sentence he states that a new screening tool also offers an \u201cunprecedented opportunity\u201d to design \u201cpotential curative surgical options.\u201d That doesn\u2019t give us a lot of confidence that curative surgical options currently exist. As we discussed in the competing NBC and LA Times reviews, patients whose cancers are caught early may still face long odds for survival. And the 100% accuracy figure touted in the story is based on a very small number of subjects. The story didn\u2019t hint at any of this context.", "answer": 0}, {"article": "They can also keep heart vessels more elastic and flexible, which helps combat the growth of plaques that can build up and rupture, causing heart attacks.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nNow a study published in the journal Circulation confirms and quantifies that benefit; women who ate three or more servings of blueberries and strawberries per week reduced their risk of heart attack by up to one third.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece mentions that \u201cwomen who ate three or more servings of blueberries and strawberries per week reduced their risk of heart attack by up to one third.\u201d Again, this is the figure associated with anthocyanin, after adjustment of multiple variables. The limited understanding of anthocyanin and its levels in the body introduces an important limitation in the study. The protective effect may have been due to other factors, which is something the researchers acknowledge in their journal article.\nFinally, the story did not make a clear statement about this study\u2019s ability only to point to a statistical association \u2013 not to establish cause-and-effect \u2013 something we describe more in the \u201cEvidence\u201d criterion below.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story offers good narrative explanations and opinions about the added value of the nuclear imaging tests, but no hard data to support the conclusions. The FDA approval processes certainly require data\u2013both preclinical and clinical\u2013and at least some of it should be cited.\nThe story\u00a0makes claims about earlier detection of recurrence, but provides no data on how much more likely this is compared to following PSA or other currently available tests, and whether this earlier detection leads to better clinical outcomes. We already have good tests to evaluate spread to bone (advanced cancers)\u00a0and\u00a0lymph nodes. We would need data to show whether the new technology is more accurate\u2013and cheaper than current tests.", "answer": 0}, {"article": "Fred Hutch\u2019s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nNewswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nUntil now, there were no systemic therapies approved by the Food and Drug Administration for this cancer, and no approved therapies once the cancer had spread.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release alludes to a study in the Lancet Oncology but it does not provide any of the measurable benefits found in that study, namely that out of 88 patients who received at least one dose of the drug avelumab, 28 achieved an \u201cobjective response\u201d within an average of about 10 months. That means that less than a third of the patients who took the drug saw something positive happen as a result. The release might make you think that, in fact, the majority of patients who take the drug see their tumors shrink. But even when a 90% reduction in tumor mass occurred (as was the case of the patient profiled), it would not automatically translate into longer survival for all patients.\nThe release states that almost a third of patients in the trial \u201cwith no hope at all of surviving\u201d benefited from the drug. What does no hope at all mean? Were all of the patients in the trial at stage 4 of the disease? The release doesn\u2019t tell us.", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\nAbout 80 percent of U.S. adult cigarette smokers who were surveyed reported seeing at least one television ad from Phase 2 of the 2014 campaign.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is focused on a study that used survey data to estimate the impact of the Tips campaign. And the release does a good job of articulating those estimated benefits. The most concrete benefit was the estimate that 104,000 people \u201cquit smoking for good\u201d as a result of the Tips campaign. That\u2019s enough to earn a \u201csatisfactory\u201d rating. But the release doesn\u2019t tell readers what quitting smoking \u201cfor good\u201d means. It appears to mean, based on the study itself, that smokers had quit for six months \u2014 that\u2019s good to know. It also doesn\u2019t place those 104,000 quitters in context. Based on the information in the release itself, there are 40 million adult smokers in the U.S., and approximately 80 percent of those smokers saw at least one of the Tips ads. That comes to 32 million smokers. If 104,000 of those smokers quit, that means that the 2014 Tips campaign helped approximately 0.3 percent of smokers who saw the campaign to quit. Is that good? Bad? It\u2019s hard to tell without comparing the 2014 Tips campaign outcome to the outcomes of other campaigns \u2014 which the release doesn\u2019t do.\u00a0 It\u2019s also important to note that the 104,000 is an extrapolation based on surveying only 4,428 subjects. Given that\u00a0about 3,500 of these subjects saw the ads, the 0.3 percent quit rate equals 10 study subjects.", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\nBut in terms of their bacterial colonies, the infants swabbed with the microbes closely resembled vaginally delivered babies, she found, especially in the first week of life.\n\u201cJust understanding that it\u2019s possible is exciting.\u201d\n\nBut it will take further studies following C-section babies for many years to know to what degree, if any, the method protects them from immune and metabolic problems, he said.\nAnal samples from the swabbed group, oddly, contained the highest abundance of bacteria usually found in the mouth.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article does a nice job of detailing the potential benefits of the microbial transfer and the results seen in the study, while giving the caveat that longer follow up studies are needed to understand the implications of various microbiome make-ups.\u00a0But to be fair, the results are from a total of 4 newborns, hardly a number on which to base any strong conclusions.", "answer": 1}, {"article": "\"This is one more reason to consume fruits and vegetables - at least 5 a day - and it's good to include tomatoes in that mix,\" Willett said.\nThe scientists found that those with the highest levels of lycopene were 55% less likely to have a stroke than those with the lowest amounts in their blood.\n\"It's a compelling study and it fits with other data that we have about risk of stroke and vegetable and fruit consumption,\" explains Dr. Daniel Labovitz, director of the Stern Stroke Center at Montefiore Medical Center in New York.\nLabovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\n\"This study adds to the evidence that a diet high in fruits and vegetables is associated with a lower risk of stroke,\" says study author Jouni Karppi, of the University of Eastern Finland in Kuopio.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story frames the benefit in relative terms, stating: \u201c\u2026those with the highest levels of lycopene were 55% less likely to have a stroke than those with the lowest amounts in their blood.\u201d\nBut since we don\u2019t know how many strokes occurred in these high- and low-lycopene groups, there\u2019s really no way to tell how meaningful this 55% reduction is. The story would have done better to put the statistics in more useful absolute terms, as\u00a0a press release that accompanied the study did: \u201cAmong the men with the lowest levels of lycopene, 25 of 258 men had a stroke. Among those with the highest levels of lycopene, 11 of 259 men had a stroke.\u201d", "answer": 0}, {"article": "A man whose P.S.A.\nscore of 1.0 or lower at age 60 had a very low individual risk of death from prostate cancer over the next 25 years, the study found: just 0.2 percent.\nBut the score does put them in a higher-risk group of men who have more to gain from regular screening, he concluded.\n\u201cThere\u2019s a strong case that they should be exempted from screening.\u201d\n\nThe advice is less clear for men with scores between 1.0 and 2.0 at the age of 60.\nscore of 2.0 or higher at the age of 60, and most of them will not develop prostate cancer, said the study\u2019s lead author, Andrew Vickers, associate attending research methodologist at Memorial Sloan-Kettering.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The way the study results were reported in this study, 75% of men have a PSA level at age 60 that is less than 2 meaning that their risk of having a problematic prostate cancer in their lifetime is less than 6%. \u00a0\nIt might have been useful to provide some context for evaluating what a 6% risk means. \u00a0How does it compare, for example, of a man\u2019s chance of dying of heart disease? \u00a0Or other types of cancer?", "answer": 1}, {"article": "\"It's a good start, but I think we have better things coming down the road.\"\nEven if a good match is found, transplant recipients can go on to have more problems with infections, such as graft-versus-host disease, in which the body basically rejects the foreign elements.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nIn this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector.\nAccording to Conley, children (mostly boys) with Wiskott-Aldrich syndrome (WAS) are born with an inherited genetic defect on the X chromosome that affects the number and size of platelets and makes the children remarkably susceptible to easy bleeding and infections, including different types of cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that the therapy resulted in\u00a0\u201cincreased platelet counts\u201d and \u201cimprovement of some immune-system cells.\u201d The story should have provided quantitative data and tried to explain what these changes might mean for patients.\u00a0Another problem is that the story didn\u2019t tell us how long\u00a0the patients were followed and how long the benefits lasted. The effects of some gene therapies fade with time because the cells injected with\u00a0DNA by viruses ultimately die and stop producing the therapeutic protein.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nIt did find enough new data to recommend for the first time against screening for older men.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story outlined for readers that the benefits of routine screening for prostate cancer are uncertain.", "answer": 1}, {"article": "But not a whole lot.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nBut since then several new studies - known as randomized controlled trials - have been completed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided fewer numbers than the WebMD story, and we wish it had presented some of the evidence in absolute terms.\u00a0The story seems to want it both ways. While the story opening does provide the reader with some understanding of the uncertainty of the review results, the quotes from one of the study authors appear to provide an endorsement that is well beyond that in the study conclusions. For example, the story notes, \u201cThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\u201d What is left unsaid is that the authors of the paper rated the evidence for that conclusion as low and \u201cFurther research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.\u201d Far from the declarative statement in the story.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the ideal would be a story that reported numerical data about what was actually found\u2013what the scope of potential benefits/harms were in the trial\u2013we\u2019ll nonetheless give this a satisfactory score. There\u2019s little doubt about the take-home message from this paragraph in the story: \u201cA year of testosterone treatment was no better than a placebo for memory and thinking, and it increased fatty plaque in coronary arteries, a risk factor for heart disease. The hormone helped anemia and low bone density in the minority of men with those conditions, which can be treated with other, proven therapies.\u201d", "answer": 1}, {"article": "But oral administration is rarely used because of toxic effects on the liver.\nCurrently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nStill, this study will not answer the question of whether it is safe to use the hormone for years, even decades, which would be necessary to maintain any benefits.\nThe researchers, who published their findings in The New England Journal of Medicine, noted that the deck might have been stacked in favor of a hazardous outcome because study participants, especially the group that received testosterone, had high rates of high blood pressure, diabetes, obesity and elevated blood lipids.\nThen again, this may be a realistic population to study, given that many candidates for hormone therapy are likely to have such health issues.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story notes that testosterone has\u00a0inconsistent effects\u00a0on sexual function, the primary reason men seek out this type of treatment. Other potential benefits of testosterone therapy\u00a0are listed as improved muscle mass, increased\u00a0bone density, decreased body fat\u00a0and total cholesterol, and improved blood sugar\u00a0metabolism.\u00a0\u00a0\nAs with the harms,\u00a0this story never provides statistical data on how often these benefits\u00a0occur and how big a benefit can be expected.\u00a0However, we\u2019re not sure these numbers with would have been helpful, since the benefits are reflected in some\u00a0fairly arcane scales (e.g. the \"libido scale,\" \"subjective vitality scale,\" etc.) that would be difficult to describe in a relatively brief piece like this. Does a 20% increase in the libido scale number mean anything to anyone other than researchers? We think the piece satisfies the spirit of the criterion\u00a0and offers enough detail for a satisfactory grade. \u00a0\u00a0", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nEach participant carried out the word-memorization tests repeatedly, with different words every time; some lists were memorized with brain stimulation, and other lists with no stimulation, which served as a control.\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state.\nThe authors then examined memory performance based on whether stimulation arrived during low- compared with high-functioning brain states.\nBefore the stimulation tests, the team determined the precise settings for each patient\u2019s high- and low-functioning states.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers get two sets of numbers on the effect size: Patients who were gently zapped when their brains were learning words during a foggy, \u201clow-functioning state\u201d\u00a0could remember words 12%-13% better. Stimulation during a clear-minded, \u201chigh-functioning state,\u201d however, resulted in 15%-20% worse performance.\nWhat\u2019s missing, however, is a definition and context for these numbers. We had a lot of questions: Do they reflect the number of words recalled? How correct (or incorrect) their order during recall was? Or that people remembered them more or for less time compared to no stimulation? Or some other measure? Were these statistically significant results? Also, how did the researchers determine if a person was experiencing a \u201chigh-functioning\u201d or \u201clow-functioning\u201d state?", "answer": 0}, {"article": ".\nThis study was funded, in part, by The Ben & Catherine Ivy Foundation.\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\nAnd, the FDA has already approved it.\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release is riddled with suggestions \u2014 but no specifics \u2014 of potential benefits. Some examples:\nThe release is explicitly silent on the fact that the research was confined to the laboratory and did not involve patients.", "answer": 0}, {"article": "Anxiety disorders plague more than one in four adolescents between the ages of 13 and 18, and many of them are treated with antidepressants and other medications to try and help them live a relatively healthy childhood.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\nBut a team of researchers from the University of Cincinnati set out to explore other treatment options that focus more on the mind and less on pharmaceutical solutions.\n\"Increasingly, patients and families are asking for additional therapeutic options, in addition to traditional medication-based treatments, that have proven effectiveness for improved symptom reduction.\nMindfulness-based therapies for mood disorders is one such example with promising evidence,\" said Cotton, adding the university is both studying and implenting these therapies.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of not \u201cover-selling\u201d the benefits seen in the cognitive therapy study on children with anxiety disorders. It refers to \u201cintegrative approaches\u201d and expanding treatment options. When discussing study results, the story talks about \u201cthe potential that\u00a0mindfulness therapy could\u00a0bring to the table,\u201d and notes that \u201cIf nothing else, it might\u00a0allow people who would\u00a0be reluctant to take medication\u00a0more\u00a0treatments to\u00a0choose from.\u201d That sort of cautious language is all to the good. However, when it comes to describing the study\u2019s findings, the language is extremely vague: \u201cCotton noted the anxiety of [study] patients was significantly reduced following treatment, and the more mindfulness they practiced, the less anxious they felt.\u201d What does \u201csignificantly reduced\u201d mean? Even a tiny improvement can be statistically \u201csignificant\u201d \u2014 is that what we\u2019re talking about here? It\u2019s not clear. This is why the criterion asks for quantified benefits, and that\u2019s lacking here.", "answer": 0}, {"article": "(His group was one of the sponsors of the Lancet study.)\nResearchers call such a hypothetical integrated system an \u201cartificial pancreas\u201d because it would mimic the way a healthy pancreas works, sensing glucose and dispensing insulin in the right dose at the right time.\nIf a diabetic person\u2019s blood sugar drops during the night and the glucose monitor alarm goes off, for example, that person may not wake up and the preprogrammed pump, operating separately, could continue to deliver insulin, making the problem worse, Dr. Kowalski said.\nResearchers in Europe and the United States have been racing to develop a fully automated system for Type 1 diabetes that would wirelessly connect an external glucose monitor with an insulin delivery device.\nIndustry analysts have estimated that 10 to 15 percent of Americans with Type 1 diabetes \u2014 perhaps 400,000 of them \u2014 use either a continuous glucose monitor or an insulin pump, or in some cases both.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We applaud the Times for avoiding the term \"artificial pancreas\" in the headline and using it sparingly in the body of the story.\u00a0The competing stories couldn\u2019t resist it. We can understand why\u00a0marketers and media relations people would favor this term because of its promotional value, but we don\u2019t think it\u2019s a\u00a0good way to describe this technology in an objective piece of journalism. \"Artificial pancreas\" is misleading because we\u2019re not really anywhere close to\u00a0being able to replicate what the normal human pancreas\u00a0does through artificial technology.\u00a0Forgetting for a moment\u00a0that the pancreas does much more\u00a0than simply dispense insulin (it also\u00a0produces a number of other hormones and\u00a0digestive enzymes that aren\u2019t impacted by diabetes),\u00a0what\u2019s more important is how the pancreas works\u00a0in concert with\u00a0the brain and other systems to regulate\u00a0glucose in a very tight range.\u00a0The normal human pancreas starts releasing\u00a0insulin before\u00a0we eat in response to complex environmental cues, whereas any artificial system would need to\u00a0be told that\u00a0meal is coming or react to the\u00a0rise in glucose after the\u00a0fact. Plus,\u00a0insulin\u00a0produced by the body\u00a0starts acting right\u00a0away, whereas insulin analogues take about 20 minutes to take\u00a0effect. Put this all together and we see that the \"artificial pancreas\" will, for the foreseeable future, require human intervention to predict\u00a0post-meal\u00a0insulin needs and dosing or else patients will be at risk of post-meal blood sugar spikes. And it\u2019s not at all clear that such a system\u00a0will improve overall blood\u00a0sugar management compared with existing methods. The term\u00a0\"artificial pancreas\" conjures up a vision of totally automated glucose management and essentially a \"cure\" for type 1 diabetes. This is\u00a0overselling what the technology can do.\u00a0 ", "answer": 1}, {"article": "Scientists speculate that substances known as flavonoids, in particular so-called flavanols, may be responsible for chocolate\u2019s apparent effects on health.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nThe women ranged in age from 49 to 83 years.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\n\u201cChocolate should be consumed in moderation as it is high in calories, fat, and sugar,\u201d she said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story went the extra mile here, providing the\u00a0absolute rates of stroke seen in the groups consuming the lowest and highest quantities of chocolate.\u00a0 \u201cAmong those with the highest weekly chocolate intake \u2014 more than 45 grams \u2014 there were 2.5 strokes per 1,000 women per year. That figure was 7.8 per 1,000 among women who ate the least (less than 8.9 grams per week).\u201d These statistics weren\u2019t provided in the study text, suggesting that the writer made the calculations based on data contained in one of the study tables. We applaud the\u00a0extra effort made to provide meaningful statistics to readers!", "answer": 1}, {"article": "The children were instructed to do an hour per day of near-vision activities such as homework or computer work.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\nAmbylopia was evaluated as resolved in nearly 17% of patched eyes but nearly 42% of the acupuncture group.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nAn improvement of two lines or more occurred in nearly 67% of those in the patching group but nearly 76% of those in the acupuncture group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a better job than the competing coverage of quantifying the extent of the benefit observed with acupuncture. It explained that children in the acupuncture group had their vision improve by about 2.3 lines on the vision chart, compared with\u00a0about 1.8 lines\u00a0in the patch group. (HeathDay, by contrast, merely said that vision \u201cimproved markedly\u201d in the acupuncture group.) It also explained that the amblyopia was considered \u201cresolved\u201d in 42% of acupuncture and 17% of patch patients. (The HealthDay we also reviewed described these patients less precisely as \u201csuccessfully treated.\u201d) Lastly, this story noted that the benefits of acupuncture were much less pronounced after 25 weeks than they were at 15 weeks, whereas HealthDay only mentioned the 15-week outcomes.", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nAs the study's authors point out, \"The mechanism(s) by which circumcision reduced acquisition of an STI [sexually transmitted infection] is thought to be related to the microenvironment of the thin, lightly keratinized mucosal lining of the inner foreskin.\"\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\nBut a new study published Monday in Cancer suggests that at least one decision our parents make FOR us may have an impact on our predisposition to certain types of cancer.\nThey concluded that circumcision before first sexual intercourse is associated with a 15% reduction in the relative risk of developing prostate cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The headline for this article \u2014 \u201c\u2018Cutting\u2019 your risk of prostate cancer\u201d \u2014 fails on two levels. Not only is the pun quite bad, but the use of the active verb suggests that there is a causal relationship between circumcision and prostate cancer, which is something this observational study can\u2019t prove. Although the text of the story communicated this fact appropriately, it should be reflected in the headline as well.\nWhile absolute risks generally cannot be estimated from case-control studies,\u00a0 extrapolating the 15% relative risk reduction to the 16% lifetime risk for being diagnosed with prostate cancer would suggest that circumcision would be associated with at most a 1% or 2% absolute risk reduction\u2013likely less for clinically important cancers.\u00a0 Of\u00a0course, the study provides no information on whether circumcision is related to prostate cancer mortality\u2013an important issue given that most prostate cancers are indolent.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits in this case are estimates of 10-year survival in those found to have lung cancer through screening, which is provided.\u00a0 Since there is no control group, there would be no way to provide an absolute risk reduction.\u00a0 But, the story does provide a 5-year chance of death estimate for those diagnosed conventionally, e.g. as a result of symptoms.\u00a0 This provides some relative comparison of what screening MIGHT offer, although it's not known for sure and readers are cautioned that direct comparisons are not possible.\u00a0 ", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nAn earlier analysis of the study concluded that women who ate five servings of fruit and vegetables and exercised 30 minutes a day had significantly improved cancer-free survival.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story not only provided the information that the two groups did not differ in terms of rates for breast cancer recurrence or death, but included the estimates of this from the study summary.", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that the study \u201cuncovered a phenomenon suggesting rates of lymph node spread are being overestimated, potentially leading to overtreatment of patients with chemo radiotherapy.\u201d There are no data offered in support of that statement.\nIt also makes the claim that \u201cThese findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\u201d Again, there are no numbers provided showing how survival rates and quality of life can be improved with a change in treatment.\nThe release should have attempted to put the main findings in meaningful context for lay readers.", "answer": 0}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nTheir results are published in Annals of Internal Medicine.\nThe picture of selenium\u2019s health benefits \u2014 or possible health risks \u2014 has been anything but clear.\nThe authors reported no serious side effects associated with selenium during the study.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The main contention of the news release is that \u201cimaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer\u2019s disease.\u201d But there\u2019s no evidence presented to show that these images have any effect \u2014 good or bad \u2014 on patients\u2019 adoption of beneficial lifestyle changes. Does performing an MRI increase the likelihood that someone will lose weight, exercise, and stop smoking?\nThe release also states, \u201cinstitutions\u2026 meld these approaches into novel ways to improve patient care,\u201d but the report doesn\u2019t detail what those \u201cnovel\u201d therapies are. Experts in the report talk about pinpointing \u201cvolume loss in the brain\u201d and characterizing imaging markers, but these are all surrogate endpoints. In other words, how do these translate to tangible health outcomes for patients?\nBottom line: The idea that a brain MRI is going to help motivate people to adopt meaningful lifestyle changes \u2014 and that those changes will, in turn, lead to an actual reduction in the number of Alzheimer\u2019s disease cases \u2014 requires several leaps of logic that have very limited support from evidence. The release owed it to readers either to point out the preliminary nature of the hypothesis or provide some evidence to back it up. The release did neither.", "answer": 0}, {"article": "\"This could be an important tool worldwide, and even here in the United States.\"\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n\"The test that we developed finally makes it possible to detect TB in a single clinic visit,\" Dr. David Alland, chief of infectious diseases at the UMDNJ-New Jersey Medical School, said in a university news release.\nTHURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story\u00a0 reported on and emphasized the speed and accuracy of the new test, noting its\u00a0advantage in\u00a0this regard over conventional TB testing.\u00a0It also mentioned the test\u2019s\u00a0ability to detect\u00a0TB that is resistant to rifampin \u2014 a drug commonly used to treat the condition.\u00a0 Nevertheless, the story never attempted to quantify\u00a0the real-world implications of the research from a data-oriented perspective. Some questions we feel the story should have attempted to answer, in quantitative terms,\u00a0include:\nWe also think the\u00a0story\u00a0should had paid a bit more attention to the issue of simultaneous\u00a0infection with tuberculosis and HIV\u2013something the new test could potentially help with.\u00a0Tuberculosis in patients with HIV is harder to detect using current\u00a0techniques, which usually involve\u00a0evaluation of lung sputum under\u00a0a microscope (called a \"smear test\"). The resulting misdiagnoses and treatment delays can be especially harmful for HIV patients given their compromised immune status. TB progresses more rapidly and is more deadly in HIV-infected individuals compared with non-infected individuals. The\u00a0new test\u00a0appears to\u00a0be effective\u00a0at diagnosing\u00a0TB even in patients who had a negative \"smear test\" \u2014 a group that would\u00a0include many HIV-positive individuals.\u00a0A comment about this potential benefit would have been appropriate.\u00a0\u00a0\u00a0\n\u00a0", "answer": 0}, {"article": "\u201cYou have to show that there\u2019s a return on investment.\u201d\nAnd researchers at Washington University School of Medicine found that compared with a control group, bronchial thermoplasty patients saw their asthma attacks drop by a third, their emergency room visits fall by 84 percent, and the number of days they lost from work and school drop by 66 percent.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nSusan Pisano, a spokeswoman for America\u2019s Health Insurance Plans, the industry trade group, said insurers are awaiting the results of an additional five-year clinical trial, required by the F.D.A.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The anecdotes and statistical reporting in this piece are skewed. Two anecdotes describe patients whose symptoms are almost totally resolved following treatment, but this is not representative of the experience of most patients who receive bronchial thermoplasty. In the most rigorously conducted trial\u00a0to date, the average improvement in asthma-related quality of life after a year was about 1.4 points on a 7-point scale in the active treatment group compared with 1.2 points in patients who received a sham treatment (a 0.2-point difference favoring the procedure). In addition, the percentage of patients who experienced a clinically meaningful improvement in that study was only slightly lower among those received a sham treatment (64%)\u00a0compared with those receiving the real treatment (79%).\u00a0\u00a0When reporting on this study,\u00a0the story does not convey\u00a0these findings (which were the study\u2019s primary outcome measures), and instead\u00a0reports only on secondary outcomes\u00a0for asthma attacks,\u00a0emergency room visits, and the number of days\u00a0lost from work and school. The story uses relative improvements to describe these benefits and does not provide absolute percentages. These choices lead to an overemphasis on the benefits of the procedure.", "answer": 0}, {"article": "Dr. Scott L. Spear, the chairman of the plastic surgery department at Hospital, has enlarged a patient\u2019s breasts only to have the patient undo his handiwork by losing weight.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nBut Dr. Stephen F. Sener, a professor of surgery at the Keck School of Medicine at the , wrote in an e-mail message: \u201cI\u2019ve seen enough injections of fat after mastectomies to tell you that fat necrosis is a real problem.\u201d It can result in a \u201cpalpable mass\u201d that needs to be biopsied to establish malignancy or infection, wrote Dr. Sener, the former president of the .\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nWhile this story cautions against misleading promises made by some surgeons, the story then features only women who said they had positive results and strongly recommended the fat graft procedure, thus leaving readers with a one-sided perspective on likely outcomes.", "answer": 0}, {"article": "Don't try this experiment at home.\nTwo months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nThe study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quickly shows the actual numbers behind the hype in the lead. The second graph says, \"The study, which appears in the Journal of Psychopharmacology, included 20 people with PTSD stemming from traumas such as sexual assault and combat stress. On two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists. The others took a placebo but received the same therapy. (All of the participants received additional therapy sessions that did not involve the drug.)\" One dozen people took a drug twice and talked to a therapist. Of those, \"Two months later, 10 of the 12 people who took MDMA had improved to the point where they no longer met the diagnostic criteria for PTSD, and three participants whose condition had prevented them from holding down a job were able to return to work.\" What the story fails to do, though, is explain whether, even with this small number of people, a significant benefit could be attributed to the drug. The press release actually does a better job by explaining that \"Prior to enrolling in the MDMA study, subjects were required to have received, and failed to obtain relief, from both psychotherapy and psychopharmacology.\"", "answer": 0}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes the benefits of these drugs in broad, qualitative terms. E.g., a drug appeared to slow down cognitive decline. That makes it difficult or impossible to tell how well either of these drugs performed in the relevant trials. Were these marginal benefits? In other coverage of these studies, an Eli Lilly consultant noted that the results \u201cdo not have a direct relationship to clinically apparent benefit.\u201d So it seems premature for anyone other than investors to be getting too excited about these findings just yet.", "answer": 0}, {"article": "Uterine serous carcinoma makes up less than 10 percent of all cancers of the endometrium, or lining of the womb, diagnosed in the United States each year, but it accounts for more than a third of the 10,000 endometrial cancer deaths annually.\nBut the results of the trial, they add, were strong enough to warrant submission to the National Comprehensive Cancer Network, which guides the design of standard treatment plans around the country.\nFader cautions that a larger study of the drug combination, or other combinations, is needed to confirm the findings and potentially extend survival even more.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\nFollow-up studies of the women who remain alive--who now number 35--continue, the researchers say, to track the impact of trastuzumab on overall survival time even after tumor progression.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job articulating what the benefits were (as expressed in months of survival during which the cancer did not spread) and how those benefits differed depending on whether patients had an advanced stage of USC or a recurrent case.\nBut the release didn\u2019t explain the limitations of progression-free survival as a surrogate for overall survival and that\u2019s a big omission.  ", "answer": 0}, {"article": "In the current review, researchers found several trials that compared different doses of radiation and different types of radiation therapy, including external beam radiation therapy, in which a radiation is delivered through a beam through the skin, or brachytherapy, in which radioactive isotopes are delivered via injection into the prostate.\n\"Some of the distinctions being made are not really supported by the evidence.\"\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lack of evidence of benefit was clear in the story.", "answer": 1}, {"article": "Using the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nLONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": " ", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nApprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data.\nThere are no previously approved therapies for TRAPS or HIDS/MKD.\nThe U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab).\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "All we learn about the benefits for patients is that the treatment \u201cmay help improve their quality of life.\u201d \u00a0It would be hard to give less information about the benefits of the treatment. The statement that \u201capprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data\u201d is inadequate.", "answer": 0}, {"article": "If you're loading up on vitamin C and zinc to stave off the sniffles, you should try an earlier bedtime instead.\nThe found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nPeople who regularly sleep six hours or less each night are four times more likely to get a cold than people who sleep just an hour longer, a new study finds.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nParticipants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites as benefits the reduced risk of getting a cold among those who got at least six hours\u2019 sleep. But this benefit is described in relative terms (e.g. \u201cthose who slept for five hours or less each night were 4.5 times more likely to catch the cold). We think absolute terms are more informative. From figure 1 in the study, we can see that about 17% of those w/ >7hrs of sleep got the cold vs. ~45% of those with <5 hrs.", "answer": 0}, {"article": "All rights reserved.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nHis study was published Wednesday in JAMA Cardiology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story employs both absolute\u00a0numbers and percentages, so that we know how great a magnitude the change was (e.g., 43 fewer heart attacks and strokes per 100,000 people).", "answer": 1}, {"article": "Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\n\u201cOur study takes this a bit further and shows that exercise may also have a role in preventing people developing depression in the first place.\u201d\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story barely passes this criterion with, \u201cPeople who said they didn\u2019t exercise at the study\u2019s start were 44% more likely to become depressed, compared to those who exercised at least 1 to 2 hours a week.\u201d Also, \u201cthey say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\u201d\nBut to be fully informative it\u2019s important to put the 44% percent in absolute terms. How many people in the exercise group developed depression, and how many people in the non-exercise group developed depression?", "answer": 1}, {"article": "\"Plenty of guys are concerned about unwanted pregnancy, almost as much as women.\"\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\nAccording to Wang, the gel was applied in two spots -- the testosterone component on the arm and the progestin component on the abdomen.\nUp to 78 percent of men receiving the drug combination in the study saw their concentrations drop to no sperm at all, versus only 23 percent of men taking testosterone alone.\nThat's apart from mild-to-moderate acne or an increase in acne, which was seen in about 21 percent of participants.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like many early stage drug studies, the study looked for surrogate markers (sperm count and motility) rather than ability to fertilize.\u00a0 The distinction is not subtle.\u00a0 The true test of the combination gel will be in the rates of unintended pregnancies.\u00a0 The story explains what percentage of men in each group had undetectable levels of sperm or levels that were below a cutoff level defined by the investigators. However, to be of value to readers, the story would need to give some sense as to how this result would affect pregnancy rates. Although the story says that the\u00a0treatment would have the effect of \u201clowering, but not eliminating, unwanted pregnancies,\u201d this isn\u2019t really specific enough. People want to know that a contraceptive will be close to 100% effective, or else it\u2019s not worth taking. The story should have asked someone \u2014 either a study researcher or the independent source \u2014 whether the effects seen in the study are likely to be consistent with that standard.\nThe story also missed an opportunity to explain what is new and potentially better about the hormone gel tested in this study compared with similar treatments delivered by injection or implant. The benefit is that the gel could potentially be applied by men at home as opposed to needing a health professional to administer it in the office.\n\u00a0", "answer": 0}, {"article": ".\nNo prior studies showed zinc lozenge use -- even up to 150 mg per day -- might cause harm aside from bad taste or constipation, Hemila said, and the most recent trial on zinc acetate indicated no significant differences between zinc and placebo groups in adverse effects even though the daily zinc dose was 92 mg.\n\nDr. Lisa Winston, an epidemiologist at San Francisco General Hospital, praised the study as a \"pretty good synthesis of the data,\" although she noted that the trials Hemila reviewed involved small numbers of participants.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nAll of the trials examined by Hemila compared zinc lozenges to placebos.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives us many figures, but it may not reveal enough for a consumer to gain much insight on benefits. It says that some clinical trials comparing zinc acetate lozenges to placebo reduced the duration of colds by an average of 42 percent. But other trials, considered by the author of the research article, used zinc salts (not acetate) at a different dosage, and got results more like 20 percent. The story gives information on the duration of a cold in aggregate and in relative but not not absolute terms. Consumers are left without critical details. It could have explained 42% of what?\u00a0 A week?", "answer": 0}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\nThe timing of treatment also mattered.\nIt\u2019s designed to stimulate nerves under the skin in the arm and block pain signals from reaching the brain.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a nice job laying out the results. Readers are not only told how effective the treatment was measured to be at certain shock frequencies, but also how the placebo arms of the study fared, too.", "answer": 1}, {"article": "For now, research continues.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nIf patients are interested in deep brain stimulation treatment, they should try to get into the study that's ongoing, Mayberg said.\nAfter two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempts to quantify the benefits in both relative and absolute terms, but it leaves readers confused because of the shifting nature of the study cohort. It looks as if the study started with 17 patients but then later it says that the study looked at 14 patients. It says, \u201cThe researchers found that 18 percent of patients went into remission after 24 weeks, 36 percent (of 14 patients) after one year. After two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\u201d The change in the number appears to be because the researchers stopped doing the deep brain stimulation on three patients, a fact that is not fully explored in the story. This all would have been more easily explained and less confusing if the story had just stuck with the absolute numbers. If you try to do the math on 18 percent of 14 patients, for example, you get 2.52 patients. Was it two patients? Was it three?\nWhy not just tell readers x number out of x number?", "answer": 0}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nSo doctors can \u2014 and some already do \u2014 use the drug off-label for the diabetic condition.\nResults of the trial were published online on Tuesday by the journal Ophthalmology.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nResearchers said the results seem to be holding up for the second year of the three-year trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided quantitative information about the possible impact on vision. But we wish there information about any measurement of\u00a0 the patients\u2019 perspective on whether they are functioning better after receiving this treatment versus standard treatment", "answer": 1}, {"article": "Oral and injectable medications are also prescribed.\nSince the optimal extended dose schedule is not known, researchers chose to look at the data in multiple ways, with the primary definition looking at extended dose history in the last 18 months, the secondary definition looking at extended dose occurring at any time in the dosing history, and for tertiary definition looking primarily at how extended dose history affects PML risk.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nPatients who test JCV antibody-positive are typically either told to not to start natalizumab, or have had treatment stopped after two years, when risk was deemed to be too high.\nResearchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions the main benefit of less frequent dosing of natalizumab (infusions every five to 12 weeks, instead of the standard every 4 weeks) as a \u201crisk reduction for PML as high as 94 percent\u201d up to 6 years. The news release mentions \u201cthe optimal extended dose schedule is not known.\u201d\nWhat we like news releases and news articles to provide readers are absolute risk reductions, rather than the relative risk reductions provided here.\nThe news release does make it clear that these results only apply to patients who test positive for antibodies to the JC Virus (JCV; the virus that causes PML) and this study did not look at drug efficacy comparing the extended to standard monthly dosing.", "answer": 0}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece presents the results in percentages; however, it would have been more meaningful to the reader if the story had also provided the actual numbers, particularly since it did not mention how many people were in each of the treatment arms. \u00a0In addition, one of the trials evaluated the efficacy of boceprevir in a black cohort\u2014a population group that usually does not respond as well to treatment\u2014but these results were not discussed in the story. Furthermore, the story does not provide any data for telaprevir, but only states that \u201coutcomes were similar\u201d to boceprevir.\n \n", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nThey also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility.\nAmong the women who had received triptorelin, the rate of early menoapuse was 8.9%, which is 17% lower.\nItalian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit from the described approach to loss of fertility in women of child-bearing age with early-stage breast cancer was described as a lowered rate of early menopause.\u00a0 The article did an excellent job of putting this in perspective by including the editorial statement cautioning the reader to not equate resumption of menstrual cycles with preserved fertility.\n", "answer": 1}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nThe Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While this story reports a specific claim of shortened flu symptoms, it also tosses in several vague claims about less severe and less frequent unspecified illness. The family that\u2019s the focus of the story seems to take elderberry to prevent illness, but the story doesn\u2019t tell us if elderberry has ever been shown to do that. Overall, the presentation is more likely to confuse than inform readers.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not provide enough information on\nthe effect of pain or the limits a hernia might place on daily activities. There is some information on this in the study in\nJAMA, but little is mentioned in story. 30% of the watchful waiting group decided to have surgery during the 4 years,\nthough reports of pain at 2 years were similar in both groups. More information on why they decided to have surgery and the\neffect of hernia pain on quality of life would be useful in order to better inform patients who are trying to make a choice.\nHowever, overall, this criterion was met. The reporter used absolute numbers, not just relative \u2014 always a good idea.", "answer": 1}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\nAccording to Bruce Bebo, executive vice president for research at the National Multiple Sclerosis Society, \"Restoring lost function is a significant unmet need for people living with MS.\"\n\nThis study examines previous findings related to the reversal of some disability in those receiving alemtuzumab, he said.\nBy the study's end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\nFor this study, Giovannoni and colleagues treated 628 patients with relapsing-remitting MS who had not responded to at least one other MS drug.\nNot only does alemtuzumab improve disability, but most patients go into long-term remission of at least five to eight years, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes\u00a0how the\u00a0researchers assessed disability levels at the start of the study and every three months for two years. By the study\u2019s end, nearly 28 percent of those given Lemtrada had improved by at least one point on a 10-point disability test, versus about 15 percent of those receiving interferon, the researchers found.\nBut the story said\u00a0the patients randomized to\u00a0Lemtrada were \u201c2.5 times more likely to have their thinking skills improve compared to those given interferon. And they were more than twice as likely to see improvement in their ability to move without tremor or clumsiness, the findings showed.\u201d\nWe need\u00a0absolute numbers to compare what the baseline levels (thinking skills, move without tremors) were, and more details on what \u201cimprovement\u201d means here, since this description alone doesn\u2019t tell us if patients improved a little bit, or a lot.\nAdditionally, this statement had us scratching our heads: \u00a0\u201cGiovannoni believes the drug could offer real relief from MS symptoms. Not only does alemtuzumab improve disability, but most patients go into long-term remission of at least five to eight years, he said.\u201d\nWhere did that determination come from? The study was only for two years and nothing presented within it showed remission.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nFor information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\nContact Shawn Farley at 703-648-8936 or PR@acr.org to arrange an interview with an ACR spokesperson.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There aren\u2019t any numbers on this, and it\u2019s a crucial part of the sales pitch. The release says that screening regularly starting at age 40 \u201csaves many more lives\u201d than screening later or done less frequently. But how many more lives are we talking about? A quick look at at hyperlink in the release \u2014 which takes you to the ACR-produced advocacy website mammographysaveslives.org \u2014 and clicking \u201cAre you confused?\u201d takes you to a page that suggests mammography has reduced the U.S. breast cancer death rate by 30 percent. But that\u2019s a relative risk reduction, and since the rate of breast cancer for women in their 40s is low, this figure may tend to inflate the size of the benefit for these women. \u00a0We would have preferred to see a number describing the absolute reduction in breast cancer deaths. For example, according to a recent US Preventive Services Task Force evidence review, screening mammography prevents 4 deaths for every 10,000 women who are screened for at least 10 years compared with no screening.\u00a0", "answer": 0}, {"article": ", ahead of print.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\nSerious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that hormone shots were effective at reducing sperm count to less than 1 million/mil within 24 weeks in 274 participants and was effective in nearly 96 percent of continuing users, with four pregnancies occurring among the men\u2019s partners during the efficacy phase of the study. It also stated that more than 75 percent of participants reporting being willing to use this method of contraception at the conclusion of the trial.\nThat\u2019s the plus side. One omission from the release was the absence of a control group. Without a control group it\u2019s not possible to accurately calculate the effectiveness. The study reported four pregnancies among the men taking the injection. How many pregnancies would be expected for a similar group not getting the shots? The news release doesn\u2019t say.", "answer": 1}, {"article": "I have fish two-three times per week and adhere to a Mediterranean style of eating.\"\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\nLeading author Roy Hardman from the Centre for Human Psychopharmacology Swinburne University of Technology Melbourne Australia and his colleagues evaluated all the available papers between 2000-2015 that investigated if and how a MedDiet may impact cognitive processes over time.\nTwo of the included studies focused on younger adults and they both found improvements in cognition using computerized assessments.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release mentions three outcomes\u2014\u201cslowed rates of cognitive decline, reduced conversion to Alzheimer\u2019s, and improved cognitive function\u201d\u2014and explains those outcomes a bit more specifically lower in the text.\u00a0 But missing from the text is information supporting the benefit claims. Slower than what? Reduced relative to what? \u00a0Improved relative to what?\u00a0 Our criteria call for releases to report the risk reduction in absolute terms if at all possible, but this release gives no numbers at all.\u00a0 ", "answer": 0}, {"article": "SAN FRANCISCO \u2014 Tech company developer conferences always feature a wacky demo or three.\nThe video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It appears the \u201cEmma\u201d watch helped a patient regain some of her hand control, enough to draw her name (which was presumably impossible \u201cfor ages,\u201d according to the patient) and a cleanly drawn square (when her pre-watch attempt was squiggly). But how much are the watch and its vibrations actually helping and for how long \u2014 we don\u2019t know, because there\u2019s no control group. It\u2019s a sample size of one, and what\u2019s shown in the video may very well be a placebo effect without either the patient, designer, or anyone else knowing.\nOnly a well-designed research study could responsibly attempt to determine the benefits of this device or its durability, but there doesn\u2019t appear to be one. The story should have made this point very strongly.", "answer": 0}, {"article": "\"But I'd hope we can get past that.\"\n\"The risk for complications increases as people get older, and the duration of disability after the operation gets longer as people get older,\" says oral surgeon Dr. Thomas Dodson.\nBut there's a serious debate between dentists and oral surgeons: should they preemptively remove someone's wisdom teeth if the patient doesn't have any symptoms?\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nBut a 2012 Cochrane review of randomized clinical trials found there's no evidence that removing wisdom teeth will prevent or reduce crowding of other teeth down the line.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While thorough in its discussion of the potential benefits and risks of either preventative surgery or a \u201cwait and see\u201d approach, this story is rather thin on numbers. This is a deficiency we\u2019ll address here rather than under the \u201cHarms\u201d or \u201cEvidence\u201d criteria \u2014 both of which we rated as satisfactory.\nFor example, the story gives plenty of space to discussion of the benefits that may be realized with preventative wisdom tooth removal \u2014 including the convenience of being able to plan your surgery and recovery dates and a reduced risk of facing a more complicated extraction in the future. But it does not attach any numbers to these benefits. An expert story source points out that older people have a higher risk of complications, experience more pain due to more deeply rooted wisdom teeth, and face a longer period of recovery from surgery. But how much less often do these complications occur in younger people and how much shorter is the recovery time for earlier surgery?\nSimilarly, when discussing the benefits of a \u201cwait and see approach,\u201d the debate is framed in general terms and there is little quantification. The story notes that the risk of surgical complications may outweigh any benefit from preventative removal. But it would\u2019ve been nice to have some estimate of how frequently wisdom teeth will end up overcrowding if they are left in, or how often patients experience surgical complications if they opt for the preventative surgery.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nHe points out that psychedelics should never be used carelessly, and that the \u201cset and setting\u201d (meaning the dose, mood, environment, company and surroundings) where a person takes them are of paramount importance.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\nBut that\u2019s changing.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unfortunately the details on the various studies cited are few and far between, though the links to the actual studies are helpful for those wishing to dig deeper. \u00a0Because of the lack of quantification of benefits permeates the piece, it can only rate as Not Satisfactory.", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses primarily on\u00a0one girl\u2019s miraculous recovery from leukemia. But unlike the competing New York Times piece, it\u00a0did provide the balancing perspective of other patients receiving this experimental treatment, at least one of whom has not\u00a0recovered completely. That gives a more realistic take on what the story calls the \u201croller-coaster learning curve\u201d associated with the treatment. The story\u00a0also largely refrained from using the hyperbolic language that was sprinkled throughout the Times\u2019 account.\nThe reader comes away with the idea that this is highly experimental and that only a handful of sustained remissions have occurred from a handful of attempts.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nIn this group, the rate of heart attack, stroke and revascularization and death was 3.7 percent among those with a low ceramide score, but 16.4 percent in people with the highest ceramide levels.\n\u201cOur research suggests that evaluating ceramide levels in patients who are not at immediate risk for coronary artery disease events may help cardiologists decide who could benefit from proactive and preventive treatment, such as statins, or lifestyle changes to prevent a serious cardiac event down the road,\u201d says Jeff Meeusen, Ph.D., a clinical chemist, co-director of Cardiovascular Laboratory Medicine at Mayo Clinic and the study\u2019s lead author.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary benefit of the test is that it might enable doctors to identify people who are at higher-than-normal risk for heart attacks and strokes even though they have normal levels of cholesterol and show no evidence of heart blockages. The news release does a good job of explaining the likelihood of having a cardiac event for those with low versus high levels of blood ceramides. In particular, it reports both absolute and relative risk, noting that, among individuals with low LDL (bad cholesterol) levels, cardiovascular disease occurred in 3.7% of those with low ceramide levels but in 16.4% of those with high ceramide levels.", "answer": 1}, {"article": "The results were astounding.\nScientists at the Victor Chang Institute have discovered simply boosting levels of this nutrient during pregnancy can potentially prevent recurrent miscarriages and birth defects.\nHowever, a recent study[i] found that despite taking vitamin supplements at least a third of pregnant women have low levels of vitamin B3 in their first trimester, which is the critical time in organ development.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\n\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release made no mention of any numbers or figures from the study that put the benefits in context. The release was also misleading since it implied that vitamin B3 supplements could prevent miscarriages and birth defects in humans when this has never been directly studied. \nThe release seems to combine two sets of research findings: The first is from a 12-year study of 13 human families that found the genetic causes of a rare birth defect called VACTERL association (the cause was found to be a deficiency of the molecule NAD).\nThe second study was done in mice, who were genetically mutated to have an NAD deficiency, and then were given niacin. The researchers reported that these mice had offspring with fewer birth defects. \nCrucially, however, the theory that niacin can prevent birth defects or miscarriages has never been tested in humans. The release was worded in a way that is very misleading considering the amount of human research that still needs to be done.", "answer": 0}, {"article": "Health officials in Norway recommend that pregnant women (and women who are trying to get pregnant) take 400 micrograms of folic acid per day.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nThe raw numbers also showed that women who took extra folic acid were less likely to have kids with Asperger syndrome or PPD-NOS, but when other factors were taken into account, the association was no longer statistically significant and could have been due to chance, the researchers found.\nThe fact that autism cases have been on the rise in the U.S. even after folic acid supplementation became mandatory is a puzzle, according to three researchers from the Centers for Disease Control and Prevention\u2019s Division of Birth Defects and Developmental Disorders.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story reports both the raw data differences in autism risk between the folic acid and non-folic acid groups (a 2-to-1 difference) and the much smaller 39 percent difference the researchers reported after adjusting for education and other maternal characteristics. However, by stating the overall absolute risk of a child with autism as 0.13% instead of about 1 in a thousand, readers of this story may not get as good an understanding of the absolute risks as readers of the Reuters Health story we also reviewed.", "answer": 1}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nThe trial involved six men and six women, aged between 30 and 64, all diagnosed with treatment-resistant depression.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does offer some specific information about the outcomes of treatment for the 12 individuals in the study. Ideally it would have explained how those outcomes were actually measured\u2013how did researchers measure what \u201csome decrease\u201d in symptoms meant? The same with \u201cpositive response.\u201d", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is tricky. We had a couple of issues with the way in which the benefits are described. The use of relative changes (\u2018\u2026reduced relapses among MS patients by 54%. Disability progression was reduced by 30%, using a standard measurement of this process.\u201d) and comparisons to other drugs studied in other clinical trials without a bit more clarification was troubling. Patients with the most common form of MS suffer between 0.4 and 0.6 relapses a year (according to Up to Date). Although the story does note that, \u201c..it is difficult to directly compare two different clinical trials,\u201d it does this anyway. Providing apparently comparative data from different studies does not educate the reader on the relative value of different treatment options. A few extra words would have clarified: \u201cNone of the available drugs to treat MS have been compared directly in a large enough clinical trial to identify true differences.\u201d", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\n\u201cIt\u2019s a holistic approach.\u201d\n\nThe fruit\u2019s appeal rests, in part, on this versatility.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nAnd, increasingly, it resonates for Westerners.\n\u201cWith the natural movement being in the forefront right now, the timing is right.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For all the claims being made in this story, not a single benefit is quantified.", "answer": 0}, {"article": "Many in the Alzheimer's research community are awaiting these drugs with bated breath, but \"none are ready for prime time,\" he said.\nThe new study was conducted and funded by the drug's manufacturer, F. Hoffmann-LaRoche Ltd., in Basel, Switzerland.\nThe new drug was given at either 60 or 200 milligrams (mg) doses.\nThe higher dose yielded greater reductions in amyloid levels, the study showed.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story adequately described the responses of study participants at different dose levels. And it clearly established that \u201cit\u2019s by no means certain that reducing levels of amyloid plaque would stave off memory loss and other mental declines.\u201d\nOther important caveats included:", "answer": 1}, {"article": "Median follow-up was 61 months.\nSpecifically in the low-risk group, the five-year RFS rate was 97.3 percent, which is superior to the 93 percent historical comparison DFS control rate (p = 0.014).\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\n\u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d\n\nA total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional and academic hospitals across the U.S.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives a lot of data. It states that 97 percent of patients were free from prostate cancer progression after five years, exceeding a historical control of 93 percent. It also says that fewer than 2 percent of patients experienced severe toxicities in their gastrointestinal, reproductive, and urinary systems, and no patients reported life-threatening or fatal toxicity. However, the news release does not attempt to say how these rates compare with other treatment options, which would help readers put the data in perspective. There are important caveats left out in the description of findings that are discussed under the evidence criterion.", "answer": 1}, {"article": "\"I would have bandages on me all the time.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nIntense discomfort that interferes with activity is a common problem after bariatric surgery, says plastic surgeon Sarah Holland, an instructor at Columbia University Medical Center in New York -- and it can be almost constant.\nThat should be the norm, says Holland.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not provide any data indicating the percentage of individuals who had had plastic surgery to remove excess skin after weight loss surgery who were satisfied with the outcomes. The perspective of a single patient was presented, concluding that for her \u201cthe pain and effort was worth the result. \u201d But the reader has no idea if this is typical or not.", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nWhat we're doing now is we're saying, OK, this key fits that lock.\nKnowing more about the genetic mutations of a tumor enables doctors to find a potentially effective drug much more quickly and accurately.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\nStill, he cautions that the targeted treatments can't be considered cures.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are described as extending a person\u2019s survival while increasing her quality of life, and a number\u20131 year, so far\u2013is attached to the treatment. The story also includes this quote from a researcher, which clarifies that the treatment is not expected to work indefinitely:\u00a0\u201cWe all have patients that have been on these drugs for years. But I don\u2019t know, I mean, I think if I was being honest eventually our expectation would be that it would stop working.\u201d\nWe\u2019ll call this good enough for a Satisfactory rating, but it would help to have more context here. For example, the article could have stated the median survival for the typical adult diagnosed today with glioblastoma, which is\u00a0about 15 months. It would also be useful to know if there are studies of patients similar to the one profiled here, and what their experience has been. That\u2019s a deficiency we\u2019ll address below in the Evidence section.", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nAbout 45 percent of patients experienced sedation with nabilone, compared with 16 percent for placebo, the findings showed.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\nPatients underwent significant overall improvement in their other behavioral symptoms, and had small benefits in their brain function and nutrition during the study.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says 36 patients were treated for 6 weeks with nabilone, followed by 6 weeks with placebo. While taking nabilone, the patients experienced a \u201csignificant decrease in agitation \u2026 the decrease was larger than is seen in currently used medications.\u201d\nHow this was measured, the dosage used, and what the quantitative changes were, are not provided.", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAlthough this story accurately reports the specific results of this drug trial, including lung function, disease symptoms, weight and sweat chloride (a measure of disease); it misses important aspects of the big picture. As the journal editorial accompanying this research report noted, the trial does not prove that this drug halts the progression of disease or that patients who take the drug will live longer.\nThe story could also have been clearer about the distinction between the small percentage of patients who have the specific gene mutation that is the target of this drug and the 90 percent of cystic fibrosis patients who have a different mutation that may not respond to this treatment. The editorial notes that the complexities of CF \u201csuggest that no single drug will be entirely suitable as a therapeutic agent.\u201d Readers should have been given this important context. \nWhen the story reported that patients doubled their ability to walk, it should have noted that this apparent benefit was not something that was measured as part of the formal trial.", "answer": 0}, {"article": "However, relatively little research has been conducted into ketamine's antidepressant effects in adolescents.\nHowever, they note that the study was limited by its small sample size, so future research will be needed to confirm these results.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nFive of the participants met the criteria for clinical response and remission.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did the bare minimum, pointing to \u201can average decrease of 42 percent\u201d in criteria contained in a depression assessment tool. It also stated that five of the 13 participants \u201cmet the criteria for response and remission\u201d and three of those were still in remission after six weeks, with the remaining two relapsed within two weeks.\nThe story would have served readers better by emphasizing those figures higher up and spelling out what \u201cresponse and remission\u201d mean in terms of a patient\u2019s symptoms.", "answer": 1}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\nThey were also 32 percent more likely to need surgery to remove the whole breast (mastectomy), and 66 percent more likely to need lymph nodes removed.\nOne group had a mammogram within the 24 months before their breast cancer diagnosis.\nThey were also more likely to have larger tumors (by 10 millimeters, on average) and to need a mastectomy than those in the 24 months or less group.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story detailed the relative harms of earlier mammograms, but did not translate those percentages into absolute numbers. For instance, women who were diagnosed with breast cancer 25 months or more after their last mammogram were \u201c50 percent more likely\u201d to need chemotherapy,\u00a0\u201c32 percent more likely\u201d to need mastectomy, and \u201c66 percent more likely\u201d to need lymph nodes removed. However, relative risk can be misleading, sometimes inflating numbers to sound scarier than when absolute numbers are used.\nAlso, we don\u2019t know what kind of risk these women had at baseline, so it\u2019s hard to know if they were higher risk.", "answer": 0}, {"article": "But are they receiving it?\nTo illustrate their point, Kozlowski and Sweanor use the example that if one type of alcoholic beverage caused 3 in 5 regular users to die prematurely \u2014 as is the case with smoking traditional cigarettes \u2014 while another caused massively fewer deaths, consumers would want to know which product was the safer alternative.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nThis \"information quarantine\" in turn helps explain the woeful lack of public knowledge about relative risks, violating basic consumer rights as well as the public health principles of individual rights and health literacy, the researchers say.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives the example that 3 in 5 regular users of cigarettes die prematurely, while smokeless tobacco products cause \u201cmassively fewer deaths.\u201d\nA\u00a0news release that is going to focus on risk reduction needs either better quantification of that risk reduction, or a sentence explaining why a more detailed description of the risk reduction is not possible.", "answer": 0}, {"article": "\"I just didn't want to do that for my children.\nAmong the women who did not have the surgery, 7 percent were later diagnosed with breast cancer.\nWomen like Toby who chose both ovary and breast removal had dramatically lower risks of getting both cancers after the surgery.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe findings of this study do provide new evidence of benefits of preventive surgery for women with BRCA1/2 gene mutations. However, the story does not provide a balanced or complete picture. It reports only relative risk reductions without also including the absolute numbers of women who did or did not develop cancer. Also, the story includes a quote from a researcher claiming mastectomy reduced the risk of death, but the study did not report that outcome. While none of the women who had a preventive mastectomy was diagnosed with breast cancer during the study \u2013 and the women who had their ovaries removed were less likely to die \u2013 the researchers did not report that mastectomy reduced the risk of death for these women.\nAlso, the only woman included in this story was someone who had preventive surgery and did not develop disease. The story obscures the fact that the overwhelming majority (93%) of women chose not to have surgery also did not develop cancer during the course of the study.\n", "answer": 0}, {"article": "Researchers in Turkey conducted experiments with 53 postmenopausal women.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story told us that a five-point scale was used to measure the severity of symptoms.\u00a0 That\u2019s better than the HealthDay story did.\u00a0 But only slightly better because the story never went on to tell us how much the scores dropped on that scale.\u00a0 So the story didn\u2019t give any sense of the scope of the benefit, using just vague, nonspecific language \u2013 \u201csignificantly lower scores.\u201d\nBy saying \u201csignificantly lower\u201d and never providing real numbers, the story leads readers to believe the evidence is definitive. Some readers may never even reach the bottom of the story. They will see the headline and the lead and assume that acupuncture may be right for them.", "answer": 0}, {"article": "We've just opened it up.\"\nWomen receiving iniparib plus chemo lived an average of 12.3 months compared to just 7.7 months in the chemo-alone group.\nIn this study, 123 patients with triple-negative breast cancer were randomized to receive a commonly used, well-tolerated chemotherapy regimen (gemcitabine and carboplatin) or to receive chemo plus iniparib.\nMore than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.\nIn a study published in the Jan. 5 online edition of the New England Journal of Medicine, the experimental drug iniparib not only shrank tumors and increased the time they took to progress, but also surprised researchers by prolonging survival in women with what's known as triple-negative breast cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are quantified.\u00a0 Women who received Iniparib plus chemotherapy lived an average of 12.3 months while those receiving chemotherapy alone lived an average of 7.7 months.\u00a0 Tumor volume decreased\u00a0in 50% of the women receiving Iniparib & 33% of women receiving only chemotherapy.", "answer": 1}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nMeta-analyses of the other types of clinical trials showed similar results.\nAll currently available antidepressants target a particular type of neurotransmitter, but a third of patients do not respond to these drugs.\nBy looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no indication of how much these anti-inflammatory drugs help relieve depression because the anti-depressive effect was a secondary effect of these clinical trials. It would be nice to know how they rated the effects on depression, but that information is not included.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explicitly notes more than once that there are no clinical trials or peer reviewed publications to support the claims\u2013and therefore no quantifiable data.\nIn the absence of medical evidence, the story uses a doctor\u2019s claims and a patient\u2019s experience to discuss what the benefits might be. The doctor\u2019s enthusiastic claims are balanced well by an independent expert who discusses the potential drawbacks.\nTo help better balance the piece, we do wish the story also had presented a range of patient opinions, instead of only a favorable one.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nThose who received acupuncture along with their daily medication for three months were able to walk longer without becoming breathless, compared to those who got the sham acupuncture treatment.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nPeople who received real acupuncture also showed improvements in their quality of life and ability to exercise, according to researchers from Kyoto University and Meiji University of Integrative Medicine in Kyoto, Japan.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article did not quantify any results from the study. It didn\u2019t quantify the size of the benefit?\u00a0 Was this a real \u201cgame changer\u201d or statistically significant while offering little real improvement in daily activities? How many acupuncture treatments did participants experience before seeing improvements in their quality of life? How much longer were these participants able to walk without becoming breathless? And how were improvements in quality of life measured by the researchers? The story also mentions that acupuncture \u201cmay improve stomach function,\u201d but how was this measured? None of these data were discussed further.", "answer": 0}, {"article": "\"I think that millions of Americans are taking aspirin \u2014 some of them are really the 'worried well,' \" he says.\nAdults between the ages of 50 and 59 who have a 10 percent or greater risk of having a heart attack or stroke in the next 10 years benefit the most from taking about 81 milligrams of aspirin every day, the panel says.\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\nNissen does agree with the general consensus that taking low dose aspirin is beneficial for people who have had a heart attack or stroke.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is clear about age ranges and health conditions that may make taking aspirin useful but does not offer any quantitative translation of the extent of benefits for these groups.\u00a0 It similarly doesn\u2019t make the quantitative case for the dearth of benefits for individuals who fall outside of these conditions.\u00a0The recommendations issued by the U.S. Preventive Services Task Force (USPSTF) suggest that the absolute benefit is in fact quite modest, unless you are already at high risk for cardiovascular diseases.", "answer": 0}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nMarch 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The claim high in the story that \u2018blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes\u2019 sounds a little too\u00a0premature. This wasn\u2019t a screening test that reaped any results from patients. It was lab research that is\u00a0several steps behind any actual screening test. This may be why neither the study nor news release use the words screen or screening. \nThe researcher\u2019s press release quote promotes the idea that in the future we could have a screening test that could identify people at high risk for diabetes, which would lead to early intervention. That would be a nice benefit. Unfortunately this research does not say it\u2019s possible. What if, by the time you have elevated amino acids, it\u2019s too late? What if these amino acids\u00a0reflect genetic or largely nonmodifiable risk factors for diabetes?\u00a0The story has\u00a0arrived early to a party that\u2019s not on the calendar yet.\n", "answer": 0}, {"article": "What a tremendous legacy this would leave for millions of people worldwide.\"\nEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\nAnd, it may be that this vaccine can lead to interruption of the transmission of leprosy all together.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does note that the study will be focused on safety and immune system response which earns a minimal Satisfactory rating for clearly establishing the purpose of a phase 1 study. \nThere is currently no information on how effective this vaccine is in human subjects. There is also no mention of how this vaccine weakens the mycobacterial load in those already exposed.", "answer": 1}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nOne of the components in the venom of the scorpion called Buthus tamulus specifically blocks the potassium channel of FLS and not the channels in other cells such as those of the nervous system,\" said first author Dr. Mark Tanner, a graduate student in the Beeton lab during the development of this project.\n\"In previous work, we identified a potassium channel on FLS of patients with rheumatoid arthritis and found that the channel was very important for the development of the disease,\" Beeton said.\nIn some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release says treatment with iberiotoxin \u201cstopped the progression of the disease. In some cases they reversed the signs of established disease, meaning that the animals had better joint mobility and less inflammation in their joints.\u201d\nThere\u2019s no data to quantify the amount of improvement that was observed. The abstract of the study also lacked any information about the degree of the improvement in rheumatoid arthritis symptoms.\nThe main point readers should keep in mind is that\u00a0 this is an early animal study and it would be inappropriate to make projections about its usefulness in humans.", "answer": 0}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of the benefits is very poor, vague and unscientific. No information is given on study participants such as ages, inclusion criteria, type of symptoms, duration, and severity of symptoms at baseline and post-intervention. The release does report that 23 out of a subset of 220 women among\u00a02,000 volunteers who took PS Plus for brain health and stress management over a two-month period, \u201cnoticed relief of premenstrual syndromes.\u201d The company claims these are \u201cstrong\u201d results.", "answer": 0}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beyond saying in the lead that three people were able to \u201csee shapes and objects,\u201d there is not much else in the story to help readers understand the levels of vision improvements that were seen and how those should be compared to the preexisting conditions or other treatments. Then, confusingly, the story narrows its focus to just one patient saying, \u201cone blind patient who had the device implanted was able to identify and find objects placed on a table in front of him, and was able to walk around a room independently.\u00a0He could even read a clock face and differentiate between seven shades of grey, the researchers said. Tests were conducted starting from seven to nine days after the device was implanted.\u201d It\u2019s tough when writing a story about a study this small to put hard numbers to the benefits, but even some acknowledgment of this limitation would have been better than some of the overly optimistic sentiments expressed. The study itself and the press released provided more ways for the story to quantify the benefits.", "answer": 0}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nOur results suggesting that the risk associated with metformin might differ by smoking history were unexpected.\nHowever, our results suggest that risk might differ by smoking history, with metformin decreasing risk among nonsmokers and increasing risk among current smokers.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nNonsmokers who used metformin for five years or longer had a 52 percent reduction in lung cancer risk, but this finding was not statistically significant.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We appreciate that the release attempts to quantify the reduction in risk associated with metformin use. However, there\u2019s a problem with the release\u2019s description of these results. The\u00a0research paper\u00a0points to\u00a0a statistically significant reduction in lung cancer risk only among diabetic patients who have never smoked. But the release generalizes this finding to all \u201cnonsmokers.\u201d The release doesn\u2019t delineate between people who have never smoked and those who did smoke but quit. The benefits appear to apply only to the group of never smokers. This is an important distinction.", "answer": 0}, {"article": "(Older, still available drugs are made from the urine of pregnant mares).\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Vague references to potential benefits of HRT with statements such as:\n\u201c(Drs) Johnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\u201d\nFirst, who are these \u201cother experts\u201d and where are the appropriate references for these claims?\nSecond, re-analysis of the data from the Women\u2019s Health Initiative study shows:", "answer": 0}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nIn this preliminary study, about three-quarters of those with insomnia said the cap helped them sleep better when the water temperature was about 57 degrees Fahrenheit.\nPrevious research has shown that the brains of people with insomnia are \"hyperaroused\" and have a higher brain metabolism in the frontal lobes, which helps explain why they have trouble drifting off to sleep and staying asleep, said study co-author Dr. Daniel Buysse, a professor of psychiatry and clinical and translational science at University of Pittsburgh School of Medicine.\nWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn't have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping) .\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t adequately place the findings into context.\nIt stated:\u00a0 \u201cWhile wearing the cooling cap, it took insomnia patients an average of 13 minutes to fall asleep and they spent 89 percent of their time in bed actually sleeping, about the same as controls who didn\u2019t have insomnia (the latter group averaged 16 minutes to fall asleep and 89 percent of the time in bed sleeping).\u201d\nBut it didn\u2019t ever define the baseline degree of insomnia these trial patients experienced.\u00a0 In other words, how long did it usually take them to fall asleep and what percent of thier time in bed did they usually sleep?", "answer": 0}, {"article": "Sumathi Reddy has details on Lunch Break.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nSo far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t make any\u00a0extravagant claims regarding the benefits of probiotics, it doesn\u2019t attempt to quantify the benefits that it does mention. That might be helpful, for example, when the study mentions that probiotics may \u201creduce the symptoms and recovery time for the common cold.\u201d In one trial that is\u00a0frequently cited to support\u00a0claims that probiotic yogurts prevent the common cold, researchers found that children would have to\u00a0consume probiotics every day for 100 days to prevent two days with cold symptoms. That kind of context would help readers determine whether the benefits are worth the expense and hassle.\nThis is the major shortcoming of the piece.\u00a0 Many alternative therapies are found to have \u201cbenefit\u201d in short and poorly conducted trials.", "answer": 0}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nThe result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\n(It's unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.)\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story (complete with table) did a fair job of balancing a digestible message with the caveats of research. It tells us that all the exercise groups lost about 2 inches off their waistline and about 5% to 6% of their bodyweight. Since average people don\u2019t really think about weight loss in terms of \u201cpercentage bodyweight,\u201d however, it would have been better for the story to tell us how much participants weighed at the start of the study and how much weight each group lost in pounds.\nAnd while the story suggests that brisker walking gives more benefit by improving glucose tolerance, it expressly cautions that this change may not be meaningful to patients: \u201cIt\u2019s unclear whether the 9 percent improvement seen will be enough to cut their risk of heart disease, though.\u201d That\u2019s a useful distinction.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nBut, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nDr. Schaefer pointed out that the kind of fish consumed is important.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\nRisk reduction was apparent only at that top level of DHA \u2014 those in the bottom three-quarters in DHA level showed no detectable difference in risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Early in the story, it mentioned that the\u00a0research involved 899 people and that 99 people developed dementia during the course of the study.\u00a0 This works out to a total incidence of dementia of 11%, something that was not explicitly stated in the story.\u00a0 The piece then went on to discuss that\u00a0 that two\u00a0or more servings of fish a week reduced the risk of dementia by 39%.\u00a0 This is a relative risk reduction.\u00a0 Before readers can put that in context, they would really need to have the absolute risk of developing dementia. \u00a0 (Read more about absolute vs. relative risk.) \nWhile it is true that the original source piece for this story did not contain this information, the story could have raised the question.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\nThe new results show people can ask friends or relatives to help examine their bodies for suspicious moles, said Robinson.\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The research letter in JAMA\u00a0Dermatology\u00a0used survey questions to assess the confidence and embarrassment that partners\u00a0felt when helping to search for cancerous moles. The story from Reuters\u00a0reported the survey results, though it didn\u2019t quantify them:\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\n\u201cTheir confidence level goes up and plateaus at eight to 12 months, and it doesn\u2019t go down,\u201d said Robinson.\nThe exams didn\u2019t become more embarrassing or less comfortable, either.\nBut, we\u2019re left to wonder: How much did their confidence levels go up? When the study or news release doesn\u2019t spell that out clearly (nor use\u00a0laymen\u2019s terms), it\u2019s up to the reporter to find out and let readers know. We recognize this isn\u2019t easy to do on deadline, but it would have made an average\u00a0story stand above the competition.", "answer": 0}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\nAnd critics say that since that trial was conducted, new drugs have come to market that allow patients with metastatic colorectal cancer to live two years with intravenous chemotherapy alone.\nThe therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\nOne randomized trial done more than a decade ago involving 105 patients in the did show a striking benefit.\nWhile some patients did seem to live much longer than expected, he said that they had been carefully selected and might have fared well even without the therapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explained:\n\u201cOne randomized trial done more than a decade ago involving 105 patients in the Netherlands did show a striking benefit. The median survival of those getting surgery and Hipec, plus intravenous chemotherapy, was 22.3 months, almost double the 12.6 months for those getting only the intravenous chemotherapy\u201d\nThat being said, the story also included the proviso that newer drugs are now available that have been shown to increase survival.", "answer": 1}, {"article": "The OFF!\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\nThe study was done outdoors in order to replicate real-world conditions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release makes a very modest result sound more beneficial than it might actually be. According to the release, \u201cThey found that the OFF! Clip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\u201d\nWhat they don\u2019t say is that the devices were suspended from stationary cages and were effective at repelling mosquitoes only within a foot or a foot and half away when the weather was calm.\u00a0 In other words, if you are using the device outside, don\u2019t move. Also, it\u2019s probably best not to count on the device if it\u2019s windy out. As the product website warns, \u201cif you move, allow a few minutes for the unit to rebuild its protection.\u201d\nIn addition, as shared in the study, but not the release, the time to cause high mortality in mosquitos was in the 30 to 60 minute range, implying (or scientifically stating) that a person wearing the device would have to be 0.3 meters from the mosquito for a prolonged period of time without either of them moving.\nWe also aren\u2019t given any quantification \u2014 percentage or absolute number \u2014 for the claim that the device caused \u201chigh mosquito mortality and knockdown.\u201d", "answer": 0}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\nThe second group, of 85, was offered the same advice in the same time frame along with 10 half-hour weekly sessions of \"traditional\" acupuncture.\nOne group of 105 patients was offered a three-month regimen of self-care advice on diet, exercise and psychological support.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s only quantified assessment is \u201cby the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\u201d That\u2019s not enough to merit a Satisfactory rating, for several reasons, including:", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only said that more than two-thirds of those taking the drug had at least a 75% reduction in psoriasis.\u00a0 That\u2019s not clear. Does that mean 75% a reduction in the number of psoriatic plaques?\u00a0 Or does it mean a 75% reduction in the severity of existing plaques?\u00a0 And 75% of what baseline?\u00a0 Were these people wth extensive psoriasis?\u00a0 What precisely were the measurements? ", "answer": 0}, {"article": "If your risk is lower it's harder to show a benefit.\"\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nTop health issues to pay attention to in 2016: The rise of personalized diets and medical treatments\n\nFor more health news, you can sign up for our weekly newsletter here.\nThe new analysis, published in Mayo Clinic Proceedings on Monday, involves a second look at 106 randomized trials with 254,301 patients that took place after 2000 and shows that during this time period patient outcomes on the two medications were remarkably similar.\nDuring that time period there was a remarkable shift in cardiovascular health care in America -- with a greater emphasis on not smoking, more statin use for cholesterol, better management of diabetes, lower targets for blood pressure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story points out that the two classes of drugs prescribed for cardiovascular disease are mostly equally effective.\u00a0 It also points out that the main difference lies with the fact that patients report that ARBs are linked to fewer unpleasant side effects, compared to ACE inhibitors.\u00a0 And since patients are\u00a0usually kept on the drugs for long periods of time, if not indefinitely, that information is important to readers. But the story never says what outcomes exactly we\u2019re talking about here \u2014 deaths, heart attacks, blood pressure? Nor does it say how effective these medications were at improving these outcomes \u2014 merely that they are equivalent. We think both of these issues should have been addressed in order to earn a Satisfactory rating here.", "answer": 0}, {"article": "The main reason for the surgery is osteoarthritis.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nPartial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\n\u201cIf surgeons aim to use partial knees in a quarter or more of their knee replacements this will substantially improve the results of knee replacement and will save money.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells readers that \u201cMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster.\u201d But it doesn\u2019t tell readers how much faster. It also doesn\u2019t make clear what the benefits of the surgery are compared to, well, not having any surgery at all.\nIn addition to not quantifying the benefits, the story also doesn\u2019t tell readers exactly what the researchers were measuring, which were \u201cquality adjusted life years\u201d (QALYs). QALYs are a way of accounting for both the quantity and quality of a patient\u2019s life, and are used primarily in an economic context. i.e., QALYs are used to assess the cost-effectiveness, or value, of a medical procedure.\nIn this case, the study found that patients had QALY gains for partial replacements, compared to total knee replacements, and that the gains varied depending on both the patient\u2019s sex and age. The QALY outcomes were also influenced by whether the person conducting the partial surgery did such operations frequently.", "answer": 0}, {"article": "Please visit http://www.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nParticipants with 5 to 6 points in the health professionals' group had a 68 percent decreased risk of lethal prostate cancer and a 38 percent decreased risk was observed in the physicians' group for the same comparison.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is where things get a little tricky. The research described in this journal article looked at data from two different studies: the Health Professionals Follow-Up Study (HPFS) and the Physicians\u2019 Health Study (PHS). The HPFS tracked 42,701 men from 1986-2010. The PHS tracked 20,324 men from 1982-2010. The release (and journal article) explain that the researchers used the HPFS data to develop a \u201chealthy lifestyle score,\u201d and then applied that score to the men in the PHS to see if it predicted whether someone would contract a lethal form of prostate cancer. The researchers identified the number of lethal cases of prostate cancer in each group to calculate benefits. The release states: \u201cParticipants with 5 to 6 points [the highest scores] in the HPFS had a 68 percent decreased risk of lethal prostate cancer[,] and a 38 percent decreased risk was observed in the [PHS] for the same comparison.\u201d Several points to make here. First, the \u2018healthy\u2019 group appeared to have been compared to the \u2018least healthy\u2019 group (score 0-1) and not all the other groups combined. This was noted in the published results but not mentioned in the release. That\u2019s important. Second, the release does not note (but the journal article does) that the 38 percent decreased risk seen in the PHS was not found to be statistically significant. That\u2019s also an important distinction. Third, this is the relative reduced risk, and doesn\u2019t tell readers what the actual, absolute reduction of risk is.", "answer": 0}, {"article": "Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\nSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\nHowever, no cardiac, pulmonary, gastrointestinal, seizure or secondary tumor effects - all of which have been reported in photon therapy studies - were seen in the current study's participants.\nTo investigate their hypothesis that proton therapy would reduce the incidence and severity of side effects without loss of treatment effectiveness, the researchers enrolled children and adolescents ages 3 to 21 - with an average age of around 6 \u00bd - who received proton therapy for medulloblastoma at the MGH from 2003 to 2009.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release quantifies some outcomes, as in this statement: \u201cOf 59 patients who enrolled, 12 died from their tumor during the study period and one from a traumatic brain injury. Significant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\u201d The release later indicates that key outcomes are comparable to photon therapy: \u201cSurvival rates and the incidence and type of tumor recurrence all were similar to what has been reported for photon radiotherapy.\u201d We\u2019ll call this good enough for a Satisfactory rating, although the release certainly could have provided more detail on what previous studies have found with respect to photon therapy.", "answer": 1}, {"article": "\u201cThis is a huge difference,\u201d said Dr. Antoni Ribas, an oncologist at the University of California, Los Angeles, who has studied vemurafenib.\nMORE HELP FOR MELANOMA PATIENTS\n\nRoche expects U.S. and European regulators to decide on approval of its drug before the end of the year.\nShe and others expect vemurafenib to be approved this year.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\nAbout 18 percent of patients developed a low-grade skin cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate job reporting the benefits seen in the two trials.", "answer": 1}, {"article": "She said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nThis was especially true in the left hemisphere regions of the brain responsible for language.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\n\"They then looked at the extent to which brain activity from one region was synchronized with brain activity from another region,\" a phenomenon known as \"EEG coherence,\" said Dawson, who was not involved in the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was about a test.\u00a0 Stories about tests should quantify how well the test worked, how sensitive, how specific, how often, how many times out of how many times tried, etc.\u00a0 This story provided none of those measurements.", "answer": 0}, {"article": "Prologo consults for Galil Medical, which funded the study.\nAlso unknown: whether men would opt for the treatment.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nDec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that men in the study lasted three times longer after the procedure, an increase from 36 seconds to 110 seconds. While this is important information to communicate, it is arguably just as important to tell us how\u00a0this increase in stamina affected the men\u2019s satisfaction with their performance. While definitions vary,\u00a0ejaculation is typically considered \u201cpremature\u201d only if it causes distress or dissatisfaction. So\u00a0treatments need to be judged on the basis of whether they improve\u00a0the individual\u2019s subjective perception of their performance. Is an additional 80 seconds of intercourse enough to make a difference in how these men felt about their sexual experiences? (Or how their partners felt?) The story does tell us that all men \u201cimproved on at least one sexual-related\u00a0symptom,\u201d but\u00a0it doesn\u2019t tell us which symptoms were affected or how much improvement was seen.", "answer": 0}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\nIn the study, published in the New England Journal of Medicine on Wednesday, 76 patients were treated with focused ultrasound, and their tremor was evaluated after the first, third, sixth, and 12th month.\n\u201cAs we make the test lesion, we see a subtle improvement in their tremor and the patients notice it,\u201d said Dr. Rees Cosgrove who is leading the trial at Brigham and Women\u2019s Hospital in Boston.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is long on description but short on numbers.\nSaying the treatment \u201chas had an immense impact on patients\u2019 lives,\u201d the story devotes quite a bit of print along with video footage to show rapid functional and quality-of-life improvements experienced by patients, focusing on one women who said her tremor \u201chas almost disappeared\u201d since she had the procedure in June. Video showing this patient before and after treatment\u2013including her attempts to write her name, trace a spiral and pour water from one cup to another\u2013do a great job of conveying the improvements. This is terrific news for this woman, but\u00a0we\u2019re not told how representative her experience\u00a0is of overall outcomes. Is she a best-case scenario? Middle of the road?\nThere are also inspiring quotes from a researcher, including a description of the \u201cremarkable moment\u201d patients experience when they realized the tremor has subsided. \u201cThey can write their names again, they can feed themselves, they are not embarrassed about being in public. So it really is extraordinarily helpful for people,\u201d he says.\nIn terms of study data, the story says researchers \u201cfound that the severity of essential tremor reduced significantly\u201d in patients who underwent the treatment as well as reported improvements in quality of life. But there are no figures. In fact, according to the study, patients experienced a 47 percent improvement in tremor scores, dropping from 18.1 points on a 32-point scale at baseline to 9.6 points three months after the procedure. That data should have been included. Also, the story should have spelled out that 56 patients received the treatment, versus 20 who experienced a fake procedure. \u00a0Also worth pointing out: We don\u2019t know the meaning or clinical significance of a reduction of this magnitude in the total score.\u00a0", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\nThe study, of 205 women, found that those randomly assigned to take Lexapro (escitalopram) for eight weeks reported less daily \u201cinterference\u201d from their hot flashes.\n\u201cBut my feeling is that it\u2019s the placebo effect,\u201d Freedman said, referring to the phenomenon of study participants on placebos improving because they believe they are getting a real treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate quantitative description of the extent and timing of hot flash reduction for the treatment group.\u00a0 Describing the response in placebo group as \u201coccurring more slowly and to a lesser degree\u201d provides an adequate sense of the difference.\u00a0 And story provided quantitative comparison for the outcome of insomnia between placebo and treatment groups.\n\u00a0", "answer": 1}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\nHall felt nothing from the seconds-long bursts from 1,024 ultrasound beams aimed at different points around her skull, and an MRI scan confirmed that the brain barrier was successfully traversed.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Since this is a single patient there is no quantification involved, so N/A.", "answer": 2}, {"article": "Watson shares were up 50 cents, or 1.2 percent, to $43.20 in morning trade.\nWomen\u2019s health advocates have welcomed the potential for another contraceptive option, but some critics contend the drug is more akin to the abortion pill, sold by Danco Laboratories as Mifeprex and also known as RU-486 or mifepristone.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nThe drugmaker has said its pill, also known by its chemical name ulipristal, works primarily by preventing ovulation of a woman\u2019s egg.\nBut the drug\u2019s effect on the lining of the uterus \u2014 critical for a fertilized egg to develop \u2014 may also play a role, according to its label in Europe.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides no quanitification of benefits from the drug. Ideally, the story would have described the likelihood of pregnancy after uNPRotected sex with or without the drug. According to British sources \"It is estimated that for every 100 women who take Ellaone up to five days after uNPRotected sex, approximately two women will become pregnant. The tablet is more effective at preventing pregnancy the earlier it is taken, so it is important to take it as soon as possible after uNPRotected sex, rather than delay it to the fifth day.\"", "answer": 0}, {"article": "The F.D.A.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nBut such talks, while encouraging, are still in the early stages, a Novartis spokesman said.\nThat represented a relative risk reduction of 20 percent using a measure known as the hazard ratio.\nBlacks and those with a previous history of the condition were at increased risk, it said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gets a hesitant satisfactory score here. Now, we know that reporters rarely, if ever, write the headlines. But somebody at the Times must take responsibility for the confusion caused by this headline, which states that the drug is \u201cSaid to Cut Death Risk by 20%.\u201d This starts the story off on an uncertain note, since it\u2019s not clear who said this or where this information is coming from. In the second paragraph, the story cites results from a clinical trial showing \u201ca 20 percent reduction in the risk of death from cardiovascular causes or hospitalization for worsening heart failure.\u201d So, it seems that the drug is not cutting the risk of death by 20 percent, but the risk of death or hospitalization for worsening heart failure. Then again, if you go to the study itself, you learn that there was indeed a 20% reduction in the outcome of \u201cdeath from cardiovascular causes,\u201d although this doesn\u2019t seem to be the figure that the headline is referring to, since it\u2019s not mentioned in the text. In terms of overall death from any cause \u2014 the outcome that most closely resembles the \u201cdeath risk\u201d mentioned in the headline \u2014 the study shows that there was a 16% reduction.\nBut that\u2019s not the whole story. Much lower down in the article, we learn that this was actually a relative risk reduction \u2014 patients in the clinical trial who took Entresto were 20 percent less likely to die or be hospitalized than patients who took a competing drug called enalapril. This sort of risk reduction is not the same as absolute risk reduction, which provides a more meaningful view of the benefit. The story does get credit for eventually providing the absolute risk of hospitalization/mortality in both groups (21.8 percent of those taking Entresto vs. 26.5 percent for those taking enalapril, or \u00a0a 4.7% difference), but putting this information far down in the story, after a confusing headline, is less than ideal.", "answer": 1}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nHCA is chemically similar to CA and is also available as a dietary supplement.\nThey often recommend taking citrate (CA), in the form of potassium citrate, a supplement that can slow crystal growth, but some people are unable to tolerate the side effects.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release merely states that, in lab tests, hydroxycitrate appears to be capable of dissolving a common component of kidney stones and could be more effective than citrate, which is often recommended in addition to diet and lifestyle changes as a way to help prevent kidney stones. There is also a cautionary note at the end of the release (which could have been placed near the top) stating that long-term safety, dosage and additional human trials are needed.", "answer": 1}, {"article": "Published online 29.10.2018. https:/\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\nA very high consumption of non-fermented dairy products, on the other hand, was associated with an increased risk of incident coronary heart disease.\nMen who eat plenty of fermented dairy products have a smaller risk of incident coronary heart disease than men who eat less of these products, according to a new study from the University of Eastern Finland.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Main findings mentioned include:\nReaders are given no sense of just how much the risk is increased or decreased in these groups.\nThe only data provided from the study is this:\nThe risk of CHD was 26% lower in those men who consumed the highest amount of low fat (<3.5%) fermented dairy (compared to the lowest consumption group).\nIt would be difficult for many readers to put that number into context without knowing how much low-fat/fermented dairy was consumed.\nSome data contained in the study might have helped put the numbers in context. According to the tables in the published manuscript, there is a modest reduction from 14 CHD events per 1,000 person years in the low intake group (of fermented dairy) to 10 CHD events per 1,000 person years in the high intake group (of fermented dairy).", "answer": 0}, {"article": "\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\nThe spectrum of ADHD and related disorders is broad, and there is no one-size-fits-all treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "An anecdote about one person\u2019s experience does not amount to quantifying potential benefits for readers. The story provides no studies/evidence to quantify benefits of the approach described.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a pretty good job of noting the apparent benefits in its narrative, but hard data are notably missing or under-reported. Readers would benefit from knowing, for example:\nHow many of the women who took estriol along with their conventional medications showed reduced relapse rates, and to what degree, compared to women who took the placebo with conventional drugs? (Telling us that these women had \u201ca third to a half as many relapses\u201d is a relative comparison \u2014 we wanted to see absolute numbers.)\nIf there were extended breaks between relapses, how long were they?\nWhat was the rate of inflammatory lesions in the brain and when did they occur? These numbers should be included for the current study, not the 2002 findings.\nFinally, the release could have noted an important reduction-in-the-reduction of relapse rates over time. For example, a\u00a0Medscape news report on the 2014 presentation noted a 47% reduction in confirmed relapses compared to placebo group in the first year and a 32% relapse rate reduction in the second year.", "answer": 0}, {"article": "More broadly, little is known about ketamine's potential side effects at different doses, which include cognitive and dissociative effects, elevated blood pressure and heart rate, liver inflammation and urinary problems.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\n\"Our results indicate a dose-titration method may be particularly useful for older patients, as the best dose was selected for each individual person to maximise ketamine's benefits while minimising its adverse side effects.\"\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u2019s presentation of study outcomes is baffling. The published paper describes a 5-week randomized controlled trial followed by a longer 6-month follow-up phase that was open label (meaning patients and doctors knew who was getting ketamine). The RCT period provides the strongest evidence, but the news release seems to offer only the 6-month open label results when it says,\n\u201cBy the six-month follow up, 43 percent of participants (7 of 14) who completed the RCT had remitted, with five remitting at amounts below the commonly-used dose of 0.5 mg/kg. Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\u201d\nFirst of all, according to the published paper, the outcomes described in the news release \u2014 \u201c7 out of 14\u201d remitters and \u201c68.8% overall response and remission rate\u201d \u2014 are from the initial 5-week RCT. The news release, however, describes them as being from the 6-month open label follow-up. That\u2019s simply incorrect. Second, 7 out of 14 is exactly 50 percent but is described as being \u201c43 percent\u201d in the news release. This 43 percent figure does not not seem to appear anywhere in the published study and we\u2019re not sure what it represents.\nLastly, the release lacks specifics that would help readers understand the magnitude of benefit.\u00a0What is an \u201coverall response and remission rate\u201d? How much better does one have to be to be considered a \u201cresponder\u201d or \u201cin remission.\u201d", "answer": 0}, {"article": "\"Does it still amaze you after all these years,\" LaPook asked.\n\"You would want them to have the least invasive procedure possible.\"\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nLiterally, no pain.\"\nThe surgery she's upset about may be archaic - but it's very common.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the main benefit of laparoscopic surgery \u2013 reduced recovery time \u2013 relative to abdominal hysterectomy.", "answer": 1}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nShe believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes.\nFindings of the clinical trial are published today in the journal, Cardiovascular Diabetology.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release makes clear that cardiovascular disease is a major risk for patients with diabetes and the study was intended to show whether the additional drug, metformin, could lower that risk. The release states that the study showed a decrease in markers indicating damaged blood vessels and an increase in markers showing blood vessel repair, among other findings. But the release falls short by not providing\u00a0any numerical data suggesting the degree of improvement in these markers, and therefore denies readers the ability to make their own determination as to the importance of this research.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nSince then, several studies have strengthened the case for the diet, says guideline co-author Brian Lacy, a professor of medicine and chief of gastroenterology at Dartmouth-Hitchcock Medical Center, Lebanon, N.H.\nBut few dietitians are trained in the diet, and insurers typically do not cover the visits, Lacy notes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story looks at the big picture here, and it does do a pretty good job quantifying the benefits, when relevant. For example, one recent study in the United States gets detailed attention in the story. In it, patients on the low-FODMAP diet perceived better relief from pain and bloating than did patients on a less restrictive diet. We\u2019re told both the percentage of subjects who reported \u201cadequate relief,\u201d hovered around 40-50% for both diets. The story quickly follows that by explaining there was no\u00a0statistically significant difference.\nThe story also highlights another study in which the low-FODMAP diet fared no better than another, less restrictive diet. \u201cThe data are not overwhelming,\u201d notes one scientist. And the story, while mentioning that the 2014 American College of Gastroenterology guidelines stated that the diet showed promise, also quotes the organization as indicating that the quality of the evidence is \u201cvery low.\u201d", "answer": 1}, {"article": "That's been the brass ring.\"\nThe study, involving 13 adults with either a high-functioning form of autism or Asperger syndrome, a mild form of the disorder, found that when the subjects inhaled the hormone oxytocin, they scored significantly better on a test that involved recognizing faces and performed much better in a game that involved tossing a ball with others.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\n\"This is the first study that looked at whether oxytocin has an effect on social behavior, which is a major deficit in autism,\" said Angela Sirigu, who directs the National Center for Scientific Research in France and led the study, published online by the Proceedings of the National Academy of Sciences.\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There were, however, wide variations in individual responses, the team noted.\n\"It\u2019s not clear whether this would be effective at all in children or in young adults who had intellectual problems.\" warned (one independent expert.)\nAlso, scientists would need to come up with a different method of delivery, (one independent expert) said.\n\"The nasal [inhaled] drugs only work for a few minutes. Potentially it would be very difficult to be using this drug once an hour or something. It doesn\u2019t make a whole lot of sense,\" he pointed out. \"But it does point the way to the possibility of raising oxytocin levels with other kinds of compounds to increase oxytocin levels more generally over a longer period of time. I don\u2019t know whether this is a realistic therapy as we have it now but, potentially, in the future it could really help these people whose primary autistic symptoms are having to do with reduction in social activity.\"", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nSpecifically, younger patients with a relapsing form of MS who were not severely disabled and who hadn't found relief with other treatments fared better than others over five years, the international team of researchers found.\nMONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nHowever, it can be considered a concrete option for patients showing aggressive MS who have not responded to approved treatments,\" said study co-author Dr. Riccardo Saccardi.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One\u00a0benefit here is progression-free survival. This is basically a yes/no question: did the patient\u2019s MS progress? For 46% of the 239 patients who could be analyzed, the answer was yes. The story tells readers that. It also tells readers that a certain subset of patients was more likely to experience these benefits than others: \u201cyounger patients with a relapsing form of MS who were not severely disabled and who hadn\u2019t found relief with other treatments fared better than others over five years.\u201d\nHowever, the story didn\u2019t convey important context for this progression-free survival figure. The reason that the 46% figure is interesting is because of this: Conventional wisdom says patients with aggressive disease would still continue to accumulate disability even if their inflammation is stopped, yet among the group\u00a0studied among which 75% had progressive disease, 46% had not progressed at the 5-year mark. This means that\u00a0some patients with progressive disease benefited from stem cell treatment\u2013against conventional wisdom.\nAs we explain below in our evidence quality criterion, the story should have made it clearer that these findings were not obtained via a randomized controlled trial.", "answer": 1}, {"article": "Those ingredients include Vitamin C and flavonoids.\nBut their work was done in a laboratory, not in humans, she noted.\nIf so, human trials might follow.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\nThe bitter melon extract killed only the cancer cells, not the healthy breast cells.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Potential benefits were exaggerated far beyond what this laboratory-only research showed.\u00a0 Again, the story stated: \nAlso?\u00a0 No human benefit was proven in this story! ", "answer": 0}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\nThat is important because it is possible for patients to benefit from simply receiving attention from a healthcare provider, or being part of small-group sessions with other people suffering from the same condition, for example.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports that 46% of patients receiving affective self-awareness therapy had a 30% or greater reduction in pain severity, which was the study\u2019s primary outcome, compared to zero patients in the control group. \u00a0This succinct summary, presented in absolute terms and unembellished with patient anecdotes, is enough to merit a satisfactory. But we wish the story had explained whether\u00a0a 30% reduction in this pain rating scale\u00a0is\u00a0a clinically important finding.\u00a0In addition,\u00a0it is\u00a0not clear why the article failed to\u00a0mention that patients receiving\u00a0affective self-awareness therapy\u00a0had improved self-reported functional status.\u00a0This is an important measure of how patients are able to get along in their daily lives.\u00a0", "answer": 1}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nThe researchers found that on average, antidepressants and Catapres each appeared to reduce hot flashes by about one per day, and Neurontin by about two per day.\nCatapres can cause some of the same symptoms and also constipation.\nAmong the antidepressants, Paxil seemed to have the strongest evidence of benefit.\nFor the other antidepressants, Prozac and Celexa, and for the plant extracts, there was no statistically significant evidence that they worked for hot flashes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Absolute reduction in number of hot flashes per day is presented for non-hormonal treatments and these are compared to the number of hot flashes with hormone treatment.", "answer": 1}, {"article": "An estimated 50,000 people a year experience end-stage ankle arthritis, in which the ankle cartilage has worn away completely, causing painful bone-on-bone contact and some level of disability.\n\u201cThey are so appreciative about how their life has been changed.\nNow another aging joint is fast becoming a candidate for replacement.\nI have absolutely no pain.\nI was even playing soccer with my grandkids a few months ago.\u201d\n\nHis surgeon, Dr. Craig S. Radnay, an associate at the Insall Scott Kelly Institute for Orthopedics and Sports Medicine in New York City and on Long Island, says he is now a \u201cbig believer\u201d in ankle replacement for certain patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Potential benefits including, decreased pain, improved physical function and quality of life, are mentioned \u2013 but no data is provided.\u00a0 How often do these occur?\u00a0 That\u2019s a pretty important piece of information for readers. ", "answer": 0}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\n\u201cThe fact that the procedure was associated ... with improvements in affective and obsessional symptoms is of key importance,\u201d they said.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nAndres Lozano, who led the study, said the results were encouraging because they pointed to a genuine therapeutic effect, rather than a placebo or hunger-increasing effect.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story \u2013 awkwardly \u2013 in the second sentence, states that this was a trial in 6 people that \u201cfound at least half put on weight and showed improvements in mood.\u201d\nAt least half of 6?\u00a0 Does that mean 3?\u00a0 4?\nLater, much deeper in the story, it explains that \u201cafter nine months, three patients weighted more than before treatment\u201d \u2013 so we guess the answer to \u201cat least half\u201d was, indeed, three. But then it says \u201cAround half also had better moods and less obsessive-compulsive behaviour.\u201d\u00a0 Again, around half of 6?\nWhy not give the precise number of people?\nAnd why did the story never give the precise amount of weight gain (in pounds or percentage of ideal body weight ) that was actually observed.\nWithout that, again, readers are lead to believe the weight gain was substantial.", "answer": 0}, {"article": "\u2022 Paulsen AJ, Cruickshanks KJ, Fischer ME, et al.\nAfter 12 weeks of treatment, as compared to vehicle, Seciera\u2122 showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p<0.0001).\n[1] Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any quantification of the results of this trial, instead it offers vague terms such as \u201cshowed statistically significant improvement in the primary end point,\u201d and \u201cshowed statistically significant improvements compared to vehicle.\u201d\u00a0 It also offers, \u201cBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset,\u201d a statement which also provides no numerical information for readers.", "answer": 0}, {"article": "They have.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nCardiologist Douglas Zipes, past president of the American Academy of Cardiology, says the problems kids suffer are typically electrical, like abnormal heart rhythms, or structural, like a thickening of the heart muscle.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\n\u00a0 \n\n \n  The story amplifies the potential benefit of routine screening of high school athletes by focusing unduly on a couple of positive anecdotes. In particular, the reporter describes the experience of one child diagnosed with a serious heart problem for whom the EKG was said to be \u201clife-saving.\u201d This characterization is problematic because we don\u2019t of course know whether this patient ultimately has been \"saved\" (the patient is said to be on a heart transplant list and the outcome of any intervention is as yet undetermined). Similarly, it is impossible to say whether this problem would have been detected by other means even if the child never received an EKG. The author leans heavily on this anecdote but provides no real data to support the contention that global screening of all athletes would identify more students at risk than the current approach. \n  \n", "answer": 0}, {"article": "Parkinson\u2019s disease is a debilitating disorder in which brain cells progressively die causing patients to experience tremors, rigidity, extreme slowness of movement, impaired balance, and difficulties in swallowing and speaking.\nWith Gocovri, which targets both dyskinesia and off time, patients will be able to reclaim about 3.6 hours of their day, CEO Gregory Went said in an interview ahead of the decision.\nThe long-acting therapy is taken once-daily at bedtime.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The only benefit information we receive is this: \u201cWith Gocovri, which targets both dyskinesia and off time, patients will be able to reclaim about 3.6 hours of their day, CEO Gregory Went said in an interview ahead of the decision.\u201d\nOne wonders how the drug was tested, and how the comparator group fared. Without this information, the story is robbed of its relevance. There is little to no information to help patients understand the potential benefits. For example, how many hours had the patients in this study \u201clost\u201d prior to going on this medicine? What is the impact on quality of life of this extra time? For how long do patients benefit from the drug?", "answer": 0}, {"article": "\"It gives us encouragement that we may be on to something here.\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nNov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does explain that only one patient remains cancer free following the study. It then details how for most of the patients cancer continued to progress after 2 months. It says that the median overall survival in both the breast cancer and ovarian cancer patients was less than 16 months. But the story is framed in such a way to highlight the one potentially positive outcome of the study and to downplay the negative. We read more sooner about the one patient who may have responded well to the vaccine than we do about the 25 other patients who did not.", "answer": 1}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\nNewswise \u2014 EAST LANSING, Mich. \u2014 A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The first sentence makes a bold claim about benefits: \u201cA chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\u201d\nBased on the research, this statement about benefits is problematic. There is nothing in the study that showed the people who used marijuana had higher cognitive function than non-users. No cognitive function was measured. Instead, researchers were looking at biomarkers for inflammation that may\u2013may\u2013be linked with cognitive decline, but no one is sure yet. So even if marijuana users have less of these particular inflammatory biomarkers, they may still suffer mental decline for other reasons. \nIt\u2019s also not clear what \u201cup to\u201d 50 percent of patients means. Does this mean that 50 out of 100 HIV patients saw their mental faculties preserved by marijuana? Or does it mean that 20 out of the 40 people mentioned in the study saw a benefit? It is unclear and misleading. That phrase \u201cup to\u201d always gives us pause. Be clear with your audience. Show them the math.", "answer": 0}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nResearchers say current guidelines should be updated to incorporate the scans into routine care.\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the diagnostic procedure:\nSupporting data from the study are not provided. It appears the release misinterpreted the results. As noted above, it would have been preferable to include absolute and not just relative numbers.", "answer": 0}, {"article": "must sanction a medical device for a specific use before a company can market that use.\nAfter reviewing Erchonia Medical\u2019s clinical study, Dr. Brian M. Kinney, a plastic surgeon in Los Angeles, said, \u201cI can\u2019t prove that it works.\u201d His concerns are that the tape measure method of gauging circumferential changes \u201cisn\u2019t consistently reliable.\u201d What\u2019s more, study participants and the placebo group were assessed only two weeks after their last treatment, not long enough to measure adequately whether results last.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\n(Such a delay is atypical, Ms. Riley said, adding, \u201cmost 510Ks are cleared within six months.\u201d)\n\nLast month, Dr. Robert B. Seltzer, a dermatologist in Pasadena, Calif., ran an advertisement in The Los Angeles Times for an informational seminar that called Zerona \u201cthe holy grail.\u201d In a phone interview, however, he said, \u201cI\u2019m not 100 percent convinced\u201d and planned to return his Zerona if he didn\u2019t continue seeing results in his patients.\nDr. Kinney doesn\u2019t have a Zerona or a Zeltiq cooling device, though in the case of the latter, he said, \u201cit is well documented that freezing fat tissue aggressively enough can lead to fat necrosis,\u201d or, fat dying, over a few months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story duly reports that unpublished research showed Zeltiq resulted in 22 percent body fat loss in targeted areas. It reports that published, funded research showed patients lost an average of 3.5 inches after six sessions of Zerona laser work. \nGiven the thin body of research, this is adequate reporting of benefits. ", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is a tough one. While the story tells us what percentage of patients benefited from treatment, it does not, in fact, quantify the extent of those benefits\u2013which is precisely what this category is designed to assess. However, the story does do a good\u2013and thorough\u2013job of describing the benefits in qualitative terms.\nThat said, if the story had only chosen one or two examples of changes in the standardized measures of depression or anxiety, this would have received an enthusiastic \u201cSatisfactory\u201d rating. One strong word of caution though: The story cites one source as saying that psilocybin may one day be used to treat a wide range of mental health issues ranging from drug addiction to obsessive-compulsive disorder. The story offers no evidence to support these claims, which were made by a source associated with an organization that exists specifically to promote research on hallucinogens. Substantial claims require substantial evidence. The story would have been much stronger if it had eliminated the unsubstantiated remarks from the source \u2014 particularly since they had no bearing on the subject of the story.", "answer": 0}, {"article": "For people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quantification of results, like hunger levels or changes in hormone levels. The story also didn\u2019t tell us how much less participants ate at the buffet following the egg breakfast vs. cereal breakfast.\u00a0 We really need such details in order to figure out if the findings are a big deal or not.", "answer": 0}, {"article": "\u201cWhy would we?\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\nBeing generous about studies with design flaws that could overstate effects, Dr. Nigg and his colleagues concluded that custom-made orthotics could help prevent and treat plantar fasciitis, a common injury to a tendon at the bottom of the foot, and stress fractures of the tibia, along the shin.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\nSo far, most of the focus in that direction has been on rigorously assessing orthotics and prosthetics for other conditions, like scoliosis, with less work on shoe orthotics for otherwise healthy athletes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article offered a brief characterization of the magnitude of benefits related to orthotics among soldiers in one study. But in general the article did not adequately frame the potential benefits of shoe inserts. \u00a0For instance, in the review that reported a benefit for orthotics in the prevention and treatment of plantar fasciitis and tibial stress fractures, how impressive was that benefit?\n\n \n", "answer": 0}, {"article": "Visit http://www.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not quantified. The release says only that the new software \u201ccould decrease delays in care\u2026giving patients a better chance at making a full recovery.\u201d In addition, it\u2019s not clear here if improved response times are purely hypothetical, or if they are based on some sort of study.\nThe release provides no direct information on how the new test results compared to the standard version. Moreover, the study was not intended to see whether outcomes were improved as a result of this new test because it was added to the standard assessment. As a result, it may have actually delayed care for patients included in the study.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not adequately quantify the benefits of the sports drink. The story does say that the protein-containing drink provides 15% more hydration than the conventional sports drink and provides the caveat that this is not a crucial difference for most people, but this is not enough information on the benefits. The story fails to explain the magnitude of the effects observed in the source studies. ", "answer": 0}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nTheir finding is published in the Journal of Neuroscience.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We identified two important problems with the way benefits are described:", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nThere was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did mention that the two approaches to treating acute kidney injury did not have different outcomes and specifically mentioned death rates, recovery of kidney function and rates of other organ failure.\u00a0 The story also mentioned a death rate in one health care system of 50-80% from acute kidney injury. ", "answer": 1}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\nAlthough some objective measures of spasticity noted improvement trends, there were no changes found to be significant in post-treatment assessments.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Absolutely no numbers were provided to give a sense of the scope of the suggested benefit.\u00a0\u00a0 How many people who took the extracts benefited?\u00a0 You\u2019d never know from the story.", "answer": 0}, {"article": "Nothing helped.\nRelated: Placebos Help Kids with Migraine as Well as Drugs Do\n\nKudrow says that there is a reduction in the frequency and intensity of the headaches for a large number of his patients taking the new class of drugs, but not all.\n\u201cIf we can block CGRP, then we can abort a migraine attack,\u201d says Kudrow.\n\u201cIt's not a pill, it's an injection that stays in the system for a long period of time and is continuously blocking that CGRP mechanism of migraine.\u201d\n\nResults from several pharmaceutical trials are expected either later this year or in early 2018.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told only that \u201cpreliminary studies sponsored by one drug maker shows patients had three to four fewer migraine days each month.\u201d Three to four fewer migraine days each month\u2013what was the starting point?\nAnother concern we had was this claim: \u201cIf we can block CGRP [a molecule], then we can abort a migraine attack,\u201d says Kudrow.\u00a0Do scientists really know that blocking this molecule is all it takes to stop migraines in all people who get them? Or does this molecule-blocking action only work for some people, and if so, for whom?\nAlso, it sounds like results from several clinical trials are due out later this year\u2013why not wait to write the story then, when there\u2019s more evidence to assess?", "answer": 0}, {"article": "Newswise \u2014 Baltimore, Md.\n\u201cEarly research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,\u201d says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.\nRadiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.\nOct. 8, 2018 \u2013 The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients.\nAccording to Dr. Vujaskovic, the new deep-tissue thermal therapy equipment, which is made by Pyrexar, will be used to treat cancers of the abdominal and pelvic region, including cancer of the bladder, rectum, cervix, ovaries, pancreas and connective tissue, which are known as sarcomas.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There are no numbers providing context on the claimed benefits, only an assertion that the combined treatments offer \u201ca potential way to boost survival chances for certain cancer patients.\u201d But how much is survival \u201cboosted?\u201d By weeks? Years? And which cancer patients are eligible? The news release broadly states that the hyperthermia equipment will be used to treat cancer in the bladder, rectum, cervix, ovaries, pancreas, and connective tissue, but does not get more specific. \nThere is no information provided about any specific study or data demonstrating the benefits of either proton beam therapy or hyperthermic therapy for patients with these cancers.", "answer": 0}, {"article": "\u201cStillbirth is a hugely underappreciated problem,\u201d he said.\nEven so, Norwitz thinks that \u201cit\u2019s a very healthy discussion to have.\u201d\n\nDue dates are calculated 40 weeks from the first day of a woman\u2019s normal menstrual period and, according to ACOG, full term is defined as a pregnancy that lasts between 39 weeks and 40 weeks and six days.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\nRather, he said, the latest literature suggests that the drugs available to soften the cervix in preparation for contractions help to decrease the Caesarean risk, adding a small caveat: For a small number of first-time mothers with \u201cunfavorable, long and hard cervixes\u201d \u2014 as opposed to cervixes that are soft and receptive to induction \u2014 the risk of Caesarean is increased.\nBefore either doctor spoke, the audience in a crowded ballroom was polled: 63 percent opposed having most women deliver at 39 weeks, 20 percent supported it and 17 percent were unsure.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes advocates of inducing labor at 39 weeks as saying it might lead to fewer Caesarean deliveries and might reduce complications, but no numbers are provided. The story also quotes an advocate as saying the risk of stillbirth and neurological injuries rises after 39 weeks.\nNot only are no numbers cited, there is also no mention of any evidence that inducing labor would change the long-term outcomes for those babies; that is, what if inducing labor earlier prevented a stillbirth, but that baby had underlying problems that lead to death soon after birth? These important questions about how to weigh any potential benefit of inducing labor earlier are not addressed in the story.", "answer": 0}, {"article": "So for many of these women, these medications are life-saving and life-altering.\"\nThe FDA advisory pointed to a single study showing a six-fold increased risk of a condition called persistent pulmonary hypertension in newborns whose mothers were taking antidepressants.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are described in broad strokes but never really quantified. We\u2019re told the FDA, back in 2006, said taking SSRI antidepressants late in pregnancy might increase the rate of PPHN six-fold \u2013 but we\u2019re never told what the absolute rates are. Mentioning a few numbers from the study would have made this story\u2019s look at the benefits more informative.\nFor example, of the 3.8 million women looked at in the study, about 102,000 took SSRI antidepressants. The rate of PPHN for that group was about 31 cases per 10,000 births, compared to 20.8 cases per 10,000 births in women who didn\u2019t take SSRIs.\u00a0The HealthDay story again did this nicely \u2014 it helps to have the overall rate of PPHN, the rate in depressed women not taking anti-depressants, and the rate on non-SSRI anti-depressants for comparison. These figures reinforce the finding that PPHN is uncommon overall, and that the risk in women who take SSRIs is not much higher than in those who don\u2019t.", "answer": 0}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some percentages\u00a0but no absolute numbers. It says:\nThe researchers found fewer and less severe injuries and health problems among the treated children: a 3.6% reduction in sexually transmitted infections; 5.8% fewer children who sought screening for sexually transmitted infections (suggesting they had had an unprotected sexual tryst); and 2% fewer teen pregnancies.\u00a0That adds up to a lot fewer teenagers in trouble.\nThe Princeton news release about the study provides actual numbers related to outcomes, including injuries, which is missing from the Wall Street Journal story even though the story makes a claim about injuries being less likely.\nIn absolute numbers in a sample of about 14,000 teens diagnosed with ADHD, it translates into 512 fewer teens contracting an STD and 998 fewer having a substance abuse disorder. There also would be 6,122 fewer yearly injury cases for children and teens under 19 years old.\nWe would have liked to have seen both types of statistics included in the story.", "answer": 0}, {"article": "Such screening is increasingly used in research.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies only two specific findings from the studies: 30 percent of the patients with mild cognitive impairment (often a precursor to Alzheimer\u2019s) that were screened in one study had no amyloid, and 88 percent of volunteers with any type of Alzheimer\u2019s or other dementia (frontotemporal, vascular or dementia with Lewy bodies) had amyloid in their brains. That\u2019s not much in the way of numbers. And the headline may set unrealistic expectations with its description of amyloid \u201cpredicting\u201d Alzheimer\u2019s. If we\u2019re going to talk about\u00a0\u201cpredicting\u201d Alzheimer\u2019s, then it\u2019s not unreasonable to expect a specific accounting of how often the test is right and how often it\u2019s wrong \u2014 which is something the story doesn\u2019t really get into.\nAs the story later explains (to its credit), the benefits at this point are more in the context of research \u2014 in identifying people who are candidates for clinical trials (which really isn\u2019t a new contribution for this study). These methods are not meant to identify people at risk of Alzheimer\u2019s in the general public.\u00a0The authors of the journal article in dementia patients conclude it has \u201cpotential clinical utility.\u201d", "answer": 0}, {"article": "A fourth drug, GlaxoSmithKline\u2019s and Biota Inc\u2019s Relenza, works by the same mechanism as Tamiflu.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nTests in rats showed Fludase, made by privately held NexBio, could stop parainfluenza viruses from replicating, the researchers reported in the Journal of Infectious Diseases.\nThe rats were pre-treated with the drug an hour before they were infected with parainfluenza.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "       \n \nThe story did not provide any data and did not tell us anything about the cells used or the number of rats included in the study. \nThe story suggests that the test drug, \u201c\u2026could stop the virus from  replicating\u2026.\u201d\u00a0In actuality, the study drug reduced the viral load as  compared to animals treated with a placebo.\u00a0The story fails to note the  small sample (20 rats total) and the limited time of treatment (3 days)  before the animals were euthanized.\u00a0The story fails to place the study  results in context potentially giving the reader a false interpretation  of the study.\n ", "answer": 0}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nAnd the study only showed an association between aspirin use and gastrointestinal cancer risk, not a cause-and-effect relationship.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nHowever, \"if considered alongside the known benefits of aspirin in the prevention of heart attacks and strokes, our data suggest the possibility that long-term regular aspirin use may have a significant benefit in prevention of the two leading causes of sickness and death in the U.S. and much of the world,\" she said.\nThe association of aspirin with reduced cancer risk was the same for women and men regardless of race, history of diabetes, family history of cancer, weight, smoking, regular use of other painkillers or taking multivitamins, the study authors added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The second sentence of the story notes that \u201cthere\u00a0was a 20 percent lower risk of cancers of the gastrointestinal tract, especially in the colon and rectum, among people taking aspirin.\u201d We think that statistic is likely to give readers an inflated sense of the benefits. Instead, we wish the story had presented the absolute reduction in risk for people taking aspirin vs. not. In other words, what was the rate of cancer in the aspirin group and what was the rate of cancer in the no-aspirin group? That would help readers understand if this is a very meaningful reduction, or if the 20% reduction is merely making an already-low risk even lower.", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The nature of the study was to determine if the app was feasible for wider research\u2013and not to see if it was more beneficial than another app (or no app at all) at tracking activity concussion symptoms. For this reason, we\u2019ll give the story a N/A rating on this one.\nHowever, we did want to stress that the story focuses on a secondary finding of the study that makes it sound like it was an intervention trial comparing cognitive activity\u00a0to physical\u00a0activity and their impact on concussion symptoms and recovery. We\u2019re told that\u00a0patients who spent more time reading, playing online games, watching television or working on a computer (so called cognitive activities) reported \u201cmore severe symptoms\u201d on the day they engaged in the activity and two days after. And it stated that more physical activity tended to correspond with fewer symptoms over the following two days. Ordinarily, we\u2019d expect to see that put in quantified terms\u2013i.e., how many symptoms is \u201cfewer?\u201d 1 or 10 or 100?", "answer": 2}, {"article": "Lisinopril is a member of a drug family called ACE (angiotensin-converting enzyme) inhibitors.\nTUESDAY, Jan. 12, 2010 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds.\n\"Also, in brain cells there is more than one kind of angiotensin receptor.\nThe new report describes an observational study, one that lacks the strict controls that are needed for convincing proof.\nBut there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are given only in relative, not absolute terms.\u00a0 See our primer on this topic.\u00a0 So when the story says \"24 percent lower incidence of dementia\" or \"The risk was 19 percent lower\" or \"The risk was nearly halved\" \u2013 readers need to know 24%\u00a0of what?\u00a0 19% of what?\u00a0 Half of what? ", "answer": 0}, {"article": "Diabetes patients' blood sugar levels become abnormally high, causing a host of serious complications including nerve damage, the need for amputations, blindness, and increased risk of heart attacks and strokes.\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nBut a special 10 member panel that was monitoring the study alerted the organizers that 257 patients r eceiving intensive treatment had died, compared with 203 receiving standard treatment, a difference of 54 deaths -- or 3 per 1,000 participants per year, officials said.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nThe new study -- known as the Action to Control Cardiovascular Risk in Diabetes, or Accord, trial -- was designed to convincingly test whether various aggressive treatment strategies reduced the risk of heart disease -- the main cause of death among diabetics.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story differentiated the two groups as having been treated to have blood sugar levels like \u2018the average person with diabetes\u2019 and \u2018closer to those of someone without diabetes.\u2019\u00a0 We would wish for more specific information about what those blood sugar levels were.\nThe point of the story was not that blood sugar levels ought not be treated, but rather what the goal ought to be in order to maximize the benefit of treatment.\n\u00a0\n\u00a0\n", "answer": 0}, {"article": "Most of the men were white and in their mid- to late-60s, on average.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\nHe said that cholesterol is a \u201ckey nutrient\u201d for cancer cells, so lower cholesterol levels in the body could prevent more aggressive forms of cancer from developing.\nWhen they accounted for whether or not men were overweight and their other health problems and medications, it turned out that those with fatal cancers were 63 percent less likely to have ever taken a statin, according to findings published in Cancer.\nBut Freedland said that other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Story explains that those with fatal cancers were 63% less likely to have ever taken a statin, but then goes on to explain that \u201cit\u2019s also possible that statins don\u2019t prevent certain cancers at all.\u201d", "answer": 1}, {"article": "It doesn't cost much.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThat means 66 people would have to get tranexamic acid to prevent one death.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focuses on mortality difference between the TXA and placebo groups and presents the results in absolute terms. It helpfully notes that TXA would need to be adminstered to 66 patients to prevent one death.\nAlthough it passes along the claim that TXA might save \"tens of thousands of people\" without questioning it,\u00a0the story\u00a0doesn\u2019t hype the assertion quite as vigorously\u00a0as the competing coverage.\u00a0\u00a0", "answer": 1}, {"article": "A sunscreen pill?\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nAnd though dermatologists who have experience with Fernblock think it offers a measure of protection, even the manufacturer warns it won't suffice alone.\nWe've long assumed sunscreens will do the trick, but then came reports that the vitamin-A compound (retinyl palmitate) integral to many of them could actually be making us more melanoma-prone.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no attempt to present any quantification of the benefits of Fernblock for preventing burns or, by extension, cancers and photo-aging.", "answer": 0}, {"article": "That's when this work will be most rewarding,\" Boppart said.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\n\"In many cases, you can't tell the difference between cancer cells and normal tissue with the naked eye, but with OCT they're very different,\" said Boppart, who also is affiliated with the Beckman Institute for Advanced Science and Technology at the U. of I.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nThey also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release describes the accuracy of the device as follows:\nThe study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity. They also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\nIt also quotes the study author who says:\n\u201cFor the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\u201d Boppart said. \u201cIt is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out. Then, the surgeon can intervene immediately.\u201d\nWe\u2019re inclined to give the benefit of the doubt given the story\u2019s good-faith attempt to use some numbers to describe the device\u2019s accuracy. However, we think the study itself had many details, not communicated in the release, that would have added to the release\u2019s credibility, understandability, and potential impact. It would have been very useful to know more about how many of the 35 women participating in the study had mastectomies, for example, how many had invasive cancers, in situ cancers, or ductal cancers; and how large a range the tumors covered.\nFor the sake of background, we\u2019d add that breast cancer surgeons used to go after wider margins (i.e. more healthy tissue at the edge of the removed tumor) than they do today. There is a large body of evidence that demonstrates that wider margins do not translate to better outcomes, and the SSO-ASTRO margin guideline statement is now fairly well accepted, noting that \u201cno ink on tumor\u201d is sufficient in many cases of invasive cancer; of course this may not apply to all cases. As more physicians adopt the 2014 guidelines, the utility of these devices may be called into question.", "answer": 1}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nIn this new study, 31 children aged three to eight years of age received a twice daily course of oxytocin in the form of a nasal spray.\n\"We used some of the most widely used assessments of social responsiveness for children with autism,\" said autism expert, Associate Professor Adam Guastella of the Brain and Mind Centre.\n\"We found that following oxytocin treatment, parents reported their child to be more socially responsive at home, and our own blind independent clinician ratings also supported improved social responsiveness in the therapy rooms of the Brain and Mind Centre,\" he said.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release headline says that oxytocin \u201chas social, emotional and behavioral benefits in young kids with autism.\u201d But our reviewers found that claim questionable. Of numerous ratings done, one caregiver-measure of social responsiveness came out as statistically positive, and a clinician-rated measure of Clinical Global Improvement came out positive. Our reviewers did not think it was accurate to report that emotional and behavioral symptoms were affected since none of the measures that specifically evaluated these symptoms came out as positive.\nThe release also says that symptoms in children with autism were \u201csignificantly improved,\u201d but it never quantifies the improvement. We are told only that children were said by their parents to be more socially responsive at home and that independent clinical ratings showed improvements in social responsiveness.\nWhat were the exact measurable benefits? According to the published study, 72% of the patients were rated by the clinical staff\u00a0 to have improved in terms of social interaction and responsiveness compared to 41% who showed such improvement when treated with a placebo. The patents were assessed at baseline and at the end of 5 weeks of treatment.", "answer": 0}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nAll patients were interviewed about diet, health habits and medical history.\nThey found 2,141 people with polyps, leaving 3,166 polyp-free controls.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The language matters.\nThe story states:\u00a0 \u201cThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps.\u201d\u00a0 (emphasis added)\nObservational studies can\u2019t prove cause and effect, so language like this just confuses the communication of the findings.", "answer": 0}, {"article": "When an ultrasound revealed she was carrying a girl, \u201cI was absolutely shocked,\u201c she said.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nOne potential worry is that women might abort fetuses of an undesired sex.\nDr. Diana Bianchi, executive director of the Mother Infant Research Institute at Tufts Medical Center in Boston and the lead author of the sex-determination report, said, \u201cA very important aspect of the study is how this advances prenatal care.\u201d\n\nBut there are potential concerns too, she said, including that women may spend more than $250 for the tests when they don\u2019t have insurance for prenatal care.\nAt least one company, Consumer Genetics, which sells the Pink or Blue test, requires customers to sign a waiver saying they are not using the test for that purpose.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Parents who fear their child may inherit gender-linked disorders, such as hemophilia, could use this test earlier in pregnancy and possibly avoid more invasive procedures, such as amniocentesis. Amniocentesis carries a risk of miscarriage. We would have liked some numbers about how many women in the US are facing this dilemma; the situations that carry benefit are few. The average gestational \u201cage\u201d at enrollment in prenatal care in the US is after the window in which most of these tests are marketed. So that means if a couple did not know that they needed to think about X-linked mental retardation \u201cfragile X\u201d (which affect males) or hemophilia, the use of the test would not really be integrated into their care. Could have been more skeptical of why they are really being marketed \u2013 closer to entertainment ultrasounds than medical care.", "answer": 0}, {"article": "In addition to fruit and vegetables, the DASH diet recommends fat-free or low-fat dairy products and limits foods that are high in saturated fats and sugar.\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\nFor the study, 964 participants with an average age of 81 were evaluated yearly for an average of six-and-a-half years.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\u201d\u00a0 Here the release is relying on relative risk reduction figures which are far less meaningful to patients than numbers that explain the absolute risk reduction.\nWe also are left wondering how closely the \u201ctop group of DASH adherers\u201d followed the DASH diet? To what extent did that differ from the \u201clowest group\u201d?", "answer": 0}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\nEfficacy Results in APOE4/4 Homozygous Patients from the JPAD Phase 3 Analyses\n\nThe published results showed the largest clinical benefit in the Alzheimer's APOE4/4 homozygous AD patients, who represent approximately 15 percent of patients in the study.3 APOE4/4 homozygous patients who received the high dose of tramiprosate showed efficacy benefit compared to placebo on both cognitive and functional measures in the Phase 3 analyses.\nIn these new subgroup analyses, the high dose of tramiprosate showed promising clinical effects in APOE4/4 homozygous AD patients already receiving maximal standard of care, and this dose was not associated with any events of vasogenic edema,\" said Susan Abushakra, MD, Chief Medical Officer of Alzheon and lead author on the JPAD publication.\n\"APOE4/4 homozygous AD patients are especially challenging since they are known to have the highest burden of amyloid pathology in cerebral cortex and blood vessels, which explains their susceptibility to ARIA-E with some amyloid-targeted treatments.\nThese effects were supported by functional benefits on the CDR-SB that showed a positive trend at Week 65 (LS means difference from placebo: 0.79, nominal p = 0.063) and were numerically in favor of tramiprosate at Week 78 (0.54, nominal p = 0.21).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that there is a \u201cmeaningful clinical benefit\u201d to the study medication, known as tramiprosate.\nBut we couldn\u2019t find a meaningful description of the benefit in clear language. What we did find was a densely technical section where effects were described as follows:\n\u201cThe effects on the ADAS-cog cognitive outcome were significant at Week 65 (LS means difference from placebo: 3.47, nominal p = 0.007) and Week 78 (2.60, nominal p = 0.043), and corresponded to 66 percent and 40 percent benefit from tramiprosate compared to placebo. These effects were supported by functional benefits on the CDR-SB that showed a positive trend at Week 65 (LS means difference from placebo: 0.79, nominal p = 0.063) and were numerically in favor of tramiprosate at Week 78 (0.54, nominal p = 0.21).\u201d\nBut even if the p values here were significant, this analysis would not mean the drug showed benefits.\nThe study itself \u2014 not the release \u2014 contains some helpful context on the sub-group analysis that might have improved the release.\n\u201cDrug effects in AD trials are considered clinically meaningful if they provide at least 25% benefit over placebo. The cognitive effect of the 150 mg BID dose in APOE4/4 AD patients corresponds to 40% benefit over placebo at week 78, and is thus clinically meaningful. This cognitive effect is also supported by positive trends on global function, which corresponds to 25% benefit on CDR-SB at the week 78 endpoint, as well as a numerically consistent effect on disability with 25% benefit on DAD. \u201c\nA news release is intended to communicate with a non-technical audience of news professionals but this release fell short of translating the science well. We would have liked some discussion of how the \u201ccognitive effect\u201d is measured in these patients. What exactly is a positive trend in global function? Some examples could have helped. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that patients with sciatica got better faster if they had disc surgery. But it does not say how much better or how much faster\u2014very important information. For example, patients actually had worse disability scores at 4 weeks if they had disc surgery. The greatest advantage for surgery was between weeks 8 to 12, and surgery continued to speed recovery only through week 36. The story also does not quantify the benefits of treatment for patients enrolled in the second study on degenerative spondylolisthesis and stenosis. If it had, readers might come away with a more nuanced message about the efficacy of both surgery and nonoperative therapies. (See also \u201cEvidence\u201d above.) For example, the majority of patients receiving nonsurgical care showed \u201cmoderate\u201d improvement, a fact the news story never mentioned but the study reported in both absolute and relative estimates. And when the researchers analyzed patients in the randomized cohort according to the treatment they were assigned (\u201cintention-to-treat analysis\u201d), they found no differences in the outcomes of the surgical and nonsurgical care. When they analyzed patients according to the treatment they actually received (\u201cas-treated analysis\u201d), they saw big differences. As the accompanying editorial in the New England Journal of Medicine by Richard A. Deyo points out, the truth probably lies somewhere in between. ", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nObesity surgeons, Fielding included, report a high success rate for the bypass.\nThe ability to control the tightness is presumably part of the reason that patients who opt for banding lose less weight, at least initially, than gastric bypass patients -- an average of 50 to 65 percent of their excess weight in the first three years.\nWhen the 6-foot Thayer edged up to 310 earlier this year at age 45, he decided to go for a second operation: adjustable banding, more commonly known as lap-band surgery, which allows for repeated stomach-tightening and thereby offers a new opportunity for reining in appetite.\nOf course, a second obesity surgery comes with increased risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story indicated that gastric banding may re-impose limitations on caloric intake that had initially been established with gastric bypass. \u00a0While it indicated that good long-term data about the utility of banding after bypass was not available, this was overshadowed by the examples of the weight loss seen in a few individuals it detailed. \u00a0", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\nAn endometriosis pain treatment was just approved by the Food and Drug Administration, and it\u2019s expected to arrive at pharmacies as soon as August.\nIn the trials, women who took the drug had greater bone loss than did those who received placebo, and this wasn\u2019t entirely surprising.\n\u201cIt\u2019s a major advance,\u201d said Dr. Louis DePaolo, head of the fertility and infertility branch at the National Institute of Child Health and Human Development, \u201cand another option women have that\u2019s effective.\u201d\n\nNow the less good news: The drug won\u2019t cure endometriosis; it\u2019ll only tamp down the pain it causes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story needed to include more information about the study results\u2013in particular, how both the drug and the placebo performed in the trials.\nAs we learn from the NEJM study, the drug reduced pain for about half of the women who took it\u2013but the placebo also reduced pain for about 35% of the women who took it. That\u2019s a good detail to include as it provides a better sense of the drug\u2019s effectiveness.", "answer": 0}, {"article": "Cardiac fibrosis itself is caused by a variety of factors including high blood pressure, overwork of cardiac muscle and long-term consumption of a diet that is high in both saturated fat and sugar--all cause increased stress to heart cells.\nThe bottom line is that this shows for the first time that cardiac fibrosis is preventable.\"\nImproving their quality of life will do wonders for these individuals.\"\nThis research was supported by the Canadian Institutes of Health Research.\n\"Prevention of fibrosis will extend the ability of the heart to function, even if at a reduced capacity.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Beginning with the headline (\u201cCanadian discovery may soon lead to the prevention of cardiac fibrosis\u201d) and first sentence (\u201cGroundbreaking research from the University of Alberta and McGill University\u2026\u201d) the release over reaches in its description of benefits \u2014 at least to humans, transgenic mice however should be thrilled.\nJumping directly from a mouse model to humans is simply wrong in our view. \u00a0As we pointed out above, suggesting that a drug in a pre-clinical study \u00a0\u201c\u2026offers hope to those who are living with heart failure,\u201d \u00a0given the long and arduous process of regulatory approval does a disservice to people living with the disease.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nDecrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.\nThe SBRT study for prostate cancer was supported by a grant from the U.S. Department of Defense.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is an odd news release. The study, described as a Phasel/ll, was conducted to assess the safety of escalating doses of radiation with the goal of determining whether varying doses of SBRT had an acceptably low rate of\u00a0toxicities. The study was not intended to\u00a0provide any definitive assessment of survival benefit, and yet that\u2019s what the release is about.\u00a0 It states:\n\u201cThe study \u2014 the first trial to publish five-year results from SBRT treatment for prostate cancer \u2014 found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\u201d\nThe \u201ccure\u201d rate referred just to men who had no evidence of rising PSA \u2014 and the study acknowledges that most men were not actually followed for 5 years so\u00a0\u201ccure rate\u201d was statistically estimated. \u00a0However, over a third of the men had low-risk cancer where the 5-year cancer-specific survival is estimated to be 100 percent. It\u2019s not certain that these men actually required treatment.\nBeyond that, the release did not quantify benefits precisely. There was only one sentence directly addressing the study results. There was no description precise study group demographics. The release does not define \u201ccure\u201d as it is used in the sentence below and the headline.", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nA 2006 multicenter double-blind randomized controlled trial that compared bright-light therapy head to head with the popular antidepressant Prozac (fluoxetine) in 96 subjects found the two treatments equally effective for alleviating winter depression, though light produced results faster, usually within a week, and with fewer side effects.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did not provide any quantified detail about the results of using light therapy for seasonal affective disorder. It quoted two patients, anecdotally, about how much they believed they had been helped. It quoted the American Psychiatric Association as saying the therapy is \u201can effective low-risk treatment\u201d for both seasonal and major depressive disorder. But it did not give any metric for how well the treatment works, or how quickly or for how long.\u00a0 How many patients getting light therapy get a little bit better?\u00a0 Much better?\u00a0 No better?", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "What we especially appreciated was the tone and the framing of the story.\nIt didn\u2019t call this idea a treatment.\u00a0 It called it a \u201cpotential treatment.\u201d\u00a0 It\u2019s not a treatment until it\u2019s been shown to actually treat someone for something.\nIt used the word \u201cpotential\u201d three times in the story.", "answer": 1}, {"article": "They also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story never really provides any data on the risk reduction seen in women with BRCA1 or BRCA 2 mutations due to removal of their ovaries and breasts. Readers are advised that removal of ovaries reduces risk of breast cancer, but no mention is made of the reduction in risk of ovarian cancer. Risk is not totally eliminated.", "answer": 0}, {"article": "Traditional heart catheterization through a vein in the neck can take 20 minutes or longer.\nReavill likes to say it's \"stupidly simple\" because the individual parts have been around for decades, but no one had thought of this particular configuration before.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nIt remains to be seen whether that saved time will result in saved lives.\n\"You get an objective number and it becomes less art, less gestalt and more evidence-based.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that the catheter:\nBut there isn\u2019t one piece of data \u2013 of evidence \u2013 presented in the entire 718-word story.\u00a0 That\u2019s not a short story these days \u2013 so there was plenty of space afforded.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe study was a small one and deserves many cautions in its interpretation. The authors of the study for example, noted, \u201c\u2026these findings suggest that brain imaging may play a valuable role in neuroprognosis\u2026.\u201d Compare that caution conclusion with, \u201cScientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\u201d Although the study did not speak to any interventions, the story suggests otherwise in a subheading, \u201cStudy Suggests Interventions to Help Dyslexics Learn to Read.\u201d\u00a0 ", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not present quantitative evidence, but rather presents qualitative viewpoints of experts.", "answer": 0}, {"article": "Paul is on Procter & Gamble's advisory board but holds no stock in the company and will not profit financially.\nChildren in all three groups got better, but those treated with the VapoRub saw the greatest improvement, and parents in this group also had improved sleep, the study found.\nBut as with any product, parents need to read the instructions carefully and keep medicines out of the reach of children.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\nNow, new research reported in the journal Pediatrics finds, the combination of camphor, menthol and eucalyptus oils actually does ease cold symptoms and help children suffering from upper-respiratory infections sleep.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not tell readers how much of a difference there was between the treatment groups. The parents did report improvements, but readers can\u2019t tell from this story just how much. The story would have been better if it pointed out that the parents were asked to rate symptoms on a seven-point scale. For instance, the effect on sleep ranged from 1 or \u201cnot at all much\u201d to 7 or \u201cvery much\u201d and the VapoRub on average nudged the symptoms just one point more than the petroleum jelly. What does it mean to feel one point better on this scale? The vague description of the relative improvement might lead readers to believe the differences were dramatic.", "answer": 0}, {"article": "That\u2019s not all.\nHere\u2019s how it compares to its predecessor Zostavax, which over all reduces the risk of shingles by 51 percent and of PHN by 67 percent.\nBut for about 15 percent of people, shingles does not end there.\nAccording to the C.D.C., Shingrix can protect 97 percent of people in their 50s and 60s and 91 percent of those in their 70s and 80s.\nAlthough most people get shingles only once, it can happen again, especially if you have a weakened immune system, which most everyone does with advancing age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides relative numbers, noting that the previous shingles vaccine, Zostavax, \u201creduces the risk of shingles by 51 percent and of PHN by 67 percent\u201d, but this new vaccine, Shingrix \u201ccan protect 97 percent of people in their 50s and 60s and 91 percent of those in their 70s and 80s. It also reduces the risk of PHN by 86 percent.\u201d\u00a0\nBut what does this mean in terms meaningful to readers, such as absolute numbers? According to a clinical trial published in the New England Journal of Medicine, of the\u00a06,541 people who got the vaccine, 23 developed shingles (about 0.35%). Of the 6,622 who got the placebo, 223 people got shingles (about 3.4%). This difference, of 3.36%, means that for every 29 people over age 70 who get the two-shot dose of Shingrix, one case of the shingles will be prevented. Another way to say this is 28 out of 29 people will see no benefit from the vaccine over three and a half years. The numbers needed to vaccinate to prevent one case of postherpatic neuralgia is more than 200.", "answer": 0}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\n\u201cWhat we learned is there is a significant amount of radiation with these CT scans, more than what we thought, and there is a significant number of cancers,\u201d said Dr. Rita Redberg, editor of the Archives of Internal Medicine, where the studies were published.\nThey found radiation dosage varied widely between different types of CT studies, from a median or midpoint of 2 millisieverts for a routine head CT scan to 31 millisieverts for a scan of the abdomen and pelvis, which often involves taking multiple images of the same organ.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nA third of the projected cancers will occur in people who were ages 35 to 54 when they got their CT, two-thirds will occur in women and 15 percent will arise from scans done in children or teens.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Because the story focused on the cancer risk associated with radiation exposure from CT scanning, it would not be necessary for the story to also quantify the benefits of CT scanning. How the story could go about quantifying the benefits of something so generic as CT scanning is also not clear.", "answer": 2}, {"article": "\"Schizophrenia is a devastating disorder, probably the most disabling disorder long term.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nIn the just-published study, the researchers evaluated 50 participants: 25 with schizophrenia and 25 with no diagnosed psychiatric disorder.\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\nIn the study, published in the May 2018 issue of the Journal of Abnormal Psychology, researchers used RETeval, a hand-held device developed to record electrical activity from the retina, to replicate and extend prior studies showing that people with schizophrenia had abnormal electrical activity in the retina.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release stated the results \u201cshow the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\u201d\nPresumably this meant that all of the patients with schizophrenia were identified, but there are no numbers. Also, the news release didn\u2019t explain whether the device accurately ruled out schizophrenia in those who didn\u2019t have it.\nThe news release and scientific article both referred to group (averaged) data, which is distinct from individual diagnosis.", "answer": 0}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n\"Folate intake had a positive association with academic achievement\" in the students studied, the authors wrote in the report published in the July 11 online edition and the August print issue of Pediatrics.\nThe researchers also looked at any possible effects of socioeconomic status and genetics.\nIn previous studies, folic acid levels have been linked to mental ability; however, until now this had not been linked with improved school performance, the study authors said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not quantify the improvement in scores as was done in the Reuters story.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "For balance, an estimate of the benefit of statin use should have been presented.\u00a0 While the story did mention that statin medications provide benefit from heart disease, it did not provide any estimate for the magnitude of this benefit.", "answer": 0}, {"article": "Newswise \u2014 Human papillomavirus-positive oropharynx cancers (cancers of the tonsils and back of the throat) are on rise.\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release did include some quantification of benefits, but we would have liked a bit more. Here is what was provided:\n\u201cThe study\u2026showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation.\u201d\nThe release would have been improved with a discussion of how \u201cless difficulty\u201d\u00a0and\u00a0\u201cimpaired nutrition\u201d were measured.\nThe published\u00a0paper makes it clear that the swallowing difficulties and nutritional impairment were self-reported using a questionaire of some kind. This also would have been useful information to include in the release.", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says that the research showed \u201csignificant increases in thalamic functional connectivity\u201d but fails to quantify the extent of those increases. Nor does it show that increased connectivity improves the patients\u2019 quality of life, although it certainly suggests that outcome. More important for patients, the release states, \u201cThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function\u2026\u201d This improvement is not quantified, nor is it put into a perspective where the patient can know what this may or may not mean in terms of life functioning (see quality of evidence section).", "answer": 0}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nAnd the leptin study suggests that the weight loss solution may eventually be a pill that tricks the brain into thinking that no weight has been lost.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\nAnd the scientists measured the effects of weight loss on the sympathetic nervous system, documenting lower levels of adrenaline in urine.\nDr. Michael Rosenbaum, the lead investigator, said the 10-week study was too short and too small to determine whether continuous leptin treatments could allow dieters to keep off their weight permanently and effortlessly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented as a benefit that leptin increased number of calories used during low level \nactivity. But it fails to mention that at higher levels of energy expenditure, this effect was not observed. ", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes clear to readers that it has no idea about the extent of the benefits: \u201cWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival.\u201d We\u2019re glad that the story makes its ignorance clear, but it raises the very serious question of why they would cover a story about which so little information is available.", "answer": 0}, {"article": "Espey agreed.\nFor women who may be hesitant to use an IUD because of pelvic infections linked to an early version called the Dalkon Shield, Gupta said that as long as women are screened for sexually transmitted diseases before getting an intrauterine system, the risk of infection is low.\n\"If women suffer with heavy periods and do not want to get pregnant -- as the levonorgestrel intrauterine system is a contraceptive -- then having the levonorgestrel intrauterine system is a very good first-line treatment option that does not require taking regular, daily oral medications,\" said the study's lead author, Dr. Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England.\nThe current study compared the use of traditional medical options -- tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone alone -- to the use of the levonorgestrel intrauterine system.\nWEDNESDAY, Jan. 9, 2013 (HealthDay News) -- Women with heavy menstrual bleeding may find some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to new research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that women using Mirena improved 32.7 points compared with 21.4 points on a symptom scale. \u00a0Unfortunately, it\u2019s not clear what symptoms were being measured.\nThe symptom scale reports a combined score that represents the effect of heavy menstrual bleeding on physical and mental health, daily life, and other areas. Researchers like scales because they are easier to work with statistically, but they don\u2019t measure something we can understand intuitively. This rating is a tough\u00a0call because the researchers themselves used a quantitative, validated measure that is virtually meaningless to readers (and confusing to doctors).The best we can say is that the story accurately reported the findings, but the outcome measure was difficult to interpret. And health care stories often need to do more than regurgitate what researchers report, but to offer some interpretation.", "answer": 0}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\nBut PSA testing is problematic because it has low specificity, which generates high false positive rates and leads to unnecessary surgical and radiotherapy treatment.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\n\u201cAn accurate, reliable urine test for prostate cancer would be an invaluable tool if it is proven to be successful on a large scale.\u201d\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers could extrapolate that if the MSMB test results are demonstrated to be reliable and reproducible, then it could be expected to reduce the number of men treated for prostate cancer who likely would never suffer ill effects from the disease.\u00a0 However it is appropriate to withhold some enthusiasm until the test\u2019s performance is demonstrated to live up to its potential. And, true to what we expect in this criterion, the story never explained the sensitivity or specificity of the test in absolute numbers; it only used unhelpful general terms such as \"found at significantly lower levels.\"\u00a0 How often?\u00a0How reliably? All the time? ", "answer": 0}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nDr. Wulf H. Utian, medical director of the North American Menopause Society, agrees that many reasons may underlie the lack of treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is ostensibly about the findings of a survey which found that women with moderate to severe menopausal symptoms aren\u2019t being treated for those symptoms. While those results are adequately quantified, the story never quantifies the claim, made three times in the text of the article, that alternatives to HRT are \u201ceffective\u201d for reducing these symptoms. What evidence supports that claim and what do the numbers say? Which treatments is the story talking about? It refers to \u201cnon-hormonal options,\u201d which might include a variety of supplements that are advertised for menopausal symptoms. Such\u00a0complementary therapies are almost uniformly poorly studied in small, uncontrolled trials. Being more specific here would have been very helpful for readers.", "answer": 0}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\nFirst, they might not know about the guidelines.\n\u201cA woman should say, \u2018What screening tests are you doing on me?\u2019\u201d\n\nAnd if doctors want women to come back again next year, women should ask them why, Saraiya said.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The story wasn\u2019t about benefits, but rather, the suggested lack of benefit from screening too often.", "answer": 2}, {"article": "Cleveland Clinic's health system includes a 165-acre main campus near downtown Cleveland, 10 regional hospitals, more than 150 northern Ohio outpatient locations - including 18 full-service family health centers and three health and wellness centers - and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\n\"Due to its inherent simplicity, requiring only a blood draw and presenting information to the physician in familiar context using a single number - just like PSA itself - we are quite hopeful in IsoPSA's future utility after further validation studies,\" said Mark Stovsky, M.D., co-author and staff member, Cleveland Clinic Glickman Urological & Kidney Institute.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release uses vague, comparative language to describe the benefits of the new blood test, such as IsoPSA may \u201csubstantially reduce\u201d the need for biopsy and IsoPSA proved \u201csignificantly superior\u201d to PSA. Here, the word \u201csignificant\u201d is ambiguous because it means \u201cstatistically significant,\u201d instead of the colloquial meaning of the term.\nIn addition, IsoPSA could \u201csignificantly reduce the rate of unnecessary biopsies by almost 50 percent.\u201d Instead of relative terms, we prefer benefit data to be written in absolute reduction risk to provide a more accurate impression of how effective the new test really is. Even if the journal article reports its results relatively, we still expect the writer to follow up with the researchers and provide some quantitative data for readers.\nBasically, the study used\u00a0the gold standard of the biopsy result to compare PSA (the current test) to IsoPSA (the new test). The study itself provides numbers for the sensitivity and specificity of these two tests to detect any cancer as well as to detect higher risk cancer. These numbers could have been provided and explained.\nWithout any raw numbers, it\u2019s hard for us to judge whether IsoPSA is indeed more accurate than PSA. We give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City.\nSelvin's group analyzed that data, and reported that a positive result for glucose and HbA1c from just a single blood sample can confirm type 2 diabetes.\n\"Diabetes moves fast, and the cost of diabetes has increased more than 20 percent since 2012,\" noted Dr. Robert Courgi.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story referred to the potential for a single test to result in quicker diagnosis and treatment of diabetes, thus \u201csaving patients time and health care costs\u201d and leading to better outcomes.\nBut it offered no data on how much more rapidly diagnosis and treatment might occur with single-sample testing, or more importantly how much difference it would make in heading off the many complications of diabetes.\nAccording to the news release, 90% of those who tests positive in both tests went on to be diagnosed with diabetes within 15 years.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the story, kratom users and advocates say the herb \u201chelps to relieve pain, gives a mild boost like coffee (the tree is part of the coffee family) \u2014 and can even help ease the pain of opioid withdrawal.\u201d\nThese benefits aren\u2019t quantified, but that\u2019s because there is no good-quality research that demonstrates those benefits. The story calls attention to the lack of evidence on kratom, which is why we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nThey do not know whether the radiation from the CT scans may raise the risk of cancer, and they do not know what the study means for light smokers, younger people, or those who have never smoked.\nAs of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presented some of the raw, absolute numbers, although we wished it had gone further. It says, \u201cAs of last month, 354 people who got CTs had died of lung cancer, compared to 442 who got ordinary X-rays. This worked out to a 20.3 percent lower risk of dying for the spiral CT group and the researchers stopped the study.\u201d What it should have added was\u00a0that, assuming 50 percent of all participants were put in each group, that would mean 1.32% died in the CT scan group and 1.65% died in the X-ray group. That\u2019s an absolute difference of 0.33%, not quite as exciting as a 20% reduction in deaths. Also, the number of people needed to treat to save one life (or NNT) is 304. That may be a justifiable number for added investment in spiral CT scans, but it should be part of the discussion. Nonethless, we\u2019ll give it the benefit of the doubt on this criterion.\n", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story made health claims without reference to data supporting the claims. \u00a0In fact, the medical literature does not support the claims made in this story.", "answer": 0}, {"article": ".\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nThey compared the benefits of using electro-acupuncture (the application of a pulsating electric current) to prescribing gabapentin, an anti-seizure medication frequently prescribed to treat sleep disturbances related to hot flashes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release stated that the use of electro-acupuncture was \u201ccomparable to, if not better than\u201d the drug (gabapentin) that was used in this comparative study in reducing \u201chot flash severity and frequency and improving overall sleep quality.\u201d\u00a0 This kind of vague statement doesn\u2019t help readers looking for some quantification, or degree of change, provided by this alternative therapy.\nThe release also states that \u201calthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be.\u201d\u00a0 But again, there is no scale of benchmark provided which would\u00a0help a reader gauge the effectiveness, and therefore the worth, of trying electro-acupuncture.", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\n\"The results were similar regardless of whether the men took one capsule or three,\" Carducci tells WebMD.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This is the crux of our criticism.\nThe story states:\u00a0 \u201cAt the start of the study, the men\u2019s PSA levels were doubling every 12 months. After six months of taking the capsules, it took 19 months for their PSA levels to double.\u201d\nSo what?\nAs one independent expert points out, \u201cit\u2019s never been proven that slowing down the PSA doubling time improves a patient\u2019s prognosis.\u201d\nSo why the headline suggesting that the pills fight prostate cancer?\nThe story also should have reported whether the differences between the groups were statistically significant and/or clinically meaningful.", "answer": 0}, {"article": "Harder\u2019s PSA was 9.\nAn MRI can also help determine how aggressive a tumor is, Yu said, and indicates if the tumor extends outside of the prostate and involves other areas \u2014 all information that helps urologists and radiation oncologists determine the best course of treatment.\nHe estimates the volume will continue to increase because VCU will attract patients not only from the Greater Richmond area but also patients such as Grandon from other parts of the country.\n\u201cIf we put those characteristic features together from each sequence then we can say with a high degree of confidence that this area is concerning for cancer and potentially target it for biopsy,\u201d said Sarah Winks, M.D., an attending physician in the Department of Radiology.\nEach of the sequences \u2014 T2 weighted imaging, diffusion-weighted imaging and dynamic contrast enhanced imaging \u2014 tells a story, and together they can be used to make a diagnosis with more than 90 percent accuracy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release offers some solid data along with confusing statements. It says MRIs and targeted biopsies have \u201cprovided relief\u201d for patients who have not been able to get an accurate diagnosis, citing data from the 2015 NCI study that showed targeted MRI biopsies detected 17 percent fewer low-risk tumors than standard biopsies. It says MRI \u201cis 30 percent more accurate\u201d in diagnosing high-risk, aggressive cancers than a standard biopsy, a misstatement. The study actually says MRI-guided biopsies \u201cdiagnosed 30 percent more high-risk cancers.\u201d\nThe news release tells readers that VCU performs about 1,200 MP-MRI-guided biopsies annually, which is useful information. But it also claims a \u201cmore than 90 percent success rate\u201d without ever explaining what that means or where the number comes from. It even quotes a patient who says he compared \u201csuccess rates\u201d at various medical facilities. Where did the patient get his figures, and what do they mean? We aren\u2019t told.\nIdeally one would like to read the sensitivity and specificity of the test \u2014 the parameters that make up a test\u2019s accuracy. Sensitivity is the test\u2019s ability to identify those who have the disease, and specificity refers to the test\u2019s ability to exclude those who do not have the disease.\nAnother statement implies that VCU\u2019s procedures are superior to \u201cmost\u201d hospitals because they have a single professional reading results and performing biopsies. There\u2019s no data to back this up.\nThe news release includes two glowing anecdotes involving patients whose cancers were promptly detected at VCU and safely treated. Were there other patients who traveled to VCU only to come away with an inconclusive finding, a negative finding, or a fatal tumor?", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the benefit in terms of an intermediate outcome, A1C. The study tells how many participants achieved an A1C < 7% by taking the new drug plus metformin vs. metformin alone. However, the story could have pointed out that the study was short-term (6 months), so it's not clear what long-term outcomes might be. While the absolute benefits are provided, the story lacks context. ", "answer": 0}, {"article": "But this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\nExposure to ACE inhibitors early in pregnancy nearly tripled the risk of birth defects, the study showed.\nThe number of women taking them early in pregnancy is unknown but probably is small, the study suggests.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nA popular class of blood-pressure medications thought to be safe in the first trimester of pregnancy appear to have caused serious birth defects in about 7 percent of babies whose mothers took them, a new study has found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was no quanitification of possible benefits to the mother for using this drug during the first trimester of pregnancy. In some women the risks of taking the drug may be less than the risk of undertreatment. ", "answer": 0}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nAccording to Servan-Schreiber, herbs and spices such as garlic, turmeric, rosemary, thyme, mint, and green tea help make the body less fertile for cancer.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not attempt to quantify the benefits of a healthy diet in terms of cancers prevented or improved survivorship.", "answer": 0}, {"article": "Holick.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states skin samples exposed to RayVio\u2019s UV LED produced \u201cmore than twice as much vitamin D3\u201d after 0.52 minutes compared to samples exposed to 32.5 minutes of sunlight.\nWe applaud the news release for giving readers absolute values for the time instead of providing relative figures. However, we\u2019re not sure from the news release exactly how much vitamin D3 was produced in these samples. And how was this measured? Was there any variation in the amount of vitamin D3 produced depending on the wavelength and skin type?\nIn the original journal article, researchers looked at the percent conversion from an intermediate chemical compound to previtamin D as a way to measure vitamin D production.\nSince benefits data were only half released, we rate this one Not Satisfactory.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Dr. Batzofin discusses his own \"numbr needed to treat\" in order to consider IVM a success (20 to one pregnancy), however, this seems arbitrary. The story should include the typical success rate of IVM compared with IVF and with other fertility treatment methods.\u00a0 There is no sense of valid expected outcomes from data. Doing this story when even the outcomes of the first three transfers is unknown is showmanship not reporting. ", "answer": 0}, {"article": "The thought never crossed my mind.\nStudies show that for kids' ear infections, antibiotics work better than waiting\n\nBeing a parent these days sometimes entails this hypocrisy: Yes, I know overuse of antibiotics is creating superbugs that may soon conquer the universe.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Insufficient data here. The blog says antibiotics are \u201cmore effective than placebos in relieving ear-infection symptoms.\u201d But the question is how much more effective are they and\u00a0does this\u00a0difference outweigh the downsides of treatment? The story could have helped readers answer this question by providing\u00a0some data on the absolute rates\u00a0of improvement reported in the\u00a0these studies.\u00a0Had it done so, readers might have observed that in one of the studies, rates of symptom resolution were 80% in the antibiotic\u00a0group after 7 days compared with 74% in the placebo group. This\u00a0might have opened\u00a0the door to a discussion of whether this 6% difference\u00a0is worth the potential risks of antibiotic therapy. Or, the story could have pointed out in the second\u00a0study,\u00a0only 18.6% of antibiotic children failed to get better by day 8,\u00a0compared to 44.9% of the placebo group \u2014 a much bigger benefit for antibiotics.\u00a0This may have prompted an exploration of the differences between the studies (for one thing, the second study was conducted in Finland, whereas the first was done in Pittsburgh) and consideration of which study\u00a0may be more representative of the benfits\u00a0readers can expect for their children. \nThe author\u2019s reliance on an unrepresentative personal anecdote about her 17-year-old daughter also deserves comment. The story suggests that the study data from infants and toddlers somehow vindicate the author\u2019s decision to procure antibiotics for her daughter. This is an extremely tenuous connection, made worse by the closing suggestion that parents are always justified in asking for antibiotics without thought to creating \u201csuperbugs.\u201d Careful consideration of benefits and harms is the cornerstone of good health care decision-making. \u00a0 ", "answer": 0}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did quantify the potential benefits, but it did so in a way that was all over the map. At first it says, \u201cWhen taken within the first 24 hours of symptoms, results from six trials showed that using zinc lozenges or syrup appeared to shorten the duration of a cold by about a day.\u201d But later it says, \u201c\u2018Usually it takes about eight days for a cold to disappear,\u2019 Prasad says, \u2018but with zinc, it cuts down by about 50%.\u2019\u201d\u00a0And then there is the absolute difference versus relative difference problem. The story never presents the data in absolute terms. \u201cAn analysis of two combined studies, representing more than 1,500 people, found about 40% fewer colds in those who were taking zinc supplements to prevent colds compared to those taking a placebo.\u201d Does that mean 10 people had colds in the placebo group, and 6 had them in the zinc group? It would be good information for readers to have because with a number like 1,500, people might leap to the assumption that hundreds of people avoided colds by taking zinc.", "answer": 0}, {"article": "\"Huge room exists for further improvement.\"\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\nBut, she said, nutrition research like this has limitations because it relies on people's memories of what they ate.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The major claim in the story is that better diets prevented more than one million premature deaths. But as noted above, this is an estimate based on a model derived from observational studies. Although better diets may be associated with lower death rates, there\u2019s no way to tell based on these studies whether dietary changes caused the benefits that the story claims. The coverage should have been clearer about this.", "answer": 0}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nCognitive behavioral therapy and educational treatment can be highly effective for some patients and the impact of a more certain prognosis would be especially beneficial for children.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Many of the deficiencies discussed above in the \"Evidence\" criterion could also be applied to this criterion.\u00a0Importantly, the story\u00a0didn\u2019t do enough to call attention to the small and highly selected sample of patients, which likely\u00a0biases the results towards greater accuracy than what would be observed in a larger and more diverse sample.\u00a0There was\u00a0also inadequate acknowledgment of the fact that this was a study of adults whereas the real need is\u00a0for diagnostic tool for use in\u00a0children. Yes, it was acknowledged that the childrens\u2019 studies hadn\u2019t been done but the outcome of these not-yet-done studies was almost treated as a fait accompli. Lastly, we\u00a0would like to have seen some discussion of a somewhat subtle but important issue that wasn\u2019t addressed.\u00a0That is, whenever we diagnose a condition with new technology, the group of individuals identified as having the condition, in this case autism, will change.\u00a0Some previously undiagnosed children will be labeled with autism and some previously labeled with autism will be told that this is not the diagnosis. In addition, the severity of the disease may change (a more sensitive test will likely identify milder cases). Anytime the spectrum of disease changes, we have to ask ourselves, Will the treatments produce the same benefits and harms? Since benefits are often smaller for individuals with milder disease but the adverse effects are the same, the risk benefit ratio often\u00a0increases with the more sensitive test.\u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nOnly now are our algorithms capable of supporting those caregivers.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\nThe researchers extracted and analyzed verbal and non-verbal language from the data.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told the algorithm can identify someone who is actually suicidal with \u201cgreat accuracy.\u201d\u00a0And it also throws out a few numbers, including that it\u2019s \u201cup to 93 percent accurate\u201d\u00a0(from a read of the study, this is in a combined group of kids and adults when assessed on speech) and \u201c85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\u201d\u00a0But, these numbers in and of themselves don\u2019t provide enough information to make sense of the findings: What are they being compared against? How has it been decided that these measurements are correct?", "answer": 0}, {"article": "Lowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAs mentioned above, the story implies that the degree of improvement in the control of blood sugar levels reported by the researchers will reduce the risk of eye, kidney and heart disease, even though these health outcomes were not measured. Although control of blood sugar levels is a widely accepted target of diabetes treatment, the trial did not measure whether or not there were any noticeable improvements in real health outcomes.", "answer": 0}, {"article": "The Biggest Loser diet and the DASH diet came in second and third, respectively, in the diabetes category.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives a nod to some of the diet\u2019s benefits (it\u2019s called \u201cheart healthy,\u201d for example) but offers no hard numbers on what that means in terms of outcomes.\nThe story gives only relative rankings of the various diets. It is unknown if the second best diet is only microscopically worse than the first, or dramatically substandard. There is no indication of range.\u00a0 Also, by not indicating how the diet ranked in all categories, it is hard to differentiate what might be important to some \u2014 cost for example \u2014 as compared to ease of implementation.\nThe National Institute of Health\u2019s decision some years ago to promote the DASH diet was based on three large trials that involved thousands of patients. Perhaps some data could have been drawn from one of the studies to engage readers and show how a diet can make a difference in health outcomes.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe animals died months earlier than healthy control animals.\n\u201cBehaviourally mice aged faster when these cells were removed during early ageing,\u201d Cai told the Guardian.\nThis time the mice lived longer than controls, typically several months more, an increase of about 15%.\nImplants of stem cells that make fresh neurons in the brain were found to put the brakes on ageing in older mice, keeping them more physically and mentally fit for months, and extending their lives by 10-15% compared to untreated animals.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says the stem cell intervention extended the rodents\u2019 lives \u201cby 10-15% compared to untreated animals.\u201d\u00a0 At another point, it said, \u201cthe mice lived longer than controls, typically several months more, an increase of about 15%.\u201d", "answer": 1}, {"article": "The findings are published in TheJournal of the American Medical Association.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nJan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of treatment in appropriate absolute terms. It explains that women taking the\u00a0antidepressant went from about 10 hot flashes per day to\u00a05.26 hot flashes a day, a decline of 47% or about\u00a04.5\u00a0fewer hot flashes a day.\u00a0By comparison,\u00a0women taking the placebo reported 6.43 hot flashes a day after treatment, a decline of 33% or about\u00a03 fewer a day. The story also quantifies the severity of the hot flashes in terms that are useful to the reader.\nThe story perhaps could have provided some context\u00a0regarding the size of the benefit compared with placebo, which was relatively small. It also could have noted noted that\u00a0symptom reductions were much more modest than\u00a0those seen with hormone treatment.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No quantification of benefits \u2013 only this:\u00a0 \u201cThe FDA says the study showed comparable overall survival rates in patients in both groups.\u201d\nDoes that mean a week?\u00a0 A month?\u00a0 A year?\u00a0 Longer?\nAnswer \u2013 not in the story:\u00a0 Both treatment groups had a median survival of about 6 months.", "answer": 0}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nAccording to findings presented at the European Society of Endocrinology annual meeting in Barcelona, individuals with higher levels of total body and abdominal fat appeared to have lower levels of vitamin D.\n\nRachida Rafiq, the lead author of the study told Newsweek at the time: \"Our results are significant as vitamin D deficiency and obesity are very common problems in our society nowadays,\" she told Newsweek, and argued that it is an important potential relationship to explore.\nProfessor Mary Fewtrell, assistant officer for health promotion at the U.K.-based Royal College of Paediatrics and Child Health, told Newsweek: \"Although the effect sizes are not given, these outcomes are certainly positive.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told kids who took vitamin D \u201chad a significantly lower BMI\u201d and \u201clower body fat, as well as healthier cholesterol levels.\u201d But this is not adequate. How much did BMI appear to improve for the kids who took vitamin D? How much fat did they appear to lose relative to kids who didn\u2019t take vitamin D? And just how much better were their cholesterol levels? We don\u2019t know, because those numbers are not included.\nThe story hints that researchers didn\u2019t provide this information, via this quote:\u00a0\u201cAlthough the effect sizes are not given, these outcomes are certainly positive.\u201d Lay readers may not understand what \u201ceffect sizes\u201d mean and why they matter.", "answer": 0}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThese findings are published in FASEB BioAdvances journal.\nThis is a generic test for cancer in an individual, regardless of the underlying mechanism that's causing their cancer.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThe test was developed at the University of Bradford, UK.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that a modified version of the original test can identify individuals with cancer more than 93% of the time.\nIt\u2019s unclear what the 93% success rate means in this context. Is that the sensitivity? What is the false positive rate? Why these terms matter.", "answer": 0}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nNutricia, a division of Dannon, sponsored the study.\nTo be effective, all three compounds must be given together, the researchers said.\nBut more research is needed before the drink could be made available to the public.\nTo show the drink's effect on the brain, patients underwent electroencephalography (EEG) throughout the trial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The results were only discussed in broad, general terms \u2013 no quantified details were provided.", "answer": 0}, {"article": "Patients who had lumpectomy plus radiation had more local recurrences than the mastectomy patients but had fewer deaths.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nTo Learn More: The full study is available on the For The Media website.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nAbout JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The summary gives an\u00a0absolute risk reduction percentage of 0.27% for patients who received radiation compared to those who did not.\u00a0It also includes the number needed to treat (370) to save one patient. This is good detail, but we would also have liked more context on the controversies of DCIS treatment. A HealthNewsReview.org podcast provides a deeper look here.", "answer": 1}, {"article": "Sept. 26, 2017.\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nCompared with patients receiving traditional warfarin dosing, patients dosed with the genetic approach had a 27 percent reduction in adverse events, which was statistically different.\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release gives results in both actual numbers of patients and the percentage of reduction of adverse events in those given the genetic test and a comparison group.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment.", "answer": 0}, {"article": "Reference: Kim, K-H. et al (2017).\nThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nFour months later the mice in the fasting group weighed less than those in the control group who continued to eat the same volume of food.\nThe lower body weight of the mice in the fasting group was not the only effect.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are given very sketchy treatment. For example, the release says, \u201cFour months later the mice in the fasting group weighed less than those in the control group who continued to eat the same volume of food.\u201d\nThe release never tells us how many mice were in the study nor how much less they weighed than the control group at the end of the trial.\nThe release also provides what it calls molecular detail about benefits to the experimental fasting mice vs. the control mice. But again, the quantities and context are not there.\n\u201cThrough an analysis into the underlying biology involved, the researchers found that such intermittent fasting tempers an immune reaction in fat cells. There are changes in certain gene pathways involved in the immune system and the body\u2019s reaction to inflammation. A type of white blood cell known to play a role in fighting inflammation is triggered. Known as anti-inflammatory macrophages, these cells stimulate the fat cells to burn stored fats or lipids by generating heat. This happens during periods of intermittent fasting because there is an increase in vascular growth factor (VEGF) that help form blood vessels and activate anti-inflammatory macrophage.\u201d\nWhat are the changes? How were they measured? We don\u2019t see any numbers in this description to help the reader evaluate the credibility of the data.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nThese results remained the same regardless of sex, age, race or education, the researchers noted.\nDr. Lon S. Schneider, director of the state of California's Alzheimer's Disease Research and Clinical Center at the University of Southern California, Los Angeles, said that these findings were \"straightforward and expected.\"\nThe participants, who were generally healthy when the study began, either took 120 milligrams of ginkgo or placebo twice a day and were routinely tested for cognitive abilities.\nTo test ginkgo's effect on cognitive decline, DeKosky's group looked at results from the ginkgo Evaluation of Memory study, which included 3,069 community-dwelling adults 72 to 96 years of age.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that the researchers found no evidence that ginkgo delayed or prevented cognitive declines. ", "answer": 1}, {"article": "But on Oct. 23, the F.D.A.\nAlthough there are still questions about peramivir\u2019s true effectiveness, some critics say the government moved too slowly to make the drug available, and that even now, access is too restricted.\nPeramivir, still being tested in clinical trials, is not approved by the Food and Drug Administration for general use.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\nVirtually all the money to develop the drug comes from $180 million in grants from the Department of Health and Human Services.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story points out that the benefits of peramivir have yet to be proven and that it is being offered only because some patients are not helped by approved drugs or are they are so sick they need a drug that can be given intravenously. The approved antiviral drugs are currently available only in pill or inhaled form.", "answer": 1}, {"article": "\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\nPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This news release is missing a few details about the benefits that would make it better. We learn that 80 percent of children required pain relief at home and that there was no difference in the effectiveness of the two medications.\nThe advantage appears to be in the reduced amount of side effects from ibuprofen compared to oral morphine. The release states:\n\u201cPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\u201cMorphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\u201d write the authors.\nWe\u2019d like the release to define what \u201csignificantly more adverse affects\u201d really means.\nHarms, or adverse effects, are a central part of this study, so a numerical comparison would be useful. As it turns out, 69 percent of children given oral morphine complained of negative side effects compared to 39 percent of those taking ibuprofen, according to the study. That\u2019s a pretty big difference. We also don\u2019t learn exactly which negative effects were most common, which turn out to be drowsiness (48 percent of study participants) and nausea (46 percent of participants).", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re given the data in absolute terms, which is very useful: 76.3% of men who got the combo radiation-hormone blocker treatment lived after 12 years, whereas 71.3% of those who received radiation alone survived 12 years after a recurrence of prostate cancer. This lets the reader clearly see how small but significant the benefit (a 5.2% difference) is. Going a step further, readers are also given the data on what actually killed men who received either treatment.", "answer": 1}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.To schedule an interview, please contact Krysten Carrera, 301-496-3583, NIDDKMEDIA@niddk.nih.gov.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the very slight benefits of a very small study (fewer than 10 patients). Unlike the control group, five people who received active stimulation of their brain \u201cconsumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\u201d But the story misses an important point here \u2014 the reduction in calories consumed was not statistically significant. That important detail deserved comment.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nThe sensor doesn\u2019t control the pump but allows a diabetic to make quicker, presumably better decisions.\nMiniMed\u2019s studies show the sensor\u2019s accuracy can be off by as much as 18 percent.\nThe device, made by Medtronic MiniMed, is called the Paradigm Real-Time, a combination insulin pump and continuous glucose sensor.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no discussion about clinical outcomes, such as by how much it might improve A1C levels, or on average, how many severe low blood sugar episodes were avoided by using this device compared to traditional devices. ", "answer": 0}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nThe researchers compared HbA1c test results from 107 women who later developed gestational diabetes to test results from 214 women who did not develop the condition.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release quantifies the results and potential benefits by noting that each 0.1 percent increase in HbA1c levels above 5.1 percent \u00a0in early pregnancy was associated with a 22 percent higher risk for gestational diabetes.", "answer": 1}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\n\"Dietary habits established during childhood often transition to adulthood, so it is hugely important to encourage children to enjoy vegetables as part of the diet in order to reap the nutrition and health benefits provided by vegetables into adulthood.\"\n\"It's important that consumption of all vegetables, particularly those that are good sources of potassium and dietary fiber, be encouraged in children,\" says Theresa A. Nicklas, DrPH, USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and one of the supplement's authors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release says that potatoes are the \u201cbest hope\u201d for delivering more fiber and potassium to kids. Based on what evidence? The study certainly doesn\u2019t show this. Here\u2019s what the study concludes:\n\u201cThe results suggest that patterns of potassium, [dietary fiber], and vitamin D intake for young children should be studied further in order to develop strategies for increasing intakes of these crucial nutrients. The consumption of a variety of all vegetables, including [white potatoes], is important to increase potassium and [dietary fiber]\u00a0intakes and should be encouraged.\u201d", "answer": 0}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\nWe showed that a subset of men whose tumours had mutations in their DNA repair machinery responded particularly well to treatment with olaparib.\nIt also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.\nOf the 16 patients with detectable DNA repair mutations, 14 responded very well to olaparib - accounting for the large majority of those who benefited from the drug.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release lacks information on key outcomes such as months of disease-free survival or death rates.\nThis is the closest we get to any quantification of benefits: \u201cWe showed that a subset of men whose tumours had mutations in their DNA repair machinery responded particularly well to treatment with olaparib.\u201d", "answer": 0}]